SETTING	O
:	O
University	O
hospital	O
-	O
based	O
,	O
tertiary	O
care	O
infertility	O
center	O
.	O

Large	B-GENE
T	I-GENE
antigen	I-GENE
was	O
coimmunoprecipitated	O
by	O
antibodies	O
to	O
epitope	O
-	O
tagged	O
TBP	B-GENE
,	O
endogenous	O
TBP	B-GENE
,	O
hTAF	B-GENE
(	I-GENE
II	I-GENE
)	I-GENE
100	I-GENE
,	O
hTAF	B-GENE
(	I-GENE
II	I-GENE
)	I-GENE
130	I-GENE
,	O
and	O
hTAF	B-GENE
(	I-GENE
II	I-GENE
)	I-GENE
250	I-GENE
,	O
under	O
conditions	O
where	O
holo	B-GENE
-	I-GENE
TFIID	I-GENE
would	O
be	O
precipitated	O
.	O

CONCLUSIONS	O
:	O
This	O
randomized	O
study	O
shows	O
that	O
Vivostat	O
fibrin	B-GENE
sealant	O
is	O
effective	O
in	O
preventing	O
air	O
leakage	O
after	O
small	O
lung	O
resections	O
in	O
pigs	O
,	O
even	O
at	O
high	O
inspiratory	O
pressures	O
.	O

We	O
propose	O
a	O
model	O
in	O
which	O
Sro7	B-GENE
function	O
is	O
involved	O
in	O
the	O
targeting	O
of	O
the	O
myosin	B-GENE
proteins	I-GENE
to	O
their	O
intrinsic	O
pathways	O
.	O

The	O
response	O
properties	O
of	O
cat	O
horizontal	O
canal	O
afferents	O
(	O
N	O
=	O
81	O
)	O
were	O
characterized	O
by	O
three	O
parameters	O
:	O
their	O
long	O
time	O
constants	O
(	O
tau	O
)	O
,	O
low	O
frequency	O
gain	O
constants	O
(	O
G1	O
)	O
,	O
and	O
middle	O
frequency	O
gain	O
constants	O
(	O
Gm	O
)	O
.	O

Glycogen	O
synthesis	O
and	O
catabolism	O
,	O
gluconeogenesis	O
,	O
glycolysis	O
,	O
motility	O
,	O
cell	O
surface	O
properties	O
and	O
adherence	O
are	O
modulated	O
by	O
csrA	B-GENE
in	I-GENE
Escherichia	I-GENE
coli	I-GENE
,	O
while	O
the	O
production	O
of	O
several	O
secreted	O
virulence	O
factors	O
,	O
the	O
plant	O
hypersensitive	O
response	O
elicitor	O
HrpN	O
(	O
Ecc	O
)	O
and	O
,	O
potentially	O
,	O
other	O
secondary	O
metabolites	O
are	O
regulated	O
by	O
rsmA	B-GENE
in	I-GENE
Erwinia	I-GENE
carotovora	I-GENE
.	O

We	O
have	O
applied	O
the	O
mRNA	O
differential	O
display	O
method	O
to	O
compare	O
and	O
analyze	O
mRNAs	O
prepared	O
from	O
five	O
normal	O
nasopharyngeal	O
epithelial	O
cell	O
cultures	O
and	O
five	O
nasopharyngeal	O
carcinoma	O
cell	O
lines	O
.	O

Lung	O
and	O
multi	O
-	O
system	O
damage	O
were	O
early	O
indicators	O
of	O
poor	O
outcome	O
in	O
severe	O
non	O
-	O
fatal	O
disease	O
.	O

Histological	O
slides	O
of	O
one	O
biopsy	O
of	O
each	O
patient	O
(	O
formalin	O
-	O
fixed	O
and	O
paraffin	O
-	O
embedded	O
)	O
were	O
stained	O
with	O
a	O
Modified	O
Giemsa	O
(	O
MG	O
)	O
,	O
the	O
Warthin	O
-	O
Starry	O
(	O
WS	O
)	O
,	O
and	O
an	O
immunohistochemical	O
method	O
(	O
IMM	O
)	O
using	O
purified	O
polyclonal	O
H	O
.	O
pylori	O
antiserum	O
(	O
DAKO	O
B471	O
)	O
.	O

BACKGROUND	O
:	O
Chemicals	O
vary	O
considerably	O
in	O
their	O
intrinsic	O
ability	O
to	O
cause	O
allergic	O
contact	O
dermatitis	O
.	O

Demispan	O
is	O
a	O
reliable	O
and	O
reproducible	O
measure	O
of	O
stature	O
in	O
the	O
elderly	O
.	O

In	O
one	O
acromegalic	O
patient	O
visual	O
improvement	O
was	O
obtained	O
while	O
the	O
abnormal	O
GH	B-GENE
secretion	O
remained	O
unaltered	O
.	O

When	O
the	O
blood	O
pressure	O
increase	O
in	O
response	O
to	O
smoking	O
was	O
blunted	O
by	O
nitroprusside	O
infusion	O
,	O
there	O
was	O
a	O
striking	O
increase	O
in	O
muscle	O
SNA	O
.	O

Multiple	O
single	O
-	O
stranded	O
cis	O
elements	O
are	O
associated	O
with	O
activated	O
chromatin	O
of	O
the	O
human	B-GENE
c	I-GENE
-	I-GENE
myc	I-GENE
gene	I-GENE
in	O
vivo	O
.	O

Removal	O
of	O
thick	O
,	O
permanently	O
altered	O
mucoas	O
is	O
recommended	O
even	O
in	O
the	O
absence	O
of	O
squamous	O
epithelium	O
.	O

The	O
position	O
,	O
transcription	O
orientation	O
,	O
and	O
imprinted	O
status	O
of	O
the	O
genes	O
immediately	O
flanking	O
Igf2r	B-GENE
have	O
been	O
assessed	O
.	O

High	O
-	O
pressure	O
effects	O
on	O
ultrafast	O
-	O
relaxation	O
kinetics	O
of	O
excitons	O
in	O
polydiacetylene	O
4BCMU	O
.	O

Interestingly	O
,	O
we	O
find	O
that	O
the	O
interaction	O
between	O
Tat	B-GENE
and	O
hCycT1	B-GENE
requires	O
zinc	O
as	O
well	O
as	O
essential	O
cysteine	O
residues	O
in	O
both	O
proteins	O
.	O

Treatment	O
of	O
2	O
patients	O
with	O
pseudohypoparathyroidism	O
type	O
I	O
with	O
vitamin	O
-	O
D	O
-	O
3	O
and	O
1	O
alpha	O
-	O
Hydroxycholecalciferol	O
consecutively	O
resulted	O
in	O
a	O
nonuniform	O
response	O
with	O
regard	O
to	O
the	O
normalisation	O
of	O
serum	O
-	O
calcium	O
.	O

Tumour	B-GENE
necrosis	I-GENE
factor	I-GENE
and	O
adult	O
respiratory	O
distress	O
syndrome	O
.	O

Immunologic	O
mechanisms	O
in	O
chronic	O
brucellosis	O
in	O
humans	O
.	O

Biological	O
evaluation	O
of	O
mibolerone	O
in	O
the	O
female	O
Beagle	O
.	O

These	O
results	O
suggest	O
that	O
Rho1p	B-GENE
regulates	O
cytoskeletal	O
reorganization	O
at	O
least	O
through	O
Bni1p	B-GENE
and	O
Pkc1p	B-GENE
.	O

This	O
protein	O
-	O
protein	O
interaction	O
does	O
not	O
require	O
the	O
simultaneous	O
binding	O
of	O
Oct	B-GENE
proteins	I-GENE
to	O
DNA	O
,	O
and	O
high	O
resolution	O
footprinting	O
of	O
the	O
Oct	B-GENE
-	I-GENE
DNA	I-GENE
interaction	O
reveals	O
that	O
binding	O
of	O
BOB	B-GENE
.	I-GENE
1	I-GENE
/	I-GENE
OBF	I-GENE
.	I-GENE
1	I-GENE
to	O
Oct1	B-GENE
or	O
Oct2	B-GENE
does	O
not	O
alter	O
the	O
interaction	O
with	O
DNA	O
.	O

The	O
lytic	O
cycle	O
of	O
KSHV	O
,	O
probably	O
under	O
the	O
initial	O
control	O
of	O
the	O
KSHV	B-GENE
/	I-GENE
Rta	I-GENE
gene	I-GENE
,	O
may	O
directly	O
contribute	O
to	O
tumor	O
pathogenesis	O
.	O

In	O
about	O
770	O
bp	O
upstream	O
region	O
of	O
Spam1	B-GENE
that	O
has	O
been	O
cloned	O
and	O
sequenced	O
,	O
multiple	O
transcription	O
factor	O
binding	O
sites	O
including	O
a	O
CRE	B-GENE
(	O
cAMP	B-GENE
-	I-GENE
responsive	I-GENE
element	I-GENE
)	O
were	O
found	O
.	O

Perfusion	O
washout	O
:	O
increasing	O
a	O
microvascular	O
free	O
flap	O
tolerance	O
to	O
ischemia	O
.	O

A	O
case	O
of	O
M	O
hemoglobinosis	O
.	O

The	O
location	O
and	O
approximate	O
length	O
of	O
the	O
intron	O
are	O
conserved	O
in	O
both	O
the	O
tomato	O
and	O
Arabidopsis	O
genes	O
,	O
with	O
the	O
intron	O
separating	O
the	O
'	O
nose	O
'	O
region	O
(	O
encoded	O
by	O
exon	O
1	O
)	O
from	O
the	O
central	O
globular	O
domain	O
(	O
exon	O
2	O
)	O
.	O

Thus	O
,	O
the	O
bovine	B-GENE
PEDF	I-GENE
cDNA	I-GENE
isolated	O
here	O
codes	O
for	O
a	O
functional	O
soluble	O
secreted	B-GENE
PEDF	I-GENE
glycoprotein	I-GENE
.	O

Using	O
16	O
strains	O
of	O
C	O
.	O
trachomatis	O
in	O
triplicate	O
assays	O
,	O
we	O
found	O
the	O
RT	O
-	O
PCR	O
method	O
consistently	O
more	O
sensitive	O
than	O
the	O
conventional	O
technique	O
for	O
all	O
eight	O
antimicrobials	O
tested	O
,	O
with	O
resultant	O
MICs	O
determined	O
by	O
RT	O
-	O
PCR	O
ranging	O
from	O
1	O
.	O
6	O
-	O
fold	O
higher	O
(	O
erythromycin	O
)	O
to	O
>	O
/	O
=	O
195	O
-	O
fold	O
higher	O
(	O
amoxicillin	O
)	O
.	O

However	O
,	O
the	O
element	O
proximal	O
to	O
the	O
transcription	O
start	O
site	O
is	O
dependent	O
on	O
the	O
SRE	B-GENE
-	I-GENE
1	I-GENE
.	O

Klebsiella	O
oxytoca	O
can	O
assimilate	O
nitrate	O
and	O
nitrite	O
by	O
using	O
enzymes	O
encoded	O
by	O
the	O
nasFEDCBA	B-GENE
operon	I-GENE
.	O

Use	O
of	O
the	O
immunofluorescence	O
method	O
for	O
identification	O
of	O
enteroviruses	O
in	O
cell	O
cultures	O
.	O

Atcys1	B-GENE
,	O
Athyp1	B-GENE
,	O
AKin10	B-GENE
and	O
the	O
ORF	O
are	O
very	O
close	O
to	O
each	O
other	O
and	O
organized	O
in	O
the	O
same	O
polarity	O
;	O
hence	O
,	O
the	O
intergenic	O
regions	O
probably	O
contain	O
,	O
within	O
less	O
than	O
0	O
.	O
5	O
kb	O
,	O
all	O
the	O
regulatory	O
elements	O
necessary	O
to	O
govern	O
initiation	O
and	O
termination	O
of	O
transcription	O
.	O

The	O
increase	O
in	O
amplitudes	O
of	O
the	O
b	O
-	O
wave	O
during	O
the	O
adaptation	O
period	O
was	O
more	O
prominent	O
in	O
lead	O
-	O
exposed	O
subjects	O
than	O
in	O
controls	O
.	O

(	O
ii	O
)	O
An	O
AF	O
G	B-GENE
-	I-GENE
CSF	I-GENE
level	O
>	O
2000	O
pg	O
/	O
ml	O
is	O
a	O
strong	O
positive	O
predictor	O
of	O
CAM	O
.	O

I	O
report	O
here	O
that	O
induction	O
of	O
HSP82	B-GENE
is	O
regulated	O
by	O
the	O
early	O
meiotic	O
IME1	B-GENE
-	I-GENE
IME2	I-GENE
transcriptional	O
cascade	O
.	O

We	O
now	O
report	O
the	O
isolation	O
and	O
expression	O
of	O
cDNAs	O
encoding	O
PTF	B-GENE
gamma	I-GENE
and	O
PTF	B-GENE
delta	I-GENE
,	O
as	O
well	O
as	O
functional	O
studies	O
with	O
cognate	O
antibodies	O
that	O
recognize	O
the	O
native	O
PTF	B-GENE
complex	I-GENE
in	O
HeLa	O
extracts	O
.	O

Primers	O
for	O
subsequent	O
rounds	O
of	O
RACE	O
were	O
designed	O
from	O
the	O
5	O
'	O
-	O
ends	O
of	O
amplified	O
RACE	B-GENE
products	I-GENE
.	O

Current	O
status	O
of	O
zinc	O
deficiency	O
in	O
the	O
pathogenesis	O
of	O
neurological	O
,	O
dermatological	O
and	O
musculoskeletal	O
disorders	O
.	O

Several	O
free	O
2nd	O
-	O
generation	O
schizonts	O
,	O
which	O
varied	O
in	O
diameter	O
from	O
11	O
to	O
21	O
.	O
6	O
micrometer	O
,	O
were	O
found	O
on	O
the	O
epithelial	O
surface	O
of	O
the	O
cecum	O
.	O

Active	O
lambda	B-GENE
and	I-GENE
kappa	I-GENE
antibody	I-GENE
gene	I-GENE
rearrangement	O
in	O
Abelson	O
murine	O
leukemia	O
virus	O
-	O
transformed	O
pre	O
-	O
B	O
cell	O
lines	O
.	O

Brainstem	O
auditory	O
evoked	O
responses	O
(	O
BAERs	O
)	O
and	O
quantitative	O
saccadic	O
eye	O
movement	O
studies	O
provide	O
information	O
on	O
the	O
integrity	O
of	O
pathways	O
traversing	O
the	O
brainstem	O
.	O

Spinal	O
cord	O
representation	O
of	O
the	O
micturition	O
reflex	O
.	O

The	O
patients	O
were	O
divided	O
into	O
ischaemia	O
and	O
non	O
-	O
ischaemia	O
groups	O
on	O
the	O
basis	O
of	O
the	O
change	O
in	O
lactate	O
extraction	O
ratio	O
during	O
balloon	O
inflation	O
.	O

Glycemic	O
response	O
to	O
malted	O
,	O
popped	O
and	O
roller	O
dried	O
wheat	O
-	O
legume	O
based	O
foods	O
in	O
normal	O
subjects	O
.	O

Sterol	O
-	O
mediated	O
suppression	O
of	O
cleavage	O
of	O
SREBP	B-GENE
-	I-GENE
1	I-GENE
was	O
found	O
to	O
be	O
dependent	O
on	O
the	O
extreme	O
COOH	O
-	O
terminal	O
region	O
(	O
residue	O
1034	O
to	O
the	O
COOH	O
terminus	O
)	O
,	O
which	O
exists	O
in	O
two	O
forms	O
as	O
a	O
result	O
of	O
alternative	O
splicing	O
.	O

The	O
difference	O
between	O
the	O
patients	O
and	O
the	O
controls	O
was	O
statistically	O
significant	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
.	O

The	O
coefficient	O
of	O
determination	O
,	O
r2	O
,	O
of	O
the	O
other	O
scores	O
ranged	O
from	O
0	O
.	O
56	O
to	O
0	O
.	O
61	O
.	O

The	O
androgen	B-GENE
receptor	I-GENE
(	O
AR	B-GENE
)	O
amino	O
-	O
terminus	O
imposes	O
androgen	O
-	O
specific	O
regulation	O
of	O
AR	B-GENE
gene	I-GENE
expression	O
via	O
an	O
exonic	O
enhancer	O
.	O

A	O
yeast	O
DNA	O
fragment	O
carrying	O
the	O
gene	B-GENE
CP	I-GENE
A1	I-GENE
encoding	O
the	O
small	O
subunit	O
of	O
the	O
arginine	O
pathway	O
carbamoyl	B-GENE
-	I-GENE
phosphate	I-GENE
synthetase	I-GENE
has	O
been	O
sequenced	O
.	O

In	O
an	O
effort	O
to	O
identify	O
the	O
USH1C	B-GENE
disease	I-GENE
gene	I-GENE
we	O
have	O
isolated	O
the	O
region	O
between	O
these	O
markers	O
in	O
yeast	O
artificial	O
chromosomes	O
(	O
YACs	O
)	O
using	O
a	O
combination	O
of	O
STS	O
content	O
mapping	O
and	O
Alu	O
-	O
PCR	O
hybridization	O
.	O

Critical	O
residues	O
required	O
for	O
repression	O
are	O
located	O
within	O
the	O
C	O
-	O
terminal	O
27	O
amino	O
acids	O
of	O
c	B-GENE
-	I-GENE
Fos	I-GENE
,	O
since	O
v	B-GENE
-	I-GENE
Fos	I-GENE
and	O
C	O
-	O
terminal	O
truncations	O
of	O
c	B-GENE
-	I-GENE
Fos	I-GENE
did	O
not	O
down	O
regulate	O
.	O

Altogether	O
these	O
results	O
indicate	O
that	O
the	O
Syn	B-GENE
5	I-GENE
locus	I-GENE
segregates	O
from	O
the	O
gene	O
specifying	O
gH	B-GENE
,	O
to	O
a	O
region	O
encompassing	O
portions	O
of	O
the	O
TK	B-GENE
and	O
UL	B-GENE
24	I-GENE
genes	I-GENE
,	O
and	O
that	O
the	O
syn	B-GENE
mutation	I-GENE
does	O
not	O
affect	O
the	O
expression	O
or	O
activity	O
of	O
TK	O
.	O

To	O
identify	O
factors	O
that	O
may	O
modify	O
the	O
heterosexual	O
transmission	O
of	O
human	O
T	O
cell	O
leukemia	O
/	O
lymphoma	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
,	O
534	O
married	O
couples	O
enrolled	O
in	O
the	O
Miyazaki	O
Cohort	O
Study	O
between	O
November	O
1984	O
and	O
April	O
1989	O
were	O
studied	O
:	O
95	O
husband	O
HTLV	O
-	O
I	O
-	O
seropositive	O
(	O
H	O
+	O
)	O
/	O
wife	O
seropositive	O
(	O
W	O
+	O
)	O
,	O
33	O
H	O
+	O
/	O
W	O
-	O
,	O
64	O
H	O
-	O
/	O
W	O
+	O
,	O
and	O
342	O
H	O
-	O
/	O
W	O
-	O
.	O

2	O
.	O

Upon	O
analysis	O
of	O
various	O
deletion	O
and	O
point	O
-	O
mutated	O
variants	O
of	O
the	O
human	B-GENE
IL	I-GENE
-	I-GENE
6	I-GENE
gene	I-GENE
promoter	I-GENE
coupled	O
to	O
a	O
reporter	O
gene	O
,	O
we	O
screened	O
for	O
possible	O
cooperating	O
transcription	O
factors	O
.	O

Characterization	O
of	O
the	O
5	O
'	O
end	O
of	O
the	O
growth	O
-	O
regulated	O
Syrian	B-GENE
hamster	I-GENE
CAD	I-GENE
gene	I-GENE
.	O

Horvath	O
,	O
I	O
.	O

Switching	O
FDC	O
-	O
P1	O
/	O
MAC	O
cells	O
from	O
growth	O
in	O
M	B-GENE
-	I-GENE
CSF	I-GENE
to	O
GM	B-GENE
-	I-GENE
CSF	I-GENE
caused	O
the	O
selective	O
degradation	O
of	O
c	B-GENE
-	I-GENE
fms	I-GENE
mRNA	I-GENE
within	O
6	O
h	O
after	O
factor	O
switching	O
.	O

Analysis	O
of	O
the	O
gag	B-GENE
and	O
rev	B-GENE
proteins	I-GENE
in	O
the	O
transfected	O
cells	O
demonstrated	O
that	O
these	O
proteins	O
were	O
not	O
detectable	O
in	O
cells	O
transfected	O
with	O
the	O
tat	B-GENE
mutants	I-GENE
but	O
could	O
be	O
readily	O
detected	O
when	O
the	O
mutations	O
were	O
complemented	O
in	O
trans	O
with	O
a	O
tat	B-GENE
expression	O
vector	O
.	O

However	O
,	O
the	O
BCH	O
group	O
showed	O
inferior	O
gross	O
motor	O
performance	O
on	O
the	O
Bruininks	O
-	O
Oseretsky	O
Test	O
of	O
Motor	O
Proficiency	O
(	O
Bruininks	O
1978	O
)	O
.	O

Repression	O
is	O
alleviated	O
when	O
the	O
two	O
(	O
for	O
E2	B-GENE
)	O
or	O
three	O
(	O
for	O
E2	B-GENE
-	I-GENE
C	I-GENE
)	O
promoter	O
-	O
proximal	O
copies	O
of	O
E2	B-GENE
-	I-GENE
RS	I-GENE
are	O
mutated	O
.	O

Our	O
findings	O
suggest	O
that	O
striatal	O
FDG	O
and	O
particularly	O
RACLO	O
are	O
sensitive	O
and	O
effective	O
measures	O
of	O
striatal	O
function	O
and	O
may	O
help	O
characterizing	O
patients	O
with	O
multiple	O
system	O
atrophy	O
.	O

A	O
prospective	O
trail	O
comparing	O
hysterectomy	O
,	O
hysterectomy	O
plus	O
vaginal	O
radium	O
,	O
and	O
uterine	O
radium	O
plus	O
hysterectomy	O
in	O
stage	O
I	O
endometrial	O
carcinoma	O
.	O

Serum	B-GENE
Fibrin	I-GENE
Degradation	O
Products	O
(	O
FDP	O
)	O
were	O
determined	O
in	O
50	O
oral	O
cancer	O
patients	O
and	O
50	O
normal	O
individuals	O
prior	O
to	O
any	O
kind	O
of	O
treatment	O
.	O

Among	O
these	O
360	O
ZFPs	B-GENE
,	O
a	O
novel	O
ZFP	B-GENE
cDNA	I-GENE
named	O
HFHZ	B-GENE
(	O
human	B-GENE
fetal	I-GENE
heart	I-GENE
ZFP	I-GENE
)	O
with	O
sequence	O
homology	O
to	O
a	O
Kruppel	B-GENE
-	I-GENE
associated	I-GENE
box	I-GENE
(	O
KRAB	B-GENE
)	O
was	O
identified	O
.	O

Such	O
a	O
mechanism	O
may	O
allow	O
acceleration	O
of	O
degenerative	O
joint	O
conditions	O
,	O
and	O
may	O
account	O
for	O
the	O
increased	O
prevalence	O
of	O
such	O
conditions	O
seen	O
with	O
HMS	O
subjects	O
.	O

Furthermore	O
,	O
stable	O
expression	O
of	O
a	O
constitutively	O
active	O
form	O
of	O
chicken	O
Notch1	B-GENE
or	O
Notch2	B-GENE
in	O
a	O
B	O
cell	O
line	O
results	O
in	O
a	O
down	O
-	O
regulation	O
of	O
surface	O
IgM	B-GENE
expression	O
,	O
which	O
is	O
accompanied	O
by	O
the	O
reduction	O
of	O
IgH	B-GENE
gene	I-GENE
transcripts	I-GENE
.	O

Cochlear	O
microphonic	O
potentials	O
in	O
patients	O
with	O
vestibular	O
schwannomas	O
.	O

A	O
case	O
of	O
chronic	O
hepatitis	O
C	O
with	O
primary	O
hypothyroidism	O
manifested	O
during	O
interferon	B-GENE
treatment	O
.	O

For	O
this	O
purpose	O
,	O
a	O
segment	O
of	O
dxr	B-GENE
was	O
amplified	O
from	O
Synechococcus	O
leopoliensis	O
SAUG	O
1402	O
-	O
1	O
DNA	O
via	O
PCR	O
using	O
oligonucleotides	O
for	O
conserved	O
regions	O
.	O

This	O
result	O
indicates	O
that	O
separate	O
complexes	O
exist	O
containing	O
ankyrin	B-GENE
and	O
fodrin	B-GENE
with	O
either	O
uvomorulin	B-GENE
or	O
Na	B-GENE
+	I-GENE
,	I-GENE
K	I-GENE
+	I-GENE
-	I-GENE
ATPase	I-GENE
.	O

Nerve	B-GENE
growth	I-GENE
factor	I-GENE
(	O
NGF	B-GENE
)	O
and	O
retinoic	O
acid	O
(	O
RA	O
)	O
exert	O
important	O
actions	O
on	O
PC12	O
cells	O
.	O

Sustained	O
ventricular	O
tachycardia	O
and	O
its	O
successful	O
prophylaxis	O
during	O
high	O
-	O
dose	O
bolus	O
interleukin	B-GENE
-	I-GENE
2	I-GENE
therapy	O
for	O
metastatic	O
renal	O
cell	O
carcinoma	O
.	O

Because	O
of	O
its	O
wide	O
spectrum	O
of	O
activity	O
particularly	O
against	O
ampicillin	O
resistant	O
strains	O
of	O
H	O
.	O
influenzae	O
and	O
because	O
of	O
its	O
good	O
tolerance	O
Cefaclor	O
is	O
very	O
useful	O
in	O
treatment	O
of	O
respiratory	O
tract	O
infections	O
in	O
children	O
.	O

Using	O
purified	O
recombinant	B-GENE
HMG	I-GENE
I	I-GENE
,	O
we	O
have	O
identified	O
several	O
high	O
-	O
affinity	O
binding	O
sites	O
which	O
overlap	O
important	O
transcription	O
factor	O
binding	O
sites	O
.	O

BCL6	B-GENE
encodes	O
a	O
POZ	B-GENE
/	I-GENE
Zn	I-GENE
finger	I-GENE
protein	I-GENE
,	O
a	O
structure	O
similar	O
to	O
that	O
of	O
many	O
Drosophila	O
developmental	O
regulators	O
and	O
to	O
another	O
protein	O
involved	O
in	O
a	O
human	O
hematopoietic	O
malignancy	O
,	O
PLZF	B-GENE
.	O

The	O
level	O
of	O
contamination	O
in	O
the	O
wound	O
can	O
be	O
determined	O
with	O
the	O
rapid	O
biopsy	O
fixation	O
technique	O
.	O

A	O
sequence	O
homology	O
analysis	O
between	O
human	B-GENE
nm23	I-GENE
-	I-GENE
H1	I-GENE
and	O
the	O
homolog	O
gene	O
of	O
the	O
rat	O
(	O
NDP	B-GENE
-	I-GENE
K	I-GENE
beta	I-GENE
)	O
shows	O
that	O
exon	O
-	O
intron	O
boundaries	O
are	O
well	O
conserved	O
between	O
these	O
two	O
species	O
.	O

The	O
presence	O
of	O
PDZ	B-GENE
and	O
SAM	B-GENE
domains	I-GENE
in	O
the	O
KS5	B-GENE
protein	I-GENE
suggests	O
that	O
it	O
may	O
act	O
as	O
a	O
molecular	O
adaptor	O
,	O
promoting	O
and	O
relaying	O
information	O
in	O
a	O
signal	O
transduction	O
pathway	O
.	O

An	O
IgG	B-GENE
monoclonal	O
gammopathy	O
was	O
present	O
in	O
the	O
serum	O
of	O
4	O
patients	O
and	O
Bence	O
-	O
Joanes	O
proteinuria	O
was	O
found	O
in	O
1	O
patient	O
.	O

The	O
eluting	O
solvent	O
was	O
methanol	O
-	O
chloroform	O
(	O
10	O
+	O
90	O
)	O
at	O
a	O
flow	O
rate	O
of	O
2	O
.	O
0	O
ml	O
/	O
min	O
.	O

HLA	B-GENE
-	I-GENE
A	I-GENE
and	I-GENE
B	I-GENE
phenotypes	O
of	O
105	O
patients	O
suffering	O
from	O
malignant	O
melanomas	O
were	O
determined	O
,	O
with	O
special	O
regard	O
for	O
metastatic	O
form	O
or	O
relapse	O
.	O

PATIENTS	O
OR	O
OTHER	O
PARTICIPANTS	O
:	O
Twenty	O
children	O
met	O
the	O
criteria	O
for	O
being	O
learning	O
disabled	O
.	O

Further	O
investigation	O
on	O
the	O
chemotactic	O
influence	O
of	O
thymic	B-GENE
hormone	I-GENE
on	O
lymphocytes	O
.	O

Tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
alpha	I-GENE
,	O
the	O
cytokine	O
that	O
participates	O
in	O
the	O
autocrine	O
growth	O
control	O
of	O
hairy	O
cell	O
leukemia	O
has	O
strong	O
bone	O
resorptive	O
properties	O
.	O

This	O
rapid	O
and	O
extensive	O
penetration	O
of	O
intrathecally	O
administered	O
chemotherapy	O
may	O
offer	O
insight	O
into	O
the	O
myelopathy	O
observed	O
with	O
these	O
treatments	O
.	O

The	O
'	O
field	O
of	O
stress	O
'	O
of	O
the	O
supervisory	O
nurse	O
.	O

Using	O
transgenic	O
Xenopus	O
embryos	O
,	O
we	O
demonstrate	O
that	O
the	O
integrity	O
of	O
these	O
two	O
sequences	O
is	O
necessary	O
for	O
correct	O
spatial	O
expression	O
of	O
a	O
Xbra2	B-GENE
promoter	I-GENE
-	I-GENE
driven	I-GENE
reporter	I-GENE
gene	I-GENE
.	O

Its	O
role	O
in	O
these	O
processes	O
suggests	O
that	O
the	O
function	O
of	O
c	B-GENE
-	I-GENE
Myb	I-GENE
may	O
be	O
important	O
early	O
in	O
the	O
establishment	O
of	O
the	O
hematopoietic	O
lineage	O
.	O

The	O
development	O
and	O
distribution	O
of	O
Trypanosoma	O
congolense	O
,	O
T	O
vivax	O
and	O
T	O
brucei	O
in	O
the	O
skin	O
of	O
goats	O
was	O
examined	O
after	O
the	O
animals	O
were	O
bitten	O
by	O
infected	O
Glossina	O
morsitans	O
centralis	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
twofold	O
:	O
(	O
1	O
)	O
to	O
present	O
a	O
parallel	O
form	O
of	O
the	O
Gudjonsson	O
Suggestibility	O
Scale	O
(	O
GSS	O
,	O
Form	O
1	O
)	O
;	O
(	O
2	O
)	O
to	O
study	O
test	O
-	O
retest	O
reliabilities	O
of	O
interrogative	O
suggestibility	O
.	O

Antimicrobial	O
Susceptibility	O
of	O
Klebsiella	O
pneumoniae	O
Producing	O
Extended	B-GENE
-	I-GENE
Spectrum	I-GENE
beta	I-GENE
-	I-GENE
lactamase	I-GENE
(	O
ESBL	B-GENE
)	O
Isolated	O
in	O
Hospitals	O
in	O
Brazil	O
.	O

Coronary	O
T1	O
and	O
T2	O
weighted	O
images	O
were	O
obtained	O
.	O

CONCLUSION	O
:	O
These	O
findings	O
imply	O
that	O
eotaxin	O
either	O
is	O
mechanistically	O
involved	O
in	O
acute	O
asthma	O
or	O
serves	O
as	O
a	O
biomarker	O
for	O
activity	O
of	O
the	O
CCR3	B-GENE
receptor	I-GENE
ligand	I-GENE
system	O
,	O
which	O
is	O
functionally	O
linked	O
to	O
asthma	O
.	O

GH	B-GENE
failed	O
to	O
stimulate	O
phosphorylation	O
or	O
activation	O
of	O
Jun	B-GENE
N	I-GENE
-	I-GENE
terminal	I-GENE
kinase	I-GENE
under	O
the	O
conditions	O
used	O
.	O

Surgical	O
treatment	O
of	O
pulmonary	O
metastases	O
.	O

We	O
found	O
that	O
the	O
expression	O
of	O
the	O
protein	O
was	O
maximum	O
in	O
mitosis	O
and	O
minimum	O
in	O
G1	O
,	O
which	O
correlated	O
with	O
the	O
expression	O
of	O
its	O
messenger	O
RNA	O
.	O

Three	O
separate	O
activation	O
subdomains	O
,	O
and	O
one	O
negative	O
-	O
acting	O
region	O
,	O
which	O
function	O
in	O
yeast	O
were	O
located	O
in	O
the	O
carboxyl	O
-	O
terminal	O
region	O
of	O
NIT4	B-GENE
.	O

The	O
existence	O
of	O
threshold	O
concentrations	O
,	O
above	O
which	O
certain	O
phenomena	O
may	O
occur	O
,	O
strengthens	O
the	O
role	O
of	O
sentinels	O
.	O

Our	O
results	O
indicate	O
that	O
Gab1	B-GENE
is	O
involved	O
in	O
the	O
control	O
of	O
egr	B-GENE
-	I-GENE
1	I-GENE
expression	O
regulated	O
by	O
insulin	B-GENE
.	O

Object	O
relations	O
,	O
affect	O
management	O
,	O
and	O
psychic	O
structure	O
formation	O
.	O

The	O
molecular	O
weight	O
of	O
in	O
vivo	O
-	O
labeled	O
proteins	O
was	O
increased	O
relative	O
to	O
that	O
of	O
in	O
vitro	O
-	O
translated	O
proteins	O
,	O
indicating	O
that	O
a	O
posttranslational	O
modification	O
had	O
occurred	O
.	O

Cross	O
-	O
linking	O
the	O
B	B-GENE
cell	I-GENE
Ag	I-GENE
receptor	I-GENE
(	O
BCR	B-GENE
)	O
to	O
surface	B-GENE
Fc	I-GENE
receptors	I-GENE
for	O
IgG	B-GENE
(	O
Fc	B-GENE
gamma	I-GENE
R	I-GENE
)	O
inhibits	O
G1	O
-	O
to	O
-	O
S	O
progression	O
;	O
the	O
mechanism	O
by	O
which	O
this	O
occurs	O
is	O
not	O
completely	O
known	O
.	O

We	O
report	O
here	O
the	O
identification	O
of	O
HSF	B-GENE
in	O
the	O
fission	O
yeast	O
Schizosaccharomyces	O
pombe	O
.	O

Role	O
of	O
secondary	O
structure	O
in	O
discrimination	O
between	O
constitutive	O
and	O
inducible	O
activators	O
.	O

A	O
study	O
of	O
the	O
E	O
.	O
O	O
.	O
R	O
.	O
T	O
.	O
C	O
.	O

METHODS	O
:	O
The	O
most	O
distal	O
muscle	O
fibres	O
from	O
the	O
deep	O
and	O
superficial	O
finger	O
flexors	O
were	O
measured	O
relative	O
to	O
the	O
pisiform	O
bone	O
in	O
18	O
cadaveric	O
specimens	O
.	O

The	O
microcirculatory	O
dynamics	O
of	O
prostaglandin	B-GENE
E1	I-GENE
and	O
/	O
or	O
nicardipine	O
and	O
their	O
different	O
reactions	O
in	O
the	O
hyper	O
-	O
and	O
hypodynamic	O
state	O
of	O
septic	O
shock	O
in	O
a	O
rat	O
model	O
.	O

A	O
new	O
,	O
flexible	O
fiberoptic	O
ventriculoscope	O
for	O
observation	O
of	O
the	O
ventricles	O
and	O
major	O
cisterns	O
is	O
reported	O
.	O

The	O
highly	O
conserved	O
ninth	O
heptad	O
,	O
which	O
is	O
involved	O
in	O
heterodimerization	O
,	O
appears	O
to	O
participate	O
in	O
the	O
receptor	O
-	O
inhibitor	O
interaction	O
,	O
suggesting	O
that	O
the	O
inhibitor	O
is	O
a	O
related	O
member	O
of	O
the	O
receptor	O
gene	O
family	O
.	O

The	O
human	B-GENE
eps15	I-GENE
gene	I-GENE
,	O
encoding	O
a	O
tyrosine	B-GENE
kinase	I-GENE
substrate	O
,	O
is	O
conserved	O
in	O
evolution	O
and	O
maps	O
to	O
1p31	O
-	O
p32	O
.	O

The	O
rate	O
of	O
decrement	O
in	O
DPOAE	O
amplitude	O
over	O
a	O
prescribed	O
time	O
period	O
was	O
utilized	O
as	O
a	O
measure	O
of	O
susceptibility	O
to	O
the	O
acoustic	O
trauma	O
.	O

Its	O
C	O
-	O
terminal	O
catalytic	O
domain	O
was	O
found	O
to	O
be	O
highly	O
conserved	O
in	O
the	O
homologues	B-GENE
p140	I-GENE
(	I-GENE
ras	I-GENE
-	I-GENE
GRF	I-GENE
)	I-GENE
and	O
Sos	B-GENE
.	O

Expression	O
of	O
six	O
genes	O
,	O
ipaB	B-GENE
,	O
ipaC	B-GENE
,	O
invE	B-GENE
,	O
invG	B-GENE
,	O
invJ	B-GENE
,	O
and	O
invK	B-GENE
,	O
was	O
apparently	O
regulated	O
by	O
the	O
positive	O
regulator	O
virF	B-GENE
.	O

These	O
combined	O
observations	O
define	O
a	O
promoter	O
and	O
an	O
enhancer	O
for	O
the	O
chicken	B-GENE
L	I-GENE
-	I-GENE
CAM	I-GENE
gene	I-GENE
.	O

METHODS	O
:	O
Fifty	O
-	O
one	O
healthy	O
eyes	O
,	O
169	O
ocular	O
hypertensive	O
eyes	O
with	O
normal	O
visual	O
fields	O
,	O
and	O
132	O
glaucomatous	O
eyes	O
with	O
early	O
visual	O
field	O
defects	O
were	O
evaluated	O
with	O
qualitative	O
and	O
quantitative	O
measures	O
of	O
structural	O
damage	O
to	O
the	O
optic	O
nerve	O
and	O
nerve	O
fiber	O
layer	O
.	O

From	O
these	O
results	O
,	O
CBF	B-GENE
-	I-GENE
A	I-GENE
is	O
a	O
novel	O
CArG	O
box	O
-	O
,	O
ssDNA	B-GENE
-	I-GENE
and	I-GENE
RNA	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
,	O
as	O
well	O
as	O
a	O
repressive	O
transcriptional	O
factor	O
.	O

We	O
have	O
tested	O
the	O
function	O
of	O
two	O
potential	O
NF	B-GENE
-	I-GENE
kappaB	I-GENE
-	I-GENE
like	I-GENE
sites	I-GENE
present	O
in	O
the	O
PAI	B-GENE
-	I-GENE
2	I-GENE
proximal	I-GENE
promoter	I-GENE
for	O
responsiveness	O
to	O
TNFalpha	B-GENE
using	O
chloramphenicol	B-GENE
acetyl	I-GENE
transferase	I-GENE
reporter	I-GENE
gene	I-GENE
deletion	O
and	O
mutation	O
analyses	O
.	O

Overexpression	O
of	O
wild	B-GENE
-	I-GENE
type	I-GENE
p53	I-GENE
also	O
induces	O
apoptosis	O
in	O
an	O
LCL	O
.	O

RESULTS	O
:	O
The	O
medians	O
of	O
average	O
daily	O
CD34	B-GENE
+	I-GENE
cell	O
yields	O
for	O
patients	O
who	O
received	O
paclitaxel	O
plus	O
CY	O
,	O
CE	O
,	O
and	O
CEP	O
with	O
G	B-GENE
-	I-GENE
CSF	I-GENE
were	O
12	O
.	O
9	O
,	O
11	O
.	O
03	O
,	O
and	O
5	O
.	O
37	O
x	O
10	O
(	O
6	O
)	O
/	O
kg	O
,	O
respectively	O
,	O
compared	O
with	O
2	O
.	O
02	O
x	O
10	O
(	O
6	O
)	O
/	O
kg	O
in	O
the	O
reference	O
group	O
that	O
received	O
CY	O
with	O
G	B-GENE
-	I-GENE
CSF	I-GENE
(	O
P	O
=	O
<	O
.	O
0001	O
,	O
.	O
002	O
,	O
and	O
.	O
09	O
,	O
respectively	O
)	O
.	O

The	O
calculated	O
pD2	O
values	O
were	O
8	O
.	O
8	O
for	O
E	O
,	O
8	O
.	O
6	O
for	O
DHE	O
and	O
6	O
.	O
6	O
for	O
M	O
.	O

Significant	O
intergroup	O
differences	O
are	O
highlighted	O
for	O
both	O
selected	O
dentoskeletal	O
and	O
soft	O
tissue	O
profile	O
variables	O
.	O

Mutations	O
in	O
the	O
VPS45	B-GENE
gene	I-GENE
,	O
a	O
SEC1	B-GENE
homologue	O
,	O
result	O
in	O
vacuolar	O
protein	O
sorting	O
defects	O
and	O
accumulation	O
of	O
membrane	O
vesicles	O
.	O

B	O
cell	O
-	O
specific	O
mb	B-GENE
-	I-GENE
1	I-GENE
and	O
B29	B-GENE
genes	I-GENE
encode	O
the	O
alpha	O
/	O
beta	O
components	O
of	O
the	O
BCR	B-GENE
-	I-GENE
associated	I-GENE
complex	I-GENE
in	O
mature	O
sIgM	B-GENE
+	I-GENE
B	O
cells	O
.	O

Comparative	O
DNA	O
sequence	O
analysis	O
showed	O
the	O
Genethon	O
microsatellite	B-GENE
D19S596	I-GENE
lies	O
2	O
.	O
2	O
kb	O
downstream	O
of	O
the	O
coding	O
region	O
of	O
FUT1	B-GENE
,	O
indicating	O
that	O
the	O
cluster	O
comprising	O
the	O
closely	O
linked	O
FUT1	B-GENE
and	O
FUT2	B-GENE
genes	I-GENE
is	O
located	O
4	O
cM	O
distal	O
to	O
D19S412	B-GENE
(	O
lod	O
score	O
13	O
.	O
7	O
)	O
and	O
9	O
cM	O
proximal	O
to	O
D19S571	B-GENE
(	O
lod	O
score	O
11	O
.	O
7	O
)	O
.	O

Only	O
17	O
%	O
of	O
all	O
patients	O
admitted	O
it	O
at	O
all	O
times	O
.	O

The	O
c	B-GENE
-	I-GENE
myc	I-GENE
gene	I-GENE
is	O
overexpressed	O
in	O
a	O
variety	O
of	O
tumor	O
types	O
and	O
appears	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
abnormal	O
growth	O
of	O
a	O
number	O
of	O
cell	O
types	O
.	O

Inhibition	O
of	O
the	O
apolipoprotein	B-GENE
B	I-GENE
mRNA	I-GENE
editing	O
enzyme	O
-	O
complex	O
by	O
hnRNP	B-GENE
C1	I-GENE
protein	I-GENE
and	O
40S	B-GENE
hnRNP	I-GENE
complexes	I-GENE
.	O

Twenty	O
-	O
six	O
(	O
55	O
%	O
)	O
(	O
95	O
%	O
CI	O
,	O
41	O
-	O
69	O
%	O
)	O
patients	O
experienced	O
>	O
or	O
=	O
grade	O
3	O
acute	O
toxicity	O
(	O
RTOG	O
)	O
.	O

To	O
estimate	O
the	O
locations	O
of	O
sources	O
with	O
the	O
TF	O
-	O
MUSIC	O
algorithm	O
,	O
we	O
first	O
set	O
the	O
target	O
region	O
on	O
the	O
spectrogram	O
of	O
the	O
somatosensory	O
responses	O
.	O

A	O
microsporidian	O
,	O
Nosema	O
algerae	O
Vavra	O
and	O
undeen	O
,	O
was	O
found	O
parasitizing	O
larvae	O
and	O
adults	O
of	O
a	O
laboratory	O
colony	O
of	O
Culex	O
pipiens	O
L	O
.	O
originated	O
from	O
Gharbia	O
Governorate	O
.	O

Serological	O
studies	O
of	O
antibodies	O
to	O
Epstein	O
-	O
Barr	O
virus	O
in	O
infectious	O
mononucleosis	O
.	O

The	O
mean	O
transfer	O
ratios	O
of	O
the	O
drug	O
into	O
the	O
genital	O
tissues	O
to	O
the	O
concentration	O
in	O
the	O
uterine	O
arterial	O
blood	O
were	O
such	O
that	O
the	O
transfer	O
ratio	O
into	O
the	O
portio	O
vaginalis	O
was	O
the	O
highest	O
,	O
followed	O
by	O
the	O
uterine	O
cervix	O
and	O
the	O
myometrium	O
,	O
and	O
that	O
into	O
the	O
oviduct	O
was	O
the	O
lowest	O
with	O
about	O
1	O
/	O
2	O
that	O
into	O
the	O
portio	O
vaginalis	O
.	O

We	O
have	O
also	O
isolated	O
and	O
analyzed	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
pea	O
33RNP	B-GENE
gene	I-GENE
.	O

We	O
conclude	O
that	O
for	O
mono	O
-	O
intronic	O
precursors	O
in	O
which	O
there	O
is	O
only	O
one	O
choice	O
of	O
splice	O
sites	O
,	O
most	O
of	O
the	O
exon	O
sequences	O
are	O
not	O
mechanistically	O
involved	O
in	O
the	O
splicing	O
process	O
.	O

Identification	O
and	O
characterization	O
of	O
two	O
putative	O
human	B-GENE
arginine	I-GENE
methyltransferases	I-GENE
(	O
HRMT1L1	B-GENE
and	O
HRMT1L2	B-GENE
)	O
.	O

The	O
contraceptive	O
pattern	O
of	O
157	O
women	O
was	O
analysed	O
and	O
13	O
.	O
8	O
percent	O
were	O
using	O
inefficient	O
methods	O
.	O

In	O
fus3	B-GENE
mutants	I-GENE
,	O
the	O
levels	O
of	O
Ty1	B-GENE
RNA	I-GENE
,	O
protein	O
synthesis	O
,	O
and	O
proteolytic	O
processing	O
were	O
not	O
altered	O
relative	O
to	O
those	O
in	O
FUS3	B-GENE
strains	O
but	O
steady	O
-	O
state	O
levels	O
of	O
TyA	B-GENE
,	O
integrase	B-GENE
,	O
and	O
reverse	B-GENE
transcriptase	I-GENE
proteins	O
and	O
Ty1	B-GENE
cDNA	I-GENE
were	O
all	O
increased	O
.	O

Patients	O
at	O
risk	O
of	O
hypothyroidism	O
.	O

Thus	O
,	O
included	O
in	O
the	O
KG1a	O
EST	O
dataset	O
are	O
candidates	O
for	O
new	O
human	O
genes	O
that	O
may	O
play	O
roles	O
in	O
hematopoietic	O
differentiative	O
progression	O
and	O
lineage	O
commitment	O
.	O

Restoration	O
of	O
opponens	O
function	O
with	O
transplantation	O
of	O
free	O
composites	O
dorsal	O
pedal	O
skin	O
flap	O
containing	O
m	O
.	O
extensor	O
hallucis	O
brevis	O
.	O

They	O
also	O
interact	O
with	O
GTPase	B-GENE
activating	I-GENE
proteins	I-GENE
encoded	O
by	O
IRA1	B-GENE
and	O
IRA2	B-GENE
.	O

Activation	O
of	O
T	O
cells	O
via	O
the	O
TCR	B-GENE
and	O
other	O
costimulatory	O
receptors	O
triggers	O
a	O
number	O
of	O
signaling	O
cascades	O
.	O

GLRaV	O
-	O
2	O
is	O
the	O
only	O
closterovirus	O
,	O
so	O
far	O
,	O
that	O
matches	O
the	O
genome	O
organization	O
of	O
the	O
type	O
member	O
of	O
the	O
group	O
,	O
BYV	O
,	O
and	O
thus	O
can	O
be	O
unambiguously	O
classified	O
as	O
a	O
definitive	O
member	O
of	O
the	O
genus	O
Closterovirus	O
.	O

Our	O
results	O
demonstrate	O
that	O
the	O
promoter	O
and	O
enhancer	O
regions	O
identified	O
here	O
are	O
essential	O
for	O
maintaining	O
the	O
efficient	O
promoter	O
activity	O
of	O
the	O
human	B-GENE
activin	I-GENE
betaA	I-GENE
subunit	I-GENE
gene	I-GENE
.	O

CONCLUSIONS	O
:	O
Significant	O
elevations	O
of	O
IL	B-GENE
-	I-GENE
1alpha	I-GENE
and	O
IL	B-GENE
-	I-GENE
1beta	I-GENE
occur	O
in	O
patients	O
with	O
bacterial	O
cystitis	O
and	O
microscopic	O
hematuria	O
.	O

Recent	O
work	O
in	O
this	O
laboratory	O
has	O
shown	O
that	O
the	O
gene	O
coding	O
for	O
acetate	B-GENE
kinase	I-GENE
(	O
ackA	B-GENE
)	O
in	O
Sinorhizobium	O
meliloti	O
is	O
up	O
-	O
regulated	O
in	O
response	O
to	O
phosphate	O
limitation	O
.	O

Five	O
additional	O
copies	O
of	O
Lian	B-GENE
elements	I-GENE
were	O
isolated	O
,	O
mapped	O
by	O
restriction	O
digestion	O
,	O
and	O
partially	O
sequenced	O
.	O

Autoimmune	O
neutropenia	O
(	O
AIN	O
)	O
is	O
a	O
frequent	O
cause	O
of	O
chronic	O
neutropenia	O
especially	O
in	O
youngest	O
children	O
.	O

Comparison	O
of	O
the	O
amino	O
acid	O
sequences	O
of	O
the	O
RPO1	B-GENE
polypeptides	I-GENE
of	I-GENE
IIV6	I-GENE
,	I-GENE
LCDV	I-GENE
,	I-GENE
and	I-GENE
MCV	I-GENE
-	I-GENE
1	I-GENE
with	O
the	O
corresponding	O
prokaryotic	O
,	O
eukaryotic	O
,	O
and	O
viral	O
proteins	O
revealed	O
differences	O
in	O
amino	O
acid	O
similarity	O
and	O
phylogenetic	O
relationships	O
.	O

Intravenous	O
antibiotic	O
therapy	O
in	O
cystic	O
fibrosis	O
:	O
in	O
hospital	O
or	O
at	O
home	O
?	O

Concordantly	O
,	O
it	O
was	O
shown	O
that	O
the	O
dnHLH	B-GENE
protein	I-GENE
Id1	B-GENE
inhibits	O
differentiation	O
of	O
muscle	O
and	O
myeloid	O
cells	O
in	O
vitro	O
.	O

Data	O
from	O
119	O
men	O
and	O
40	O
women	O
undergoing	O
coronary	O
angiography	O
provide	O
an	O
opportunity	O
to	O
compare	O
these	O
associations	O
in	O
relation	O
to	O
a	O
direct	O
and	O
continuous	O
measure	O
of	O
atherosclerosis	O
while	O
controlling	O
for	O
age	O
,	O
sex	O
,	O
income	O
,	O
hypertension	O
,	O
serum	O
cholesterol	O
,	O
smoking	O
,	O
angina	O
,	O
diabetes	O
,	O
family	O
history	O
of	O
heart	O
disease	O
,	O
Type	O
A	O
behavior	O
pattern	O
,	O
and	O
hostility	O
.	O

The	O
Drosophila	B-GENE
melanogaster	I-GENE
suppressor	I-GENE
of	I-GENE
sable	I-GENE
gene	I-GENE
,	O
su	B-GENE
(	I-GENE
s	I-GENE
)	I-GENE
,	O
encodes	O
a	O
novel	O
,	O
150	O
-	O
kDa	O
nuclear	O
RNA	O
binding	O
protein	O
,	O
SU	B-GENE
(	I-GENE
S	I-GENE
)	I-GENE
,	O
that	O
negatively	O
regulates	O
RNA	O
accumulation	O
from	O
mutant	O
alleles	O
of	O
other	O
genes	O
that	O
have	O
transposon	O
insertions	O
in	O
the	O
5	O
'	O
transcribed	O
region	O
.	O

0	O
.	O
61	O
+	O
/	O
-	O
0	O
.	O
04	O
)	O
.	O

In	O
addition	O
,	O
both	O
the	O
exon	O
1	O
-	O
and	O
exon	O
2	O
-	O
initiated	O
forms	O
of	O
the	O
c	B-GENE
-	I-GENE
Myc	I-GENE
protein	I-GENE
stimulated	O
transcription	O
of	O
a	O
Myc	B-GENE
/	I-GENE
Max	I-GENE
-	I-GENE
responsive	I-GENE
reporter	I-GENE
construct	I-GENE
to	O
a	O
similar	O
level	O
.	O

Productive	O
growth	O
of	O
phage	O
P22	O
in	O
wild	O
-	O
type	O
Salmonella	O
typhimurium	O
correlates	O
with	O
the	O
presence	O
of	O
Abc2	B-GENE
,	O
but	O
is	O
independent	O
of	O
the	O
absolute	O
level	O
of	O
ATP	B-GENE
-	I-GENE
dependent	I-GENE
nuclease	I-GENE
activity	O
,	O
suggesting	O
a	O
qualitative	O
change	O
in	O
the	O
nature	O
of	O
Abc2	O
-	O
modified	O
RecBCD	B-GENE
nuclease	I-GENE
activity	O
relative	O
to	O
the	O
native	O
enzyme	O
.	O

These	O
data	O
may	O
also	O
aid	O
in	O
the	O
localization	O
of	O
other	O
disease	O
loci	O
mapped	O
to	O
this	O
region	O
,	O
including	O
the	O
gene	O
for	O
tricho	O
-	O
dento	O
-	O
osseous	O
syndrome	O
and	O
a	O
murine	O
locus	O
for	O
susceptibility	O
to	O
ozone	O
-	O
induced	O
acute	O
lung	O
injury	O
.	O

Thus	O
,	O
endemic	O
cumlations	O
of	O
hepatitis	O
A	O
diseases	O
are	O
possible	O
.	O

Systematic	O
review	O
of	O
diagnostic	O
tests	O
for	O
vaginal	O
trichomoniasis	O
.	O

Modification	O
by	O
this	O
latter	O
compound	O
was	O
so	O
extensive	O
that	O
the	O
amount	O
of	O
membrane	O
-	O
associated	O
N	O
-	O
myristoylated	O
protein	O
was	O
decreased	O
.	O

Rearrangements	O
of	O
the	O
NFKB2	B-GENE
gene	I-GENE
are	O
associated	O
with	O
lymphoid	O
malignancies	O
,	O
but	O
the	O
functional	O
significance	O
of	O
these	O
alterations	O
is	O
not	O
known	O
.	O

Using	O
fluorescence	O
in	O
situ	O
hybridization	O
,	O
we	O
mapped	O
the	O
chromosome	O
-	O
17	O
breakpoint	O
in	O
a	O
patient	O
with	O
acampomelic	O
CMPD	O
and	O
sex	O
reversal	O
,	O
who	O
carries	O
a	O
de	O
novo	O
constitutional	O
t	O
(	O
12	O
;	O
17	O
)	O
translocation	O
,	O
between	O
two	O
known	O
cosmid	O
markers	O
in	O
the	O
17q24	O
-	O
q25	O
region	O
.	O

Thus	O
,	O
in	O
the	O
presence	O
of	O
active	B-GENE
S	I-GENE
-	I-GENE
CDKs	I-GENE
and	O
Dbf4	B-GENE
/	I-GENE
Cdc7	I-GENE
,	O
Mcms	B-GENE
may	O
open	O
origins	O
and	O
thereby	O
facilitate	O
the	O
loading	O
of	O
RPA	B-GENE
.	O

In	O
canrenoate	O
-	O
treated	O
rats	O
,	O
ANP	B-GENE
infusion	O
caused	O
greater	O
increases	O
in	O
sodium	O
excretion	O
(	O
FENA	O
from	O
3	O
.	O
05	O
+	O
/	O
-	O
0	O
.	O
71	O
to	O
7	O
.	O
21	O
+	O
/	O
-	O
0	O
.	O
45	O
%	O
;	O
P	O
<	O
0	O
.	O
05	O
;	O
n	O
=	O
8	O
)	O
than	O
saline	O
infusion	O
(	O
FENA	O
from	O
4	O
.	O
16	O
+	O
/	O
-	O
1	O
.	O
11	O
to	O
5	O
.	O
47	O
+	O
/	O
-	O
0	O
.	O
66	O
%	O
;	O
n	O
=	O
6	O
)	O
,	O
despite	O
the	O
hypocapnia	O
.	O

RT	O
-	O
PCR	O
analysis	O
showed	O
that	O
PLP	B-GENE
-	I-GENE
H	I-GENE
as	O
well	O
as	O
PLP	B-GENE
-	I-GENE
C	I-GENE
and	O
PLP	B-GENE
-	I-GENE
D	I-GENE
are	O
expressed	O
in	O
all	O
rat	O
strains	O
examined	O
,	O
confirming	O
that	O
PLP	B-GENE
diversity	O
is	O
not	O
due	O
to	O
strain	O
differences	O
.	O

In	O
rats	O
bearing	O
Walker	O
-	O
256	O
-	O
carcinosarcoma	O
4	O
-	O
EPI	O
was	O
effective	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Resultant	O
activation	O
of	O
c	B-GENE
-	I-GENE
Jun	I-GENE
N	I-GENE
-	I-GENE
terminal	I-GENE
kinase	I-GENE
/	I-GENE
stress	I-GENE
-	I-GENE
activated	I-GENE
protein	I-GENE
kinase	I-GENE
(	O
JNK	B-GENE
/	I-GENE
SAPK	I-GENE
)	O
.	O

This	O
makes	O
these	O
compounds	O
attractive	O
as	O
vehicles	O
for	O
these	O
and	O
other	O
gases	O
in	O
-	O
vivo	O
and	O
in	O
-	O
vitro	O
.	O

Chem	O
.	O

We	O
now	O
show	O
that	O
the	O
BAT1	B-GENE
translation	I-GENE
product	I-GENE
is	O
the	O
homolog	O
of	O
the	O
rat	B-GENE
p47	I-GENE
nuclear	I-GENE
protein	I-GENE
,	O
the	O
WM6	B-GENE
Drosophila	I-GENE
gene	I-GENE
product	I-GENE
,	O
and	O
probably	O
also	O
Ce08102	B-GENE
of	O
Caenorhabditis	O
elegans	O
,	O
all	O
members	O
of	O
the	O
DEAD	B-GENE
protein	I-GENE
family	I-GENE
of	O
ATP	B-GENE
-	I-GENE
dependent	I-GENE
RNA	I-GENE
helicases	I-GENE
.	O

In	O
synchronized	O
HeLa	O
cells	O
,	O
expression	O
of	O
luciferase	B-GENE
activity	O
was	O
induced	O
at	O
the	O
beginning	O
of	O
DNA	O
synthesis	O
and	O
was	O
dependent	O
on	O
the	O
presence	O
of	O
an	O
E2F	B-GENE
-	I-GENE
binding	I-GENE
site	I-GENE
in	O
the	O
H2A	B-GENE
.	I-GENE
1	I-GENE
promoter	I-GENE
.	O

The	O
DNA	O
binding	O
domain	O
of	O
NirA	B-GENE
was	O
expressed	O
as	O
a	O
fusion	O
protein	O
with	O
the	O
glutathione	B-GENE
S	I-GENE
-	I-GENE
transferase	I-GENE
of	O
Schistosoma	O
japonicum	O
.	O

Seventy	O
-	O
one	O
supplementary	O
doses	O
of	O
vecuronium	O
were	O
used	O
for	O
muscle	O
relaxation	O
during	O
a	O
22	O
-	O
h	O
-	O
long	O
NLA	O
II	O
anaesthesia	O
.	O

Strikingly	O
,	O
these	O
cells	O
contain	O
a	O
missense	O
mutation	O
of	O
the	O
p53	B-GENE
gene	I-GENE
at	O
codon	O
242	O
(	O
p53	O
(	O
242	O
)	O
)	O
,	O
which	O
substitutes	O
alanine	O
for	O
glycine	O
.	O

The	O
mapping	O
was	O
completed	O
with	O
Southern	O
blotting	O
and	O
restriction	O
analysis	O
.	O

Together	O
,	O
the	O
data	O
suggest	O
that	O
cAMP	O
-	O
dependent	O
control	O
of	O
the	O
amounts	O
of	O
the	O
activator	O
SF	B-GENE
-	I-GENE
1	I-GENE
vs	O
.	O
the	O
repressor	O
COUP	B-GENE
-	I-GENE
TF	I-GENE
could	O
influence	O
CRS2	O
-	O
dependent	O
transcription	O
.	O

Altogether	O
these	O
results	O
suggest	O
that	O
,	O
in	O
KG1a	O
cells	O
,	O
TNFalpha	B-GENE
can	O
stimulate	O
in	O
parallel	O
PC	B-GENE
-	I-GENE
PLC	I-GENE
and	O
PLD	B-GENE
,	O
whose	O
lipid	O
products	O
activate	O
in	O
turn	O
mitogen	B-GENE
-	I-GENE
activated	I-GENE
protein	I-GENE
kinase	I-GENE
(	O
MAP	B-GENE
kinase	I-GENE
)	O
and	O
NF	B-GENE
-	I-GENE
kappaB	I-GENE
signalling	O
respectively	O
.	O

The	O
findings	O
are	O
discussed	O
in	O
the	O
context	O
of	O
known	O
properties	O
of	O
cortical	O
-	O
bar	O
detectors	O
.	O

Human	B-GENE
alpha	I-GENE
-	I-GENE
galactosidase	I-GENE
A	I-GENE
:	O
nucleotide	O
sequence	O
of	O
a	O
cDNA	O
clone	O
encoding	O
the	O
mature	O
enzyme	O
.	O

In	O
the	O
absence	O
of	O
MHC	B-GENE
class	I-GENE
II	I-GENE
,	O
purified	B-GENE
soluble	I-GENE
D10	I-GENE
TCR	I-GENE
bound	O
to	O
Staphylococcus	B-GENE
aureus	I-GENE
enterotoxin	I-GENE
C2	I-GENE
with	O
an	O
association	O
rate	O
of	O
1	O
.	O
69	O
+	O
/	O
-	O
0	O
.	O
12	O
x	O
10	O
(	O
4	O
)	O
M	O
(	O
-	O
1	O
)	O
sec	O
(	O
-	O
1	O
)	O
and	O
a	O
dissociation	O
rate	O
of	O
1	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
47	O
x	O
10	O
(	O
-	O
2	O
)	O
sec	O
(	O
-	O
1	O
)	O
,	O
giving	O
a	O
dissociation	O
constant	O
of	O
1	O
.	O
1	O
microM	O
.	O

The	O
case	O
for	O
completing	O
the	O
lymphadenectomy	O
when	O
positive	O
lymph	O
nodes	O
are	O
found	O
during	O
radical	O
hysterectomy	O
for	O
cervical	O
carcinoma	O
.	O

To	O
further	O
characterize	O
the	O
structure	O
and	O
evolutionary	O
synthesis	O
of	O
the	O
CMT1A	B-GENE
-	I-GENE
REP	I-GENE
repeat	I-GENE
,	O
fluorescent	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
analysis	O
and	O
heterologous	O
PCR	O
-	O
based	O
assays	O
were	O
carried	O
out	O
for	O
a	O
series	O
of	O
primates	O
.	O

When	O
expressed	O
per	O
kilogram	O
body	O
weight	O
,	O
mean	O
GIT	O
increased	O
in	O
the	O
dF	O
group	O
from	O
0	O
.	O
14	O
%	O
to	O
0	O
.	O
16	O
%	O
above	O
RMR	O
,	O
with	O
a	O
significant	O
decrease	O
from	O
0	O
.	O
15	O
%	O
to	O
0	O
.	O
13	O
%	O
in	O
the	O
P	O
group	O
.	O

The	O
mature	O
chromosome	O
4	O
FRG1	B-GENE
transcript	I-GENE
is	O
1042	O
bp	O
in	O
length	O
and	O
contains	O
nine	O
exons	O
which	O
encode	O
a	O
putative	O
protein	O
of	O
258	O
amino	O
acid	O
residues	O
.	O

Various	O
transcripts	O
are	O
generated	O
from	O
the	O
VCSA1	B-GENE
gene	I-GENE
by	O
alternative	O
splicing	O
and	O
poly	O
(	O
A	O
)	O
processing	O
in	O
the	O
rat	O
submandibular	O
gland	O
.	O

A	O
stochastic	O
version	O
of	O
Kernell	O
'	O
s	O
(	O
1968	O
,	O
1972	O
)	O
model	O
with	O
cumulative	O
afterhyperpolarization	O
(	O
AHP	O
)	O
was	O
simulated	O
.	O

The	O
data	O
indicate	O
that	O
etr	B-GENE
-	I-GENE
1	I-GENE
is	O
essential	O
for	O
muscle	O
development	O
in	O
C	O
.	O
elegans	O
,	O
perhaps	O
by	O
playing	O
a	O
role	O
in	O
post	O
-	O
transcriptional	O
processing	O
of	O
some	O
muscle	O
component	O
,	O
and	O
thus	O
suggesting	O
a	O
possible	O
conservation	O
of	O
gene	O
function	O
with	O
human	B-GENE
CUG	I-GENE
-	I-GENE
bp	I-GENE
.	O

This	O
hypothesis	O
was	O
tested	O
by	O
introducing	O
mutations	O
at	O
each	O
of	O
the	O
three	O
histidine	O
pairs	O
,	O
the	O
H382	B-GENE
-	I-GENE
X2	I-GENE
-	I-GENE
H385	I-GENE
pair	I-GENE
,	O
the	O
H411	B-GENE
-	I-GENE
X2	I-GENE
-	I-GENE
H414	I-GENE
pair	I-GENE
and	O
the	O
H430	B-GENE
-	I-GENE
X5	I-GENE
-	I-GENE
H436	I-GENE
pair	I-GENE
,	O
which	O
constitute	O
the	O
histidine	O
-	O
rich	O
region	O
near	O
the	O
C	O
terminus	O
of	O
gp17	B-GENE
.	O

The	O
isolated	O
plasmin	O
fragments	O
of	O
VEGF	B-GENE
were	O
compared	O
with	O
respect	O
to	O
heparin	O
binding	O
,	O
interaction	O
with	O
soluble	O
VEGF	B-GENE
receptors	I-GENE
,	O
and	O
ability	O
to	O
promote	O
endothelial	O
cell	O
mitogenesis	O
.	O

Hepatitis	O
A	O
infected	O
food	O
handler	O
at	O
an	O
Edmonton	O
,	O
Alberta	O
retail	O
food	O
facility	O
:	O
public	O
health	O
protection	O
strategies	O
.	O

METHODS	O
:	O
126	O
patients	O
with	O
histologically	O
confirmed	O
MFH	O
were	O
analyzed	O
.	O

A	O
recently	O
reported	O
new	O
member	O
of	O
the	O
Vav	B-GENE
family	I-GENE
proteins	I-GENE
,	O
Vav3	B-GENE
has	O
been	O
identified	O
as	O
a	O
Ros	B-GENE
receptor	B-GENE
protein	I-GENE
tyrosine	I-GENE
kinase	I-GENE
(	O
RPTK	B-GENE
)	O
interacting	O
protein	O
by	O
yeast	O
two	O
-	O
hybrid	O
screening	O
.	O

Our	O
purpose	O
was	O
to	O
determine	O
if	O
intact	O
perianal	O
(	O
S4	O
-	O
5	O
)	O
pin	O
sensation	O
(	O
PPS	O
)	O
and	O
bulbocavernosus	O
(	O
S2	O
-	O
4	O
)	O
reflex	O
(	O
BCR	O
)	O
shortly	O
after	O
spinal	O
cord	O
injury	O
(	O
SCI	O
)	O
are	O
predictive	O
of	O
bladder	O
function	O
recovery	O
.	O

Further	O
studies	O
demonstrated	O
that	O
the	O
PPARalpha	B-GENE
ligand	O
8	O
(	O
S	O
)	O
-	O
hydroxyeicosatetraenoic	O
acid	O
strongly	O
promotes	O
the	O
interaction	O
of	O
PPARalpha	B-GENE
with	O
the	O
co	O
-	O
activator	O
RIP	B-GENE
-	I-GENE
140	I-GENE
but	O
decreases	O
the	O
interaction	O
of	O
PPARalpha	B-GENE
with	O
the	O
co	O
-	O
repressor	O
SMRT	B-GENE
.	O

When	O
O2	O
therapy	O
was	O
controlled	O
for	O
,	O
the	O
association	O
between	O
RBT	O
and	O
RLF	O
did	O
not	O
achieve	O
statistical	O
significance	O
(	O
P	O
=	O
.	O
07	O
)	O
.	O

In	O
the	O
brain	O
,	O
muscarinic	B-GENE
receptors	I-GENE
mediate	O
motor	O
and	O
memory	O
function	O
by	O
interaction	O
with	O
their	O
ligand	O
acetylcholine	O
.	O

Batch	O
cultures	O
of	O
S	O
.	O
mutans	O
serotype	O
a	O
demonstrated	O
no	O
growth	O
on	O
MSB	O
agar	O
.	O

Management	O
often	O
involves	O
beta	O
-	O
and	O
calcium	O
channel	O
blocking	O
drugs	O
or	O
type	O
IC	O
antiarrhythmic	O
drugs	O
.	O

Sensitivity	O
and	O
specificity	O
was	O
established	O
for	O
the	O
Pharmacia	O
CAP	O
System	O
and	O
the	O
DPC	O
AlaSTAT	O
System	O
by	O
comparison	O
with	O
results	O
of	O
the	O
skin	O
prick	O
test	O
.	O

The	O
interferon	O
-	O
inducible	O
protein	B-GENE
kinase	I-GENE
PKR	I-GENE
modulates	O
the	O
transcriptional	O
activation	O
of	O
immunoglobulin	B-GENE
kappa	I-GENE
gene	I-GENE
.	O

We	O
report	O
a	O
case	O
of	O
vasculitis	O
(	O
cutaneous	O
and	O
neurologic	O
)	O
which	O
led	O
to	O
the	O
discovery	O
of	O
a	O
selective	O
immunodeficit	O
towards	O
EBV	O
,	O
similar	O
to	O
Purtilo	O
'	O
s	O
syndrome	O
.	O

A	O
stretch	O
of	O
16	O
nucleotides	O
just	O
upstream	O
of	O
the	O
IL	B-GENE
-	I-GENE
4RE	I-GENE
contributed	O
to	O
IL	B-GENE
-	I-GENE
4	I-GENE
inducibility	O
and	O
formed	O
nucleoprotein	O
complexes	O
with	O
constitutive	O
factors	O
.	O

Inhibition	O
appears	O
to	O
result	O
from	O
titration	O
of	O
general	O
transcription	O
factors	O
because	O
MDM2	B-GENE
overexpression	O
inhibits	O
c	B-GENE
-	I-GENE
fos	I-GENE
as	O
well	O
as	O
other	O
promoters	O
in	O
vivo	O
and	O
basal	O
transcription	O
in	O
vitro	O
.	O

A	O
13	O
-	O
bp	O
cis	O
-	O
regulatory	O
element	O
in	O
the	O
LTR	O
promoter	O
of	O
the	O
tobacco	B-GENE
retrotransposon	I-GENE
Tto1	I-GENE
is	O
involved	O
in	O
responsiveness	O
to	O
tissue	O
culture	O
,	O
wounding	O
,	O
methyl	O
jasmonate	O
and	O
fungal	O
elicitors	O
.	O

Serum	O
leptin	B-GENE
concentrations	O
in	O
women	O
during	O
gonadotropin	B-GENE
stimulation	O
cycles	O
.	O

In	O
this	O
study	O
,	O
we	O
purified	O
and	O
characterized	O
the	O
recombinant	B-GENE
furin	I-GENE
from	O
the	O
conditioned	O
medium	O
of	O
these	O
cells	O
.	O

The	O
presence	O
of	O
regulatory	O
sequences	O
for	O
the	O
binding	O
of	O
transcription	O
factors	O
such	O
as	O
NF	B-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
and	O
AP	B-GENE
-	I-GENE
2	I-GENE
,	O
whose	O
activation	O
is	O
associated	O
with	O
the	O
immediate	O
response	O
of	O
the	O
cell	O
to	O
an	O
injury	O
,	O
may	O
be	O
an	O
indication	O
of	O
the	O
important	O
role	O
which	O
HO	B-GENE
-	I-GENE
1	I-GENE
may	O
play	O
in	O
defense	O
mechanisms	O
against	O
tissue	O
injury	O
.	O

Moreover	O
,	O
the	O
effect	O
exerted	O
by	O
TIS1	B-GENE
appeared	O
to	O
be	O
selective	O
for	O
the	O
MCK	B-GENE
promoter	I-GENE
.	O

CD7	B-GENE
+	I-GENE
/	I-GENE
CD3	I-GENE
-	I-GENE
T	O
-	O
cell	O
precursors	O
exhibit	O
V	B-GENE
delta	I-GENE
2D	I-GENE
delta	I-GENE
3	I-GENE
rearrangements	I-GENE
.	O

GCR1	B-GENE
gene	I-GENE
function	O
is	O
required	O
for	O
high	O
-	O
level	O
glycolytic	O
gene	O
expression	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

Crohn	O
'	O
s	O
disease	O
in	O
prolonged	O
remission	O
:	O
should	O
one	O
augment	O
protein	O
-	O
calorie	O
intake	O
as	O
compared	O
to	O
healthy	O
subjects	O
?	O
The	O
aim	O
of	O
our	O
two	O
year	O
prospective	O
study	O
was	O
to	O
evaluate	O
whether	O
adult	O
Crohn	O
'	O
s	O
disease	O
patients	O
in	O
prolonged	O
remission	O
(	O
CDAI	O
<	O
150	O
)	O
,	O
in	O
order	O
to	O
maintain	O
their	O
body	O
weight	O
as	O
close	O
as	O
possible	O
to	O
the	O
ideal	O
one	O
,	O
need	O
a	O
protein	O
-	O
calorie	O
intake	O
higher	O
than	O
the	O
predicted	O
one	O
and	O
that	O
of	O
healthy	O
controls	O
.	O

We	O
are	O
reporting	O
an	O
autopsy	O
case	O
of	O
so	O
-	O
called	O
"	O
acute	O
multiple	O
sclerosis	O
"	O
that	O
was	O
difficult	O
to	O
differentiate	O
from	O
a	O
brain	O
tumor	O
on	O
MRI	O
findings	O
.	O

Thus	O
,	O
this	O
study	O
provides	O
evidence	O
that	O
a	O
novel	O
,	O
ubiquitous	O
factor	O
(	O
HF	B-GENE
-	I-GENE
1a	I-GENE
)	O
and	O
a	O
muscle	O
factor	O
(	O
HF	B-GENE
-	I-GENE
1b	I-GENE
/	I-GENE
MEF	I-GENE
-	I-GENE
2	I-GENE
)	O
can	O
form	O
a	O
novel	O
,	O
E	O
-	O
box	O
-	O
independent	O
pathway	O
for	O
muscle	O
-	O
specific	O
expression	O
in	O
ventricular	O
cardiac	O
muscle	O
cells	O
.	O

Thyroid	O
function	O
tests	O
were	O
performed	O
on	O
300	O
admissions	O
,	O
leaving	O
707	O
untested	O
.	O

Molecular	O
cloning	O
and	O
expression	O
of	O
RPE65	B-GENE
,	O
a	O
novel	O
retinal	O
pigment	O
epithelium	O
-	O
specific	O
microsomal	O
protein	O
that	O
is	O
post	O
-	O
transcriptionally	O
regulated	O
in	O
vitro	O
.	O

The	O
concentrations	O
of	O
apo	B-GENE
A	I-GENE
-	I-GENE
I	I-GENE
and	O
apo	B-GENE
A	I-GENE
-	I-GENE
II	I-GENE
of	O
abstainers	O
decreased	O
significantly	O
compared	O
with	O
the	O
corresponding	O
changes	O
in	O
controls	O
.	O

Inclusion	O
of	O
the	O
extended	O
N	O
terminus	O
into	O
the	O
originally	O
reported	O
protein	O
resulted	O
in	O
a	O
striking	O
similarity	O
to	O
the	O
lymphoid	B-GENE
factor	I-GENE
Lef	I-GENE
-	I-GENE
1	I-GENE
.	O

These	O
results	O
provide	O
the	O
first	O
demonstration	O
that	O
an	O
SR	B-GENE
protein	I-GENE
can	O
influence	O
splicing	O
of	O
specific	O
pre	O
-	O
mRNAs	O
in	O
vivo	O
.	O

Yeast	O
mutants	O
assigned	O
to	O
the	O
pet	O
complementation	O
group	O
G104	O
were	O
found	O
to	O
lack	O
alpha	B-GENE
-	I-GENE
ketoglutarate	I-GENE
dehydrogenase	I-GENE
activity	O
as	O
a	O
result	O
of	O
mutations	O
in	O
the	O
dihydrolipoyl	B-GENE
transsuccinylase	I-GENE
(	O
KE2	B-GENE
)	O
component	O
of	O
the	O
complex	O
.	O

We	O
show	O
,	O
by	O
injection	O
of	O
synthetic	O
mRNAs	O
,	O
that	O
the	O
cis	O
-	O
acting	O
sequences	O
responsible	O
for	O
repression	O
of	O
cyclin	B-GENE
B1	I-GENE
mRNA	I-GENE
reside	O
within	O
its	O
3	O
'	O
UTR	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
sensitivity	O
and	O
specificity	O
of	O
AMP	O
CT	O
(	O
Gen	O
-	O
Probe	O
Incorporated	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
on	O
urogenital	O
specimens	O
taken	O
from	O
symptomatic	O
patients	O
and	O
on	O
first	O
void	O
urine	O
(	O
FVU	O
)	O
specimens	O
from	O
asymptomatic	O
patients	O
.	O

The	O
range	O
of	O
eosinophils	O
was	O
22	O
-	O
56	O
%	O
of	O
the	O
number	O
of	O
peripheral	O
white	O
blood	O
cells	O
(	O
mean	O
nadir	O
33	O
%	O
)	O
.	O

There	O
were	O
35	O
boys	O
and	O
15	O
girls	O
,	O
with	O
a	O
mean	O
age	O
of	O
five	O
and	O
a	O
half	O
years	O
.	O

Analysis	O
of	O
mig	B-GENE
/	I-GENE
CAT	I-GENE
chimeric	O
constructs	O
transiently	O
transfected	O
into	O
the	O
RAW	O
264	O
.	O
7	O
mouse	O
monocytic	O
cell	O
line	O
revealed	O
a	O
unique	O
IFN	B-GENE
-	I-GENE
gamma	I-GENE
-	I-GENE
responsive	I-GENE
element	I-GENE
(	O
gamma	B-GENE
RE	I-GENE
-	I-GENE
1	I-GENE
)	O
.	O

In	O
most	O
cases	O
,	O
DR4	O
-	O
homozygous	O
,	O
DRB1	O
-	O
heterozygous	O
individuals	O
could	O
be	O
genotyped	O
with	O
the	O
panel	O
of	O
probes	O
.	O

In	O
study	O
2	O
,	O
the	O
correlation	O
coefficients	O
between	O
the	O
ISO2	O
measurements	O
obtained	O
at	O
the	O
ulcer	O
margin	O
and	O
at	O
the	O
adjacent	O
normal	O
mucosa	O
,	O
and	O
delta	O
ISO2	O
obtained	O
by	O
the	O
experienced	O
observer	O
and	O
one	O
of	O
the	O
three	O
learners	O
were	O
0	O
.	O
94	O
,	O
0	O
.	O
97	O
,	O
and	O
0	O
.	O
94	O
,	O
respectively	O
.	O

More	O
specific	O
adverse	O
events	O
,	O
also	O
frequently	O
considered	O
as	O
dose	O
-	O
limiting	O
toxicities	O
,	O
include	O
hypotension	O
with	O
IL	B-GENE
-	I-GENE
1	I-GENE
,	O
severe	O
headache	O
or	O
skin	O
rash	O
with	O
IL	B-GENE
-	I-GENE
3	I-GENE
,	O
and	O
nasal	O
congestion	O
and	O
gastroduodenal	O
lesions	O
with	O
IL	B-GENE
-	I-GENE
4	I-GENE
.	O

Much	O
evidence	O
indicates	O
that	O
p38	B-GENE
is	O
an	O
activator	O
of	O
MyoD	B-GENE
:	O
(	O
i	O
)	O
p38	B-GENE
kinase	I-GENE
activity	O
is	O
required	O
for	O
the	O
expression	O
of	O
MyoD	B-GENE
-	I-GENE
responsive	I-GENE
genes	I-GENE
,	O
(	O
ii	O
)	O
enforced	O
induction	O
of	O
p38	B-GENE
stimulates	O
the	O
transcriptional	O
activity	O
of	O
a	O
Gal4	B-GENE
-	I-GENE
MyoD	I-GENE
fusion	I-GENE
protein	I-GENE
and	O
allows	O
efficient	O
activation	O
of	O
chromatin	O
-	O
integrated	O
reporters	O
by	O
MyoD	B-GENE
,	O
and	O
(	O
iii	O
)	O
MyoD	O
-	O
dependent	O
myogenic	O
conversion	O
is	O
reduced	O
in	O
mouse	O
embryonic	O
fibroblasts	O
derived	O
from	O
p38alpha	B-GENE
(	I-GENE
-	I-GENE
/	I-GENE
-	I-GENE
)	I-GENE
embryos	O
.	O

Magnetic	O
storm	O
indicators	O
could	O
be	O
used	O
in	O
medicine	O
,	O
in	O
geophysics	O
and	O
for	O
special	O
purposes	O
.	O

However	O
,	O
a	O
strongly	O
increased	O
frequency	O
of	O
CpG	O
dinucleotides	O
was	O
found	O
.	O

Thus	O
,	O
as	O
expected	O
,	O
trans	O
-	O
splicing	O
depends	O
on	O
the	O
integrity	O
of	O
U2	B-GENE
,	O
U4	B-GENE
,	O
and	O
U6	B-GENE
snRNAs	I-GENE
.	O

An	O
exaggerated	O
tissue	O
response	O
adjacent	O
to	O
the	O
cyanoacrylate	O
site	O
suggested	O
a	O
potential	O
toxic	O
chemical	O
or	O
thermal	O
reaction	O
,	O
or	O
both	O
,	O
to	O
the	O
tissue	O
adhesive	O
,	O
but	O
there	O
was	O
no	O
evidence	O
of	O
any	O
distant	O
ocular	O
effects	O
.	O

The	O
protein	O
folds	O
correctly	O
with	O
two	O
disulfide	O
bonds	O
and	O
a	O
free	O
thiol	O
group	O
at	O
Cys25	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
footprinting	O
and	O
gel	O
mobility	O
retardation	O
assays	O
to	O
reveal	O
that	O
bacterially	O
synthesized	O
Zta	B-GENE
fusion	I-GENE
proteins	I-GENE
bound	O
directly	O
to	O
six	O
TGTGCAA	B-GENE
-	I-GENE
like	I-GENE
motifs	I-GENE
within	O
DSL	B-GENE
.	O

Dsh	B-GENE
is	O
required	O
for	O
two	O
different	O
pathways	O
,	O
the	O
Wnt	B-GENE
pathway	O
and	O
planar	O
polarity	O
pathway	O
in	O
Drosophila	O
.	O

The	O
C2C	B-GENE
-	I-GENE
Prx	I-GENE
is	O
encoded	O
as	O
a	O
preprotein	O
of	O
273	O
amino	O
acids	O
containing	O
a	O
putative	O
chloroplast	O
-	O
targeting	O
signal	O
of	O
65	O
amino	O
acids	O
at	O
its	O
N	O
-	O
terminus	O
.	O

In	O
throttling	O
valves	O
,	O
the	O
aim	O
is	O
to	O
correlate	O
the	O
effect	O
of	O
shear	O
to	O
a	O
parameter	O
related	O
to	O
the	O
inner	O
geometry	O
of	O
the	O
valve	O
and	O
to	O
operating	O
conditions	O
.	O

Here	O
we	O
show	O
in	O
mouse	O
fibroblasts	O
stably	O
transformed	O
by	O
v	B-GENE
-	I-GENE
Src	I-GENE
that	O
mRNA	O
and	O
protein	O
levels	O
of	O
p21	B-GENE
(	O
WAF1	B-GENE
/	I-GENE
CIP1	I-GENE
)	O
,	O
cyclin	B-GENE
D1	I-GENE
,	O
and	O
cyclin	B-GENE
E	I-GENE
are	O
elevated	O
.	O

These	O
experiments	O
confirm	O
that	O
the	O
6	O
-	O
S	O
liganded	O
form	O
of	O
the	O
receptor	O
identified	O
in	O
nuclear	O
extracts	O
of	O
cells	O
treated	O
with	O
2	O
,	O
3	O
,	O
7	O
,	O
8	O
-	O
tetrachlorodibenzo	O
-	O
p	O
-	O
dioxin	O
(	O
TCDD	O
)	O
contains	O
the	O
Ah	B-GENE
receptor	I-GENE
protein	I-GENE
and	O
ARNT	B-GENE
but	O
not	O
the	O
90	B-GENE
-	I-GENE
kDa	I-GENE
heat	I-GENE
shock	I-GENE
protein	I-GENE
.	O

These	O
children	O
were	O
grouped	O
into	O
four	O
diagnostic	O
categories	O
:	O
1	O
)	O
idiopathic	O
GH	B-GENE
deficiency	O
(	O
n	O
=	O
10	O
)	O
;	O
2	O
)	O
organic	O
hypopituitarism	O
(	O
n	O
=	O
7	O
)	O
;	O
3	O
)	O
intrauterine	O
growth	O
retardation	O
(	O
n	O
=	O
5	O
)	O
;	O
and	O
4	O
)	O
constitutional	O
delay	O
of	O
growth	O
and	O
/	O
or	O
familial	O
short	O
stature	O
(	O
n	O
=	O
18	O
)	O
,	O
by	O
standard	O
clinical	O
criteria	O
and	O
physiological	O
and	O
pharmacological	O
tests	O
of	O
GH	B-GENE
reserve	O
.	O

A	O
total	O
of	O
125	O
acute	O
leukemia	O
adult	O
patients	O
were	O
autografted	O
with	O
bone	O
marrow	O
(	O
BM	O
)	O
purged	O
by	O
mafosfamide	O
(	O
ASTA	O
Z	O
)	O
during	O
the	O
period	O
of	O
January	O
1983	O
to	O
January	O
1993	O
.	O

Members	O
of	O
the	O
meis1	B-GENE
and	O
pbx	B-GENE
homeodomain	I-GENE
protein	I-GENE
families	I-GENE
cooperatively	O
bind	O
a	O
cAMP	B-GENE
-	I-GENE
responsive	I-GENE
sequence	I-GENE
(	O
CRS1	B-GENE
)	O
from	O
bovine	B-GENE
CYP17	I-GENE
.	O

We	O
have	O
investigated	O
the	O
contribution	O
of	O
specific	O
TATA	B-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
(	O
TBP	B-GENE
)	O
-	O
TATA	O
interactions	O
to	O
the	O
promoter	O
activity	O
of	O
a	O
constitutively	O
expressed	O
silkworm	B-GENE
tRNA	I-GENE
(	I-GENE
C	I-GENE
)	I-GENE
(	I-GENE
Ala	I-GENE
)	I-GENE
gene	I-GENE
and	O
have	O
also	O
asked	O
whether	O
the	O
lack	O
of	O
similar	O
interactions	O
accounts	O
for	O
the	O
low	O
promoter	O
activity	O
of	O
a	O
silk	B-GENE
gland	I-GENE
-	I-GENE
specific	I-GENE
tRNA	I-GENE
(	I-GENE
SG	I-GENE
)	I-GENE
(	I-GENE
Ala	I-GENE
)	I-GENE
gene	I-GENE
.	O

Differences	O
in	O
the	O
clinical	O
presentation	O
and	O
the	O
gross	O
appearance	O
of	O
the	O
two	O
cases	O
are	O
described	O
,	O
and	O
similarities	O
in	O
the	O
microscopic	O
features	O
are	O
discussed	O
.	O

Superoxide	B-GENE
dismutase	I-GENE
(	O
SOD	B-GENE
)	O
activity	O
decreased	O
significantly	O
in	O
sperm	O
subjected	O
to	O
direct	O
electric	O
current	O
in	O
comparison	O
to	O
the	O
control	O
or	O
the	O
sample	O
incubated	O
with	O
electrolyzed	O
medium	O
.	O

Thus	O
,	O
in	O
normal	O
intestinal	O
epithelial	O
goblet	O
cells	O
,	O
TbetaRI	B-GENE
and	O
TbetaRII	B-GENE
can	O
respond	O
to	O
autocrine	O
but	O
not	O
exogenous	O
TGF	B-GENE
-	I-GENE
beta	I-GENE
without	O
the	O
participation	O
of	O
TbetaRIII	B-GENE
.	O

Reverse	O
transcription	O
-	O
PCR	O
was	O
then	O
used	O
to	O
clone	O
from	O
human	O
poly	O
(	O
A	O
)	O
+	O
RNA	O
the	O
cDNA	O
corresponding	O
to	O
the	O
expressed	O
homolog	O
of	O
psi	B-GENE
ARF	I-GENE
4	I-GENE
,	O
referred	O
to	O
as	O
human	B-GENE
ARF	I-GENE
4	I-GENE
.	O

A	O
full	B-GENE
-	I-GENE
length	I-GENE
PRL	I-GENE
receptor	I-GENE
(	O
PRLR	B-GENE
)	O
complementary	O
DNA	O
from	O
pigeons	O
was	O
obtained	O
by	O
screening	O
pigeon	O
crop	O
sac	O
libraries	O
and	O
by	O
reverse	O
transcription	O
coupled	O
with	O
polymerase	B-GENE
chain	O
reaction	O
.	O

Individual	O
mutations	O
in	O
motifs	B-GENE
III	I-GENE
,	I-GENE
IV	I-GENE
,	I-GENE
and	I-GENE
V	I-GENE
had	O
distinctive	O
effects	O
on	O
the	O
affinity	O
of	O
enzyme	O
for	O
GTP	O
,	O
the	O
rate	O
of	O
covalent	O
catalysis	O
(	O
EpG	O
formation	O
)	O
,	O
or	O
the	O
transfer	O
of	O
GMP	O
from	O
enzyme	O
to	O
RNA	O
.	O

Mutagenesis	O
of	O
each	O
NRF	B-GENE
-	I-GENE
1	I-GENE
motif	I-GENE
in	O
the	O
ALAS	B-GENE
promoter	I-GENE
gave	O
substantially	O
lowered	O
levels	O
of	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
expression	O
,	O
whereas	O
mutagenesis	O
of	O
both	O
NRF	B-GENE
-	I-GENE
1	I-GENE
motifs	I-GENE
resulted	O
in	O
the	O
almost	O
complete	O
loss	O
of	O
expression	O
.	O

The	O
C	O
-	O
terminal	O
mutants	O
were	O
strongly	O
dominant	O
over	O
TraR	B-GENE
,	O
suggesting	O
that	O
they	O
can	O
form	O
heteromultimers	O
with	O
the	O
wild	O
-	O
type	O
activator	O
.	O

The	O
major	O
RNase	B-GENE
E	I-GENE
cleavage	O
product	O
(	O
denoted	O
pSok	B-GENE
-	I-GENE
6	I-GENE
)	O
is	O
rapidly	O
degraded	O
by	O
polynucleotide	B-GENE
phosphorylase	I-GENE
(	O
PNPase	B-GENE
)	O
.	O

Gel	O
mobility	O
shift	O
assays	O
using	O
a	O
synthetic	O
E6	B-GENE
motif	I-GENE
detected	O
a	O
B	O
-	O
cell	O
-	O
specific	O
complex	O
in	O
addition	O
to	O
a	O
ubiquitous	O
band	O
found	O
also	O
in	O
T	O
cells	O
and	O
HeLa	O
cells	O
.	O

Mutations	O
in	O
either	O
gene	O
block	O
some	O
crucial	O
late	O
step	O
in	O
assembly	O
of	O
F1	B-GENE
,	O
causing	O
the	O
alpha	O
and	O
beta	O
subunits	O
to	O
accumulate	O
in	O
mitochondria	O
as	O
inactive	O
aggregates	O
(	O
Ackerman	O
,	O
S	O
.	O

Sp1	B-GENE
and	O
two	O
Sp3	B-GENE
isoforms	I-GENE
were	O
detected	O
as	O
the	O
primary	O
cellular	O
constituents	O
of	O
DNA	O
-	O
protein	O
complexes	O
formed	O
with	O
the	O
NF	B-GENE
-	I-GENE
kappaB	I-GENE
-	I-GENE
proximal	I-GENE
site	I-GENE
.	O

Strains	O
bearing	O
the	O
drs2	B-GENE
mutation	I-GENE
process	O
the	O
20S	B-GENE
precursor	I-GENE
of	O
the	O
mature	B-GENE
18S	I-GENE
rRNA	I-GENE
slowly	O
and	O
are	O
deficient	O
in	O
40S	B-GENE
ribosomal	I-GENE
subunits	I-GENE
.	O

We	O
observed	O
abundant	O
levels	O
of	O
Rev	B-GENE
-	I-GENE
erbA	I-GENE
alpha	I-GENE
mRNA	I-GENE
in	O
dividing	O
C2C12	O
myoblasts	O
,	O
which	O
were	O
suppressed	O
when	O
the	O
cells	O
differentiated	O
into	O
postmitotic	O
multinucleated	O
myotubes	O
.	O

The	O
recovery	O
of	O
labelled	O
methoxydextrane	O
is	O
98	O
+	O
/	O
-	O
7	O
%	O
.	O

RESULTS	O
:	O
The	O
overall	O
FNF	O
for	O
1992	O
was	O
12	O
.	O
3	O
%	O
and	O
was	O
19	O
.	O
1	O
%	O
,	O
22	O
.	O
2	O
%	O
,	O
3	O
.	O
8	O
%	O
and	O
6	O
.	O
1	O
%	O
per	O
successive	O
quarters	O
in	O
1992	O
.	O

In	O
cerebrospinal	O
fluid	O
,	O
an	O
ADA	B-GENE
catalytic	O
concentration	O
above	O
0	O
.	O
15	O
mu	O
kat	O
/	O
L	O
strongly	O
suggests	O
tuberculous	O
meningitis	O
in	O
patients	O
older	O
than	O
7	O
years	O
(	O
sensitivity	O
1	O
.	O
00	O
,	O
specificity	O
0	O
.	O
99	O
and	O
efficiency	O
0	O
.	O
99	O
)	O
.	O

Along	O
with	O
previously	O
mapped	O
genes	O
including	O
Ly	B-GENE
-	I-GENE
1	I-GENE
and	O
CD20	B-GENE
,	O
OSBP	B-GENE
defines	O
a	O
new	O
conserved	O
syntenic	O
group	O
on	O
the	O
long	O
arm	O
of	O
chromosome	O
11	O
in	O
the	O
human	O
and	O
the	O
proximal	O
end	O
of	O
chromosome	O
19	O
in	O
the	O
mouse	O
.	O

The	O
proteins	O
are	O
more	O
than	O
90	O
%	O
identical	O
to	O
each	O
other	O
within	O
the	O
protein	B-GENE
kinase	I-GENE
domain	I-GENE
but	O
only	O
51	O
-	O
59	O
%	O
identical	O
to	O
other	O
casein	B-GENE
kinase	I-GENE
I	I-GENE
isoforms	I-GENE
within	O
this	O
region	O
.	O

The	O
conserved	O
ninth	O
C	O
-	O
terminal	O
heptad	O
in	O
thyroid	O
hormone	O
and	O
retinoic	B-GENE
acid	I-GENE
receptors	I-GENE
mediates	O
diverse	O
responses	O
by	O
affecting	O
heterodimer	O
but	O
not	O
homodimer	O
formation	O
.	O

Secondly	O
,	O
an	O
ethanol	B-GENE
repression	I-GENE
autoregulation	I-GENE
(	I-GENE
ERA	I-GENE
)	I-GENE
/	I-GENE
twelve	I-GENE
-	I-GENE
fold	I-GENE
TA	I-GENE
repeat	I-GENE
(	I-GENE
TAB	I-GENE
)	I-GENE
repressor	I-GENE
element	I-GENE
was	O
identified	O
within	O
the	O
promoter	O
region	O
of	O
the	O
GLK1	B-GENE
gene	I-GENE
.	O

With	O
a	O
sample	O
of	O
mothers	O
of	O
healthy	O
infants	O
,	O
all	O
three	O
subscales	O
of	O
the	O
revised	O
instrument	O
,	O
WPL	O
-	O
R	O
,	O
had	O
acceptable	O
levels	O
of	O
internal	O
consistency	O
at	O
7	O
,	O
30	O
,	O
and	O
90	O
days	O
postpartum	O
,	O
and	O
stability	O
across	O
administrations	O
.	O

These	O
results	O
implicate	O
a	O
precursor	O
-	O
specific	O
base	O
-	O
paired	O
structure	O
involving	O
sequences	O
on	O
both	O
sides	O
of	O
the	O
mature	O
cleavage	O
site	O
in	O
the	O
3	O
'	O
processing	O
of	O
human	B-GENE
U2	I-GENE
RNA	I-GENE
.	O

To	O
further	O
understand	O
the	O
role	O
of	O
cis	O
-	O
acting	O
elements	O
in	O
these	O
regulatory	O
mechanisms	O
,	O
we	O
have	O
characterized	O
a	O
transcriptional	O
promoter	O
that	O
drives	O
germline	O
expression	O
of	O
TCR	B-GENE
beta	I-GENE
gene	I-GENE
segments	I-GENE
in	O
vivo	O
.	O

It	O
corresponds	O
to	O
the	O
complete	O
mitochondrial	O
presequence	O
and	O
the	O
lipoyl	O
-	O
bearing	O
domain	O
that	O
are	O
encoded	O
by	O
exons	O
I	O
through	O
IV	O
of	O
the	O
functional	O
E2	B-GENE
gene	I-GENE
.	O

Viscosity	O
experiments	O
on	O
the	O
catalytic	O
fragment	O
kinase	B-GENE
reaction	O
demonstrated	O
that	O
the	O
chemical	O
(	O
phosphoryl	O
transfer	O
)	O
step	O
had	O
a	O
reduced	O
rate	O
.	O

To	O
define	O
the	O
mechanism	O
responsible	O
for	O
the	O
loss	O
of	O
transcription	O
elongation	O
blockage	O
and	O
resulting	O
c	B-GENE
-	I-GENE
myc	I-GENE
deregulation	O
in	O
Burkitt	O
'	O
s	O
lymphoma	O
,	O
we	O
analyzed	O
transcription	O
patterns	O
after	O
transfer	O
of	O
normal	O
and	O
Burkitt	O
'	O
s	O
lymphoma	O
c	B-GENE
-	I-GENE
myc	I-GENE
alleles	O
into	O
murine	O
cells	O
and	O
Xenopus	O
oocyte	O
germinal	O
vesicles	O
.	O

Mutation	O
analyses	O
identified	O
the	O
cobalt	O
-	O
responsive	O
sequences	O
as	O
the	O
stress	B-GENE
-	I-GENE
response	I-GENE
elements	I-GENE
(	O
StREs	B-GENE
)	O
.	O

Space	O
limitations	O
prevent	O
an	O
exhaustive	O
review	O
of	O
all	O
biologic	O
pharmaceuticals	O
,	O
such	O
as	O
tissue	B-GENE
plasminogen	I-GENE
activating	I-GENE
substance	I-GENE
,	O
hormones	O
(	O
e	O
.	O
g	O
.	O
,	O
thyroid	O
,	O
insulin	B-GENE
,	O
growth	B-GENE
hormone	I-GENE
,	O
erythropoietin	B-GENE
)	O
,	O
clotting	O
factors	O
,	O
and	O
blood	O
products	O
.	O

Molecular	O
characterization	O
of	O
type	B-GENE
-	I-GENE
specific	I-GENE
capsular	I-GENE
polysaccharide	I-GENE
biosynthesis	I-GENE
genes	I-GENE
of	I-GENE
Streptococcus	I-GENE
agalactiae	I-GENE
type	I-GENE
Ia	O
.	O

The	O
model	O
also	O
predicts	O
that	O
blood	O
flow	O
shunt	O
fraction	O
(	O
Qs	O
/	O
QT	O
)	O
is	O
directly	O
related	O
to	O
the	O
oxygen	O
sine	O
-	O
wave	O
amplitude	O
perturbations	O
transmitted	O
to	O
end	O
-	O
expired	O
air	O
and	O
arterial	O
and	O
mixed	O
-	O
venous	O
blood	O
through	O
two	O
simple	O
equations	O
.	O

Filter	O
and	O
cytocentrifuge	O
preparations	O
of	O
the	O
urine	O
were	O
studied	O
and	O
all	O
cases	O
displayed	O
numerous	O
scattered	O
aggregates	O
or	O
single	O
tumor	O
cells	O
in	O
an	O
inflammatory	O
background	O
.	O

Mean	O
longitudinal	O
extension	O
of	O
the	O
epidural	O
lesion	O
was	O
2	O
.	O
6	O
vertebral	O
segments	O
.	O

The	O
effects	O
of	O
these	O
mutations	O
on	O
RNA	B-GENE
polymerase	I-GENE
II	I-GENE
activity	O
were	O
assayed	O
by	O
measuring	O
the	O
ability	O
of	O
mutant	O
genes	O
to	O
confer	O
alpha	B-GENE
-	I-GENE
amanitin	I-GENE
resistance	O
after	O
transfection	O
of	O
susceptible	O
rodent	O
cells	O
.	O

Cis	O
-	O
acting	O
CCAAT	B-GENE
elements	I-GENE
are	O
frequently	O
found	O
in	O
eukaryotic	O
promoter	O
regions	O
.	O

Expression	O
of	O
Bcl	B-GENE
-	I-GENE
XL	I-GENE
inhibited	O
the	O
association	O
of	O
Apaf	B-GENE
-	I-GENE
1	I-GENE
with	O
caspase	B-GENE
-	I-GENE
9	I-GENE
in	O
mammalian	O
cells	O
.	O

SF	B-GENE
-	I-GENE
1	I-GENE
does	O
not	O
have	O
an	O
N	B-GENE
-	I-GENE
terminal	I-GENE
AF1	I-GENE
domain	I-GENE
.	O

Basing	O
on	O
experimental	O
toxicity	O
research	O
it	O
was	O
established	O
that	O
,	O
out	O
of	O
50	O
atmosphere	O
metal	O
corrosion	O
inhibitors	O
,	O
some	O
14	O
per	O
cent	O
were	O
found	O
extremely	O
hazardous	O
,	O
42	O
per	O
cent	O
-	O
-	O
of	O
high	O
level	O
hazardous	O
,	O
33	O
percent	O
-	O
-	O
of	O
moderate	O
and	O
11	O
per	O
cent	O
-	O
-	O
of	O
low	O
hazardous	O
.	O

Paralemmin	B-GENE
is	O
also	O
phosphorylated	O
,	O
and	O
its	O
mRNA	O
is	O
differentially	O
spliced	O
in	O
a	O
tissue	O
-	O
specific	O
and	O
developmentally	O
regulated	O
manner	O
.	O

Azygos	O
vein	O
abutting	O
the	O
posterior	O
wall	O
of	O
the	O
right	O
main	O
and	O
upper	O
lobe	O
bronchi	O
:	O
a	O
normal	O
CT	O
variant	O
.	O

We	O
also	O
report	O
that	O
AHR	B-GENE
interacts	O
with	O
COUP	B-GENE
-	I-GENE
TF	I-GENE
in	O
transfected	O
CV	O
-	O
1	O
cells	O
.	O

Acute	O
pancreatitis	O
as	O
a	O
complication	O
of	O
polyarteritis	O
nodosa	O
.	O

Cluster	O
formation	O
of	O
E	B-GENE
-	I-GENE
cadherin	I-GENE
on	O
the	O
cell	O
surface	O
is	O
believed	O
to	O
be	O
of	O
major	O
importance	O
for	O
cell	O
-	O
cell	O
adhesion	O
.	O

DPA	O
attenuated	O
the	O
increase	O
of	O
the	O
intensity	O
of	O
the	O
ischemic	O
and	O
pressure	O
pain	O
components	O
with	O
increasing	O
ischemia	O
duration	O
,	O
but	O
only	O
the	O
effect	O
on	O
the	O
pressure	O
pain	O
component	O
was	O
significant	O
.	O

Following	O
seven	O
days	O
'	O
incubation	O
both	O
at	O
20	O
degrees	O
C	O
and	O
28	O
degrees	O
C	O
,	O
Ae	O
.	O
vexans	O
nip	O
.	O
was	O
capable	O
of	O
transmitting	O
the	O
virus	O
.	O

Interplane	O
coupling	O
in	O
the	O
superconductor	O
Y2Ba4Cu7O15	O
as	O
revealed	O
by	O
NQR	O
spin	O
-	O
echo	O
double	O
resonance	O
.	O

The	O
evidence	O
in	O
support	O
of	O
this	O
was	O
derived	O
from	O
the	O
fact	O
that	O
the	O
affinity	O
or	O
interaction	O
between	O
the	O
two	O
subunits	O
was	O
impaired	O
as	O
indicated	O
by	O
the	O
first	O
order	O
rate	O
constant	O
of	O
hCG	B-GENE
alpha	I-GENE
1	I-GENE
beta	I-GENE
(	O
km	O
=	O
4	O
.	O
1	O
x	O
10	O
(	O
-	O
2	O
)	O
min	O
-	O
1	O
)	O
at	O
pH	O
3	O
.	O
0	O
at	O
23	O
degrees	O
C	O
which	O
is	O
one	O
order	O
of	O
magnitude	O
greater	O
relative	O
to	O
rehCG	B-GENE
(	O
kw	O
=	O
4	O
.	O
6	O
x	O
10	O
(	O
-	O
3	O
)	O
min	O
-	O
1	O
)	O
.	O

Correlation	O
coefficients	O
between	O
the	O
reference	O
methods	O
and	O
NIT	O
were	O
>	O
or	O
=	O
0	O
.	O
95	O
for	O
water	O
,	O
fat	O
,	O
crude	O
protein	O
and	O
connective	O
-	O
tissue	O
-	O
protein	O
frei	O
meat	O
protein	O
,	O
and	O
>	O
or	O
=	O
0	O
.	O
86	O
for	O
connective	O
-	O
tissue	O
-	O
protein	O
.	O

Further	O
analysis	O
of	O
AP	B-GENE
-	I-GENE
1	I-GENE
DNA	O
binding	O
activities	O
in	O
7	O
-	O
to	O
14	O
-	O
day	O
culture	O
activated	O
HSCs	O
led	O
to	O
the	O
discovery	O
of	O
high	B-GENE
mobility	I-GENE
AP	I-GENE
-	I-GENE
1	I-GENE
complexes	I-GENE
(	O
HMAP	B-GENE
-	I-GENE
1	I-GENE
)	O
.	O

Sci	O
.	O

A	O
miracle	O
cure	O
and	O
its	O
solution	O
.	O

The	O
human	B-GENE
SHBG	I-GENE
proximal	I-GENE
promoter	I-GENE
was	O
analyzed	O
by	O
DNase	B-GENE
I	I-GENE
footprinting	O
,	O
and	O
the	O
functional	O
significance	O
of	O
6	O
footprinted	O
regions	O
(	O
FP1	O
-	O
FP6	O
)	O
within	O
the	O
proximal	O
promoter	O
was	O
studied	O
in	O
human	O
HepG2	O
hepatoblastoma	O
cells	O
.	O

Two	O
activities	O
of	O
the	O
D	B-GENE
protein	I-GENE
of	O
the	O
miniF	O
plasmid	O
have	O
been	O
found	O
.	O

No	O
patient	O
in	O
group	O
2	O
developed	O
HAT	O
(	O
P	O
=	O
0	O
.	O
006	O
versus	O
group	O
1	O
)	O
.	O

After	O
nitric	O
oxide	O
inhalation	O
,	O
the	O
results	O
showed	O
moderate	O
increases	O
in	O
PaO2	O
and	O
SaO2	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
and	O
a	O
significant	O
decrease	O
in	O
Qs	O
/	O
Q	O
tau	O
ratio	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
mass	O
of	O
UO2	O
in	O
the	O
extrapulmonary	O
bronchi	O
and	O
first	O
bifurcation	O
decreased	O
more	O
slowly	O
over	O
0	O
-	O
-	O
8	O
d	O
after	O
inhalation	O
than	O
the	O
corresponding	O
mass	O
on	O
the	O
trachea	O
.	O

This	O
region	O
is	O
required	O
for	O
activation	O
of	O
DNA	O
binding	O
of	O
MyoD	B-GENE
and	O
E12	B-GENE
homodimers	I-GENE
and	O
E12	B-GENE
/	I-GENE
MyoD	I-GENE
heterodimers	I-GENE
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
a	O
detailed	O
study	O
of	O
the	O
structure	O
and	O
the	O
functional	O
role	O
of	O
the	O
MalT	B-GENE
binding	I-GENE
sites	I-GENE
located	O
in	O
the	O
adjacent	O
and	O
divergent	O
pulAp	B-GENE
and	O
pulCp	B-GENE
promoters	I-GENE
.	O

Thus	O
,	O
the	O
presence	O
of	O
the	O
Cln2	B-GENE
PEST	I-GENE
domain	I-GENE
was	O
sufficient	O
to	O
destabilize	O
a	O
heterologous	O
protein	O
.	O

Interestingly	O
,	O
EGF	B-GENE
,	O
but	O
not	O
insulin	B-GENE
,	O
stimulated	O
tyrosine	O
phosphorylation	O
of	O
c	B-GENE
-	I-GENE
cbl	I-GENE
and	O
its	O
association	O
with	O
Crk	B-GENE
-	I-GENE
II	I-GENE
.	O

Interferon	B-GENE
-	I-GENE
alpha	I-GENE
may	O
exacerbate	O
cryoblobulinemia	O
-	O
related	O
ischemic	O
manifestations	O
:	O
an	O
adverse	O
effect	O
potentially	O
related	O
to	O
its	O
anti	O
-	O
angiogenic	O
activity	O
.	O

Two	O
such	O
genes	O
,	O
designated	O
hsiggll150	B-GENE
and	O
hsiggll295	B-GENE
,	O
were	O
cloned	O
and	O
sequenced	O
from	O
genomic	O
DNA	O
.	O

Cyclin	B-GENE
D1	I-GENE
could	O
not	O
be	O
displaced	O
from	O
cdk4	B-GENE
in	O
the	O
resistant	O
184A1L5R	O
cell	O
lysates	O
.	O

These	O
characteristics	O
indicated	O
the	O
pronounced	O
activity	O
of	O
collagenous	O
fiber	O
synthesis	O
and	O
the	O
matrix	O
of	O
the	O
osteoid	O
tissue	O
.	O

RESULTS	O
:	O
Patients	O
in	O
Group	O
A	O
had	O
a	O
higher	O
incidence	O
of	O
posterolateral	O
wall	O
motion	O
abnormalities	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
on	O
radionuclide	O
ventriculography	O
,	O
a	O
larger	O
infarct	O
area	O
(	O
as	O
evidenced	O
by	O
higher	O
peak	O
creatine	B-GENE
kinase	I-GENE
levels	O
)	O
(	O
p	O
<	O
0	O
.	O
02	O
)	O
and	O
a	O
lower	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
LVEF	O
)	O
at	O
hospital	O
discharge	O
(	O
p	O
<	O
0	O
.	O
008	O
)	O
than	O
those	O
in	O
Group	O
B	O
.	O

The	O
incompatibility	O
group	O
W	O
plasmid	O
pSa	O
suppresses	O
Agrobacterium	O
tumefaciens	O
oncogenicity	O
(	O
J	O
.	O

In	O
this	O
report	O
,	O
we	O
identify	O
and	O
characterize	O
two	O
overlapping	O
ELL	B-GENE
functional	I-GENE
domains	I-GENE
that	O
govern	O
its	O
interaction	O
with	O
RNA	B-GENE
polymerase	I-GENE
II	I-GENE
and	O
the	O
ternary	O
elongation	O
complex	O
.	O

The	O
Spo0F	B-GENE
residues	I-GENE
making	O
up	O
the	O
hydrophobic	O
patch	O
are	O
very	O
similar	O
in	O
all	O
response	O
regulators	O
suggesting	O
that	O
the	O
binding	O
is	O
initiated	O
through	O
the	O
same	O
residues	O
in	O
all	O
interacting	O
response	O
regulator	O
-	O
kinase	O
pairs	O
.	O

We	O
performed	O
dipole	O
estimation	O
of	O
spikes	O
and	O
SEP	O
components	O
in	O
identical	O
patients	O
.	O

The	O
so	O
-	O
called	O
"	B-GENE
SH3	I-GENE
"	I-GENE
segment	I-GENE
of	O
the	O
linker	O
domain	O
,	O
in	O
contrast	O
,	O
shows	O
species	O
-	O
specific	O
sequence	O
identity	O
in	O
all	O
but	O
one	O
amino	O
acid	O
residues	O
in	O
both	O
factors	O
,	O
in	O
cattle	O
,	O
human	O
,	O
and	O
mouse	O
.	O

Early	O
indicators	O
of	O
the	O
effect	O
of	O
a	O
breast	O
cancer	O
screening	O
program	O
for	O
low	O
-	O
income	O
women	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
developmental	O
scores	O
at	O
9	O
or	O
18	O
months	O
,	O
although	O
PDF	O
infants	O
had	O
a	O
2	O
.	O
8	O
(	O
-	O
1	O
.	O
3	O
-	O
6	O
.	O
8	O
)	O
point	O
advantage	O
in	O
Bayley	O
motor	O
score	O
scales	O
.	O

Analysis	O
of	O
its	O
genomic	O
region	O
revealed	O
that	O
the	O
13	O
-	O
kb	O
Cdc6	B-GENE
gene	I-GENE
is	O
divided	O
into	O
12	O
exons	O
by	O
11	O
introns	O
.	O

These	O
incisors	O
were	O
studied	O
by	O
scanning	O
electron	O
microscopy	O
-	O
energy	O
dispersive	O
spectroscopy	O
analysis	O
(	O
SEM	O
-	O
EDS	O
)	O
and	O
light	O
microscopy	O
to	O
examine	O
the	O
calciotraumatic	O
lines	O
of	O
strontium	O
in	O
the	O
rat	B-GENE
incisor	I-GENE
labial	I-GENE
dentin	I-GENE
.	O

Private	O
hospital	O
accreditation	O
.	O

One	O
of	O
these	O
is	O
located	O
in	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
,	O
and	O
may	O
encode	O
regulatory	O
sequences	O
.	O

Glomerular	O
mesangial	O
cells	O
expressed	O
an	O
abundant	O
1	O
.	O
1	O
kb	O
mRNA	O
transcript	O
for	O
Id1	B-GENE
,	O
but	O
in	O
contrast	O
to	O
other	O
cell	O
types	O
Id1	B-GENE
mRNA	I-GENE
was	O
expressed	O
in	O
both	O
randomly	O
cycling	O
cells	O
and	O
in	O
serum	O
-	O
deprived	O
,	O
quiescent	O
cultures	O
.	O

CNS	O
effects	O
of	O
local	O
anesthetics	O
only	O
partially	O
dependent	O
on	O
biogenic	O
amine	O
mechanisms	O
.	O

By	O
Felix	O
Lagrange	O
,	O
1918	O
.	O

Transcriptional	O
activity	O
was	O
measured	O
by	O
slot	O
-	O
blot	O
hybridization	O
with	O
steady	O
-	O
state	O
RNA	O
isolated	O
from	O
lacZ	B-GENE
+	I-GENE
M	I-GENE
.	I-GENE
smegmatis	I-GENE
clones	O
.	O

CONCLUSION	O
:	O
The	O
MTD	O
for	O
CPT	O
-	O
11	O
administered	O
in	O
a	O
3	O
consecutive	O
-	O
days	O
-	O
every	O
-	O
3	O
weeks	O
schedule	O
in	O
this	O
patient	O
population	O
is	O
115	O
mg	O
/	O
m2	O
/	O
day	O
.	O

4	O
.	O

ICP4	B-GENE
has	O
been	O
shown	O
to	O
form	O
tripartite	O
complexes	O
cooperatively	O
with	O
the	O
TATA	B-GENE
box	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
and	O
TFIIB	B-GENE
on	O
DNA	O
containing	O
an	O
ICP4	B-GENE
binding	I-GENE
site	I-GENE
and	O
a	O
TATA	O
box	O
(	O
C	O
.	O

However	O
,	O
a	O
specific	O
ICE	B-GENE
/	I-GENE
caspase	I-GENE
-	I-GENE
1	I-GENE
inhibitor	O
called	O
N1445	O
completely	O
abolished	O
the	O
CK	O
-	O
induced	O
apoptosis	O
by	O
reactivating	O
PKB	B-GENE
,	O
but	O
without	O
affecting	O
the	O
CK	O
-	O
induced	O
suppression	O
of	O
Ras	B-GENE
transformation	O
.	O

OBJECTIVE	O
:	O
Our	O
purpose	O
was	O
to	O
determine	O
the	O
simultaneous	O
concentrations	O
of	O
serum	O
cotinine	O
in	O
both	O
fetal	O
and	O
maternal	O
blood	O
.	O

Records	O
of	O
31	O
children	O
with	O
AIDS	O
or	O
AIDS	O
-	O
related	O
complex	O
admitted	O
to	O
the	O
pediatric	O
intensive	O
care	O
unit	O
for	O
acute	O
respiratory	O
failure	O
throughout	O
a	O
46	O
-	O
month	O
period	O
were	O
reviewed	O
.	O

The	O
artery	O
cuff	O
was	O
slightly	O
superior	O
to	O
the	O
fat	O
wrap	O
,	O
particularly	O
in	O
having	O
fewer	O
adhesions	O
and	O
a	O
better	O
histological	O
picture	O
.	O

Liquid	O
chromatographic	O
separation	O
was	O
achieved	O
on	O
a	O
Zorbax	O
RX	O
C8	O
analytical	O
column	O
using	O
gradient	O
elution	O
.	O

Estrogen	O
treatment	O
in	O
high	O
doses	O
is	O
effective	O
in	O
reducing	O
adult	O
stature	O
in	O
constitutionally	O
tall	O
girls	O
.	O

A	O
cDNA	O
clone	O
corresponding	O
to	O
the	O
putative	O
GA	B-GENE
20	I-GENE
-	I-GENE
oxidase	I-GENE
genomic	I-GENE
sequence	I-GENE
was	O
constructed	O
with	O
the	O
reverse	O
transcription	O
-	O
PCR	O
method	O
,	O
and	O
the	O
identity	O
of	O
the	O
cDNA	O
clone	O
was	O
confirmed	O
by	O
analyzing	O
the	O
capability	O
of	O
the	O
fusion	O
protein	O
expressed	O
in	O
Escherichia	O
coli	O
to	O
convert	O
GA53	B-GENE
to	O
GA44	B-GENE
and	O
GA19	B-GENE
to	O
GA20	B-GENE
.	O

The	O
incidence	O
of	O
DNCB	O
reactions	O
was	O
78	O
per	O
cent	O
for	O
Stage	O
I	O
and	O
II	O
cancers	O
(	O
37	O
patinets	O
)	O
,	O
73	O
per	O
cent	O
for	O
resectable	O
Stage	O
III	O
cancer	O
(	O
22	O
patients	O
)	O
,	O
and	O
66	O
per	O
cent	O
in	O
patients	O
with	O
unresectable	O
or	O
inoperable	O
Stage	O
III	O
cancer	O
.	O

An	O
analysis	O
of	O
the	O
dynamics	O
is	O
performed	O
of	O
exactly	O
solvable	O
models	O
for	O
fragile	O
and	O
strong	O
glasses	O
,	O
exploiting	O
the	O
partitioning	O
of	O
the	O
free	O
-	O
energy	O
landscape	O
in	O
inherent	O
structures	O
.	O

Moreover	O
,	O
elderly	O
men	O
with	O
bioavailable	O
estradiol	O
levels	O
below	O
the	O
median	O
[	O
40	O
pmol	O
/	O
liter	O
(	O
11	O
pg	O
/	O
ml	O
)	O
]	O
had	O
significantly	O
higher	O
rates	O
of	O
bone	O
loss	O
and	O
levels	O
of	O
bone	O
resorption	O
markers	O
than	O
men	O
with	O
bioavailable	O
estradiol	O
levels	O
above	O
40	O
pmol	O
/	O
liter	O
.	O

We	O
also	O
report	O
here	O
the	O
complete	O
structural	O
organization	O
of	O
the	O
goat	B-GENE
alpha	I-GENE
s1	I-GENE
-	I-GENE
casein	I-GENE
transcription	I-GENE
unit	I-GENE
,	O
deduced	O
from	O
polymerase	O
chain	O
reaction	O
experiments	O
.	O

Replacing	O
residues	O
405	O
-	O
419	O
on	O
delta419	O
with	O
the	O
conserved	O
AF	B-GENE
-	I-GENE
2	I-GENE
domain	I-GENE
from	O
the	O
vitamin	B-GENE
D3	I-GENE
receptor	I-GENE
or	O
the	O
estrogen	B-GENE
receptor	I-GENE
results	O
in	O
a	O
receptor	O
with	O
wild	O
-	O
type	O
or	O
low	O
transcriptional	O
activity	O
,	O
respectively	O
.	O

Psychological	O
disturbance	O
was	O
greater	O
in	O
the	O
high	O
life	O
stress	O
group	O
as	O
indicated	O
by	O
significant	O
elevations	O
on	O
the	O
global	O
severity	O
index	O
of	O
the	O
Symptom	O
Checklist	O
-	O
90	O
and	O
elevations	O
on	O
somatization	O
,	O
obsessive	O
compulsive	O
,	O
interpersonal	O
sensitivity	O
,	O
depression	O
,	O
anxiety	O
and	O
psychoticism	O
subscales	O
.	O

Since	O
electrical	O
stimulation	O
of	O
neurones	O
may	O
activate	O
not	O
only	O
cell	O
bodies	O
but	O
also	O
neuronal	O
fibres	O
,	O
this	O
study	O
aimed	O
to	O
test	O
a	O
selectively	O
cholinergic	O
neurochemical	O
stimulation	O
of	O
the	O
rat	O
substantia	O
innominata	O
(	O
SI	O
)	O
by	O
the	O
local	O
microinjection	O
of	O
carbachol	O
;	O
the	O
effects	O
of	O
this	O
acetylcholine	O
agonist	O
were	O
compared	O
with	O
glutamate	O
.	O

Eucaryotic	O
transcription	O
factors	O
that	O
stimulate	O
RNA	B-GENE
polymerase	I-GENE
II	I-GENE
by	O
increasing	O
the	O
efficiency	O
of	O
elongation	O
of	O
specifically	O
or	O
randomly	O
initiated	O
RNA	O
chains	O
have	O
been	O
isolated	O
and	O
characterized	O
.	O

The	O
mRNAs	O
of	O
these	O
genes	O
contain	O
respectively	O
one	O
(	O
YAP1	B-GENE
uORF	I-GENE
)	O
and	O
two	O
(	O
YAP2	B-GENE
uORF1	I-GENE
and	O
uORF2	B-GENE
)	O
upstream	O
open	O
reading	O
frames	O
.	O
uORF	O
-	O
mediated	O
modulation	O
of	O
post	O
-	O
termination	O
events	O
on	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
(	O
5	O
'	O
-	O
UTR	O
)	O
directs	O
differential	O
control	O
not	O
only	O
of	O
translation	O
but	O
also	O
of	O
mRNA	O
decay	O
.	O

We	O
used	O
a	O
rev	O
-	O
and	O
RRE	O
-	O
defective	O
HIV	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
molecular	O
clone	O
in	O
complementation	O
experiments	O
to	O
establish	O
a	O
method	O
for	O
the	O
rapid	O
isolation	O
of	O
posttranscriptional	O
regulatory	O
elements	O
from	O
the	O
mammalian	O
genome	O
by	O
selecting	O
for	O
rescue	O
of	O
virus	O
replication	O
.	O

Evolutionary	O
conservation	O
of	O
homeodomain	B-GENE
-	I-GENE
binding	I-GENE
sites	I-GENE
and	O
other	O
sequences	O
upstream	O
and	O
within	O
the	O
major	O
transcription	O
unit	O
of	O
the	O
Drosophila	B-GENE
segmentation	I-GENE
gene	I-GENE
engrailed	I-GENE
.	O

Furthermore	O
,	O
the	O
NH2	O
-	O
terminal	O
portion	O
of	O
the	O
homologue	O
was	O
not	O
translocated	O
into	O
the	O
outer	O
membrane	O
without	O
its	O
COOH	O
-	O
terminal	O
part	O
.	O

The	O
5	O
'	O
flanking	O
regions	O
of	O
both	O
pelA	B-GENE
and	O
pelB	B-GENE
were	O
translationally	O
fused	O
to	O
the	O
beta	B-GENE
-	I-GENE
glucuronidase	I-GENE
gene	I-GENE
and	O
introduced	O
into	O
F	O
.	O
solani	O
f	O
.	O
sp	O
.	O
pisi	O
,	O
and	O
beta	B-GENE
-	I-GENE
glucuronidase	I-GENE
activities	O
of	O
the	O
transformants	O
were	O
measured	O
.	O

The	O
results	O
suggest	O
that	O
GATA	B-GENE
-	I-GENE
5	I-GENE
may	O
have	O
specific	O
downstream	O
targets	O
and	O
that	O
GATA	B-GENE
-	I-GENE
4	I-GENE
,	I-GENE
-	I-GENE
5	I-GENE
,	I-GENE
and	I-GENE
-	I-GENE
6	I-GENE
can	O
only	O
partially	O
substitute	O
for	O
each	O
other	O
in	O
cardiogenesis	O
.	O

A	O
human	O
recombinant	O
cDNA	O
clone	O
that	O
encoded	O
253	O
amino	O
acids	O
residues	O
of	O
a	O
zinc	B-GENE
-	I-GENE
finger	I-GENE
protein	I-GENE
(	O
THZif	B-GENE
-	I-GENE
1	I-GENE
)	O
was	O
cloned	O
by	O
screening	O
a	O
cDNA	O
library	O
prepared	O
from	O
human	O
promyelocytic	O
leukemia	O
HL60	O
cells	O
with	O
synthetic	O
oligodeoxynucleotide	O
probes	O
that	O
corresponded	O
to	O
the	O
amino	O
acid	O
sequences	O
of	O
tryptic	O
peptides	O
derived	O
from	O
the	O
DNA	O
-	O
binding	O
protein	O
specific	O
for	O
the	O
nuclease	B-GENE
-	I-GENE
hypersensitive	I-GENE
element	I-GENE
(	O
NHE	B-GENE
)	O
of	O
the	O
human	B-GENE
c	I-GENE
-	I-GENE
myc	I-GENE
gene	I-GENE
.	O

Human	B-GENE
papillomavirus	I-GENE
type	I-GENE
31b	I-GENE
late	I-GENE
gene	I-GENE
expression	O
is	O
regulated	O
through	O
protein	B-GENE
kinase	I-GENE
C	O
-	O
mediated	O
changes	O
in	O
RNA	O
processing	O
.	O

Amino	O
acid	O
residues	O
of	O
beta	O
1	O
'	O
,	O
alpha	O
A	O
'	O
,	O
alpha	O
B	O
'	O
,	O
and	O
the	O
loop	O
containing	O
His539	O
of	O
the	O
RNase	B-GENE
H	I-GENE
domain	I-GENE
interact	O
with	O
the	O
primer	O
strand	O
of	O
the	O
dsDNA	O
.	O

Regulated	O
activity	O
of	O
the	O
distal	O
promoter	O
-	O
like	O
element	O
of	O
the	O
human	B-GENE
corticotropin	I-GENE
-	I-GENE
releasing	I-GENE
hormone	I-GENE
gene	I-GENE
and	O
secondary	O
structural	O
features	O
of	O
its	O
corresponding	O
transcripts	O
.	O

In	O
this	O
study	O
,	O
we	O
further	O
investigated	O
the	O
regulation	O
of	O
the	O
synthesis	O
of	O
the	O
c	B-GENE
-	I-GENE
mos	I-GENE
oncogene	I-GENE
product	I-GENE
,	O
which	O
is	O
necessary	O
for	O
the	O
activation	O
of	O
Cdc2	B-GENE
.	O

The	O
60A	B-GENE
transcripts	I-GENE
and	O
protein	O
are	O
first	O
detected	O
at	O
the	O
onset	O
of	O
gastrulation	O
,	O
primarily	O
in	O
the	O
mesoderm	O
of	O
the	O
extending	O
germ	O
band	O
.	O

An	O
11	O
-	O
month	O
-	O
old	O
girl	O
suffering	O
from	O
Dandy	O
-	O
Walker	O
malformation	O
(	O
DWM	O
)	O
associated	O
with	O
tetralogy	O
of	O
Fallot	O
(	O
TOF	O
)	O
is	O
presented	O
.	O

Determination	O
of	O
transaminases	B-GENE
with	O
an	O
autoanalyzer	O
.	O

The	O
proteins	O
encoded	O
downstream	O
of	O
rpoN	B-GENE
are	O
known	O
to	O
negatively	O
regulate	O
sigma	B-GENE
54	I-GENE
activity	O
.	O

Sings	O
which	O
are	O
indicative	O
of	O
metaplastic	O
erythropoiesis	O
are	O
absent	O
.	O

The	O
genomic	O
and	O
transcriptional	O
complexity	O
of	O
the	O
Crry	B-GENE
and	O
Crry	B-GENE
-	I-GENE
ps	I-GENE
genes	I-GENE
.	O

The	O
apparatus	O
consists	O
of	O
an	O
Am	O
-	O
241	O
exciting	O
source	O
(	O
300	O
mCi	O
)	O
and	O
pure	O
Ge	O
detector	O
(	O
50	O
mm2	O
X	O
5	O
mm	O
)	O
for	O
measuring	O
K	O
alpha	O
fluorescent	O
x	O
-	O
rays	O
(	O
28	O
.	O
3	O
and	O
28	O
.	O
6	O
KeV	O
)	O
emitted	O
from	O
exited	O
iodine	O
.	O

The	O
potentially	O
SLE	O
-	O
inducing	O
drugs	O
are	O
reviewed	O
.	O

In	O
this	O
study	O
,	O
we	O
sought	O
to	O
identify	O
mechanisms	O
that	O
could	O
account	O
for	O
the	O
antimitogenic	O
effects	O
of	O
IL	B-GENE
-	I-GENE
4	I-GENE
.	O

12	O
:	O
2684	O
-	O
2697	O
,	O
1998	O
)	O
:	O
a	O
key	O
step	O
of	O
this	O
model	O
is	O
the	O
activation	O
of	O
the	O
MAPK	B-GENE
Fus3p	I-GENE
through	O
the	O
G	O
(	O
betagamma	O
)	O
-	O
dependent	O
relocalization	O
of	O
the	O
Ste5p	B-GENE
-	I-GENE
MAPK	I-GENE
cascade	I-GENE
to	O
the	O
plasma	O
membrane	O
.	O

Subsequent	O
cloning	O
and	O
nucleotide	O
sequence	O
analysis	O
of	O
the	O
S	B-GENE
.	I-GENE
pombe	I-GENE
adenylate	I-GENE
kinase	I-GENE
gene	I-GENE
,	O
adk1	B-GENE
,	O
revealed	O
a	O
coding	O
region	O
of	O
660	O
nucleotides	O
.	O

Three	O
subgenomes	O
also	O
comprised	O
15	O
to	O
75	O
nucleotides	O
derived	O
from	O
the	O
5	O
'	O
part	O
of	O
the	O
NS2	B-GENE
gene	I-GENE
.	O

The	O
present	O
investigation	O
sought	O
to	O
identify	O
the	O
principal	O
dimensions	O
of	O
the	O
Framingham	O
Type	O
A	O
scale	O
(	O
FTAS	O
)	O
and	O
then	O
to	O
examine	O
their	O
physiological	O
and	O
psychological	O
correlates	O
.	O

SCL	O
prolonged	O
promptly	O
after	O
verapamil	O
,	O
and	O
sinus	O
arrest	O
developed	O
in	O
two	O
of	O
10	O
group	O
2	O
and	O
two	O
of	O
five	O
group	O
3	O
animals	O
.	O

The	O
CRE	B-GENE
,	O
5	B-GENE
'	I-GENE
-	I-GENE
TGACGTCA	I-GENE
-	I-GENE
3	I-GENE
'	I-GENE
,	O
has	O
been	O
described	O
as	O
the	O
consensus	O
sequence	O
for	O
the	O
cis	O
-	O
element	O
that	O
directs	O
cAMP	O
-	O
regulated	O
gene	O
expression	O
.	O

Enhanced	O
hepatic	O
portal	O
blood	O
flow	O
induced	O
by	O
prostaglandin	O
E1	O
following	O
liver	O
transplantation	O
in	O
pigs	O
.	O

The	O
promoter	O
of	O
the	O
rat	B-GENE
PGS	I-GENE
-	I-GENE
2	I-GENE
gene	I-GENE
contains	O
a	O
CAAT	B-GENE
enhancer	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
consensus	I-GENE
site	I-GENE
(	I-GENE
CAAT	I-GENE
box	I-GENE
)	I-GENE
which	O
can	O
confer	O
hormone	O
inducibility	O
to	O
a	O
PGS	B-GENE
-	I-GENE
2	I-GENE
.	I-GENE
CAT	I-GENE
reporter	I-GENE
gene	I-GENE
,	O
as	O
well	O
as	O
a	O
putative	O
E	O
-	O
box	O
region	O
.	O

A	O
3	O
-	O
week	O
regimen	O
of	O
erythropoietin	B-GENE
may	O
help	O
prevent	O
the	O
donor	O
'	O
s	O
need	O
to	O
receive	O
allogeneic	O
blood	O
transfusion	O
,	O
when	O
the	O
initial	O
Hb	B-GENE
levels	O
were	O
below	O
130	O
milligrams	O
.	O

Nutritional	O
cataracts	O
in	O
timber	O
wolves	O
.	O

Nine	O
strains	O
were	O
subtyped	O
as	O
Camp	O
.	O
jejuni	O
subsp	O
.	O
jejuni	O
biotype	O
II	O
and	O
the	O
remaining	O
ones	O
as	O
biotype	O
I	O
.	O

Molecular	O
and	O
functional	O
characterization	O
of	O
the	O
promoter	O
of	O
ETS2	B-GENE
,	O
the	O
human	O
c	B-GENE
-	I-GENE
ets	I-GENE
-	I-GENE
2	I-GENE
gene	O
.	O

Calcification	O
of	O
a	O
cariogenic	O
Streptococcus	O
and	O
of	O
Corynebacterium	O
(	O
Bacterionema	O
)	O
matruchotii	O
.	O

E	O
.	O
,	O
Scott	O
,	O
J	O
.	O

These	O
results	O
suggest	O
that	O
HAC1	B-GENE
may	O
also	O
be	O
one	O
of	O
the	O
meiotic	O
genes	O
.	O

Examination	O
of	O
the	O
MMP	B-GENE
-	I-GENE
2	I-GENE
RE1	I-GENE
sequence	I-GENE
revealed	O
an	O
incomplete	O
Y	B-GENE
-	I-GENE
box	I-GENE
sequence	I-GENE
(	O
CTGCTGGGCAAG	B-GENE
)	O
,	O
which	O
specifically	O
interacted	O
with	O
recombinant	B-GENE
YB	I-GENE
-	I-GENE
1	I-GENE
on	O
DMS	O
protection	O
footprinting	O
analysis	O
.	O

In	O
some	O
of	O
the	O
cases	O
of	O
solitary	O
lesion	O
,	O
serum	B-GENE
TSH	I-GENE
levels	O
,	O
serum	B-GENE
thyroglobulin	I-GENE
values	O
,	O
and	O
131I	O
protein	O
bounded	O
iodine	O
(	O
131I	O
-	O
PBI	O
)	O
were	O
measured	O
,	O
but	O
there	O
were	O
no	O
significant	O
differences	O
between	O
successful	O
and	O
unsuccessful	O
therapy	O
.	O

RESULTS	O
:	O
Each	O
year	O
,	O
on	O
average	O
39	O
%	O
of	O
cases	O
seen	O
in	O
Sardinia	O
are	O
notified	O
;	O
646	O
(	O
40	O
%	O
)	O
of	O
the	O
1591	O
patients	O
notified	O
during	O
the	O
study	O
period	O
were	O
never	O
seen	O
by	O
regional	O
medical	O
centres	O
.	O

Northern	O
blot	O
and	O
in	O
situ	O
hybridization	O
analyses	O
revealed	O
GPR34	B-GENE
mRNA	I-GENE
transcripts	I-GENE
in	O
several	O
human	O
and	O
rat	O
brain	O
regions	O
.	O

A	O
high	O
reactor	O
pH	O
(	O
+	O
/	O
-	O
8	O
)	O
,	O
a	O
short	O
solid	O
retention	O
time	O
(	O
<	O
150	O
days	O
)	O
,	O
and	O
the	O
presence	O
of	O
a	O
substantial	O
SRB	O
population	O
in	O
the	O
inoculum	O
may	O
considerably	O
reduce	O
the	O
time	O
required	O
for	O
acetate	O
-	O
utilising	O
SRB	O
to	O
outcompete	O
MB	O
.	O

The	O
study	O
included	O
139	O
eyes	O
with	O
presumed	O
ocular	O
histoplasmosis	O
syndrome	O
(	O
POHS	O
)	O
and	O
age	O
-	O
related	O
macular	O
degeneration	O
(	O
AMD	O
)	O
.	O

Five	O
of	O
the	O
patients	O
with	O
increased	O
L	O
-	O
L	O
size	O
had	O
a	O
normal	O
A	O
-	O
P	O
diameter	O
.	O

Antibodies	O
directed	O
against	O
the	O
SNM1	B-GENE
protein	I-GENE
immunoprecipitated	O
RNase	B-GENE
MRP	I-GENE
RNA	I-GENE
from	O
whole	O
-	O
cell	O
extracts	O
without	O
precipitating	O
the	O
structurally	O
and	O
functionally	O
related	O
RNase	B-GENE
P	I-GENE
RNA	I-GENE
.	O

METHOD	O
:	O
50	O
consecutive	O
children	O
aged	O
from	O
6	O
months	O
to	O
17	O
years	O
were	O
included	O
into	O
the	O
study	O
which	O
comprised	O
questionnaires	O
of	O
patient	O
and	O
family	O
histories	O
,	O
serological	O
screening	O
tests	O
for	O
common	O
inhalational	O
allergens	O
(	O
CAP	O
SX1	O
)	O
,	O
and	O
determination	O
of	O
total	O
serum	B-GENE
immunoglobulin	I-GENE
E	I-GENE
(	O
IgE	B-GENE
)	O
and	O
of	O
latex	O
-	O
specific	O
serum	B-GENE
IgE	I-GENE
by	O
solid	O
-	O
phase	O
immunoassays	O
.	O

We	O
have	O
cloned	O
and	O
sequenced	O
COX12	B-GENE
,	O
the	O
nuclear	O
gene	O
for	O
subunit	B-GENE
VIb	I-GENE
of	O
Saccharomyces	B-GENE
cerevisiae	I-GENE
cytochrome	I-GENE
c	I-GENE
oxidase	I-GENE
.	O

Steroidogenic	B-GENE
factor	I-GENE
1	I-GENE
,	O
an	O
orphan	B-GENE
nuclear	I-GENE
receptor	I-GENE
,	O
regulates	O
the	O
expression	O
of	O
the	O
rat	B-GENE
aromatase	I-GENE
gene	I-GENE
in	O
gonadal	O
tissues	O
.	O

The	O
efficacy	O
of	O
these	O
immunosuppressive	O
drugs	O
is	O
clinical	O
proven	O
.	O

Neonatal	O
lupus	O
erythematosus	O
is	O
most	O
often	O
associated	O
with	O
autoantibodies	O
against	O
Ro	B-GENE
and	O
La	B-GENE
antigens	O
.	O

The	O
etiology	O
,	O
pathology	O
,	O
brain	O
CT	O
scan	O
features	O
,	O
clinical	O
manifestations	O
and	O
treatment	O
of	O
these	O
accidents	O
were	O
discussed	O
.	O

Among	O
booked	O
patients	O
the	O
maternal	O
mortality	O
rate	O
was	O
0	O
.	O
32	O
and	O
among	O
unbooked	O
patients	O
11	O
.	O
13	O
per	O
1000	O
deliveries	O
.	O

The	O
peroxisome	O
biogenesis	O
disorders	O
(	O
PBDs	O
)	O
are	O
a	O
set	O
of	O
lethal	O
genetic	O
diseases	O
characterized	O
by	O
peroxisomal	O
metabolic	O
deficiencies	O
,	O
multisystem	O
abnormalities	O
,	O
mental	O
retardation	O
,	O
and	O
premature	O
death	O
.	O

Effect	O
of	O
nitrous	O
oxide	O
(	O
N2O	O
)	O
on	O
the	O
somatosympathetic	O
A	O
-	O
and	O
C	O
-	O
reflexes	O
was	O
investigated	O
using	O
artificially	O
ventilated	O
rats	O
anesthetized	O
with	O
alpha	O
-	O
chloralose	O
and	O
urethane	O
.	O

The	O
sensitivity	O
of	O
the	O
vas	O
deferens	O
to	O
adrenaline	O
was	O
also	O
reduced	O
in	O
scorbutic	O
guinea	O
pigs	O
,	O
thus	O
decreasing	O
their	O
fertility	O
rate	O
.	O

An	O
amino	O
-	O
acid	O
sequence	O
comparison	O
revealed	O
that	O
Bacillus	B-GENE
YM55	I-GENE
-	I-GENE
1	I-GENE
aspartase	I-GENE
shared	O
71	O
%	O
homology	O
with	O
Bacillus	B-GENE
subtilis	I-GENE
aspartase	I-GENE
and	O
49	O
%	O
with	O
Escherichia	O
coli	O
and	O
Pseudomonas	B-GENE
fluorescens	I-GENE
aspartases	I-GENE
.	O

In	O
contrast	O
,	O
the	O
full	O
mu	O
-	O
opioid	O
agonists	O
fentanyl	O
,	O
morphine	O
,	O
I	O
-	O
methadone	O
and	O
levorphanol	O
produced	O
50	O
%	O
fentanyl	O
-	O
appropriate	O
responding	O
at	O
doses	O
only	O
1	O
.	O
3	O
to	O
10	O
.	O
9	O
times	O
smaller	O
than	O
those	O
required	O
to	O
decrease	O
response	O
rates	O
by	O
50	O
%	O
.	O

This	O
activity	O
is	O
stimulated	O
by	O
complex	O
formation	O
with	O
the	O
other	O
eIF2B	B-GENE
subunits	I-GENE
.	O

A	O
portion	O
of	O
p193	B-GENE
is	O
nuclear	O
and	O
localizes	O
to	O
the	O
mitotic	O
spindle	O
.	O

Evolutive	O
morphology	O
of	O
the	O
olfactory	O
bulb	O
in	O
man	O
and	O
certain	O
non	O
-	O
human	O
mammals	O
.	O

The	O
core	O
promoter	O
of	O
human	B-GENE
thioredoxin	I-GENE
reductase	I-GENE
1	I-GENE
.	I-GENE
cloning	O
,	O
transcriptional	O
activity	O
,	O
and	O
oct	B-GENE
-	I-GENE
1	I-GENE
,	O
sp1	B-GENE
,	O
and	O
sp3	B-GENE
binding	O
reveal	O
a	O
housekeeping	O
-	O
type	O
promoter	O
for	O
the	O
au	O
-	O
rich	O
element	O
-	O
regulated	O
gene	O
.	O

The	O
five	O
-	O
drug	O
combination	O
of	O
fluorouracil	O
imidazole	O
carboxamide	O
dimethyl	O
triazeno	O
,	O
vincristine	O
,	O
bis	O
-	O
chloroethyl	O
nitrosourea	O
,	O
and	O
prednisone	O
(	O
FIVB	O
+	O
P	O
)	O
was	O
given	O
to	O
120	O
women	O
with	O
metastatic	O
breast	O
cancer	O
.	O

Recombinant	B-GENE
prenylcysteine	I-GENE
lyase	I-GENE
was	O
produced	O
in	O
a	O
baculovirus	O
-	O
Sf9	O
expression	O
system	O
.	O

Here	O
,	O
we	O
correlate	O
Dox	O
effects	O
on	O
cell	O
cycle	O
with	O
changes	O
of	O
E2F	B-GENE
/	I-GENE
DP	I-GENE
complexes	I-GENE
and	O
activity	O
in	O
differentiating	O
C2C12	B-GENE
myocytes	O
.	O

We	O
have	O
determined	O
the	O
structure	O
of	O
the	O
WNT	B-GENE
-	I-GENE
2B	I-GENE
gene	I-GENE
.	O

Positive	O
genetic	O
selections	O
for	O
inhibition	O
of	O
cyclin	B-GENE
/	I-GENE
CDK	I-GENE
function	O
were	O
characterized	O
using	O
the	O
E	B-GENE
.	I-GENE
coli	I-GENE
neo	I-GENE
and	O
yeast	B-GENE
LEU2	I-GENE
genes	I-GENE
.	O

Finger	B-GENE
associated	I-GENE
box	I-GENE
-	I-GENE
zinc	I-GENE
finger	I-GENE
proteins	I-GENE
(	O
FAX	B-GENE
-	I-GENE
ZFPs	I-GENE
)	O
constitute	O
a	O
subfamily	O
of	O
the	O
many	O
C2H2	B-GENE
type	I-GENE
ZFPs	I-GENE
in	O
Xenopus	O
laevis	O
.	O

Neither	O
class	O
II	O
nor	O
IV	O
infections	O
precluded	O
transplantation	O
.	O

This	O
report	O
has	O
reviewed	O
some	O
of	O
the	O
reasons	O
for	O
treatment	O
failures	O
and	O
has	O
presented	O
a	O
philosophy	O
for	O
their	O
management	O
.	O

Ceftazidime	O
shows	O
promise	O
as	O
single	O
-	O
agent	O
therapy	O
for	O
serious	O
gram	O
-	O
negative	O
bacillary	O
infections	O
.	O

Anti	O
-	O
anxiety	O
action	O
of	O
diazepam	O
after	O
intra	O
-	O
amygdaloid	O
application	O
in	O
the	O
rat	O
.	O

The	O
Ogg1	B-GENE
protein	I-GENE
efficiently	O
cleaves	O
a	O
DNA	O
duplex	O
where	O
a	O
preformed	O
AP	B-GENE
site	I-GENE
is	O
placed	O
opposite	O
a	O
cytosine	O
(	O
AP	O
/	O
C	O
)	O
.	O

We	O
report	O
here	O
that	O
a	O
25	O
-	O
bp	O
promoter	O
element	O
previously	O
shown	O
to	O
be	O
important	O
for	O
the	O
G1	O
-	O
S	O
activation	O
of	O
the	O
human	B-GENE
thymidine	I-GENE
kinase	I-GENE
(	O
htk	B-GENE
)	O
promoter	O
in	O
growth	O
-	O
stimulated	O
cells	O
is	O
a	O
cellular	O
target	O
of	O
cyclin	B-GENE
A	I-GENE
and	O
the	O
p33cdk2	B-GENE
complexes	I-GENE
.	O

Molecular	O
structure	O
and	O
evolutionary	O
origin	O
of	O
human	B-GENE
cardiac	I-GENE
muscle	I-GENE
actin	I-GENE
gene	I-GENE
.	O

Serine	O
phosphorylation	O
of	O
STAT3	B-GENE
was	O
only	O
apparent	O
after	O
somatostatin	B-GENE
treatment	O
and	O
was	O
abolished	O
by	O
pertussis	B-GENE
toxin	I-GENE
or	O
PD	O
98059	O
,	O
together	O
with	O
the	O
associated	O
increases	O
in	O
proliferation	O
.	O

The	O
genome	O
of	O
avian	O
erythroblastosis	O
virus	O
contains	O
two	O
independently	O
expressed	O
genetic	O
loci	O
(	O
v	B-GENE
-	I-GENE
erbA	I-GENE
and	O
v	B-GENE
-	I-GENE
erbB	I-GENE
)	O
whose	O
activities	O
are	O
probably	O
responsible	O
for	O
oncogenesis	O
by	O
the	O
virus	O
.	O

This	O
phenomenon	O
did	O
not	O
require	O
DNA	O
binding	O
by	O
the	O
"	O
interfering	O
"	O
receptor	O
but	O
required	O
it	O
to	O
be	O
hormone	O
-	O
bound	O
,	O
indicating	O
that	O
a	O
transcriptionally	O
active	O
form	O
of	O
the	O
interfering	O
receptor	O
is	O
essential	O
for	O
the	O
interfering	O
effect	O
.	O

Here	O
we	O
report	O
that	O
in	O
cultured	O
cells	O
from	O
Drosophila	O
melanogaster	O
human	B-GENE
Sp1	I-GENE
efficiently	O
activates	O
transcription	O
from	O
synthetic	O
promoters	O
containing	O
TATA	O
boxes	O
,	O
but	O
not	O
from	O
promoters	O
that	O
contain	O
an	O
initiator	O
instead	O
of	O
a	O
TATA	O
box	O
.	O

We	O
recommend	O
that	O
paracervical	O
block	O
with	O
lignocaine	O
should	O
be	O
used	O
in	O
conjunction	O
with	O
i	O
.	O
v	O
.	O
sedation	O
/	O
analgesia	O
during	O
egg	O
collection	O
performed	O
through	O
the	O
transvaginal	O
route	O
under	O
ultrasound	O
guidance	O
(	O
TUGOR	O
)	O
to	O
reduce	O
the	O
pain	O
of	O
the	O
procedure	O
.	O

Thyroid	O
disease	O
and	O
pregnancy	O
.	O

To	O
study	O
retinoid	O
signalling	O
in	O
zebrafish	O
embryos	O
,	O
we	O
developed	O
a	O
novel	O
method	O
to	O
detect	O
endogenous	O
retinoids	O
in	O
situ	O
in	O
embryos	O
,	O
using	O
a	O
fusion	O
protein	O
of	O
the	O
ligand	O
inducible	O
transactivation	O
domain	O
of	O
a	O
retinoic	B-GENE
acid	I-GENE
receptor	I-GENE
and	O
a	O
heterologous	O
DNA	O
binding	O
domain	O
.	O

Northern	O
blot	O
analysis	O
revealed	O
that	O
mlt	B-GENE
1	I-GENE
is	O
normally	O
expressed	O
in	O
brain	O
,	O
spleen	O
,	O
stom	O
ach	O
,	O
and	O
liver	O
.	O

The	O
results	O
indicated	O
that	O
two	O
genes	O
(	O
citA	B-GENE
and	O
citB	B-GENE
)	O
have	O
separate	O
promoters	O
,	O
and	O
the	O
location	O
of	O
the	O
promoter	O
for	O
the	O
citB	B-GENE
gene	I-GENE
in	O
the	O
Tn3411	B-GENE
nucleotide	O
sequence	O
was	O
different	O
from	O
that	O
in	O
pMS185	O
.	O

This	O
distinction	O
was	O
based	O
upon	O
whether	O
the	O
diagnosis	O
provided	O
a	O
straightforward	O
range	O
of	O
prognoses	O
or	O
an	O
ambiguous	O
clinical	O
implication	O
.	O

However	O
,	O
vancomycin	O
and	O
fosfomycin	O
,	O
which	O
revealed	O
suboptimal	O
in	O
vitro	O
bactericidal	O
activity	O
,	O
proved	O
as	O
efficacious	O
as	O
penicillin	O
G	O
and	O
imipenem	O
in	O
an	O
experimental	O
mode	O
of	O
murine	O
gas	O
gangrene	O
.	O

For	O
HeLa	O
,	O
293	O
,	O
U937	O
,	O
and	O
A549	O
cells	O
,	O
participation	O
of	O
E2F	B-GENE
-	I-GENE
1	I-GENE
,	O
DP	B-GENE
-	I-GENE
1	I-GENE
,	O
cyclin	B-GENE
A	I-GENE
,	O
and	O
RB	B-GENE
was	O
involved	O
in	O
formation	O
of	O
some	O
complexes	O
only	O
,	O
assuming	O
participation	O
of	O
factors	O
different	O
from	O
E2F	B-GENE
-	I-GENE
1	I-GENE
or	O
DP	B-GENE
-	I-GENE
1	I-GENE
in	O
others	O
.	O

The	O
severity	O
of	O
clinical	O
course	O
was	O
expressed	O
by	O
means	O
of	O
SOFA	O
score	O
(	O
group	O
A	O
0	O
.	O
3	O
-	O
1	O
-	O
1	O
.	O
3	O
point	O
,	O
group	O
B	O
2	O
.	O
2	O
-	O
2	O
.	O
9	O
-	O
2	O
.	O
6	O
point	O
,	O
group	O
C	O
7	O
.	O
4	O
-	O
8	O
.	O
3	O
-	O
7	O
.	O
7	O
point	O
)	O
and	O
APACHE	O
II	O
score	O
(	O
group	O
A	O
3	O
.	O
7	O
-	O
7	O
.	O
6	O
-	O
8	O
.	O
1	O
point	O
,	O
group	O
B	O
8	O
.	O
6	O
-	O
11	O
.	O
1	O
-	O
10	O
.	O
5	O
point	O
,	O
group	O
C	O
16	O
.	O
3	O
-	O
15	O
.	O
2	O
-	O
14	O
.	O
3	O
point	O
)	O
.	O

5	O
microU	O
/	O
l	O
thyrotropin	O
:	O
75	O
%	O
(	O
1974	O
)	O
,	O
45	O
%	O
(	O
1977	O
)	O
and	O
20	O
%	O
(	O
1980	O
)	O
.	O

Partial	O
N	O
-	O
terminal	O
amino	O
acid	O
sequence	O
analysis	O
showed	O
that	O
the	O
43K	B-GENE
and	I-GENE
42K	I-GENE
T	I-GENE
antigens	I-GENE
contain	O
methionine	O
at	O
residues	O
1	O
and	O
5	O
,	O
as	O
predicted	O
from	O
the	O
DNA	O
sequence	O
,	O
whereas	O
no	O
methionine	O
was	O
released	O
from	O
the	O
39K	B-GENE
T	I-GENE
antigen	I-GENE
during	O
the	O
first	O
six	O
cycles	O
of	O
Edman	O
degradation	O
.	O

A	O
new	O
Onchocerca	O
species	O
,	O
a	O
parasite	O
of	O
domestic	O
cattle	O
,	O
in	O
Senegal	O
.	O

Ga	O
-	O
67	O
and	O
Tl	O
-	O
201	O
scintigraphy	O
in	O
extramedullary	O
plasmacytoma	O
:	O
a	O
case	O
report	O
.	O

The	O
addition	O
of	O
diatrizoate	O
to	O
the	O
IPRK	O
led	O
to	O
a	O
dose	O
-	O
dependent	O
biphasic	O
change	O
in	O
RPF	O
and	O
GFR	O
characterized	O
by	O
an	O
initial	O
transient	O
increase	O
followed	O
by	O
a	O
marked	O
and	O
sustained	O
decrease	O
.	O

Role	O
of	O
estrogen	B-GENE
receptor	I-GENE
ligand	O
and	O
estrogen	B-GENE
response	I-GENE
element	I-GENE
sequence	O
on	O
interaction	O
with	O
chicken	B-GENE
ovalbumin	I-GENE
upstream	I-GENE
promoter	I-GENE
transcription	I-GENE
factor	I-GENE
(	O
COUP	B-GENE
-	I-GENE
TF	I-GENE
)	O
.	O

Chemical	O
stability	O
tests	O
and	O
site	O
-	O
specific	O
mutagenesis	O
identified	O
amino	O
acids	O
H219	O
and	O
D63	O
of	O
RegS	B-GENE
and	O
RegR	B-GENE
,	O
respectively	O
,	O
as	O
the	O
phosphorylated	O
residues	O
.	O

Prostacyclin	O
formation	O
,	O
reflected	O
by	O
the	O
excretion	O
rate	O
of	O
its	O
stable	O
metabolite	O
6	O
-	O
keto	O
-	O
prostaglandin	O
F1	O
alpha	O
,	O
was	O
measured	O
by	O
means	O
of	O
radioimmunoassay	O
in	O
4	O
-	O
hour	O
urine	O
specimens	O
obtained	O
during	O
a	O
smoking	O
-	O
free	O
period	O
and	O
after	O
participants	O
had	O
inhaled	O
smoke	O
from	O
four	O
high	O
-	O
nicotine	O
cigarettes	O
.	O

There	O
were	O
gene	O
clusters	O
encoding	O
photosynthesis	O
components	O
such	O
as	O
the	O
psbB	B-GENE
-	I-GENE
psbH	I-GENE
-	I-GENE
petB	I-GENE
-	I-GENE
petD	I-GENE
and	O
the	O
psbE	B-GENE
-	I-GENE
psbF	I-GENE
clusters	I-GENE
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
EGF	B-GENE
/	I-GENE
Ras	I-GENE
/	I-GENE
Raf	I-GENE
induces	O
transcription	O
via	O
combined	O
activation	O
of	O
ATF3	B-GENE
/	I-GENE
c	I-GENE
-	I-GENE
Jun	I-GENE
and	O
a	O
52	O
-	O
kDa	O
nuclear	O
factor	O
,	O
whereas	O
JunD	B-GENE
acts	O
as	O
a	O
repressor	O
of	O
this	O
response	O
.	O

Both	O
Rep78	B-GENE
and	O
Rep68	B-GENE
cut	O
the	O
terminal	O
AAV	O
sequence	O
at	O
the	O
same	O
site	O
(	O
nucleotide	O
124	O
)	O
.	O

The	O
SR	B-GENE
protein	I-GENE
family	I-GENE
is	O
involved	O
in	O
constitutive	O
and	O
regulated	O
pre	O
-	O
mRNA	O
splicing	O
and	O
has	O
been	O
found	O
to	O
be	O
evolutionarily	O
conserved	O
in	O
metazoan	O
organisms	O
.	O

Here	O
we	O
describe	O
and	O
map	O
two	O
more	O
new	O
genes	O
identified	O
as	O
allele	O
-	O
specific	O
suppressors	O
that	O
compensate	O
for	O
carboxy	O
-	O
terminal	O
truncation	O
of	O
PET122	B-GENE
.	O

2	O
.	O

Analysis	O
of	O
Msy2	B-GENE
mRNA	I-GENE
expression	O
in	O
prepubertal	O
and	O
adult	O
mouse	O
testes	O
,	O
and	O
in	O
isolated	O
populations	O
of	O
germ	O
cells	O
,	O
reveals	O
maximal	O
expression	O
in	O
postmeiotic	O
round	O
spermatids	O
,	O
a	O
cell	O
type	O
with	O
abundant	O
amounts	O
of	O
stored	O
messenger	O
ribonucleoproteins	O
.	O

Northern	O
(	O
RNA	O
)	O
analysis	O
demonstrated	O
expression	O
of	O
human	O
PI	B-GENE
3	I-GENE
-	I-GENE
kinase	I-GENE
in	O
all	O
tissues	O
and	O
cell	O
lines	O
tested	O
.	O

In	O
vitro	O
metabolism	O
of	O
progesterone	O
by	O
the	O
human	O
undescended	O
testis	O
.	O

Asthmatic	O
patients	O
showed	O
greater	O
responses	O
of	O
both	O
parameters	O
to	O
adrenaline	O
than	O
controls	O
indicating	O
that	O
long	O
-	O
term	O
corticosteroid	O
treatment	O
enhances	O
the	O
acute	O
responses	O
of	O
plasminogen	B-GENE
activator	I-GENE
and	O
clotting	B-GENE
factor	I-GENE
VIII	I-GENE
to	O
adrenaline	O
infusion	O
.	O

The	O
heart	O
rate	O
,	O
respiratory	O
rate	O
,	O
arterial	O
O2	O
and	O
systemic	O
vascular	O
resistance	O
were	O
not	O
significantly	O
altered	O
.	O

National	O
abortion	O
laws	O
usually	O
do	O
not	O
allow	O
abortion	O
when	O
a	O
foetus	O
is	O
independently	O
viable	O
,	O
i	O
.	O
e	O
.	O
from	O
a	O
gestational	O
age	O
of	O
about	O
24	O
weeks	O
.	O

Chernoff	O
,	O
submitted	O
for	O
publication	O
)	O
.	O

Although	O
E2FBP1	B-GENE
lacks	O
the	O
transactivation	O
domain	O
,	O
it	O
stimulates	O
E2F	B-GENE
site	O
-	O
dependent	O
transcription	O
in	O
cooperation	O
with	O
E2F	B-GENE
-	I-GENE
1	I-GENE
.	O

Although	O
olfactory	O
associative	O
conditioning	O
in	O
newborn	O
rats	O
produces	O
marked	O
structural	O
and	O
functional	O
changes	O
in	O
the	O
olfactory	O
bulb	O
,	O
recent	O
evidence	O
suggests	O
that	O
extrabulbar	O
circuits	O
must	O
be	O
involved	O
in	O
storing	O
these	O
early	O
memories	O
.	O

The	O
3	O
'	O
region	O
,	O
GA2	B-GENE
,	O
is	O
necessary	O
for	O
maximal	O
expression	O
.	O

There	O
was	O
no	O
clear	O
correlation	O
between	O
the	O
MFA	O
and	O
the	O
severity	O
of	O
the	O
UTS	O
phenotype	O
.	O

A	O
high	O
degree	O
of	O
correlation	O
in	O
the	O
sense	O
of	O
the	O
classic	O
conception	O
of	O
brain	O
localization	O
of	O
neuropsychological	O
syndromes	O
was	O
found	O
.	O

Encouraged	O
by	O
a	O
Dutch	O
study	O
using	O
etidronate	O
/	O
fluoride	O
in	O
corticoid	O
-	O
induced	O
osteoporosis	O
,	O
we	O
performed	O
a	O
pilot	O
study	O
in	O
33	O
men	O
with	O
severe	O
established	O
primary	O
osteoporosis	O
giving	O
cyclically	O
etidronate	O
for	O
14	O
days	O
followed	O
by	O
fluoride	O
plus	O
calcium	O
/	O
vitamin	O
D	O
for	O
76	O
days	O
.	O

The	O
prevalence	O
of	O
malnutrition	O
was	O
30	O
%	O
in	O
the	O
47	O
patients	O
without	O
CVD	O
and	O
was	O
significantly	O
higher	O
(	O
70	O
%	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
the	O
70	O
patients	O
with	O
CVD	O
,	O
who	O
also	O
had	O
lower	O
tHcy	O
,	O
SAlb	O
,	O
plasma	B-GENE
IGF	I-GENE
-	I-GENE
1	I-GENE
,	O
serum	O
creatinine	O
(	O
SCr	O
)	O
,	O
and	O
blood	B-GENE
hemoglobin	I-GENE
.	O

The	O
assay	O
exhibits	O
a	O
dynamic	O
range	O
of	O
0	O
.	O
1	O
-	O
100	O
micrograms	O
l	O
-	O
1	O
using	O
a	O
monoclonal	O
antibody	O
or	O
alternatively	O
10	O
micrograms	O
l	O
-	O
1	O
to	O
10	O
mg	O
l	O
-	O
1	O
using	O
commercially	O
available	O
antiserum	O
.	O

Mapping	O
results	O
suggested	O
that	O
the	O
complementation	O
group	O
identified	O
by	O
these	O
mutants	O
is	O
allelic	O
to	O
the	O
ag	B-GENE
alpha	I-GENE
1	I-GENE
mutation	O
identified	O
previously	O
.	O

Some	O
of	O
the	O
mutations	O
obtained	O
do	O
not	O
contain	O
a	O
copy	O
of	O
the	O
Ulysses	B-GENE
element	I-GENE
at	O
the	O
mutant	O
locus	O
,	O
suggesting	O
that	O
a	O
different	O
transposable	O
element	O
may	O
be	O
responsible	O
for	O
the	O
mutation	O
.	O

3	O
.	O
04	O
+	O
/	O
-	O
1	O
.	O
2	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
,	O
large	O
accelerations	O
/	O
30	O
min	O
(	O
1	O
.	O
46	O
+	O
/	O
-	O
1	O
.	O
96	O
vs	O
.	O

We	O
describe	O
a	O
total	O
of	O
39	O
DEAH	B-GENE
helicases	I-GENE
in	O
these	O
four	O
species	O
.	O

Quantitation	O
of	O
exocrine	B-GENE
IgA	I-GENE
in	O
human	O
serum	O
in	O
health	O
and	O
disease	O
.	O

For	O
228	O
of	O
425	O
deaths	O
(	O
54	O
%	O
)	O
occurring	O
among	O
26	O
100	O
people	O
of	O
known	O
age	O
in	O
the	O
Malumfashi	O
area	O
of	O
northern	O
Nigeria	O
,	O
data	O
were	O
collected	O
on	O
symptoms	O
present	O
prior	O
to	O
death	O
.	O

The	O
transcription	O
of	O
most	O
RP	B-GENE
genes	I-GENE
is	O
activated	O
by	O
two	O
Rap1p	B-GENE
binding	I-GENE
sites	I-GENE
,	O
250	O
to	O
400	O
bp	O
upstream	O
from	O
the	O
initiation	O
of	O
transcription	O
.	O

As	O
regards	O
lipid	O
metabolism	O
,	O
the	O
mean	O
values	O
for	O
total	O
triglycerides	O
,	O
cholesterol	O
,	O
LDL	O
-	O
cholesterol	O
and	O
HDL	O
-	O
cholesterol	O
seen	O
at	O
the	O
end	O
of	O
five	O
years	O
of	O
Norplant	O
-	O
2	O
rod	O
use	O
and	O
six	O
months	O
postremoval	O
were	O
similar	O
to	O
the	O
preinsertion	O
mean	O
.	O

We	O
have	O
recently	O
shown	O
that	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
the	O
RAR	B-GENE
beta	I-GENE
2	I-GENE
gene	I-GENE
in	I-GENE
mouse	I-GENE
embryos	I-GENE
is	O
regulated	O
at	O
the	O
translational	O
level	O
by	O
short	O
upstream	O
open	O
reading	O
frames	O
(	O
uORFs	O
)	O
In	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
(	O
Zimmer	O
,	O
A	O
.	O
,	O
A	O
.	O
M	O
.	O

Frequent	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
of	O
>	O
30	O
%	O
of	O
the	O
informative	O
cases	O
was	O
observed	O
on	O
chromosomes	O
3p	O
(	O
41	O
.	O
1	O
%	O
)	O
,	O
5q	O
(	O
52	O
.	O
6	O
%	O
)	O
,	O
6p	O
(	O
30	O
.	O
4	O
%	O
)	O
,	O
8p	O
(	O
33	O
.	O
3	O
%	O
)	O
,	O
9p	O
(	O
35	O
.	O
7	O
%	O
)	O
,	O
9q	O
(	O
30	O
.	O
8	O
%	O
)	O
,	O
11p	O
(	O
32	O
.	O
4	O
%	O
)	O
,	O
13q	O
(	O
52	O
.	O
7	O
%	O
)	O
,	O
17p	O
(	O
55	O
.	O
2	O
%	O
)	O
,	O
17q	O
(	O
33	O
.	O
3	O
%	O
)	O
,	O
18q	O
(	O
45	O
.	O
7	O
%	O
)	O
,	O
and	O
19q	O
(	O
30	O
.	O
4	O
%	O
)	O
.	O

PowerBLAST	O
analysis	O
identified	O
six	O
clusters	O
of	O
expressed	O
sequence	O
tags	O
(	O
ESTs	O
)	O
,	O
two	O
known	O
genes	O
(	O
BIR	B-GENE
,	O
SUR1	B-GENE
)	O
mapped	O
previously	O
to	O
this	O
region	O
,	O
and	O
a	O
previously	O
characterized	O
but	O
unmapped	O
gene	B-GENE
NEFA	I-GENE
(	O
DNA	B-GENE
binding	I-GENE
/	I-GENE
EF	I-GENE
hand	I-GENE
/	I-GENE
acidic	I-GENE
amino	I-GENE
-	I-GENE
acid	I-GENE
-	I-GENE
rich	I-GENE
)	O
.	O

A	O
cDNA	O
clone	O
pCZ1	O
,	O
with	O
a	O
1	O
.	O
1	O
kb	O
insert	O
,	O
was	O
isolated	O
from	O
a	O
NaCl	O
-	O
adapted	O
tobacco	O
cell	O
cDNA	O
library	O
that	O
encodes	O
an	O
apparently	O
full	O
-	O
length	O
29	O
kDa	O
protein	O
(	O
251	O
amino	O
acids	O
)	O
with	O
a	O
calculated	O
pI	O
of	O
5	O
.	O
7	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
The	O
two	O
groups	O
were	O
similar	O
on	O
entry	O
into	O
the	O
study	O
,	O
including	O
mean	O
FEV1	O
measurements	O
(	O
0	O
.	O
70	O
L	O
atropine	O
/	O
0	O
.	O
60	O
L	O
metaproterenol	O
,	O
P	O
greater	O
than	O
.	O
05	O
)	O
.	O

Decreased	O
levels	O
of	O
alpha2	B-GENE
-	I-GENE
antiplasmin	I-GENE
were	O
also	O
observed	O
in	O
the	O
mediastinum	O
(	O
0	O
.	O
50	O
versus	O
0	O
.	O
61	O
U	O
/	O
mL	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Postnatal	O
volumetric	O
development	O
of	O
the	O
prefrontal	O
cortex	O
in	O
the	O
rat	O
.	O

There	O
was	O
no	O
significant	O
correlation	O
between	O
baseline	O
PC40	O
methacholine	O
and	O
the	O
maximal	O
fall	O
in	O
Vp30	O
after	O
either	O
the	O
first	O
(	O
12	O
micrograms	O
)	O
or	O
the	O
second	O
dose	O
(	O
24	O
micrograms	O
)	O
of	O
platelet	B-GENE
activating	I-GENE
factor	I-GENE
.	O

S1	B-GENE
nuclease	I-GENE
analysis	O
of	O
RNA	O
prepared	O
after	O
transfection	O
of	O
these	O
HIV	O
constructs	O
into	O
HeLa	O
cells	O
infected	O
with	O
wild	O
-	O
type	O
adenovirus	O
indicated	O
that	O
the	O
enhancer	O
,	O
SP1	B-GENE
,	O
TATA	O
,	O
and	O
a	O
portion	O
of	O
the	O
transactivation	B-GENE
-	I-GENE
responsive	I-GENE
element	I-GENE
were	O
each	O
required	O
for	O
complete	O
E1A	O
/	O
E1B	O
-	O
mediated	O
activation	O
of	O
the	O
HIV	B-GENE
LTR	I-GENE
.	O

Long	O
-	O
range	O
mapping	O
of	O
the	O
11q23	O
region	O
involved	O
in	O
chromosome	O
aberrations	O
in	O
human	O
tumors	O
by	O
pulsed	O
-	O
field	O
gel	O
electrophoresis	O
with	O
a	O
yeast	O
artificial	O
chromosome	O
.	O

An	O
implant	O
may	O
release	O
a	O
drug	O
either	O
by	O
diffusion	O
concurrent	O
with	O
dissolution	O
of	O
the	O
polymeric	O
implant	O
material	O
without	O
depolymerization	O
(	O
Type	O
A	O
)	O
or	O
by	O
bioerosion	O
involving	O
depolymerization	O
(	O
Type	O
B	O
)	O
.	O

Plasma	B-GENE
secretin	I-GENE
,	O
pancreozymin	B-GENE
,	O
and	O
somatostatin	B-GENE
-	I-GENE
like	I-GENE
hormone	I-GENE
in	O
chronic	O
renal	O
failure	O
patients	O
.	O

Insertion	O
of	O
4	O
bp	O
reduced	O
SV40	O
early	O
promoter	O
-	O
dependent	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
(	O
CAT	B-GENE
)	O
expression	O
by	O
six	O
-	O
to	O
eightfold	O
.	O

CONCLUSIONS	O
:	O
AMVT	O
is	O
rare	O
but	O
a	O
potentially	O
lethal	O
emergency	O
disease	O
.	O

Lewis	O
,	O
N	O
.	O

The	O
preferences	O
were	O
for	O
intact	O
vis	O
-	O
a	O
-	O
vis	O
castrated	O
males	O
,	O
though	O
injections	O
of	O
TP	O
restored	O
the	O
castrates	O
'	O
attractiveness	O
to	O
the	O
females	O
.	O

This	O
animal	O
model	O
of	O
dystonia	O
appears	O
to	O
be	O
a	O
model	O
of	O
NAD	O
in	O
man	O
from	O
the	O
viewpoint	O
of	O
treatment	O
-	O
response	O
.	O

These	O
changes	O
correlate	O
directly	O
with	O
an	O
increase	O
in	O
the	O
acetylation	O
levels	O
of	O
all	O
four	O
core	B-GENE
histones	I-GENE
in	O
vivo	O
.	O

In	O
group	O
B	O
37	O
MBq	O
in	O
150	O
microL	O
of	O
99mTc	O
-	O
HSA	O
nanocolloid	O
was	O
additionally	O
injected	O
intradermally	O
18	O
h	O
before	O
surgery	O
(	O
3	O
-	O
6	O
aliquots	O
injected	O
perilesionally	O
)	O
.	O

Coronary	O
flow	O
was	O
reduced	O
by	O
10	O
%	O
in	O
the	O
phosphocreatine	O
and	O
by	O
18	O
%	O
in	O
the	O
control	O
group	O
.	O

In	O
vivo	O
,	O
MyoD	B-GENE
requires	O
this	O
tryptophan	O
motif	O
to	O
evoke	O
chromatin	O
remodeling	O
in	O
the	O
Myogenin	B-GENE
promoter	I-GENE
and	O
to	O
activate	O
Myogenin	B-GENE
transcription	O
.	O

Using	O
autoantibodies	O
from	O
a	O
Sjogren	O
'	O
s	O
syndrome	O
patient	O
,	O
we	O
have	O
previously	O
identified	O
a	O
230	O
-	O
kDa	O
peripheral	O
membrane	O
protein	O
associated	O
with	O
the	O
cytosolic	O
face	O
of	O
the	O
trans	O
-	O
Golgi	O
(	O
Kooy	O
,	O
J	O
.	O
,	O
Toh	O
,	O
B	O
.	O

The	O
single	O
strandedness	O
is	O
manifested	O
as	O
a	O
terminal	O
extension	O
of	O
the	O
G	O
-	O
rich	O
strand	O
(	O
G	O
tails	O
)	O
that	O
can	O
occur	O
independently	O
of	O
telomerase	B-GENE
,	O
suggesting	O
that	O
cdc17	B-GENE
/	I-GENE
pol1	I-GENE
mutants	I-GENE
exhibit	O
defects	O
in	O
telomeric	O
lagging	O
-	O
strand	O
synthesis	O
.	O

The	O
plasmatic	B-GENE
albumin	I-GENE
concentration	O
(	O
3	O
.	O
5	O
-	O
4	O
.	O
5	O
g	O
/	O
dl	O
)	O
represents	O
about	O
60	O
%	O
of	O
the	O
total	O
plasma	O
protein	O
.	O

Group	O
6	O
was	O
given	O
physostigmine	O
,	O
0	O
.	O
1	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
,	O
known	O
to	O
inhibit	O
cholinesterase	B-GENE
degradation	O
,	O
5	O
min	O
before	O
bupivacaine	O
administration	O
,	O
and	O
Group	O
7	O
received	O
a	O
combination	O
of	O
physostigmine	O
pretreatment	O
and	O
electrical	O
vagal	O
stimulation	O
.	O

We	O
conclude	O
that	O
,	O
with	O
autonomic	O
nervous	O
system	O
activity	O
intact	O
,	O
carotid	O
chemoreceptor	O
reflex	O
activation	O
can	O
elicit	O
an	O
absolute	O
reflexly	O
mediated	O
reduction	O
in	O
coronary	O
blood	O
flow	O
in	O
the	O
normal	O
,	O
conscious	O
dog	O
,	O
despite	O
an	O
increase	O
in	O
arterial	O
pressure	O
.	O

Furthermore	O
,	O
in	O
the	O
ischemia	O
/	O
angiotension	O
II	O
-	O
induced	O
AHF	O
model	O
,	O
NIC	O
decreased	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
(	O
LVEDP	O
)	O
.	O

These	O
results	O
suggest	O
that	O
decreased	O
class	B-GENE
I	I-GENE
enhancer	I-GENE
activity	O
in	O
Ad12	O
-	O
transformed	O
cells	O
may	O
,	O
at	O
least	O
in	O
part	O
,	O
be	O
due	O
to	O
the	O
higher	O
levels	O
of	O
an	O
enhancer	O
-	O
specific	O
factor	O
,	O
possibly	O
acting	O
as	O
a	O
repressor	O
.	O

Evaluation	O
of	O
thyroid	O
function	O
.	O

Combined	O
expression	O
of	O
c	B-GENE
-	I-GENE
Jun	I-GENE
and	O
p65	B-GENE
induced	O
vigorous	O
transcription	O
of	O
IL	B-GENE
-	I-GENE
2	I-GENE
promoter	O
-	O
and	O
CD28RE	B-GENE
-	I-GENE
driven	I-GENE
reporter	I-GENE
constructs	I-GENE
in	O
both	O
LFA	O
-	O
3	O
-	O
and	O
B7	O
-	O
1	O
-	O
costimulated	O
Jurkat	O
cells	O
.	O

Treadmill	O
training	O
at	O
least	O
for	O
2	O
weeks	O
can	O
reduce	O
the	O
infarction	O
size	O
and	O
edema	O
caused	O
by	O
MCA	O
occlusion	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

However	O
,	O
unlike	O
the	O
SIN3	B-GENE
gene	I-GENE
of	O
Saccharomyces	O
cerevisiae	O
,	O
pst1	B-GENE
(	I-GENE
+	I-GENE
)	I-GENE
is	O
essential	O
for	O
cell	O
viability	O
.	O

Calmodulin	B-GENE
-	I-GENE
binding	I-GENE
peptide	I-GENE
(	O
CBP	B-GENE
)	O
,	O
a	O
peptide	O
of	O
26	O
amino	O
acids	O
derived	O
from	O
muscle	B-GENE
myosin	I-GENE
light	I-GENE
chain	I-GENE
kinase	I-GENE
(	O
MLCK	B-GENE
)	O
,	O
binds	O
to	O
calmodulin	B-GENE
with	O
nanomolar	O
affinity	O
.	O

After	O
the	O
meal	O
containing	O
potato	O
,	O
plasma	O
glucose	O
levels	O
rose	O
sharply	O
,	O
peaked	O
at	O
30	O
-	O
45	O
min	O
and	O
fell	O
below	O
initial	O
levels	O
2	O
to	O
3	O
h	O
later	O
.	O

ATP	O
gamma	O
S	O
inhibition	O
can	O
be	O
overcome	O
by	O
high	O
concentrations	O
of	O
ATP	O
,	O
dATP	O
,	O
araATP	O
,	O
or	O
ddATP	O
.	O

The	O
gene	O
encodes	O
an	O
ATP	B-GENE
-	I-GENE
binding	I-GENE
cassette	I-GENE
,	I-GENE
ABC	I-GENE
transporter	I-GENE
.	O

Muscle	B-GENE
GSH	I-GENE
-	I-GENE
Px	I-GENE
activity	O
after	O
prolonged	O
exercise	O
,	O
training	O
,	O
and	O
selenium	O
supplementation	O
.	O

RESULTS	O
:	O
The	O
bovine	O
cDNA	O
insert	O
sequence	O
was	O
273	O
nucleotides	O
in	O
length	O
for	O
the	O
entire	O
mRNA	O
coding	O
region	O
,	O
212	O
nucleotides	O
in	O
the	O
5	O
'	O
untranslated	O
region	O
,	O
83	O
nucleotides	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
and	O
a	O
poly	O
(	O
A	O
)	O
tail	O
.	O

Therapeutic	O
use	O
of	O
cannabis	O
.	O

Toxicity	O
was	O
mild	O
,	O
mainly	O
consisting	O
of	O
emesis	O
(	O
81	O
%	O
of	O
the	O
patients	O
;	O
66	O
%	O
of	O
the	O
courses	O
)	O
,	O
leukopenia	O
of	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
grade	O
1	O
to	O
2	O
(	O
47	O
%	O
of	O
the	O
patients	O
;	O
18	O
%	O
of	O
the	O
courses	O
)	O
,	O
and	O
thrombocytopenia	O
(	O
12	O
%	O
of	O
the	O
patients	O
;	O
3	O
%	O
of	O
the	O
courses	O
)	O
.	O

Refractory	O
periods	O
of	O
the	O
AV	O
junction	O
were	O
altered	O
in	O
a	O
comparable	O
fashion	O
to	O
conduction	O
through	O
the	O
AV	O
node	O
.	O

Development	O
of	O
a	O
yeast	O
system	O
to	O
assay	O
mutational	O
specificity	O
.	O

Although	O
some	O
residues	O
are	O
found	O
reactive	O
toward	O
dimethylsulphate	O
and	O
kethoxal	O
in	O
regions	O
predicted	O
to	O
be	O
unpaired	O
by	O
the	O
phylogenetic	O
secondary	O
structure	O
model	O
of	O
4	B-GENE
.	I-GENE
5S	I-GENE
RNA	I-GENE
,	O
generally	O
the	O
reactivity	O
is	O
low	O
,	O
and	O
some	O
residues	O
in	O
internal	O
loops	O
are	O
not	O
reactive	O
at	O
all	O
.	O

Interpersonal	O
style	O
differences	O
among	O
drug	O
abusers	O
were	O
explored	O
using	O
Ryan	O
'	O
s	O
(	O
1977	O
)	O
typological	O
system	O
of	O
FIRO	O
-	O
B	O
interpretation	O
.	O

Fasting	O
plasma	O
and	O
lipoprotein	O
lipid	O
concentrations	O
,	O
adipose	B-GENE
tissue	I-GENE
lipoprotein	I-GENE
lipase	I-GENE
activity	O
,	O
anthropometric	O
data	O
,	O
alcohol	O
consumption	O
,	O
smoking	O
habits	O
,	O
weekly	O
mileage	O
run	O
and	O
performance	O
on	O
a	O
bicycle	O
ergometer	O
were	O
recorded	O
before	O
and	O
after	O
the	O
training	O
period	O
.	O

The	O
presence	O
of	O
circulating	O
platelet	O
aggregates	O
and	O
elevated	O
levels	O
of	O
fibrinopeptide	B-GENE
A	I-GENE
(	O
a	O
cleavage	O
product	O
of	O
fibrin	B-GENE
)	O
suggests	O
that	O
platelet	O
activation	O
and	O
fibrin	B-GENE
deposition	O
may	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
this	O
disorder	O
.	O

Additionally	O
in	O
seven	O
subjects	O
adrenaline	O
(	O
A	O
)	O
and	O
noradrenaline	O
(	O
NA	O
)	O
concentrations	O
were	O
determined	O
.	O

Direct	O
current	O
polarography	O
and	O
differential	O
pulse	O
polarographic	O
methods	O
have	O
been	O
developed	O
for	O
the	O
qualitative	O
as	O
well	O
as	O
quantitative	O
analysis	O
of	O
vitamin	O
B1	O
,	O
B2	O
and	O
B6	O
.	O

Body	O
fat	O
distribution	O
was	O
determined	O
by	O
abdominal	O
computed	O
tomography	O
.	O

Induction	O
of	O
Jurkat	O
leukemic	O
T	O
cells	O
with	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
and	O
ionomycin	O
did	O
not	O
affect	O
the	O
level	O
of	O
FKBP	B-GENE
mRNA	I-GENE
.	O

Because	O
the	O
DPPD	B-GENE
gene	I-GENE
is	O
not	O
present	O
in	O
non	O
-	O
tuberculous	O
bacilli	O
,	O
these	O
results	O
suggest	O
that	O
this	O
molecule	O
can	O
be	O
an	O
additional	O
tool	O
for	O
a	O
more	O
specific	O
diagnosis	O
of	O
tuberculosis	O
.	O

Mo	O
+	O
SV	O
M	O
-	O
MuLV	O
-	O
inoculated	O
animals	O
became	O
moribund	O
at	O
3	O
to	O
13	O
months	O
postinoculation	O
,	O
whereas	O
delta	O
Mo	O
+	O
SV	O
M	O
-	O
MuLV	O
-	O
inoculated	O
animals	O
became	O
moribund	O
at	O
6	O
to	O
24	O
months	O
postinoculation	O
.	O

Cowpox	O
virus	O
contains	O
two	O
copies	O
of	O
an	O
early	O
gene	O
encoding	O
a	O
soluble	O
secreted	O
form	O
of	O
the	O
type	B-GENE
II	I-GENE
TNF	I-GENE
receptor	I-GENE
.	O

Fetal	O
growth	O
retardation	O
as	O
a	O
cause	O
of	O
impaired	O
ovarian	O
development	O
.	O

Gas6	B-GENE
contains	O
an	O
NH2	O
-	O
terminal	O
Gla	O
domain	O
followed	O
by	O
four	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
-	I-GENE
like	I-GENE
repeats	I-GENE
and	O
tandem	O
globular	O
(	O
G	O
)	O
domains	O
.	O

As	O
control	O
,	O
the	O
cells	O
were	O
transfected	O
with	O
DNA	O
mixtures	O
containing	O
vector	O
mU6	O
-	O
C1	O
or	O
mU6	O
-	O
C2	O
.	O

This	O
result	O
suggests	O
that	O
phosphorylation	O
of	O
Thr	O
14	O
and	O
/	O
or	O
Tyr	O
15	O
inhibits	O
p34cdc2	B-GENE
kinase	I-GENE
activity	O
,	O
in	O
line	O
with	O
the	O
location	O
of	O
these	O
residues	O
within	O
the	O
putative	O
ATP	O
binding	O
site	O
of	O
the	O
kinase	B-GENE
.	O

We	O
have	O
previously	O
identified	O
a	O
liver	O
-	O
enriched	O
transcription	O
factor	O
,	O
HNF	B-GENE
-	I-GENE
6	I-GENE
,	O
which	O
is	O
required	O
for	O
HNF	B-GENE
-	I-GENE
3	I-GENE
beta	I-GENE
promoter	I-GENE
activity	O
and	O
also	O
recognizes	O
the	O
regulatory	O
region	O
of	O
numerous	O
hepatocyte	O
-	O
specific	O
genes	O
.	O

Two	O
evolutionarily	O
conserved	O
kinases	B-GENE
,	O
the	O
cyclin	B-GENE
B	I-GENE
(	I-GENE
Clb	I-GENE
)	I-GENE
/	I-GENE
cyclin	I-GENE
-	I-GENE
dependent	I-GENE
kinase	I-GENE
(	O
Cdk	B-GENE
/	I-GENE
Cdc28p	I-GENE
)	O
and	O
Cdc7p	B-GENE
along	O
with	O
its	O
interacting	O
factor	O
Dbf4p	B-GENE
,	O
are	O
required	O
late	O
in	O
G1	O
to	O
initiate	O
DNA	O
replication	O
.	O

An	O
ion	O
chromatographic	O
method	O
was	O
used	O
to	O
determine	O
Br	O
ion	O
in	O
the	O
urine	O
of	O
Greyhounds	O
.	O

On	O
the	O
other	O
hand	O
,	O
knowledge	O
of	O
the	O
epidemiology	O
of	O
Parkinson	O
'	O
s	O
disease	O
is	O
necessary	O
in	O
creating	O
etiological	O
hypotheses	O
,	O
since	O
only	O
hypotheses	O
consistent	O
with	O
the	O
epidemiological	O
profile	O
deserve	O
careful	O
testing	O
.	O

To	O
define	O
transcriptional	O
control	O
elements	O
responsible	O
for	O
muscle	O
-	O
specific	O
expression	O
of	O
the	O
human	B-GENE
myoglobin	I-GENE
gene	I-GENE
,	O
we	O
performed	O
mutational	O
analysis	O
of	O
upstream	O
sequences	O
(	O
nucleotide	O
positions	O
-	O
373	O
to	O
+	O
7	O
relative	O
to	O
the	O
transcriptional	O
start	O
site	O
)	O
linked	O
to	O
a	O
firefly	B-GENE
luciferase	I-GENE
gene	I-GENE
.	O

A	O
DNA	O
fragment	O
carrying	O
1	O
,	O
100	O
nucleotides	O
derived	O
from	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
UGT1A1	B-GENE
gene	I-GENE
was	O
enough	O
for	O
MC	O
induction	O
.	O

The	O
present	O
chemotherapy	O
of	O
AE	O
is	O
based	O
on	O
the	O
administration	O
of	O
benzimidazole	O
carbamate	O
derivatives	O
,	O
such	O
as	O
mebendazole	O
and	O
albendazole	O
.	O

Limits	O
of	O
energy	O
turnover	O
in	O
relation	O
to	O
physical	O
performance	O
were	O
addressed	O
in	O
terms	O
of	O
upper	O
and	O
lower	O
limit	O
,	O
changes	O
during	O
a	O
training	O
programme	O
and	O
how	O
to	O
regulate	O
energy	O
balance	O
at	O
a	O
changing	O
energy	O
turnover	O
.	O

Non	O
-	O
poliomyelitis	O
AFP	O
rate	O
had	O
increased	O
from	O
0	O
.	O
9	O
in	O
1997	O
to	O
2	O
.	O
8	O
in	O
1998	O
.	O

Most	O
yeast	B-GENE
peroxisomal	I-GENE
matrix	I-GENE
proteins	I-GENE
contain	O
a	O
type	B-GENE
1C	I-GENE
-	I-GENE
terminal	I-GENE
peroxisomal	I-GENE
targeting	I-GENE
signal	I-GENE
(	O
PTS1	B-GENE
)	O
consisting	O
of	O
the	O
tripeptide	B-GENE
SKL	I-GENE
or	O
a	O
conservative	O
variant	O
thereof	O
.	O

On	O
the	O
basis	O
of	O
these	O
relations	O
,	O
a	O
risk	O
factor	O
-	O
selection	O
scale	O
(	O
RFSS	O
)	O
(	O
range	O
,	O
0	O
to	O
10	O
)	O
was	O
developed	O
by	O
computing	O
appropriate	O
weights	O
for	O
each	O
risk	O
factor	O
.	O

Mis3	B-GENE
is	O
needed	O
for	O
the	O
formation	O
of	O
18S	B-GENE
ribosome	I-GENE
RNA	I-GENE
,	O
and	O
may	O
hence	O
direct	O
the	O
level	O
of	O
proteins	O
required	O
for	O
the	O
coupling	O
.	O

GRFI	B-GENE
bound	O
to	O
sequences	O
at	O
the	O
negative	O
regulatory	O
elements	O
(	O
silencers	O
)	O
of	O
the	O
silent	B-GENE
mating	I-GENE
type	I-GENE
loci	I-GENE
HML	B-GENE
E	I-GENE
and	O
HMR	B-GENE
E	I-GENE
and	O
to	O
the	O
upstream	B-GENE
activating	I-GENE
sequence	I-GENE
(	O
UAS	B-GENE
)	O
required	O
for	O
transcription	O
of	O
the	O
MAT	B-GENE
alpha	I-GENE
genes	I-GENE
.	O

Large	O
-	O
scale	O
sequencing	O
of	O
two	O
regions	O
in	O
human	O
chromosome	O
7q22	O
:	O
analysis	O
of	O
650	O
kb	O
of	O
genomic	O
sequence	O
around	O
the	O
EPO	B-GENE
and	O
CUTL1	B-GENE
loci	I-GENE
reveals	O
17	O
genes	O
.	O

Taken	O
together	O
,	O
our	O
results	O
indicate	O
that	O
the	O
FCR1	B-GENE
gene	I-GENE
behaves	O
as	O
a	O
negative	O
regulator	O
of	O
drug	O
resistance	O
in	O
C	O
.	O
albicans	O
and	O
constitute	O
the	O
first	O
evidence	O
that	O
FCZ	O
resistance	O
can	O
result	O
from	O
the	O
inactivation	O
of	O
a	O
regulatory	O
factor	O
such	O
as	O
Fcr1p	B-GENE
.	O

This	O
emancipation	O
of	O
the	O
ability	O
to	O
copulate	O
from	O
hormonal	O
influence	O
makes	O
female	O
sexual	O
motivation	O
the	O
primary	O
regulator	O
of	O
mating	O
in	O
primates	O
.	O

These	O
data	O
demonstrate	O
that	O
the	O
STR	B-GENE
family	I-GENE
of	O
genes	O
is	O
represented	O
in	O
a	O
nematode	O
whose	O
ancestor	O
appeared	O
well	O
before	O
the	O
branching	O
that	O
gave	O
rise	O
to	O
the	O
Arthropoda	O
and	O
Chordata	O
.	O

The	O
Saccharomyces	B-GENE
cerevisiae	I-GENE
APS1	I-GENE
gene	I-GENE
encodes	O
a	O
homolog	O
of	O
the	O
small	O
subunit	O
of	O
the	O
mammalian	B-GENE
clathrin	I-GENE
AP	B-GENE
-	I-GENE
1	I-GENE
complex	I-GENE
:	O
evidence	O
for	O
functional	O
interaction	O
with	O
clathrin	B-GENE
at	O
the	O
Golgi	O
complex	O
.	O

In	O
girls	O
prolactin	B-GENE
levels	O
rise	O
at	O
stage	O
2	O
,	O
and	O
are	O
higher	O
after	O
menarche	O
;	O
in	O
boys	O
there	O
is	O
no	O
change	O
in	O
prolactin	B-GENE
levels	O
.	O

Spasmus	O
nutans	O
:	O
a	O
syndrome	O
of	O
auto	O
-	O
arousal	O
.	O

The	O
effects	O
of	O
diltiazem	O
were	O
stereoselective	O
,	O
thus	O
the	O
potentiation	O
induced	O
by	O
d	O
-	O
cis	O
diltiazem	O
was	O
significantly	O
greater	O
in	O
all	O
cases	O
than	O
that	O
induced	O
by	O
l	O
-	O
cis	O
diltiazem	O
,	O
which	O
suggests	O
that	O
calcium	O
channel	O
blockade	O
plays	O
a	O
role	O
in	O
these	O
interactions	O
.	O

These	O
results	O
suggest	O
that	O
the	O
c	B-GENE
-	I-GENE
met	I-GENE
gene	I-GENE
is	O
also	O
a	O
target	O
of	O
p53	B-GENE
gene	I-GENE
regulation	O
.	O

Dorsal	O
foot	O
TcpO2	O
was	O
measured	O
by	O
using	O
oxygen	O
-	O
sensing	O
electrodes	O
with	O
surface	O
temperatures	O
of	O
42	O
degrees	O
C	O
and	O
45	O
degrees	O
C	O
;	O
in	O
theory	O
,	O
changes	O
in	O
sympathetic	O
activity	O
should	O
affect	O
vasomotor	O
tone	O
and	O
TcpO2	O
in	O
skin	O
beneath	O
an	O
electrode	O
at	O
42	O
degrees	O
C	O
(	O
submaximal	O
vasodilation	O
)	O
,	O
but	O
not	O
at	O
45	O
degrees	O
C	O
(	O
maximal	O
vasodilation	O
)	O
.	O

The	O
84	B-GENE
.	I-GENE
1C	I-GENE
mAb	I-GENE
recognizes	O
a	O
site	O
on	O
IgE	B-GENE
which	O
is	O
identical	O
or	O
very	O
close	O
to	O
the	O
Fc	B-GENE
epsilon	I-GENE
R	I-GENE
binding	I-GENE
site	I-GENE
,	O
and	O
95	O
.	O
3	O
recognizes	O
a	O
site	O
on	O
IgE	B-GENE
which	O
is	O
related	O
,	O
but	O
not	O
identical	O
to	O
the	O
Fc	B-GENE
epsilon	I-GENE
R	I-GENE
binding	I-GENE
site	I-GENE
.	O

Previous	O
studies	O
have	O
shown	O
that	O
the	O
pro	O
-	O
inflammatory	O
cytokines	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
alpha	I-GENE
and	O
interferon	B-GENE
gamma	I-GENE
reduce	O
the	O
expression	O
of	O
the	O
cystic	B-GENE
fibrosis	I-GENE
transmembrane	I-GENE
conductance	I-GENE
regulator	I-GENE
(	O
CFTR	B-GENE
)	O
gene	O
(	O
CFTR	B-GENE
)	O
in	O
HT	O
-	O
29	O
and	O
T84	O
cells	O
by	O
acting	O
post	O
-	O
transcriptionally	O
.	O

Therefore	O
,	O
we	O
propose	O
that	O
p27	B-GENE
represents	O
a	O
crucial	O
molecule	O
in	O
HMBA	O
signaling	O
that	O
cannot	O
be	O
replaced	O
by	O
p21	B-GENE
.	O

No	O
case	O
of	O
SMF	O
demonstrated	O
expansive	O
tumorous	O
growth	O
.	O

The	O
injection	O
of	O
XDRP1	B-GENE
protein	I-GENE
into	O
fertilized	O
Xenopus	O
eggs	O
blocked	O
embryonic	O
cell	O
division	O
.	O

Lck	B-GENE
has	O
been	O
postulated	O
to	O
dimerize	O
through	O
the	O
SH2	B-GENE
and	O
SH3	B-GENE
domains	I-GENE
.	O

The	O
kinase	O
activity	O
of	O
PfPK6	B-GENE
is	O
sensitive	O
to	O
CDK	B-GENE
inhibitors	O
such	O
as	O
olomoucine	O
and	O
roscovitine	O
.	O

Both	O
HERV	O
-	O
K	O
type	O
1	O
and	O
2	O
clones	O
were	O
isolated	O
.	O

These	O
results	O
were	O
compared	O
with	O
the	O
estimates	O
of	O
penetration	O
from	O
steady	O
-	O
state	O
calculations	O
,	O
square	O
root	O
of	O
time	O
calculations	O
,	O
and	O
a	O
biologically	O
based	O
mathematical	O
model	O
.	O

Human	B-GENE
immunodeficiency	I-GENE
virus	I-GENE
type	I-GENE
1	I-GENE
Vpr	I-GENE
is	O
a	O
virion	O
-	O
associated	O
,	O
regulatory	O
protein	O
that	O
is	O
required	O
for	O
efficient	O
viral	O
replication	O
in	O
monocytes	O
/	O
macrophages	O
.	O

Treatment	O
of	O
Paget	O
'	O
s	O
disease	O
.	O

Furthermore	O
,	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
from	O
LAT	O
-	O
deficient	O
mice	O
displayed	O
reduced	O
phagocytic	O
efficiency	O
in	O
comparison	O
to	O
the	O
macrophages	O
from	O
wild	O
-	O
type	O
mice	O
.	O

SETTING	O
:	O
University	O
of	O
Paris	O
VII	O
hospital	O
.	O
Patient	O
(	O
s	O
)	O
:	O
Nine	O
women	O
had	O
embolization	O
for	O
symptomatic	O
myoma	O
,	O
with	O
12	O
pregnancies	O
observed	O
.	O

Analysis	O
of	O
functional	O
domains	O
of	O
Arix	B-GENE
reveals	O
an	O
N	O
-	O
terminal	O
activation	O
domain	O
and	O
a	O
C	O
-	O
terminal	O
repression	O
domain	O
.	O

Nuclear	B-GENE
receptors	I-GENE
(	O
NRs	B-GENE
)	O
can	O
function	O
as	O
ligandinducible	O
transregulators	O
in	O
both	O
mammalian	O
and	O
yeast	O
cells	O
,	O
indicating	O
that	O
important	O
features	O
of	O
transcriptional	O
control	O
have	O
been	O
conserved	O
throughout	O
evolution	O
.	O

Mn2	O
+	O
increased	O
both	O
the	O
junction	O
binding	O
and	O
cleaving	O
activities	O
of	O
the	O
mutant	O
proteins	O
.	O

The	O
Drosophila	B-GENE
suppressor	I-GENE
of	I-GENE
sable	I-GENE
gene	I-GENE
encodes	O
a	O
polypeptide	O
with	O
regions	O
similar	O
to	O
those	O
of	O
RNA	O
-	O
binding	O
proteins	O
.	O

High	O
resolution	O
computed	O
tomography	O
of	O
the	O
lungs	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
.	O

RESULTS	O
:	O
During	O
the	O
7	O
-	O
year	O
period	O
,	O
10	O
,	O
331	O
symptomatic	O
duodenal	O
ulcer	O
diseases	O
were	O
diagnosed	O
.	O

In	O
our	O
opinion	O
,	O
the	O
SM	O
-	O
CMA	O
system	O
is	O
,	O
despite	O
some	O
shortcomings	O
in	O
its	O
user	O
-	O
interface	O
,	O
a	O
useful	O
and	O
versatile	O
instrument	O
for	O
examination	O
of	O
human	O
semen	O
samples	O
,	O
with	O
desirable	O
features	O
.	O

These	O
results	O
support	O
the	O
diagnostic	O
validity	O
of	O
NFPD	O
in	O
CP	O
/	O
NCA	O
patients	O
,	O
because	O
such	O
patients	O
had	O
a	O
family	O
history	O
of	O
panic	O
disorder	O
similar	O
to	O
patients	O
with	O
a	O
more	O
classical	O
panic	O
disorder	O
presentation	O
.	O

On	O
the	O
basis	O
of	O
histopathological	O
findings	O
,	O
the	O
origin	O
of	O
amyloid	O
appeared	O
to	O
be	O
closely	O
related	O
to	O
the	O
fibroblasts	O
.	O

We	O
have	O
isolated	O
a	O
Drosophila	O
melanogaster	O
(	O
Dm	O
)	O
cDNA	O
encoding	O
a	O
polypeptide	O
that	O
has	O
extensive	O
sequence	O
similarity	O
to	O
the	O
mammalian	B-GENE
MAPKAPK	I-GENE
-	I-GENE
2	I-GENE
.	O

Here	O
,	O
we	O
present	O
evidence	O
that	O
exposure	O
of	O
DT40	O
lymphoma	O
B	O
cells	O
to	O
low	O
energy	O
electromagnetic	O
field	O
(	O
EMF	O
)	O
results	O
in	O
a	O
tyrosine	O
kinase	O
-	O
dependent	O
activation	O
of	O
phospholipase	B-GENE
Cgamma2	I-GENE
(	O
PLC	B-GENE
-	I-GENE
gamma2	I-GENE
)	O
leading	O
to	O
increased	O
inositol	O
phospholipid	O
turnover	O
.	O

Inhibition	O
of	O
RNA2	B-GENE
translation	O
was	O
selective	O
,	O
with	O
no	O
effect	O
on	O
general	O
cellular	O
translation	O
or	O
translation	O
of	O
BMV	O
RNA1	B-GENE
-	I-GENE
encoded	I-GENE
replication	I-GENE
factor	I-GENE
1a	I-GENE
,	O
and	O
was	O
independent	O
of	O
p20	B-GENE
,	O
a	O
cellular	O
antagonist	O
of	O
DED1	B-GENE
function	O
in	O
translation	O
.	O

Clinical	O
and	O
anatomical	O
considerations	O
.	O

Salazopyrine	O
desensitization	O
.	O

Despite	O
the	O
favourable	O
natural	O
history	O
of	O
acute	O
BI	O
,	O
mild	O
,	O
moderate	O
,	O
and	O
severe	O
posttraumatic	O
changes	O
were	O
shown	O
to	O
appear	O
as	O
cicatricial	O
-	O
adhesive	O
and	O
atrophic	O
processes	O
,	O
intracerebral	O
cysts	O
,	O
porencephaly	O
,	O
which	O
result	O
in	O
posttraumatic	O
epilepsy	O
,	O
hydrocephalus	O
,	O
etc	O
.	O

Third	O
-	O
and	O
later	O
-	O
parity	O
cows	O
were	O
randomly	O
assigned	O
after	O
each	O
parturition	O
to	O
Charolais	O
and	O
Red	O
Poll	O
bulls	O
in	O
multiple	O
-	O
sire	O
pastures	O
.	O

Under	O
our	O
conditions	O
,	O
the	O
combination	O
O3	O
/	O
UV	O
did	O
not	O
improve	O
the	O
degradation	O
rate	O
obtained	O
by	O
ozonation	O
.	O

For	O
sputum	B-GENE
interleukin	I-GENE
-	I-GENE
8	I-GENE
there	O
was	O
an	O
estimated	O
true	O
treatment	O
median	O
difference	O
of	O
142	O
pg	O
/	O
ml	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
8	O
to	O
2866	O
pg	O
/	O
ml	O
)	O
in	O
favour	O
of	O
placebo	O
;	O
while	O
for	O
maximal	O
expiratory	O
flow	O
at	O
25	O
%	O
(	O
MEF25	O
%	O
)	O
remaining	O
forced	O
vital	O
capacity	O
predicted	O
for	O
sex	O
and	O
height	O
there	O
was	O
a	O
15	O
percentage	O
points	O
(	O
pp	O
)	O
(	O
95	O
%	O
CI	O
4	O
to	O
26	O
pp	O
)	O
mean	O
treatment	O
difference	O
in	O
favour	O
of	O
placebo	O
.	O

Genetic	O
alterations	O
in	O
elements	O
of	O
normal	O
signal	O
transduction	O
mechanisms	O
are	O
known	O
to	O
be	O
oncogenic	O
events	O
often	O
resulting	O
in	O
aberrant	O
activation	O
of	O
programs	O
of	O
gene	O
transcription	O
.	O

In	O
the	O
diabetics	O
,	O
Ca2	O
+	O
infusions	O
induced	O
a	O
rise	O
of	O
plasma	O
Ca2	O
+	O
up	O
to	O
3	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
1	O
mmol	O
/	O
1	O
and	O
a	O
fall	O
of	O
circulating	O
glucagon	B-GENE
(	O
-	O
26	O
.	O
4	O
+	O
/	O
-	O
5	O
.	O
7	O
%	O
;	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
glucose	O
(	O
-	O
23	O
.	O
3	O
+	O
/	O
-	O
3	O
.	O
6	O
%	O
;	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

This	O
gene	O
spans	O
23	O
kb	O
and	O
is	O
composed	O
of	O
five	O
exons	O
and	O
four	O
introns	O
.	O

They	O
observed	O
depressed	O
protein	B-GENE
C	I-GENE
activity	O
that	O
significantly	O
(	O
p	O
<	O
0	O
.	O
005	O
)	O
increased	O
and	O
became	O
normal	O
immediately	O
after	O
hemodialysis	O
while	O
factor	B-GENE
X	I-GENE
and	O
factor	B-GENE
VII	I-GENE
increased	O
(	O
p	O
<	O
0	O
.	O
01	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
despite	O
heparinization	O
together	O
with	O
amount	O
of	O
serum	B-GENE
lipoprotein	I-GENE
(	I-GENE
a	I-GENE
)	I-GENE
.	O

The	O
data	O
presented	O
in	O
this	O
work	O
indicate	O
that	O
thi1	B-GENE
may	O
also	O
be	O
involved	O
in	O
DNA	O
damage	O
tolerance	O
in	O
plant	O
cells	O
.	O

For	O
the	O
5HT5A	B-GENE
receptor	I-GENE
the	O
addition	O
of	O
yohimbine	O
resulted	O
in	O
a	O
similar	O
but	O
smaller	O
effect	O
.	O

Sequence	O
comparisons	O
have	O
shown	O
that	O
Aps1p	B-GENE
is	O
more	O
similar	O
to	O
the	O
sigma	O
subunit	O
of	O
the	O
Golgi	O
-	O
localized	O
mammalian	O
AP	B-GENE
-	I-GENE
1	I-GENE
complex	I-GENE
than	O
Aps2p	B-GENE
,	O
which	O
is	O
more	O
related	O
to	O
the	O
plasma	O
membrane	O
AP	B-GENE
-	I-GENE
2	I-GENE
sigma	I-GENE
subunit	O
.	O

The	O
levels	O
of	O
fibrinogen	B-GENE
as	O
well	O
as	O
antithrombin	B-GENE
III	I-GENE
(	O
ATIII	B-GENE
)	O
and	O
heparin	B-GENE
cofactor	I-GENE
II	I-GENE
(	O
HCII	B-GENE
)	O
activities	O
were	O
steadily	O
increased	O
in	O
loop	O
-	O
bearing	O
animals	O
.	O

Another	O
group	O
of	O
HIPP	O
-	O
and	O
HCX	O
-	O
lesioned	O
animals	O
trained	O
on	O
the	O
tasks	O
after	O
the	O
lesion	O
showed	O
reduced	O
impairments	O
of	O
the	O
type	O
described	O
above	O
,	O
suggesting	O
that	O
extrahippocampal	O
structures	O
trained	O
after	O
the	O
lesion	O
can	O
assume	O
the	O
role	O
of	O
the	O
hippocampus	O
to	O
some	O
degree	O
.	O

Two	O
domains	O
of	O
EBNA2	B-GENE
defined	O
by	O
deletion	O
of	O
amino	O
acids	O
247	O
-	O
337	O
and	O
437	O
-	O
476	O
were	O
found	O
to	O
be	O
important	O
for	O
the	O
activation	O
of	O
both	O
promoters	O
,	O
while	O
two	O
different	O
domains	O
corresponding	O
to	O
residues	O
4	O
-	O
18	O
and	O
118	O
-	O
198	O
were	O
required	O
solely	O
for	O
the	O
LMP1	B-GENE
promoter	I-GENE
.	O

These	O
results	O
indicate	O
that	O
the	O
total	O
number	O
of	O
subunit	O
c	O
in	O
F0	B-GENE
should	O
be	O
a	O
multiple	O
of	O
2	O
and	O
3	O
.	O

At	O
termination	O
(	O
gd	O
20	O
)	O
,	O
confirmed	O
-	O
pregnant	O
females	O
(	O
21	O
to	O
25	O
per	O
group	O
)	O
were	O
evaluated	O
for	O
clinical	O
status	O
and	O
gestational	O
outcome	O
;	O
live	O
fetuses	O
were	O
examined	O
for	O
external	O
,	O
visceral	O
,	O
and	O
skeletal	O
malformations	O
.	O

Is	O
more	O
better	O
?	O
About	O
dose	O
levels	O
of	O
ACE	B-GENE
inhibitors	O
in	O
chronic	O
heart	O
failure	O
.	O

To	O
determine	O
which	O
region	O
of	O
SulA	B-GENE
is	O
essential	O
for	O
the	O
inhibition	O
of	O
cell	O
division	O
,	O
we	O
constructed	O
a	O
series	O
of	O
N	O
-	O
terminal	O
and	O
C	O
-	O
terminal	O
deletions	O
of	O
SulA	B-GENE
and	O
a	O
series	O
of	O
alanine	O
substitution	O
mutants	O
.	O

Shape	O
factor	O
correlated	O
well	O
with	O
hemodynamic	O
data	O
for	O
RV	O
/	O
LV	O
systolic	O
pressure	O
ratios	O
(	O
r	O
=	O
0	O
.	O
93	O
,	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
for	O
normalized	O
interventricular	O
pressure	O
differences	O
(	O
r	O
=	O
-	O
0	O
.	O
95	O
,	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

The	O
mutation	O
experiments	O
showed	O
that	O
the	O
most	O
critical	O
sequence	O
for	O
the	O
repression	O
of	O
PTH	B-GENE
was	O
5	B-GENE
'	I-GENE
-	I-GENE
GGGGGAGGGGAG	I-GENE
-	I-GENE
3	I-GENE
'	I-GENE
(	I-GENE
+	I-GENE
1	I-GENE
to	I-GENE
+	I-GENE
12	I-GENE
)	I-GENE
of	O
PTHSR	B-GENE
.	O

In	O
general	O
,	O
the	O
filtration	O
rate	O
in	O
relevant	O
areas	O
appears	O
to	O
be	O
an	O
integrative	O
and	O
easily	O
determined	O
parameter	O
,	O
reflecting	O
hormonal	O
and	O
neurogenic	O
vascular	O
as	O
well	O
as	O
local	O
interstitial	O
control	O
of	O
the	O
Starling	O
forces	O
.	O

Two	O
putative	O
12	B-GENE
-	I-GENE
O	I-GENE
-	I-GENE
tetradecanoyl	I-GENE
-	I-GENE
phorbol	I-GENE
-	I-GENE
13	I-GENE
-	I-GENE
acetate	I-GENE
(	I-GENE
TPA	I-GENE
)	I-GENE
response	I-GENE
elements	I-GENE
,	O
that	O
might	O
serve	O
as	O
binding	O
sites	O
for	O
the	O
transcription	B-GENE
factor	I-GENE
AP	I-GENE
-	I-GENE
1	I-GENE
and	O
a	O
consensus	O
sequence	O
of	O
a	O
transforming	B-GENE
growth	I-GENE
factor	I-GENE
beta	I-GENE
1	I-GENE
(	O
TGF	B-GENE
-	I-GENE
beta	I-GENE
1	I-GENE
)	O
inhibitory	O
element	O
were	O
found	O
in	O
the	O
promoter	O
region	O
.	O

Crosstalk	O
among	O
the	O
pathways	O
may	O
explain	O
how	O
some	O
forms	O
of	O
stress	O
can	O
contribute	O
to	O
the	O
development	O
of	O
a	O
malignancy	O
.	O

Analysis	O
of	O
electrically	O
evoked	O
response	O
(	O
EER	O
)	O
in	O
relation	O
to	O
the	O
central	O
visual	O
pathway	O
of	O
the	O
cat	O
(	O
1	O
)	O
.	O

The	O
effectiveness	O
of	O
alpha	O
-	O
mercapto	O
-	O
beta	O
-	O
(	O
2	O
-	O
furyl	O
)	O
acrylic	O
acid	O
(	O
MFA	O
)	O
and	O
N	O
-	O
benzyl	O
-	O
N	O
-	O
dithiocarboxy	O
-	O
D	O
-	O
glucamine	O
(	O
NaB	O
)	O
,	O
used	O
in	O
combination	O
,	O
in	O
the	O
mobilization	O
and	O
excretion	O
of	O
lead	O
was	O
investigated	O
in	O
rats	O
.	O

The	O
319	O
base	O
pair	O
region	O
immediately	O
upstream	O
of	O
the	O
CAP	O
site	O
is	O
characterized	O
by	O
the	O
lack	O
of	O
a	O
proximal	O
TATA	O
box	O
and	O
the	O
presence	O
of	O
sequences	O
similar	O
to	O
GC	O
boxes	O
,	O
CACCC	O
boxes	O
,	O
CCAAT	O
boxes	O
,	O
activator	B-GENE
protein	I-GENE
2	I-GENE
(	O
Ap	B-GENE
-	I-GENE
2	I-GENE
)	O
sites	O
,	O
partial	O
glucocorticoid	B-GENE
response	I-GENE
elements	I-GENE
(	O
GREs	B-GENE
)	O
,	O
and	O
partial	O
cyclic	B-GENE
AMP	I-GENE
response	I-GENE
elements	I-GENE
(	O
CREs	B-GENE
)	O
.	O

This	O
two	O
-	O
helix	O
motif	O
is	O
thought	O
to	O
be	O
involved	O
in	O
specific	O
DNA	O
sequence	O
recognition	O
by	O
CAP	B-GENE
.	O

Vitamin	O
D3	O
and	O
calcium	O
absorption	O
in	O
the	O
chick	O
.	O

Far	O
from	O
this	O
being	O
the	O
case	O
,	O
however	O
,	O
the	O
measurement	O
of	O
apo	B-GENE
B	I-GENE
has	O
met	O
every	O
reasonable	O
standard	O
of	O
laboratory	O
precision	O
and	O
reliability	O
to	O
allow	O
its	O
widespread	O
introduction	O
in	O
clinical	O
laboratories	O
.	O

Under	O
halothane	O
anesthesia	O
,	O
the	O
flow	O
pneumocardiogram	O
(	O
PnCG	O
)	O
and	O
its	O
time	O
derivative	O
(	O
acceleration	O
pneumocardiogram	O
or	O
dPn	O
/	O
dt	O
)	O
were	O
transduced	O
during	O
apnea	O
by	O
a	O
small	O
high	O
-	O
gain	O
pneumotachograph	O
.	O

Phosphorylation	O
of	O
myosin	B-GENE
-	I-GENE
binding	I-GENE
subunit	I-GENE
(	O
MBS	B-GENE
)	O
of	O
myosin	B-GENE
phosphatase	I-GENE
by	O
Rho	B-GENE
-	I-GENE
kinase	I-GENE
in	O
vivo	O
.	O

GTRE	B-GENE
,	O
TRE	B-GENE
,	O
and	O
CRE	B-GENE
oligonucleotides	O
all	O
compete	O
more	O
efficiently	O
for	O
protein	O
binding	O
to	O
their	O
labeled	O
congeners	O
than	O
for	O
protein	O
binding	O
to	O
either	O
of	O
the	O
other	O
labeled	O
oligonucleotides	O
,	O
suggesting	O
that	O
the	O
GTRE	B-GENE
,	O
TRE	B-GENE
,	O
and	O
CRE	B-GENE
oligonucleotides	O
,	O
suggesting	O
that	O
the	O
GTRE	B-GENE
,	O
TRE	B-GENE
,	O
and	O
CRE	B-GENE
oligonucleotides	O
each	O
bind	O
unique	O
as	O
well	O
as	O
common	O
proteins	O
,	O
likely	O
to	O
be	O
members	O
of	O
the	O
Jun	B-GENE
/	I-GENE
Fos	I-GENE
and	O
cAMP	B-GENE
-	I-GENE
responsive	I-GENE
element	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
/	I-GENE
activating	I-GENE
transcription	I-GENE
factors	I-GENE
(	O
CREB	B-GENE
/	I-GENE
ATF	I-GENE
)	O
families	O
of	O
transcription	O
factors	O
,	O
in	O
chromaffin	O
cells	O
.	O

We	O
have	O
generated	O
various	O
base	O
substitutions	O
and	O
internal	O
deletions	O
in	O
and	O
around	O
DRE	B-GENE
(	O
nucleotide	O
positions	O
-	O
93	O
to	O
-	O
100	O
with	O
respect	O
to	O
the	O
transcription	O
initiation	O
site	O
)	O
of	O
the	O
PCNA	B-GENE
gene	I-GENE
in	O
vitro	O
and	O
subsequently	O
examined	O
their	O
effects	O
on	O
the	O
binding	O
to	O
DREF	B-GENE
(	O
DRE	B-GENE
-	I-GENE
binding	I-GENE
factor	I-GENE
)	O
and	O
PCNA	B-GENE
gene	I-GENE
promote	O
activity	O
in	O
cultured	O
Drosophila	O
Kc	O
cells	O
as	O
well	O
as	O
in	O
living	O
flies	O
.	O

Transient	O
transfections	O
showed	O
that	O
a	O
single	O
mutation	O
(	O
556M	O
)	O
decreased	O
TBLV	B-GENE
enhancer	I-GENE
activity	O
at	O
least	O
20	O
-	O
fold	O
in	O
two	O
different	O
T	O
-	O
cell	O
lines	O
.	O

Fas	B-GENE
has	O
been	O
shown	O
to	O
require	O
ICE	B-GENE
(	O
interleukin	B-GENE
-	I-GENE
1	I-GENE
beta	I-GENE
-	I-GENE
converting	I-GENE
enzyme	I-GENE
)	O
family	O
proteases	O
to	O
induce	O
apoptosis	O
from	O
studies	O
utilizing	O
the	O
cowpox	O
ICE	B-GENE
inhibitor	I-GENE
protein	I-GENE
CrmA	B-GENE
,	O
the	O
synthetic	O
tetrapeptide	O
ICE	B-GENE
inhibitor	O
YVAD	B-GENE
-	I-GENE
CMK	I-GENE
,	O
and	O
the	O
tripeptide	O
pan	O
-	O
ICE	O
inhibitor	O
Z	B-GENE
-	I-GENE
VAD	I-GENE
-	I-GENE
FMK	I-GENE
.	O

However	O
,	O
the	O
lens	O
dose	O
(	O
3	O
.	O
6	O
Gy	O
/	O
25	O
fractions	O
)	O
was	O
higher	O
compared	O
to	O
the	O
other	O
techniques	O
.	O

An	O
inverted	O
Alu	B-GENE
repeat	I-GENE
element	I-GENE
,	O
flanked	O
by	O
nonamer	O
direct	O
repeats	O
,	O
was	O
identified	O
within	O
the	O
region	O
-	O
913	O
/	O
-	O
620	O
,	O
relative	O
to	O
the	O
cap	O
site	O
.	O

Studies	O
using	O
a	O
reporter	O
plasmid	O
with	O
a	O
functionally	O
disrupted	O
sterol	B-GENE
-	I-GENE
responsive	I-GENE
element	I-GENE
(	O
SRE	B-GENE
)	O
-	O
1	O
revealed	O
a	O
reduced	O
stimulatory	O
response	O
to	O
IL	B-GENE
-	I-GENE
6	I-GENE
.	O

The	O
proposed	O
algorithm	O
consists	O
of	O
several	O
steps	O
.	O

Ganciclovir	O
and	O
foscarnet	O
efficacy	O
in	O
AIDS	O
-	O
related	O
CMV	O
polyradiculopathy	O
.	O

A	O
.	O

Although	O
both	O
transfected	O
cell	O
lines	O
contain	O
FGF	B-GENE
-	I-GENE
1	I-GENE
cell	I-GENE
surface	I-GENE
receptors	I-GENE
as	O
judged	O
by	O
crosslinking	O
studies	O
,	O
the	O
wild	O
-	O
type	O
transfectants	O
are	O
refractory	O
to	O
exogenous	O
FGF	B-GENE
-	I-GENE
1	I-GENE
,	O
whereas	O
the	O
mutant	O
transfectants	O
respond	O
normally	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

This	O
report	O
presents	O
the	O
isolation	O
and	O
characterization	O
of	O
the	O
5	O
'	O
-	O
flanking	O
region	O
(	O
1	O
.	O
2	O
kb	O
)	O
and	O
exon	O
1	O
of	O
the	O
human	B-GENE
RII	I-GENE
alpha	I-GENE
gene	I-GENE
.	O

It	O
is	O
also	O
homologous	O
to	O
other	O
sugar	O
carriers	O
from	O
human	O
,	O
mouse	O
and	O
Escherichia	O
coli	O
.	O

Our	O
results	O
confirm	O
the	O
participation	O
of	O
intron	O
1	O
in	O
transcriptional	O
regulation	O
of	O
the	O
c	B-GENE
-	I-GENE
myb	I-GENE
gene	I-GENE
(	O
in	O
mouse	O
and	O
human	O
)	O
and	O
implicate	O
multiple	O
and	O
complex	O
regulatory	O
mechanisms	O
of	O
activation	O
during	O
myelomonocytic	O
differentiation	O
and	O
leukemic	O
cell	O
growth	O
control	O
.	O

There	O
was	O
a	O
general	O
broadening	O
of	O
proton	O
resonances	O
for	O
a	O
three	O
-	O
nucleotide	O
segment	O
centered	O
about	O
the	O
lesion	O
site	O
which	O
resulted	O
in	O
a	O
tentative	O
assignment	O
for	O
the	O
sugar	O
protons	O
of	O
the	O
C7	O
residue	O
in	O
the	O
spectrum	O
of	O
the	O
adduct	O
duplex	O
.	O

We	O
report	O
here	O
the	O
cloning	O
of	O
the	O
human	B-GENE
goosecoid	I-GENE
gene	I-GENE
(	O
GSC	B-GENE
)	O
from	O
a	O
genomic	O
library	O
and	O
the	O
sequence	O
of	O
its	O
encoded	O
protein	O
.	O

The	O
accumulated	O
products	O
of	O
ancient	O
duplication	O
events	O
can	O
be	O
readily	O
observed	O
among	O
the	O
genes	O
encoding	O
voltage	O
-	O
dependent	O
Ca	O
(	O
2	O
+	O
)	O
ion	O
channels	O
.	O

On	O
the	O
other	O
hand	O
,	O
lack	O
of	O
conservation	O
of	O
the	O
membrane	B-GENE
attachment	I-GENE
sequence	I-GENE
arginine	I-GENE
-	I-GENE
glycine	I-GENE
-	I-GENE
aspartic	I-GENE
acid	I-GENE
argues	O
against	O
its	O
functional	O
importance	O
in	O
CgA	B-GENE
.	O

The	O
hcKrox	B-GENE
gene	O
family	O
regulates	O
multiple	O
extracellular	O
matrix	O
genes	O
.	O

A	O
noncatalytic	O
domain	O
conserved	O
among	O
cytoplasmic	B-GENE
protein	I-GENE
-	I-GENE
tyrosine	I-GENE
kinases	I-GENE
modifies	O
the	O
kinase	O
function	O
and	O
transforming	O
activity	O
of	O
Fujinami	B-GENE
sarcoma	I-GENE
virus	I-GENE
P130gag	I-GENE
-	I-GENE
fps	I-GENE
.	O

Northern	O
blot	O
analysis	O
indicates	O
that	O
AHA2	B-GENE
mRNA	I-GENE
relative	O
to	O
total	O
cellular	O
RNA	O
is	O
expressed	O
at	O
significantly	O
higher	O
levels	O
in	O
root	O
tissue	O
as	O
compared	O
with	O
shoot	O
tissue	O
.	O

A	O
unified	O
approach	O
to	O
the	O
standardization	O
of	O
allergens	O
.	O

Sevelamer	O
hydrochloride	O
(	O
Renagel	O
)	O
is	O
a	O
nonabsorbed	O
phosphate	O
-	O
binding	O
polymer	O
marketed	O
for	O
the	O
treatment	O
of	O
hyperphosphatemia	O
in	O
adult	O
patients	O
receiving	O
hemodialysis	O
.	O

Here	O
we	O
show	O
that	O
messenger	O
RNAs	O
encoding	O
trans	B-GENE
-	I-GENE
sialidases	I-GENE
containing	O
the	O
repeats	O
are	O
not	O
present	O
in	O
epimastigotes	O
but	O
are	O
abundant	O
in	O
trypomastigotes	O
.	O

Doctor	O
Berglund	O
warns	O
members	O
of	O
union	O
pitfalls	O
.	O

Enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
for	O
screening	O
aflatoxin	B-GENE
B1	I-GENE
in	O
cottonseed	O
products	O
and	O
mixed	O
feed	O
:	O
collaborative	O
study	O
.	O

Molecular	O
characterization	O
and	O
expression	O
of	O
the	O
Erwinia	B-GENE
carotovora	I-GENE
hrpNEcc	I-GENE
gene	I-GENE
,	O
which	O
encodes	O
an	O
elicitor	O
of	O
the	O
hypersensitive	O
reaction	O
.	O

CONCLUSIONS	O
:	O
Although	O
the	O
levels	O
of	O
oxLDL	B-GENE
antibodies	I-GENE
might	O
be	O
modified	O
in	O
early	O
hypertension	O
,	O
once	O
advanced	O
coronary	O
artery	O
disease	O
has	O
developed	O
the	O
presence	O
of	O
hypertension	O
does	O
not	O
affect	O
anti	B-GENE
-	I-GENE
oxLDL	I-GENE
levels	O
.	O

The	O
strategy	O
has	O
been	O
used	O
to	O
determine	O
2	O
.	O
6	O
kilobases	O
of	O
nucleotide	O
sequence	O
in	O
the	O
Saccharomyces	B-GENE
cerevisiae	I-GENE
ADE	I-GENE
1	I-GENE
locus	I-GENE
.	O

A	O
subset	O
of	O
mutations	O
in	O
the	O
Psi	B-GENE
synthase	I-GENE
domain	I-GENE
impairs	O
association	O
of	O
the	O
altered	O
Cbf5p	B-GENE
proteins	I-GENE
with	O
selected	O
box	O
H	B-GENE
/	I-GENE
ACA	I-GENE
snoRNAs	I-GENE
,	O
suggesting	O
that	O
the	O
functional	O
catalytic	O
domain	O
is	O
essential	O
for	O
that	O
interaction	O
.	O

Female	O
Wistar	O
rats	O
were	O
fed	O
a	O
liquid	O
diet	O
,	O
Sustacal	O
,	O
which	O
contained	O
ethanol	O
(	O
40	O
%	O
of	O
calories	O
)	O
or	O
isocaloric	O
sucrose	O
.	O

They	O
share	O
many	O
downstream	O
targets	O
,	O
including	O
remodeling	O
of	O
the	O
actin	B-GENE
cytoskeleton	O
,	O
activation	O
of	O
p70	B-GENE
(	I-GENE
S6	I-GENE
)	I-GENE
kinase	I-GENE
and	O
c	B-GENE
-	I-GENE
jun	I-GENE
N	I-GENE
-	I-GENE
terminal	I-GENE
kinase	I-GENE
(	O
JNK	B-GENE
)	O
,	O
and	O
regulation	O
of	O
transcription	O
and	O
cell	O
proliferation	O
.	O

272	O
,	O
19107	O
-	O
19110	O
)	O
.	O

In	O
the	O
further	O
development	O
of	O
bladder	O
neck	O
suspension	O
according	O
to	O
Stamey	O
-	O
Pereyra	O
,	O
the	O
use	O
of	O
miniature	O
bone	O
anchors	O
received	O
considerable	O
support	O
.	O

GHB	O
,	O
2	O
CB	O
,	O
HMB	O
,	O
are	O
some	O
of	O
these	O
recent	O
substances	O
.	O

Previous	O
transactivation	O
experiments	O
indicated	O
that	O
three	O
amino	O
acids	O
residing	O
in	O
this	O
region	O
,	O
Gly	O
,	O
Ser	O
and	O
Val	O
,	O
appear	O
to	O
be	O
critical	O
for	O
target	O
-	O
site	O
discrimination	O
.	O

Control	O
of	O
fatty	O
liver	O
syndrome	O
in	O
a	O
Jersey	O
herd	O
by	O
a	O
change	O
of	O
diet	O
and	O
the	O
use	O
of	O
recombinant	O
bovine	O
somatotrophin	B-GENE
.	O

A	O
comparison	O
of	O
physical	O
and	O
cytogenetic	O
estimates	O
of	O
radiation	O
dose	O
in	O
patients	O
treated	O
with	O
iodine	O
-	O
131	O
for	O
thyroid	O
carcinoma	O
.	O

Initial	O
experience	O
with	O
the	O
new	O
technology	O
indicates	O
that	O
SieScape	O
is	O
an	O
alternative	O
to	O
other	O
methods	O
such	O
as	O
CT	O
and	O
MRI	O
.	O

To	O
map	O
this	O
regulatory	O
serine	O
phosphorylation	O
site	O
we	O
developed	O
a	O
baculovirus	O
-	O
mediated	O
expression	O
system	O
for	O
wild	B-GENE
-	I-GENE
type	I-GENE
annexin	I-GENE
II	I-GENE
and	O
for	O
a	O
series	O
of	O
annexin	B-GENE
II	I-GENE
mutants	I-GENE
which	O
contained	O
substitutions	O
in	O
one	O
or	O
more	O
serine	O
residues	O
present	O
in	O
the	O
N	O
-	O
terminal	O
domain	O
.	O

No	O
difference	O
in	O
elastin	B-GENE
peptide	I-GENE
concentration	O
was	O
observed	O
between	O
emphysematous	O
patients	O
and	O
control	O
subjects	O
(	O
mean	O
+	O
/	O
-	O
SD	O
=	O
2	O
.	O
39	O
+	O
/	O
-	O
1	O
.	O
18	O
micrograms	O
/	O
ml	O
in	O
patients	O
versus	O
2	O
.	O
55	O
+	O
/	O
-	O
1	O
.	O
34	O
micrograms	O
/	O
ml	O
in	O
policemen	O
and	O
2	O
.	O
59	O
+	O
/	O
-	O
1	O
.	O
20	O
micrograms	O
/	O
ml	O
in	O
coal	O
miners	O
)	O
.	O

CONCLUSIONS	O
:	O
In	O
healthy	O
individuals	O
,	O
whole	O
body	O
insulin	B-GENE
sensitivity	O
is	O
related	O
,	O
or	O
"	O
coupled	O
,	O
"	O
to	O
the	O
anaerobic	O
threshold	O
.	O

The	O
survival	O
rate	O
at	O
forty	O
months	O
in	O
15	O
patients	O
with	O
N2	O
disease	O
who	O
underwent	O
R2b	O
operation	O
was	O
51	O
%	O
.	O

Furthermore	O
,	O
we	O
have	O
identified	O
a	O
43	O
-	O
bp	O
region	O
of	O
the	O
24p3	B-GENE
promoter	I-GENE
required	O
for	O
the	O
Dex	O
responsiveness	O
.	O

Histamine	O
reactivity	O
was	O
significantly	O
reduced	O
after	O
the	O
nifedipine	O
aerosol	O
,	O
the	O
geometric	O
mean	O
provocative	O
concentration	O
causing	O
a	O
35	O
%	O
fall	O
in	O
specific	O
airway	O
conductance	O
,	O
rising	O
from	O
5	O
.	O
0	O
to	O
10	O
.	O
9	O
mg	O
/	O
ml	O
of	O
histamine	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Handgrip	O
dynamometry	O
was	O
also	O
carried	O
out	O
in	O
249	O
of	O
the	O
patients	O
.	O

By	O
applying	O
the	O
potentiometric	O
method	O
,	O
in	O
aqueous	O
medium	O
of	O
ionic	O
strength	O
mu	O
=	O
0	O
.	O
2	O
,	O
the	O
stability	O
constants	O
,	O
log	O
beta	O
1	O
=	O
4	O
.	O
42	O
and	O
log	O
beta	O
2	O
=	O
8	O
.	O
57	O
were	O
obtained	O
.	O

Induction	O
of	O
B	O
cell	O
apoptosis	O
by	O
co	O
-	O
cross	O
-	O
linking	O
CD23	B-GENE
and	O
sIg	B-GENE
involves	O
aberrant	O
regulation	O
of	O
c	B-GENE
-	I-GENE
myc	I-GENE
and	O
is	O
inhibited	O
by	O
bcl	B-GENE
-	I-GENE
2	I-GENE
.	O

SAECG	O
,	O
echocardiography	O
and	O
thallium	O
-	O
201	O
imaging	O
were	O
performed	O
before	O
and	O
1	O
month	O
after	O
attempted	O
angioplasty	O
.	O

Our	O
results	O
suggest	O
that	O
protein	O
binding	O
to	O
the	O
E2F	B-GENE
-	I-GENE
like	I-GENE
sequences	I-GENE
may	O
act	O
to	O
reduce	O
expression	O
.	O

The	O
patient	O
was	O
homozygous	O
for	O
the	O
underlying	O
mutation	O
,	O
which	O
was	O
found	O
to	O
be	O
a	O
G	O
-	O
-	O
>	O
T	O
transversion	O
within	O
the	O
acceptor	O
splice	O
site	O
between	O
intron	O
e	O
and	O
exon	O
6	O
,	O
abolishing	O
normal	O
RNA	O
splicing	O
.	O

The	O
genomic	O
structure	O
of	O
four	O
members	O
of	O
the	O
SRC	B-GENE
-	I-GENE
family	I-GENE
revealed	O
nearly	O
identical	O
exon	O
/	O
intron	O
boundaries	O
within	O
the	O
catalytic	O
domain	O
of	O
this	O
family	O
.	O

The	O
students	O
who	O
had	O
abnormal	O
urine	O
screening	O
results	O
at	O
the	O
first	O
time	O
received	O
a	O
second	O
urine	O
analysis	O
10	O
to	O
15	O
days	O
later	O
to	O
confirm	O
the	O
abnormal	O
urine	O
analysis	O
.	O

However	O
,	O
addition	O
of	O
core	B-GENE
DNA	I-GENE
polymerase	I-GENE
III	I-GENE
to	O
preinitiation	O
complex	O
,	O
fully	O
reconstituting	O
holoenzyme	O
resulted	O
in	O
replacement	O
of	O
gamma	O
by	O
alpha	O
at	O
the	O
primer	O
terminus	O
.	O

Characterisation	O
of	O
the	O
chicken	B-GENE
apolipoprotein	I-GENE
A	I-GENE
-	I-GENE
I	I-GENE
gene	I-GENE
5	O
'	O
-	O
flanking	O
region	O
.	O

Plasma	O
,	O
LDL	B-GENE
and	O
liver	O
cholesterol	O
concentrations	O
were	O
higher	O
in	O
the	O
hyperlipidemic	O
control	O
than	O
the	O
nonhyperlipidemic	O
control	O
and	O
lower	O
in	O
the	O
groups	O
fed	O
diets	O
containing	O
pectin	B-GENE
or	O
prune	O
fiber	O
than	O
in	O
the	O
hyperlipidemic	O
control	O
group	O
.	O

All	O
of	O
these	O
data	O
suggest	O
that	O
replication	O
of	O
UV	O
-	O
damaged	O
templates	O
occurs	O
in	O
vitro	O
as	O
it	O
does	O
in	O
vivo	O
and	O
that	O
this	O
replication	O
results	O
in	O
mutation	O
fixation	O
.	O

In	O
group	O
I	O
adults	O
both	O
of	O
these	O
variables	O
increased	O
.	O

The	O
plasma	B-GENE
growth	I-GENE
hormone	I-GENE
concentration	O
of	O
the	O
foetal	O
lamb	O
.	O

Despite	O
resolution	O
of	O
the	O
solid	O
portion	O
of	O
the	O
tumor	O
,	O
serial	O
MRI	O
showed	O
enlargement	O
of	O
a	O
bilobar	O
tumor	O
cyst	O
3	O
years	O
after	O
the	O
original	O
diagnosis	O
.	O

This	O
approximately	O
125	O
-	O
nt	O
RNA	O
proved	O
to	O
arise	O
via	O
RNase	B-GENE
E	I-GENE
cleavage	O
from	O
the	O
3	O
'	O
-	O
terminal	O
region	O
of	O
the	O
mRNAs	O
bearing	O
the	O
terminator	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
using	O
crude	O
extracts	O
from	O
FREJ4	O
cells	O
revealed	O
the	O
binding	O
of	O
a	O
member	O
(	O
s	O
)	O
of	O
the	O
Ets	B-GENE
family	I-GENE
of	I-GENE
transcription	I-GENE
factors	I-GENE
to	O
the	O
P4	B-GENE
EBS	I-GENE
,	O
as	O
well	O
as	O
the	O
interaction	O
of	O
two	O
members	O
of	O
the	O
Sp1	B-GENE
family	I-GENE
,	O
Sp1	B-GENE
and	O
Sp3	B-GENE
,	O
with	O
the	O
adjacent	O
GC	O
box	O
.	O

The	O
binary	O
and	O
tertiary	O
combinations	O
of	O
plant	O
-	O
derived	O
molluscicides	O
Azadirachta	O
indica	O
and	O
Cedrus	O
deodara	O
oil	O
with	O
synergists	O
MGK	O
-	O
264	O
,	O
piperonyl	O
butoxide	O
(	O
PB	O
)	O
and	O
fruit	O
powder	O
of	O
Embelia	O
ribes	O
were	O
used	O
against	O
the	O
Lymnaea	O
acuminata	O
.	O

The	O
known	O
B1	O
-	O
deficiency	O
reaches	O
excessive	O
high	O
values	O
with	O
light	O
exercise	O
.	O

The	O
rate	O
of	O
enzymic	O
stimulation	O
induced	O
by	O
a	O
given	O
nitrate	O
correlates	O
closely	O
with	O
the	O
rate	O
of	O
measured	O
NO	O
production	O
from	O
the	O
nitrate	O
molecule	O
.	O

Physiology	O
and	O
Physiopathology	O
.	O

Experiments	O
were	O
performed	O
in	O
which	O
brain	O
-	O
stem	O
auditory	O
-	O
evoked	O
responses	O
(	O
BAERs	O
)	O
were	O
elicited	O
by	O
two	O
types	O
of	O
pseudorandom	O
pulse	O
trains	O
:	O
maximum	O
length	O
sequences	O
(	O
MLS	O
)	O
and	O
Legendre	O
sequences	O
(	O
LGS	O
)	O
.	O

Six	O
patients	O
with	O
the	O
diagnosis	O
of	O
acute	O
mania	O
were	O
treated	O
with	O
high	O
doses	O
of	O
the	O
beta	O
-	O
adrenergic	O
blocking	O
agent	O
propranolol	O
.	O

PKA	B-GENE
phosphorylated	O
WT1	B-GENE
at	O
Ser	O
-	O
365	O
and	O
Ser	O
-	O
393	O
in	O
vitro	O
,	O
as	O
well	O
as	O
at	O
additional	O
sites	O
,	O
and	O
this	O
phosphorylation	O
abolished	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
WT1	B-GENE
in	O
vitro	O
.	O

The	O
color	O
-	O
word	O
interference	O
effect	O
previously	O
reported	O
with	O
normal	O
populations	O
when	O
given	O
the	O
Stroop	O
test	O
was	O
demonstrated	O
for	O
this	O
retarded	O
sample	O
using	O
a	O
special	O
format	O
.	O

Estral	O
cycle	O
in	O
white	O
rats	O
in	O
the	O
low	O
and	O
high	O
mountains	O
of	O
Kirghizia	O
.	O

Use	O
of	O
Selenastrum	O
capricornutum	O
and	O
Microfeast	O
as	O
food	O
for	O
Daphnia	O
pulex	O
.	O

The	O
other	O
is	O
located	O
at	O
-	O
1335	O
,	O
outside	O
this	O
highly	O
conserved	O
region	O
.	O

No	O
consistent	O
correlation	O
between	O
blood	O
pressure	O
change	O
and	O
SCR	O
-	O
change	O
was	O
seen	O
.	O

Although	O
YopH	B-GENE
is	O
a	O
highly	O
active	O
PTP	B-GENE
,	O
it	O
preferentially	O
targets	O
a	O
subset	O
of	O
tyrosine	O
-	O
phosphorylated	O
proteins	O
in	O
host	O
cells	O
,	O
including	O
p130Cas	B-GENE
.	O

These	O
results	O
indicate	O
that	O
baculovirus	O
-	O
expressed	O
TR	B-GENE
mediates	O
transcriptional	O
activation	O
and	O
repression	O
in	O
a	O
promoter	O
-	O
specific	O
manner	O
in	O
vitro	O
.	O

The	O
carboxyl	O
-	O
terminal	O
proline	O
-	O
rich	O
domain	O
of	O
SOS1	B-GENE
is	O
involved	O
in	O
the	O
interaction	O
with	O
the	O
PLC	B-GENE
-	I-GENE
gamma1	I-GENE
SH3	B-GENE
domain	I-GENE
.	O

The	O
pilE	B-GENE
gene	I-GENE
product	I-GENE
of	I-GENE
Pseudomonas	I-GENE
aeruginosa	I-GENE
,	O
required	O
for	O
pilus	O
biogenesis	O
,	O
shares	O
amino	O
acid	O
sequence	O
identity	O
with	O
the	O
N	O
-	O
termini	O
of	O
type	B-GENE
4	I-GENE
prepilin	I-GENE
proteins	I-GENE
.	O

In	O
contrast	O
to	O
the	O
signaling	O
triggered	O
by	O
surface	O
Ig	O
engagement	O
in	O
B	O
lymphocytes	O
,	O
CD38	B-GENE
ligation	O
did	O
not	O
appear	O
to	O
induce	O
tyrosine	O
phosphorylation	O
of	O
the	O
src	B-GENE
-	I-GENE
like	I-GENE
protein	I-GENE
tyrosine	I-GENE
kinases	I-GENE
lyn	B-GENE
,	O
fyn	B-GENE
,	O
and	O
btk	B-GENE
,	O
or	O
of	O
vav	O
-	O
and	O
ras	B-GENE
-	I-GENE
GTPase	I-GENE
-	I-GENE
activating	I-GENE
protein	I-GENE
,	O
nor	O
did	O
it	O
induce	O
detectable	O
changes	O
in	O
cytosolic	O
CA2	O
+	O
concentrations	O
.	O

A	O
total	O
of	O
57	O
patients	O
with	O
Hodgkin	O
'	O
s	O
disease	O
limited	O
to	O
above	O
the	O
diaphragm	O
(	O
Stages	O
I	O
and	O
II	O
,	O
A	O
and	O
B	O
)	O
were	O
treated	O
with	O
radiation	O
therapy	O
alone	O
at	O
the	O
University	O
of	O
Florida	O
between	O
1964	O
and	O
1974	O
.	O

The	O
RET	B-GENE
/	I-GENE
PTC3	I-GENE
rearrangement	I-GENE
is	O
formed	O
by	O
fusion	O
of	O
the	O
ELE1	B-GENE
and	O
RET	B-GENE
genes	I-GENE
,	O
and	O
is	O
highly	O
prevalent	O
in	O
radiation	O
-	O
induced	O
post	O
-	O
Chernobyl	O
papillary	O
thyroid	O
carcinomas	O
.	O

The	O
ns2	B-GENE
gene	I-GENE
comprises	O
an	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
encoding	O
a	O
putative	O
nonstructural	O
(	O
ns	O
)	O
protein	O
of	O
279	O
amino	O
acids	O
with	O
a	O
predicted	O
molecular	O
mass	O
of	O
32	O
-	O
kDa	O
.	O

These	O
cognitive	O
deficits	O
were	O
prevented	O
in	O
animals	O
treated	O
with	O
MK	O
-	O
801	O
during	O
SE	O
.	O

We	O
previously	O
showed	O
that	O
v	B-GENE
-	I-GENE
Rel	I-GENE
,	O
the	O
oncoprotein	O
of	O
the	O
avian	O
retrovirus	O
Rev	O
-	O
T	O
,	O
can	O
increase	O
expression	O
from	O
promoters	O
containing	O
binding	O
sites	O
for	O
the	O
cellular	O
transcription	O
factor	O
Sp1	B-GENE
in	O
chicken	O
embryo	O
fibroblasts	O
(	O
S	O
.	O

Allergic	O
reaction	O
to	O
Patent	O
Blue	O
Violet	O
during	O
lymphography	O
.	O

The	O
data	O
indicate	O
that	O
Bmp2	B-GENE
is	O
directly	O
regulated	O
by	O
retinoic	B-GENE
acid	I-GENE
-	I-GENE
bound	I-GENE
receptors	I-GENE
and	O
Sp1	B-GENE
.	O

NuA4	B-GENE
has	O
an	O
apparent	O
molecular	O
mass	O
of	O
1	O
.	O
3	O
MDa	O
.	O

We	O
also	O
raised	O
a	O
polyclonal	O
antibody	O
against	O
the	O
glutathione	B-GENE
S	I-GENE
-	I-GENE
transferase	I-GENE
fusion	I-GENE
protein	I-GENE
containing	O
the	O
NH2	O
-	O
terminal	O
86	O
amino	O
acids	O
of	O
human	B-GENE
NRAMP2	I-GENE
.	O

The	O
protein	O
coding	O
region	O
,	O
1	O
,	O
696	O
bps	O
long	O
,	O
is	O
divided	O
by	O
an	O
intron	O
into	O
two	O
exons	O
.	O

Transcription	O
of	O
the	O
gene	O
for	O
ivanolysin	B-GENE
O	I-GENE
and	O
expression	O
of	O
other	O
genes	O
of	O
the	O
virulence	B-GENE
gene	I-GENE
cluster	I-GENE
in	I-GENE
L	I-GENE
.	I-GENE
ivanovii	I-GENE
were	O
dependent	O
on	O
PrfA	B-GENE
.	O

MBP	B-GENE
-	I-GENE
Rep68	I-GENE
delta	I-GENE
-	I-GENE
mediated	I-GENE
DNA	I-GENE
-	I-GENE
RNA	I-GENE
helicase	I-GENE
activity	O
required	O
ATP	O
hydrolysis	O
and	O
the	O
presence	O
of	O
Mg2	O
+	O
ions	O
and	O
was	O
inhibited	O
by	O
high	O
ionic	O
strength	O
.	O

The	O
nm23	B-GENE
-	I-GENE
H1	I-GENE
/	I-GENE
nm23	I-GENE
-	I-GENE
H2	I-GENE
gene	I-GENE
transcriptional	O
activity	O
ratio	O
varied	O
depending	O
on	O
the	O
cell	O
line	O
.	O

Experimentally	O
in	O
green	O
monkeys	O
,	O
Syrian	O
hamsters	O
and	O
white	O
mice	O
the	O
authors	O
studied	O
the	O
pathogenic	O
properties	O
of	O
a	O
new	O
virus	O
Issyk	O
-	O
Kul	O
.	O

METHODS	O
:	O
Millipore	O
ultrafiltration	O
membranes	O
of	O
three	O
different	O
pore	O
sizes	O
were	O
used	O
as	O
model	O
lenticule	O
materials	O
.	O
The	O
nominal	O
membrane	O
pore	O
sizes	O
were	O
0	O
.	O
1	O
microm	O
,	O
0	O
.	O
45	O
microm	O
,	O
and	O
3	O
microm	O
;	O
the	O
surface	O
roughness	O
increased	O
in	O
the	O
same	O
order	O
The	O
membranes	O
were	O
coated	O
with	O
a	O
thin	O
layer	O
of	O
collagen	B-GENE
I	I-GENE
and	O
implanted	O
in	O
a	O
circular	O
pocket	O
of	O
the	O
anterior	O
cornea	O
of	O
adult	O
cats	O
,	O
and	O
were	O
clinically	O
evaluated	O
for	O
the	O
extent	O
of	O
epithelialization	O
and	O
the	O
persistence	O
of	O
epithelial	O
attachment	O
.	O

Comparative	O
study	O
on	O
acute	O
oral	O
overload	O
using	O
tolbutamide	O
and	O
tolazamide	O
in	O
normal	O
and	O
diabetic	O
subjects	O
.	O

3	O
.	O

According	O
to	O
the	O
changes	O
of	O
perfusion	O
defects	O
between	O
Ex	O
,	O
RD	O
and	O
ReI	O
images	O
,	O
they	O
were	O
classified	O
into	O
3	O
types	O
:	O
Type	O
I	O
;	O
perfusion	O
defect	O
on	O
the	O
RD	O
image	O
was	O
identical	O
to	O
ReI	O
image	O
(	O
75	O
%	O
)	O
Type	O
I	O
was	O
divided	O
into	O
2	O
subgroups	O
whether	O
perfusion	O
defect	O
at	O
Ex	O
was	O
unchanged	O
(	O
Ia	O
,	O
42	O
%	O
)	O
or	O
improved	O
(	O
Ib	O
,	O
33	O
%	O
)	O
on	O
the	O
RD	O
image	O
.	O

The	O
associations	O
between	O
sex	B-GENE
-	I-GENE
hormone	I-GENE
-	I-GENE
binding	I-GENE
globulin	I-GENE
capacity	O
(	O
SHBG	B-GENE
)	O
,	O
age	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
,	O
and	O
physical	O
fitness	O
have	O
been	O
studied	O
in	O
34	O
men	O
and	O
36	O
women	O
.	O

In	O
Malmo	O
,	O
Sweden	O
,	O
17	O
,	O
181	O
school	O
children	O
born	O
in	O
the	O
years	O
1961	O
-	O
1965	O
were	O
screened	O
for	O
scoliosis	O
once	O
a	O
year	O
between	O
the	O
ages	O
of	O
7	O
and	O
16	O
years	O
,	O
during	O
1971	O
-	O
1980	O
.	O

A	O
platelet	B-GENE
-	I-GENE
derived	I-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
(	O
PDGF	B-GENE
-	I-GENE
R	I-GENE
)	O
phosphopeptide	O
containing	O
Tyr	O
-	O
857	O
does	O
not	O
bind	O
appreciably	O
to	O
the	O
Src	B-GENE
SH2	I-GENE
domain	I-GENE
,	O
suggesting	O
it	O
is	O
not	O
the	O
PDGF	B-GENE
-	I-GENE
R	I-GENE
binding	O
site	O
for	O
Src	B-GENE
as	O
previously	O
reported	O
.	O

Amplification	O
and	O
overexpression	O
of	O
the	O
c	B-GENE
-	I-GENE
erbB	I-GENE
-	I-GENE
2	I-GENE
gene	I-GENE
in	O
21MT	O
-	O
2	O
and	O
21MT	O
-	O
1	O
human	O
breast	O
carcinoma	O
cells	O
results	O
in	O
progressively	O
elevated	O
levels	O
of	O
constitutively	O
tyrosine	B-GENE
-	I-GENE
phosphorylated	I-GENE
p185erbB	I-GENE
-	I-GENE
2	I-GENE
and	O
is	O
associated	O
with	O
progressive	O
insulin	B-GENE
-	I-GENE
like	I-GENE
growth	I-GENE
factor	I-GENE
(	O
IGF	B-GENE
)	O
and	O
combined	O
IGF	B-GENE
/	I-GENE
epidermal	I-GENE
growth	I-GENE
factor	I-GENE
(	O
EGF	B-GENE
)	O
independence	O
in	O
culture	O
.	O

Here	O
we	O
have	O
tested	O
the	O
hypothesis	O
that	O
the	O
short	O
transcripts	O
,	O
or	O
proteins	O
translated	O
from	O
the	O
short	O
transcripts	O
,	O
are	O
also	O
required	O
for	O
respiration	O
.	O

Also	O
,	O
the	O
human	B-GENE
glycoprotein	I-GENE
alpha	I-GENE
-	I-GENE
subunit	I-GENE
promoter	I-GENE
was	O
induced	O
10	O
-	O
fold	O
by	O
FSK	B-GENE
in	O
GH4	O
rat	O
pituitary	O
cells	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Three	O
chromosomal	B-GENE
crsA	I-GENE
mutations	I-GENE
,	O
crsA1	B-GENE
,	O
crsA4	B-GENE
,	O
and	O
crsA47	B-GENE
,	O
were	O
transferred	O
by	O
the	O
"	O
gene	O
conversion	O
"	O
process	O
to	O
B	O
.	O
subtilis	O
plasmid	O
pRPD11	O
,	O
which	O
consists	O
of	O
the	O
entire	O
wild	B-GENE
-	I-GENE
type	I-GENE
rpoD	I-GENE
coding	I-GENE
sequence	I-GENE
,	O
encoding	O
the	O
major	B-GENE
sigma	I-GENE
43	I-GENE
factor	I-GENE
of	I-GENE
B	I-GENE
.	I-GENE
subtilis	I-GENE
RNA	I-GENE
polymerase	I-GENE
,	O
and	O
pUB110	O
.	O

Lymphocytes	O
from	O
all	O
3	O
species	O
yielded	O
maximum	O
responses	O
with	O
a	O
48	O
-	O
hour	O
prelabel	O
and	O
12	O
-	O
to	O
-	O
16	O
hour	O
postlabel	O
incubation	O
period	O
at	O
41	O
C	O
and	O
1	O
:	O
20	O
blood	O
dilution	O
.	O

The	O
persistence	O
of	O
members	O
of	O
the	O
prostigmatid	O
families	O
Tydeidae	O
,	O
Nanorchestidae	O
and	O
Tarsonemidae	O
in	O
the	O
moisture	O
-	O
deficient	O
90	O
%	O
-	O
concentration	O
treatments	O
supports	O
previous	O
evidence	O
of	O
adaptations	O
to	O
low	O
-	O
water	O
-	O
content	O
habitats	O
.	O

Unlike	O
class	B-GENE
II	I-GENE
-	I-GENE
and	I-GENE
III	I-GENE
-	I-GENE
specific	I-GENE
TBP	I-GENE
-	I-GENE
TAF	I-GENE
complexes	I-GENE
,	O
the	O
corresponding	O
murine	O
and	O
human	B-GENE
class	I-GENE
I	I-GENE
-	I-GENE
specific	I-GENE
transcription	I-GENE
initiation	I-GENE
factor	I-GENE
TIF	I-GENE
-	I-GENE
IB	I-GENE
/	I-GENE
SL1	I-GENE
exhibits	O
a	O
pronounced	O
selectivity	O
for	O
its	O
homologous	O
promoter	O
.	O

The	O
suppression	O
was	O
also	O
demonstrated	O
in	O
a	O
transient	O
expression	O
assay	O
in	O
vivo	O
using	O
isolated	O
barley	O
endosperms	O
.	O

CREST	O
syndrome	O
;	O
a	O
changing	O
clinical	O
significance	O
.	O

Hormonal	O
regulation	O
of	O
multiple	O
promoters	O
of	O
the	O
rat	B-GENE
mitochondrial	I-GENE
glycerol	I-GENE
-	I-GENE
3	I-GENE
-	I-GENE
phosphate	I-GENE
dehydrogenase	I-GENE
gene	I-GENE
:	O
identification	O
of	O
a	O
complex	O
hormone	B-GENE
-	I-GENE
response	I-GENE
element	I-GENE
in	O
the	O
ubiquitous	O
promoter	O
B	O
.	O

Mutants	O
with	O
mild	O
lace	B-GENE
alleles	I-GENE
grow	O
to	O
become	O
adults	O
with	O
multiple	O
aberrant	O
morphologies	O
in	O
the	O
appendages	O
,	O
compound	O
eye	O
,	O
and	O
bristles	O
.	O

Isolation	O
and	O
characterization	O
of	O
a	O
vinculin	B-GENE
cDNA	I-GENE
from	I-GENE
chick	I-GENE
-	I-GENE
embryo	I-GENE
fibroblasts	I-GENE
.	O

Long	O
-	O
term	O
effects	O
of	O
clofibrate	O
(	O
Atromid	O
-	O
S	O
)	O
on	O
serum	O
lipids	O
in	O
man	O
.	O

Drosophila	O
230	O
-	O
kD	O
TFIID	B-GENE
subunit	O
,	O
a	O
functional	O
homolog	O
of	O
the	O
human	O
cell	O
cycle	O
gene	O
product	O
,	O
negatively	O
regulates	O
DNA	O
binding	O
of	O
the	O
TATA	B-GENE
box	I-GENE
-	I-GENE
binding	I-GENE
subunit	I-GENE
of	I-GENE
TFIID	I-GENE
.	O

Recent	O
investigations	O
have	O
shown	O
that	O
Grenz	O
rays	O
can	O
suppress	O
the	O
allergic	O
contact	O
dermatitis	O
reaction	O
completely	O
and	O
that	O
Langerhans	O
cells	O
,	O
identified	O
by	O
OKT6	B-GENE
antibodies	I-GENE
and	O
electron	O
microscopy	O
,	O
disappear	O
from	O
the	O
epidermis	O
at	O
the	O
same	O
time	O
.	O

SBF	B-GENE
binds	O
to	O
the	O
promoter	O
prior	O
to	O
the	O
activation	O
of	O
transcription	O
in	O
late	O
G1	O
,	O
suggesting	O
that	O
Cln	B-GENE
/	I-GENE
Cdc28	I-GENE
kinase	I-GENE
regulates	O
the	O
ability	O
of	O
previously	O
bound	O
SBF	B-GENE
to	O
activate	O
transcription	O
.	O

Recombinant	B-GENE
Leishmania	I-GENE
surface	I-GENE
glycoprotein	I-GENE
GP63	I-GENE
is	O
secreted	O
in	O
the	O
baculovirus	O
expression	O
system	O
as	O
a	O
latent	O
metalloproteinase	B-GENE
.	O

The	O
mean	O
jitter	O
and	O
the	O
fiber	O
density	O
did	O
not	O
change	O
significantly	O
from	O
day	O
0	O
(	O
30	O
.	O
1	O
+	O
/	O
-	O
3	O
.	O
6	O
microseconds	O
;	O
1	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
07	O
)	O
to	O
day	O
30	O
(	O
34	O
.	O
5	O
+	O
/	O
-	O
2	O
.	O
7	O
microseconds	O
;	O
1	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
13	O
)	O
.	O

9	O
,	O
11	O
-	O
Seco	O
steroids	O
derived	O
from	O
estradiol	O
3	O
-	O
methyl	O
ether	O
.	O

Several	O
demographic	O
indices	O
of	O
isolated	O
populations	O
in	O
Uzbekistan	O
.	O

Interferon	B-GENE
-	I-GENE
alpha	I-GENE
may	O
exacerbate	O
cryoblobulinemia	O
-	O
related	O
ischemic	O
manifestations	O
:	O
an	O
adverse	O
effect	O
potentially	O
related	O
to	O
its	O
anti	O
-	O
angiogenic	O
activity	O
.	O

Our	O
findings	O
confirm	O
the	O
high	O
frequency	O
of	O
proximal	O
nerve	O
lesions	O
in	O
early	O
GBS	O
and	O
CIDP	O
,	O
not	O
all	O
of	O
which	O
are	O
associated	O
with	O
distal	O
motor	O
conduction	O
abnormalities	O
,	O
and	O
suggest	O
that	O
assessment	O
of	O
multiple	O
F	O
wave	O
parameters	O
,	O
in	O
particular	O
chronodispersion	O
,	O
mean	O
latency	O
and	O
mean	O
amplitude	O
(	O
in	O
addition	O
to	O
absence	O
and	O
minimum	O
latency	O
)	O
,	O
increases	O
the	O
yield	O
of	O
F	O
wave	O
studies	O
.	O

Each	O
causative	O
organism	O
has	O
a	O
species	O
-	O
specific	O
preference	O
and	O
requirement	O
for	O
temperature	O
,	O
salinity	O
,	O
pH	O
,	O
the	O
basic	O
nutrients	O
,	O
and	O
growth	B-GENE
factors	I-GENE
,	O
and	O
the	O
toxin	O
formation	O
is	O
affected	O
by	O
these	O
environmental	O
factors	O
.	O

Structural	O
analysis	O
and	O
characterization	O
of	O
tissue	O
and	O
hormonal	O
responsive	O
expression	O
of	O
the	O
avian	B-GENE
bone	I-GENE
sialoprotein	I-GENE
(	O
BSP	B-GENE
)	O
gene	O
.	O

I	O
.	O

This	O
emphasizes	O
the	O
conclusion	O
that	O
CDF	B-GENE
-	I-GENE
1	I-GENE
is	O
not	O
an	O
E2F	B-GENE
family	I-GENE
member	I-GENE
and	O
points	O
to	O
profound	O
differences	O
in	O
the	O
cell	O
cycle	O
regulation	O
of	O
CDF	B-GENE
-	I-GENE
1	I-GENE
and	O
E2F	B-GENE
.	O

Identical	O
results	O
were	O
obtained	O
when	O
transfections	O
and	O
mobility	O
shift	O
assays	O
were	O
performed	O
in	O
primary	O
rat	O
hepatocytes	O
in	O
which	O
the	O
endogenous	O
ALS	B-GENE
gene	I-GENE
is	O
expressed	O
.	O

Elimination	O
of	O
gamma	O
-	O
irradiation	O
induced	O
oxidation	O
in	O
aqueous	O
drug	O
preparations	O
.	O

The	O
timing	O
of	O
fla	B-GENE
gene	I-GENE
expression	O
in	O
the	O
cell	O
cycle	O
is	O
determined	O
by	O
specialized	O
forms	O
of	O
RNA	B-GENE
polymerase	I-GENE
and	O
the	O
appearance	O
and	O
/	O
or	O
activation	O
of	O
regulatory	O
proteins	O
.	O

Growth	O
,	O
4	O
-	O
PA	O
and	O
14C	O
turnover	O
data	O
indicated	O
that	O
WB	O
contributed	O
to	O
B	O
-	O
6	O
intake	O
of	O
these	O
rats	O
.	O

Catheter	O
transit	O
slows	O
the	O
response	O
to	O
a	O
step	O
increase	O
in	O
concentration	O
by	O
about	O
0	O
.	O
13	O
s	O
(	O
from	O
10	O
per	O
cent	O
-	O
90	O
per	O
cent	O
)	O
and	O
prolongs	O
the	O
transit	O
time	O
through	O
the	O
catheter	O
for	O
a	O
volatile	O
anesthetic	O
by	O
about	O
0	O
.	O
04	O
s	O
more	O
than	O
N2	O
.	O

Advances	O
in	O
the	O
management	O
of	O
gynecologic	O
cancer	O
-	O
-	O
radiation	O
therapy	O
.	O

To	O
test	O
the	O
role	O
of	O
ML	O
in	O
human	O
reproductive	O
axis	O
,	O
128	O
healthy	O
children	O
,	O
68	O
boys	O
and	O
60	O
girls	O
,	O
were	O
studied	O
.	O

It	O
has	O
been	O
suggested	O
that	O
members	O
of	O
this	O
protein	O
family	O
exhibit	O
both	O
prolyl	B-GENE
isomerase	I-GENE
and	O
chaperone	O
activity	O
.	O

Recently	O
,	O
identical	O
RBE	B-GENE
sequences	I-GENE
have	O
been	O
identified	O
at	O
other	O
locations	O
in	O
the	O
human	O
genome	O
.	O

The	O
appropriate	O
use	O
and	O
benefits	O
of	O
bile	O
acid	O
sequestrants	O
,	O
nicotinic	O
acid	O
,	O
fibric	O
acids	O
,	O
3	B-GENE
-	I-GENE
hydroxy	I-GENE
-	I-GENE
3	I-GENE
-	I-GENE
methylglutaryl	I-GENE
coenzyme	I-GENE
A	I-GENE
(	I-GENE
HMG	I-GENE
-	I-GENE
CoA	I-GENE
)	I-GENE
reductase	I-GENE
inhibitors	O
,	O
and	O
probucol	O
are	O
individually	O
discussed	O
,	O
whereas	O
nonpharmacologic	O
approaches	O
used	O
in	O
conjunction	O
with	O
the	O
drugs	O
are	O
recommended	O
emphatically	O
.	O

Increased	O
granulocyte	B-GENE
-	I-GENE
colony	I-GENE
stimulating	I-GENE
factor	I-GENE
(	O
G	B-GENE
-	I-GENE
CSF	I-GENE
)	O
levels	O
in	O
neonates	O
with	O
perinatal	O
complications	O
.	O

In	O
some	O
instances	O
,	O
this	O
is	O
partly	O
mediated	O
by	O
the	O
expression	O
of	O
virally	O
encoded	O
proteases	B-GENE
which	O
lead	O
to	O
the	O
cleavage	O
of	O
initiation	B-GENE
factor	I-GENE
eIF4G	I-GENE
.	O

In	O
contrast	O
,	O
tobacco	B-GENE
GS	I-GENE
-	I-GENE
2	I-GENE
is	O
composed	O
of	O
subunits	O
of	O
identical	O
size	O
in	O
all	O
organs	O
examined	O
.	O

Women	O
'	O
s	O
opportunities	O
for	O
paid	O
work	O
outside	O
the	O
home	O
are	O
constrained	O
by	O
their	O
role	O
as	O
primary	O
carer	O
within	O
the	O
family	O
,	O
writes	O
Trudy	O
Wynne	O
.	O

Multi	O
drug	O
regimens	O
like	O
C	O
-	O
MOPP	O
,	O
CHOP	O
and	O
BACOP	O
led	O
to	O
high	O
remission	O
rates	O
and	O
in	O
some	O
cases	O
probably	O
also	O
to	O
a	O
cure	O
of	O
the	O
disease	O
.	O

The	O
mean	O
percentage	O
of	O
linoleic	O
acid	O
in	O
the	O
triglycerides	O
of	O
the	O
subcutaneous	O
adipose	O
tissue	O
(	O
PLASAT	O
)	O
of	O
these	O
subjects	O
was	O
substantially	O
higher	O
than	O
that	O
in	O
a	O
similar	O
group	O
examined	O
in	O
1975	O
-	O
1976	O
.	O

However	O
,	O
the	O
ratio	O
M	O
/	O
Pc	O
provides	O
a	O
useful	O
index	O
that	O
seems	O
to	O
be	O
independent	O
of	O
the	O
metabolic	O
demand	O
.	O

Cys	O
-	O
757	O
within	O
the	O
(	B-GENE
Fe4S4	I-GENE
)	I-GENE
-	I-GENE
siroheme	I-GENE
-	I-GENE
binding	I-GENE
domain	I-GENE
was	O
essential	O
for	O
native	O
enzyme	O
activity	O
.	O

The	O
amplitude	O
of	O
detrusor	O
contractions	O
at	O
6	O
,	O
12	O
,	O
and	O
24	O
hours	O
showed	O
no	O
significant	O
difference	O
from	O
that	O
in	O
the	O
controls	O
.	O

A	O
third	O
is	O
a	O
partial	O
element	O
terminating	O
at	O
a	O
probable	O
internal	O
restriction	O
site	O
used	O
for	O
cloning	O
.	O

Zebrafish	O
cyclops	B-GENE
(	O
cyc	B-GENE
)	O
encodes	O
a	O
Transforming	B-GENE
Growth	I-GENE
Factor	I-GENE
beta	I-GENE
(	O
TGFbeta	B-GENE
)	O
signaling	O
factor	O
closely	O
related	O
to	O
mouse	O
Nodal	B-GENE
.	O

Breitbart	O
,	O
L	O
.	O

A	O
newly	O
synthesized	O
anti	O
-	O
inflammatory	O
agent	O
,	O
Y	O
-	O
8004	O
demonstrated	O
a	O
greater	O
inhibition	O
than	O
did	O
indomethacin	O
(	O
IM	O
)	O
.	O
on	O
inflammatory	O
response	O
such	O
as	O
ultraviolet	O
erythema	O
in	O
guinea	O
pigs	O
,	O
carrageenin	O
edema	O
,	O
evans	O
blue	O
and	O
carrageenin	O
-	O
induced	O
pleuritis	O
and	O
acetic	O
acid	O
-	O
induced	O
peritonitis	O
in	O
rats	O
.	O

Polyvinyl	O
alcohol	O
as	O
a	O
solution	O
mediator	O
.	O

Herein	O
PPARgamma	B-GENE
,	O
liganded	O
by	O
either	O
natural	O
(	O
15d	O
-	O
PGJ	O
(	O
2	O
)	O
and	O
PGD	O
(	O
2	O
)	O
)	O
or	O
synthetic	O
ligands	O
(	O
BRL49653	O
and	O
troglitazone	O
)	O
,	O
selectively	O
inhibited	O
expression	O
of	O
the	O
cyclin	B-GENE
D1	I-GENE
gene	I-GENE
.	O

Ovaries	O
of	O
10	O
animals	O
per	O
group	O
from	O
16	O
studies	O
in	O
CD	O
-	O
1	O
mice	O
and	O
1	O
study	O
each	O
in	O
C3H	O
and	O
C57BL	O
/	O
6	O
mice	O
were	O
sectioned	O
serially	O
at	O
6	O
&	O
mgr	O
;	O
m	O
.	O

5	O
'	O
-	O
RACE	O
analysis	O
suggested	O
a	O
single	O
transcription	O
initiation	O
site	O
187	O
bp	O
upstream	O
from	O
the	O
translational	O
start	O
site	O
.	O

Treatment	O
also	O
led	O
to	O
a	O
significant	O
dose	O
dependent	O
reduction	O
in	O
the	O
sum	O
of	O
ST	O
segment	O
depression	O
at	O
both	O
trough	O
and	O
peak	O
concentrations	O
.	O

Our	O
data	O
demonstrate	O
directly	O
that	O
Rpm1r	B-GENE
is	O
transcribed	O
with	O
its	O
substrates	O
,	O
tRNA	B-GENE
met	I-GENE
f	I-GENE
and	O
tRNAPro	B-GENE
,	O
from	O
a	O
promoter	O
located	O
upstream	O
of	O
the	O
tRNA	B-GENE
met	I-GENE
f	I-GENE
gene	I-GENE
and	O
suggest	O
that	O
a	O
portion	O
also	O
originates	O
from	O
a	O
second	O
promoter	O
,	O
located	O
between	O
the	O
tRNA	B-GENE
met	I-GENE
f	I-GENE
gene	I-GENE
and	O
RPM1	B-GENE
.	O

Furthermore	O
,	O
expression	O
of	O
the	O
promoter	O
in	O
embryonic	O
Drosophila	O
melanogaster	O
cells	O
that	O
lack	O
MyoD1	B-GENE
and	O
Sp1	B-GENE
is	O
strictly	O
dependent	O
on	O
all	O
three	O
sites	O
remaining	O
intact	O
and	O
on	O
the	O
presence	O
of	O
exogenously	O
supplied	O
Sp1	B-GENE
and	O
MyoD1	B-GENE
.	O

Retinoid	O
-	O
dependent	O
activation	O
of	O
the	O
tissue	B-GENE
transglutaminase	I-GENE
promoter	I-GENE
depends	O
on	O
both	O
a	O
proximal	O
regulatory	O
region	O
containing	O
sequences	O
highly	O
conserved	O
between	O
the	O
human	O
and	O
the	O
mouse	B-GENE
tissue	I-GENE
transglutaminase	I-GENE
promoters	I-GENE
and	O
a	O
distal	O
region	O
that	O
includes	O
a	O
30	B-GENE
-	I-GENE
base	I-GENE
pair	I-GENE
retinoid	I-GENE
response	I-GENE
element	I-GENE
(	I-GENE
mTGRRE1	I-GENE
)	I-GENE
.	O
mTGRRE1	B-GENE
contains	O
three	O
hexanucleotide	O
half	O
-	O
sites	O
(	O
two	O
canonical	O
and	O
one	O
non	O
-	O
canonical	O
)	O
in	O
a	O
DR7	B-GENE
/	I-GENE
DR5	I-GENE
motif	I-GENE
that	O
bind	O
both	O
RAR	B-GENE
*	I-GENE
RXR	I-GENE
heterodimers	I-GENE
and	O
RXR	B-GENE
homodimers	I-GENE
.	O

However	O
,	O
the	O
published	O
reports	O
consist	O
of	O
a	O
small	O
number	O
of	O
patients	O
and	O
limited	O
data	O
.	O

Relationship	O
between	O
mitochondrial	B-GENE
NADH	I-GENE
-	I-GENE
ubiquinone	I-GENE
reductase	I-GENE
and	O
a	O
bacterial	B-GENE
NAD	I-GENE
-	I-GENE
reducing	I-GENE
hydrogenase	I-GENE
.	O

The	O
combination	O
of	O
hydralazine	O
hydrochloride	O
and	O
isosorbide	O
dinitrate	O
also	O
improves	O
survival	O
,	O
but	O
direct	O
comparison	O
of	O
both	O
regimens	O
provided	O
evidence	O
for	O
a	O
less	O
favourable	O
effect	O
than	O
that	O
of	O
the	O
ACE	B-GENE
inhibitors	O
.	O

Quinone	O
-	O
binding	O
domain	O
and	O
amino	O
acid	O
residues	O
involved	O
in	O
quinone	O
binding	O
.	O

In	O
fact	O
,	O
families	O
of	O
polypeptides	O
were	O
produced	O
by	O
initiation	O
of	O
translation	O
at	O
AUG	O
codons	O
within	O
sequences	O
coding	O
for	O
VP1	B-GENE
and	O
T	B-GENE
,	O
presumably	O
as	O
a	O
result	O
of	O
transcription	O
initiation	O
events	O
that	O
generated	O
5	O
'	O
ends	O
immediately	O
upstream	O
from	O
these	O
AUGs	O
.	O

Although	O
the	O
expression	O
of	O
the	O
4E	B-GENE
-	I-GENE
BP1	I-GENE
gene	I-GENE
alone	O
has	O
not	O
yet	O
been	O
accomplished	O
,	O
the	O
gene	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
[	O
BL21	O
(	O
DE3	O
)	O
]	O
as	O
a	O
fusion	O
gene	O
with	O
the	O
glutathione	B-GENE
-	I-GENE
S	I-GENE
-	I-GENE
transferase	I-GENE
(	O
GST	B-GENE
)	O
gene	O
using	O
a	O
prokaryotic	O
gene	O
fusion	O
vector	O
(	O
pGEX	O
-	O
4T	O
-	O
2	O
)	O
,	O
which	O
contains	O
a	O
gene	O
sequence	O
coding	O
the	O
cleavage	O
site	O
for	O
a	O
specific	O
protease	B-GENE
,	O
alpha	B-GENE
-	I-GENE
thrombin	I-GENE
.	O

Reporter	O
gene	O
expression	O
analyses	O
indicate	O
that	O
both	O
WASP	B-GENE
promoters	I-GENE
show	O
high	O
levels	O
of	O
expression	O
in	O
different	O
hematopoietic	O
cell	O
lines	O
.	O

The	O
geometric	O
mean	O
hemagglutination	O
-	O
inhibition	O
antibody	O
titers	O
(	O
GMT	O
)	O
of	O
non	O
-	O
immunized	O
,	O
once	O
-	O
immunized	O
,	O
and	O
twice	O
-	O
immunized	O
chickens	O
were	O
compared	O
at	O
2	O
-	O
week	O
intervals	O
following	O
primary	O
immunization	O
,	O
secondary	O
immunization	O
,	O
and	O
challenge	O
.	O

These	O
results	O
suggest	O
that	O
FK	O
506	O
is	O
a	O
useful	O
immunosuppressive	O
agent	O
in	O
kidney	O
transplantation	O
.	O

The	O
micturition	O
pressure	O
was	O
significantly	O
decreased	O
only	O
after	O
injection	O
with	O
BUP	O
-	O
4	O
in	O
both	O
normal	O
and	O
obstructed	O
rats	O
.	O

We	O
have	O
previously	O
isolated	O
a	O
cDNA	O
for	O
a	O
transcription	O
factor	O
referred	O
to	O
as	O
Zfhep	B-GENE
(	O
zinc	B-GENE
finger	I-GENE
homeodomain	I-GENE
enhancer	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
)	O
containing	O
two	O
separate	O
zinc	O
finger	O
domains	O
,	O
ZD1	B-GENE
and	O
ZD2	B-GENE
,	O
each	O
of	O
which	O
binds	O
DNA	O
,	O
and	O
a	O
homeodomain	O
.	O

Inactivation	O
of	O
p53	B-GENE
but	O
not	O
p73	B-GENE
by	O
adenovirus	B-GENE
type	I-GENE
5	I-GENE
E1B	I-GENE
55	I-GENE
-	I-GENE
kilodalton	I-GENE
and	I-GENE
E4	I-GENE
34	I-GENE
-	I-GENE
kilodalton	I-GENE
oncoproteins	I-GENE
.	O

Following	O
EPI	O
-	O
C0401	O
,	O
but	O
not	O
saline	O
or	O
DepoFoam	O
vehicle	O
,	O
there	O
were	O
transient	O
(	O
<	O
72	O
hr	O
)	O
decreases	O
in	O
food	O
consumption	O
,	O
arousal	O
,	O
hindlimb	O
muscle	O
tone	O
,	O
and	O
body	O
temperature	O
.	O

Upstream	B-GENE
activating	I-GENE
sequences	I-GENE
(	O
UASs	B-GENE
)	O
derived	O
from	O
known	O
Ste12p	O
-	O
dependent	O
genes	O
have	O
previously	O
been	O
characterized	O
to	O
require	O
either	O
multiple	O
PREs	B-GENE
or	O
a	O
single	O
PRE	B-GENE
coupled	O
to	O
a	O
binding	O
site	O
for	O
a	O
second	O
protein	O
.	O

Deletion	O
studies	O
identified	O
a	O
distal	O
response	O
element	O
that	O
is	O
responsible	O
for	O
the	O
cytokine	O
response	O
and	O
has	O
properties	O
of	O
an	O
inducible	O
transcriptional	O
enhancer	O
.	O

195mPt	O
-	O
labeled	O
cisplatin	O
was	O
administered	O
iv	O
and	O
ip	O
to	O
control	O
mice	O
and	O
to	O
mice	O
bearing	O
Sarcoma	O
180	O
.	O

Both	O
groups	O
rejected	O
pops	O
with	O
added	O
SOA	O
,	O
decreasing	O
mouthing	O
times	O
as	O
SOA	O
concentration	O
increased	O
.	O

One	O
millimolar	O
ouabain	O
completely	O
inhibited	O
net	O
HCO3	O
-	O
secretion	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
well	O
established	O
polarity	O
of	O
RXR	B-GENE
heterodimer	O
binding	O
to	O
bipartite	B-GENE
hormone	I-GENE
response	I-GENE
elements	I-GENE
,	O
with	O
the	O
VDR	B-GENE
recognizing	O
the	O
3	O
'	O
-	O
half	O
-	O
element	O
.	O

The	O
uncomplicated	O
cases	O
of	O
typhoid	O
fever	O
were	O
found	O
to	O
have	O
an	O
intact	O
CMIR	O
as	O
compared	O
to	O
the	O
complicated	O
cases	O
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

Zatebradine	O
weakly	O
depressed	O
the	O
ectopic	O
ventricular	O
rate	O
but	O
not	O
the	O
arrhythmic	O
ratio	O
of	O
the	O
ventricular	O
arrhythmias	O
induced	O
by	O
two	O
-	O
stage	O
coronary	O
ligation	O
24	O
h	O
after	O
the	O
ligation	O
in	O
conscious	O
dogs	O
.	O

The	O
sense	O
of	O
self	O
.	O

On	O
catabolism	O
of	O
aminoketones	O
in	O
climacteric	O
age	O
.	O

The	O
existence	O
of	O
these	O
two	O
categories	O
of	O
strains	O
offers	O
a	O
new	O
genetic	O
system	O
in	O
which	O
the	O
properties	O
of	O
a	O
potential	O
invertebrate	O
retrovirus	O
can	O
be	O
tested	O
.	O

(	O
ii	O
)	O
ICP27	B-GENE
binds	O
preferentially	O
to	O
less	O
modified	O
forms	O
of	O
ICP4	B-GENE
,	O
a	O
protein	O
that	O
is	O
extensively	O
modified	O
posttranslationally	O
.	O

To	O
prepare	O
for	O
analyses	O
with	O
the	O
family	O
variables	O
,	O
we	O
next	O
present	O
descriptive	O
data	O
based	O
on	O
separate	O
principal	O
components	O
analysis	O
(	O
PCA	O
)	O
and	O
multidimensional	O
scaling	O
analysis	O
(	O
MDS	O
)	O
of	O
14	O
self	O
-	O
reported	O
health	O
scores	O
for	O
husbands	O
and	O
for	O
wives	O
.	O

Based	O
on	O
16S	B-GENE
rRNA	I-GENE
gene	I-GENE
sequence	I-GENE
analysis	O
,	O
the	O
11	O
species	O
having	O
two	O
tuf	B-GENE
genes	I-GENE
all	O
have	O
a	O
common	O
ancestor	O
,	O
while	O
the	O
six	O
species	O
having	O
only	O
one	O
copy	O
diverged	O
from	O
the	O
enterococcal	O
lineage	O
before	O
that	O
common	O
ancestor	O
.	O

In	O
addition	O
,	O
the	O
acetyltransferase	B-GENE
activity	O
of	O
p300	B-GENE
was	O
observed	O
to	O
be	O
distinct	O
from	O
the	O
broadly	O
essential	O
activation	O
function	O
of	O
the	O
CH3	B-GENE
domain	I-GENE
/	I-GENE
E1A	I-GENE
-	I-GENE
binding	I-GENE
region	I-GENE
.	O

The	O
locus	O
encoding	O
the	O
XD	B-GENE
gene	I-GENE
(	O
designated	O
Xd	B-GENE
)	O
was	O
mapped	O
to	O
the	O
distal	O
part	O
of	O
mouse	O
chromosome	O
17	O
by	O
haplotype	O
analysis	O
of	O
114	O
interspecific	O
backcross	O
mice	O
.	O

Merosin	B-GENE
positive	O
congenital	O
muscular	O
dystrophy	O
with	O
mental	O
deficiency	O
,	O
epilepsy	O
and	O
MRI	O
changes	O
in	O
the	O
cerebral	O
white	O
matter	O
.	O

Lacrimal	O
secretion	O
in	O
hyperthyroidism	O
.	O

Once	O
ICP	O
reaches	O
critical	O
values	O
(	O
>	O
30	O
mm	O
Hg	O
)	O
herniation	O
occurs	O
,	O
usually	O
within	O
2	O
to	O
5	O
days	O
.	O

The	O
proofreading	O
domain	O
of	O
Escherichia	B-GENE
coli	I-GENE
DNA	I-GENE
polymerase	I-GENE
I	I-GENE
and	O
other	O
DNA	B-GENE
and	I-GENE
/	I-GENE
or	I-GENE
RNA	I-GENE
exonuclease	I-GENE
domains	I-GENE
.	O

Changes	O
following	O
periodontal	O
surgery	O
.	O

Pro	O
-	O
inflammatory	O
cytokine	O
,	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
-	I-GENE
alpha	I-GENE
(	O
TNF	B-GENE
-	I-GENE
alpha	I-GENE
)	O
,	O
produced	O
from	O
adipose	O
tissues	O
in	O
obese	O
subjects	O
,	O
is	O
known	O
to	O
play	O
a	O
predominant	O
role	O
in	O
inducing	O
insulin	B-GENE
resistance	O
.	O

Below	O
50	O
%	O
decrease	O
of	O
PaO2	O
,	O
NADH	O
was	O
reduced	O
largely	O
.	O

In	O
all	O
cases	O
,	O
high	O
-	O
level	O
expression	O
of	O
the	O
truncated	B-GENE
avian	I-GENE
integrins	I-GENE
was	O
obtained	O
.	O

Her	O
serum	O
FT3	O
concentration	O
was	O
,	O
however	O
,	O
much	O
higher	O
than	O
the	O
ranges	O
in	O
normal	O
pregnancy	O
or	O
in	O
GTD	O
patients	O
without	O
clinical	O
hyperthyroidism	O
.	O

A	O
system	O
is	O
described	O
in	O
which	O
the	O
volume	O
flow	O
rate	O
of	O
blood	O
in	O
a	O
vessel	O
is	O
determined	O
using	O
transverse	O
colour	O
Doppler	O
ultrasound	O
imaging	O
.	O

Studies	O
of	O
lipogenesis	O
by	O
labelled	O
precursors	O
in	O
the	O
pregnant	O
rat	O
.	O

A	O
prospective	O
trial	O
was	O
carried	O
out	O
in	O
156	O
unselected	O
patients	O
(	O
41	O
men	O
,	O
mean	O
age	O
67	O
.	O
5	O
years	O
,	O
115	O
women	O
,	O
mean	O
age	O
71	O
.	O
4	O
years	O
)	O
who	O
had	O
undergone	O
total	O
hip	O
joint	O
replacement	O
because	O
of	O
degenerative	O
or	O
inflammatory	O
arthritis	O
or	O
fracture	O
of	O
the	O
neck	O
of	O
the	O
femur	O
.	O

Nucleotide	O
sequence	O
and	O
transcriptional	O
analysis	O
of	O
the	O
DNA	B-GENE
polymerase	I-GENE
gene	I-GENE
of	I-GENE
Bombyx	I-GENE
mori	I-GENE
nuclear	I-GENE
polyhedrosis	I-GENE
virus	I-GENE
.	O

In	O
view	O
of	O
these	O
results	O
,	O
simultaneous	O
pancreas	O
-	O
kidney	O
transplantation	O
appears	O
to	O
be	O
the	O
treatment	O
of	O
choice	O
for	O
Type	O
I	O
diabetic	O
patients	O
.	O

Sequence	O
analysis	O
of	O
a	O
6	O
.	O
3	O
-	O
kbp	O
genomic	O
EcoRI	O
-	O
fragment	O
of	O
Alcaligenes	O
eutrophus	O
,	O
which	O
was	O
recently	O
identified	O
by	O
using	O
a	O
dihydrolipoamide	O
dehydrogenase	O
-	O
specific	O
DNA	O
probe	O
(	O
A	O
.	O

Polysome	O
analysis	O
further	O
indicated	O
that	O
these	O
germ	B-GENE
cell	I-GENE
-	I-GENE
specific	I-GENE
Sp1	I-GENE
mRNAs	I-GENE
are	O
translated	O
,	O
albeit	O
with	O
a	O
lower	O
efficiency	O
than	O
the	O
somatic	O
transcript	O
.	O

Transgenic	O
tobacco	O
plants	O
(	O
ppa	O
-	O
1	O
)	O
constitutively	O
expressing	O
Escherichia	B-GENE
coli	I-GENE
pyrophosphatase	I-GENE
behind	O
the	O
35S	B-GENE
CaMV	I-GENE
promoter	I-GENE
accumulate	O
high	O
levels	O
of	O
soluble	O
sugars	O
in	O
their	O
leaves	O
[	O
27	O
]	O
.	O

Deletions	O
were	O
examined	O
in	O
the	O
LYS2	B-GENE
gene	I-GENE
,	O
using	O
a	O
set	O
of	O
31	O
-	O
to	O
156	O
-	O
bp	O
inserts	O
that	O
included	O
inserts	O
with	O
no	O
apparent	O
potential	O
for	O
secondary	O
structure	O
as	O
well	O
as	O
two	O
quasipalindromes	O
.	O

Since	O
1948	O
,	O
the	O
use	O
of	O
saline	O
-	O
washed	O
red	O
cells	O
(	O
WRBCs	O
)	O
has	O
been	O
advocated	O
to	O
minimize	O
hemolysis	O
after	O
transfusion	O
to	O
patients	O
with	O
PNH	O
.	O

Diagnosis	O
and	O
differential	O
diagnosis	O
.	O

In	O
addition	O
,	O
the	O
utility	O
of	O
beta	B-GENE
2	I-GENE
transferrin	I-GENE
assay	O
in	O
the	O
diagnosis	O
of	O
cerebrospinal	O
fluid	O
otorrhea	O
is	O
presented	O
.	O

We	O
show	O
here	O
that	O
,	O
despite	O
their	O
structural	O
and	O
functional	O
similarities	O
,	O
the	O
pop1	B-GENE
and	O
pop2	B-GENE
genes	I-GENE
fail	O
to	O
complement	O
each	O
other	O
'	O
s	O
deletion	O
phenotypes	O
,	O
indicating	O
that	O
they	O
perform	O
non	O
-	O
redundant	O
,	O
but	O
potentially	O
interdependent	O
,	O
functions	O
in	O
proteolysis	O
.	O

To	O
identify	O
the	O
precise	O
location	O
of	O
the	O
phosphorylation	O
site	O
on	O
the	O
64	O
-	O
kDa	O
protein	O
,	O
a	O
step	O
-	O
by	O
-	O
step	O
mutagenesis	O
procedures	O
was	O
followed	O
.	O

A	O
major	O
task	O
for	O
sports	O
scientists	O
may	O
be	O
to	O
verify	O
empirically	O
the	O
nature	O
of	O
an	O
integrated	O
model	O
of	O
the	O
sport	O
performer	O
.	O

To	O
better	O
understand	O
the	O
role	O
of	O
Ets	B-GENE
proteins	I-GENE
in	O
Ras	B-GENE
transformation	O
,	O
we	O
have	O
now	O
analyzed	O
the	O
effects	O
of	O
stably	O
expressing	O
a	O
variety	O
of	O
Ets2	B-GENE
constructs	I-GENE
in	O
Ras	O
-	O
transformed	O
NIH3T3	O
(	O
DT	O
)	O
cells	O
.	O

They	O
were	O
randomly	O
allocated	O
to	O
receive	O
either	O
625	O
mg	O
of	O
calcium	O
carbonate	O
(	O
250	O
mg	O
of	O
elemental	O
calcium	O
)	O
at	O
the	O
end	O
of	O
a	O
meal	O
three	O
times	O
a	O
day	O
(	O
group	O
A	O
,	O
n	O
=	O
26	O
)	O
or	O
calcium	O
carbonate	O
in	O
the	O
same	O
manner	O
plus	O
0	O
.	O
625	O
mg	O
/	O
day	O
of	O
conjugated	O
equine	O
estrogen	O
and	O
5	O
mg	O
medrogestone	O
acetate	O
from	O
day	O
1	O
-	O
12	O
each	O
month	O
(	O
group	O
B	O
,	O
n	O
=	O
30	O
)	O
.	O

In	O
addition	O
to	O
the	O
signals	O
obtained	O
by	O
ligation	O
of	O
the	O
TCR	B-GENE
,	O
T	O
cells	O
need	O
additional	O
,	O
co	O
-	O
stimulatory	O
signals	O
to	O
be	O
activated	O
.	O

However	O
,	O
most	O
produced	O
significant	O
alteration	O
of	O
small	O
intestinal	O
permeability	O
.	O

Cyclin	B-GENE
D1	I-GENE
promoter	I-GENE
activity	O
was	O
stimulated	O
by	O
overexpression	O
of	O
mitogen	B-GENE
-	I-GENE
activated	I-GENE
protein	I-GENE
kinase	I-GENE
(	O
p41MAPK	B-GENE
)	O
or	O
c	B-GENE
-	I-GENE
Ets	I-GENE
-	I-GENE
2	I-GENE
through	O
the	O
proximal	O
22	O
base	O
pairs	O
.	O

Synthetic	O
enantiomers	O
of	O
drugs	O
.	O

Furthermore	O
,	O
in	O
vitro	O
decay	O
reaction	O
mixtures	O
supplemented	O
with	O
the	O
20	O
-	O
nt	O
sense	O
RNA	O
transcript	O
resulted	O
in	O
stabilization	O
of	O
R2	B-GENE
message	I-GENE
.	O

The	O
5	O
'	O
and	O
3	O
'	O
untranslated	O
sequences	O
contain	O
characteristic	O
sequences	O
that	O
are	O
involved	O
in	O
the	O
initiation	O
and	O
termination	O
of	O
transcription	O
,	O
including	O
two	O
possible	O
promoters	O
,	O
one	O
of	O
which	O
may	O
contain	O
two	O
overlapping	O
-	O
10	O
sequences	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
inducible	O
expression	O
of	O
the	O
flt	B-GENE
-	I-GENE
1	I-GENE
gene	I-GENE
during	O
the	O
activation	O
of	O
THP	O
-	O
1	O
cells	O
.	O

Estimated	O
daily	O
intakes	O
(	O
EDIs	O
)	O
per	O
person	O
were	O
0	O
.	O
56	O
microgram	O
for	O
total	O
HCH	O
,	O
0	O
.	O
20	O
microgram	O
for	O
gamma	O
-	O
HCH	O
,	O
0	O
.	O
09	O
microgram	O
for	O
dieldrin	O
,	O
1	O
.	O
42	O
micrograms	O
for	O
total	O
DDT	O
,	O
and	O
0	O
.	O
15	O
microgram	O
for	O
HCB	O
.	O

A	O
protocol	O
is	O
elaborated	O
for	O
the	O
preparation	O
and	O
characterization	O
of	O
a	O
quality	O
control	O
material	O
(	O
QCM	O
)	O
containing	O
intrinsic	O
concentration	O
of	O
cadmium	O
(	O
Cd	O
)	O
(	O
0	O
.	O
8	O
microgram	O
/	O
L	O
)	O
and	O
lead	O
(	O
Pb	O
)	O
(	O
13	O
.	O
4	O
micrograms	O
/	O
dL	O
)	O
from	O
bovine	O
blood	O
and	O
an	O
elevated	O
QCM	O
containing	O
Cd	O
(	O
5	O
.	O
0	O
micrograms	O
/	O
L	O
)	O
,	O
mercury	O
(	O
Hg	O
)	O
(	O
11	O
.	O
2	O
micrograms	O
/	O
L	O
)	O
,	O
and	O
Pb	O
(	O
34	O
.	O
5	O
micrograms	O
/	O
dL	O
)	O
from	O
bovine	O
blood	O
spiked	O
with	O
aqueous	O
spiking	O
-	O
solutions	O
prepared	O
with	O
salts	O
of	O
Cd	O
,	O
Hg	O
,	O
and	O
Pb	O
.	O

Gab2	B-GENE
,	O
a	O
new	O
pleckstrin	B-GENE
homology	O
domain	O
-	O
containing	O
adapter	O
protein	O
,	O
acts	O
to	O
uncouple	O
signaling	O
from	O
ERK	B-GENE
kinase	I-GENE
to	O
Elk	B-GENE
-	I-GENE
1	I-GENE
.	O

In	O
HeLa	O
cells	O
,	O
it	O
activated	O
transcription	O
from	O
the	O
herpes	B-GENE
simplex	I-GENE
virus	I-GENE
type	I-GENE
1	I-GENE
thymidine	I-GENE
kinase	I-GENE
promoter	I-GENE
linked	O
to	O
the	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
gene	I-GENE
when	O
located	O
in	O
inverted	O
orientation	O
upstream	O
of	O
the	O
thymidine	B-GENE
kinase	I-GENE
promoter	I-GENE
or	O
downstream	O
of	O
the	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
gene	I-GENE
coding	I-GENE
sequence	I-GENE
.	O

Guiding	O
patients	O
in	O
the	O
decision	O
should	O
involve	O
a	O
multidisciplinary	O
team	O
composed	O
of	O
a	O
surgical	O
oncologist	O
,	O
geneticist	O
,	O
pathologist	O
,	O
psychotherapist	O
and	O
plastic	O
surgeon	O
.	O

Neither	O
model	O
,	O
as	O
applied	O
,	O
provided	O
a	O
satisfactory	O
account	O
of	O
the	O
effects	O
of	O
the	O
main	O
variables	O
of	O
number	O
of	O
tones	O
and	O
amount	O
of	O
perturbation	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Treatment	O
of	O
ovarian	O
neoplasms	O
.	O

The	O
variable	O
HMG	B-GENE
dosage	O
regimen	O
was	O
found	O
to	O
offer	O
no	O
advantages	O
when	O
compared	O
with	O
our	O
standard	O
daily	O
dosage	O
regimen	O
.	O

The	O
improved	O
CSF	O
outflow	O
conductance	O
may	O
increase	O
the	O
intracranial	O
compliance	O
and	O
thereby	O
dampen	O
a	O
pathological	O
ICP	O
waveform	O
.	O

The	O
sequence	O
of	O
this	O
region	O
shows	O
high	O
G	O
+	O
C	O
content	O
(	O
62	O
%	O
)	O
,	O
which	O
is	O
particularly	O
emphasized	O
in	O
the	O
200	O
bp	O
upstream	O
from	O
the	O
mRNA	O
start	O
(	O
80	O
%	O
G	O
+	O
C	O
)	O
.	O

This	O
difference	O
may	O
result	O
from	O
the	O
lower	O
match	O
to	O
the	O
ARG	B-GENE
box	I-GENE
consensus	I-GENE
of	O
the	O
O	B-GENE
(	I-GENE
rocD	I-GENE
)	I-GENE
site	I-GENE
.	O

Expression	O
,	O
nucleotide	O
sequence	O
and	O
mutational	O
analysis	O
of	O
two	O
open	O
reading	O
frames	O
in	O
the	O
nif	B-GENE
gene	I-GENE
region	I-GENE
of	I-GENE
Anabaena	I-GENE
sp	I-GENE
.	I-GENE
strain	I-GENE
PCC7120	I-GENE
.	O

We	O
postulate	O
that	O
CaM	B-GENE
binding	O
by	O
HIV	B-GENE
envelope	I-GENE
proteins	I-GENE
is	O
likely	O
to	O
exert	O
diverse	O
modulatory	O
effects	O
,	O
and	O
the	O
mechanism	O
for	O
HIV	O
-	O
induced	O
cytotoxicity	O
may	O
involve	O
,	O
in	O
part	O
,	O
inhibition	O
of	O
CaM	O
-	O
regulated	O
cellular	O
functions	O
.	O

Both	O
of	O
these	O
domains	O
have	O
striking	O
sequence	O
homology	O
with	O
human	O
SIM	B-GENE
and	O
Drosophila	O
SIM	B-GENE
proteins	O
.	O

Truncations	O
composed	O
of	O
78	O
and	O
64	O
amino	O
acids	O
were	O
translocated	O
across	O
the	O
endoplasmic	O
reticulum	O
membrane	O
,	O
and	O
translocation	O
was	O
found	O
to	O
be	O
strictly	O
co	O
-	O
translational	O
and	O
SRP	O
-	O
dependent	O
.	O

Toxicity	O
was	O
very	O
mild	O
with	O
both	O
regimens	O
,	O
although	O
sedation	O
was	O
significantly	O
higher	O
in	O
arm	O
B	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

6	O
.	O

The	O
uterine	O
response	O
to	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
and	O
prostaglandin	O
F2alpha	O
(	O
administered	O
by	O
intravenous	O
and	O
intrauterine	O
routes	O
)	O
was	O
evaluated	O
during	O
different	O
phases	O
of	O
the	O
menstrual	O
cycle	O
in	O
five	O
functionally	O
infertile	O
women	O
.	O

Shift	O
-	O
down	O
experiments	O
indicated	O
that	O
the	O
10	O
(	O
4	O
)	O
-	O
to	O
10	O
(	O
5	O
)	O
-	O
fold	O
reduction	O
in	O
virus	O
yield	O
at	O
the	O
nonpermissive	O
temperature	O
was	O
due	O
to	O
the	O
disfunction	O
of	O
alpha	B-GENE
TIF	I-GENE
late	O
in	O
infection	O
,	O
presumably	O
in	O
virion	O
maturation	O
.	O

Specifically	O
,	O
the	O
deduced	O
FR	B-GENE
-	I-GENE
19	I-GENE
amino	I-GENE
acid	I-GENE
sequence	I-GENE
has	O
approximately89	O
,	O
77	O
,	O
and	O
68	O
%	O
overall	O
identity	O
to	O
chicken	B-GENE
TEF	I-GENE
-	I-GENE
1A	I-GENE
,	O
mouse	B-GENE
TEF	I-GENE
-	I-GENE
1	I-GENE
,	O
and	O
mouse	B-GENE
embryonic	I-GENE
TEA	I-GENE
domain	I-GENE
-	I-GENE
containing	I-GENE
factor	I-GENE
,	O
respectively	O
.	O

We	O
examined	O
the	O
effects	O
of	O
long	O
-	O
term	O
perfusion	O
with	O
pyridoxalated	O
hemoglobin	B-GENE
polyoxyethylene	O
conjugate	O
(	O
PHP	O
)	O
solution	O
on	O
cardiac	O
function	O
of	O
isolated	O
rat	O
hearts	O
.	O

Two	O
classes	O
of	O
mutations	O
were	O
obtained	O
:	O
(	O
i	O
)	O
those	O
that	O
altered	O
the	O
coding	O
region	O
of	O
HOL1	B-GENE
,	O
conferring	O
the	O
ability	O
to	O
take	O
up	O
histidinol	O
;	O
and	O
(	O
ii	O
)	O
cis	O
-	O
acting	O
mutations	O
(	O
selected	O
in	O
a	O
mutant	O
HOL1	B-GENE
-	I-GENE
1	I-GENE
background	O
)	O
that	O
increased	O
expression	O
of	O
the	O
Hol1	B-GENE
protein	I-GENE
.	O

INTERVENTION	O
(	O
S	O
)	O
:	O
Twenty	O
-	O
six	O
hemostasis	O
parameters	O
evaluated	O
repeatedly	O
in	O
patients	O
undergoing	O
IVF	O
-	O
ET	O
.	O

NF	B-GENE
kappa	I-GENE
B	I-GENE
was	O
activated	O
to	O
a	O
much	O
greater	O
extent	O
by	O
roscovitine	O
in	O
the	O
WT	O
cells	O
than	O
in	O
Y8	O
cells	O
.	O

Although	O
pathological	O
thyroid	O
function	O
is	O
related	O
to	O
changes	O
in	O
energy	O
expenditure	O
and	O
body	O
composition	O
,	O
its	O
possible	O
influence	O
on	O
leptin	B-GENE
levels	O
remains	O
to	O
be	O
determined	O
.	O

Identification	O
and	O
characterization	O
of	O
the	O
promoter	O
for	O
the	O
cytotactin	B-GENE
gene	I-GENE
.	O

A	O
coiled	O
-	O
coil	O
domain	O
,	O
conserved	O
within	O
each	O
encoded	O
protein	O
,	O
serves	O
as	O
a	O
potential	O
interaction	O
motif	O
for	O
FLI	B-GENE
LRR	I-GENE
.	O

We	O
have	O
identified	O
two	O
Marek	O
'	O
s	O
Disease	O
Virus	O
(	O
MDV	O
)	O
genes	O
within	O
the	O
EcoRI	B-GENE
-	I-GENE
B	I-GENE
fragment	I-GENE
of	O
MDV	O
-	O
GA	O
genomic	O
DNA	O
.	O

Twenty	O
-	O
eight	O
were	O
excluded	O
as	O
gallstones	O
were	O
not	O
proved	O
:	O
of	O
the	O
remainder	O
,	O
21	O
patients	O
received	O
glucagon	B-GENE
and	O
22	O
placebo	O
.	O

Fibrinogen	B-GENE
determination	O
using	O
the	O
KZM	O
-	O
1	O
meter	O
.	O

Unexpectedly	O
,	O
ALK7	B-GENE
signaling	O
produced	O
a	O
remarkable	O
change	O
in	O
cell	O
morphology	O
characterized	O
by	O
cell	O
flattening	O
and	O
elaboration	O
of	O
blunt	O
,	O
short	O
cell	O
processes	O
.	O

The	O
effect	O
of	O
echothiophate	O
on	O
the	O
biphasic	O
response	O
of	O
rabbit	O
ocular	O
pressure	O
to	O
dipivefrin	O
.	O

At	O
the	O
time	O
of	O
the	O
blind	O
therapeutic	O
doses	O
,	O
Tg	O
-	O
off	O
values	O
ranged	O
from	O
8	O
to	O
608	O
microg	O
/	O
l	O
.	O

We	O
report	O
here	O
the	O
cloning	O
of	O
the	O
murine	B-GENE
p44	I-GENE
MAP	I-GENE
kinase	I-GENE
(	O
extracellular	B-GENE
signal	I-GENE
-	I-GENE
regulated	I-GENE
kinase	I-GENE
1	I-GENE
)	O
gene	O
,	O
the	O
determination	O
of	O
its	O
intron	O
/	O
exon	O
boundaries	O
,	O
and	O
the	O
characterization	O
of	O
its	O
promoter	O
.	O

Besides	O
,	O
we	O
found	O
in	O
3	O
patients	O
increased	O
serum	O
immunoglobulins	O
,	O
chiefly	O
IgG	B-GENE
,	O
as	O
first	O
Russe	O
,	O
Busey	O
and	O
Barbeau	O
demonstrated	O
in	O
a	O
large	O
French	O
-	O
Canadian	O
family	O
.	O

Uptake	O
of	O
ofloxacin	O
by	O
Escherichia	O
coli	O
.	O

A	O
rapid	O
staining	O
technique	O
for	O
Leishmania	O
parasites	O
in	O
splenic	O
aspirate	O
smears	O
.	O

Role	O
of	O
superoxide	B-GENE
dismutase	I-GENE
in	O
cellular	O
oxidative	O
processes	O
and	O
method	O
of	O
its	O
determination	O
in	O
biological	O
materials	O
.	O

This	O
study	O
analyzed	O
whether	O
the	O
localization	O
of	O
an	O
accessory	O
pathway	O
could	O
be	O
predicted	O
by	O
using	O
the	O
polarity	O
of	O
the	O
QRS	O
complex	O
during	O
sinus	O
rhythm	O
on	O
the	O
surface	O
ECG	O
,	O
instead	O
of	O
the	O
delta	O
wave	O
polarity	O
as	O
used	O
in	O
many	O
reports	O
.	O

Here	O
we	O
show	O
that	O
phosphorylation	O
-	O
induced	O
loss	O
of	O
the	O
protein	B-GENE
kinase	I-GENE
activity	O
of	O
DNA	B-GENE
-	I-GENE
PK	I-GENE
is	O
restored	O
by	O
the	O
addition	O
of	O
the	O
purified	O
catalytic	O
subunit	O
of	O
either	O
protein	B-GENE
phosphatase	I-GENE
1	I-GENE
or	O
protein	B-GENE
phosphatase	I-GENE
2A	I-GENE
(	O
PP2A	B-GENE
)	O
and	O
that	O
this	O
reactivation	O
is	O
blocked	O
by	O
the	O
potent	O
protein	B-GENE
phosphatase	I-GENE
inhibitor	O
,	O
microcystin	O
.	O

Transcripts	O
for	O
both	O
ODV	B-GENE
-	I-GENE
E18	I-GENE
and	O
ODV	B-GENE
-	I-GENE
EC27	I-GENE
initiate	O
from	O
conserved	O
TAAG	O
motifs	O
,	O
and	O
transcripts	O
are	O
detected	O
from	O
16	O
through	O
72	O
hr	O
p	O
.	O
i	O
.	O

Control	O
of	O
transcription	O
of	O
the	O
erbB	B-GENE
-	I-GENE
2	I-GENE
gene	I-GENE
is	O
an	O
important	O
determinant	O
of	O
receptor	O
expression	O
.	O

The	O
incidence	O
of	O
second	O
malignant	O
neoplasms	O
was	O
lower	O
(	O
1	O
.	O
3	O
%	O
)	O
in	O
the	O
group	O
treated	O
with	O
5	O
-	O
fluorouracil	O
,	O
doxorubicin	O
,	O
and	O
cyclophosphamide	O
than	O
in	O
the	O
historical	O
control	O
group	O
(	O
4	O
.	O
8	O
%	O
)	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
antimicrobial	O
susceptibility	O
to	O
10	O
currently	O
used	O
antimicrobial	O
agents	O
of	O
50	O
strains	O
of	O
P	O
.	O
acnes	O
isolated	O
from	O
acne	O
lesions	O
and	O
identified	O
using	O
a	O
Rap	O
ID	O
ANA	O
II	O
panel	O
.	O

Polyhomeotic	B-GENE
and	I-GENE
Posterior	I-GENE
Sex	I-GENE
Combs	I-GENE
may	O
participate	O
in	O
a	O
more	O
general	O
transcriptional	O
mechanism	O
that	O
causes	O
modulated	O
gene	O
repression	O
,	O
whereas	O
the	O
inclusion	O
of	O
Polycomb	B-GENE
protein	I-GENE
in	O
the	O
complex	O
at	O
PREs	B-GENE
leads	O
to	O
stable	O
silencing	O
.	O

The	O
tumorigenic	O
E1A	B-GENE
+	O
cHa	B-GENE
-	I-GENE
ras	I-GENE
cells	O
are	O
characterized	O
by	O
high	O
and	O
constitutive	O
DNA	O
binding	O
activities	O
of	O
AP	B-GENE
-	I-GENE
1	I-GENE
,	O
in	O
contrast	O
to	O
nontransformed	O
cells	O
and	O
the	O
E1A	B-GENE
cells	O
.	O

Unitary	O
-	O
group	O
approach	O
to	O
spin	O
-	O
dependent	O
operators	O
.	O

The	O
transcription	O
factor	O
E2F	B-GENE
plays	O
an	O
important	O
role	O
in	O
G	O
(	O
1	O
)	O
to	O
S	O
phase	O
transition	O
in	O
the	O
higher	O
eukaryotic	O
cell	O
cycle	O
.	O

The	O
RMR	O
was	O
measured	O
twice	O
in	O
each	O
phase	O
and	O
found	O
to	O
be	O
similar	O
(	O
F	O
(	O
1	O
,	O
18	O
)	O
=	O
0	O
.	O
863	O
)	O
across	O
the	O
follicular	O
(	O
5018	O
kJ	O
/	O
24	O
h	O
)	O
and	O
the	O
luteal	O
(	O
5098	O
kJ	O
/	O
24	O
h	O
)	O
phases	O
.	O

Inductively	O
coupled	O
plasma	O
atomic	O
emission	O
spectroscopy	O
was	O
employed	O
to	O
obtain	O
the	O
tissue	O
silicon	O
measurements	O
.	O

The	O
expression	O
of	O
alpha	B-GENE
-	I-GENE
amylase	I-GENE
can	O
be	O
transactivated	O
by	O
the	O
transcription	O
factor	O
GAMyb	B-GENE
,	O
which	O
is	O
itself	O
induced	O
by	O
GA	O
.	O

Zn	B-GENE
(	I-GENE
II	I-GENE
)	I-GENE
coordination	I-GENE
domain	I-GENE
mutants	O
of	O
T4	O
gene	B-GENE
32	I-GENE
protein	O
.	O

Deletion	O
of	O
the	O
NF	B-GENE
-	I-GENE
IL6	I-GENE
beta	I-GENE
leucine	I-GENE
zipper	I-GENE
domain	I-GENE
also	O
greatly	O
diminished	O
the	O
interaction	O
between	O
these	O
two	O
proteins	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
increase	O
in	O
V	O
O2	O
may	O
have	O
been	O
a	O
consequence	O
of	O
the	O
increase	O
in	O
Q	O
O2	O
rather	O
than	O
a	O
response	O
to	O
the	O
procedure	O
itself	O
.	O

Significant	O
alterations	O
in	O
CBC	O
results	O
and	O
serum	B-GENE
CRP	I-GENE
concentration	O
,	O
compared	O
with	O
baseline	O
values	O
,	O
were	O
lacking	O
in	O
dogs	O
of	O
the	O
control	O
group	O
.	O

For	O
Al	O
,	O
the	O
exposure	O
to	O
1	O
.	O
36	O
mg	O
/	O
m3	O
during	O
the	O
shift	O
corresponded	O
to	O
a	O
urinary	O
concentration	O
at	O
the	O
end	O
of	O
the	O
shift	O
of	O
200	O
microgram	O
/	O
g	O
creatinine	O
.	O

The	O
tetraphasic	O
action	O
of	O
lidocaine	O
on	O
CNS	O
electrical	O
activity	O
and	O
behavior	O
in	O
cats	O
.	O

An	O
analytic	O
method	O
for	O
comparative	O
parameter	O
weighting	O
in	O
magnetic	O
resonance	O
(	O
MR	O
)	O
imaging	O
has	O
been	O
developed	O
using	O
the	O
concept	O
of	O
"	O
fractional	O
sensitivity	O
.	O
"	O
This	O
new	O
approach	O
results	O
in	O
easily	O
calculated	O
indexes	O
for	O
T1	O
,	O
T2	O
,	O
and	O
hydrogen	O
weighting	O
.	O

Here	O
we	O
report	O
the	O
purification	O
of	O
this	O
larger	O
form	O
as	O
an	O
approximately	O
320	O
-	O
kDa	O
particle	O
that	O
contains	O
mRNP3	B-GENE
+	I-GENE
4	I-GENE
and	O
nine	O
additional	O
polypeptides	O
,	O
including	O
mRNA	B-GENE
-	I-GENE
binding	I-GENE
polypeptides	I-GENE
of	I-GENE
34	I-GENE
and	I-GENE
36	I-GENE
kDa	I-GENE
and	O
a	O
doublet	O
of	O
110	O
/	O
105	O
kDa	O
that	O
proved	O
to	O
be	O
nucleolin	B-GENE
.	O

SIP1	B-GENE
(	O
Smad	B-GENE
interacting	I-GENE
protein	I-GENE
1	I-GENE
)	O
and	O
deltaEF1	B-GENE
(	O
delta	B-GENE
-	I-GENE
crystallin	I-GENE
enhancer	I-GENE
binding	I-GENE
factor	I-GENE
)	O
are	O
structurally	O
similar	O
transcriptional	O
repressors	O
.	O

A	O
new	O
non	O
-	O
LTR	O
retrotransposon	O
provides	O
evidence	O
for	O
multiple	O
distinct	O
site	O
-	O
specific	O
elements	O
in	O
Crithidia	O
fasciculata	O
miniexon	O
arrays	O
.	O

Overproduction	O
of	O
HrcA	B-GENE
protein	I-GENE
from	O
a	O
second	O
copy	O
of	O
hrcA	B-GENE
derived	O
from	O
a	O
plasmid	O
(	O
phrcA	O
+	O
)	O
in	O
B	O
.	O
subtilis	O
wild	O
-	O
type	O
and	O
delta	O
hrcA	B-GENE
strains	O
prevented	O
heat	O
shock	O
induction	O
of	O
the	O
dnaK	B-GENE
and	O
groE	B-GENE
operons	I-GENE
at	O
the	O
level	O
of	O
transcription	O
almost	O
completely	O
and	O
strongly	O
reduced	O
the	O
amounts	O
of	O
mRNA	O
at	O
a	O
low	O
temperature	O
as	O
well	O
.	O

The	O
construct	O
was	O
introduced	O
into	O
BW2001	O
(	O
xth	O
-	O
11	O
,	O
nfo	O
-	O
2	O
)	O
strain	O
cells	O
of	O
Escherichia	O
coli	O
.	O

These	O
data	O
suggest	O
that	O
:	O
(	O
a	O
)	O
proSRIF	B-GENE
cleavage	O
is	O
initiated	O
in	O
the	O
TGN	O
,	O
and	O
(	O
b	O
)	O
this	O
reaction	O
requires	O
an	O
acidic	O
pH	O
which	O
is	O
facilitated	O
by	O
a	O
Golgi	B-GENE
-	I-GENE
associated	I-GENE
vacuolar	I-GENE
-	I-GENE
type	I-GENE
ATPase	I-GENE
.	O

High	O
-	O
resolution	O
structure	O
of	O
the	O
diphtheria	B-GENE
toxin	I-GENE
repressor	I-GENE
complexed	O
with	O
cobalt	O
and	O
manganese	O
reveals	O
an	O
SH3	B-GENE
-	I-GENE
like	I-GENE
third	O
domain	O
and	O
suggests	O
a	O
possible	O
role	O
of	O
phosphate	O
as	O
co	O
-	O
corepressor	O
.	O

Second	O
,	O
nitrate	O
induction	O
of	O
aeg	B-GENE
-	I-GENE
46	I-GENE
.	I-GENE
5	I-GENE
operon	I-GENE
expression	O
is	O
substantially	O
enhanced	O
in	O
narL	B-GENE
null	O
strains	O
(	O
M	O
.	O
H	O
.	O

In	O
spite	O
of	O
this	O
and	O
other	O
complications	O
of	O
corticosteroids	O
,	O
she	O
made	O
a	O
full	O
recovery	O
from	O
the	O
fungal	O
infection	O
following	O
treatment	O
with	O
amphotericin	O
B	O
and	O
surgical	O
excision	O
of	O
the	O
lung	O
abscess	O
.	O

The	O
GALT	O
-	O
primed	O
calves	O
had	O
increased	O
serum	O
IgG	B-GENE
,	O
lavage	O
IgG	B-GENE
and	O
IgA	B-GENE
and	O
increased	O
LNA	B-GENE
titers	O
in	O
both	O
lavage	O
fluids	O
and	O
serum	O
following	O
the	O
SC	O
dose	O
of	O
killed	O
bacteria	O
.	O

We	O
describe	O
a	O
case	O
of	O
a	O
perinephric	O
abscess	O
treated	O
with	O
amphotericin	O
B	O
and	O
nephrectomy	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
binding	O
of	O
CBF	B-GENE
/	I-GENE
NF	I-GENE
-	I-GENE
Y	I-GENE
to	O
the	O
inverted	O
CCAAT	O
box	O
is	O
responsible	O
for	O
transcriptional	O
activation	O
of	O
the	O
nTPH	B-GENE
gene	I-GENE
.	O

Mutation	O
of	O
the	O
C	B-GENE
/	I-GENE
EBP	I-GENE
binding	I-GENE
sites	I-GENE
in	O
the	O
Rous	O
sarcoma	O
virus	O
long	O
terminal	O
repeat	O
and	O
gag	B-GENE
enhancers	I-GENE
.	O

There	O
were	O
27	O
men	O
and	O
156	O
women	O
.	O

A	O
new	O
set	O
of	O
cDNA	O
clones	O
spanning	O
approximately	O
3	O
.	O
2	O
kb	O
was	O
isolated	O
from	O
a	O
lambda	O
-	O
ZAP	O
goose	O
liver	O
cDNA	O
library	O
using	O
the	O
5	O
'	O
-	O
most	O
exon	O
-	O
containing	O
fragment	O
of	O
the	O
5	O
'	O
-	O
most	O
genomic	O
DNA	O
clone	O
.	O

The	O
sequence	O
contains	O
an	O
open	O
reading	O
frame	O
of	O
1744	O
nt	O
in	O
the	O
virus	O
-	O
sense	O
strand	O
,	O
a	O
3	O
'	O
untranslated	O
region	O
of	O
1360	O
nt	O
and	O
a	O
3	O
'	O
poly	O
(	O
A	O
)	O
tail	O
.	O

We	O
found	O
that	O
total	O
PSA	B-GENE
can	O
be	O
detected	O
in	O
all	O
cyst	O
fluids	O
and	O
in	O
about	O
75	O
%	O
of	O
female	O
sera	O
.	O

Depending	O
on	O
the	O
location	O
and	O
size	O
of	O
the	O
mass	O
,	O
a	O
wide	O
range	O
of	O
clinical	O
presentations	O
is	O
associated	O
with	O
the	O
lesion	O
.	O

Human	O
adenovirus	O
type	O
41	O
contains	O
two	O
fibers	O
.	O

The	O
likelihood	O
that	O
a	O
common	O
region	O
of	O
deletions	O
would	O
contain	O
a	O
tumor	O
suppressor	O
is	O
strongly	O
enhanced	O
by	O
coincidence	O
of	O
that	O
region	O
with	O
a	O
chromosome	O
fragment	O
suppressing	O
tumorigenicity	O
upon	O
introduction	O
in	O
tumor	O
cells	O
.	O

Denaturation	O
of	O
the	O
simian	O
virus	O
40	O
origin	O
of	O
replication	O
mediated	O
by	O
human	B-GENE
replication	I-GENE
protein	I-GENE
A	O
.	O

In	O
both	O
these	O
respects	O
,	O
however	O
,	O
the	O
DBP	B-GENE
mRNA	I-GENE
resembles	O
the	O
late	O
messengers	O
of	O
SV40	O
and	O
polyoma	O
viruses	O
.	O

Genomic	O
clones	O
encompassing	O
the	O
human	B-GENE
ETS1	I-GENE
gene	I-GENE
were	O
isolated	O
and	O
utilized	O
to	O
define	O
its	O
molecular	O
organization	O
.	O

Type	O
2	O
genomes	O
containing	O
this	O
sequence	O
presumably	O
more	O
closely	O
reflect	O
the	O
structure	O
of	O
the	O
infectious	O
,	O
replication	O
-	O
competent	O
retrovirus	O
ancestors	O
of	O
the	O
HERV	O
-	O
K	O
family	O
than	O
do	O
type	O
1	O
genomes	O
that	O
lack	O
the	O
sequence	O
.	O

Multidrug	O
resistance	O
in	O
Saccharomyces	O
cerevisiae	O
mainly	O
results	O
from	O
the	O
overexpression	O
of	O
genes	O
coding	O
for	O
the	O
membrane	O
efflux	O
pumps	O
,	O
the	O
major	O
facilitators	O
and	O
the	O
ABC	B-GENE
binding	I-GENE
cassette	I-GENE
transporters	I-GENE
,	O
under	O
the	O
control	O
of	O
key	O
transcription	O
regulators	O
encoded	O
by	O
the	O
PDR1	B-GENE
and	O
PDR3	B-GENE
genes	I-GENE
.	O

In	O
the	O
Oct	B-GENE
-	I-GENE
1	I-GENE
crystal	O
,	O
the	O
POU	B-GENE
-	I-GENE
specific	I-GENE
domain	I-GENE
recognizes	O
a	O
GCAT	B-GENE
half	I-GENE
-	I-GENE
site	I-GENE
,	O
while	O
the	O
corresponding	O
sequence	O
recognized	O
by	O
the	O
Pit	B-GENE
-	I-GENE
1	I-GENE
POU	I-GENE
-	I-GENE
specific	I-GENE
domain	I-GENE
,	O
GTAT	B-GENE
,	O
is	O
on	O
the	O
opposing	O
strand	O
.	O

Blood	O
samples	O
were	O
obtained	O
daily	O
during	O
this	O
supplementation	O
period	O
and	O
5	O
d	O
thereafter	O
(	O
d	O
11	O
to	O
15	O
)	O
.	O

We	O
were	O
able	O
to	O
detect	O
significant	O
differences	O
in	O
functional	O
residual	O
capacity	O
adjusted	O
for	O
weight	O
or	O
height	O
,	O
and	O
compliance	O
of	O
the	O
respiratory	O
system	O
adjusted	O
for	O
weight	O
or	O
lung	O
volume	O
in	O
the	O
ILD	O
infants	O
compared	O
to	O
the	O
healthy	O
controls	O
or	O
infants	O
who	O
had	O
PPHN	O
,	O
indicating	O
that	O
these	O
PFTs	O
were	O
sensitive	O
enough	O
to	O
determine	O
abnormal	O
lung	O
function	O
in	O
this	O
age	O
group	O
.	O

The	O
in	O
vitro	O
antibacterial	O
potency	O
is	O
greatest	O
when	O
the	O
1	O
-	O
substituent	O
is	O
2	O
,	O
4	O
-	O
difluorophenyl	O
and	O
the	O
7	O
-	O
substituent	O
is	O
a	O
3	O
-	O
amino	O
-	O
1	O
-	O
pyrrolidinyl	O
group	O
.	O

Previous	O
analysis	O
of	O
the	O
98	O
-	O
bp	O
sequence	O
has	O
delineated	O
several	O
protein	O
-	O
binding	O
domains	O
that	O
are	O
recognized	O
by	O
nuclear	O
factors	O
present	O
in	O
human	O
brain	O
cells	O
.	O

There	O
is	O
no	O
correlation	O
between	O
C2	O
-	O
C3	O
disk	O
morphology	O
and	O
the	O
diskographically	O
provoked	O
response	O
.	O

In	O
experiment	O
2	O
the	O
rats	O
had	O
free	O
access	O
to	O
two	O
bottles	O
,	O
one	O
of	O
which	O
contained	O
tap	O
water	O
,	O
and	O
the	O
other	O
contained	O
either	O
an	O
ethanol	O
(	O
6	O
%	O
)	O
or	O
a	O
sucrose	O
(	O
5	O
%	O
)	O
solution	O
.	O

The	O
phenotypes	O
of	O
the	O
ICP0	B-GENE
nonsense	O
mutants	O
were	O
intermediate	O
between	O
those	O
of	O
the	O
wild	O
-	O
type	O
virus	O
and	O
7134	O
in	O
that	O
the	O
more	O
ICP0	B-GENE
-	I-GENE
coding	I-GENE
sequence	I-GENE
expressed	O
by	O
a	O
given	O
nonsense	O
mutant	O
,	O
the	O
more	O
wild	O
type	O
-	O
like	O
was	O
its	O
phenotype	O
.	O

Here	O
we	O
describe	O
a	O
mutant	O
alpha	O
subunit	O
designed	O
to	O
inhibit	O
receptor	O
-	O
mediated	O
hormonal	O
activation	O
of	O
Gs	B-GENE
,	O
the	O
stimulatory	O
regulator	O
of	O
adenylyl	B-GENE
cyclase	I-GENE
.	O

An	O
inactive	O
analog	O
of	O
wortmannin	O
,	O
WM12	O
,	O
did	O
not	O
affect	O
TCR	O
/	O
CD3	O
-	O
induced	O
Erk2	B-GENE
activation	O
,	O
and	O
wortmannin	O
had	O
no	O
effect	O
on	O
the	O
activity	O
of	O
Erk2	B-GENE
when	O
added	O
directly	O
to	O
the	O
in	O
vitro	O
assays	O
.	O

Concordance	O
of	O
IBDQ	O
scores	O
was	O
tested	O
in	O
280	O
stable	O
subjects	O
.	O

The	O
UCR	B-GENE
core	I-GENE
sequence	I-GENE
,	O
CGCCATTTT	B-GENE
,	O
binds	O
a	O
ubiquitous	O
nuclear	O
factor	O
and	O
mediates	O
negative	O
regulation	O
of	O
MuLV	O
promoter	O
activity	O
.	O

The	O
systolic	O
peak	O
of	O
pulmonary	O
vein	O
was	O
higher	O
than	O
the	O
diastolic	O
peak	O
in	O
45	O
out	O
of	O
56	O
cases	O
.	O

The	O
effects	O
of	O
Codonopsis	O
pilosula	O
oral	O
liquor	O
(	O
CPOL	O
)	O
on	O
tissue	B-GENE
-	I-GENE
type	I-GENE
plasminogen	I-GENE
activator	I-GENE
(	O
t	B-GENE
-	I-GENE
PA	I-GENE
)	O
and	O
plasminogen	B-GENE
activator	I-GENE
inhibitor	I-GENE
(	O
PAI	B-GENE
)	O
in	O
the	O
plasma	O
of	O
25	O
patients	O
of	O
coronary	O
heart	O
disease	O
with	O
blood	O
stasis	O
were	O
studied	O
.	O

Here	O
,	O
the	O
PEX5	B-GENE
-	I-GENE
TPR	I-GENE
domains	I-GENE
from	O
human	O
,	O
tobacco	O
,	O
and	O
nematode	O
were	O
inserted	O
into	O
a	O
TPR	O
-	O
less	O
yeast	O
Pex5p	B-GENE
construct	O
to	O
generate	O
Pex5p	B-GENE
chimaeras	O
.	O

Despite	O
total	O
tumor	O
resection	O
,	O
multiple	O
intraperitoneal	O
tumor	O
nodules	O
of	O
varying	O
sizes	O
were	O
found	O
and	O
resected	O
six	O
months	O
and	O
one	O
year	O
later	O
.	O

Primary	O
adrenal	O
hypersensitivity	O
to	O
ACTH	B-GENE
drive	O
in	O
obesity	O
has	O
also	O
been	O
suggested	O
.	O

The	O
goal	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
feasibility	O
of	O
retrovirus	O
mediated	O
expression	O
of	O
rp47phox	B-GENE
in	O
the	O
HL60	O
and	O
U937	O
human	O
hematopoietic	O
cell	O
lines	O
,	O
and	O
in	O
an	O
Epstein	O
-	O
Barr	O
virus	O
transformed	O
B	O
-	O
lymphocyte	O
cell	O
line	O
(	O
EBV	O
-	O
BCL	O
)	O
derived	O
from	O
a	O
p47phox	O
-	O
deficient	O
CGD	O
patient	O
.	O

To	O
determine	O
which	O
sequences	O
in	O
the	O
rat	B-GENE
P450c17	I-GENE
promoter	I-GENE
may	O
be	O
responsible	O
for	O
basal	O
and	O
cAMP	O
-	O
stimulated	O
gene	O
transcription	O
,	O
deletion	O
constructs	O
containing	O
between	O
-	O
1	O
,	O
560	O
and	O
-	O
53	O
base	O
pairs	O
of	O
5	O
'	O
-	O
flanking	O
DNA	O
from	O
the	O
rat	B-GENE
P450c17	I-GENE
gene	I-GENE
were	O
ligated	O
to	O
plasmids	O
expressing	O
the	O
reporter	O
gene	O
luciferase	B-GENE
and	O
transfected	O
into	O
two	O
mouse	O
cell	O
lines	O
,	O
adrenal	O
Y	O
-	O
1	O
cells	O
,	O
and	O
testicular	O
Leydig	O
MA	O
-	O
10	O
cells	O
.	O

Eliminating	O
any	O
subset	O
of	O
ASCUS	O
reduces	O
the	O
ASCUS	O
/	O
SIL	O
ratio	O
but	O
also	O
significantly	O
diminishes	O
the	O
sensitivity	O
of	O
the	O
Papanicolaou	O
test	O
.	O

However	O
,	O
besides	O
the	O
kinase	O
catalytic	O
domain	O
and	O
double	O
leucine	O
/	O
isoleucine	O
zippers	O
,	O
there	O
was	O
no	O
significant	O
homology	O
with	O
known	O
proteins	O
.	O

We	O
characterized	O
the	O
structure	O
of	O
this	O
leader	O
mRNA	O
by	O
using	O
the	O
program	O
Mfold	O
and	O
a	O
combination	O
of	O
nested	O
and	O
internal	O
deletions	O
transcriptionally	O
fused	O
to	O
a	O
promoterless	O
lac	B-GENE
operon	I-GENE
.	O

Despite	O
continuous	O
compliance	O
,	O
unexplained	O
resurgence	O
of	O
serum	O
ferritin	B-GENE
levels	O
occurred	O
in	O
4	O
/	O
7	O
patients	O
of	O
the	O
'	O
veteran	O
'	O
group	O
after	O
4	O
-	O
5	O
years	O
on	O
L1	O
.	O

Signal	O
transduction	O
via	O
modulation	O
of	O
phosphorylation	O
after	O
selective	O
inhibition	O
of	O
protein	B-GENE
phosphatase	I-GENE
(	I-GENE
PP	I-GENE
)	I-GENE
1	I-GENE
and	O
/	O
or	O
PP2A	B-GENE
appears	O
to	O
play	O
a	O
role	O
in	O
okadaic	O
acid	O
(	O
OA	O
)	O
-	O
mediated	O
effects	O
.	O

The	O
dual	O
specificity	O
kinases	O
mitogen	B-GENE
-	I-GENE
activated	I-GENE
protein	I-GENE
kinase	I-GENE
(	I-GENE
MAPK	I-GENE
)	I-GENE
kinase	I-GENE
(	O
MKK	B-GENE
)	O
7	O
and	O
MKK4	B-GENE
are	O
the	O
only	O
molecules	O
known	O
to	O
directly	O
activate	O
the	O
stress	B-GENE
kinases	I-GENE
stress	B-GENE
-	I-GENE
activated	I-GENE
protein	I-GENE
kinases	I-GENE
(	O
SAPKs	B-GENE
)	O
/	B-GENE
c	I-GENE
-	I-GENE
Jun	I-GENE
N	I-GENE
-	I-GENE
terminal	I-GENE
kinases	I-GENE
(	O
JNKs	B-GENE
)	O
in	O
response	O
to	O
environmental	O
or	O
mitogenic	O
stimuli	O
.	O

After	O
2	O
min	O
of	O
dobutamine	O
injection	O
,	O
or	O
after	O
20	O
min	O
of	O
pimobendan	O
injection	O
,	O
the	O
myocardium	O
was	O
removed	O
,	O
and	O
used	O
for	O
determination	O
of	O
the	O
tissue	O
levels	O
of	O
metabolites	O
of	O
energy	O
and	O
carbohydrate	O
metabolism	O
.	O

Quantitative	O
evaluation	O
of	O
the	O
steady	O
state	O
kinetics	O
of	O
MEK	B-GENE
inhibition	O
by	O
these	O
compounds	O
reveals	O
that	O
U0126	O
has	O
approximately	O
100	O
-	O
fold	O
higher	O
affinity	O
for	O
deltaN3	B-GENE
-	I-GENE
S218E	I-GENE
/	I-GENE
S222D	I-GENE
MEK	I-GENE
than	O
does	O
PD098059	O
.	O

Technetium	O
-	O
99m	O
methylene	O
diphosphonate	O
scintimammography	O
for	O
evaluation	O
of	O
palpable	O
breast	O
masses	O
.	O

Although	O
there	O
was	O
a	O
high	O
correlation	O
between	O
sap	O
flux	O
densities	O
registered	O
by	O
the	O
old	O
and	O
new	O
sensors	O
,	O
significant	O
differences	O
in	O
sap	O
flux	O
densities	O
between	O
the	O
duplicated	O
sensors	O
were	O
detected	O
.	O

Modern	O
cancer	O
therapy	O
has	O
included	O
surgery	O
,	O
radiotherapy	O
,	O
chemotherapy	O
,	O
and	O
most	O
recently	O
,	O
immunotherapy	O
and	O
hyperthermia	O
.	O

One	O
skull	O
does	O
not	O
a	O
species	O
make	O
.	O

Clones	O
33F	O
and	O
34B	O
encoded	O
identical	O
aromatase	B-GENE
proteins	I-GENE
of	O
503	O
amino	O
acids	O
,	O
but	O
differed	O
in	O
size	O
due	O
to	O
alternative	O
polyadenylation	O
signal	O
usage	O
for	O
the	O
corresponding	O
mRNAs	O
.	O

Constitutive	O
phosphorylation	O
and	O
nuclear	O
localization	O
of	O
Smad3	B-GENE
are	O
correlated	O
with	O
increased	O
collagen	B-GENE
gene	I-GENE
transcription	O
in	O
activated	O
hepatic	O
stellate	O
cells	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
risk	O
factors	O
for	O
background	O
diabetic	O
retinopathy	O
(	O
BDR	O
)	O
and	O
PDR	O
by	O
following	O
394	O
Japanese	O
patients	O
with	O
early	O
-	O
onset	O
type	O
2	O
diabetes	O
diagnosed	O
before	O
30	O
years	O
of	O
age	O
(	O
mean	O
age	O
27	O
,	O
mean	O
blood	O
pressure	O
at	O
entry	O
116	O
/	O
73	O
mm	O
Hg	O
)	O
.	O

The	O
possible	O
benefits	O
of	O
LMW	O
heparin	O
(	O
reduced	O
frequency	O
of	O
bleeding	O
,	O
alleviation	O
of	O
hypertriglyceridemia	O
)	O
were	O
not	O
,	O
however	O
,	O
apparent	O
,	O
possibly	O
because	O
of	O
the	O
short	O
observation	O
period	O
and	O
the	O
low	O
incidence	O
of	O
hemorrhagic	O
complications	O
in	O
routine	O
dialyses	O
.	O

Percentages	O
of	O
recovery	O
for	O
overload	O
and	O
dilution	O
tests	O
were	O
between	O
87	O
and	O
120	O
%	O
.	O

Different	O
cortical	O
malformations	O
were	O
produced	O
in	O
rats	O
by	O
a	O
single	O
dose	O
of	O
X	O
-	O
rays	O
(	O
200	O
cGy	O
)	O
given	O
on	O
different	O
days	O
during	O
gestation	O
.	O

Thus	O
,	O
growth	B-GENE
factor	I-GENE
activation	O
of	O
ER	B-GENE
can	O
mediate	O
transactivation	O
vs	O
ER	B-GENE
/	I-GENE
Sp1	I-GENE
binding	O
to	O
GC	O
-	O
rich	O
sites	O
and	O
represents	O
a	O
novel	O
pathway	O
for	O
ligand	O
-	O
independent	O
ER	B-GENE
action	O
.	O

The	O
yeast	O
gene	O
that	O
encodes	O
eIF	B-GENE
-	I-GENE
5	I-GENE
,	O
designated	O
TIF5	B-GENE
,	O
has	O
been	O
isolated	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
to	O
yield	O
a	O
catalytically	O
active	O
eIF	B-GENE
-	I-GENE
5	I-GENE
protein	I-GENE
.	O

After	O
nerve	O
injury	O
,	O
the	O
nociceptive	O
responses	O
through	O
type	O
I	O
neurons	O
,	O
which	O
are	O
polymodal	O
C	O
-	O
fibers	O
and	O
drive	O
NK1	B-GENE
-	I-GENE
receptor	I-GENE
mechanisms	O
in	O
spinal	O
pain	O
transmission	O
,	O
were	O
completely	O
lost	O
,	O
but	O
without	O
changes	O
in	O
type	O
II	O
ones	O
,	O
which	O
are	O
polymodal	O
C	O
-	O
fibers	O
and	O
drive	O
NMDA	O
receptor	O
-	O
mechanisms	O
,	O
while	O
type	O
III	O
ones	O
,	O
which	O
are	O
capsaicin	O
-	O
insensitive	O
(	O
possibly	O
A	O
-	O
fibers	O
)	O
and	O
drive	O
NMDA	B-GENE
-	I-GENE
receptor	I-GENE
mechanisms	O
,	O
were	O
markedly	O
enhanced	O
.	O

Respondents	O
who	O
lived	O
with	O
a	O
spouse	O
/	O
partner	O
only	O
were	O
less	O
likely	O
to	O
have	O
an	O
unfavorable	O
BMI	O
status	O
than	O
people	O
in	O
the	O
other	O
two	O
groups	O
.	O

Catalytic	O
activation	O
of	O
mitogen	B-GENE
-	I-GENE
activated	I-GENE
protein	I-GENE
(	I-GENE
MAP	I-GENE
)	I-GENE
kinase	I-GENE
phosphatase	I-GENE
-	I-GENE
1	I-GENE
by	O
binding	O
to	O
p38	B-GENE
MAP	I-GENE
kinase	I-GENE
:	O
critical	O
role	O
of	O
the	O
p38	B-GENE
C	I-GENE
-	I-GENE
terminal	I-GENE
domain	I-GENE
in	O
its	O
negative	O
regulation	O
.	O

Mastocytosis	O
.	O

Whereas	O
a	O
PR55	B-GENE
beta	I-GENE
transcript	I-GENE
of	O
about	O
2	O
.	O
3	O
kb	O
was	O
detected	O
at	O
high	O
levels	O
in	O
the	O
neuroblastoma	O
derived	O
cell	O
line	O
LA	O
-	O
N	O
-	O
1	O
,	O
the	O
level	O
of	O
the	O
mRNA	O
was	O
very	O
low	O
in	O
the	O
other	O
human	O
cell	O
lines	O
analyzed	O
.	O

These	O
observations	O
indicate	O
that	O
there	O
are	O
multiple	O
mechanisms	O
by	O
which	O
an	O
individual	O
transcript	O
can	O
be	O
degraded	O
following	O
deadenylation	O
.	O

Total	O
PGE	O
levels	O
in	O
synovial	O
fluid	O
remained	O
significantly	O
depressed	O
in	O
the	O
patient	O
group	O
for	O
24	O
hours	O
after	O
the	O
400	O
-	O
mg	O
test	O
dose	O
of	O
tolmetin	O
on	O
day	O
8	O
.	O

Mutually	O
exclusive	O
interaction	O
of	O
the	O
adenovirus	B-GENE
E4	I-GENE
-	I-GENE
6	I-GENE
/	I-GENE
7	I-GENE
protein	I-GENE
and	O
the	O
retinoblastoma	B-GENE
gene	I-GENE
product	I-GENE
with	O
internal	O
domains	O
of	O
E2F	B-GENE
-	I-GENE
1	I-GENE
and	O
DP	B-GENE
-	I-GENE
1	I-GENE
.	O

BACKGROUND	O
/	O
PURPOSE	O
:	O
Anomalous	O
arrangement	O
of	O
the	O
pancreaticobiliary	O
duct	O
(	O
AAPBD	O
)	O
is	O
closely	O
related	O
to	O
congenital	O
biliary	O
dilatation	O
and	O
frequently	O
associated	O
with	O
biliary	O
tract	O
malignancy	O
.	O

These	O
results	O
indicate	O
that	O
mutL	B-GENE
,	O
miaA	B-GENE
,	O
and	O
hfq	B-GENE
expression	O
could	O
be	O
regulated	O
by	O
multiple	O
mechanisms	O
,	O
including	O
degree	O
of	O
cotranscription	O
from	O
upstream	O
genes	O
,	O
modulation	O
of	O
internal	O
promoter	O
strength	O
,	O
and	O
by	O
RNase	B-GENE
E	I-GENE
activity	O
.	O

Transfection	O
and	O
in	O
vitro	O
binding	O
studies	O
identified	O
within	O
HEFT1	B-GENE
a	I-GENE
promoter	I-GENE
whose	O
basal	O
activity	O
required	O
a	O
GC	O
box	O
activated	O
by	O
Sp1	B-GENE
or	O
Sp3	B-GENE
.	O

The	O
RAS	B-GENE
-	I-GENE
cyclic	I-GENE
AMP	I-GENE
-	I-GENE
dependent	I-GENE
protein	I-GENE
kinase	I-GENE
cAPK	I-GENE
pathway	O
prevents	O
the	O
UAS	B-GENE
activity	O
of	O
IREu	B-GENE
in	O
the	O
presence	O
of	O
glucose	O
as	O
the	O
sole	O
carbon	O
source	O
,	O
while	O
the	O
transcriptional	O
activators	O
Msn2p	B-GENE
and	O
Msn4p	B-GENE
promote	O
the	O
UAS	B-GENE
activity	O
of	O
this	O
repeat	O
in	O
the	O
presence	O
of	O
acetate	O
.	O

CONCLUSIONS	O
:	O
In	O
essential	O
hypertension	O
an	O
acute	O
protein	O
load	O
induces	O
a	O
decrease	O
in	O
GFR	O
that	O
may	O
normalize	O
under	O
antihypertensive	O
treatment	O
.	O

In	O
contrast	O
,	O
peak	O
filling	O
rate	O
(	O
PFR	O
)	O
,	O
normalized	O
to	O
end	O
diastolic	O
volume	O
(	O
EDV	O
)	O
,	O
or	O
stroke	O
volume	O
(	O
SV	O
)	O
,	O
or	O
expressed	O
as	O
the	O
ratio	O
of	O
PFR	O
-	O
to	O
-	O
PER	O
was	O
reduced	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
time	O
to	O
PFR	O
(	O
TPFR	O
)	O
was	O
prolonged	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
echocardiographic	O
left	O
ventricular	O
mass	O
index	O
was	O
higher	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
in	O
patients	O
with	O
acromegaly	O
compared	O
to	O
normals	O
.	O

Beta	O
blocking	O
agents	O
.	O

There	O
was	O
no	O
further	O
increase	O
in	O
oxygen	O
consumption	O
when	O
these	O
subjects	O
breathed	O
with	O
inspiratory	O
pressures	O
above	O
SIP	O
.	O

This	O
dimer	O
interface	O
is	O
likely	O
important	O
for	O
increasing	O
the	O
DNA	O
-	O
binding	O
specificity	O
and	O
affinity	O
of	O
the	O
trimeric	O
form	O
of	O
HSF	B-GENE
,	O
as	O
well	O
as	O
for	O
increasing	O
cooperativity	O
between	O
adjacent	O
trimers	O
.	O

Three	O
missense	O
mutants	O
in	O
subunit	O
a	O
of	O
the	O
Escherichia	B-GENE
coli	I-GENE
F1F0	I-GENE
-	I-GENE
ATPase	I-GENE
were	O
isolated	O
and	O
characterized	O
after	O
hydroxylamine	O
mutagenesis	O
of	O
a	O
plasmid	O
carrying	O
the	O
uncB	B-GENE
(	I-GENE
subunit	I-GENE
a	I-GENE
)	I-GENE
gene	I-GENE
.	O

CONCLUSIONS	O
:	O
The	O
surgical	O
or	O
multimodality	O
treatment	O
of	O
MSGT	O
has	O
provided	O
a	O
good	O
locoregional	O
control	O
(	O
78	O
%	O
)	O
and	O
68	O
%	O
10	O
-	O
year	O
survival	O
in	O
a	O
series	O
of	O
patients	O
treated	O
at	O
the	O
oncology	O
department	O
of	O
a	O
general	O
hospital	O
in	O
Quito	O
,	O
Ecuador	O
.	O

The	O
predicted	O
DNA	O
-	O
binding	O
,	O
zinc	O
finger	O
domain	O
protein	O
sequence	O
was	O
strictly	O
conserved	O
.	O

In	O
transient	O
cotransfection	O
assays	O
using	O
Chang	O
liver	O
cells	O
(	O
CCL	O
13	O
)	O
,	O
pM1	O
DNA	O
exerts	O
a	O
6	O
-	O
to	O
10	O
-	O
fold	O
trans	O
-	O
activating	O
effect	O
on	O
the	O
expression	O
of	O
the	O
pSV2CAT	O
reporter	O
plasmid	O
.	O

During	O
treatment	O
,	O
the	O
phosphorylation	O
state	O
of	O
Rb	B-GENE
shifted	O
to	O
a	O
hypophosphorylated	O
form	O
.	O
mRNA	O
for	O
the	O
HPV	B-GENE
E6	I-GENE
/	I-GENE
E7	I-GENE
genes	I-GENE
decreased	O
;	O
however	O
,	O
significant	O
changes	O
in	O
the	O
E7	B-GENE
protein	I-GENE
were	O
not	O
observed	O
,	O
while	O
increased	O
levels	O
of	O
Rb	B-GENE
immunoprecipitated	O
with	O
anti	B-GENE
-	I-GENE
E7	I-GENE
antibodies	I-GENE
were	O
observed	O
.	O

51	O
.	O
9	O
%	O
(	O
P	O
=	O
0	O
.	O
0006	O
)	O
in	O
the	O
MMF	O
versus	O
the	O
AZA	O
groups	O
,	O
respectively	O
.	O

The	O
General	O
Practice	O
Research	O
Database	O
(	O
GPRD	O
)	O
is	O
the	O
world	O
'	O
s	O
largest	O
computerized	O
database	O
of	O
anonymized	O
longitudinal	O
patient	O
records	O
from	O
general	O
practice	O
and	O
is	O
a	O
unique	O
public	O
health	O
research	O
tool	O
.	O

Velocity	O
sedimentation	O
,	O
cross	O
-	O
linking	O
,	O
and	O
immunoprecipitation	O
analyses	O
of	O
detergent	O
-	O
solubilized	O
rat	O
brain	O
revealed	O
that	O
the	O
32	O
and	O
34	O
kDa	O
polypeptides	O
reside	O
within	O
heterotetramers	O
.	O

Characterization	O
of	O
the	O
3	O
'	O
ends	O
of	O
the	O
plus	O
-	O
strand	O
DNA	O
fragments	O
reveals	O
(	O
1	O
)	O
that	O
the	O
upstream	O
fragment	O
is	O
elongated	O
beyond	O
PPT2	B-GENE
creating	O
a	O
plus	O
-	O
strand	O
overlap	O
and	O
(	O
2	O
)	O
that	O
the	O
majority	O
of	O
plus	O
-	O
strand	O
strong	O
-	O
stop	O
DNA	O
fragments	O
bear	O
a	O
copy	O
of	O
the	O
minus	O
-	O
strand	O
primer	O
binding	O
site	O
in	O
agreement	O
with	O
the	O
accepted	O
model	O
of	O
retroviral	O
genomic	O
RNA	O
reverse	O
transcription	O
.	O

Further	O
,	O
they	O
are	O
consistent	O
with	O
the	O
suggestion	O
that	O
sites	O
homologous	O
to	O
the	O
CAR1	B-GENE
URS	I-GENE
may	O
be	O
situated	O
in	O
the	O
5	O
'	O
-	O
flanking	O
regions	O
of	O
multiple	O
unrelated	O
yeast	O
genes	O
.	O

A23187	O
did	O
not	O
induce	O
any	O
modifications	O
of	O
the	O
endolymphatic	O
potential	O
,	O
the	O
ampullar	O
direct	O
current	O
or	O
the	O
frequency	O
of	O
the	O
evoked	O
afferent	O
spikes	O
.	O

Electrophoretic	O
characteriaztion	O
of	O
virus	O
-	O
induced	O
interferon	B-GENE
of	O
the	O
blood	O
and	O
urine	O
in	O
rabbits	O
.	O

GnRH	B-GENE
treatment	O
was	O
found	O
to	O
increase	O
the	O
phosphorylation	O
of	O
tyrosine	O
residues	O
of	O
MAPK	B-GENE
and	O
to	O
increase	O
MAPK	B-GENE
activity	O
,	O
as	O
determined	O
by	O
an	O
immune	O
complex	O
kinase	B-GENE
assay	O
.	O

Hemodynamics	O
changes	O
in	O
man	O
during	O
flight	O
.	O

Nasal	O
absorption	O
was	O
rapid	O
,	O
nasal	O
bioavailability	O
was	O
43	O
%	O
,	O
and	O
the	O
iv	O
and	O
nasal	O
elimination	O
profiles	O
were	O
similar	O
.	O

In	O
experiment	O
2	O
,	O
no	O
difference	O
in	O
gastric	O
emptying	O
of	O
40	O
%	O
peptone	O
or	O
25	O
%	O
glucose	O
was	O
found	O
between	O
rats	O
receiving	O
TPN	O
and	O
those	O
receiving	O
intragastric	O
nutrition	O
for	O
10	O
to	O
12	O
days	O
.	O

To	O
derive	O
quantitative	O
concentration	O
changes	O
from	O
measurements	O
of	O
light	O
attenuation	O
,	O
the	O
optical	O
path	O
length	O
must	O
be	O
known	O
.	O

Analysis	O
of	O
chromosomal	O
DNA	O
sequence	O
immediately	O
downstream	O
of	O
the	O
transposon	O
insertion	O
identified	O
two	O
open	O
reading	O
frames	O
,	O
designated	O
csrR	B-GENE
and	O
csrS	B-GENE
,	O
which	O
exhibited	O
sequence	O
similarity	O
to	O
bacterial	O
two	O
-	O
component	O
regulatory	O
systems	O
.	O

Rev	B-GENE
-	I-GENE
erbAalpha	I-GENE
/	I-GENE
beta	I-GENE
)	I-GENE
,	O
Mxi	B-GENE
-	I-GENE
1	I-GENE
and	O
Mad	B-GENE
bHLH	I-GENE
-	I-GENE
zip	I-GENE
proteins	I-GENE
and	O
the	O
oncoproteins	O
PLZF	B-GENE
and	O
LAZ3	B-GENE
/	I-GENE
BCL6	I-GENE
is	O
mediated	O
by	O
the	O
corepressors	O
N	B-GENE
-	I-GENE
CoR	I-GENE
and	O
SMRT	B-GENE
.	O

Reporting	O
of	O
adverse	O
events	O
occurring	O
during	O
clinical	O
trials	O
of	O
investigational	O
drugs	O
is	O
a	O
complex	O
and	O
controversial	O
issue	O
.	O

The	O
effects	O
of	O
two	O
levels	O
of	O
caffeine	O
ingestion	O
on	O
excess	O
postexercise	O
oxygen	O
consumption	O
in	O
untrained	O
women	O
.	O

Of	O
the	O
117	O
patients	O
(	O
out	O
of	O
the	O
136	O
)	O
with	O
serologic	O
evidence	O
of	O
chronic	O
thyroiditis	O
who	O
could	O
be	O
studied	O
,	O
eight	O
(	O
7	O
%	O
)	O
had	O
hyperthyroidism	O
and	O
45	O
(	O
38	O
%	O
)	O
were	O
hypothyroid	O
.	O

Unfortunately	O
,	O
these	O
preservatives	O
may	O
also	O
interfere	O
with	O
microbiological	O
assays	O
used	O
to	O
determine	O
product	O
sterility	O
or	O
bioburden	O
levels	O
.	O

Where	O
UMDNJ	O
is	O
headed	O
.	O

Serum	B-GENE
relaxin	I-GENE
levels	O
in	O
prostaglandin	O
E2	O
induced	O
abortions	O
.	O

Human	B-GENE
GATA	I-GENE
-	I-GENE
3	I-GENE
:	O
a	O
lineage	O
-	O
restricted	O
transcription	O
factor	O
that	O
regulates	O
the	O
expression	O
of	O
the	O
T	B-GENE
cell	I-GENE
receptor	I-GENE
alpha	I-GENE
gene	I-GENE
.	O

Induction	O
of	O
Fas	B-GENE
ligand	I-GENE
expression	O
by	O
HIV	O
involves	O
the	O
interaction	O
of	O
Nef	B-GENE
with	O
the	O
T	B-GENE
cell	I-GENE
receptor	I-GENE
zeta	I-GENE
chain	I-GENE
.	O

Telomeres	O
prevent	O
end	O
-	O
to	O
-	O
end	O
fusions	O
and	O
exonucleolytic	O
degradation	O
,	O
enable	O
the	O
end	O
of	O
the	O
linear	O
DNA	O
molecule	O
to	O
replicate	O
,	O
and	O
function	O
in	O
cell	O
division	O
.	O

Specifically	O
,	O
by	O
the	O
type	O
of	O
adjuvant	O
therapy	O
,	O
the	O
median	O
disease	O
-	O
free	O
interval	O
and	O
survival	O
from	O
stage	O
IVA	O
for	O
23	O
patients	O
receiving	O
Corynebacterium	O
parvum	O
were	O
6	O
.	O
9	O
and	O
19	O
months	O
;	O
for	O
39	O
patients	O
receiving	O
BCG	O
,	O
eight	O
months	O
and	O
26	O
months	O
;	O
for	O
24	O
patients	O
receiving	O
BCG	O
+	O
DTIC	O
,	O
eight	O
and	O
17	O
.	O
4	O
months	O
;	O
and	O
for	O
all	O
51	O
DTIC	O
treated	O
patients	O
6	O
.	O
3	O
and	O
17	O
.	O
8	O
months	O
,	O
respectively	O
.	O

Merr	O
.	O
)	O
embryo	O
library	O
.	O

Altogether	O
,	O
we	O
confirm	O
that	O
all	O
genes	O
of	O
the	O
Rad52	B-GENE
recombinational	I-GENE
repair	I-GENE
pathway	I-GENE
are	O
required	O
for	O
the	O
survival	O
of	O
rad27	B-GENE
Delta	I-GENE
strains	O
at	O
both	O
permissive	O
(	O
23	O
degrees	O
C	O
)	O
and	O
semipermissive	O
(	O
30	O
degrees	O
C	O
)	O
temperatures	O
for	O
growth	O
.	O

A	O
single	O
amino	O
acid	O
substitution	O
in	O
the	O
cyclin	B-GENE
D	I-GENE
binding	I-GENE
domain	I-GENE
of	O
the	O
infected	B-GENE
cell	I-GENE
protein	I-GENE
no	O
.	O

Improving	O
the	O
evidence	O
base	O
for	O
anaesthesia	O
.	O

Seven	O
of	O
these	O
had	O
counterparts	O
in	O
the	O
US	O
of	O
herpes	O
simplex	O
type	O
1	O
(	O
HSV	O
-	O
1	O
)	O
,	O
pseudorabies	O
virus	O
(	O
PRV	O
)	O
,	O
and	O
equine	O
herpesvirus	O
type	O
1	O
(	O
EHV	O
-	O
1	O
)	O
.	O

Since	O
high	O
levels	O
of	O
immunoglobulin	B-GENE
G	I-GENE
were	O
demonstrated	O
against	O
the	O
surface	O
of	O
the	O
NVS	O
after	O
immunization	O
,	O
passive	O
transfer	O
experiments	O
were	O
initiated	O
.	O

Our	O
results	O
show	O
that	O
CVN	B-GENE
specifically	O
recognizes	O
with	O
nanomolar	O
affinity	O
Man	B-GENE
(	I-GENE
9	I-GENE
)	I-GENE
GlcNAc	I-GENE
(	I-GENE
2	I-GENE
)	I-GENE
and	O
the	O
D1D3	B-GENE
isomer	I-GENE
of	O
Man	B-GENE
(	I-GENE
8	I-GENE
)	I-GENE
GlcNAc	I-GENE
(	I-GENE
2	I-GENE
)	I-GENE
.	O

No	O
definite	O
conclusions	O
are	O
possible	O
because	O
of	O
the	O
small	O
number	O
of	O
patients	O
involved	O
in	O
this	O
phase	O
II	O
trial	O
.	O

Out	O
of	O
these	O
families	O
74	O
,	O
3	O
%	O
planned	O
next	O
pregnancy	O
(	O
table	O
IX	O
)	O
,	O
57	O
,	O
6	O
%	O
wanted	O
to	O
have	O
prenatal	O
diagnosis	O
(	O
table	O
VI	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
special	O
clinical	O
presentation	O
of	O
our	O
case	O
of	O
possible	O
Gardner	O
'	O
s	O
syndrome	O
is	O
discussed	O
.	O

Interestingly	O
,	O
addition	O
of	O
purified	O
CBP	B-GENE
to	O
the	O
nuclear	O
extracts	O
of	O
T47D	O
cells	O
markedly	O
stimulated	O
progesterone	O
-	O
and	O
PR	O
-	O
dependent	O
transcription	O
from	O
a	O
nucleosome	O
-	O
free	O
,	O
progesterone	B-GENE
response	I-GENE
element	I-GENE
(	O
PRE	B-GENE
)	O
-	O
linked	O
reporter	O
DNA	O
template	O
.	O

Therefore	O
,	O
it	O
was	O
concluded	O
that	O
thrombotic	O
tendency	O
certainly	O
existed	O
in	O
patients	O
with	O
MS	O
compared	O
to	O
those	O
with	O
non	O
RHD	O
and	O
that	O
it	O
was	O
one	O
of	O
the	O
causes	O
of	O
the	O
significantly	O
high	O
incidence	O
of	O
thromboembolism	O
in	O
comparison	O
with	O
non	O
RHD	O
.	O

Before	O
PO3	O
administration	O
,	O
more	O
than	O
half	O
(	O
57	O
.	O
4	O
%	O
)	O
of	O
the	O
patients	O
received	O
only	O
1	O
or	O
2	O
antituberculous	O
drugs	O
(	O
ethambutole	O
and	O
ethionamide	O
or	O
ethambutole	O
and	O
oprofloxacin	O
)	O
.	O

Routine	O
psychometric	O
screening	O
of	O
IHD	O
patients	O
may	O
provide	O
a	O
cost	O
-	O
effective	O
means	O
of	O
alerting	O
cardiologists	O
and	O
internists	O
to	O
the	O
relatively	O
high	O
levels	O
of	O
distress	O
among	O
their	O
patients	O
.	O

In	O
addition	O
,	O
computer	O
analysis	O
suggests	O
that	O
sequences	O
similar	O
to	O
the	O
A	O
stem	O
element	O
are	O
present	O
within	O
the	O
three	O
AAV	B-GENE
promoter	I-GENE
regions	O
.	O

Another	O
cis	O
-	O
acting	O
element	O
,	O
exonic	B-GENE
splicing	I-GENE
suppressor	I-GENE
1	I-GENE
(	O
ESS1	B-GENE
)	O
,	O
represses	O
use	O
of	O
the	O
nt	O
3225	O
3	O
'	O
splice	O
site	O
.	O

After	O
hemodynamic	O
stabilization	O
,	O
the	O
goal	O
of	O
therapy	O
is	O
to	O
diminish	O
the	O
chance	O
that	O
an	O
ulcer	O
will	O
continue	O
to	O
bleed	O
or	O
will	O
rebleed	O
.	O

Two	O
splice	O
variants	O
of	O
ALF1	B-GENE
cDNA	I-GENE
have	O
been	O
found	O
,	O
differing	O
by	O
a	O
72	O
-	O
bp	O
insertion	O
,	O
coding	O
for	O
putative	O
proteins	O
of	O
682	O
and	O
706	O
amino	O
acids	O
.	O

Our	O
results	O
suggest	O
that	O
while	O
many	O
muscle	O
gene	O
E	O
-	O
boxes	O
are	O
capable	O
of	O
binding	O
the	O
previously	O
characterized	O
spectrum	O
of	O
MDF	B-GENE
/	I-GENE
bH	I-GENE
-	I-GENE
L	I-GENE
-	I-GENE
H	I-GENE
heterodimers	I-GENE
in	O
vitro	O
,	O
MCK	B-GENE
-	I-GENE
L	I-GENE
type	O
E	O
-	O
boxes	O
probably	O
bind	O
qualitatively	O
different	O
factors	O
in	O
vivo	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
matrilysin	B-GENE
-	I-GENE
2	I-GENE
also	O
contains	O
a	O
threonine	O
residue	O
adjacent	O
to	O
the	O
Zn	O
-	O
binding	O
site	O
that	O
has	O
been	O
defined	O
as	O
a	O
specific	O
feature	O
of	O
matrilysin	B-GENE
.	O

Value	O
of	O
determination	O
of	O
alkaline	B-GENE
phosphatase	I-GENE
isoenzymes	I-GENE
for	O
differential	O
diagnosis	O
of	O
obstructive	O
jaundice	O
and	O
biliary	O
liver	O
cirrhosis	O
.	O

Aedes	O
aegypti	O
(	O
L	O
.	O
)	O
and	O
Aedes	O
albopictus	O
(	O
Skuse	O
)	O
in	O
Singapore	O
City	O
.	O

Ras	B-GENE
-	I-GENE
and	I-GENE
ultra	I-GENE
-	I-GENE
violet	I-GENE
-	I-GENE
responsive	I-GENE
protein	I-GENE
kinases	I-GENE
that	O
phosphorylate	O
c	B-GENE
-	I-GENE
Jun	I-GENE
on	O
serine	O
residues	O
at	O
positions	O
63	O
and	O
73	O
and	O
stimulate	O
its	O
transcriptional	O
activity	O
have	O
been	O
identified	O
.	O

CONCLUSIONS	O
:	O
Lymphoscintigraphy	O
of	O
the	O
cynomolgus	O
monkey	O
eyelids	O
reveals	O
discrete	O
lymphatic	O
drainage	O
pathways	O
for	O
the	O
upper	O
and	O
lower	O
eyelids	O
and	O
a	O
dual	O
pathway	O
for	O
the	O
central	O
upper	O
eyelid	O
.	O

Regional	O
blood	O
blow	O
was	O
measured	O
by	O
means	O
of	O
microspheres	O
in	O
predefined	O
regions	O
of	O
the	O
C6	O
,	O
T11	O
,	O
and	O
L6	O
vertebrae	O
.	O

CMV	O
hyperimmunoglobulin	B-GENE
treatment	O
(	O
Cytotect	O
,	O
Biotest	O
)	O
was	O
started	O
(	O
2	O
ml	O
/	O
kg	O
bw	O
on	O
day	O
1	O
and	O
3	O
,	O
and	O
1	O
ml	O
/	O
kg	O
on	O
days	O
5	O
,	O
7	O
and	O
9	O
)	O
,	O
which	O
led	O
to	O
the	O
eradication	O
of	O
the	O
residual	O
infiltrate	O
and	O
CMV	O
-	O
DNA	O
in	O
the	O
myocardium	O
.	O

The	O
ewes	O
were	O
returned	O
to	O
normoxia	O
,	O
and	O
monitoring	O
was	O
continued	O
for	O
1	O
h	O
.	O

The	O
major	O
promoter	O
responds	O
strongly	O
to	O
virus	O
-	O
encoded	O
trans	O
activators	O
EIA	B-GENE
and	O
EIV	B-GENE
and	O
contains	O
four	O
elements	O
:	O
a	O
TAGA	O
motif	O
analogous	O
to	O
the	O
TATA	O
box	O
,	O
two	O
EIIF	B-GENE
sites	I-GENE
present	O
in	O
an	O
inverted	O
orientation	O
,	O
and	O
an	O
ATF	B-GENE
/	I-GENE
CREB	I-GENE
site	I-GENE
.	O

Interestingly	O
,	O
in	O
the	O
adult	O
,	O
transgene	O
expression	O
patterns	O
within	O
the	O
cerebellum	O
in	O
two	O
lines	O
appeared	O
to	O
mark	O
distinct	O
anterior	O
-	O
posterior	O
compartments	O
.	O

Heterogeneous	B-GENE
nuclear	I-GENE
ribonucleoprotein	I-GENE
A1	I-GENE
binds	O
to	O
the	O
transcription	O
-	O
regulatory	O
region	O
of	O
mouse	O
hepatitis	O
virus	O
RNA	O
.	O

In	O
17	O
patients	O
with	O
deletions	O
,	O
the	O
parental	O
origin	O
of	O
deletion	O
was	O
determined	O
.	O

Clinical	O
accuracy	O
of	O
updated	O
version	O
of	O
the	O
Phadebas	O
RAST	O
test	O
.	O

On	O
the	O
basis	O
of	O
the	O
mechanism	O
of	O
action	O
,	O
two	O
groups	O
of	O
inodilators	O
are	O
distinguished	O
,	O
the	O
phosphodiesterase	B-GENE
inhibitors	O
and	O
the	O
dopaminergic	O
agents	O
.	O

The	O
detection	O
ratio	O
peaked	O
at	O
ages	O
30	O
to	O
34	O
and	O
decreased	O
heavily	O
during	O
the	O
next	O
15	O
years	O
of	O
age	O
.	O

Phase	O
II	O
trial	O
of	O
the	O
anti	B-GENE
-	I-GENE
G	I-GENE
(	I-GENE
D2	I-GENE
)	I-GENE
monoclonal	I-GENE
antibody	I-GENE
3F8	I-GENE
and	O
granulocyte	B-GENE
-	I-GENE
macrophage	I-GENE
colony	I-GENE
-	I-GENE
stimulating	I-GENE
factor	I-GENE
for	O
neuroblastoma	O
.	O

Another	O
ORF	O
,	O
dda	B-GENE
.	I-GENE
2	I-GENE
located	O
between	O
modA	B-GENE
and	O
dda	B-GENE
,	O
shares	O
sequence	O
similarity	O
with	O
sigma70	B-GENE
,	O
and	O
we	O
call	O
it	O
srd	B-GENE
.	O

The	O
authors	O
present	O
the	O
only	O
two	O
studies	O
that	O
have	O
proved	O
successful	O
in	O
treating	O
animal	O
models	O
of	O
osteoarthritis	O
using	O
gene	O
therapy	O
,	O
and	O
propose	O
an	O
overview	O
of	O
several	O
strategies	O
for	O
the	O
development	O
of	O
gene	O
therapy	O
in	O
osteoarthritis	O
treatment	O
in	O
the	O
future	O
.	O

There	O
was	O
significant	O
correlation	O
of	O
LVM	O
/	O
M2	O
and	O
PWVn	O
for	O
pre	O
-	O
AVR	O
and	O
post	O
AVR	O
studies	O
.	O

A	O
gene	O
in	O
Drosophila	O
melanogaster	O
that	O
maps	O
cytologically	O
to	O
2C1	O
-	O
3	O
on	O
the	O
distal	O
portion	O
of	O
the	O
X	O
-	O
chromosome	O
encodes	O
a	O
member	O
of	O
the	O
steroid	B-GENE
/	I-GENE
thyroid	I-GENE
hormone	I-GENE
receptor	I-GENE
superfamily	I-GENE
.	O

We	O
investigated	O
the	O
diagnostic	O
value	O
of	O
a	O
new	O
in	O
vitro	O
test	O
,	O
Pharmacia	O
CAP	O
System	O
(	O
Pharmacia	O
Diagnostics	O
AB	O
,	O
Uppsala	O
,	O
Sweden	O
)	O
,	O
for	O
the	O
quantitative	O
measurement	O
of	O
allergen	B-GENE
-	I-GENE
specific	I-GENE
IgE	I-GENE
antibodies	I-GENE
by	O
comparison	O
with	O
RAST	O
in	O
2	O
groups	O
of	O
patients	O
,	O
71	O
atopic	O
and	O
48	O
non	O
-	O
atopic	O
.	O

One	O
complex	O
containing	O
a	O
70	O
D	O
protein	O
was	O
found	O
to	O
be	O
associated	O
specifically	O
with	O
transcriptionally	O
active	O
leukemia	O
cells	O
.	O

This	O
finding	O
suggested	O
that	O
the	O
PI3K	B-GENE
-	I-GENE
Akt	I-GENE
activation	I-GENE
pathway	I-GENE
plays	O
some	O
role	O
in	O
the	O
antiapoptotic	O
effect	O
of	O
EPO	B-GENE
.	O

G	O
.	O

Strikingly	O
,	O
this	O
subdomain	O
is	O
also	O
present	O
in	O
the	O
otherwise	O
unrelated	O
N	O
-	O
terminal	O
activating	O
region	O
of	O
p58c	B-GENE
-	I-GENE
ets	I-GENE
-	I-GENE
2	I-GENE
and	O
was	O
thus	O
named	O
BEC	B-GENE
for	O
Ets	B-GENE
-	I-GENE
1	I-GENE
-	I-GENE
beta	I-GENE
/	I-GENE
Ets	I-GENE
-	I-GENE
2	I-GENE
-	I-GENE
Conserved	I-GENE
sequence	I-GENE
.	O

Consistent	O
with	O
the	O
hepatic	O
and	O
epidermal	O
expression	O
of	O
histidase	B-GENE
,	O
this	O
finding	O
suggests	O
that	O
histidase	B-GENE
transcription	O
may	O
be	O
regulated	O
by	O
these	O
factors	O
.	O

The	O
respiratory	O
rate	O
was	O
13	O
+	O
/	O
-	O
1	O
breaths	O
/	O
min	O
with	O
52	O
+	O
/	O
-	O
4	O
%	O
of	O
the	O
respiratory	O
cycle	O
spent	O
in	O
inspiration	O
;	O
end	O
-	O
tidal	O
CO2	O
pressure	O
increased	O
by	O
3	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
0	O
Torr	O
during	O
runs	O
at	O
SIP	O
.	O

Previous	O
studies	O
have	O
indicated	O
that	O
a	O
hamster	O
cell	O
line	O
(	O
ts13	O
)	O
with	O
a	O
point	O
mutation	O
in	O
the	O
TAF	B-GENE
(	I-GENE
II	I-GENE
)	I-GENE
250	I-GENE
/	I-GENE
CCG1	I-GENE
(	O
TAF	B-GENE
(	I-GENE
II	I-GENE
)	I-GENE
250	I-GENE
)	O
gene	O
shows	O
temperature	O
-	O
sensitive	O
expression	O
of	O
a	O
subset	O
of	O
genes	O
and	O
arrests	O
in	O
late	O
G1	O
at	O
39	O
.	O
5	O
degrees	O
C	O
.	O

Model	O
of	O
spatiotemporal	O
dynamics	O
of	O
stick	O
-	O
slip	O
motion	O
.	O

A	O
hydrodynamic	O
description	O
of	O
the	O
osmotic	O
reflection	O
coefficient	O
with	O
application	O
to	O
the	O
pore	O
theory	O
of	O
transcapillary	O
exchange	O
.	O

Sequential	O
MR	O
examinations	O
of	O
the	O
nasal	O
cavity	O
and	O
paranasal	O
sinuses	O
were	O
performed	O
within	O
a	O
6	O
-	O
8	O
h	O
period	O
in	O
five	O
normal	O
volunteers	O
.	O

Comparison	O
of	O
patients	O
receiving	O
phenytoin	O
and	O
those	O
who	O
were	O
not	O
showed	O
significantly	O
lower	O
serum	O
folate	O
in	O
the	O
sub	O
-	O
group	O
receiving	O
phenytoin	O
,	O
but	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
sub	O
-	O
groups	O
with	O
respect	O
to	O
vitamin	O
B12	O
or	O
behaviour	O
problem	O
rating	O
.	O

Jerseys	O
had	O
higher	O
hepatic	O
Cu	O
concentrations	O
than	O
did	O
Holsteins	O
on	O
d	O
60	O
(	O
346	O
vs	O
.	O

A	O
region	O
approximately	O
100	O
bp	O
upstream	O
from	O
the	O
transcription	O
start	O
point	O
of	O
virB	B-GENE
was	O
identified	O
as	O
being	O
necessary	O
for	O
full	O
activation	O
of	O
this	O
promoter	O
by	O
VirF	B-GENE
.	O

We	O
also	O
found	O
that	O
the	O
same	O
males	O
,	O
breeding	O
in	O
different	O
years	O
on	O
the	O
same	O
territories	O
,	O
had	O
significantly	O
larger	O
harems	O
in	O
the	O
years	O
they	O
had	O
familiar	O
neighbors	O
.	O

Galoyan	O
has	O
summarized	O
the	O
results	O
of	O
his	O
discovery	O
of	O
cardioactive	O
neurohormones	O
.	O

The	O
authors	O
proposed	O
that	O
the	O
highly	O
convergent	O
inputs	O
to	O
the	O
entorhinal	O
cortex	O
indicate	O
this	O
region	O
may	O
be	O
particularly	O
important	O
for	O
selecting	O
or	O
compressing	O
information	O
.	O

Serum	B-GENE
TNF	I-GENE
concentrations	O
were	O
elevated	O
at	O
diagnosis	O
and	O
gradually	O
decreased	O
toward	O
the	O
reference	O
limits	O
by	O
week	O
16	O
.	O

In	O
group	O
III	O
,	O
patients	O
also	O
received	O
their	O
own	O
mediastinal	O
drainage	O
blood	O
,	O
shed	O
for	O
6	O
hours	O
after	O
operation	O
,	O
after	O
concentration	O
and	O
washing	O
in	O
a	O
MBRS	O
.	O

The	O
importance	O
of	O
selective	O
renal	O
vein	O
phlebography	O
in	O
the	O
evaluation	O
of	O
unexplained	O
hematuria	O
and	O
filing	O
defects	O
in	O
the	O
excretory	O
urogram	O
is	O
illustrated	O
.	O

Gluzman	O
,	O
EMBO	O
J	O
.	O

Comparison	O
was	O
made	O
with	O
other	O
neuroradiological	O
imaging	O
modalities	O
including	O
CT	O
,	O
myelography	O
,	O
CT	O
ventriculography	O
,	O
and	O
CT	O
myelocisternography	O
.	O

The	O
best	O
regression	O
model	O
for	O
predicting	O
changes	O
in	O
the	O
WCXR	O
included	O
time	O
to	O
first	O
positive	O
culture	O
and	O
antibody	O
titer	O
for	O
Pa	B-GENE
elastase	I-GENE
.	O

Two	O
patients	O
had	O
immediate	O
adverse	O
effects	O
from	O
NMF	O
;	O
one	O
had	O
a	O
grand	O
mal	O
seizure	O
and	O
the	O
other	O
developed	O
severe	O
abdominal	O
pain	O
.	O

A	O
possible	O
role	O
for	O
the	O
mixed	O
function	O
oxidase	B-GENE
enzyme	I-GENE
system	I-GENE
in	O
the	O
requirement	O
for	O
selenium	O
in	O
the	O
rat	O
.	O

Monospecific	O
antibodies	O
raised	O
against	O
rat	B-GENE
cytochrome	I-GENE
P	I-GENE
-	I-GENE
450	I-GENE
1A1	I-GENE
recognized	O
a	O
protein	O
in	O
the	O
hepatic	O
microsomes	O
of	O
the	O
double	O
-	O
crested	O
cormorant	O
,	O
and	O
also	O
in	O
those	O
of	O
the	O
great	O
blue	O
heron	O
(	O
Ardea	O
herodias	O
)	O
,	O
using	O
immunoblotting	O
.	O

Blood	O
sampling	O
procedures	O
were	O
videotaped	O
.	O

Calcimimetic	O
agents	O
directly	O
inhibit	O
PTH	B-GENE
secretion	O
by	O
activating	O
the	O
calcium	O
-	O
sensing	O
receptor	O
in	O
the	O
parathyroid	O
glands	O
,	O
but	O
clinical	O
experience	O
with	O
them	O
is	O
limited	O
.	O

The	O
drug	O
-	O
resistant	O
cell	O
lines	O
P388	O
/	O
ADR	O
/	O
3	O
and	O
P388	O
/	O
ADR	O
/	O
7	O
express	O
a	O
shortened	O
topo	B-GENE
II	I-GENE
alpha	I-GENE
mRNA	I-GENE
transcript	I-GENE
in	O
addition	O
to	O
the	O
native	O
transcript	O
present	O
in	O
the	O
drug	O
-	O
sensitive	O
P388	O
/	O
4	O
cell	O
line	O
.	O

Taken	O
together	O
,	O
differences	O
in	O
signaling	O
and	O
tissue	O
expression	O
suggest	O
that	O
the	O
human	B-GENE
intermediate	I-GENE
PRLr	I-GENE
differs	O
from	O
the	O
long	B-GENE
PRLr	I-GENE
in	O
physiological	O
function	O
.	O

Conservative	O
treatment	O
of	O
bladder	O
carcinoma	O
by	O
partial	O
cystectomy	O
and	O
interstitial	O
iridium	O
192	O
.	O

This	O
fragment	O
can	O
bind	O
several	O
trans	O
-	O
acting	O
factors	O
in	O
vitro	O
,	O
including	O
GATA	B-GENE
-	I-GENE
1	I-GENE
and	O
members	O
of	O
the	O
Ets	B-GENE
family	I-GENE
.	O

This	O
study	O
determined	O
the	O
arthritogenic	O
potential	O
of	O
silicone	O
gel	O
by	O
either	O
mixing	O
it	O
with	O
bovine	B-GENE
collagen	I-GENE
II	I-GENE
(	O
BII	B-GENE
)	O
or	O
by	O
injecting	O
silicone	O
gel	O
alone	O
in	O
DA	O
rats	O
.	O

Administration	O
of	O
the	O
dopamine	O
agonist	O
bromocriptine	O
(	O
2	O
.	O
5	O
mg	O
three	O
times	O
a	O
day	O
for	O
4	O
days	O
)	O
suppressed	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
mean	O
24	O
-	O
h	O
plasma	O
18	O
-	O
OHB	O
levels	O
from	O
21	O
.	O
9	O
+	O
/	O
-	O
2	O
.	O
0	O
to	O
14	O
.	O
8	O
+	O
/	O
-	O
1	O
.	O
4	O
ng	O
/	O
dl	O
.	O

Group	O
I	O
comprised	O
5	O
adult	O
Collies	O
that	O
received	O
at	O
least	O
400	O
microg	O
/	O
kg	O
ivermectin	O
p	O
.	O
o	O
.	O
and	O
were	O
presented	O
to	O
the	O
VMTH	O
3	O
hours	O
after	O
intoxication	O
.	O

At	O
cuticular	O
positions	O
exhibiting	O
the	O
Brd	B-GENE
bristle	I-GENE
loss	I-GENE
phenotype	I-GENE
,	O
we	O
have	O
found	O
that	O
the	O
progeny	O
of	O
the	O
multiplied	O
SOPs	O
develop	O
aberrantly	O
,	O
in	O
that	O
neurons	O
and	O
thecogen	O
(	O
sheath	O
)	O
cells	O
appear	O
but	O
not	O
trichogen	O
(	O
shaft	O
)	O
and	O
tormogen	O
(	O
socket	O
)	O
cells	O
.	O

Optimal	O
activation	O
of	O
T	O
cells	O
requires	O
at	O
least	O
two	O
signals	O
.	O

Use	O
of	O
free	O
-	O
access	O
minerals	O
.	O

63	O
.	O
3	O
micromol	O
/	O
1	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
area	O
under	O
the	O
plasma	O
concentration	O
-	O
time	O
curve	O
extrapolated	O
to	O
infinity	O
AUC	O
9	O
(	O
0	O
-	O
infinity	O
)	O
(	O
518	O
.	O
7	O
vs	O
.	O

Purified	B-GENE
Pra	I-GENE
was	O
also	O
shown	O
to	O
physically	O
interact	O
with	O
pyruvate	B-GENE
kinase	I-GENE
(	O
Pk	B-GENE
)	O
;	O
Pk	B-GENE
and	O
Pra	B-GENE
can	O
form	O
a	O
complex	O
,	O
but	O
when	O
the	O
12	B-GENE
-	I-GENE
kDa	I-GENE
Ndk	I-GENE
,	O
Pk	B-GENE
,	O
and	O
Pra	B-GENE
are	O
all	O
present	O
,	O
Pk	B-GENE
has	O
a	O
higher	O
affinity	O
than	O
Pra	B-GENE
for	O
forming	O
a	O
complex	O
with	O
the	O
12	B-GENE
-	I-GENE
kDa	I-GENE
Ndk	I-GENE
.	O

The	O
data	O
suggest	O
that	O
plasminogen	B-GENE
,	O
alpha	B-GENE
2AP	I-GENE
,	O
and	O
C1	B-GENE
-	I-GENE
INH	I-GENE
,	O
should	O
be	O
considered	O
equine	B-GENE
acute	I-GENE
-	I-GENE
phase	I-GENE
proteins	I-GENE
.	O

We	O
here	O
demonstrate	O
that	O
a	O
temperature	O
-	O
sensitive	O
fission	O
yeast	O
mutant	O
which	O
has	O
a	O
mutation	O
in	O
a	O
homologous	O
gene	O
,	O
and	O
two	O
of	O
three	O
additional	O
(	O
mtr1	B-GENE
/	I-GENE
prp20	I-GENE
/	I-GENE
srm1	I-GENE
)	O
mutants	O
accumulate	O
nuclear	O
poly	O
(	O
A	O
)	O
+	O
RNA	O
at	O
37	O
degrees	O
C	O
.	O

Grossly	O
,	O
the	O
experimental	O
vulvitis	O
was	O
identical	O
to	O
the	O
field	O
condition	O
,	O
and	O
bacteria	O
indistinguishable	O
from	O
the	O
inoculated	O
strains	O
were	O
reisolated	O
.	O

Inhibition	O
of	O
the	O
Mek	B-GENE
/	I-GENE
Erk	I-GENE
pathway	I-GENE
in	O
Rat1	O
/	O
ras	O
cells	O
,	O
using	O
the	O
Mek	B-GENE
inhibitor	O
,	O
PD98059	O
,	O
resulted	O
in	O
complete	O
cytoskeletal	O
recovery	O
,	O
indistinguishable	O
from	O
that	O
induced	O
by	O
HR12	O
.	O

In	O
Saccharomyces	O
cerevisiae	O
,	O
PHO85	B-GENE
encodes	O
a	O
cyclin	B-GENE
-	I-GENE
dependent	I-GENE
protein	I-GENE
kinase	I-GENE
(	O
Cdk	B-GENE
)	O
catalytic	O
subunit	O
with	O
multiple	O
regulatory	O
roles	O
thought	O
to	O
be	O
specified	O
by	O
association	O
with	O
different	O
cyclin	B-GENE
partners	O
(	O
Pcls	B-GENE
)	O
.	O

Tonometry	O
of	O
blood	O
samples	O
from	O
patients	O
may	O
also	O
be	O
used	O
in	O
the	O
determination	O
of	O
acid	O
-	O
base	O
quantities	O
and	O
hemoglobin	O
-	O
oxygen	O
affinity	O
e	O
.	O
g	O
.	O
p50	O
.	O

The	O
natural	O
history	O
of	O
these	O
lesions	O
,	O
locoregional	O
efficiency	O
of	O
the	O
different	O
treatments	O
used	O
,	O
the	O
part	O
played	O
by	O
chemotherapy	O
,	O
survival	O
,	O
causes	O
of	O
death	O
and	O
therapeutic	O
modalities	O
used	O
as	O
a	O
last	O
measure	O
,	O
have	O
been	O
analysed	O
.	O

The	O
homologies	O
between	O
RAD16	B-GENE
,	O
RAD54	B-GENE
and	O
SNF2	B-GENE
are	O
also	O
shared	O
by	O
several	O
additional	O
,	O
recently	O
isolated	O
yeast	O
and	O
Drosophila	O
genes	O
.	O

Plasma	B-GENE
secretin	I-GENE
levels	O
also	O
augmented	O
after	O
the	O
administration	O
of	O
ethanol	O
solutions	O
,	O
with	O
a	O
delay	O
of	O
about	O
one	O
hour	O
after	O
the	O
onset	O
of	O
acid	O
secretion	O
.	O

Background	O
/	O
Aims	O
:	O
Hepatitis	O
C	O
and	O
nonalcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFL	O
)	O
are	O
the	O
two	O
most	O
common	O
forms	O
of	O
liver	O
disease	O
in	O
the	O
United	O
States	O
.	O

The	O
progression	O
of	O
acute	O
bronchitis	O
is	O
associated	O
with	O
elevated	O
blood	O
concentrations	O
of	O
acute	B-GENE
-	I-GENE
phase	I-GENE
proteins	I-GENE
,	O
KKS	B-GENE
activation	O
in	O
the	O
blood	O
and	O
high	O
serotonin	O
and	O
lactic	O
acid	O
content	O
in	O
the	O
humor	O
condensated	O
from	O
the	O
exhaled	O
air	O
.	O

Topical	O
1	O
percent	O
isoproterenol	O
in	O
the	O
presence	O
of	O
the	O
phosphodiesterase	B-GENE
inhibitor	O
theophylline	O
was	O
tested	O
for	O
its	O
ability	O
to	O
stimulate	O
the	O
rate	O
of	O
aqueous	O
humor	O
flow	O
through	O
the	O
anterior	O
chamber	O
of	O
the	O
normal	O
and	O
the	O
partially	O
adrenergically	O
denervated	O
human	O
eye	O
(	O
Horner	O
'	O
s	O
syndrome	O
)	O
.	O

Copyright	O
2000	O
Academic	O
Press	O
.	O

Some	O
mutations	O
affected	O
Dhfr	B-GENE
in	O
a	O
qualitative	O
manner	O
,	O
such	O
as	O
by	O
changing	O
the	O
startpoint	O
of	O
one	O
of	O
the	O
major	O
Dhfr	B-GENE
transcripts	I-GENE
or	O
changing	O
the	O
relative	O
abundance	O
of	O
the	O
two	O
major	O
Dhfr	B-GENE
transcripts	I-GENE
.	O

The	O
sequencing	O
of	O
Stellate	B-GENE
copies	O
located	O
along	O
the	O
discontinuous	O
cluster	O
revealed	O
a	O
complex	O
pattern	O
of	O
diversification	O
.	O

These	O
results	O
suggest	O
that	O
the	O
phenotype	O
of	O
XLP	O
may	O
result	O
from	O
perturbed	O
signaling	O
not	O
only	O
through	O
SLAM	B-GENE
,	O
but	O
also	O
other	O
cell	O
surface	O
molecules	O
that	O
utilize	O
SAP	B-GENE
as	O
a	O
signaling	O
adaptor	O
protein	O
.	O

Only	O
one	O
ADR	O
was	O
related	O
definitely	O
to	O
ciprofloxacin	O
therapy	O
.	O

Here	O
,	O
a	O
case	O
of	O
Sjogren	O
'	O
s	O
syndrome	O
is	O
presented	O
that	O
was	O
initially	O
diagnosed	O
because	O
of	O
dental	O
complaints	O
,	O
and	O
long	O
-	O
term	O
treatment	O
of	O
Sjogren	O
'	O
s	O
patients	O
is	O
discussed	O
.	O

The	O
12S	B-GENE
E1A	I-GENE
product	I-GENE
does	O
not	O
activate	O
a	O
TRE	B-GENE
sequence	I-GENE
,	O
but	O
cotransfection	O
with	O
c	B-GENE
-	I-GENE
jun	I-GENE
circumvents	O
this	O
lack	O
of	O
stimulation	O
.	O

Second	O
,	O
the	O
wild	B-GENE
-	I-GENE
type	I-GENE
m8	I-GENE
3	I-GENE
'	I-GENE
UTR	I-GENE
strongly	O
reduces	O
accumulation	O
of	O
heterologous	O
transcripts	O
in	O
vivo	O
,	O
an	O
activity	O
that	O
requires	O
its	O
K	O
box	O
sequences	O
.	O

Thus	O
it	O
appears	O
that	O
insertion	O
of	O
a	O
transposable	O
element	O
near	O
the	O
5	O
'	O
terminus	O
of	O
the	O
structural	O
gene	O
can	O
produce	O
constitutive	O
expression	O
of	O
a	O
normally	O
glucose	O
-	O
repressed	O
enzyme	O
.	O

The	O
IE13	O
.	O
1	O
cell	O
line	O
was	O
able	O
to	O
complement	O
a	O
recombinant	O
virus	O
in	O
which	O
both	O
copies	O
of	O
the	O
IE	B-GENE
gene	I-GENE
were	O
replaced	O
by	O
insertion	O
of	O
the	O
Escherichia	B-GENE
coli	I-GENE
lacZ	I-GENE
gene	I-GENE
.	O

After	O
taking	O
smears	O
from	O
lesions	O
of	O
the	O
oral	O
mucosa	O
(	O
tongue	O
,	O
cheeks	O
,	O
palate	O
)	O
and	O
the	O
contiguous	O
denture	O
surface	O
by	O
cotton	O
wool	O
swabs	O
and	O
inoculating	O
them	O
onto	O
Sabouraud	O
glucose	O
agar	O
and	O
CHROMagar	O
Candida	O
,	O
individual	O
yeast	O
species	O
were	O
identified	O
by	O
a	O
germ	O
tube	O
,	O
filamentous	O
,	O
and	O
assimilation	O
tests	O
employing	O
the	O
commercial	O
kit	O
AuxaColor	O
.	O

[	O
18F	O
]	O
(	O
+	O
)	O
-	O
4	O
-	O
fluorobenzyltrozamicol	O
(	O
FBT	O
)	O
,	O
which	O
selectively	O
binds	O
to	O
the	O
vesicular	O
acetylcholine	B-GENE
transporter	I-GENE
in	O
the	O
presynaptic	O
cholinergic	O
neuron	O
,	O
has	O
previously	O
been	O
shown	O
to	O
be	O
a	O
useful	O
ligand	O
for	O
the	O
study	O
of	O
cholinergic	O
terminal	O
density	O
in	O
the	O
basal	O
ganglia	O
with	O
PET	O
.	O

A	O
genomic	O
clone	O
was	O
isolated	O
that	O
contained	O
12	O
.	O
5	O
kb	O
of	O
the	O
5	O
'	O
-	O
flanking	O
region	O
and	O
the	O
first	O
exon	O
of	O
the	O
p69	B-GENE
/	I-GENE
71	I-GENE
2	I-GENE
-	I-GENE
5A	I-GENE
synthetase	I-GENE
gene	I-GENE
.	O

Here	O
we	O
report	O
the	O
cloning	O
and	O
characterization	O
of	O
Xenopus	B-GENE
Pax	I-GENE
-	I-GENE
5	I-GENE
and	O
Pax	B-GENE
-	I-GENE
8	I-GENE
,	O
two	O
orthologues	O
of	O
the	O
Pax	B-GENE
-	I-GENE
2	I-GENE
/	I-GENE
5	I-GENE
/	I-GENE
8	I-GENE
gene	I-GENE
family	I-GENE
.	O

However	O
,	O
cotransfection	O
studies	O
indicate	O
that	O
RVR	B-GENE
does	O
not	O
activate	O
transcription	O
when	O
this	O
hormone	B-GENE
response	I-GENE
element	I-GENE
is	O
linked	O
to	O
a	O
reporter	O
gene	O
but	O
rather	O
acts	O
as	O
a	O
potent	O
competitive	O
repressor	O
of	O
ROR	B-GENE
alpha	I-GENE
function	O
.	O

The	O
level	O
of	O
carboxyl	B-GENE
-	I-GENE
terminal	I-GENE
parathyroid	I-GENE
hormone	I-GENE
in	O
the	O
patients	O
with	O
thyroid	O
carcinoma	O
was	O
higher	O
than	O
that	O
in	O
the	O
patients	O
without	O
thyroid	O
carcinoma	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
prothrombin	B-GENE
gene	I-GENE
G20210A	I-GENE
mutation	I-GENE
is	O
not	O
found	O
among	O
Japanese	O
patients	O
with	O
deep	O
vein	O
thrombosis	O
and	O
healthy	O
individuals	O
.	O

The	O
correct	O
termination	O
of	O
retroviral	O
transcripts	O
at	O
the	O
3	O
'	O
LTR	B-GENE
R	I-GENE
/	I-GENE
U5	I-GENE
junction	I-GENE
is	O
primarily	O
dependent	O
on	O
the	O
canonical	O
AAUAAA	B-GENE
polyadenylation	O
signal	O
,	O
so	O
we	O
have	O
analyzed	O
the	O
effect	O
of	O
mutating	O
the	O
polyadenylation	O
signal	O
sequences	O
on	O
the	O
properties	O
of	O
a	O
selectable	O
murine	O
retroviral	O
vector	O
.	O

When	O
the	O
coronary	O
sinus	O
pressure	O
reached	O
15	O
torr	O
,	O
there	O
was	O
a	O
significant	O
decrease	O
in	O
cardiac	O
index	O
(	O
3	O
.	O
60	O
+	O
/	O
-	O
0	O
.	O
5	O
to	O
2	O
.	O
70	O
+	O
/	O
-	O
0	O
.	O
6	O
L	O
/	O
min	O
/	O
m2	O
,	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
coronary	O
blood	O
flow	O
(	O
13	O
.	O
7	O
+	O
/	O
-	O
3	O
.	O
1	O
to	O
7	O
.	O
0	O
+	O
/	O
-	O
2	O
.	O
1	O
ml	O
/	O
min	O
,	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
rate	O
of	O
rise	O
of	O
left	O
ventricular	O
pressure	O
(	O
1	O
,	O
567	O
+	O
/	O
-	O
275	O
to	O
1	O
,	O
331	O
+	O
/	O
-	O
314	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
and	O
an	O
increase	O
in	O
coronary	O
arteriovenous	O
difference	O
(	O
62	O
.	O
8	O
%	O
+	O
/	O
-	O
9	O
.	O
3	O
%	O
to	O
70	O
.	O
5	O
%	O
+	O
/	O
-	O
5	O
.	O
4	O
%	O
saturation	O
,	O
p	O
less	O
than	O
0	O
.	O
03	O
)	O
.	O

These	O
results	O
suggest	O
that	O
ULK2	B-GENE
is	O
involved	O
in	O
a	O
previously	O
uncharacterized	O
signaling	O
pathway	O
in	O
mammalian	O
cells	O
.	O

We	O
compared	O
previously	O
the	O
methylation	O
status	O
between	O
normal	O
liver	O
and	O
liver	O
tumors	O
in	O
SV40	B-GENE
T	I-GENE
/	I-GENE
t	I-GENE
antigen	I-GENE
transgenic	O
mice	O
(	O
MT	O
-	O
D2	O
mice	O
)	O
using	O
Restriction	O
Landmark	O
Genomic	O
Scanning	O
for	O
Methylation	O
(	O
RLGS	O
-	O
M	O
)	O
and	O
identified	O
several	O
loci	O
/	O
spots	O
that	O
appeared	O
to	O
be	O
methylated	O
frequently	O
in	O
liver	O
tumors	O
.	O

The	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
human	B-GENE
lactoferrin	I-GENE
gene	I-GENE
was	O
isolated	O
from	O
a	O
human	O
placental	O
genomic	O
library	O
.	O

Additionally	O
,	O
observations	O
that	O
patients	O
with	O
mitral	O
versus	O
aortic	O
regurgitation	O
respond	O
differently	O
to	O
valve	O
replacement	O
suggest	O
that	O
differences	O
exist	O
preoperatively	O
between	O
these	O
two	O
types	O
of	O
volume	O
overload	O
.	O

GH	B-GENE
deficiency	O
may	O
be	O
absolute	O
,	O
but	O
often	O
is	O
not	O
and	O
the	O
diagnosis	O
may	O
be	O
complicated	O
by	O
a	O
constellation	O
of	O
physical	O
and	O
hormonal	O
findings	O
that	O
are	O
along	O
a	O
spectrum	O
from	O
low	O
normal	O
GH	B-GENE
sufficiency	O
to	O
absent	O
GH	B-GENE
secretion	O
.	O

The	O
bovine	B-GENE
PGHS	I-GENE
-	I-GENE
2	I-GENE
cDNA	I-GENE
was	O
cloned	O
by	O
a	O
combination	O
of	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
and	O
cDNA	O
library	O
screening	O
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
moderate	O
cooling	O
increases	O
the	O
responsiveness	O
of	O
vascular	B-GENE
alpha2	I-GENE
-	I-GENE
adrenoceptors	I-GENE
.	O

Copyright	O
2002	O
American	O
Cancer	O
Society	O
.	O
DOI	O
10	O
.	O
1002	O
/	O
cncr	O
.	O
10318	O

Stable	O
association	O
of	O
U2	B-GENE
snRNP	I-GENE
with	O
the	O
branchpoint	O
sequence	O
of	O
mammalian	O
pre	O
-	O
mRNAs	O
requires	O
binding	O
of	O
a	O
non	B-GENE
-	I-GENE
snRNP	I-GENE
protein	I-GENE
to	O
the	O
polypyrimidine	O
tract	O
.	O

Patterns	O
defined	O
by	O
combinations	O
of	O
normal	O
and	O
abnormal	O
laboratory	O
results	O
had	O
decreased	O
the	O
likelihood	O
of	O
PEM	O
from	O
an	O
all	O
-	O
2	O
to	O
all	O
-	O
0	O
pattern	O
.	O

Nucleotide	O
sequencing	O
indicates	O
that	O
this	O
E1	B-GENE
alpha	I-GENE
cDNA	I-GENE
clone	O
is	O
1821	O
base	O
pairs	O
(	O
bp	O
)	O
in	O
length	O
with	O
an	O
open	O
reading	O
frame	O
of	O
1365	O
bp	O
and	O
a	O
3	O
'	O
-	O
untranslated	O
region	O
of	O
356	O
bp	O
.	O

Retinoblastoma	O
:	O
a	O
study	O
of	O
natural	O
history	O
and	O
prognosis	O
of	O
268	O
cases	O
.	O

We	O
have	O
recently	O
identified	O
a	O
mouse	O
enzyme	O
termed	O
gamma	B-GENE
-	I-GENE
glutamyl	I-GENE
leukotrienase	I-GENE
(	O
GGL	B-GENE
)	O
that	O
converts	O
leukotriene	O
C4	O
(	O
LTC4	O
)	O
to	O
leukotriene	O
D4	O
(	O
LTD4	O
)	O
.	O

The	O
results	O
suggest	O
that	O
the	O
role	O
of	O
S	O
.	O
argyrostoma	O
in	O
the	O
dissemination	O
of	O
Trichinella	O
larvae	O
in	O
nature	O
is	O
limited	O
in	O
comparison	O
to	O
the	O
role	O
played	O
by	O
mammals	O
with	O
scavenger	O
and	O
cannibalistic	O
behavior	O
.	O

Karger	O
AG	O
,	O
Basel	O

Proceedings	O
:	O
Reversible	O
complete	O
heart	O
block	O
following	O
surgery	O
of	O
congenital	O
heart	O
defects	O
.	O

GABA	B-GENE
(	I-GENE
B	I-GENE
)	I-GENE
R1g	I-GENE
was	O
expressed	O
in	O
both	O
brain	O
and	O
peripheral	O
tissues	O
.	O

A	O
malignant	O
true	O
teratoma	O
of	O
liver	O
in	O
childhood	O
.	O

To	O
assess	O
the	O
health	O
significance	O
of	O
the	O
early	O
renal	O
changes	O
after	O
chronic	O
exposure	O
to	O
cadmium	O
,	O
23	O
workers	O
removed	O
from	O
exposure	O
because	O
of	O
the	O
discovery	O
of	O
an	O
increased	O
urinary	O
excretion	O
of	O
beta	B-GENE
2	I-GENE
-	I-GENE
microglobulin	I-GENE
or	O
retinol	B-GENE
binding	I-GENE
protein	I-GENE
,	O
or	O
both	O
,	O
have	O
been	O
examined	O
once	O
a	O
year	O
for	O
five	O
years	O
.	O

We	O
have	O
examined	O
reporter	O
gene	O
(	O
beta	B-GENE
-	I-GENE
gal	I-GENE
)	O
expression	O
directed	O
by	O
human	B-GENE
heat	I-GENE
shock	I-GENE
transcription	I-GENE
factors	I-GENE
1	I-GENE
and	I-GENE
2	I-GENE
(	O
HSF1	B-GENE
and	O
HSF2	B-GENE
)	O
in	O
HeLa	O
cells	O
and	O
in	O
yeast	O
(	O
Saccharomyces	O
cerevisiae	O
)	O
.	O

Therefore	O
,	O
use	O
of	O
presaturation	O
is	O
recommended	O
for	O
myocardial	O
motion	O
studies	O
using	O
cine	O
PC	O
velocity	O
data	O
.	O

The	O
histological	O
grading	O
was	O
certified	O
in	O
68	O
cases	O
:	O
12	O
G1	O
,	O
39	O
G2	O
,	O
17	O
G3	O
;	O
extracapsular	O
spread	O
was	O
found	O
in	O
20	O
/	O
54	O
cases	O
(	O
37	O
%	O
)	O
.	O

(	O
3	O
)	O
.	O

Expression	O
of	O
Msp	B-GENE
was	O
toxic	O
to	O
E	O
.	O
coli	O
when	O
the	O
entire	O
msp	B-GENE
gene	I-GENE
was	O
present	O
.	O

High	B-GENE
-	I-GENE
mobility	I-GENE
-	I-GENE
group	I-GENE
protein	I-GENE
I	I-GENE
can	O
modulate	O
binding	O
of	O
transcription	O
factors	O
to	O
the	O
U5	B-GENE
region	I-GENE
of	O
the	O
human	B-GENE
immunodeficiency	I-GENE
virus	I-GENE
type	I-GENE
1	I-GENE
proviral	I-GENE
promoter	I-GENE
.	O

There	O
was	O
a	O
significant	O
correlation	O
between	O
tubular	O
diameter	O
and	O
spg	O
(	O
r	O
=	O
0	O
.	O
68	O
,	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
suggesting	O
that	O
tubular	O
diameter	O
measurements	O
in	O
histological	O
sections	O
could	O
be	O
used	O
to	O
predict	O
sperm	O
production	O
.	O

The	O
rho	B-GENE
genes	I-GENE
comprise	O
an	O
evolutionarily	O
conserved	O
family	O
with	O
significant	O
homology	O
to	O
the	O
ras	B-GENE
oncogene	I-GENE
family	I-GENE
.	O

The	O
effect	O
of	O
ICRF	O
-	O
187	O
on	O
the	O
antitumor	O
response	O
induced	O
by	O
the	O
combination	O
of	O
ADR	O
and	O
WBH	O
was	O
also	O
investigated	O
in	O
order	O
to	O
assess	O
alterations	O
in	O
the	O
therapeutic	O
index	O
of	O
this	O
combined	O
therapeutic	O
modality	O
treatment	O
.	O

The	O
syndrome	O
of	O
resistance	O
to	O
thyroid	O
hormone	O
is	O
characterized	O
by	O
elevated	O
serum	O
free	O
thyroid	O
hormones	O
,	O
failure	O
to	O
suppress	O
pituitary	B-GENE
thyrotropin	I-GENE
secretion	O
,	O
and	O
variable	O
peripheral	O
refractoriness	O
to	O
hormone	O
action	O
.	O

Survival	O
rates	O
for	O
the	O
original	O
treatment	O
group	O
were	O
84	O
.	O
5	O
%	O
and	O
57	O
.	O
6	O
%	O
at	O
12	O
and	O
21	O
months	O
,	O
respectively	O
;	O
for	O
the	O
delayed	O
treatment	O
group	O
,	O
78	O
.	O
8	O
%	O
and	O
64	O
.	O
6	O
%	O
at	O
12	O
and	O
21	O
months	O
,	O
respectively	O
,	O
and	O
78	O
.	O
8	O
%	O
and	O
47	O
.	O
5	O
%	O
at	O
12	O
and	O
21	O
months	O
,	O
respectively	O
,	O
for	O
77	O
subjects	O
with	O
AIDS	O
and	O
93	O
.	O
0	O
%	O
and	O
71	O
.	O
8	O
%	O
,	O
respectively	O
,	O
for	O
50	O
subjects	O
with	O
AIDS	O
-	O
related	O
complex	O
in	O
the	O
original	O
treatment	O
group	O
.	O

The	O
signalling	O
molecules	O
Wnt1	B-GENE
and	O
Sonic	B-GENE
hedgehog	I-GENE
,	O
implicated	O
in	O
the	O
activation	O
of	O
Myf5	B-GENE
in	O
myogenic	O
progenitor	O
cells	O
in	O
the	O
somite	O
,	O
are	O
also	O
produced	O
in	O
the	O
viscinity	O
of	O
the	O
Myf5	B-GENE
expression	I-GENE
domain	I-GENE
in	O
the	O
mesencephalon	O
.	O

Sequence	O
analysis	O
of	O
this	O
100	O
-	O
bp	O
Col2a1	B-GENE
enhancer	I-GENE
revealed	O
several	O
sequence	O
motifs	O
similar	O
to	O
motifs	O
present	O
within	O
the	O
regulatory	O
region	O
of	O
the	O
link	B-GENE
protein	I-GENE
gene	I-GENE
,	O
another	O
cartilage	O
gene	O
.	O

This	O
is	O
in	O
contrast	O
with	O
the	O
classical	O
'	O
oxygen	O
debt	O
hypothesis	O
'	O
,	O
which	O
states	O
that	O
the	O
oxygen	O
debt	O
and	O
lactate	O
clearance	O
are	O
linked	O
.	O

Mental	O
development	O
is	O
generally	O
normal	O
.	O

Reactivities	O
to	O
horse	B-GENE
anti	I-GENE
-	I-GENE
lymphocyte	I-GENE
globulin	I-GENE
.	O

Further	O
studies	O
in	O
T	O
-	O
24	O
cells	O
demonstrated	O
that	O
HA	O
fragments	O
also	O
induced	O
I	B-GENE
kappa	I-GENE
B	I-GENE
alpha	I-GENE
phosphorylation	O
and	O
degradation	O
,	O
kappa	B-GENE
B	I-GENE
-	I-GENE
linked	I-GENE
reporter	I-GENE
gene	I-GENE
expression	O
,	O
and	O
ICAM	B-GENE
-	I-GENE
1	I-GENE
promoter	I-GENE
activity	O
in	O
an	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
manner	O
.	O

Acetoin	O
can	O
be	O
reused	O
by	O
the	O
bacteria	O
during	O
stationary	O
phase	O
when	O
other	O
carbon	O
sources	O
have	O
been	O
depleted	O
.	O

An	O
epidemic	O
of	O
hepatitis	O
B	O
virus	O
infection	O
among	O
intravenous	O
drug	O
users	O
in	O
Iceland	O
.	O

Transformations	O
in	O
the	O
morphine	O
series	O
.	O

Morphology	O
of	O
bacteriophages	O
of	O
Klebsiella	O
bacilli	O
.	O

During	O
the	O
biosynthesis	O
of	O
all	O
three	O
mutant	O
polypeptides	O
,	O
the	O
signal	O
peptide	O
is	O
efficiently	O
and	O
accurately	O
cleaved	O
from	O
the	O
nascent	O
protein	O
,	O
even	O
though	O
in	O
mutants	O
X2	O
and	O
X3	O
the	O
cleavage	O
site	O
itself	O
has	O
been	O
altered	O
.	O

Influence	O
of	O
cyclo	B-GENE
-	I-GENE
oxygenase	I-GENE
inhibition	O
and	O
of	O
leukotriene	B-GENE
receptor	I-GENE
blockade	O
on	O
pulmonary	O
vascular	O
pressure	O
/	O
cardiac	O
index	O
relationships	O
in	O
hyperoxic	O
and	O
in	O
hypoxic	O
dogs	O
.	O

Of	O
the	O
remaining	O
seven	O
,	O
five	O
reacted	O
either	O
with	O
immediate	O
and	O
strong	O
symptoms	O
or	O
had	O
spontaneously	O
reduced	O
gluten	B-GENE
intake	O
,	O
or	O
had	O
an	O
acquired	O
IgA	B-GENE
deficiency	O
.	O

Polysorbate	O
80	O
did	O
not	O
have	O
a	O
direct	O
stimulant	O
or	O
relaxant	O
effect	O
on	O
either	O
guinea	O
pig	O
ileum	O
or	O
rat	O
uterus	O
,	O
however	O
,	O
it	O
antagonised	O
the	O
contractions	O
induced	O
by	O
acetylcholine	O
,	O
histamine	O
,	O
barium	O
,	O
5	O
-	O
hydroxytryptamine	O
and	O
carbachol	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
molecular	O
mechanism	O
by	O
which	O
Gle2p	B-GENE
and	O
the	O
Gle2p	B-GENE
-	I-GENE
Nup116p	I-GENE
interaction	O
function	O
in	O
mRNA	O
export	O
is	O
unknown	O
.	O

The	O
C4BP	B-GENE
alpha	I-GENE
gene	I-GENE
is	O
organized	O
as	O
follows	O
:	O
the	O
first	O
exon	O
codes	O
for	O
the	O
first	O
198	O
nucleotides	O
of	O
the	O
5	O
'	O
UTR	O
.	O

EXERCISE	O
IN	O
THE	O
TERRESTRIAL	O
CHRISTMAS	O
ISLAND	O
RED	O
CRAB	O
GECARCOIDEA	O
NATALIS	O
-	O
ENERGETICS	O
OF	O
LOCOMOTION	O
.	O

We	O
have	O
now	O
located	O
the	O
5	O
'	O
ends	O
of	O
the	O
two	O
remaining	O
late	O
mRNAs	O
.	O

Acta	O
572	O
,	O
113	O
-	O
120	O
]	O
.	O

The	O
RNA	B-GENE
polymerase	I-GENE
III	I-GENE
-	I-GENE
recruiting	I-GENE
factor	I-GENE
TFIIIB	I-GENE
induces	O
a	O
DNA	O
bend	O
between	O
the	O
TATA	O
box	O
and	O
the	O
transcriptional	O
start	O
site	O
.	O

To	O
search	O
for	O
genes	O
that	O
interact	O
with	O
the	O
SLK1	B-GENE
-	I-GENE
SLT2	I-GENE
pathway	O
,	O
a	O
synthetic	O
lethal	O
suppression	O
screen	O
was	O
carried	O
out	O
.	O

Scotchbond	O
2	O
showed	O
the	O
least	O
dye	O
penetration	O
but	O
not	O
statistically	O
less	O
than	O
the	O
XR	O
bond	O
/	O
Silus	O
Plus	O
combination	O
.	O

The	O
consequences	O
of	O
intensive	O
swine	O
production	O
on	O
the	O
environment	O
and	O
possible	O
solutions	O
by	O
means	O
of	O
nutrition	O
are	O
outlined	O
.	O

Pitx2	B-GENE
rescues	O
the	O
GABAergic	O
differentiation	O
defect	O
and	O
partially	O
rescues	O
the	O
axon	O
guidance	O
and	O
behavioral	O
phenotypes	O
of	O
unc	B-GENE
-	I-GENE
30	I-GENE
mutants	I-GENE
,	O
indicating	O
a	O
high	O
degree	O
of	O
functional	O
conservation	O
between	O
these	O
evolutionarily	O
related	O
genes	O
.	O

These	O
data	O
strongly	O
implicate	O
the	O
normal	O
product	O
of	O
the	O
int	B-GENE
-	I-GENE
2	I-GENE
gene	I-GENE
,	O
which	O
is	O
related	O
to	O
the	O
fibroblast	B-GENE
growth	I-GENE
factor	I-GENE
family	I-GENE
,	O
as	O
a	O
contributory	O
factor	O
in	O
virally	O
induced	O
mammary	O
tumors	O
.	O

Similarity	O
of	O
DNA	O
binding	O
and	O
transcriptional	O
regulation	O
by	O
Caenorhabditis	B-GENE
elegans	I-GENE
MAB	I-GENE
-	I-GENE
3	I-GENE
and	O
Drosophila	B-GENE
melanogaster	I-GENE
DSX	I-GENE
suggests	O
conservation	O
of	O
sex	O
determining	O
mechanisms	O
.	O

Serum	O
gastrin	B-GENE
and	O
AFP	B-GENE
levels	O
had	O
the	O
same	O
evolution	O
and	O
appear	O
to	O
have	O
the	O
same	O
interest	O
to	O
follow	O
the	O
course	O
of	O
the	O
disease	O
.	O

Pokeweed	B-GENE
mitogen	I-GENE
(	O
PWM	B-GENE
)	O
or	O
anti	B-GENE
-	I-GENE
CD3	I-GENE
significantly	O
increases	O
c	B-GENE
-	I-GENE
jun	I-GENE
messenger	I-GENE
RNA	I-GENE
(	I-GENE
mRNA	I-GENE
)	I-GENE
levels	O
in	O
T	O
cells	O
.	O

The	O
same	O
trend	O
was	O
noted	O
between	O
YG	O
4	O
.	O
5	O
heifers	O
and	O
YG	O
5	O
.	O
5	O
steers	O
,	O
indicating	O
a	O
sex	O
-	O
related	O
deposition	O
of	O
seam	O
fat	O
in	O
fed	O
cattle	O
.	O

Nucleoprotein	O
(	O
N	O
)	O
expressed	O
by	O
both	O
recombinant	O
vaccinia	O
virus	O
and	O
TGEV	O
had	O
a	O
relative	O
molecular	O
mass	O
(	O
Mr	O
)	O
of	O
47	O
,	O
000	O
and	O
was	O
susceptible	O
to	O
degradation	O
at	O
the	O
C	O
-	O
terminus	O
yielding	O
discrete	O
breakdown	O
products	O
.	O

A	O
herpesvirus	B-GENE
proteinase	I-GENE
activity	O
has	O
been	O
identified	O
and	O
partially	O
characterized	O
by	O
using	O
the	O
cloned	O
enzyme	O
and	O
substrate	O
genes	O
in	O
transient	O
transfection	O
assays	O
.	O

Molecular	O
cloning	O
and	O
expression	O
of	O
human	B-GENE
UDP	I-GENE
-	I-GENE
d	I-GENE
-	I-GENE
Xylose	I-GENE
:	I-GENE
proteoglycan	I-GENE
core	I-GENE
protein	I-GENE
beta	B-GENE
-	I-GENE
d	I-GENE
-	I-GENE
xylosyltransferase	I-GENE
and	O
its	O
first	O
isoform	B-GENE
XT	I-GENE
-	I-GENE
II	I-GENE
.	O

Microwave	O
hyperthermia	O
-	O
induced	O
blood	O
-	O
brain	O
barrier	O
alterations	O
.	O

These	O
results	O
suggest	O
that	O
less	O
antidopaminergic	O
activity	O
of	O
RHAL	O
in	O
this	O
neuroleptic	O
test	O
might	O
be	O
explained	O
by	O
the	O
lesser	O
conversion	O
of	O
RHAL	O
to	O
HAL	O
.	O

All	O
patients	O
had	O
the	O
CA	B-GENE
125	I-GENE
assay	O
performed	O
within	O
one	O
week	O
before	O
their	O
second	O
-	O
look	O
operation	O
.	O

Early	O
disagnosis	O
of	O
cancer	O
-	O
-	O
50	O
per	O
cent	O
of	O
all	O
patients	O
could	O
be	O
cured	O
.	O

Thiopentone	O
sodium	O
administered	O
at	O
30	O
and	O
10	O
min	O
before	O
or	O
5	O
,	O
10	O
and	O
15	O
min	O
after	O
exposure	O
to	O
NOC	O
-	O
5	O
,	O
but	O
not	O
thereafter	O
,	O
significantly	O
attenuated	O
NO	O
-	O
induced	O
neurotoxicity	O
compared	O
with	O
controls	O
.	O

Essentially	O
,	O
2	O
'	O
-	O
O	O
-	O
methyl	O
oligoribonucleotides	O
(	O
2	O
'	O
OMeRNA	O
)	O
were	O
delivered	O
to	O
the	O
nuclei	O
of	O
primary	O
mdx	O
myoblasts	O
in	O
culture	O
.	O

Microscopic	O
anatomy	O
and	O
cell	O
population	O
dynamics	O
.	O

Angina	O
(	O
Q	O
)	O
persistence	O
showed	O
marked	O
associations	O
with	O
previous	O
myocardial	O
infarction	O
,	O
diagnosed	O
angina	O
,	O
electrocardiogram	O
ischemia	O
,	O
and	O
subsequent	O
major	O
ischemic	O
heart	O
disease	O
events	O
from	O
Q5	O
onward	O
.	O

We	O
propose	O
that	O
Mad	B-GENE
and	O
Medea	B-GENE
encode	O
rate	O
-	O
limiting	O
components	O
integral	O
to	O
dpp	B-GENE
pathways	I-GENE
throughout	O
development	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
transcription	O
from	O
the	O
MMTV	B-GENE
5	I-GENE
'	I-GENE
LTR	I-GENE
is	O
highly	O
active	O
in	O
the	O
absence	O
of	O
Stat5a	B-GENE
,	O
a	O
transcription	O
factor	O
that	O
had	O
been	O
shown	O
previously	O
to	O
be	O
required	O
for	O
transcription	O
from	O
the	O
MMTV	B-GENE
LTR	I-GENE
.	O

Functional	O
magnetic	O
resonance	O
imaging	O
(	O
fMRI	O
)	O
has	O
been	O
increasingly	O
used	O
in	O
studying	O
human	O
brain	O
function	O
given	O
its	O
non	O
-	O
invasive	O
feature	O
and	O
good	O
spatial	O
resolution	O
.	O

Viral	O
infections	O
have	O
long	O
been	O
suspected	O
to	O
be	O
causative	O
agents	O
in	O
a	O
number	O
of	O
inner	O
ear	O
dysfunctions	O
.	O

Microdetermination	O
of	O
adrenocortical	O
steroids	O
by	O
double	O
isotope	O
method	O
.	O

STUDY	O
DESIGN	O
:	O
Salivary	B-GENE
immunoglobulin	I-GENE
A	I-GENE
levels	O
of	O
each	O
of	O
20	O
subjects	O
were	O
determined	O
on	O
3	O
occasions	O
:	O
first	O
,	O
while	O
the	O
subject	O
was	O
still	O
smoking	O
;	O
second	O
,	O
7	O
days	O
after	O
cessation	O
of	O
smoking	O
;	O
third	O
,	O
on	O
the	O
14th	O
day	O
after	O
cessation	O
.	O

Practical	O
interest	O
of	O
such	O
studies	O
is	O
limited	O
since	O
the	O
pharmacokinetic	O
parameters	O
are	O
systematically	O
evaluated	O
in	O
man	O
during	O
phase	O
I	O
trials	O
.	O

Martin	O
Luther	O
and	O
his	O
physicians	O
.	O

40	O
,	O
000	O
)	O
.	O

These	O
results	O
also	O
suggest	O
the	O
involvement	O
of	O
additional	O
elements	O
in	O
the	O
UPR	O
.	O

RESULTS	O
:	O
Abnormal	O
color	O
perception	O
was	O
found	O
in	O
32	O
%	O
of	O
the	O
epilepsy	O
patients	O
treated	O
with	O
vigabatrin	O
monotherapy	O
and	O
28	O
%	O
of	O
the	O
epilepsy	O
patients	O
treated	O
with	O
carbamazepine	O
monotherapy	O
.	O

Cramps	O
in	O
extrapyramidal	O
disorders	O
.	O

Interestingly	O
,	O
the	O
similarities	O
with	O
the	O
endophilin	B-GENE
proteins	I-GENE
cover	O
the	O
entire	O
sequence	O
of	O
the	O
SH3GLB	B-GENE
family	I-GENE
,	O
suggesting	O
a	O
common	O
fold	O
and	O
presumably	O
a	O
common	O
mode	O
of	O
action	O
.	O

Each	O
of	O
these	O
spliced	O
mRNAs	O
has	O
an	O
untranslated	O
leader	O
sequence	O
of	O
249	O
bases	O
and	O
a	O
single	O
intron	O
of	O
approximately	O
540	O
bases	O
which	O
are	O
contained	O
entirely	O
within	O
TRs	O
/	O
IRs	O
sequences	O
.	O

We	O
previously	O
described	O
the	O
purification	O
of	O
an	O
83	B-GENE
-	I-GENE
kDa	I-GENE
phosphatidic	I-GENE
acid	I-GENE
phosphatase	I-GENE
(	O
PAP	B-GENE
)	O
from	O
the	O
porcine	O
thymus	O
membranes	O
(	O
Kanoh	O
,	O
H	O
.	O
,	O
Imai	O
,	O
S	O
.	O
-	O
i	O
.	O
,	O
Yamada	O
,	O
K	O
.	O
and	O
Sakane	O
,	O
F	O
.	O
(	O
1992	O
)	O
J	O
.	O

Tilmicosin	O
is	O
a	O
novel	O
macrolide	O
antibiotic	O
developed	O
for	O
exclusive	O
use	O
in	O
veterinary	O
medicine	O
.	O

TSC1	B-GENE
mutations	I-GENE
include	O
two	O
nonsense	O
mutations	O
,	O
four	O
insertions	O
,	O
and	O
three	O
splice	O
mutations	O
.	O

We	O
have	O
now	O
tested	O
all	O
known	O
mammalian	B-GENE
Groucho	I-GENE
family	I-GENE
members	I-GENE
for	O
their	O
ability	O
to	O
interact	O
specifically	O
with	O
individual	O
Tcf	B-GENE
/	I-GENE
Lef	I-GENE
family	I-GENE
members	I-GENE
.	O

Fenfluramine	O
(	O
in	O
doses	O
ranging	O
from	O
0	O
.	O
0625	O
-	O
4	O
.	O
0	O
mg	O
/	O
kg	O
/	O
infusion	O
)	O
did	O
not	O
maintain	O
self	O
-	O
administration	O
behavior	O
at	O
or	O
above	O
the	O
minimum	O
requirement	O
(	O
FR	O
30	O
)	O
.	O

No	O
difference	O
in	O
telomere	O
length	O
was	O
seen	O
in	O
mutants	O
affected	O
in	O
the	O
regulation	O
of	O
Cdc2	B-GENE
,	O
whereas	O
some	O
of	O
the	O
DNA	O
repair	O
mutants	O
examined	O
had	O
slightly	O
longer	O
telomeres	O
than	O
did	O
the	O
wild	O
type	O
.	O

Using	O
an	O
opsonophagocytic	O
bacterial	O
assay	O
and	O
a	O
suckling	O
rat	O
model	O
of	O
GBS	O
sepsis	O
,	O
we	O
analyzed	O
a	O
modified	O
human	B-GENE
immunoglobulin	I-GENE
for	O
opsonic	O
and	O
protective	O
antibody	O
.	O

Near	O
term	O
,	O
under	O
experimental	O
conditions	O
,	O
maternal	O
and	O
fetal	O
blood	O
gases	O
,	O
pH	O
,	O
uterine	O
and	O
umbilical	O
blood	O
flows	O
were	O
measured	O
or	O
calculated	O
.	O

Translation	O
of	O
the	O
coding	O
segment	O
,	O
which	O
was	O
designated	O
MsPRP2	B-GENE
,	O
suggested	O
it	O
encodes	O
a	O
chimeric	O
40	O
,	O
569	O
Da	O
cell	O
wall	O
protein	O
with	O
an	O
amino	O
-	O
terminal	O
signal	O
sequence	O
,	O
a	O
repetitive	O
proline	O
-	O
rich	O
sequence	O
,	O
and	O
a	O
cysteine	O
-	O
rich	O
carboxyl	O
-	O
terminal	O
sequence	O
homologous	O
to	O
nonspecific	O
lipid	O
transfer	O
proteins	O
.	O

Cloning	O
,	O
expression	O
,	O
and	O
nucleotide	O
sequence	O
of	O
rat	B-GENE
liver	I-GENE
sterol	I-GENE
carrier	I-GENE
protein	I-GENE
2	I-GENE
cDNAs	I-GENE
.	O

Just	O
before	O
inserting	O
on	O
the	O
anterior	O
margin	O
and	O
apex	O
of	O
the	O
iliac	O
crest	O
it	O
widens	O
,	O
assuming	O
the	O
aspect	O
of	O
a	O
small	O
cone	O
.	O

Integrated	O
mapping	O
analysis	O
of	O
the	O
Werner	B-GENE
syndrome	I-GENE
region	I-GENE
of	O
chromosome	O
8	O
.	O

The	O
cis	O
-	O
acting	O
regulatory	O
properties	O
of	O
an	O
872	O
bp	O
promoter	O
fragment	O
of	O
a	O
B	O
.	O
napus	O
oleosin	B-GENE
gene	I-GENE
were	O
examined	O
by	O
analysis	O
of	O
beta	B-GENE
-	I-GENE
glucuronidase	I-GENE
(	O
GUS	B-GENE
)	O
expression	O
in	O
transgenic	O
tobacco	O
plants	O
containing	O
an	O
oleosin	B-GENE
promoter	I-GENE
-	I-GENE
GUS	I-GENE
transcriptional	I-GENE
fusion	I-GENE
.	O

Plasma	O
DHE	O
concentration	O
rose	O
promptly	O
above	O
5	O
ng	O
/	O
ml	O
after	O
the	O
application	O
of	O
the	O
PSA	O
tape	O
onto	O
the	O
damaged	O
skin	O
in	O
hairless	O
rat	O
.	O

39	O
-	O
47	O
.	O

In	O
the	O
first	O
group	O
,	O
0	O
.	O
02	O
%	O
Prazosin	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
was	O
administered	O
intravenously	O
for	O
1	O
.	O
5	O
hours	O
before	O
the	O
application	O
of	O
Oxy	O
-	O
Hb	O
or	O
PGF2	B-GENE
alpha	I-GENE
.	O

Based	O
on	O
previous	O
mapping	O
of	O
the	O
G	B-GENE
beta	I-GENE
gamma	I-GENE
binding	I-GENE
region	I-GENE
of	O
beta	B-GENE
ARK	I-GENE
,	O
and	O
conserved	O
residues	O
within	O
the	O
PH	B-GENE
domain	I-GENE
,	O
we	O
have	O
constructed	O
a	O
series	O
of	O
mutants	O
in	O
the	O
carboxyl	O
terminus	O
of	O
beta	B-GENE
ARK	I-GENE
in	O
order	O
to	O
determine	O
important	O
residues	O
involved	O
in	O
G	B-GENE
beta	I-GENE
gamma	I-GENE
and	O
PIP2	O
binding	O
.	O

Altogether	O
,	O
the	O
results	O
demonstrate	O
that	O
the	O
two	O
isoforms	O
elicit	O
similar	O
responses	O
in	O
vivo	O
despite	O
differences	O
in	O
their	O
regulation	O
.	O

An	O
InlC	B-GENE
deletion	I-GENE
mutant	I-GENE
shows	O
reduced	O
virulence	O
when	O
tested	O
in	O
an	O
intravenous	O
mouse	O
model	O
,	O
but	O
intracellular	O
replication	O
of	O
the	O
mutant	O
in	O
Caco	O
-	O
2	O
and	O
J774	O
cells	O
appears	O
to	O
be	O
comparable	O
with	O
that	O
of	O
the	O
wild	O
-	O
type	O
strain	O
.	O

Zinc	O
fingers	O
(	O
Zf	O
)	O
are	O
a	O
common	O
structural	O
motif	O
found	O
in	O
many	O
nucleic	O
acid	O
-	O
binding	O
proteins	O
.	O

When	O
normalized	O
for	O
imaging	O
time	O
,	O
all	O
parameters	O
are	O
significantly	O
higher	O
with	O
RASE	O
,	O
with	O
a	O
C	O
/	O
A	O
per	O
unit	O
time	O
that	O
was	O
338	O
%	O
higher	O
.	O

The	O
levels	O
of	O
NPY	B-GENE
-	I-GENE
ir	I-GENE
in	O
the	O
rat	O
vas	O
deferens	O
were	O
not	O
affected	O
by	O
either	O
surgical	O
or	O
pharmacological	O
treatment	O
.	O

Gimpl	O
,	O
F	O
.	O

A	O
transparent	O
overlay	O
for	O
assessing	O
amplitude	O
of	O
ECG	O
wave	O
forms	O
.	O

Mono	O
-	O
ADP	O
-	O
ribosylation	O
is	O
a	O
reversible	O
modification	O
of	O
proteins	O
,	O
with	O
NAD	O
:	O
arginine	B-GENE
ADP	I-GENE
-	I-GENE
ribosyltransferases	I-GENE
(	O
EC	B-GENE
2	I-GENE
.	I-GENE
4	I-GENE
.	I-GENE
2	I-GENE
.	I-GENE
31	I-GENE
)	O
and	O
ADP	B-GENE
-	I-GENE
ribosylarginine	I-GENE
hydrolases	I-GENE
(	O
EC	B-GENE
3	I-GENE
.	I-GENE
2	I-GENE
.	I-GENE
2	I-GENE
.	I-GENE
19	I-GENE
)	O
catalyzing	O
the	O
opposing	O
reactions	O
in	O
an	O
ADP	O
-	O
ribosylation	O
cycle	O
.	O

A	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
in	O
exon	O
2	O
,	O
which	O
is	O
tightly	O
liked	O
to	O
another	O
SNP	O
(	O
GTG83	O
/	O
ATG83	O
)	O
,	O
creates	O
an	O
additional	O
alternative	O
in	O
-	O
frame	O
AUG	O
in	O
B	B-GENE
-	I-GENE
type	I-GENE
MTH1	I-GENE
mRNAs	I-GENE
yielding	O
the	O
fourth	O
MTH1	B-GENE
polypeptide	I-GENE
,	O
p26	B-GENE
that	O
possesses	O
an	O
additional	O
mitochondrial	O
targeting	O
signal	O
.	O

Ovulation	O
was	O
induced	O
in	O
8	O
(	O
56	O
.	O
7	O
%	O
)	O
patients	O
who	O
conceived	O
.	O

In	O
contrast	O
,	O
despite	O
external	O
radiation	O
therapy	O
,	O
brain	O
metastases	O
proved	O
fatal	O
.	O

As	O
determined	O
in	O
a	O
modified	O
yeast	O
two	O
-	O
hybrid	O
system	O
,	O
mIRS3	B-GENE
bound	O
strongly	O
to	O
the	O
p85	B-GENE
subunit	I-GENE
of	O
phosphatidylinositol	B-GENE
3	I-GENE
-	I-GENE
kinase	I-GENE
.	O

Analysis	O
of	O
liver	O
biopsy	O
specimens	O
from	O
patients	O
with	O
hepatitis	O
showed	O
a	O
large	O
variation	O
in	O
the	O
mean	O
iron	O
content	O
of	O
the	O
liver	O
ferritin	B-GENE
molecules	O
.	O

Electrical	O
activity	O
was	O
evaluated	O
by	O
monitoring	O
the	O
general	O
electrocorticogram	O
(	O
ECoG	O
)	O
as	O
well	O
as	O
local	O
DC	O
steady	O
potential	O
(	O
two	O
sites	O
)	O
.	O

The	O
antigen	B-GENE
-	I-GENE
specific	I-GENE
IgG4	I-GENE
antibody	I-GENE
seems	O
to	O
be	O
an	O
index	O
in	O
evaluating	O
immunotherapy	O
objectively	O
.	O

BACKGROUND	O
:	O
The	O
c	B-GENE
-	I-GENE
myc	I-GENE
proto	I-GENE
-	I-GENE
oncogene	I-GENE
has	O
been	O
suggested	O
to	O
play	O
key	O
roles	O
in	O
cell	O
proliferation	O
,	O
differentiation	O
,	O
transformation	O
and	O
apoptosis	O
.	O

Simultaneous	O
,	O
bilateral	O
and	O
permanent	O
ventilation	O
with	O
a	O
diaphragm	O
pacing	O
in	O
childhood	O
:	O
the	O
implantation	O
technique	O
and	O
indications	O
.	O

T7	O
transcription	O
could	O
be	O
manipulated	O
to	O
achieve	O
different	O
levels	O
of	O
constitutive	O
expression	O
,	O
through	O
the	O
use	O
of	O
promoter	O
mutations	O
.	O

Interferon	B-GENE
beta	I-GENE
therapy	O
was	O
discontinued	O
for	O
4	O
weeks	O
.	O

Deletion	O
analysis	O
indicates	O
that	O
TBP	B-GENE
and	O
hTAFII18	B-GENE
bind	O
to	O
distinct	O
domains	O
of	O
hTAFII28	B-GENE
.	O
hTAFII18	B-GENE
also	O
interacts	O
with	O
TBP	B-GENE
,	O
but	O
it	O
interacts	O
more	O
strongly	O
with	O
hTAFII28	B-GENE
and	O
hTAFII30	B-GENE
.	O

The	O
coding	O
region	O
of	O
mkh1	B-GENE
is	O
contained	O
within	O
a	O
single	O
exon	O
encoding	O
a	O
1	O
,	O
116	O
-	O
amino	O
-	O
acid	O
protein	O
.	O

The	O
outer	O
diameter	O
and	O
the	O
thickness	O
of	O
the	O
rotor	O
are	O
60	O
mm	O
and	O
8	O
mm	O
,	O
respectively	O
.	O

Clinical	O
research	O
of	O
non	O
-	O
A	O
,	O
non	O
-	O
B	O
post	O
-	O
transfusion	O
hepatitis	O
.	O

The	O
highest	O
postoperative	O
CK	B-GENE
-	I-GENE
MB	I-GENE
level	O
was	O
less	O
after	O
BC	O
(	O
BC	O
,	O
31	O
+	O
/	O
-	O
17	O
U	O
/	O
L	O
;	O
CC	O
,	O
56	O
+	O
/	O
-	O
13	O
U	O
/	O
L	O
;	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
current	O
study	O
defines	O
the	O
vinculin	B-GENE
-	I-GENE
and	O
FAK	B-GENE
-	I-GENE
interaction	I-GENE
domains	I-GENE
on	O
paxillin	B-GENE
and	O
identifies	O
the	O
principal	O
paxillin	B-GENE
focal	B-GENE
adhesion	I-GENE
targeting	I-GENE
motif	I-GENE
.	O

In	O
44	O
evaluable	O
patients	O
the	O
response	O
rate	O
was	O
50	O
%	O
,	O
with	O
one	O
complete	O
response	O
.	O

The	O
effect	O
of	O
treatment	O
may	O
thus	O
be	O
divided	O
into	O
two	O
main	O
phases	O
-	O
-	O
an	O
initial	O
phase	O
with	O
a	O
reduction	O
in	O
LV	O
mass	O
and	O
a	O
reduction	O
in	O
cardiac	O
output	O
and	O
no	O
change	O
in	O
total	O
peripheral	O
resistance	O
-	O
-	O
and	O
a	O
second	O
phase	O
with	O
a	O
constant	O
LV	O
mass	O
but	O
an	O
increase	O
in	O
cardiac	O
output	O
to	O
the	O
pretreatment	O
level	O
again	O
and	O
a	O
concomitant	O
decrease	O
in	O
total	O
peripheral	O
resistance	O
.	O

NF	B-GENE
-	I-GENE
kappaB	I-GENE
,	O
which	O
is	O
probably	O
important	O
for	O
basal	O
activity	O
of	O
the	O
human	B-GENE
NOS	I-GENE
II	I-GENE
promoter	I-GENE
,	O
is	O
unlikely	O
to	O
function	O
as	O
a	O
major	O
effector	O
of	O
CM	O
in	O
DLD	O
-	O
1	O
cells	O
.	O

A	O
false	O
positive	O
marker	O
screen	O
was	O
associated	O
with	O
the	O
occurrence	O
of	O
hand	O
-	O
foot	O
syndrome	O
even	O
when	O
the	O
effect	O
of	O
regimen	O
was	O
accounted	O
for	O
by	O
stratification	O
(	O
p	O
=	O
.	O
01	O
)	O
.	O

With	O
the	O
exception	O
of	O
virus	O
assay	O
and	O
quantitation	O
,	O
these	O
methods	O
are	O
simple	O
and	O
inexpensive	O
enough	O
to	O
be	O
done	O
in	O
typical	O
shellfish	O
microbiology	O
laboratories	O
.	O

Pulmonary	O
vascular	O
resistance	O
was	O
not	O
altered	O
,	O
ejection	O
fraction	O
remained	O
unchanged	O
and	O
isovolumic	O
relaxation	O
period	O
was	O
lengthened	O
(	O
119	O
+	O
/	O
-	O
20	O
.	O
1	O
to	O
147	O
.	O
39	O
+	O
/	O
-	O
21	O
.	O
15	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Presently	O
four	O
unique	O
variants	O
carrying	O
distinct	O
GAF	B-GENE
sequences	I-GENE
in	O
the	O
N	O
-	O
terminal	O
region	O
have	O
been	O
identified	O
.	O

Through	O
a	O
stretch	O
of	O
56	O
amino	O
acids	O
,	O
constituting	O
the	O
MADS	B-GENE
domain	I-GENE
,	O
the	O
two	O
proteins	O
are	O
identical	O
except	O
for	O
two	O
conservative	O
amino	O
acid	O
substitutions	O
.	O

The	O
ability	O
of	O
SMRT	B-GENE
to	O
associate	O
with	O
these	O
transcription	O
factors	O
and	O
thereby	O
to	O
mediate	O
repression	O
is	O
strongly	O
inhibited	O
by	O
activation	O
of	O
tyrosine	B-GENE
kinase	I-GENE
signaling	O
pathways	O
,	O
such	O
as	O
that	O
represented	O
by	O
the	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
.	O

Finally	O
,	O
we	O
determined	O
that	O
the	O
P68	B-GENE
amino	O
terminus	O
was	O
both	O
necessary	O
and	O
sufficient	O
for	O
binding	O
dsRNA	O
as	O
we	O
were	O
able	O
to	O
transfer	O
dsRNA	O
-	O
binding	O
properties	O
to	O
a	O
reporter	O
gene	O
product	O
previously	O
unable	O
to	O
bind	O
RNA	O
.	O

METHODS	O
:	O
A	O
total	O
of	O
15	O
pigs	O
were	O
randomised	O
to	O
ligation	O
of	O
left	O
marginal	O
arteries	O
(	O
infarction	O
group	O
,	O
n	O
=	O
5	O
)	O
,	O
to	O
TMLR	O
of	O
the	O
left	O
lateral	O
wall	O
using	O
a	O
holmium	O
:	O
yttrium	O
-	O
aluminium	O
garnet	O
(	O
Ho	O
:	O
YAG	O
)	O
laser	O
(	O
laser	O
group	O
,	O
n	O
=	O
5	O
)	O
,	O
and	O
to	O
both	O
(	O
laser	O
-	O
infarction	O
group	O
,	O
n	O
=	O
5	O
)	O
.	O

Moreover	O
,	O
promoters	O
containing	O
a	O
TATA	O
box	O
in	O
the	O
absence	O
of	O
Sp1	B-GENE
sites	I-GENE
or	O
Sp1	B-GENE
sites	I-GENE
in	O
the	O
absence	O
of	O
a	O
TATA	O
box	O
were	O
equally	O
inducible	O
in	O
vitro	O
,	O
as	O
was	O
an	O
RNA	B-GENE
polymerase	I-GENE
III	I-GENE
promoter	I-GENE
.	O

Further	O
research	O
is	O
recommended	O
to	O
identify	O
the	O
coping	O
styles	O
associated	O
with	O
the	O
high	O
EE	O
/	O
low	O
EE	O
research	O
classification	O
.	O

Curiously	O
,	O
testololactone	O
was	O
earlier	O
and	O
more	O
widely	O
used	O
than	O
aminoglutethimide	O
in	O
treating	O
advanced	O
breast	O
carcinoma	O
.	O

Responses	O
to	O
the	O
Plowright	O
Rinderpest	O
vaccine	O
by	O
43	O
calves	O
and	O
70	O
adult	O
cattle	O
in	O
Uganda	O
in	O
1990	O
,	O
through	O
the	O
production	O
of	O
IgG	B-GENE
antibodies	I-GENE
,	O
were	O
monitored	O
for	O
4	O
weeks	O
using	O
the	O
ELISA	O
assay	O
.	O

Fifty	O
-	O
one	O
patients	O
with	O
primary	O
refractory	O
or	O
relapsed	O
malignant	O
lymphoma	O
(	O
47	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
and	O
four	O
Hodgkin	O
'	O
s	O
disease	O
)	O
were	O
treated	O
with	O
a	O
new	O
chemotherapeutic	O
regimen	O
(	O
cisplatinum	O
,	O
methyl	O
GAG	O
,	O
bleomocyin	O
,	O
methyl	O
prednisolon	O
)	O
.	O

In	O
addition	O
,	O
marked	O
hypertension	O
accompanied	O
this	O
disorder	O
and	O
all	O
abnormalities	O
,	O
including	O
the	O
hypertension	O
,	O
responded	O
to	O
1	B-GENE
-	I-GENE
desamino	I-GENE
-	I-GENE
8	I-GENE
-	I-GENE
D	I-GENE
-	I-GENE
arginine	I-GENE
vasopressin	I-GENE
therapy	O
.	O

These	O
two	O
contigs	O
contain	O
a	O
total	O
of	O
163	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
in	O
26	O
-	O
29	O
putative	O
operons	O
;	O
56	O
ORFs	O
could	O
be	O
identified	O
with	O
reasonable	O
certainty	O
.	O

Toxicity	O
was	O
significant	O
in	O
selected	O
cases	O
;	O
three	O
patients	O
developed	O
WBC	O
counts	O
less	O
than	O
1	O
,	O
000	O
/	O
mm3	O
and	O
one	O
of	O
these	O
patients	O
died	O
with	O
sepsis	O
.	O

Over	O
-	O
expression	O
of	O
the	O
cofactor	O
p300	B-GENE
,	O
which	O
functions	O
as	O
a	O
coactivator	O
of	O
myoD	O
-	O
mediated	O
transcription	O
,	O
alleviated	O
repression	O
by	O
COUP	B-GENE
-	I-GENE
TF	I-GENE
II	I-GENE
.	O

Interaction	O
of	O
the	O
Fur	B-GENE
repressor	I-GENE
with	O
a	O
150	O
-	O
bp	O
fragment	O
encompassing	O
the	O
pvdS	B-GENE
promoter	I-GENE
was	O
demonstrated	O
in	O
vivo	O
by	O
the	O
Fur	B-GENE
titration	O
assay	O
and	O
confirmed	O
in	O
vitro	O
by	O
gel	O
retardation	O
experiments	O
with	O
a	O
partially	O
purified	O
Fur	B-GENE
preparation	O
.	O

The	O
selective	O
5	B-GENE
-	I-GENE
HT3	I-GENE
receptor	I-GENE
antagonists	O
ramosetron	O
(	O
YM060	O
)	O
,	O
YM114	O
(	O
KAE	O
-	O
393	O
)	O
,	O
granisetron	O
and	O
ondansetron	O
,	O
and	O
the	O
substituted	O
benzamides	O
(	O
5	B-GENE
-	I-GENE
HT4	I-GENE
receptor	I-GENE
agonist	O
/	O
5	O
-	O
HT3	O
receptor	O
antagonists	O
)	O
cisapride	O
mosapride	O
and	O
SC	O
-	O
53116	O
dose	O
-	O
dependently	O
enhanced	O
gastric	O
emptying	O
in	O
normal	O
rats	O
.	O

IFN	B-GENE
alpha	I-GENE
and	O
IFN	B-GENE
gamma	I-GENE
inducibility	O
is	O
mediated	O
by	O
a	O
single	O
element	O
:	O
a	O
high	O
affinity	O
,	O
nearly	O
palindromic	O
version	O
of	O
the	O
IFN	B-GENE
gamma	I-GENE
activation	I-GENE
site	I-GENE
(	O
GAS	B-GENE
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
characterized	O
cis	O
-	O
elements	O
of	O
the	O
human	B-GENE
PCI	I-GENE
gene	I-GENE
required	O
for	O
expression	O
in	O
the	O
hepatoma	O
-	O
derived	O
cell	O
line	O
,	O
HepG2	O
cells	O
,	O
and	O
also	O
evaluated	O
rat	B-GENE
PCI	I-GENE
mRNA	I-GENE
expression	O
,	O
particularly	O
on	O
the	O
effect	O
of	O
androgen	O
in	O
rat	O
reproductive	O
tissues	O
.	O

The	O
transcription	B-GENE
factor	I-GENE
CHOP	I-GENE
(	O
C	B-GENE
/	I-GENE
EBP	I-GENE
homologous	I-GENE
protein	I-GENE
10	I-GENE
)	O
is	O
a	O
bZIP	B-GENE
protein	I-GENE
induced	O
by	O
a	O
variety	O
of	O
stimuli	O
that	O
evoke	O
cellular	O
stress	O
responses	O
and	O
has	O
been	O
shown	O
to	O
arrest	O
cell	O
growth	O
and	O
to	O
promote	O
programmed	O
cell	O
death	O
.	O

All	O
ribosomal	B-GENE
protein	I-GENE
(	O
rp	B-GENE
)	O
gene	O
promoters	O
from	O
Saccharomyces	O
cerevisiae	O
studied	O
so	O
far	O
contain	O
either	O
(	O
usually	O
two	O
)	O
binding	O
sites	O
for	O
the	O
global	O
gene	O
regulator	O
Rap1p	B-GENE
or	O
one	O
binding	O
site	O
for	O
another	O
global	O
factor	O
,	O
Abf1p	B-GENE
.	O

Therefore	O
,	O
this	O
study	O
has	O
demonstrated	O
that	O
prenatal	O
disturbance	O
can	O
induce	O
a	O
lasting	O
change	O
in	O
cytokine	O
biology	O
,	O
which	O
persists	O
well	O
beyond	O
the	O
fetal	O
and	O
infant	O
stage	O
.	O

Seventeen	O
of	O
them	O
were	O
on	O
treatment	O
with	O
systemic	O
steroids	O
.	O

In	O
contrast	O
,	O
c	B-GENE
-	I-GENE
Src	I-GENE
activated	O
by	O
isoproterenol	O
led	O
to	O
tyrosine	O
phosphorylation	O
of	O
Shc	B-GENE
and	O
subsequent	O
Erk	B-GENE
activation	O
,	O
but	O
not	O
tyrosine	O
phosphorylation	O
of	O
cortactin	B-GENE
or	O
Stat3	B-GENE
.	O

Identity	O
of	O
GABP	B-GENE
with	O
NRF	B-GENE
-	I-GENE
2	I-GENE
,	O
a	O
multisubunit	O
activator	O
of	O
cytochrome	B-GENE
oxidase	I-GENE
expression	O
,	O
reveals	O
a	O
cellular	O
role	O
for	O
an	O
ETS	B-GENE
domain	I-GENE
activator	O
of	O
viral	O
promoters	O
.	O

Thus	O
it	O
appears	O
that	O
the	O
management	O
of	O
blood	O
,	O
including	O
washing	O
is	O
of	O
great	O
importance	O
.	O

In	O
order	O
to	O
investigate	O
the	O
blood	O
compatibility	O
of	O
autogenous	O
vein	O
graft	O
(	O
AVG	O
)	O
,	O
changes	O
in	O
prostacyclin	O
(	O
PGI2	O
)	O
production	O
following	O
harvesting	O
and	O
arterial	O
implantation	O
were	O
studied	O
experimentally	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
:	O
Associations	O
of	O
factor	O
analysis	O
-	O
derived	O
syndromes	O
with	O
risk	O
factors	O
for	O
chemical	O
interactions	O
that	O
inhibit	O
butyrylcholinesterase	B-GENE
and	O
neuropathy	O
target	O
esterase	B-GENE
.	O

State	O
of	O
the	O
body	O
in	O
disorders	O
of	O
diurnal	O
physiological	O
rhythms	O
and	O
long	O
-	O
term	O
hypokinesia	O
.	O

OsBBPI	B-GENE
was	O
found	O
to	O
be	O
rapidly	O
induced	O
in	O
rice	O
seedling	O
leaf	O
in	O
response	O
to	O
cut	B-GENE
,	O
exogenous	O
jasmonic	O
acid	O
(	O
JA	O
)	O
,	O
and	O
two	O
potent	O
protein	B-GENE
phosphatase	I-GENE
2A	I-GENE
(	O
PP2A	B-GENE
)	O
inhibitors	O
,	O
cantharidin	O
(	O
CN	O
)	O
and	O
endothall	O
(	O
EN	O
)	O
,	O
in	O
a	O
light	O
/	O
dark	O
-	O
,	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
manner	O
;	O
this	O
induction	O
was	O
completely	O
inhibited	O
by	O
cycloheximide	O
(	O
CHX	O
)	O
,	O
indicating	O
a	O
requirement	O
for	O
de	O
novo	O
protein	O
synthesis	O
in	O
its	O
induction	O
.	O

Moreover	O
,	O
a	O
high	O
proportion	O
of	O
blood	O
samples	O
from	O
a	O
random	O
sample	O
of	O
the	O
rest	O
of	O
the	O
suspects	O
tested	O
positive	O
for	O
trypanosome	O
-	O
specific	O
DNA	O
by	O
PCR	O
(	O
79	O
.	O
9	O
%	O
for	O
T	O
.	O
b	O
.	O
gambiense	O
and	O
13	O
.	O
9	O
%	O
for	O
T	O
.	O
b	O
.	O
rhodesiense	O
)	O
.	O

Mutations	O
in	O
the	O
small	O
subunit	O
of	O
ribulosebisphosphate	B-GENE
carboxylase	I-GENE
affect	O
subunit	O
binding	O
and	O
catalysis	O
.	O

Increased	O
dietary	O
energy	O
decreased	O
PAB	O
and	O
the	O
use	O
of	O
added	O
dietary	O
CO	O
rather	O
than	O
PF	O
decreased	O
PSHL	O
in	O
broiler	O
breeders	O
between	O
26	O
and	O
47	O
wk	O
of	O
age	O
.	O

Our	O
data	O
showed	O
that	O
activation	O
of	O
the	O
raf	B-GENE
-	I-GENE
ERK	I-GENE
pathway	O
led	O
to	O
activation	O
of	O
TF	B-GENE
expression	O
in	O
breast	O
carcinoma	O
cells	O
and	O
suggested	O
that	O
constitutive	O
activation	O
of	O
this	O
pathway	O
leads	O
to	O
high	O
TF	B-GENE
expression	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
.	O

As	O
expected	O
,	O
homologous	B-GENE
loxP	I-GENE
sequences	I-GENE
efficiently	O
underwent	O
Cre	O
-	O
mediated	O
recombination	O
.	O

IL	B-GENE
-	I-GENE
1beta	I-GENE
was	O
significantly	O
higher	O
in	O
endometrioma	O
than	O
in	O
lesions	O
of	O
other	O
localizations	O
.	O

Evolution	O
of	O
lesions	O
did	O
not	O
necessarily	O
follow	O
a	O
regular	O
progression	O
through	O
the	O
later	O
stages	O
of	O
the	O
vitelliform	O
classification	O
.	O

To	O
get	O
further	O
insights	O
into	O
the	O
molecular	O
mechanisms	O
that	O
control	O
tal	B-GENE
-	I-GENE
1	I-GENE
expression	O
,	O
we	O
have	O
isolated	O
5	O
'	O
sequences	O
of	O
the	O
murine	O
gene	O
and	O
compared	O
them	O
to	O
their	O
human	O
counterparts	O
.	O

Serum	O
antibody	O
titre	O
was	O
not	O
significantly	O
associated	O
with	O
the	O
recurrence	O
rate	O
or	O
the	O
duration	O
of	O
infection	O
.	O

A	O
series	O
of	O
5	O
'	O
-	O
deletions	O
revealed	O
that	O
the	O
fragment	O
-	O
218	O
to	O
+	O
4	O
from	O
the	O
TSS	O
had	O
the	O
highest	O
promoter	O
activity	O
,	O
nearly	O
1000	O
-	O
fold	O
greater	O
than	O
the	O
promoterless	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
construct	I-GENE
.	O

Areas	O
with	O
significantly	O
greater	O
rCBF	O
for	O
targeting	O
were	O
the	O
left	O
motor	O
cortex	O
,	O
left	O
intraparietal	O
sulcus	O
,	O
and	O
left	O
caudate	O
.	O

A	O
v	B-GENE
-	I-GENE
erbB	I-GENE
-	I-GENE
related	I-GENE
protooncogene	I-GENE
,	O
c	B-GENE
-	I-GENE
erbB	I-GENE
-	I-GENE
2	I-GENE
,	O
is	O
distinct	O
from	O
the	O
c	B-GENE
-	I-GENE
erbB	I-GENE
-	I-GENE
1	I-GENE
/	I-GENE
epidermal	I-GENE
growth	I-GENE
factor	I-GENE
-	I-GENE
receptor	I-GENE
gene	I-GENE
and	O
is	O
amplified	O
in	O
a	O
human	O
salivary	O
gland	O
adenocarcinoma	O
.	O

Finally	O
,	O
using	O
in	O
vitro	O
binding	O
studies	O
,	O
we	O
showed	O
that	O
SREBP2	B-GENE
was	O
able	O
to	O
displace	O
ADD1	B-GENE
/	I-GENE
SREBP1	I-GENE
binding	O
from	O
the	O
sterol	B-GENE
regulatory	I-GENE
element	I-GENE
(	O
SRE	B-GENE
)	O
site	O
.	O

Chronic	O
nutritional	O
diseases	O
of	O
infectious	O
origin	O
:	O
an	O
assessment	O
of	O
a	O
nascent	O
field	O
.	O

Isolation	O
and	O
characterization	O
of	O
the	O
rat	O
chromosomal	O
gene	O
for	O
a	O
polypeptide	O
(	O
pS1	B-GENE
)	O
antigenically	O
related	O
to	O
statin	B-GENE
.	O

Deformities	O
of	O
the	O
tip	O
of	O
the	O
olecranon	O
and	O
of	O
the	O
coronoid	O
process	O
are	O
also	O
described	O
(	O
De	O
Palma	O
1956	O
,	O
Jordan	O
1958	O
,	O
Ahlberg	O
1965	O
,	O
Weseloh	O
1973	O
)	O
.	O

Deletion	O
of	O
both	O
prfA	B-GENE
and	O
ponA	B-GENE
resulted	O
in	O
extremely	O
slow	O
growth	O
and	O
a	O
reduction	O
in	O
sporulation	O
efficiency	O
.	O

Secretion	O
of	O
interleukin	B-GENE
-	I-GENE
8	I-GENE
,	O
RANTES	B-GENE
,	O
macrophage	B-GENE
inflammatory	I-GENE
protein	I-GENE
1alpha	I-GENE
,	O
and	O
10	B-GENE
-	I-GENE
kappaDa	I-GENE
IFN	I-GENE
-	I-GENE
gamma	I-GENE
-	I-GENE
inducible	I-GENE
protein	I-GENE
were	O
increased	O
in	O
differentiating	O
keratinocytes	O
by	O
E6	B-GENE
.	O

Stimulation	O
of	O
the	O
caudate	O
nucleus	O
'	O
dophamine	O
-	O
reactive	O
system	O
in	O
dogs	O
by	O
means	O
of	O
administration	O
of	O
dophamine	O
(	O
60	O
micrograms	O
)	O
and	O
phenamine	O
led	O
to	O
deterioration	O
of	O
conditioned	O
and	O
unconditioned	O
components	O
of	O
feeding	O
behaviour	O
.	O

Binding	O
to	O
sulphatides	O
and	O
the	O
alpha	B-GENE
-	I-GENE
dystroglycan	I-GENE
receptor	I-GENE
was	O
much	O
stronger	O
and	O
required	O
at	O
least	O
two	O
LG	B-GENE
modules	I-GENE
.	O

The	O
immune	O
response	O
of	O
past	O
-	O
infection	O
of	O
cytomegalovirus	O
in	O
the	O
patients	O
of	O
RTID	O
is	O
rather	O
remarkable	O
.	O

The	O
effect	O
of	O
CBZ	O
and	O
DPH	O
can	O
be	O
explained	O
by	O
interference	O
with	O
thyroid	O
hormone	O
binding	O
to	O
TBG	B-GENE
combined	O
with	O
enzyme	O
-	O
induced	O
increased	O
metabolic	O
clearance	O
rate	O
of	O
thyroid	O
hormones	O
without	O
homeostatic	O
maintenance	O
of	O
premedication	O
levels	O
of	O
FT4	O
and	O
FT3	O
.	O

Reverse	B-GENE
transcriptase	I-GENE
and	O
protease	B-GENE
activities	O
of	O
avian	O
leukosis	O
virus	O
Gag	B-GENE
-	I-GENE
Pol	I-GENE
fusion	I-GENE
proteins	I-GENE
expressed	O
in	O
insect	O
cells	O
.	O

Erythrocytic	O
stages	O
of	O
mammalian	O
malarial	O
parasites	O
contain	O
acristate	O
mitochondria	O
whose	O
functions	O
are	O
not	O
well	O
understood	O
.	O

New	O
techniques	O
for	O
the	O
mass	O
spectrometry	O
of	O
natural	O
products	O
.	O

Thromboxane	B-GENE
B2	I-GENE
increased	O
(	O
97	O
+	O
/	O
-	O
105	O
versus	O
40	O
+	O
/	O
-	O
26	O
pg	O
/	O
ml	O
)	O
and	O
was	O
significantly	O
higher	O
during	O
heparin	O
free	O
hemodialysis	O
than	O
during	O
hemodialysis	O
with	O
heparin	O
(	O
p	O
=	O
0	O
.	O
01	O
,	O
Wilcoxon	O
matched	O
pairs	O
signed	O
rank	O
test	O
)	O
.	O

None	O
were	O
restricted	O
from	O
clinical	O
duties	O
,	O
were	O
given	O
varicella	B-GENE
-	I-GENE
zoster	I-GENE
immune	I-GENE
globulin	I-GENE
,	O
or	O
developed	O
disease	O
.	O

D	O
.	O

This	O
0	O
.	O
74	O
kb	O
cDNA	O
contains	O
an	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
of	O
477	O
bp	O
encoding	O
a	O
polypeptide	O
of	O
159	O
amino	O
acids	O
(	O
aa	O
)	O
which	O
differs	O
at	O
only	O
one	O
position	O
(	O
position	O
65	O
)	O
from	O
the	O
human	B-GENE
U1	I-GENE
-	I-GENE
C	I-GENE
protein	I-GENE
.	O

Our	O
results	O
demonstrated	O
that	O
50	O
%	O
of	O
the	O
hepatic	O
artery	O
-	O
alone	O
ALT	O
graft	O
showed	O
almost	O
normal	O
structure	O
histologically	O
at	O
1	O
month	O
after	O
grafting	O
,	O
with	O
bile	O
secretion	O
preserved	O
.	O

Human	B-GENE
bcl3	I-GENE
protein	I-GENE
specifically	O
displaces	O
(	B-GENE
p50	I-GENE
)	I-GENE
2	I-GENE
-	I-GENE
DNA	I-GENE
complexes	I-GENE
.	O

Observations	O
on	O
saccules	O
of	O
rats	O
exposed	O
to	O
long	O
-	O
term	O
hypergravity	O
.	O

Videonystagmoscopy	O
has	O
been	O
used	O
to	O
subjectively	O
observe	O
the	O
responses	O
of	O
the	O
vestibular	O
system	O
in	O
a	O
population	O
of	O
patients	O
with	O
vestibular	O
deficits	O
.	O

In	O
conclusion	O
,	O
these	O
studies	O
indicate	O
that	O
LiCl	O
(	O
1	O
)	O
decreases	O
histamine	O
-	O
stimulated	O
gastric	O
acid	O
secretion	O
,	O
and	O
(	O
2	O
)	O
diminishes	O
bile	O
-	O
induced	O
disruption	O
of	O
the	O
gastric	O
mucosal	O
barrier	O
in	O
the	O
canine	O
Heidenhain	O
pouch	O
.	O

We	O
have	O
previously	O
reported	O
that	O
high	O
level	O
human	B-GENE
desmin	I-GENE
expression	O
depends	O
on	O
a	O
280	O
-	O
base	O
pair	O
muscle	O
-	O
specific	O
enhancer	O
which	O
can	O
function	O
not	O
only	O
in	O
myotubes	O
,	O
but	O
can	O
also	O
activate	O
gene	O
expression	O
in	O
myoblasts	O
.	O

Treatment	O
of	O
human	O
myeloid	O
cell	O
lines	O
HL	O
-	O
60	O
and	O
U937	O
with	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
increased	O
within	O
2	O
h	O
cellular	O
levels	O
of	O
the	O
RNA	O
hybridizable	O
to	O
LD78	B-GENE
cDNA	I-GENE
.	O

Analysis	O
of	O
intron	O
/	O
exon	O
boundaries	O
of	O
the	O
genomic	O
BAC	O
clones	O
demonstrate	O
that	O
junctin	B-GENE
,	O
junctate	B-GENE
,	O
and	O
aspartyl	B-GENE
beta	I-GENE
-	I-GENE
hydroxylase	I-GENE
result	O
from	O
alternative	O
splicing	O
of	O
the	O
same	O
gene	O
.	O

We	O
have	O
examined	O
the	O
regulation	O
of	O
the	O
FGFR	B-GENE
-	I-GENE
1	I-GENE
gene	I-GENE
(	O
cek	B-GENE
-	I-GENE
1	I-GENE
)	O
in	O
avian	O
myogenic	O
cultures	O
by	O
immunocytochemistry	O
and	O
Northern	O
blot	O
analysis	O
.	O

A	O
low	O
aspirin	B-GENE
esterase	I-GENE
activity	O
may	O
be	O
a	O
contributory	O
factor	O
in	O
precipitating	O
these	O
aspirin	O
sensitive	O
reactions	O
.	O

On	O
the	O
character	O
of	O
changes	O
in	O
the	O
enzyme	O
activity	O
in	O
the	O
brain	O
tissue	O
during	O
reflex	O
epilepsy	O
.	O

Localized	O
fluorescence	O
was	O
detectable	O
only	O
in	O
cells	O
containing	O
a	O
visible	O
midcell	O
constriction	O
,	O
suggesting	O
that	O
FtsK	B-GENE
targeting	O
normally	O
occurs	O
only	O
at	O
a	O
late	O
stage	O
of	O
septation	O
.	O

The	O
NarX	B-GENE
and	O
NarQ	B-GENE
proteins	I-GENE
with	O
amino	O
acid	O
substitutions	O
at	O
the	O
first	O
conserved	O
histidine	O
position	O
were	O
also	O
unable	O
to	O
dephosphorylate	O
NarL	O
-	O
phosphate	O
in	O
vitro	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Chloramphenicol	B-GENE
acetyltransferase	I-GENE
assays	O
examining	O
the	O
ability	O
of	O
IE86	B-GENE
to	O
repress	O
activity	O
from	O
the	O
HCMV	O
major	O
IE	B-GENE
promoter	I-GENE
or	O
activate	O
the	O
HCMV	B-GENE
early	I-GENE
promoter	I-GENE
for	O
the	O
2	O
.	O
2	O
-	O
kb	O
class	O
of	O
RNAs	O
demonstrated	O
the	O
functional	O
integrity	O
of	O
the	O
IE86	B-GENE
protein	I-GENE
.	O

Piroximone	O
is	O
a	O
new	O
phosphodiesterase	B-GENE
III	I-GENE
inhibitor	O
that	O
combines	O
inotropic	O
and	O
vasodilator	O
properties	O
.	O

This	O
enzyme	O
is	O
designated	O
(	B-GENE
1	I-GENE
-	I-GENE
-	I-GENE
>	I-GENE
4	I-GENE
)	I-GENE
-	I-GENE
beta	I-GENE
-	I-GENE
xylan	I-GENE
endohydrolase	I-GENE
isoenzyme	I-GENE
X	I-GENE
-	I-GENE
I	I-GENE
.	O

Because	O
the	O
number	O
of	O
parameters	O
required	O
by	O
a	O
Volterra	O
series	O
grows	O
rapidly	O
with	O
both	O
the	O
length	O
of	O
its	O
memory	O
and	O
the	O
order	O
of	O
its	O
nonlinearity	O
,	O
methods	O
for	O
identifying	O
these	O
models	O
from	O
measurements	O
of	O
input	O
/	O
output	O
data	O
are	O
limited	O
to	O
low	O
-	O
order	O
systems	O
with	O
relatively	O
short	O
memories	O
.	O

In	O
macrophages	O
,	O
LPS	O
-	O
inducible	O
HIV	O
-	O
1	O
gene	O
expression	O
is	O
mediated	O
in	O
part	O
by	O
binding	O
of	O
NF	B-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
to	O
identical	O
tandem	O
binding	O
sites	O
located	O
within	O
the	O
long	B-GENE
terminal	I-GENE
repeat	I-GENE
(	O
LTR	B-GENE
)	O
.	O

Both	O
normal	O
and	O
transforming	O
PCPH	B-GENE
proteins	I-GENE
have	O
guanosine	B-GENE
diphosphatase	I-GENE
activity	O
but	O
only	O
the	O
oncoprotein	O
cooperates	O
with	O
Ras	B-GENE
in	O
activating	O
extracellular	B-GENE
signal	I-GENE
-	I-GENE
regulated	I-GENE
kinase	I-GENE
ERK1	B-GENE
.	O

New	O
Langevin	O
equations	O
for	O
a	O
translating	O
and	O
simultaneously	O
rotating	O
asymmetric	O
top	O
.	O

The	O
early	O
dg	O
.	O
of	O
rejection	O
and	O
especially	O
acute	O
rejection	O
,	O
it	O
'	O
s	O
adequate	O
management	O
,	O
decreased	O
risk	O
for	O
the	O
future	O
chronic	O
rejection	O
nephropathy	O
.	O

Improvement	O
of	O
the	O
CRT	O
display	O
of	O
an	O
averager	O
.	O

The	O
half	O
-	O
life	O
of	O
the	O
serum	O
-	O
induced	O
CBP	B-GENE
/	I-GENE
tk	I-GENE
binding	O
activity	O
was	O
estimated	O
to	O
be	O
less	O
than	O
1	O
h	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Seventy	O
-	O
two	O
of	O
73	O
negative	O
controls	O
and	O
all	O
positive	O
blocks	O
as	O
seen	O
on	O
soft	O
tissue	O
radiographs	O
(	O
STRs	O
)	O
were	O
correctly	O
coded	O
(	O
specificity	O
98	O
.	O
6	O
%	O
,	O
sensitivity	O
100	O
%	O
)	O
.	O

The	O
method	O
requires	O
a	O
reversed	O
-	O
phase	O
column	O
and	O
a	O
paired	O
-	O
ion	O
technique	O
to	O
separate	O
docusate	O
sodium	O
from	O
other	O
components	O
.	O

This	O
study	O
was	O
aimed	O
at	O
assessing	O
whether	O
c	O
-	O
DDP	O
administration	O
immediately	O
before	O
radiotherapy	O
could	O
increase	O
frequency	O
and	O
duration	O
of	O
objective	O
responses	O
,	O
as	O
well	O
as	O
survival	O
,	O
in	O
patients	O
affected	O
with	O
locally	O
advanced	O
stages	O
of	O
squamous	O
carcinomas	O
of	O
the	O
head	O
and	O
neck	O
.	O

Chem	O
.	O

In	O
contrast	O
,	O
in	O
LL	O
patients	O
during	O
ENL	O
the	O
ConA	O
-	O
induced	O
suppressor	O
response	O
was	O
markedly	O
reduced	O
.	O

In	O
contrast	O
,	O
cotransfection	O
of	O
TFIIB	B-GENE
and	O
IRF	B-GENE
-	I-GENE
1	I-GENE
into	O
NIH	O
3T3	O
cells	O
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
repression	O
of	O
promoter	O
activation	O
which	O
occurred	O
in	O
a	O
TATA	O
-	O
dependent	O
manner	O
.	O

Fetal	O
lung	O
volume	O
:	O
estimation	O
at	O
MR	O
imaging	O
-	O
initial	O
results	O
.	O

It	O
contains	O
three	O
putative	O
binding	O
sites	O
for	O
transcription	B-GENE
factor	I-GENE
Sp1	I-GENE
as	O
well	O
as	O
several	O
short	O
sequences	O
that	O
are	O
similar	O
to	O
known	O
cis	O
-	O
acting	O
enhancers	O
or	O
binding	O
sites	O
for	O
transcription	O
factors	O
.	O

Thus	O
,	O
the	O
system	O
can	O
be	O
used	O
to	O
detect	O
and	O
study	O
dynamic	O
perfusion	O
changes	O
from	O
the	O
brain	O
surface	O
with	O
minimal	O
tissue	O
damage	O
.	O

No	O
'	O
TATA	O
'	O
motif	O
was	O
identified	O
near	O
either	O
the	O
GABPalpha	B-GENE
or	O
ATPsynCF6	B-GENE
transcription	O
start	O
sites	O
.	O

Addition	O
of	O
soluble	O
recombinant	B-GENE
human	I-GENE
SLF	I-GENE
to	O
SI4	O
-	O
h220	O
cultures	O
enhanced	O
reduction	O
of	O
cell	O
-	O
surface	O
c	B-GENE
-	I-GENE
kit	I-GENE
expression	O
and	O
its	O
protein	O
degradation	O
.	O

Transcription	O
factors	O
containing	O
a	O
basic	B-GENE
helix	I-GENE
-	I-GENE
loop	I-GENE
-	I-GENE
helix	I-GENE
(	I-GENE
bHLH	I-GENE
)	I-GENE
motif	I-GENE
regulate	O
the	O
expression	O
of	O
tissue	O
-	O
specific	O
genes	O
in	O
a	O
number	O
of	O
mammalian	O
and	O
insect	O
systems	O
.	O

Also	O
,	O
transient	O
overexpression	O
of	O
this	O
protein	O
in	O
C2C12	O
cells	O
reduced	O
the	O
transcription	O
of	O
a	O
CAT	B-GENE
-	I-GENE
reporter	I-GENE
regulated	O
by	O
an	O
E12	B-GENE
/	I-GENE
MyoD	I-GENE
driven	I-GENE
enhancer	I-GENE
.	O

Two	O
patients	O
were	O
treated	O
with	O
both	O
regimens	O
.	O

271	O
:	O
31290	O
-	O
31295	O
,	O
1996	O
)	O
.	O

A	O
1	O
.	O
8	O
-	O
kb	O
cDNA	O
clone	O
(	O
designed	O
hKID	O
,	O
gene	B-GENE
symbol	I-GENE
AQP2L	I-GENE
)	O
with	O
homology	O
to	O
the	O
aquaporins	B-GENE
was	O
isolated	O
from	O
a	O
human	O
kidney	O
cDNA	O
library	O
.	O

The	O
Lm	O
increased	O
and	O
the	O
alveoli	O
/	O
mm2	O
and	O
elastic	O
recoil	O
pressure	O
decreased	O
.	O

Serum	O
-	O
ferritin	O
in	O
diagnosis	O
of	O
haemochromatosis	O
.	O

Comparison	O
of	O
1	O
.	O
5	O
Tesla	O
and	O
0	O
.	O
35	O
Tesla	O
field	O
strength	O
magnetic	O
resonance	O
imaging	O
scans	O
in	O
the	O
morphometric	O
evaluation	O
of	O
the	O
lumbar	O
intervertebral	O
foramina	O
.	O

Plasmid	O
pAL618	O
contains	O
the	O
genetic	O
determinants	O
for	O
H2	O
uptake	O
(	O
hup	B-GENE
)	O
from	O
Rhizobium	O
leguminosarum	O
bv	O
.	O
viciae	O
,	O
including	O
a	O
cluster	O
of	O
17	O
genes	O
named	O
hupSLCDEFGHIJK	B-GENE
-	I-GENE
hypABFCDE	I-GENE
.	O

Chronic	O
endotoxemia	O
appears	O
to	O
be	O
associated	O
with	O
an	O
elevated	O
pulmonary	O
microvascular	O
permeability	O
and	O
a	O
tendency	O
toward	O
a	O
hyperdynamic	O
circulation	O
but	O
with	O
an	O
appreciable	O
degree	O
of	O
refractoriness	O
associated	O
with	O
regional	O
hemodynamics	O
and	O
eicosanoid	O
biosynthesis	O
.	O

These	O
rearrangements	O
result	O
in	O
the	O
formation	O
of	O
chimeric	O
genes	O
showing	O
the	O
tyrosine	B-GENE
kinase	I-GENE
domain	I-GENE
of	O
ret	B-GENE
fused	O
with	O
the	O
5	O
'	O
end	O
sequences	O
of	O
different	O
genes	O
.	O

The	O
TATA	B-GENE
box	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
(	O
TBP	B-GENE
)	O
plays	O
an	O
essential	O
role	O
in	O
transcription	O
by	O
all	O
three	O
eukaryotic	O
nuclear	B-GENE
RNA	I-GENE
polymerases	I-GENE
,	O
polymerases	B-GENE
(	I-GENE
Pol	I-GENE
)	I-GENE
I	I-GENE
,	I-GENE
II	I-GENE
,	I-GENE
and	I-GENE
III	I-GENE
.	O

Mutation	O
of	O
nucleotides	O
adjacent	O
to	O
the	O
AP	B-GENE
-	I-GENE
1	I-GENE
cis	I-GENE
-	I-GENE
response	I-GENE
elements	I-GENE
had	O
no	O
effect	O
on	O
trans	O
-	O
activation	O
.	O

Endurance	O
training	O
resulted	O
in	O
an	O
increase	O
of	O
stiffness	O
associated	O
with	O
a	O
decrease	O
of	O
type	O
II	O
fibers	O
.	O

Dual	O
innervation	O
of	O
fast	O
fibers	O
in	O
trunk	O
muscles	O
of	O
lamprey	O
larvae	O
.	O

Mucolipidosis	O
type	O
IV	O
:	O
clinical	O
spectrum	O
and	O
natural	O
history	O
.	O

At	O
necropsy	O
28	O
days	O
post	O
-	O
inoculation	O
,	O
F344	O
rats	O
had	O
no	O
gross	O
lung	O
lesions	O
,	O
even	O
those	O
given	O
the	O
maximum	O
dose	O
of	O
1	O
.	O
4	O
X	O
10	O
(	O
9	O
)	O
colony	O
-	O
forming	O
units	O
of	O
M	O
.	O
pulmonis	O
.	O

The	O
Epstein	B-GENE
-	I-GENE
Barr	I-GENE
virus	I-GENE
transactivator	I-GENE
Zta	I-GENE
triggers	O
lytic	O
gene	O
expression	O
and	O
is	O
essential	O
for	O
replication	O
of	O
the	O
lytic	O
origin	O
,	O
oriLyt	B-GENE
.	O

Simple	O
reaction	O
time	O
(	O
RT	O
)	O
to	O
a	O
peripheral	O
visual	O
target	O
(	O
S2	O
)	O
is	O
shortened	O
when	O
a	O
non	O
-	O
informative	O
cue	O
(	O
S1	O
)	O
is	O
flashed	O
at	O
the	O
S2	O
location	O
100	O
-	O
150	O
ms	O
before	O
target	O
onset	O
(	O
early	O
facilitation	O
)	O
.	O

We	O
have	O
determined	O
the	O
molecular	O
lesions	O
of	O
nine	O
Scm	B-GENE
mutant	I-GENE
alleles	I-GENE
,	O
which	O
identify	O
functional	O
requirements	O
for	O
specific	O
domains	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
Of	O
the	O
17	O
men	O
and	O
17	O
women	O
,	O
who	O
were	O
21	O
to	O
80	O
years	O
of	O
age	O
,	O
27	O
had	O
hereditary	O
motor	O
and	O
sensory	O
neuropathy	O
type	O
I	O
and	O
7	O
had	O
acquired	O
demyelinating	O
polyneuropathy	O
.	O

Anti	B-GENE
-	I-GENE
B	I-GENE
.	I-GENE
burgdorferi	I-GENE
,	O
anti	B-GENE
-	I-GENE
B	I-GENE
.	I-GENE
turicatae	I-GENE
and	O
anti	B-GENE
-	I-GENE
B	I-GENE
.	I-GENE
parkeri	I-GENE
antibodies	I-GENE
,	O
tested	O
by	O
the	O
indirect	O
immunofluorescent	O
assay	O
(	O
IFA	O
)	O
,	O
were	O
detected	O
in	O
10	O
.	O
8	O
,	O
16	O
.	O
1	O
and	O
8	O
.	O
2	O
%	O
of	O
the	O
serum	O
samples	O
tested	O
,	O
and	O
confirmed	O
by	O
IFA	O
-	O
ABS	O
in	O
1	O
.	O
3	O
,	O
1	O
.	O
3	O
and	O
1	O
.	O
0	O
%	O
,	O
respectively	O
.	O

Tobramycin	O
60	O
mg	O
did	O
not	O
show	O
any	O
remarkable	O
effect	O
,	O
but	O
dibecacin	O
100	O
mg	O
produced	O
a	O
slight	O
potentiating	O
effect	O
on	O
the	O
action	O
of	O
d	O
-	O
tubocurarine	O
.	O

Ventricular	O
volume	O
stiffness	O
vs	O
.	O
the	O
mean	O
wall	O
stress	O
relationship	O
of	O
LVH	O
shifted	O
upward	O
,	O
whereas	O
the	O
normalized	O
wall	O
muscle	O
stiffness	O
vs	O
.	O
the	O
mean	O
wall	O
stress	O
relationship	O
of	O
LVH	O
showed	O
a	O
smaller	O
slope	O
.	O

OBJECTIVE	O
:	O
1998	O
Surveillance	O
,	O
Epidemiology	O
,	O
and	O
End	O
Results	O
(	O
SEER	O
)	O
data	O
estimate	O
an	O
83	O
.	O
1	O
%	O
5	O
-	O
year	O
survival	O
rate	O
for	O
corpus	O
uteri	O
adenocarcinoma	O
FIGO	O
stage	O
II	O
.	O

Intron	O
K1	B-GENE
cox1	I-GENE
.	I-GENE
2	I-GENE
is	O
not	O
found	O
in	O
S	O
.	O
cerevisiae	O
and	O
appears	O
at	O
an	O
unique	O
location	O
in	O
K	O
.	O
lactis	O
.	O

In	O
B	O
cells	O
,	O
HEF1	B-GENE
is	O
phosphorylated	O
by	O
a	O
cytoskeleton	O
-	O
dependent	O
mechanism	O
that	O
is	O
triggered	O
by	O
integrin	B-GENE
ligation	O
.	O

Attenuation	O
from	O
the	O
vit	B-GENE
A2	I-GENE
consensus	O
ERE	B-GENE
is	O
not	O
necessarily	O
dependent	O
on	O
DNA	O
binding	O
as	O
the	O
TR	B-GENE
alpha	I-GENE
DNA	O
binding	O
mutant	O
was	O
still	O
able	O
to	O
inhibit	O
E	O
-	O
dependent	O
transactivation	O
.	O

We	O
conclude	O
that	O
this	O
new	O
measurement	O
technique	O
provides	O
an	O
easy	O
and	O
accurate	O
P0	O
.	O
1	O
measurement	O
using	O
standard	O
respiratory	O
equipment	O
when	O
tested	O
in	O
a	O
lung	O
model	O
.	O

The	O
data	O
indicate	O
that	O
the	O
minimal	O
catalytic	O
domain	O
of	O
Nmt1p	B-GENE
is	O
located	O
between	O
Ile59	O
-	O
-	O
>	O
Phe96	O
and	O
Gly451	O
-	O
-	O
>	O
Leu455	O
.	O

This	O
family	O
of	O
proteins	O
binds	O
GC	O
-	O
rich	O
motifs	O
widely	O
distributed	O
in	O
gene	O
promoters	O
,	O
resulting	O
in	O
distinct	O
activation	O
or	O
repression	O
of	O
transcriptional	O
activities	O
.	O

Rare	O
neurogenic	O
tumor	O
with	O
metastasis	O
to	O
mouth	O
,	O
jaw	O
and	O
face	O
regions	O
.	O

Studies	O
using	O
an	O
inhibitor	O
or	O
a	O
mutant	B-GENE
Lb	I-GENE
proteinase	I-GENE
indicated	O
that	O
stimulation	O
of	O
IRES	O
-	O
driven	O
translation	O
is	O
mediated	O
via	O
proteolysis	O
of	O
some	O
cellular	O
component	O
(	O
s	O
)	O
.	O

The	O
subjects	O
were	O
diagnosed	O
on	O
the	O
basis	O
of	O
DSM	O
-	O
IV	O
pathological	O
gambling	O
criteria	O
and	O
completed	O
the	O
Turkish	O
Version	O
of	O
South	O
Oaks	O
Gambling	O
Screen	O
(	O
SOGS	O
)	O
.	O

The	O
newly	O
defined	O
region	O
contains	O
an	O
intron	O
that	O
may	O
be	O
alternatively	O
spliced	O
and	O
seven	O
polyadenylation	O
signal	O
sequences	O
.	O

The	O
psaD	B-GENE
,	O
psaF	B-GENE
,	O
psaH	B-GENE
,	O
and	O
psaL	B-GENE
products	I-GENE
have	O
two	O
isoforms	O
each	O
that	O
are	O
distinguished	O
by	O
different	O
mobilities	O
in	O
polyacrylamide	O
gel	O
electrophoresis	O
,	O
and	O
the	O
psaE	B-GENE
product	I-GENE
has	O
four	O
isoforms	O
.	O

Fans	O
in	O
tunnels	O
and	O
open	O
windows	O
at	O
aboveground	O
locations	O
appeared	O
to	O
greatly	O
reduce	O
the	O
likelihood	O
of	O
high	O
PH3	O
concentrations	O
in	O
enclosed	O
areas	O
.	O

These	O
well	O
-	O
characterized	O
brain	O
regions	O
may	O
provide	O
a	O
basis	O
for	O
future	O
studies	O
of	O
RPTP	B-GENE
-	I-GENE
kappa	I-GENE
function	O
.	O

The	O
crystal	O
structure	O
of	O
the	O
VP16	B-GENE
core	I-GENE
has	O
been	O
determined	O
at	O
2	O
.	O
1	O
A	O
resolution	O
.	O

A	O
sequence	O
representing	O
about	O
50	O
%	O
of	O
the	O
expected	O
complete	O
sequence	O
was	O
obtained	O
by	O
translation	O
of	O
the	O
two	O
open	O
reading	O
frames	O
present	O
on	O
a	O
1	O
.	O
6	O
kb	O
DNA	O
genomic	O
fragment	O
.	O

Drosophila	B-GENE
UbcD1	I-GENE
encodes	O
a	O
highly	O
conserved	O
ubiquitin	O
-	O
conjugating	O
enzyme	O
involved	O
in	O
selective	O
protein	O
degradation	O
.	O

In	O
vitro	O
expression	O
of	O
four	O
different	O
naturally	O
occurring	O
nonsense	O
and	O
missense	O
mutations	O
revealed	O
a	O
dramatically	O
altered	O
subcellular	O
location	O
of	O
the	O
protein	O
in	O
cultured	O
cells	O
.	O

Five	O
of	O
these	O
eight	O
patients	O
in	O
group	O
II	O
also	O
received	O
8	O
-	O
in	O
-	O
1	O
chemotherapy	O
.	O

What	O
young	O
people	O
think	O
and	O
do	O
when	O
the	O
option	O
for	O
cystic	O
fibrosis	O
carrier	O
testing	O
is	O
available	O
.	O

The	O
controversy	O
of	O
significance	O
testing	O
:	O
misconceptions	O
and	O
alternatives	O
.	O

These	O
results	O
indicate	O
that	O
the	O
p33	B-GENE
subunit	I-GENE
of	O
eIF3	B-GENE
plays	O
an	O
important	O
role	O
in	O
the	O
initiation	O
phase	O
of	O
protein	O
synthesis	O
and	O
that	O
its	O
RNA	O
-	O
binding	O
domain	O
is	O
required	O
for	O
optimal	O
activity	O
.	O

It	O
has	O
been	O
shown	O
in	O
experiments	O
in	O
vitro	O
that	O
the	O
hepatotrophic	O
organic	O
anions	O
,	O
the	O
radiographic	O
contrast	O
agent	O
(	O
RCA	O
)	O
bilignost	O
used	O
in	O
cholecystography	O
and	O
Bengal	O
pink	O
,	O
have	O
an	O
affinity	O
,	O
unlike	O
the	O
urographic	O
RCA	O
triombrin	O
and	O
renotrophic	O
dye	O
indigo	O
-	O
carmine	O
,	O
for	O
the	O
plasmatic	O
membranes	O
(	O
PM	O
)	O
of	O
liver	O
cells	O
.	O

The	O
alpha	B-GENE
7A	I-GENE
form	I-GENE
RNA	I-GENE
contains	O
an	O
additional	O
113	O
nucleotides	O
compared	O
to	O
the	O
B	O
form	O
,	O
and	O
a	O
common	O
coding	O
region	O
in	O
the	O
A	O
and	O
B	O
form	O
RNAs	O
is	O
used	O
in	O
alternate	O
reading	O
frames	O
.	O

The	O
across	O
-	O
fiber	O
pattern	O
of	O
the	O
responses	O
to	O
hypotonic	O
NaCl	O
solutions	O
correlated	O
strongly	O
to	O
that	O
elicited	O
by	O
distilled	O
H2O	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

A	O
Bub2p	O
-	O
dependent	O
spindle	O
checkpoint	O
pathway	O
regulates	O
the	O
Dbf2p	B-GENE
kinase	I-GENE
in	I-GENE
budding	I-GENE
yeast	I-GENE
.	O

All	O
six	O
ARF	B-GENE
cDNAs	I-GENE
are	O
more	O
similar	O
to	O
each	O
other	O
than	O
to	O
other	O
approximately	O
20	B-GENE
-	I-GENE
kDa	I-GENE
guanine	I-GENE
nucleotide	I-GENE
-	I-GENE
binding	I-GENE
proteins	I-GENE
.	O

We	O
have	O
subcloned	O
into	O
pBR322	O
deoxyribonucleic	O
acid	O
(	O
DNA	O
)	O
sequences	O
mapping	O
either	O
in	O
the	O
coding	O
region	O
,	O
the	O
5	O
'	O
spacer	O
,	O
or	O
the	O
3	O
'	O
spacer	O
of	O
the	O
H2B	B-GENE
histone	I-GENE
gene	I-GENE
.	O

The	O
rrd1	B-GENE
,	I-GENE
2delta	I-GENE
mutant	I-GENE
was	O
partially	O
rescued	O
by	O
inactivation	O
of	O
HOG1	B-GENE
or	O
PBS2	B-GENE
,	O
suggesting	O
an	O
interaction	O
between	O
the	O
RRD	B-GENE
genes	I-GENE
and	O
the	O
Hog1p	B-GENE
signal	I-GENE
transduction	I-GENE
pathway	I-GENE
.	O

Oscilloscope	O
triggering	O
circuit	O
for	O
recording	O
long	O
transients	O
at	O
fast	O
sweep	O
speeds	O
.	O

The	O
negative	O
predictive	O
value	O
is	O
92	O
%	O
,	O
vs	O
80	O
%	O
for	O
the	O
NCEP	O
I	O
.	O

The	O
matrix	O
surrounding	O
the	O
clusters	O
either	O
showed	O
a	O
normal	O
morphology	O
or	O
a	O
homogeneous	O
appearance	O
,	O
within	O
which	O
faint	O
cross	O
striations	O
but	O
no	O
distinctly	O
fibrillar	O
outlines	O
could	O
be	O
identified	O
.	O

The	O
muskox	O
is	O
a	O
new	O
host	O
record	O
for	O
T	O
.	O
gondii	O
.	O

The	O
patient	O
'	O
s	O
role	O
,	O
organized	O
by	O
the	O
prerequisites	O
of	O
expressive	O
freedom	O
,	O
is	O
counter	O
posed	O
with	O
the	O
psychoanalyst	O
'	O
s	O
,	O
which	O
is	O
structured	O
to	O
empower	O
listening	O
and	O
understanding	O
.	O

Fas	O
-	O
resistant	O
DT	O
-	O
40	O
lymphoma	O
B	O
-	O
cells	O
rendered	O
BTK	O
-	O
deficient	O
through	O
targeted	O
disruption	O
of	O
the	O
btk	B-GENE
gene	I-GENE
by	O
homologous	O
recombination	O
knockout	O
underwent	O
apoptosis	O
after	O
Fas	B-GENE
ligation	O
,	O
but	O
wild	O
-	O
type	O
DT	O
-	O
40	O
cells	O
or	O
BTK	O
-	O
deficient	O
DT	O
-	O
40	O
cells	O
reconstituted	O
with	O
wild	B-GENE
-	I-GENE
type	I-GENE
human	I-GENE
btk	I-GENE
gene	I-GENE
did	O
not	O
.	O

Immunoreactive	O
AR	B-GENE
content	O
in	O
transfected	O
COS	O
-	O
1	O
cells	O
was	O
not	O
influenced	O
by	O
exposure	O
to	O
8	O
-	O
Br	O
-	O
cAMP	O
.	O

Erythrocyte	O
protoporphyrin	O
concentration	O
increased	O
significantly	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
by	O
14	O
days	O
in	O
dogs	O
fed	O
the	O
basal	O
diet	O
,	O
and	O
remained	O
significantly	O
high	O
relative	O
to	O
that	O
in	O
dogs	O
of	O
the	O
other	O
dietary	O
groups	O
for	O
the	O
remainder	O
of	O
the	O
study	O
.	O

A	O
case	O
of	O
Goodpasture	O
'	O
s	O
syndrome	O
.	O

RXR	B-GENE
-	I-GENE
gamma	I-GENE
expression	O
produced	O
significant	O
reduction	O
in	O
levels	O
of	O
RA	O
-	O
responsive	O
genes	O
including	O
the	O
cyclin	B-GENE
-	I-GENE
dependent	I-GENE
kinase	I-GENE
inhibitors	I-GENE
p21Cip1	B-GENE
/	I-GENE
WAF1	I-GENE
and	O
p27Kip1	B-GENE
,	O
resulting	O
in	O
increased	O
cdc2	B-GENE
and	O
cdk2	B-GENE
kinase	I-GENE
activity	O
and	O
RB	B-GENE
phosphorylation	O
.	O

Lower	O
limits	O
(	O
to	O
10	O
micrograms	O
/	O
kg	O
)	O
were	O
detectable	O
,	O
but	O
with	O
lower	O
reliability	O
(	O
60	O
%	O
)	O
.	O

Insulin	B-GENE
-	I-GENE
like	I-GENE
growth	I-GENE
factor	I-GENE
II	I-GENE
(	O
IGFII	B-GENE
)	O
is	O
a	O
mitogenic	O
polypeptide	O
,	O
the	O
mRNAs	O
of	O
which	O
are	O
present	O
in	O
multiple	O
forms	O
,	O
despite	O
derivation	O
from	O
a	O
single	O
gene	O
.	O

The	O
more	O
traditional	O
SERMS	O
,	O
clomiphene	O
citrate	O
and	O
tamoxifen	O
,	O
will	O
be	O
reviewed	O
along	O
with	O
such	O
modern	O
drugs	O
as	O
raloxifene	O
and	O
faslodex	O
,	O
with	O
emphasis	O
upon	O
their	O
actions	O
on	O
breast	O
,	O
uterus	O
,	O
bone	O
and	O
lipids	O
.	O

We	O
have	O
cloned	O
cDNA	O
and	O
genomic	O
DNA	O
for	O
a	O
mouse	O
gene	O
encoding	O
a	O
protein	O
with	O
significant	O
sequence	O
similarity	O
to	O
conserved	O
domains	O
found	O
in	O
proteins	O
of	O
the	O
Spo11p	B-GENE
family	I-GENE
.	O

If	O
E	O
.	O
coli	O
is	O
present	O
in	O
any	O
source	O
water	O
sample	O
,	O
the	O
borehole	O
and	O
any	O
directly	O
connected	O
borehole	O
should	O
be	O
embargoed	O
.	O

One	O
of	O
these	O
is	O
surrounded	O
by	O
an	O
adenine	O
-	O
uridine	O
rich	O
region	O
that	O
can	O
form	O
an	O
11	O
-	O
base	O
pair	O
stem	O
structure	O
.	O

An	O
important	O
mechanism	O
by	O
which	O
the	O
tumor	O
suppressor	O
p53	B-GENE
maintains	O
genomic	O
stability	O
is	O
to	O
induce	O
cell	O
cycle	O
arrest	O
through	O
activation	O
of	O
the	O
cyclin	B-GENE
-	I-GENE
dependent	I-GENE
kinase	I-GENE
inhibitor	I-GENE
p21	I-GENE
(	I-GENE
WAF1	I-GENE
/	I-GENE
Cip1	I-GENE
)	I-GENE
gene	I-GENE
.	O

However	O
,	O
the	O
mouse	O
has	O
previously	O
been	O
shown	O
to	O
possess	O
only	O
three	O
forms	O
of	O
ADH	B-GENE
.	O

The	O
effect	O
of	O
antilymphocyte	O
sera	O
on	O
formation	O
of	O
transplantation	O
and	O
anti	O
-	O
infection	O
immunity	O
in	O
mice	O
.	O

The	O
quantity	O
of	O
each	O
population	O
(	O
L	O
.	O
bulgaricus	O
,	O
S	O
.	O
thermophilus	O
)	O
was	O
then	O
estimated	O
in	O
the	O
pellet	O
by	O
PyMS	O
,	O
and	O
the	O
data	O
were	O
analysed	O
by	O
artificial	O
neural	O
networks	O
(	O
ANNs	O
)	O
.	O

LysR	B-GENE
proteins	I-GENE
have	O
been	O
shown	O
to	O
regulate	O
urease	B-GENE
in	I-GENE
Klebsiella	I-GENE
aerogenes	I-GENE
(	O
NAC	B-GENE
)	O
,	O
and	O
catalase	B-GENE
in	I-GENE
Escherichia	I-GENE
coli	I-GENE
(	O
OxyR	B-GENE
)	O
,	O
which	O
offers	O
the	O
intracellular	O
bacterium	O
protection	O
from	O
phagolysosome	O
damage	O
.	O

Experiments	O
on	O
narcotized	O
cats	O
demonstrated	O
that	O
the	O
derivatives	O
of	O
2	O
-	O
mercaptobenzimidazole	O
possessing	O
the	O
properties	O
of	O
specific	O
bradycardic	O
agents	O
and	O
coded	O
as	O
CM	O
-	O
251	O
,	O
CM	O
-	O
266	O
,	O
and	O
CM	O
-	O
345	O
,	O
reduce	O
the	O
mean	O
rise	O
of	O
segment	O
ST	O
on	O
numerous	O
leads	O
of	O
the	O
epicardial	O
electrogram	O
during	O
5	O
-	O
min	O
occlusion	O
of	O
the	O
anterior	O
descending	O
branch	O
of	O
the	O
left	O
coronary	O
artery	O
.	O

Ten	O
weeks	O
after	O
reconstruction	O
,	O
the	O
regenerating	O
nerves	O
already	O
resembled	O
normal	O
nerves	O
.	O

Franz	O
Schubert	O
-	O
-	O
his	O
life	O
,	O
music	O
and	O
diseases	O
.	O

The	O
emerging	O
view	O
based	O
on	O
studies	O
in	O
yeast	O
is	O
that	O
each	O
class	O
of	O
snoRNPs	B-GENE
is	O
composed	O
of	O
a	O
unique	O
set	O
of	O
proteins	O
.	O

Conclusion	O
:	O
inlet	O
type	O
VSD	O
and	O
perimembranous	O
type	O
TOF	O
have	O
anatomic	O
features	O
in	O
which	O
the	O
proximal	O
His	O
bundle	O
tends	O
to	O
be	O
jeopardized	O
by	O
suturing	O
for	O
VSD	O
closure	O
.	O

Svensson	O
et	O
al	O
.	O

This	O
study	O
suggests	O
that	O
BSPMs	O
are	O
useful	O
in	O
the	O
assessment	O
of	O
AMI	O
in	O
terms	O
of	O
diagnosis	O
,	O
location	O
and	O
extent	O
of	O
myocardial	O
infarct	O
.	O

Erratum	O
:	O
Absence	O
of	O
precursor	O
effects	O
above	O
the	O
martensitic	O
transformation	O
in	O
a	O
virgin	O
crystal	O
of	O
Li	O
metal	O
[	O
Phys	O
.	O

B	B-GENE
-	I-GENE
myb	I-GENE
is	O
essential	O
for	O
G1	O
/	O
S	O
transition	O
and	O
has	O
been	O
shown	O
to	O
be	O
phosphorylated	O
by	O
the	O
cyclin	B-GENE
A2	I-GENE
/	I-GENE
cdk2	I-GENE
complex	I-GENE
.	O

Movement	O
programming	O
depends	O
on	O
understanding	O
of	O
behavioral	O
requirements	O
.	O

Its	O
neuromuscular	O
effects	O
are	O
similar	O
to	O
a	O
single	O
ED90	O
dose	O
of	O
vecuronium	O
.	O

The	O
hp55	B-GENE
gamma	I-GENE
protein	I-GENE
interacts	O
strongly	O
with	O
the	O
activated	O
IGFIR	B-GENE
but	O
not	O
with	O
the	O
kinase	O
-	O
negative	O
mutant	O
receptor	O
.	O
hp55	B-GENE
gamma	I-GENE
also	O
interacts	O
with	O
the	O
insulin	B-GENE
receptor	I-GENE
(	O
IR	B-GENE
)	O
in	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
.	O

In	O
humans	O
,	O
four	O
AMP	B-GENE
deaminase	I-GENE
variants	I-GENE
,	O
termed	O
M	O
(	O
muscle	O
)	O
,	O
L	O
(	O
liver	O
)	O
,	O
E1	B-GENE
,	O
and	O
E2	B-GENE
(	O
erythrocyte	O
)	O
can	O
be	O
distinguished	O
by	O
a	O
variety	O
of	O
biochemical	O
and	O
immunological	O
criteria	O
.	O

In	O
a	O
longitudinal	O
study	O
,	O
14	O
low	O
-	O
risk	O
fetuses	O
were	O
studied	O
at	O
2	O
-	O
week	O
intervals	O
from	O
32	O
weeks	O
of	O
gestation	O
onward	O
.	O

However	O
the	O
sequence	O
surrounding	O
the	O
transcription	O
start	O
site	O
CTCA	O
(	O
+	O
1	O
)	O
TTCC	O
was	O
similar	O
to	O
the	O
consensus	O
CTCA	O
(	O
+	O
1	O
)	O
NTCT	O
(	O
N	O
is	O
any	O
nucleoside	O
)	O
for	O
an	O
initiator	O
element	O
found	O
in	O
terminal	B-GENE
deoxynucleotidyltransferase	I-GENE
and	O
a	O
number	O
of	O
other	O
highly	O
regulated	O
genes	O
.	O

C	B-GENE
.	I-GENE
elegans	I-GENE
KLP	I-GENE
-	I-GENE
11	I-GENE
/	I-GENE
OSM	I-GENE
-	I-GENE
3	I-GENE
/	I-GENE
KAP	I-GENE
-	I-GENE
1	I-GENE
:	O
orthologs	O
of	O
the	O
sea	B-GENE
urchin	I-GENE
kinesin	I-GENE
-	I-GENE
II	I-GENE
,	O
and	O
mouse	B-GENE
KIF3A	I-GENE
/	I-GENE
KIFB	I-GENE
/	I-GENE
KAP3	I-GENE
kinesin	I-GENE
complexes	I-GENE
.	O

Increase	O
in	O
blood	O
NEFA	O
was	O
further	O
augmented	O
by	O
fat	O
plus	O
AA	O
supplementation	O
,	O
but	O
no	O
changes	O
in	O
concentrations	O
of	O
Lys	O
or	O
Met	O
in	O
blood	O
were	O
found	O
.	O

Most	O
eukaryotic	O
mRNAs	O
are	O
translated	O
by	O
a	O
"	O
scanning	O
ribosome	O
"	O
mechanism	O
.	O

According	O
to	O
the	O
biochemical	O
tests	O
,	O
high	O
activity	O
(	O
over	O
200	O
U	O
/	O
l	O
)	O
of	O
alkaline	B-GENE
phosphatase	I-GENE
was	O
recorded	O
exclusively	O
in	O
patients	O
with	O
the	O
lymphogranulomatosis	O
-	O
induced	O
liver	O
damage	O
.	O

During	O
sub	O
-	O
maximal	O
exercise	O
,	O
DCR	O
in	O
the	O
UT	O
dogs	O
decreased	O
from	O
a	O
resting	O
value	O
of	O
4	O
.	O
08	O
+	O
/	O
-	O
0	O
.	O
18	O
mm	O
Hg	O
X	O
ml	O
-	O
1	O
X	O
min	O
-	O
1	O
to	O
1	O
.	O
91	O
+	O
/	O
-	O
0	O
.	O
17	O
mm	O
Hg	O
X	O
ml	O
-	O
1	O
X	O
min	O
-	O
1	O
at	O
a	O
workload	O
of	O
6	O
.	O
4	O
kph	O
(	O
speed	O
)	O
/	O
16	O
%	O
(	O
grade	O
)	O
.	O

The	O
incidence	O
of	O
HSV	O
-	O
2	O
positive	O
subjects	O
(	O
HSV	B-GENE
-	I-GENE
2	I-GENE
/	I-GENE
HSV	I-GENE
-	I-GENE
1	I-GENE
antibody	I-GENE
ratio	O
>	O
or	O
=	O
1	O
)	O
was	O
low	O
in	O
the	O
Jewish	O
Israeli	O
population	O
,	O
compared	O
to	O
other	O
demographic	O
areas	O
.	O

The	O
sorption	O
mechanisms	O
changed	O
from	O
adsorption	O
to	O
partition	O
in	O
the	O
process	O
of	O
repetitious	O
sorption	O
.	O

According	O
to	O
their	O
staining	O
affinity	O
for	O
anti	B-GENE
-	I-GENE
T	I-GENE
antibodies	I-GENE
,	O
the	O
glandular	O
tissue	O
cells	O
were	O
classified	O
as	O
T	O
-	O
,	O
T	O
+	O
,	O
T	O
+	O
+	O
,	O
and	O
T	O
and	O
the	O
annual	O
changes	O
in	O
the	O
numbers	O
of	O
these	O
cell	O
populations	O
,	O
as	O
well	O
as	O
in	O
the	O
volume	O
occupied	O
by	O
the	O
glandular	O
tissue	O
,	O
were	O
calculated	O
.	O

Cardiac	O
preservation	O
.	O

A	O
new	O
method	O
for	O
the	O
in	O
vitro	O
transfer	O
of	O
delayed	O
hypersensitivity	O
by	O
dialysed	O
transfer	B-GENE
factor	I-GENE
.	O

Karger	O
AG	O
,	O
Basel	O

The	O
cloned	O
alcR	B-GENE
gene	I-GENE
provided	O
in	O
trans	O
restored	O
these	O
siderophore	O
system	O
activities	O
to	O
the	O
mutants	O
.	O

Study	O
of	O
bacterial	O
motility	O
and	O
rate	O
of	O
movement	O
using	O
a	O
closed	O
circuit	O
television	O
.	O

Analysis	O
of	O
lacZ	B-GENE
transcriptional	I-GENE
fusions	I-GENE
shows	O
that	O
the	O
KdgR	B-GENE
-	I-GENE
binding	I-GENE
sites	I-GENE
negatively	O
affect	O
the	O
expression	O
of	O
rsmB	B-GENE
.	O

Extramedullary	O
plasmacytoma	O
of	O
the	O
parotid	O
gland	O
.	O

In	O
addition	O
,	O
a	O
21	O
-	O
mer	O
subrepeat	O
structure	O
is	O
also	O
present	O
in	O
each	O
unit	O
.	O

Intravenous	O
glucose	O
tolerance	O
tests	O
were	O
performed	O
before	O
operation	O
,	O
before	O
starting	O
CyA	O
and	O
after	O
3	O
weeks	O
.	O

Modulation	O
of	O
AUUUA	B-GENE
response	I-GENE
element	I-GENE
binding	O
by	O
heterogeneous	B-GENE
nuclear	I-GENE
ribonucleoprotein	I-GENE
A1	I-GENE
in	O
human	O
T	O
lymphocytes	O
.	O

The	O
data	O
provide	O
strong	O
evidence	O
that	O
ThlA	B-GENE
is	O
involved	O
in	O
the	O
metabolism	O
of	O
both	O
acid	O
and	O
solvent	O
formation	O
,	O
whereas	O
the	O
physiological	O
function	O
of	O
ThlB	B-GENE
has	O
yet	O
to	O
be	O
elucidated	O
.	O

Selection	O
of	O
the	O
22	O
items	O
of	O
the	O
Clinical	O
Institute	O
Withdrawal	O
Assessment	O
-	O
Benzodiazepines	O
(	O
CIWA	O
-	O
B	O
)	O
was	O
based	O
on	O
statistically	O
significant	O
differences	O
between	O
baseline	O
and	O
critical	O
withdrawal	O
periods	O
in	O
high	O
-	O
dose	O
subjects	O
and	O
between	O
symptoms	O
associated	O
with	O
placebo	O
and	O
diazepam	O
in	O
low	O
-	O
dose	O
subjects	O
,	O
using	O
contingency	O
tables	O
and	O
logistic	O
regression	O
analysis	O
.	O

We	O
also	O
observed	O
that	O
cell	B-GENE
surface	I-GENE
CD4	I-GENE
(	I-GENE
-	I-GENE
)	I-GENE
CD8	I-GENE
(	I-GENE
-	I-GENE
)	I-GENE
CD3	I-GENE
(	I-GENE
-	I-GENE
)	I-GENE
cells	O
with	O
rearranged	B-GENE
TCR	I-GENE
genes	I-GENE
developed	O
from	O
Id3	O
-	O
transduced	O
but	O
not	O
from	O
control	O
-	O
transduced	O
pre	O
-	O
T	O
cells	O
in	O
an	O
FTOC	O
.	O

In	O
order	O
to	O
define	O
potential	O
candidate	O
genes	O
for	O
inherited	O
disorders	O
characterized	O
by	O
aberrant	O
gene	O
expression	O
,	O
we	O
utilized	O
Kruppel	B-GENE
-	I-GENE
related	I-GENE
sequences	I-GENE
to	O
isolate	O
zinc	O
finger	O
-	O
containing	O
cDNAs	O
.	O

Praziquantel	O
and	O
Albendazole	O
were	O
found	O
effective	O
in	O
the	O
treatment	O
of	O
neurocysticercosis	O
,	O
but	O
because	O
of	O
serious	O
side	O
effects	O
encountered	O
in	O
some	O
cases	O
,	O
the	O
drugs	O
should	O
be	O
used	O
cautiously	O
in	O
selected	O
cases	O
only	O
.	O

The	O
results	O
raise	O
the	O
possibility	O
that	O
pH	O
induced	O
post	O
-	O
translational	O
modifications	O
of	O
DdRPA	B-GENE
are	O
involved	O
in	O
events	O
that	O
halt	O
cell	O
proliferation	O
and	O
induce	O
differentiation	O
in	O
Dictyostelium	O
.	O

However	O
,	O
activation	O
of	O
the	O
cAMP	O
pathway	O
,	O
which	O
is	O
known	O
to	O
regulate	O
inhibin	B-GENE
alpha	I-GENE
expression	O
,	O
greatly	O
enhanced	O
the	O
actions	O
of	O
SF	B-GENE
-	I-GENE
1	I-GENE
.	O

At	O
different	O
times	O
of	O
the	O
surgical	O
procedures	O
(	O
thorax	O
opening	O
and	O
closure	O
,	O
period	O
of	O
cardiopulmonary	O
bypass	O
)	O
67	O
to	O
100	O
%	O
of	O
the	O
patients	O
in	O
group	O
1	O
had	O
vancomycin	O
concentrations	O
in	O
the	O
studied	O
tissues	O
above	O
the	O
MIC	O
90	O
for	O
Staphylococcus	O
aureus	O
(	O
1	O
microgram	O
/	O
g	O
)	O
and	O
Staphylococcus	O
epidermidis	O
(	O
2	O
micrograms	O
/	O
g	O
)	O
.	O

Ent	B-GENE
-	I-GENE
kaurene	I-GENE
synthase	I-GENE
from	I-GENE
the	I-GENE
fungus	I-GENE
Phaeosphaeria	I-GENE
sp	O
.	O

Data	O
Management	O
in	O
Practice	O
-	O
based	O
Research	O
.	O

The	O
incidence	O
of	O
cardiac	O
death	O
(	O
one	O
per	O
group	O
)	O
,	O
Q	O
wave	O
MI	O
(	O
propofol	O
,	O
n	O
=	O
7	O
;	O
midazolam	O
,	O
n	O
=	O
3	O
;	O
P	O
=	O
0	O
.	O
27	O
)	O
,	O
or	O
non	O
Q	O
wave	O
MI	O
(	O
propofol	O
,	O
n	O
=	O
16	O
;	O
midazolam	O
,	O
n	O
=	O
18	O
;	O
P	O
=	O
0	O
.	O
81	O
)	O
did	O
not	O
differ	O
between	O
treatment	O
groups	O
.	O

Evidence	O
is	O
presented	O
that	O
Leber	O
'	O
s	O
military	O
aneurysm	O
retinitis	O
is	O
not	O
a	O
separate	O
entity	O
but	O
a	O
special	O
form	O
of	O
Coats	O
'	O
disease	O
.	O

Here	O
,	O
we	O
alter	O
the	O
dimerization	O
specificity	O
of	O
Fos	B-GENE
by	O
precisely	O
replacing	O
its	O
leucine	O
zipper	O
with	O
that	O
from	O
GCN4	B-GENE
.	O

We	O
confirmed	O
the	O
interaction	O
between	O
TLS	B-GENE
and	O
p65	B-GENE
by	O
the	O
pull	O
-	O
down	O
assay	O
in	O
vitro	O
and	O
by	O
a	O
coimmunoprecipitation	O
experiment	O
followed	O
by	O
Western	O
blot	O
of	O
the	O
cultured	O
cell	O
in	O
vivo	O
.	O

The	O
cycle	O
length	O
of	O
induced	O
VT	O
(	O
n	O
=	O
10	O
VTs	O
)	O
was	O
380	O
+	O
/	O
-	O
41	O
msec	O
.	O

Nucleotide	O
sequence	O
,	O
genome	O
organization	O
and	O
phylogenetic	O
analysis	O
of	O
pineapple	O
mealybug	O
wilt	O
-	O
associated	O
virus	O
-	O
2	O
.	O

Observations	O
on	O
the	O
flight	O
activities	O
of	O
Chrysops	O
caecutiens	O
L	O
.	O

Stimulation	O
of	O
[	O
3H	O
]	O
PA	O
production	O
upon	O
CD3	B-GENE
cross	O
-	O
linking	O
was	O
77	O
%	O
lower	O
in	O
permeabilized	O
CD45	B-GENE
-	I-GENE
cells	O
than	O
in	O
CD45	B-GENE
+	I-GENE
cells	O
,	O
consistent	O
with	O
the	O
reduced	O
activity	O
of	O
p59fyn	B-GENE
in	O
CD45	B-GENE
-	I-GENE
cells	O
.	O

In	O
a	O
series	O
of	O
402	O
consecutive	O
autopsies	O
,	O
parietal	O
pleural	O
plaques	O
(	O
PP	O
)	O
were	O
found	O
in	O
68	O
individuals	O
above	O
40	O
years	O
of	O
age	O
.	O

In	O
contrast	O
,	O
high	O
COUP	B-GENE
-	I-GENE
TFI	I-GENE
expression	O
impeded	O
the	O
neuronal	O
differentiation	O
of	O
P19	O
cells	O
induced	O
with	O
RA	O
,	O
resulting	O
in	O
cell	O
cultures	O
lacking	O
neurons	O
.	O

We	O
show	O
that	O
several	O
heme	O
-	O
responsive	O
mechanisms	O
combine	O
to	O
regulate	O
DAN	B-GENE
/	I-GENE
TIR	I-GENE
gene	I-GENE
expression	O
.	O

NGF	B-GENE
,	O
but	O
not	O
EGF	B-GENE
,	O
enhances	O
the	O
upper	O
bands	O
,	O
corresponding	O
to	O
phosphorylated	B-GENE
Fra	I-GENE
-	I-GENE
2	I-GENE
.	O

The	O
FFA	O
levels	O
were	O
not	O
affected	O
(	O
P	O
greater	O
than	O
.	O
1	O
)	O
by	O
meal	O
interval	O
.	O

A	O
survey	O
is	O
given	O
of	O
the	O
pharmacological	O
backgrounds	O
that	O
are	O
relevant	O
for	O
the	O
drug	O
treatment	O
of	O
essential	O
hypertension	O
in	O
the	O
elderly	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
minimal	O
requirements	O
for	O
induction	O
of	O
PEPCK	B-GENE
by	O
PKA	B-GENE
and	O
inhibition	O
by	O
insulin	B-GENE
include	O
:	O
1	O
)	O
the	O
CREB	B-GENE
activation	I-GENE
domain	I-GENE
,	O
2	O
)	O
the	O
PEPCK	B-GENE
TATA	I-GENE
sequence	I-GENE
,	O
and	O
3	O
)	O
insulin	O
-	O
responsive	O
hepatoma	O
cells	O
.	O

The	O
Drosophila	B-GENE
melanogaster	I-GENE
Gart	I-GENE
gene	I-GENE
encodes	O
three	O
enzymatic	O
activities	O
in	O
the	O
pathway	O
for	O
purine	O
de	O
novo	O
synthesis	O
.	O

In	O
contrast	O
,	O
we	O
did	O
not	O
detect	O
a	O
significant	O
correlation	O
between	O
plasma	B-GENE
TNFalpha	I-GENE
and	O
radiation	O
pneumonitis	O
.	O

Unlike	O
the	O
mammalian	O
proteins	O
,	O
XFGF3	B-GENE
is	O
efficiently	O
secreted	O
as	O
a	O
Mr	O
31	O
,	O
000	O
glycoprotein	O
,	O
gp31	B-GENE
,	O
which	O
undergoes	O
proteolytic	O
cleavage	O
to	O
produce	O
an	O
NH2	O
-	O
terminally	O
truncated	O
product	O
,	O
gp27	B-GENE
.	O

Enhancement	O
of	O
the	O
immune	O
response	O
by	O
aspecific	O
action	O
of	O
vaccine	O
additives	O
in	O
the	O
aerogenic	O
immunization	O
of	O
swine	O
against	O
swine	O
plague	O
.	O

The	O
effect	O
of	O
six	O
arginine	O
mutations	O
of	O
oxidative	O
phosphorylation	O
and	O
AAC	B-GENE
expression	O
.	O

Neuregulin	B-GENE
stimulates	O
ErbB2	B-GENE
,	O
ErbB3	B-GENE
,	O
and	O
ErbB4	B-GENE
,	O
members	O
of	O
the	O
ErbB	B-GENE
family	I-GENE
of	O
receptor	B-GENE
tyrosine	I-GENE
kinases	I-GENE
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
the	O
TATA	O
element	O
is	O
critical	O
for	O
basal	O
and	O
Tat	O
-	O
induced	O
HIV	O
-	O
1	O
gene	O
expression	O
.	O

Furthermore	O
,	O
cpxA	B-GENE
*	I-GENE
mutations	O
suppress	O
the	O
toxicity	O
conferred	O
by	O
the	O
LamB	B-GENE
-	I-GENE
LacZ	I-GENE
hybrid	I-GENE
protein	I-GENE
,	O
which	O
exerts	O
its	O
effects	O
in	O
the	O
cytoplasm	O
,	O
sequestered	O
from	O
DegP	B-GENE
.	O

They	O
include	O
genes	O
encoding	O
three	O
subunits	O
of	O
the	O
cytochrome	B-GENE
oxidase	I-GENE
(	O
cox1	B-GENE
to	I-GENE
3	I-GENE
)	O
,	O
apocytochrome	B-GENE
b	I-GENE
(	O
cob	B-GENE
)	O
,	O
seven	O
subunits	O
of	O
the	O
NADH	B-GENE
dehydrogenase	I-GENE
complex	I-GENE
(	O
nad1	B-GENE
to	I-GENE
6	I-GENE
,	O
nad4L	B-GENE
)	O
,	O
two	O
ATPase	B-GENE
subunits	O
(	O
atp6	B-GENE
and	O
atp9	B-GENE
)	O
,	O
three	O
ribosomal	O
RNAs	O
(	O
rrn5	B-GENE
,	O
srn	B-GENE
and	O
lrn	B-GENE
)	O
,	O
23	O
tRNAs	O
and	O
four	O
ribosomal	B-GENE
proteins	I-GENE
(	O
rps3	B-GENE
,	O
rps11	B-GENE
,	O
rps12	B-GENE
and	O
rpl16	B-GENE
)	O
.	O

OUTCOME	O
:	O
Acetylcholine	B-GENE
receptor	I-GENE
antibodies	I-GENE
and	O
single	O
-	O
fibre	O
electromyogram	O
were	O
useful	O
in	O
the	O
diagnosis	O
of	O
myasthenia	O
gravis	O
.	O

In	O
the	O
PMR	O
target	O
area	O
but	O
not	O
in	O
the	O
nontreated	O
area	O
an	O
improvement	O
in	O
regional	O
myocardial	O
flow	O
reserve	O
occurs	O
in	O
wall	O
segments	O
with	O
initially	O
severely	O
or	O
moderately	O
reduced	O
stress	O
perfusion	O
.	O

Therefore	O
,	O
ICSBP	B-GENE
may	O
be	O
involved	O
in	O
maintaining	O
submaximal	O
transcriptional	O
activity	O
of	O
IFN	O
-	O
inducible	O
genes	O
in	O
hematopoietic	O
cells	O
.	O

Blood	O
eosinophils	O
in	O
patients	O
with	O
Taenia	O
saginata	O
taeniasis	O
.	O

Our	O
results	O
suggest	O
that	O
WASP	B-GENE
activates	O
transcription	O
following	O
TCR	B-GENE
stimulation	O
in	O
a	O
manner	O
that	O
is	O
independent	O
of	O
its	O
role	O
in	O
Arp2	B-GENE
/	O
3	O
-	O
directed	O
actin	B-GENE
polymerization	O
.	O

O2	O
and	O
CO2	O
in	O
the	O
tracheostomy	O
tube	O
were	O
continuously	O
monitored	O
by	O
mass	O
spectrometry	O
using	O
a	O
special	O
sample	O
-	O
hold	O
phase	O
-	O
locked	O
sampling	O
technique	O
.	O

Removal	O
of	O
the	O
carboxyl	O
region	O
severely	O
reduced	O
transcriptional	O
activation	O
.	O

Aortic	O
diameters	O
in	O
infants	O
and	O
young	O
children	O
:	O
normative	O
angiographic	O
data	O
.	O

Using	O
a	O
3	O
'	O
-	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
strategy	O
,	O
we	O
have	O
cloned	O
cDNAs	O
representing	O
the	O
3	O
'	O
-	O
termini	O
of	O
both	O
the	O
native	O
and	O
mutant	O
transcripts	O
from	O
both	O
P388	O
/	O
ADR	O
/	O
3	O
and	O
P388	O
/	O
ADR	O
/	O
7	O
cells	O
.	O

Mutations	O
at	O
three	O
sites	O
have	O
larger	O
effects	O
in	O
muscle	O
than	O
nonmuscle	O
cells	O
;	O
an	O
A	O
/	O
T	O
-	O
rich	O
site	O
mutation	O
has	O
a	O
pronounced	O
effect	O
in	O
both	O
striated	O
muscle	O
types	O
,	O
mutations	O
at	O
the	O
MEF1	B-GENE
(	I-GENE
Right	I-GENE
E	I-GENE
-	I-GENE
box	I-GENE
)	I-GENE
site	I-GENE
are	O
relatively	O
specific	O
to	O
expression	O
in	O
skeletal	O
muscle	O
,	O
and	O
mutations	O
at	O
the	O
CArG	O
site	O
are	O
relatively	O
specific	O
to	O
expression	O
in	O
cardiac	O
muscle	O
.	O

Therefore	O
,	O
in	O
our	O
in	O
vitro	O
model	O
,	O
the	O
localization	O
of	O
the	O
mutation	O
in	O
the	O
K	B-GENE
-	I-GENE
ras	I-GENE
gene	I-GENE
predisposes	O
to	O
a	O
different	O
level	O
of	O
aggressiveness	O
in	O
the	O
transforming	O
phenotype	O
.	O

Induction	O
of	O
anaesthesia	O
was	O
standardised	O
:	O
fentanyl	O
(	O
3	O
micrograms	O
/	O
kg	O
)	O
,	O
thiopentone	O
(	O
5	O
mg	O
/	O
kg	O
)	O
,	O
atracurium	O
(	O
0	O
.	O
4	O
mg	O
/	O
kg	O
)	O
.	O

Moreover	O
,	O
Western	O
blots	O
demonstrated	O
at	O
least	O
six	O
types	O
of	O
Ypt	B-GENE
in	O
both	O
Cr	O
and	O
Vc	O
,	O
suggesting	O
that	O
these	O
Ypt	B-GENE
are	O
used	O
for	O
household	O
functions	O
responsible	O
for	O
vesicle	O
transport	O
rather	O
than	O
for	O
cellular	O
differentiation	O
.	O

In	O
on	O
-	O
going	O
screening	O
programmes	O
,	O
the	O
Haemoccult	O
test	O
consists	O
of	O
six	O
slides	O
and	O
a	O
test	O
is	O
considered	O
positive	O
if	O
at	O
least	O
one	O
slide	O
is	O
coloured	O
.	O

The	O
results	O
obtained	O
were	O
as	O
follows	O
:	O
The	O
mitral	O
valve	O
orifice	O
area	O
(	O
MVA	O
)	O
was	O
significantly	O
smaller	O
in	O
patients	O
with	O
type	O
III	O
of	O
the	O
LVIT	O
flow	O
velocity	O
pattern	O
than	O
in	O
patients	O
with	O
type	O
I	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Our	O
data	O
indicate	O
that	O
SIP1	B-GENE
is	O
required	O
to	O
confine	O
XBra	B-GENE
gene	I-GENE
expression	O
to	O
the	O
mesoderm	O
.	O

Menstrual	O
-	O
cycle	O
phase	O
did	O
not	O
significantly	O
affect	O
personality	O
variables	O
in	O
either	O
group	O
.	O

Here	O
we	O
show	O
that	O
these	O
synthetic	O
binding	O
sites	O
have	O
a	O
more	O
restricted	O
and	O
specific	O
ability	O
to	O
enhance	O
transcription	O
when	O
assayed	O
in	O
transformed	O
embryos	O
.	O

Administration	O
of	O
anticoagulants	O
,	O
i	O
.	O
e	O
.	O
,	O
heparin	O
,	O
prostaglandin	O
E1	O
and	O
ticlopidine	O
seems	O
to	O
be	O
effective	O
in	O
alleviating	O
symptoms	O
and	O
might	O
prevent	O
further	O
deterioration	O
.	O

Both	O
tear	O
volume	O
and	O
tear	O
flow	O
were	O
found	O
to	O
be	O
significantly	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
decreased	O
up	O
to	O
6	O
h	O
after	O
instillation	O
,	O
reaching	O
a	O
minimum	O
90	O
min	O
after	O
application	O
(	O
tear	O
volume	O
:	O
-	O
63	O
%	O
;	O
tear	O
flow	O
:	O
-	O
71	O
%	O
)	O
.	O

Experimental	O
reproduction	O
of	O
malignant	O
catarrhal	O
fever	O
in	O
Bali	O
cattle	O
.	O

Deletion	O
analysis	O
was	O
carried	O
out	O
within	O
a	O
part	O
of	O
the	O
5	O
'	O
-	O
flanking	O
region	O
showing	O
homology	O
to	O
the	O
upstream	O
region	O
of	O
the	O
yeast	B-GENE
CYC1	I-GENE
gene	I-GENE
.	O

The	O
fusion	O
proteins	O
were	O
tested	O
by	O
ELISA	O
for	O
reactivity	O
with	O
a	O
panel	O
of	O
human	B-GENE
anti	I-GENE
-	I-GENE
La	I-GENE
sera	I-GENE
in	O
order	O
to	O
define	O
the	O
nature	O
of	O
the	O
epitopes	O
.	O

Class	B-GENE
I	I-GENE
alpha1	I-GENE
,	I-GENE
2	I-GENE
-	I-GENE
mannosidases	I-GENE
play	O
an	O
essential	O
role	O
in	O
the	O
elaboration	O
of	O
complex	O
and	O
hybrid	O
N	O
-	O
glycans	O
in	O
mammalian	O
cells	O
.	O

Recent	O
developments	O
in	O
drugs	O
antagonistic	O
to	O
factors	O
causing	O
peptic	O
ulcer	O
-	O
-	O
clinical	O
efficacy	O
and	O
problems	O
;	O
gastrin	B-GENE
receptor	I-GENE
blockaders	O
.	O

SCOB	O
testing	O
of	O
food	O
-	O
restricted	O
animals	O
,	O
using	O
a	O
multiple	O
fixed	O
ratio	O
(	O
FR	O
)	O
/	O
fixed	O
interval	O
(	O
FI	O
)	O
schedule	O
(	O
FR20	O
:	O
FI120	O
)	O
,	O
was	O
conducted	O
prior	O
to	O
each	O
exposure	O
to	O
maintain	O
the	O
operant	O
behavior	O
;	O
the	O
data	O
from	O
Weeks	O
-	O
1	O
,	O
4	O
,	O
8	O
,	O
and	O
13	O
were	O
evaluated	O
for	O
evidence	O
of	O
neurotoxicity	O
.	O

Two	O
overlapping	O
clones	O
contained	O
the	O
complete	O
Adh	B-GENE
-	I-GENE
2	I-GENE
gene	I-GENE
composed	O
of	O
nine	O
exons	O
in	O
a	O
12	O
-	O
kb	O
region	O
,	O
with	O
the	O
placement	O
of	O
introns	O
matching	O
that	O
observed	O
in	O
other	O
mammalian	B-GENE
ADH	I-GENE
genes	I-GENE
.	O

The	O
imprinted	O
expression	O
of	O
the	O
endogenous	O
gene	O
can	O
be	O
recapitulated	O
in	O
mice	O
by	O
using	O
a	O
14	O
-	O
kb	O
transgene	O
encompassing	O
4	O
kb	O
of	O
5	O
'	O
-	O
flanking	O
sequence	O
,	O
8	O
kb	O
of	O
3	O
'	O
-	O
flanking	O
sequence	O
,	O
which	O
includes	O
the	O
two	O
endoderm	O
-	O
specific	O
enhancers	O
,	O
and	O
an	O
internally	O
deleted	O
structural	O
gene	O
.	O

The	O
strong	O
conservation	O
of	O
the	O
inverted	O
terminal	O
repeat	O
sequence	O
may	O
reflect	O
a	O
common	O
integration	O
mechanism	O
for	O
VL30	B-GENE
elements	I-GENE
and	O
MuLV	O
proviruses	O
.	O

A	O
method	O
of	O
three	O
-	O
station	O
three	O
-	O
dimensional	O
magnetic	O
resonance	O
(	O
MR	O
)	O
angiography	O
of	O
the	O
lower	O
extremities	O
with	O
segmented	O
volume	O
acquisition	O
is	O
presented	O
.	O

The	O
presence	O
of	O
unidentified	O
macroscopic	O
or	O
microscopic	O
clusters	O
of	O
neoplastic	O
cells	O
,	O
lying	O
around	O
,	O
more	O
or	O
less	O
close	O
to	O
,	O
the	O
line	O
of	O
insertion	O
of	O
lesion	O
,	O
could	O
render	O
any	O
attempt	O
to	O
gain	O
a	O
"	O
radical	O
"	O
excision	O
useless	O
.	O

Psychological	O
examinations	O
in	O
patients	O
with	O
chronic	O
kidney	O
insufficiency	O
.	O

Pathological	O
processes	O
in	O
the	O
cervix	O
uteri	O
.	O

After	O
the	O
first	O
cycle	O
,	O
18	O
cases	O
were	O
treated	O
at	O
dose	O
level	O
1	O
,	O
after	O
a	O
second	O
cycle	O
,	O
13	O
cases	O
were	O
treated	O
at	O
dose	O
level	O
2	O
.	O

Their	O
hydropathic	O
plots	O
are	O
very	O
similar	O
and	O
both	O
possess	O
three	O
hydrophobic	O
segments	O
that	O
are	O
likely	O
alpha	O
-	O
helical	O
transmembrane	O
segments	O
.	O

We	O
propose	O
that	O
Mnt	B-GENE
:	O
Max	B-GENE
:	O
Sin3	B-GENE
complexes	O
normally	O
function	O
to	O
restrict	O
Myc	B-GENE
:	O
Max	B-GENE
activities	O
associated	O
with	O
cell	O
proliferation	O
.	O

We	O
recently	O
characterized	O
a	O
single	O
yeast	B-GENE
hnRNP	I-GENE
methyltransferase	I-GENE
(	O
HMT1	B-GENE
)	O
.	O

The	O
factor	O
which	O
binds	O
to	O
the	O
TR	B-GENE
promoter	I-GENE
co	O
-	O
sedimented	O
with	O
SV40	O
chromosomes	O
extracted	O
late	O
in	O
infection	O
.	O

Complexes	O
of	O
qTBP42	B-GENE
with	O
each	O
complementary	O
strand	O
of	O
telomeric	O
DNA	O
and	O
with	O
quadruplex	O
forms	O
of	O
the	O
guanine	O
-	O
rich	O
strand	O
had	O
3	O
.	O
7	O
-	O
14	O
.	O
6	O
nM	O
dissociation	O
constants	O
,	O
Kd	O
,	O
whereas	O
complexes	O
with	O
double	O
-	O
stranded	O
telomeric	O
DNA	O
had	O
up	O
to	O
100	O
-	O
fold	O
higher	O
Kd	O
values	O
.	O

Between	O
the	O
subgroups	O
of	O
dementia	O
disorders	O
there	O
were	O
no	O
significant	O
differences	O
in	O
basal	O
cortisol	O
levels	O
.	O

Certain	O
characteristics	O
of	O
eye	O
changes	O
in	O
patients	O
with	O
pheochromocytoma	O
including	O
Sipple	O
'	O
s	O
syndrome	O
.	O

Proteomic	O
patterns	O
of	O
nipple	O
aspirate	O
fluids	O
obtained	O
by	O
SELDI	O
-	O
TOF	O
:	O
potential	O
for	O
new	O
biomarkers	O
to	O
aid	O
in	O
the	O
diagnosis	O
of	O
breast	O
cancer	O
.	O

Correlation	O
of	O
skin	O
disorders	O
with	O
CD4	B-GENE
lymphocyte	O
counts	O
in	O
patients	O
with	O
HIV	O
/	O
AIDS	O
.	O

An	O
intact	O
5	O
.	O
7	O
-	O
kb	O
provirus	O
of	O
the	O
avian	O
erythroblastosis	O
virus	O
E26	O
has	O
been	O
molecularly	O
cloned	O
for	O
comparisons	O
with	O
avian	O
myeloblastosis	O
virus	O
(	O
AMV	O
)	O
and	O
other	O
avian	O
tumor	O
viruses	O
.	O

RESULTS	O
:	O
For	O
E1	O
,	O
itraconazole	O
plasma	O
drug	O
concentration	O
extrapolated	O
to	O
time	O
zero	O
(	O
IV	O
dose	O
)	O
was	O
5	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
4	O
micrograms	O
/	O
ml	O
,	O
and	O
mean	O
residence	O
time	O
(	O
MRT	O
)	O
was	O
37	O
+	O
/	O
-	O
16	O
hours	O
.	O

It	O
was	O
shown	O
that	O
administration	O
of	O
immunomodulator	O
neurotropin	B-GENE
(	O
NSP	B-GENE
)	O
results	O
in	O
more	O
steady	O
consolidation	O
and	O
retention	O
of	O
feeding	O
and	O
avoidance	O
behavior	O
,	O
and	O
some	O
neurophysiological	O
mechanisms	O
of	O
that	O
phenomena	O
were	O
revealed	O
.	O

Intriguingly	O
,	O
three	O
hypomorphic	O
Scm	B-GENE
mutations	O
,	O
which	O
map	O
within	O
an	O
mbt	B-GENE
repeat	I-GENE
,	O
interact	O
with	O
PcG	B-GENE
mutations	I-GENE
more	O
strongly	O
than	O
do	O
Scm	B-GENE
null	O
alleles	O
.	O

Serial	O
measurements	O
of	O
total	O
serum	O
IgE	B-GENE
appears	O
to	O
be	O
a	O
useful	O
index	O
of	O
disease	O
activity	O
in	O
ABPA	O
.	O

Dynamic	O
decision	O
making	O
:	O
human	O
control	O
of	O
complex	O
systems	O
.	O

Autopsy	O
demonstrated	O
good	O
survival	O
of	O
the	O
transplanted	O
cells	O
with	O
good	O
integration	O
with	O
the	O
brain	O
of	O
the	O
recipient	O
and	O
traces	O
of	O
positive	O
immunocytochemical	O
reaction	O
for	O
tyrosine	B-GENE
hydroxylase	I-GENE
.	O

After	O
profound	O
normovolemic	O
hemodilution	O
(	O
Hct	O
9	O
%	O
)	O
superiority	O
of	O
LV	O
MC	O
and	O
LV	O
diastolic	O
properties	O
was	O
found	O
,	O
when	O
myocardial	O
oxygenation	O
was	O
supported	O
by	O
i	O
.	O
v	O
.	O
perflubron	O
emulsion	O
,	O
a	O
temporary	O
O2	O
carrier	O
.	O

The	O
inner	O
ears	O
were	O
exposed	O
by	O
microdissection	O
,	O
and	O
the	O
vestibular	O
sensory	O
regions	O
were	O
either	O
sectioned	O
and	O
studied	O
with	O
light	O
or	O
electron	O
microscopy	O
,	O
or	O
prepared	O
and	O
studied	O
with	O
the	O
surface	O
specimen	O
technique	O
.	O

One	O
of	O
these	O
fragments	O
shows	O
the	O
highest	O
amino	O
acid	O
sequence	O
homology	O
to	O
the	O
insect	O
ecdysone	O
inducible	O
gene	B-GENE
E75	I-GENE
.	O

The	O
domain	O
structure	O
of	O
bovine	B-GENE
LTBP	I-GENE
-	I-GENE
2	I-GENE
is	O
very	O
similar	O
to	O
that	O
of	O
the	O
human	B-GENE
LTBP	I-GENE
-	I-GENE
2	I-GENE
,	O
containing	O
20	O
examples	O
of	O
6	O
-	O
cysteine	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
-	I-GENE
like	I-GENE
repeats	I-GENE
,	O
16	O
of	O
which	O
have	O
the	O
consensus	O
sequence	O
for	O
calcium	O
binding	O
,	O
together	O
with	O
4	O
examples	O
of	O
8	B-GENE
-	I-GENE
cysteine	I-GENE
motifs	I-GENE
characteristic	O
of	O
fibrillins	B-GENE
and	O
LTBP	B-GENE
-	I-GENE
1	I-GENE
.	O

Stat	B-GENE
activation	O
in	O
response	O
to	O
GH	B-GENE
and	O
IL	B-GENE
-	I-GENE
6	I-GENE
was	O
determined	O
by	O
reporter	O
gene	O
induction	O
.	O

During	O
early	O
neurogenesis	O
,	O
Vnd	B-GENE
protein	I-GENE
is	O
restricted	O
to	O
ventral	O
column	O
neuroectoderm	O
and	O
neuroblasts	O
;	O
later	O
it	O
is	O
detected	O
in	O
a	O
complex	O
pattern	O
of	O
neurons	O
.	O

The	O
median	O
post	O
-	O
treatment	O
,	O
pre	O
-	O
operative	O
serum	B-GENE
PSA	I-GENE
was	O
0	O
.	O
4	O
ng	O
/	O
ml	O
.	O

The	O
growth	B-GENE
factor	I-GENE
receptor	I-GENE
-	I-GENE
bound	I-GENE
protein	I-GENE
2	I-GENE
(	O
Grb2	B-GENE
)	O
adaptor	O
when	O
complexed	O
with	O
Sos	B-GENE
(	O
Son	B-GENE
of	I-GENE
sevenless	I-GENE
)	O
,	O
the	O
exchange	O
factor	O
of	O
Ras	B-GENE
,	O
conveys	O
the	O
signal	O
induced	O
by	O
tyrosine	B-GENE
kinase	I-GENE
-	I-GENE
activated	I-GENE
receptor	I-GENE
to	O
Ras	B-GENE
by	O
recruiting	O
Sos	B-GENE
to	O
the	O
membrane	O
,	O
allowing	O
activation	O
of	O
Ras	B-GENE
.	O

Thus	O
,	O
despite	O
the	O
potential	O
for	O
common	O
regulatory	O
mechanisms	O
,	O
the	O
available	O
evidence	O
indicates	O
that	O
the	O
Mtx	B-GENE
minimal	I-GENE
promoter	I-GENE
does	O
not	O
significantly	O
affect	O
Thbs3	B-GENE
gene	I-GENE
expression	O
.	O

Phosphatidylinositol	B-GENE
3	I-GENE
-	I-GENE
kinase	I-GENE
potentiates	O
,	O
but	O
does	O
not	O
trigger	O
,	O
T	O
cell	O
proliferation	O
mediated	O
by	O
the	O
IL	B-GENE
-	I-GENE
2	I-GENE
receptor	I-GENE
.	O

Value	O
of	O
the	O
EMG	O
in	O
the	O
diagnosis	O
of	O
a	O
cardiomyopathy	O
associated	O
with	O
a	O
myotonic	O
myopathy	O
.	O

As	O
a	O
result	O
of	O
alternative	O
splicing	O
,	O
the	O
BGP	B-GENE
gene	I-GENE
is	O
transcribed	O
into	O
at	O
least	O
seven	O
distinct	O
mRNA	O
species	O
.	O

Finally	O
,	O
some	O
point	O
mutations	O
in	O
the	O
Gag	B-GENE
-	I-GENE
Pol	I-GENE
PR	B-GENE
domain	I-GENE
inhibited	O
activation	O
of	O
RT	B-GENE
in	O
trans	O
by	O
a	O
wild	B-GENE
-	I-GENE
type	I-GENE
PR	I-GENE
,	O
suggesting	O
that	O
the	O
correct	O
conformation	O
of	O
the	O
PR	B-GENE
domain	I-GENE
in	O
Gag	B-GENE
-	I-GENE
Pol	I-GENE
is	O
prerequisite	O
for	O
activation	O
of	O
RT	O
.	O

Three	O
different	O
site	O
-	O
directed	O
mutations	O
of	O
the	O
cyclic	B-GENE
AMP	I-GENE
response	I-GENE
element	I-GENE
each	O
reduced	O
the	O
nerve	B-GENE
growth	I-GENE
factor	I-GENE
effect	O
by	O
>	O
90	O
%	O
.	O

Significant	O
GMBF	O
reductions	O
occurred	O
in	O
early	O
shock	O
in	O
both	O
treatment	O
groups	O
.	O

HBB	O
concentration	O
in	O
the	O
fetuses	O
indicated	O
little	O
,	O
if	O
any	O
accumulation	O
.	O

SPP	B-GENE
also	O
induced	O
transient	O
tyrosine	O
phosphorylation	O
of	O
focal	B-GENE
adhesion	I-GENE
kinase	I-GENE
(	O
p125	B-GENE
(	I-GENE
FAK	I-GENE
)	I-GENE
)	O
,	O
a	O
cytosolic	B-GENE
tyrosine	I-GENE
kinase	I-GENE
that	O
localizes	O
in	O
focal	O
adhesions	O
,	O
and	O
of	O
the	O
cytoskeleton	B-GENE
-	I-GENE
associated	I-GENE
protein	I-GENE
paxillin	I-GENE
.	O

Unlike	O
the	O
introns	O
of	O
other	O
duplicated	O
ribosomal	O
protein	O
genes	O
which	O
are	O
highly	O
diverged	O
,	O
the	O
duplicated	O
S13	B-GENE
genes	I-GENE
have	O
two	O
nearly	O
identical	O
DNA	O
sequences	O
of	O
25	O
and	O
31	O
bp	O
in	O
length	O
within	O
their	O
introns	O
.	O

Changes	O
induced	O
in	O
the	O
gills	O
of	O
milkfish	O
(	O
Chanos	O
chanos	O
Forsskal	O
)	O
fingerlings	O
after	O
acute	O
exposure	O
to	O
nifurpirinol	O
(	O
Furanace	O
;	O
P	O
-	O
7138	O
)	O
.	O

In	O
agreement	O
with	O
these	O
data	O
,	O
western	O
blot	O
experiments	O
using	O
an	O
antibody	O
directed	O
against	O
the	O
carboxy	O
-	O
terminal	O
portion	O
of	O
the	O
mouse	O
c	B-GENE
-	I-GENE
kit	I-GENE
protein	I-GENE
showed	O
that	O
a	O
polypeptide	O
,	O
of	O
the	O
size	O
predicted	O
by	O
the	O
open	O
reading	O
frame	O
of	O
the	O
spermatid	B-GENE
-	I-GENE
specific	I-GENE
c	I-GENE
-	I-GENE
kit	I-GENE
cDNA	I-GENE
,	O
accumulates	O
in	O
the	O
latest	O
stages	O
of	O
spermatogenesis	O
and	O
in	O
epididymal	O
spermatozoa	O
.	O

Both	O
the	O
presence	O
of	O
arginine	O
and	O
anaerobiosis	O
are	O
needed	O
to	O
trigger	O
induction	O
of	O
the	O
pathway	O
.	O

The	O
relatively	O
mild	O
defects	O
observed	O
in	O
Rpd3	B-GENE
mutants	I-GENE
suggest	O
that	O
the	O
recently	O
identified	O
Groucho	B-GENE
and	O
dCtBP	B-GENE
corepressor	I-GENE
proteins	I-GENE
do	O
not	O
function	O
solely	O
through	O
the	O
recruitment	O
of	O
histone	B-GENE
deacetylases	I-GENE
.	O

Since	O
September	O
1980	O
to	O
June	O
1983	O
we	O
have	O
treated	O
32	O
patients	O
with	O
ovarian	O
cancer	O
.	O

Nonreturn	O
rates	O
can	O
be	O
used	O
to	O
derive	O
more	O
elementary	O
biological	O
measures	O
for	O
reproductive	O
efficiency	O
,	O
such	O
as	O
conception	O
rate	O
and	O
calving	O
rate	O
,	O
which	O
separately	O
might	O
be	O
more	O
reliable	O
than	O
nonreturn	O
rate	O
itself	O
to	O
evaluate	O
the	O
fertility	O
of	O
a	O
bull	O
or	O
the	O
performance	O
of	O
an	O
AI	O
technician	O
.	O

Waves	O
N1	O
,	O
P3	O
and	O
CNV	O
were	O
recorded	O
during	O
a	O
CNV	O
paradigm	O
in	O
a	O
simple	O
reaction	O
time	O
task	O
with	O
a	O
constant	O
interstimulus	O
interval	O
(	O
ISI	O
)	O
of	O
1	O
sec	O
.	O

In	O
the	O
B6	O
-	O
derived	O
Db	B-GENE
mutant	I-GENE
B6	I-GENE
.	I-GENE
CH	I-GENE
-	I-GENE
2bm13	I-GENE
(	I-GENE
bm13	I-GENE
)	I-GENE
strain	O
,	O
part	O
of	O
the	O
class	B-GENE
I	I-GENE
Db	I-GENE
antigen	I-GENE
-	I-GENE
presenting	I-GENE
groove	I-GENE
is	O
shaped	O
by	O
a	O
class	B-GENE
I	I-GENE
Kb	I-GENE
-	I-GENE
encoded	I-GENE
sequence	I-GENE
.	O

The	O
stability	O
of	O
isoniazid	O
solutions	O
increases	O
markedly	O
with	O
increasing	O
NTA	O
or	O
EDTA	O
concentration	O
up	O
to	O
1	O
mmol	O
/	O
l	O
.	O

Prolonged	O
suspension	O
induced	O
a	O
significant	O
change	O
in	O
the	O
geometric	O
configuration	O
of	O
the	O
femur	O
middiaphysis	O
by	O
increasing	O
the	O
minimum	O
diameter	O
(	O
12	O
%	O
)	O
without	O
any	O
significant	O
alterations	O
in	O
cortical	O
area	O
,	O
density	O
,	O
mineral	O
,	O
and	O
collagen	B-GENE
concentrations	O
.	O

The	O
dynamic	O
properties	O
of	O
this	O
protein	O
fragment	O
were	O
measured	O
and	O
analyzed	O
using	O
both	O
isotropic	O
and	O
anisotropic	O
models	O
of	O
molecular	O
motion	O
.	O

The	O
original	O
technique	O
was	O
developed	O
in	O
the	O
1960	O
'	O
s	O
to	O
analyze	O
the	O
inner	O
ear	O
fluid	O
as	O
a	O
diagnostic	O
procedure	O
(	O
i	O
.	O
e	O
.	O
,	O
diagnostic	O
labyrinthotomy	O
)	O
in	O
acoustic	O
neuroma	O
suspects	O
.	O

This	O
study	O
utilizes	O
the	O
mammalian	O
two	O
-	O
hybrid	O
system	O
to	O
examine	O
the	O
role	O
of	O
ligand	O
in	O
the	O
dimerization	O
of	O
human	B-GENE
progesterone	I-GENE
receptor	I-GENE
(	O
hPR	B-GENE
)	O
.	O

No	O
mutation	O
of	O
the	O
NRL	B-GENE
gene	I-GENE
was	O
found	O
in	O
any	O
of	O
the	O
two	O
families	O
.	O

The	O
Nmd3	B-GENE
protein	I-GENE
sequence	I-GENE
does	O
not	O
contain	O
readily	O
recognizable	O
motifs	O
of	O
known	O
function	O
.	O

Several	O
distinct	O
apoptotic	O
stimuli	O
induce	O
the	O
expression	O
and	O
caspase	O
-	O
dependent	O
cleavage	O
of	O
hTAF	B-GENE
(	I-GENE
II	I-GENE
)	I-GENE
80	I-GENE
delta	I-GENE
.	O
hTAF	B-GENE
(	I-GENE
II	I-GENE
)	I-GENE
80	I-GENE
delta	I-GENE
,	O
unlike	O
hTAF	B-GENE
(	I-GENE
II	I-GENE
)	I-GENE
80	I-GENE
,	O
forms	O
a	O
TFIID	B-GENE
-	I-GENE
like	I-GENE
complex	I-GENE
lacking	O
hTAF	B-GENE
(	I-GENE
II	I-GENE
)	I-GENE
31	I-GENE
.	O

A	O
computed	O
tomographic	O
scan	O
obtained	O
after	O
EOE	O
-	O
13	O
infusion	O
accurately	O
showed	O
the	O
perfusion	O
pattern	O
of	O
the	O
implanted	O
catheter	O
.	O

Therefore	O
,	O
in	O
conjunction	O
with	O
a	O
positive	O
pregnancy	O
test	O
and	O
the	O
patient	O
'	O
s	O
clinical	O
history	O
,	O
a	O
severely	O
depressed	O
or	O
absent	O
serum	O
PAPP	B-GENE
-	I-GENE
A	I-GENE
level	O
may	O
aid	O
in	O
the	O
diagnosis	O
of	O
extrauterine	O
pregnancy	O
.	O

Aneurysmal	O
bone	O
cyst	O
of	O
the	O
jaws	O
:	O
analysis	O
of	O
11	O
cases	O
.	O

An	O
8	O
-	O
bp	O
sequence	O
(	O
ATTTCAAA	B-GENE
)	O
within	O
the	O
protected	O
region	O
shares	O
significant	O
homology	O
with	O
promoter	O
sequences	O
required	O
for	O
ethylene	O
responsiveness	O
from	O
the	O
tomato	O
fruit	O
-	O
ripening	O
E4	B-GENE
gene	I-GENE
.	O

However	O
,	O
the	O
a1	B-GENE
isoform	I-GENE
is	O
expressed	O
most	O
heavily	O
in	O
brain	O
and	O
heart	O
,	O
a2	B-GENE
in	O
liver	O
and	O
kidney	O
,	O
and	O
a3	B-GENE
in	O
liver	O
,	O
lung	O
,	O
heart	O
,	O
brain	O
,	O
spleen	O
,	O
and	O
kidney	O
.	O

The	O
R2	B-GENE
region	I-GENE
within	O
the	O
class	B-GENE
I	I-GENE
enhancer	I-GENE
acts	O
as	O
a	O
negative	O
element	O
in	O
Ad12	O
-	O
transformed	O
cells	O
and	O
exhibits	O
a	O
stronger	O
binding	O
activity	O
than	O
is	O
observed	O
in	O
nontumorigenic	O
Ad5	O
-	O
transformed	O
cells	O
,	O
which	O
are	O
not	O
reduced	O
in	O
class	B-GENE
I	I-GENE
expression	O
.	O

Diverse	O
endogenous	O
light	O
chains	O
contribute	O
to	O
basement	O
membrane	O
reactivity	O
in	O
nonautoimmune	O
mice	O
transgenic	O
for	O
an	O
anti	B-GENE
-	I-GENE
laminin	I-GENE
Ig	I-GENE
heavy	I-GENE
chain	I-GENE
.	O

UF	O
-	O
021	O
ophthalmic	O
solution	O
(	O
0	O
.	O
03	O
to	O
0	O
.	O
24	O
%	O
)	O
,	O
when	O
topically	O
applied	O
to	O
the	O
eyes	O
of	O
rabbits	O
,	O
caused	O
dose	O
-	O
dependent	O
IOP	O
reduction	O
(	O
2	O
.	O
8	O
to	O
5	O
.	O
2	O
mmHg	O
)	O
,	O
without	O
transient	O
IOP	O
rise	O
.	O

All	O
9	O
untreated	O
patients	O
underwent	O
laparoscopy	O
,	O
which	O
identified	O
3	O
intra	O
-	O
abdominal	O
,	O
3	O
vanished	O
and	O
2	O
peeping	O
testes	O
,	O
and	O
1	O
atrophic	O
testis	O
in	O
the	O
inguinal	O
canal	O
.	O

This	O
slope	O
tended	O
to	O
be	O
higher	O
(	O
approximately	O
1	O
.	O
6	O
dB	O
/	O
dB	O
)	O
for	O
L1	O
=	O
L2	O
greater	O
than	O
80	O
dB	O
.	O

Another	O
stem	O
-	O
loop	O
called	O
structure	O
III	O
near	O
the	O
3	O
'	O
-	O
end	O
of	O
repY	B-GENE
sequesters	O
both	O
the	O
5	B-GENE
'	I-GENE
-	I-GENE
rCGCC	I-GENE
-	I-GENE
3	I-GENE
'	I-GENE
sequence	I-GENE
and	O
the	O
repZ	B-GENE
ribosome	I-GENE
-	I-GENE
binding	I-GENE
site	I-GENE
.	O

We	O
further	O
studied	O
the	O
effects	O
of	O
SIE	B-GENE
-	I-GENE
1	I-GENE
hypermethylation	O
on	O
p21WAF1	B-GENE
induction	O
by	O
STAT	B-GENE
activation	O
.	O

Tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
-	I-GENE
alpha	I-GENE
(	O
TNF	B-GENE
alpha	I-GENE
)	O
,	O
a	O
proinflammatory	O
cytokine	O
,	O
inhibits	O
cAMP	O
-	O
stimulated	O
testosterone	O
production	O
in	O
mouse	O
Leydig	O
cells	O
.	O

Positive	O
shifts	O
of	O
basal	O
skin	O
potentials	O
during	O
human	O
sleep	O
.	O

To	O
explore	O
the	O
functional	O
properties	O
of	O
the	O
protein	O
encoded	O
by	O
neu	B-GENE
,	O
we	O
created	O
a	O
fusion	O
gene	O
that	O
joins	O
the	O
cytoplasmic	O
domain	O
of	O
neu	B-GENE
to	O
the	O
extracellular	O
portion	O
of	O
an	O
immunoglobulin	B-GENE
heavy	I-GENE
chain	I-GENE
.	O

Dermal	O
toxicity	O
and	O
carcinogenicity	O
of	O
4	O
-	O
vinyl	O
-	O
1	O
-	O
cyclohexene	O
diepoxide	O
in	O
Fischer	O
rats	O
and	O
B6C3F1	O
mice	O
.	O

Radiogallium	O
imaging	O
is	O
thus	O
of	O
limited	O
use	O
in	O
evaluation	O
of	O
suspected	O
giant	O
cell	O
tumors	O
of	O
bone	O
.	O

In	O
vivo	O
epiluminescence	O
microscopy	O
of	O
pigmented	O
skin	O
lesions	O
.	O

In	O
invertebrates	O
,	O
Fhit	B-GENE
is	O
encoded	O
as	O
a	O
fusion	O
protein	O
with	O
Nit	B-GENE
,	O
a	O
member	O
of	O
the	O
nitrilase	B-GENE
superfamily	I-GENE
.	O

Here	O
we	O
localize	O
a	O
transferable	O
40	O
-	O
amino	O
acid	O
region	O
within	O
the	O
LBDs	B-GENE
of	O
RXR	B-GENE
,	O
RAR	B-GENE
,	O
TR	B-GENE
,	O
and	O
chicken	B-GENE
ovalbumin	I-GENE
upstream	I-GENE
promoter	I-GENE
transcription	I-GENE
factor	I-GENE
that	O
is	O
critical	O
for	O
determining	O
identity	O
in	O
the	O
heterodimeric	O
interaction	O
and	O
for	O
high	O
-	O
affinity	O
DNA	O
binding	O
.	O

Recently	O
,	O
the	O
3	B-GENE
.	I-GENE
6	I-GENE
-	I-GENE
kb	I-GENE
full	I-GENE
-	I-GENE
length	I-GENE
alpha	I-GENE
-	I-GENE
GalNAc	I-GENE
cDNA	I-GENE
sequence	I-GENE
was	O
isolated	O
and	O
found	O
to	O
have	O
remarkable	O
nucleotide	O
and	O
predicted	O
amino	O
acid	O
homology	O
(	O
55	O
.	O
8	O
and	O
46	O
.	O
9	O
%	O
,	O
respectively	O
)	O
with	O
the	O
human	B-GENE
alpha	I-GENE
-	I-GENE
galactosidase	I-GENE
A	I-GENE
(	O
alpha	B-GENE
-	I-GENE
Gal	I-GENE
A	I-GENE
)	O
cDNA	O
.	O

Re	O
-	O
examination	O
of	O
the	O
ED01	O
study	O
.	O

In	O
the	O
treatment	O
of	O
opioid	O
naive	O
patients	O
who	O
underwent	O
surgery	O
and	O
received	O
opioids	O
for	O
acute	O
pain	O
,	O
oral	O
ADL	O
8	O
-	O
2698	O
(	O
6	O
.	O
0	O
mg	O
)	O
improved	O
the	O
management	O
of	O
postoperative	O
ileus	O
(	O
POI	O
)	O
by	O
shortening	O
the	O
time	O
to	O
achieve	O
normal	O
bowel	O
function	O
and	O
,	O
ultimately	O
,	O
hospital	O
stay	O
.	O

The	O
CPK	B-GENE
-	I-GENE
MB	I-GENE
isoenzyme	I-GENE
showed	O
no	O
percentage	O
increase	O
of	O
total	O
CPK	B-GENE
higher	O
than	O
5	O
%	O
,	O
measured	O
at	O
6	O
,	O
12	O
,	O
and	O
24	O
h	O
after	O
the	O
shock	O
,	O
independent	O
of	O
the	O
number	O
of	O
attempts	O
of	O
cardioversion	O
.	O

Latanoprost	O
produces	O
an	O
additional	O
reduction	O
of	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
when	O
used	O
in	O
combination	O
with	O
timolol	O
,	O
pilocarpine	O
,	O
acetazolamide	O
and	O
dipivefrin	O
.	O

The	O
inhibitory	O
response	O
to	O
taps	O
is	O
essentially	O
a	O
protective	O
reflex	O
which	O
probably	O
serves	O
to	O
reduce	O
the	O
activity	O
of	O
the	O
jaw	O
-	O
closing	O
muscles	O
when	O
one	O
bites	O
unexpectedly	O
on	O
hard	O
objects	O
.	O

A	O
flow	O
rate	O
of	O
at	O
least	O
5	O
mL	O
/	O
h	O
is	O
required	O
through	O
the	O
receptor	O
(	O
volume	O
,	O
0	O
.	O
4	O
mL	O
)	O
for	O
accurate	O
results	O
.	O

We	O
conclude	O
that	O
Hansel	O
'	O
s	O
stain	O
substantially	O
improves	O
the	O
recognition	O
of	O
eosinophiluria	O
as	O
compared	O
with	O
Wright	O
'	O
s	O
stain	O
.	O

Histopathologically	O
,	O
a	O
cystic	O
lymphangioma	O
was	O
diagnosed	O
because	O
of	O
the	O
morphological	O
features	O
and	O
the	O
immunohistochemical	O
stainings	O
of	O
CD34	B-GENE
and	O
Factor	B-GENE
VIII	I-GENE
related	I-GENE
antigen	I-GENE
which	O
were	O
observed	O
positive	O
reactions	O
in	O
endothelial	O
cells	O
of	O
the	O
cysts	O
.	O

These	O
changes	O
in	O
virus	O
entry	O
features	O
may	O
result	O
in	O
coronaviruses	O
with	O
novel	O
pathogenic	O
properties	O
.	O

Allelic	O
variation	O
in	O
HLA	B-GENE
-	I-GENE
B	I-GENE
and	O
HLA	B-GENE
-	I-GENE
C	I-GENE
sequences	I-GENE
and	O
the	O
evolution	O
of	O
the	O
HLA	B-GENE
-	I-GENE
B	I-GENE
alleles	I-GENE
.	O

Nephrectomy	O
applied	O
to	O
cattle	O
.	O

Structure	O
and	O
localization	O
of	O
the	O
human	B-GENE
gene	I-GENE
encoding	I-GENE
SR	I-GENE
-	I-GENE
BI	I-GENE
/	I-GENE
CLA	I-GENE
-	I-GENE
1	I-GENE
.	O

Rhesus	O
macaques	O
and	O
BALB	O
/	O
c	O
mice	O
inoculated	O
with	O
the	O
Mengo	O
virus	O
SIV	O
recombinants	O
failed	O
to	O
develop	O
CTL	O
responses	O
against	O
the	O
SIV	O
gene	O
products	O
,	O
while	O
one	O
of	O
the	O
HIV	B-GENE
-	I-GENE
Nef	I-GENE
recombinants	I-GENE
induced	O
a	O
weak	O
CTL	O
response	O
in	O
mice	O
directed	O
to	O
an	O
HIV1	B-GENE
Nef	I-GENE
peptide	I-GENE
spanning	O
positions	O
182	O
-	O
198	O
.	O

We	O
cloned	O
and	O
sequenced	O
the	O
cDNAs	O
against	O
genomic	O
RNA	O
and	O
mRNA	O
for	O
phosphoprotein	O
(	O
P	O
)	O
of	O
human	O
parainfluenza	O
type	O
2	O
virus	O
(	O
PIV	O
-	O
2	O
)	O
.	O
cDNA	O
clone	O
from	O
genomic	O
RNA	O
was	O
1439	O
nucleotides	O
in	O
length	O
excluding	O
poly	O
(	O
A	O
)	O
and	O
was	O
found	O
to	O
have	O
two	O
small	O
open	O
reading	O
frames	O
encoding	O
proteins	O
of	O
233	O
and	O
249	O
amino	O
acids	O
.	O

Also	O
,	O
samples	O
of	O
serum	O
were	O
absorbed	O
with	O
the	O
various	O
solid	O
-	O
phase	O
allergens	O
and	O
the	O
reactivity	O
of	O
the	O
remaining	O
IgE	B-GENE
antibodies	I-GENE
was	O
determined	O
.	O

This	O
study	O
demonstrates	O
that	O
alteration	O
of	O
CDKN2	B-GENE
is	O
one	O
of	O
the	O
most	O
frequent	O
genetic	O
abnormalities	O
in	O
prostate	O
cancer	O
and	O
may	O
contribute	O
to	O
prostate	O
carcinogenesis	O
.	O

The	O
chick	O
axon	O
-	O
associated	O
surface	O
glycoprotein	O
neurofascin	B-GENE
is	O
implicated	O
in	O
axonal	O
growth	O
and	O
fasciculation	O
as	O
revealed	O
by	O
antibody	O
perturbation	O
experiments	O
.	O

In	O
contrast	O
,	O
overproduction	O
of	O
Der3p	B-GENE
is	O
lethal	O
in	O
a	O
sec61	B-GENE
-	I-GENE
2	I-GENE
strain	O
at	O
the	O
permissive	O
temperature	O
of	O
25	O
degrees	O
C	O
.	O

The	O
unilateral	O
vestibular	O
hypofunction	O
.	O

The	O
lysozyme	B-GENE
FEF	I-GENE
site	I-GENE
is	O
immediately	O
5	O
'	O
to	O
a	O
PU	B-GENE
.	O

The	O
authors	O
have	O
tested	O
the	O
interference	O
of	O
the	O
hemoglobin	B-GENE
by	O
two	O
routine	O
methods	O
(	O
Berthelot	O
classic	O
and	O
Berthelot	O
modified	O
)	O
for	O
the	O
determination	O
of	O
plasmatic	O
urea	O
.	O

The	O
nit	B-GENE
-	I-GENE
3	I-GENE
gene	I-GENE
of	I-GENE
the	I-GENE
filamentous	I-GENE
fungus	I-GENE
Neurospora	I-GENE
crassa	I-GENE
encodes	O
nitrate	B-GENE
reductase	I-GENE
,	O
the	O
enzyme	O
which	O
catalyzes	O
the	O
first	O
step	O
in	O
nitrate	O
assimilation	O
.	O

IgG	B-GENE
and	O
IgM	B-GENE
antibody	O
activity	O
was	O
determined	O
by	O
adding	O
a	O
1	O
:	O
100	O
dilution	O
of	O
serum	O
to	O
plates	O
coated	O
with	O
A60	B-GENE
antigen	I-GENE
.	O

GAL4	O
-	O
VP16	O
-	O
mediated	O
antirepression	O
required	O
an	O
auxiliary	O
factor	O
,	O
denoted	O
as	O
a	O
co	O
-	O
antirepressor	O
,	O
which	O
was	O
partially	O
purified	O
from	O
Drosophila	O
embryos	O
.	O

A	O
consensus	O
binding	O
site	O
for	O
the	O
transcription	O
factor	O
SP1	B-GENE
was	O
identified	O
in	O
intron	O
As	O
downstream	O
of	O
the	O
proenkephalin	B-GENE
germ	I-GENE
cell	I-GENE
cap	I-GENE
site	I-GENE
region	I-GENE
.	O

The	O
isolation	O
of	O
this	O
gene	O
was	O
based	O
on	O
the	O
identification	O
of	O
the	O
Y	O
-	O
231	O
cosmid	O
that	O
contains	O
CpG	O
rich	O
sequences	O
(	O
HTF	B-GENE
islands	I-GENE
)	O
in	O
its	O
human	O
insert	O
.	O

Sulfuric	O
acid	O
concentration	O
in	O
the	O
catalyzed	O
breathalyzer	O
ampules	O
.	O

Additionally	O
,	O
a	O
CaCO3	O
-	O
CO2	O
/	O
N2	O
buffered	O
solution	O
was	O
necessary	O
to	O
maintain	O
a	O
pH	O
of	O
8	O
.	O

For	O
this	O
reason	O
,	O
the	O
particle	O
forming	O
capacity	O
of	O
derivatives	O
of	O
the	O
HIV	B-GENE
-	I-GENE
1	I-GENE
group	I-GENE
specific	I-GENE
core	I-GENE
antigen	I-GENE
p55	I-GENE
gag	I-GENE
was	O
assayed	O
and	O
compared	O
dependent	O
on	O
various	O
expression	O
systems	O
:	O
recombinant	O
bacteria	O
,	O
vaccinia	O
-	O
and	O
baculoviruses	O
were	O
established	O
encoding	O
the	O
entire	O
core	B-GENE
protein	I-GENE
p55	I-GENE
either	O
in	O
its	O
authentic	O
sequence	O
or	O
lacking	O
the	O
myristylation	O
consensus	O
signal	O
.	O

Ketanserin	O
,	O
a	O
hypotensive	O
drug	O
with	O
5	B-GENE
-	I-GENE
HT2	I-GENE
receptor	I-GENE
antagonism	O
,	O
when	O
administered	O
by	O
topical	O
infusion	O
of	O
a	O
0	O
.	O
25	O
%	O
w	O
/	O
v	O
solution	O
by	O
corneal	O
and	O
scleral	O
applications	O
,	O
was	O
found	O
to	O
lower	O
intraocular	O
pressure	O
with	O
four	O
times	O
more	O
activity	O
than	O
its	O
metabolite	O
,	O
ketanserinol	O
.	O

The	O
starting	O
point	O
is	O
the	O
consideration	O
that	O
the	O
conceptions	O
underlying	O
the	O
ICIDH	O
are	O
not	O
suitable	O
to	O
serve	O
as	O
a	O
mainstay	O
of	O
a	O
model	O
for	O
diagnostics	O
in	O
rehabilitation	O
because	O
they	O
do	O
not	O
reflect	O
essential	O
characteristics	O
of	O
the	O
diagnostic	O
process	O
which	O
is	O
the	O
basis	O
for	O
intervention	O
.	O

Analysis	O
of	O
the	O
entire	O
16	O
.	O
7	O
-	O
kb	O
mt	O
genome	O
determined	O
that	O
a	O
MDP1	B-GENE
mediates	O
cleavage	O
of	O
chick	O
mtDNA	O
in	O
vitro	O
at	O
three	O
H	O
-	O
and	O
two	O
L	O
-	O
strand	O
sequence	O
-	O
specific	O
target	O
sites	O
located	O
within	O
a	O
90	O
-	O
bp	O
A	O
+	O
T	O
-	O
rich	O
genomic	O
tract	O
,	O
theoretically	O
capable	O
of	O
forming	O
stable	O
secondary	O
structures	O
,	O
approximately	O
200	O
bases	O
upstream	O
from	O
the	O
H	O
-	O
strand	O
origin	O
(	O
OH	O
)	O
of	O
replication	O
.	O

Utility	O
of	O
OAE	O
screener	O
(	O
GSI	O
70	O
)	O
for	O
the	O
evaluation	O
of	O
distortion	O
product	O
otoacoustic	O
emissions	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
ability	O
of	O
the	O
OAE	O
screener	O
GSI	O
70	O
to	O
evaluate	O
of	O
cochlea	O
function	O
in	O
neonates	O
,	O
infants	O
and	O
adults	O
.	O

The	O
3	O
'	O
UTR	O
has	O
several	O
stable	O
hairpins	O
that	O
are	O
flanked	O
by	O
single	B-GENE
-	I-GENE
stranded	I-GENE
(	I-GENE
A	I-GENE
/	I-GENE
U	I-GENE
)	I-GENE
UGC	I-GENE
sequences	I-GENE
.	O

Terazosin	O
,	O
a	O
structural	O
analog	O
of	O
prazosin	O
,	O
also	O
inhibits	O
alpha	B-GENE
1	I-GENE
adrenoceptors	I-GENE
and	O
is	O
recommended	O
as	O
once	O
or	O
twice	O
-	O
daily	O
therapy	O
.	O

The	O
extraction	O
measurements	O
were	O
used	O
to	O
test	O
for	O
extracerebral	O
contamination	O
of	O
venous	O
outflow	O
.	O

The	O
patients	O
are	O
two	O
healthy	O
adult	O
males	O
.	O

Supplementation	O
was	O
stopped	O
when	O
pl	B-GENE
-	I-GENE
ALB	I-GENE
reached	O
2	O
.	O
0	O
g	O
/	O
dL	O
.	O

Treatment	O
of	O
recurrent	O
FSGS	O
has	O
included	O
high	O
-	O
dose	O
steroids	O
,	O
high	O
-	O
dose	O
cyclosporine	O
(	O
CSA	O
)	O
,	O
plasmapheresis	O
,	O
and	O
ACE	B-GENE
inhibitors	O
with	O
mixed	O
results	O
.	O

Effect	O
of	O
proteolytic	O
enzymes	O
and	O
polypeptides	O
on	O
the	O
antacid	O
activity	O
of	O
almagate	O
and	O
other	O
antacids	O
.	O

We	O
propose	O
that	O
the	O
ambiguous	O
discrimination	O
required	O
a	O
greater	O
time	O
for	O
simulus	O
evaluation	O
and	O
that	O
this	O
was	O
reflected	O
in	O
the	O
delayed	O
P3	O
latencies	O
.	O

The	O
median	O
preoperative	O
best	O
-	O
corrected	O
visual	O
acuity	O
of	O
0	O
.	O
08	O
(	O
range	O
hand	O
motions	O
/	O
0	O
.	O
003	O
to	O
0	O
.	O
4	O
)	O
,	O
improved	O
by	O
5	O
lines	O
to	O
a	O
median	O
final	O
postoperative	O
best	O
-	O
corrected	O
visual	O
acuity	O
of	O
0	O
.	O
25	O
(	O
range	O
0	O
.	O
025	O
-	O
0	O
.	O
5	O
)	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

In	O
the	O
second	O
case	O
,	O
an	O
epidermal	O
cyst	O
was	O
diagnosed	O
.	O

The	O
colony	B-GENE
-	I-GENE
stimulating	I-GENE
factors	I-GENE
(	O
CSFs	B-GENE
)	O
principally	O
involved	O
in	O
the	O
production	O
of	O
neutrophils	O
and	O
monocytes	O
are	O
granulocyte	B-GENE
CSF	I-GENE
,	O
granulocyte	B-GENE
-	I-GENE
macrophage	I-GENE
CSF	I-GENE
,	O
macrophage	B-GENE
CSF	I-GENE
,	O
and	O
interleukin	B-GENE
3	I-GENE
(	O
sometimes	O
called	O
multi	B-GENE
-	I-GENE
CSF	I-GENE
)	O
.	O

By	O
treating	O
monkey	O
COS	O
cells	O
with	O
oligonucleotides	O
linked	O
to	O
psoralen	O
,	O
we	O
have	O
generated	O
targeted	O
mutations	O
in	O
a	O
simian	O
virus	O
40	O
(	O
SV40	O
)	O
vector	O
contained	O
within	O
the	O
cells	O
via	O
intracellular	O
triple	O
helix	O
formation	O
.	O

Deltamethrin	O
was	O
most	O
effective	O
on	O
the	O
thatched	O
surface	O
and	O
produced	O
100	O
%	O
mortality	O
of	O
An	O
.	O
culicifacies	O
adults	O
up	O
to	O
12	O
weeks	O
,	O
even	O
when	O
exposed	O
at	O
the	O
lowest	O
dose	O
/	O
12	O
.	O
5	O
mg	O
/	O
m2	O
.	O

The	O
DNA	O
sequence	O
adjacent	O
to	O
the	O
lacZ	B-GENE
gene	I-GENE
has	O
been	O
determined	O
for	O
91	O
vegetative	O
fusion	O
genes	O
whose	O
products	O
have	O
been	O
localized	O
and	O
for	O
43	O
meiotically	O
induced	O
fusions	O
.	O

This	O
study	O
proposes	O
an	O
estimator	O
for	O
such	O
global	O
synchronizing	O
effects	O
upon	O
unit	O
-	O
pair	O
correlations	O
based	O
on	O
local	O
field	O
potentials	O
(	O
LFPs	O
)	O
.	O

RESULTS	O
:	O
Neither	O
basal	O
FSH	B-GENE
level	O
nor	O
stimulated	O
FSH	B-GENE
level	O
alone	O
were	O
statistically	O
significant	O
predictors	O
of	O
IVF	O
success	O
;	O
however	O
,	O
no	O
patient	O
with	O
a	O
day	O
3	O
FSH	B-GENE
level	O
>	O
11	O
.	O
1	O
mIU	O
/	O
ml	O
or	O
a	O
stimulated	O
day	O
10	O
FSH	B-GENE
level	O
>	O
13	O
.	O
5	O
mIU	O
/	O
ml	O
conceived	O
and	O
carried	O
a	O
pregnancy	O
.	O

The	O
serum	B-GENE
insulin	I-GENE
response	O
cannot	O
.	O

Significant	O
correlations	O
were	O
obtained	O
between	O
changes	O
in	O
SSEP	O
in	O
response	O
to	O
AS	O
and	O
the	O
presence	O
of	O
not	O
deep	O
residual	O
-	O
organic	O
disturbances	O
,	O
so	O
-	O
called	O
"	O
ground	O
"	O
in	O
psychogenic	O
disorders	O
.	O

In	O
rats	O
,	O
we	O
examined	O
the	O
effect	O
of	O
an	O
omentum	O
wrapping	O
on	O
the	O
vascularization	O
of	O
the	O
trachea	O
and	O
on	O
regeneration	O
of	O
the	O
mucosal	O
epithelium	O
in	O
the	O
very	O
early	O
stage	O
after	O
free	O
tracheal	O
grafting	O
.	O

To	O
evaluate	O
the	O
hepatic	O
regenerative	O
response	O
in	O
patients	O
with	O
alcoholic	O
liver	O
disease	O
,	O
sera	O
from	O
263	O
patients	O
with	O
severe	O
alcoholic	O
hepatitis	O
and	O
/	O
or	O
cirrhosis	O
were	O
analyzed	O
for	O
hepatocyte	B-GENE
growth	I-GENE
factor	I-GENE
(	O
HGF	B-GENE
)	O
and	O
alpha	B-GENE
-	I-GENE
fetoprotein	I-GENE
(	O
AFP	B-GENE
)	O
.	O

Composites	O
as	O
restoration	O
materials	O
.	O

The	O
high	O
selectivity	O
of	O
arrestins	B-GENE
for	O
this	O
particular	O
functional	O
form	O
of	O
receptor	O
ensures	O
their	O
timely	O
binding	O
and	O
dissociation	O
.	O

Primary	O
invasive	O
Haemophilus	O
influenzae	O
type	O
b	O
disease	O
:	O
a	O
population	O
-	O
based	O
assessment	O
of	O
risk	O
factors	O
.	O

However	O
,	O
while	O
the	O
sequence	O
similarity	O
between	O
the	O
membrane	O
exons	O
of	O
avian	B-GENE
mIgY	I-GENE
and	O
mammalian	B-GENE
mIgG	I-GENE
and	I-GENE
IgE	I-GENE
is	O
striking	O
,	O
the	O
overall	O
similarity	O
with	O
Xenopus	B-GENE
mIgY	I-GENE
is	O
very	O
low	O
.	O

The	O
same	O
-	O
sized	O
EBNA	B-GENE
protein	I-GENE
(	I-GENE
approximately	I-GENE
78	I-GENE
,	I-GENE
000	I-GENE
)	I-GENE
was	O
made	O
after	O
transfection	O
with	O
BamHI	B-GENE
-	I-GENE
K	I-GENE
(	I-GENE
5	I-GENE
.	I-GENE
2	I-GENE
kilobase	I-GENE
pairs	I-GENE
[	I-GENE
kbp	I-GENE
]	I-GENE
)	I-GENE
or	O
the	O
I1f	B-GENE
subfragment	I-GENE
(	I-GENE
2	I-GENE
.	I-GENE
9	I-GENE
kbp	I-GENE
)	I-GENE
.	O

VP5	B-GENE
,	O
which	O
encodes	O
the	O
major	B-GENE
capsid	I-GENE
protein	I-GENE
,	O
each	O
fused	O
to	O
the	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
gene	I-GENE
.	O

Alternative	O
splicing	O
of	O
RNA	O
transcripts	O
encoded	O
by	O
the	O
murine	B-GENE
p105	I-GENE
NF	I-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
gene	I-GENE
generates	O
I	B-GENE
kappa	I-GENE
B	I-GENE
gamma	I-GENE
isoforms	I-GENE
with	O
different	O
inhibitory	O
activities	O
.	O

Elevation	O
of	O
the	O
tissues	O
of	O
the	O
face	O
is	O
essentially	O
vertical	O
and	O
acts	O
on	O
the	O
forehead	O
,	O
temporal	O
region	O
,	O
gaze	O
and	O
cheekbones	O
.	O

If	O
facilities	O
for	O
measurements	O
of	O
O2	O
consumption	O
and	O
hence	O
metabolic	O
rate	O
are	O
available	O
,	O
these	O
should	O
be	O
utilized	O
.	O

The	O
P165	O
component	O
,	O
however	O
,	O
could	O
be	O
differentiated	O
from	O
the	O
two	O
later	O
components	O
since	O
it	O
increased	O
in	O
amplitude	O
with	O
increased	O
task	O
demands	O
while	O
the	O
N2	O
and	O
P3	O
amplitudes	O
remained	O
constant	O
.	O

Patients	O
with	O
moderate	O
PDDAT	O
were	O
impaired	O
on	O
all	O
serial	O
positions	O
for	O
both	O
spatial	O
order	O
and	O
spatial	O
recognition	O
memory	O
.	O

At	O
the	O
time	O
of	O
the	O
13	O
latest	O
BPVs	O
,	O
age	O
ranged	O
from	O
three	O
days	O
to	O
13	O
.	O
1	O
years	O
(	O
mean	O
5	O
.	O
7	O
+	O
/	O
-	O
SD	O
4	O
.	O
8	O
years	O
)	O
.	O

Stably	O
transfected	O
human	O
kidney	O
293	O
cells	O
expressing	O
the	O
wild	B-GENE
type	I-GENE
rat	I-GENE
LH	I-GENE
/	I-GENE
CG	I-GENE
receptor	I-GENE
(	O
rLHR	B-GENE
)	O
or	O
receptors	O
with	O
C	O
-	O
terminal	O
tails	O
truncated	O
at	O
residues	O
653	O
,	O
631	O
,	O
or	O
628	O
(	O
designated	O
rLHR	B-GENE
-	I-GENE
t653	I-GENE
,	O
rLHR	B-GENE
-	I-GENE
t631	I-GENE
,	O
and	O
rLHR	B-GENE
-	I-GENE
t628	I-GENE
)	O
were	O
used	O
to	O
probe	O
the	O
importance	O
of	O
this	O
region	O
on	O
the	O
regulation	O
of	O
hormonal	O
responsiveness	O
.	O

We	O
examined	O
the	O
hypothesis	O
that	O
the	O
coronary	O
vasomotor	O
responses	O
to	O
etomidate	O
(	O
ETO	O
)	O
,	O
propofol	O
(	O
PRO	O
)	O
,	O
and	O
sodium	O
thiopental	O
(	O
STP	O
)	O
are	O
mediated	O
through	O
contrasting	O
effects	O
on	O
the	O
resting	O
nitric	O
oxide	O
(	O
NO	O
)	O
-	O
dependent	O
vasodilator	O
tone	O
that	O
opposes	O
adrenergic	O
vasoconstrictor	O
activity	O
in	O
the	O
intact	O
dog	O
.	O

Here	O
we	O
have	O
examined	O
the	O
ability	O
of	O
the	O
cellular	O
protein	O
YB	B-GENE
-	I-GENE
1	I-GENE
to	O
modulate	O
transcription	O
of	O
the	O
HIV	B-GENE
-	I-GENE
1	I-GENE
promoter	I-GENE
in	O
a	O
human	O
astrocytic	O
cell	O
line	O
(	O
U	O
-	O
87MG	O
)	O
,	O
a	O
neuronal	O
cell	O
line	O
(	O
SK	O
-	O
N	O
-	O
MC	O
)	O
and	O
lymphoid	O
cells	O
(	O
Jurkat	O
)	O
by	O
transfection	O
assay	O
.	O

In	O
this	O
study	O
we	O
examined	O
hepatic	O
stellate	O
cell	O
regulation	O
of	O
M6P	B-GENE
/	I-GENE
IGFIIR	I-GENE
expression	O
and	O
found	O
that	O
M6P	B-GENE
/	I-GENE
IGFIIR	I-GENE
mRNA	I-GENE
transcript	I-GENE
levels	O
increased	O
in	O
stellate	O
cells	O
from	O
rats	O
exposed	O
to	O
carbon	O
tetrachloride	O
(	O
CCl4	O
)	O
,	O
a	O
potent	O
fibrogenic	O
stimulant	O
.	O

However	O
,	O
other	O
regions	O
of	O
the	O
plasmid	O
are	O
also	O
efficiently	O
repaired	O
.	O

Lack	O
of	O
effect	O
of	O
the	O
appetite	O
stimulant	O
pizotifen	O
(	O
BC	O
105	O
)	O
on	O
the	O
absorption	O
of	O
isonicotinylhydrazine	O
.	O

We	O
have	O
improved	O
our	O
system	O
for	O
nuclear	O
contour	O
digitization	O
and	O
determined	O
its	O
theoretical	O
limitations	O
by	O
digitizing	O
standardized	O
objects	O
.	O

To	O
evaluate	O
the	O
comparative	O
safety	O
of	O
U	O
-	O
P	O
and	O
D	O
&	O
E	O
,	O
we	O
analyzed	O
2	O
,	O
805	O
U	O
-	O
P	O
and	O
9	O
,	O
572	O
D	O
&	O
E	O
abortions	O
at	O
13	O
to	O
24	O
menstrual	O
weeks	O
'	O
gestation	O
.	O

2	O
.	O

These	O
corrections	O
do	O
not	O
involve	O
sequences	O
predicted	O
to	O
function	O
as	O
transcription	O
factor	O
binding	O
sites	O
.	O

Our	O
results	O
showed	O
that	O
compared	O
to	O
the	O
primary	O
photon	O
fluence	O
,	O
the	O
extra	O
-	O
focal	O
photon	O
fluence	O
from	O
the	O
primary	O
collimator	O
and	O
the	O
flattening	O
filter	O
was	O
11	O
%	O
-	O
16	O
%	O
at	O
the	O
isocenter	O
,	O
among	O
which	O
70	O
%	O
was	O
contributed	O
by	O
the	O
flattening	O
filter	O
.	O

In	O
men	O
with	O
BMI	O
<	O
30	O
,	O
the	O
OR	O
was	O
1	O
.	O
83	O
for	O
postprandial	O
TG	O
(	O
P	O
=	O
.	O
041	O
)	O
and	O
2	O
.	O
77	O
for	O
postprandial	O
RP	O
(	O
P	O
=	O
.	O
032	O
)	O
in	O
models	O
that	O
included	O
fasting	O
TG	O
,	O
LDL	O
-	O
C	O
,	O
and	O
hypertension	O
.	O

The	O
kinase	B-GENE
inhibitor	O
staurosporine	O
(	O
1	O
microM	O
)	O
blocks	O
LPA	O
-	O
induced	O
,	O
but	O
not	O
epidermal	O
growth	O
factor	O
-	O
induced	O
,	O
activation	O
of	O
p21ras	B-GENE
and	O
MAP	B-GENE
kinase	I-GENE
,	O
consistent	O
with	O
an	O
intermediate	B-GENE
protein	I-GENE
kinase	I-GENE
linking	O
the	O
LPA	B-GENE
receptor	I-GENE
to	O
p21ras	B-GENE
activation	O
.	O

The	O
histochemistry	O
and	O
ultrastructure	O
of	O
calcified	O
cerebellar	O
deposits	O
described	O
by	O
Tonge	O
et	O
al	O
.	O

Three	O
of	O
these	O
subunits	O
are	O
also	O
homologous	O
to	O
the	O
dimeric	O
POR	B-GENE
from	O
a	O
mesophilic	O
archaeon	O
,	O
Halobacterium	O
halobium	O
(	O
21	O
%	O
identity	O
)	O
.	O

The	O
RNA	O
transcripts	O
structurally	O
equivalent	O
to	O
I	B-GENE
(	I-GENE
2	I-GENE
)	I-GENE
sgRNAs	I-GENE
of	O
TMV	O
U1	O
and	O
crTMV	B-GENE
,	O
but	O
containing	O
a	O
hairpin	O
structure	O
(	O
H	O
)	O
immediately	O
upstream	O
of	O
IRES	B-GENE
(	I-GENE
MP	I-GENE
,	I-GENE
75	I-GENE
)	I-GENE
(	I-GENE
HIRES	I-GENE
(	I-GENE
MP	I-GENE
)	I-GENE
,	I-GENE
(	I-GENE
75	I-GENE
)	I-GENE
(	I-GENE
CR	I-GENE
)	I-GENE
-	I-GENE
MP	I-GENE
-	I-GENE
CP	I-GENE
-	I-GENE
3	I-GENE
'	I-GENE
UTR	I-GENE
;	O
HIRES	B-GENE
(	I-GENE
MP	I-GENE
,	I-GENE
75	I-GENE
)	I-GENE
(	I-GENE
U1	I-GENE
)	I-GENE
-	I-GENE
MP	I-GENE
-	I-GENE
CP	I-GENE
-	I-GENE
3	I-GENE
'	I-GENE
UTR	I-GENE
)	O
,	O
were	O
able	O
to	O
express	O
the	O
MP	B-GENE
gene	I-GENE
in	O
vitro	O
.	O

In	O
addition	O
a	O
greater	O
proportion	O
of	O
women	O
in	O
the	O
sweeping	O
group	O
had	O
a	O
cervical	O
dilatation	O
of	O
4	O
cm	O
or	O
more	O
at	O
the	O
first	O
vaginal	O
examination	O
in	O
the	O
labour	O
ward	O
(	O
16	O
/	O
33	O
(	O
49	O
%	O
)	O
vs	O
5	O
/	O
32	O
(	O
16	O
%	O
)	O
;	O
OR	O
4	O
.	O
39	O
;	O
95	O
%	O
CI	O
1	O
.	O
56	O
to	O
12	O
.	O
32	O
;	O
P	O
=	O
0	O
.	O
005	O
)	O
.	O

Exposure	O
of	O
endothelium	O
to	O
pulsatile	O
shear	O
stresses	O
that	O
followed	O
a	O
tape	O
recording	O
of	O
physiological	O
flow	O
waveforms	O
(	O
electromagnetic	O
flowmeter	O
)	O
did	O
not	O
cause	O
gross	O
injury	O
or	O
denudation	O
even	O
when	O
peak	O
shear	O
exceeded	O
1500	O
dyne	O
/	O
cm2	O
.	O

We	O
report	O
the	O
preliminary	O
biochemical	O
characterization	O
of	O
the	O
T	B-GENE
antigens	I-GENE
encoded	O
by	O
three	O
SV40	O
mutants	O
,	O
5030	O
,	O
5031	O
,	O
and	O
5061	O
,	O
each	O
of	O
which	O
have	O
altered	O
residues	O
within	O
or	O
near	O
the	O
ATP	O
binding	O
pocket	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
showed	O
that	O
two	O
adjacent	O
SP1	B-GENE
sites	I-GENE
proximal	O
to	O
exon	O
1	O
were	O
equally	O
important	O
in	O
sustaining	O
basal	O
promoter	O
activity	O
.	O

Taken	O
together	O
,	O
these	O
results	O
are	O
consistent	O
with	O
the	O
possibility	O
that	O
p202	B-GENE
protein	I-GENE
contributes	O
to	O
the	O
cell	O
growth	O
retardation	O
activity	O
of	O
the	O
IFNs	B-GENE
,	O
at	O
least	O
in	O
part	O
,	O
by	O
modulating	O
p21	B-GENE
protein	I-GENE
levels	O
.	O

Genomic	O
organization	O
of	O
the	O
human	O
phosphodiesterase	B-GENE
PDE11A	I-GENE
gene	I-GENE
.	O

To	O
modulate	O
transcription	O
,	O
regulatory	O
factors	O
communicate	O
with	O
basal	O
transcription	O
factors	O
and	O
/	O
or	O
RNA	B-GENE
polymerases	I-GENE
in	O
a	O
variety	O
of	O
ways	O
.	O

In	O
Mv1Lu	O
lung	O
epithelial	O
cells	O
,	O
ActR	B-GENE
-	I-GENE
IB	I-GENE
and	O
T	B-GENE
beta	I-GENE
R	I-GENE
-	I-GENE
I	I-GENE
signal	O
a	O
common	O
set	O
of	O
growth	O
-	O
inhibitory	O
and	O
transcriptional	O
responses	O
in	O
association	O
with	O
their	O
corresponding	O
ligands	O
and	O
type	B-GENE
II	I-GENE
receptors	I-GENE
.	O

The	O
observed	O
phenotypes	O
may	O
be	O
explained	O
by	O
(	O
i	O
)	O
a	O
selective	O
disruption	O
of	O
very	B-GENE
-	I-GENE
low	I-GENE
-	I-GENE
density	I-GENE
lipoprotein	I-GENE
secretion	O
due	O
to	O
decreased	O
expression	O
of	O
genes	O
encoding	O
apolipoprotein	B-GENE
B	I-GENE
and	O
microsomal	B-GENE
triglyceride	I-GENE
transfer	I-GENE
protein	I-GENE
,	O
(	O
ii	O
)	O
an	O
increase	O
in	O
hepatic	O
cholesterol	O
uptake	O
due	O
to	O
increased	O
expression	O
of	O
the	O
major	O
high	B-GENE
-	I-GENE
density	I-GENE
lipoprotein	I-GENE
receptor	I-GENE
,	O
scavenger	B-GENE
receptor	I-GENE
BI	I-GENE
,	O
and	O
(	O
iii	O
)	O
a	O
decrease	O
in	O
bile	O
acid	O
uptake	O
to	O
the	O
liver	O
due	O
to	O
down	O
-	O
regulation	O
of	O
the	O
major	O
basolateral	B-GENE
bile	I-GENE
acid	I-GENE
transporters	I-GENE
sodium	B-GENE
taurocholate	I-GENE
cotransporter	I-GENE
protein	I-GENE
and	O
organic	B-GENE
anion	I-GENE
transporter	I-GENE
protein	I-GENE
1	O
.	O

Two	O
estrogen	B-GENE
receptor	I-GENE
(	O
ER	B-GENE
)	O
isoforms	O
with	O
different	O
estrogen	O
dependencies	O
are	O
generated	O
from	O
the	O
trout	B-GENE
ER	I-GENE
gene	I-GENE
.	O

In	O
the	O
context	O
of	O
the	O
ADH2	B-GENE
upstream	I-GENE
regulatory	I-GENE
region	I-GENE
,	O
including	O
UAS1	B-GENE
,	O
working	O
in	O
concert	O
with	O
the	O
ADH2	B-GENE
basal	I-GENE
promoter	I-GENE
elements	I-GENE
,	O
UAS2	O
-	O
dependent	O
gene	O
activation	O
was	O
dependent	O
on	O
orientation	O
,	O
copy	O
number	O
,	O
and	O
helix	O
phase	O
.	O

Measurements	O
were	O
done	O
with	O
a	O
commercial	O
haematofluorometer	O
Buchler	O
ZF	O
which	O
was	O
calibrated	O
to	O
the	O
average	O
haematocrit	O
value	O
of	O
0	O
.	O
42	O
.	O

Paracrine	O
activation	O
of	O
the	O
HIV	B-GENE
-	I-GENE
1	I-GENE
LTR	I-GENE
promoter	I-GENE
by	O
the	O
viral	B-GENE
Tat	I-GENE
protein	I-GENE
is	O
mechanistically	O
similar	O
to	O
trans	O
-	O
activation	O
within	O
a	O
cell	O
.	O

Furthermore	O
,	O
binding	O
of	O
recombinant	B-GENE
Myb	I-GENE
and	O
Ets	B-GENE
-	I-GENE
2	I-GENE
protein	I-GENE
to	O
these	O
fragments	O
could	O
be	O
competed	O
with	O
an	O
excess	O
of	O
double	O
stranded	O
oligodeoxynucleotides	O
containing	O
canonical	O
,	O
but	O
not	O
mutated	O
,	O
Myb	O
-	O
or	O
Ets	B-GENE
-	I-GENE
binding	I-GENE
sites	I-GENE
.	O

A	O
total	O
of	O
117	O
EVS	O
treatments	O
were	O
performed	O
on	O
34	O
patients	O
.	O

O	B-GENE
.	I-GENE
novo	I-GENE
-	I-GENE
ulmi	I-GENE
RNA	I-GENE
-	I-GENE
7	I-GENE
,	O
previously	O
believed	O
to	O
be	O
a	O
satellite	O
-	O
like	O
RNA	O
,	O
is	O
shown	O
to	O
be	O
a	O
defective	O
RNA	O
,	O
derived	O
from	O
OnuMV4	B-GENE
-	I-GENE
Ld	I-GENE
RNA	I-GENE
by	O
multiple	O
internal	O
deletions	O
.	O

Diffuse	O
myalgias	O
were	O
more	O
frequent	O
in	O
patients	O
with	O
than	O
without	O
an	O
MMF	O
lesion	O
at	O
deltoid	O
muscle	O
biopsy	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

Successful	O
treatment	O
with	O
nasal	O
continuous	O
positive	O
airway	O
pressure	O
(	O
8	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
5	O
cmH2O	O
)	O
for	O
3	O
days	O
caused	O
a	O
significant	O
decrease	O
in	O
mean	O
blood	O
pressure	O
in	O
OSAS	O
.	O

DNA	O
binding	O
assays	O
confirmed	O
the	O
interference	O
of	O
p30	B-GENE
(	I-GENE
II	I-GENE
)	I-GENE
with	O
the	O
assembly	O
of	O
CREB	B-GENE
-	I-GENE
Tax	I-GENE
-	I-GENE
p300	I-GENE
/	I-GENE
CBP	I-GENE
multiprotein	I-GENE
complexes	I-GENE
on	O
21	O
-	O
bp	O
repeat	O
oligonucleotides	O
in	O
vitro	O
.	O

Full	B-GENE
-	I-GENE
length	I-GENE
AT	I-GENE
-	I-GENE
PHH1	I-GENE
,	O
and	O
both	O
AT	B-GENE
-	I-GENE
PHH1	I-GENE
and	O
AT	B-GENE
-	I-GENE
PHH1	I-GENE
delta	I-GENE
C	I-GENE
-	I-GENE
513	I-GENE
(	O
truncated	O
to	O
be	O
approximately	O
the	O
size	O
of	O
microbial	B-GENE
photolyase	I-GENE
genes	I-GENE
)	O
cDNAs	O
,	O
were	O
overexpressed	O
,	O
respectively	O
,	O
in	O
yeast	O
and	O
Escherichia	O
coli	O
mutants	O
hypersensitive	O
to	O
ultraviolet	O
light	O
.	O

GAP	B-GENE
-	I-GENE
N	I-GENE
bound	O
constitutively	O
to	O
p190	B-GENE
in	O
both	O
serum	O
-	O
deprived	O
and	O
growth	O
factor	O
-	O
stimulated	O
cells	O
.	O

Binding	O
activity	O
in	O
rat	O
liver	O
nuclear	O
extracts	O
includes	O
these	O
orphan	B-GENE
receptors	I-GENE
as	O
judged	O
from	O
electromobility	O
supershift	O
experiments	O
and	O
from	O
results	O
obtained	O
with	O
expressed	O
receptors	O
,	O
although	O
the	O
element	O
in	O
CYP2C11	B-GENE
did	O
not	O
bind	O
HNF	B-GENE
-	I-GENE
4	I-GENE
.	O

Muscular	O
pathology	O
.	O

Further	O
,	O
the	O
ORFs	O
of	O
components	O
3	O
and	O
5	O
potentially	O
encoded	O
proteins	O
of	O
about	O
20	O
kDa	O
,	O
the	O
size	O
of	O
the	O
BBTV	B-GENE
coat	I-GENE
protein	I-GENE
.	O

This	O
computation	O
is	O
performed	O
by	O
a	O
parallel	O
network	O
of	O
locally	O
connected	O
neuron	O
-	O
like	O
elements	O
.	O

SFP	O
was	O
significantly	O
elevated	O
in	O
Hn	O
(	O
s	O
)	O
.	O

Neither	O
the	O
p42	B-GENE
/	I-GENE
44	I-GENE
nor	O
the	O
JNK	B-GENE
pathway	O
was	O
involved	O
in	O
the	O
action	O
of	O
IL	B-GENE
-	I-GENE
1beta	I-GENE
.	O

Linkage	O
studies	O
have	O
shown	O
locus	O
heterogeneity	O
with	O
one	O
TSC	B-GENE
gene	I-GENE
mapped	O
to	O
chromosome	O
9q34	O
and	O
a	O
second	O
to	O
16p13	O
.	O
3	O
.	O

These	O
results	O
suggest	O
KCC3	B-GENE
is	O
a	O
new	O
member	O
of	O
the	O
KCC	B-GENE
family	I-GENE
that	O
is	O
under	O
distinct	O
regulation	O
from	O
KCC1	B-GENE
.	O

The	O
primary	O
structure	O
of	O
a	O
2671	O
bp	O
DNA	O
fragment	O
between	O
the	O
pla	B-GENE
gene	I-GENE
(	O
encoding	O
plasminogen	B-GENE
activator	I-GENE
)	O
and	O
the	O
origin	O
of	O
replication	O
of	O
the	O
wild	O
-	O
type	O
Yersinia	O
pestis	O
plasmid	O
pYP358	O
was	O
determined	O
.	O

A	O
single	O
amino	O
acid	O
difference	O
in	O
the	O
C	O
-	O
terminal	O
region	O
influences	O
dominant	O
negative	O
activity	O
and	O
receptor	O
dimer	O
formation	O
.	O

Progressive	O
study	O
and	O
robustness	O
test	O
of	O
QSAR	O
model	O
based	O
on	O
quantum	O
chemical	O
parameters	O
for	O
predicting	O
BCF	O
of	O
selected	O
polychlorinated	O
organic	O
compounds	O
(	O
PCOCs	O
)	O
.	O

EEA1	B-GENE
is	O
a	O
conserved	O
alpha	O
-	O
helical	O
peripheral	O
membrane	O
protein	O
flanked	O
by	O
cysteine	O
"	O
fingers	O
"	O
and	O
contains	O
a	O
calmodulin	B-GENE
-	I-GENE
binding	I-GENE
IQ	I-GENE
motif	I-GENE
.	O

In	O
a	O
series	O
of	O
16	O
full	O
-	O
scale	O
fire	O
tests	O
,	O
investigators	O
at	O
the	O
IIT	O
Research	O
Institute	O
have	O
concluded	O
that	O
automatic	O
door	O
control	O
in	O
the	O
room	O
of	O
fire	O
origin	O
can	O
significantly	O
reduce	O
the	O
spread	O
of	O
toxic	O
smoke	O
and	O
gases	O
.	O

Two	O
studies	O
on	O
the	O
relationship	O
between	O
taking	O
a	O
commercial	O
coaching	O
course	O
and	O
performance	O
on	O
the	O
Medical	O
College	O
Admission	O
Test	O
(	O
MCAT	O
)	O
are	O
reported	O
.	O

However	O
,	O
in	O
some	O
of	O
them	O
either	O
pattern	O
may	O
predominate	O
or	O
be	O
exclusively	O
present	O
.	O

The	O
consensus	O
gene	O
order	O
deduced	O
by	O
combining	O
data	O
from	O
both	O
crosses	O
is	O
D2Mit1	B-GENE
-	I-GENE
(	O
Dbh	B-GENE
,	O
Notch1	B-GENE
)	O
-	O
(	O
Col5a1	B-GENE
,	O
Rxra	B-GENE
)	O
-	B-GENE
Spna2	I-GENE
-	I-GENE
Ab	I-GENE
l	I-GENE
-	I-GENE
(	O
Ak1	B-GENE
,	O
Fpgs	B-GENE
)	O
-	O
(	O
Grp78	B-GENE
,	O
Pbx3	B-GENE
)	O
-	O
(	O
Epb7	B-GENE
.	I-GENE
2	I-GENE
,	I-GENE
Hc	I-GENE
,	I-GENE
Gsn	I-GENE
)	O
-	B-GENE
Acra	I-GENE
.	O

One	O
form	O
of	O
the	O
SBEI	B-GENE
gene	I-GENE
transcript	I-GENE
in	O
12	O
-	O
day	O
old	O
kernels	O
contained	O
the	O
exon	O
I	O
+	O
II	O
+	O
III	O
combination	O
at	O
the	O
5	O
'	O
end	O
,	O
whereas	O
other	O
forms	O
differed	O
by	O
inclusion	O
of	O
intron	O
1	O
or	O
exclusion	O
of	O
exon	O
II	O
sequences	O
.	O

CHAP	O
and	O
the	O
Department	O
of	O
Veterans	O
Affairs	O
.	O

The	O
remainder	O
(	O
18	O
.	O
4	O
%	O
)	O
was	O
with	O
IgA	B-GENE
nephropathy	O
,	O
which	O
was	O
histologically	O
mild	O
.	O

Cardiac	O
output	O
(	O
CO	O
)	O
was	O
significantly	O
higher	O
(	O
p	O
less	O
than	O
0	O
.	O
0005	O
)	O
in	O
the	O
MBBF	O
group	O
.	O

The	O
presence	O
of	O
AS	O
-	O
oligo	O
had	O
no	O
further	O
effect	O
on	O
the	O
FSH	O
-	O
mediated	O
activation	O
of	O
the	O
EB	B-GENE
*	I-GENE
-	I-GENE
mTf	I-GENE
-	I-GENE
CAT	I-GENE
construct	I-GENE
but	O
reduced	O
cAMP	O
-	O
mediated	O
activation	O
.	O

Among	O
eight	O
graminaceous	O
species	O
tested	O
,	O
Ids3	B-GENE
expression	O
was	O
observed	O
only	O
in	O
Fe	O
-	O
deficient	O
roots	O
of	O
H	O
.	O
vulgare	O
and	O
Secale	O
cereale	O
.	O
which	O
not	O
only	O
secrete	O
2	O
'	O
-	O
deoxymugineic	O
acid	O
(	O
DMA	O
)	O
,	O
but	O
also	O
mugineic	O
acid	O
(	O
MA	O
)	O
and	O
3	O
-	O
epihydroxymugineic	O
acid	O
(	O
epiHMA	O
,	O
H	O
.	O
vulgare	O
)	O
,	O
and	O
3	O
-	O
hydroxymugineic	O
acid	O
(	O
HMA	O
,	O
S	O
.	O
cereale	O
)	O
.	O

We	O
also	O
found	O
that	O
environmental	O
conditions	O
for	O
meiosis	O
finely	O
regulate	O
the	O
transcript	O
levels	O
of	O
KIN28	B-GENE
and	O
CCL1	B-GENE
,	O
such	O
that	O
nitrogen	O
starvation	O
first	O
elevates	O
them	O
but	O
subsequent	O
alkalization	O
of	O
medium	O
decreases	O
them	O
.	O

PURPOSE	O
:	O
To	O
determine	O
the	O
effects	O
of	O
hypercholesterolemia	O
and	O
atherosclerosis	O
-	O
induced	O
chronic	O
cavernosal	O
arterial	O
insufficiency	O
on	O
cavernosal	O
smooth	O
muscle	O
tone	O
,	O
nitric	B-GENE
oxide	I-GENE
synthase	I-GENE
(	O
NOS	B-GENE
)	O
activity	O
and	O
cavernosal	O
tissue	O
synthesis	O
of	O
constrictor	O
eicosanoids	O
.	O

The	O
multiple	O
factors	O
affecting	O
plasma	O
renin	B-GENE
activity	O
in	O
essential	O
hypertension	O
.	O

Transient	O
co	O
-	O
transfection	O
assays	O
involving	O
NFKB2	B-GENE
expression	O
vectors	O
and	O
kappa	O
B	O
-	O
driven	O
reporter	O
plasmids	O
indicate	O
that	O
NFKB2	B-GENE
p85	B-GENE
has	O
lost	O
the	O
transcriptional	O
repressor	O
functions	O
typical	O
of	O
normal	O
NFKB2	B-GENE
p52	B-GENE
.	O

We	O
suggest	O
that	O
ventriculopleural	O
shunting	O
should	O
be	O
considered	O
as	O
the	O
preferred	O
alternative	O
to	O
peritoneal	O
drainage	O
in	O
children	O
with	O
intra	O
-	O
abdominal	O
adhesions	O
or	O
with	O
a	O
history	O
of	O
recent	O
peritoneal	O
infection	O
.	O

We	O
have	O
obtained	O
the	O
human	B-GENE
EP4	I-GENE
receptor	I-GENE
gene	I-GENE
sequence	I-GENE
and	O
determined	O
its	O
structure	O
relative	O
to	O
EP4R	B-GENE
cDNA	I-GENE
synthesized	O
from	O
peripheral	O
blood	O
lymphocytes	O
.	O

Model	O
IV	O
:	O
primary	O
abutments	O
with	O
the	O
lateral	O
incisor	O
and	O
the	O
second	O
molar	O
as	O
secondary	O
abutments	O
.	O

Skeletal	O
muscle	O
metaboreceptor	O
exercise	O
responses	O
are	O
attenuated	O
in	O
heart	O
failure	O
.	O

We	O
use	O
the	O
term	O
corticosteroid	O
-	O
dependent	O
IA	O
to	O
refer	O
to	O
the	O
serious	O
problem	O
of	O
chronic	O
IA	O
requiring	O
maintenance	O
prednisone	O
therapy	O
.	O

The	O
maximum	O
amplitude	O
of	O
evoked	O
responses	O
in	O
the	O
cervical	O
sympathetic	O
trunk	O
was	O
obtained	O
when	O
the	O
T2	O
white	O
ramus	O
was	O
stimulated	O
and	O
decreased	O
gradually	O
when	O
followed	O
by	O
the	O
stimulation	O
of	O
T1	O
,	O
T3	O
,	O
T4	O
and	O
T5	O
white	O
rami	O
.	O

CONCLUSION	O
:	O
Local	O
control	O
was	O
highest	O
with	O
Preop	O
in	O
patients	O
presenting	O
primarily	O
with	O
gross	O
disease	O
,	O
and	O
with	O
Postop	O
in	O
patients	O
presenting	O
primarily	O
following	O
gross	O
total	O
excision	O
.	O

Studies	O
of	O
lipoprotein	B-GENE
-	I-GENE
X	I-GENE
(	O
LP	B-GENE
-	I-GENE
X	I-GENE
)	O
and	O
bile	O
acids	O
in	O
familial	O
LCAT	B-GENE
deficiency	O
.	O

Oligonucleotide	O
mutagenesis	O
of	O
these	O
binding	O
domains	O
indicated	O
their	O
importance	O
in	O
the	O
transcriptional	O
regulation	O
of	O
the	O
E3	B-GENE
promoter	I-GENE
in	O
yeast	O
cells	O
.	O

Residual	O
amphotericin	O
B	O
was	O
detected	O
in	O
the	O
feces	O
of	O
the	O
mice	O
only	O
while	O
they	O
were	O
receiving	O
the	O
0	O
.	O
3	O
mg	O
/	O
ml	O
dose	O
level	O
.	O

Neither	O
Ha	B-GENE
-	I-GENE
Ras	I-GENE
(	O
G12V	O
,	O
T35S	O
)	O
(	O
Ha	B-GENE
-	I-GENE
RasV12S35	I-GENE
)	O
,	O
which	O
activates	O
the	O
Rafl	B-GENE
signaling	O
pathway	O
,	O
nor	O
Ha	B-GENE
-	I-GENE
Ras	I-GENE
(	I-GENE
G12V	I-GENE
,	I-GENE
E37G	I-GENE
)	I-GENE
(	O
Ha	B-GENE
-	I-GENE
RasV12G37	I-GENE
)	O
,	O
which	O
stimulates	O
the	O
RalGDS	B-GENE
pathway	O
,	O
did	O
not	O
have	O
significant	O
effects	O
on	O
factor	O
-	O
withdrawal	O
apoptosis	O
of	O
myeloid	O
cells	O
.	O

Effects	O
of	O
ionizing	O
radiation	O
in	O
the	O
human	O
oral	O
cavity	O
and	O
oropharynx	O
:	O
results	O
of	O
a	O
survey	O
.	O

This	O
report	O
describes	O
the	O
identification	O
of	O
a	O
gene	O
of	O
related	O
function	O
,	O
SMD1	B-GENE
,	O
located	O
immediately	O
3	O
'	O
to	O
PRP38	B-GENE
.	O

Preventive	O
effect	O
of	O
ONO	O
-	O
3708	O
on	O
thrombosis	O
and	O
vasospasms	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

CONCLUSION	O
:	O
Rheumatic	O
fever	O
in	O
the	O
Nazareth	O
area	O
is	O
still	O
manifest	O
.	O

Water	O
content	O
and	O
equilibrium	O
water	O
partition	O
in	O
immature	O
cartilage	O
.	O

A	O
novel	O
cDNA	O
clone	O
termed	O
R2	O
was	O
isolated	O
by	O
subtractive	O
hybridization	O
of	O
a	O
cDNA	O
library	O
of	O
phytohemagglutinin	B-GENE
(	O
PHA	B-GENE
)	O
/	O
phorbol	O
myristate	O
acetate	O
-	O
stimulated	O
Jurkat	O
cells	O
and	O
by	O
rescreening	O
a	O
cDNA	O
library	O
of	O
PHA	O
-	O
stimulated	O
peripheral	O
blood	O
lymphocytes	O
.	O

Diltiazem	O
decreased	O
the	O
total	O
body	O
clearance	O
from	O
34	O
.	O
0	O
+	O
/	O
-	O
8	O
.	O
0	O
to	O
28	O
.	O
6	O
+	O
/	O
-	O
6	O
.	O
1	O
mL	O
/	O
min	O
(	O
P	O
less	O
than	O
.	O
01	O
)	O
,	O
and	O
prolonged	O
the	O
elimination	O
half	O
-	O
life	O
from	O
12	O
.	O
6	O
+	O
/	O
-	O
3	O
.	O
0	O
to	O
14	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
5	O
hours	O
(	O
P	O
less	O
than	O
.	O
01	O
)	O
of	O
antipyrine	O
without	O
any	O
changes	O
in	O
volume	O
of	O
distribution	O
.	O

The	O
yeast	B-GENE
RER2	I-GENE
gene	I-GENE
,	O
identified	O
by	O
endoplasmic	O
reticulum	O
protein	O
localization	O
mutations	O
,	O
encodes	O
cis	B-GENE
-	I-GENE
prenyltransferase	I-GENE
,	O
a	O
key	O
enzyme	O
in	O
dolichol	O
synthesis	O
.	O

In	O
electromobility	O
shift	O
assays	O
,	O
EWS	B-GENE
-	I-GENE
FLI	I-GENE
-	I-GENE
1	I-GENE
binding	O
to	O
the	O
SRE	B-GENE
is	O
detectable	O
in	O
the	O
absence	O
of	O
SRF	B-GENE
whereas	O
the	O
binding	O
of	O
FLI	B-GENE
-	I-GENE
1	I-GENE
is	O
not	O
,	O
suggesting	O
that	O
the	O
interaction	O
with	O
DNA	O
is	O
the	O
step	O
which	O
limits	O
ternary	O
complex	O
formation	O
by	O
FLI	B-GENE
-	I-GENE
1	I-GENE
.	O

We	O
characterized	O
three	O
Arabidopsis	O
thaliana	O
cDNA	O
clones	O
that	O
could	O
rescue	O
the	O
sterile	O
phenotype	O
of	O
the	O
Schizosaccharomyces	B-GENE
pombe	I-GENE
pde1	I-GENE
mutant	I-GENE
,	O
which	O
is	O
defective	O
in	O
cAMP	B-GENE
phosphodiesterase	I-GENE
.	O

Cortical	O
afferents	O
to	O
the	O
entorhinal	O
cortex	O
of	O
the	O
Rhesus	O
monkey	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
the	O
isolation	O
and	O
characterization	O
of	O
the	O
entire	O
rat	B-GENE
GSTA3	I-GENE
(	O
rGST	B-GENE
Yc1	I-GENE
)	O
subunit	O
gene	O
.	O

Ras2p	B-GENE
activates	O
invasive	O
growth	O
using	O
either	O
of	O
two	O
downstream	O
signaling	O
pathways	O
,	O
the	O
filamentation	O
MAPK	B-GENE
(	O
Cdc42p	B-GENE
/	I-GENE
Ste20p	I-GENE
/	I-GENE
MAPK	I-GENE
)	O
cascade	O
or	O
the	O
cAMP	B-GENE
-	I-GENE
dependent	I-GENE
protein	I-GENE
kinase	I-GENE
(	O
Cyr1p	B-GENE
/	I-GENE
cAMP	I-GENE
/	I-GENE
PKA	I-GENE
)	O
pathway	O
.	O

Gamma	B-GENE
glutamyl	I-GENE
transpeptidase	I-GENE
activity	O
was	O
increased	O
up	O
to	O
15	O
times	O
above	O
the	O
upper	O
normal	O
limit	O
in	O
children	O
,	O
who	O
received	O
aminopyrine	O
for	O
two	O
weeks	O
or	O
longer	O
.	O

CONCLUSIONS	O
:	O
Use	O
of	O
the	O
first	O
method	O
was	O
associated	O
with	O
a	O
reduction	O
in	O
the	O
time	O
patients	O
remained	O
in	O
the	O
ICU	O
before	O
transfer	O
to	O
another	O
unit	O
and	O
savings	O
in	O
nursing	O
time	O
,	O
but	O
the	O
two	O
methods	O
did	O
not	O
differ	O
according	O
to	O
clinical	O
outcomes	O
.	O

In	O
part	O
as	O
a	O
result	O
of	O
its	O
inability	O
to	O
sustain	O
radiative	O
loses	O
,	O
the	O
BB	O
resonator	O
has	O
extremely	O
low	O
RF	O
power	O
requirements	O
.	O

Hypoxic	O
ventilatory	O
responses	O
were	O
-	O
1	O
.	O
99	O
+	O
/	O
-	O
0	O
.	O
37	O
L	O
/	O
min	O
/	O
%	O
SaO2	O
in	O
the	O
relatives	O
and	O
-	O
1	O
.	O
54	O
+	O
/	O
-	O
0	O
.	O
25	O
L	O
/	O
min	O
/	O
%	O
SaO2	O
in	O
the	O
control	O
subjects	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

They	O
also	O
discuss	O
the	O
existing	O
nomenclature	O
.	O

These	O
data	O
indicate	O
that	O
the	O
interaction	O
of	O
eIF4A	B-GENE
with	O
the	O
middle	O
region	O
of	O
eIF4GI	B-GENE
is	O
necessary	O
for	O
translation	O
,	O
whereas	O
the	O
interaction	O
of	O
eIF4A	B-GENE
with	O
the	O
C	O
-	O
terminal	O
region	O
plays	O
a	O
modulatory	O
role	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
hGCN5	B-GENE
is	O
also	O
an	O
HAT	B-GENE
and	O
has	O
the	O
same	O
substrate	O
specificity	O
as	O
yGCN5	B-GENE
.	O

Instead	O
,	O
some	O
small	O
negative	O
effects	O
are	O
observed	O
,	O
particularly	O
involving	O
effects	O
of	O
husbands	O
'	O
retirement	O
on	O
the	O
marital	O
satisfaction	O
of	O
employed	O
wives	O
.	O

We	O
previously	O
described	O
two	O
alanine	O
cluster	O
mutations	O
,	O
R77	O
to	O
A	O
(	O
R77A	O
)	O
-	O
K79A	O
and	O
E192A	O
-	O
E194A	O
,	O
which	O
selectively	O
inactivated	O
the	O
triphosphatase	B-GENE
component	I-GENE
.	O

CKII	B-GENE
as	O
a	O
CD44	B-GENE
-	I-GENE
associated	I-GENE
serine	I-GENE
kinase	I-GENE
therefore	O
may	O
serve	O
as	O
an	O
important	O
molecule	O
in	O
a	O
signaling	O
cascade	O
that	O
produces	O
a	O
variety	O
of	O
cellular	O
responses	O
in	O
MDA231	O
breast	O
cancer	O
cells	O
.	O

This	O
is	O
the	O
first	O
example	O
of	O
a	O
eukaryotic	O
transcription	O
factor	O
complex	O
containing	O
both	O
a	O
MADS	B-GENE
-	I-GENE
box	I-GENE
and	O
a	O
forkhead	B-GENE
protein	I-GENE
,	O
and	O
it	O
has	O
important	O
implications	O
for	O
the	O
regulation	O
of	O
mammalian	O
gene	O
expression	O
.	O

To	O
investigate	O
the	O
requirements	O
for	O
CBF2	B-GENE
binding	O
,	O
we	O
synthesized	O
a	O
series	O
of	O
oligonucleotides	O
carrying	O
double	O
transversion	O
mutations	O
spanning	O
both	O
the	O
conserved	O
core	O
sequence	O
and	O
outside	O
flanking	O
sequences	O
.	O

Biol	O
.	O

Replacement	O
of	O
the	O
wild	O
-	O
type	O
5	O
'	O
-	O
regulatory	O
region	O
with	O
either	O
of	O
the	O
mutants	O
'	O
cis	O
-	O
acting	O
regulatory	O
element	O
resulted	O
in	O
the	O
anaerobic	O
expression	O
of	O
active	B-GENE
Mn	I-GENE
-	I-GENE
superoxide	I-GENE
dismutase	I-GENE
.	O

To	O
study	O
the	O
functional	O
differences	O
between	O
cutaneous	O
HPV5	O
and	O
HPV8	O
E7s	B-GENE
and	O
genital	B-GENE
HPV16	I-GENE
E7	I-GENE
,	O
we	O
cloned	O
each	O
of	O
the	O
E7	B-GENE
open	O
reading	O
frames	O
and	O
tested	O
their	O
immortalizing	O
and	O
transforming	O
activities	O
,	O
the	O
binding	O
ability	O
of	O
their	O
products	O
with	O
retinoblastoma	B-GENE
protein	I-GENE
(	O
RB	B-GENE
)	O
and	O
their	O
complementation	O
activity	O
of	O
a	O
RB	B-GENE
-	I-GENE
nonbinding	I-GENE
adenovirus	I-GENE
E1A	I-GENE
mutant	I-GENE
.	O

Immunohistochemical	O
staining	O
was	O
positive	O
for	O
S	B-GENE
-	I-GENE
100	I-GENE
in	O
all	O
9	O
cases	O
stained	O
,	O
positive	O
for	O
HMB	B-GENE
-	I-GENE
45	I-GENE
in	O
9	O
(	O
90	O
%	O
)	O
of	O
10	O
,	O
and	O
negative	O
for	O
cytokeratin	B-GENE
in	O
all	O
9	O
cases	O
in	O
which	O
myxoid	O
melanoma	O
remained	O
in	O
the	O
block	O
after	O
previous	O
sections	O
.	O

Pneumothorax	O
complicated	O
by	O
chronic	O
steroid	O
treatment	O
.	O

The	O
response	O
of	O
the	O
plasma	B-GENE
fibrinogen	I-GENE
level	O
to	O
the	O
subucutaneous	O
injection	O
of	O
turpentine	O
and	O
to	O
the	O
intravenous	O
injection	O
of	O
endotoxin	O
was	O
measured	O
in	O
normal	O
rabbits	O
and	O
in	O
rabbits	O
made	O
granulocytopenic	O
and	O
thrombocytopenic	O
with	O
busulfan	O
.	O

The	O
spleen	O
rate	O
of	O
about	O
600	O
villagers	O
of	O
RK	O
I	O
examined	O
was	O
54	O
.	O
3	O
%	O
and	O
the	O
parasite	O
rate	O
13	O
.	O
2	O
%	O
before	O
the	O
drug	O
intervention	O
.	O

A	O
thermal	O
Kubo	O
-	O
Martin	O
-	O
Schwinger	O
condition	O
arises	O
due	O
to	O
the	O
coupling	O
of	O
a	O
computer	O
to	O
a	O
strong	O
periodic	O
source	O
,	O
namely	O
,	O
the	O
daily	O
and	O
weekly	O
usage	O
patterns	O
of	O
the	O
system	O
.	O

This	O
region	O
binds	O
two	O
ubiquitous	O
nuclear	O
factors	O
,	O
USF	B-GENE
/	I-GENE
MLTF	I-GENE
and	O
the	O
CAAT	B-GENE
-	I-GENE
binding	I-GENE
transcription	I-GENE
factor	I-GENE
/	I-GENE
nuclear	I-GENE
factor	I-GENE
1	I-GENE
(	O
CTF	B-GENE
/	I-GENE
NF1	I-GENE
)	O
.	O

Among	O
the	O
LE6	B-GENE
deletions	O
,	O
only	O
one	O
had	O
a	O
reduced	O
transformation	O
efficiency	O
,	O
while	O
seven	O
transformed	O
cells	O
at	O
least	O
as	O
efficiently	O
as	O
wild	B-GENE
-	I-GENE
type	I-GENE
LE6	I-GENE
.	O

Changes	O
of	O
plasma	O
cortisol	O
level	O
in	O
late	O
asthmatic	O
responses	O
.	O

All	O
patients	O
with	O
deterioriation	O
in	O
mental	O
status	O
showed	O
a	O
marked	O
increase	O
in	O
liver	O
enzymes	O
(	O
aspartate	B-GENE
and	I-GENE
alanine	I-GENE
aminotransaminases	I-GENE
)	O
and	O
severe	O
coagulopathy	O
.	O

The	O
results	O
also	O
showed	O
that	O
although	O
oyster	O
shell	O
supplementation	O
generally	O
increased	O
alkaline	B-GENE
phosphatase	I-GENE
activity	O
,	O
bone	O
mineralization	O
was	O
relatively	O
uninfluenced	O
as	O
judged	O
by	O
the	O
low	O
coefficients	O
of	O
variation	O
(	O
CV	O
)	O
of	O
3	O
.	O
14	O
-	O
3	O
.	O
51	O
%	O
and	O
3	O
.	O
39	O
-	O
4	O
.	O
82	O
%	O
for	O
calcium	O
and	O
phosphorus	O
content	O
in	O
the	O
femur	O
and	O
tibia	O
respectively	O
.	O

1	O
A	O
colonic	O
delivery	O
system	O
is	O
described	O
to	O
deliver	O
orally	O
ingested	O
drugs	O
to	O
the	O
colon	O
and	O
release	O
them	O
at	O
that	O
site	O
by	O
coating	O
with	O
an	O
acrylic	O
based	O
resin	O
(	O
Eudragit	O
S	O
)	O
.	O

Treating	O
renal	O
anaemia	O
with	O
recombinant	O
human	O
erythropoietin	B-GENE
.	O

The	O
resulting	O
clone	O
pKB11	B-GENE
,	O
which	O
has	O
a	O
1369	O
-	O
base	O
pair	O
(	O
bp	O
)	O
cDNA	O
insert	O
,	O
overlapping	O
pCAD142	B-GENE
by	O
781	O
bp	O
,	O
was	O
identified	O
by	O
hybridization	O
methods	O
and	O
sequence	O
analysis	O
and	O
found	O
to	O
contain	O
the	O
entire	O
cDNA	O
sequence	O
for	O
the	O
amino	O
end	O
of	O
the	O
CAD	B-GENE
polypeptide	I-GENE
.	O

Treatment	O
of	O
unstable	O
angina	O
:	O
role	O
of	O
antithrombotic	O
therapy	O
.	O

Acad	O
.	O

Biochemical	O
studies	O
revealed	O
the	O
expected	O
loss	O
of	O
ChAT	B-GENE
activity	O
in	O
the	O
dorsal	O
and	O
ventral	O
hippocampi	O
of	O
lesioned	O
animals	O
along	O
with	O
elevated	O
levels	O
of	O
norepinephrine	O
(	O
NE	O
)	O
in	O
the	O
dorsal	O
hippocampus	O
of	O
MS	O
/	O
HSI	O
animals	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Recognition	O
of	O
emphysema	O
was	O
poor	O
when	O
radiographs	O
of	O
inadequate	O
quality	O
were	O
included	O
(	O
anteroposterior	O
films	O
or	O
films	O
from	O
patients	O
with	O
acute	O
or	O
chronic	O
lung	O
disease	O
)	O
.	O

Vasopressin	B-GENE
(	O
AVP	B-GENE
)	O
,	O
the	O
antidiuretic	O
hormone	O
,	O
is	O
a	O
cyclic	O
nonapeptide	O
that	O
acts	O
through	O
binding	O
to	O
G	B-GENE
protein	I-GENE
-	I-GENE
coupled	I-GENE
specific	I-GENE
membrane	I-GENE
receptors	I-GENE
pharmacologically	O
divided	O
into	O
three	O
subtypes	O
(	O
V1a	B-GENE
,	O
V1b	B-GENE
,	O
and	O
V2	B-GENE
)	O
linked	O
to	O
distinct	O
second	O
messengers	O
.	O

Immunofluorescence	O
studies	O
in	O
C2C12	O
myotubes	O
show	O
that	O
Smad2	B-GENE
and	O
MEF2A	B-GENE
co	O
-	O
localise	O
in	O
the	O
nucleus	O
of	O
multinuclear	O
myotubes	O
during	O
differentiation	O
.	O

Homozygous	O
mutation	O
in	O
two	O
children	O
led	O
to	O
amputation	O
of	O
legs	O
due	O
to	O
purpura	O
fulminans	O
.	O

The	O
effect	O
of	O
salmon	B-GENE
calcitonin	I-GENE
nasal	O
spray	O
in	O
women	O
with	O
established	O
osteoporosis	O
has	O
also	O
been	O
studied	O
.	O

Studies	O
in	O
mammalian	O
cells	O
have	O
correlated	O
induction	O
of	O
inhibitory	O
tyrosine	O
15	O
(	O
Y15	O
)	O
phosphorylation	O
on	O
p34cdc2	B-GENE
with	O
the	O
response	O
to	O
DNA	O
damage	O
.	O

Altogether	O
46	O
phase	O
III	O
activities	O
were	O
recorded	O
.	O

Using	O
a	O
battery	O
of	O
I	B-GENE
kappa	I-GENE
B	I-GENE
alpha	I-GENE
mutants	I-GENE
,	O
we	O
show	O
that	O
(	O
i	O
)	O
a	O
dimer	O
binds	O
a	O
single	O
I	B-GENE
kappa	I-GENE
B	I-GENE
alpha	I-GENE
molecule	I-GENE
,	O
(	O
ii	O
)	O
the	O
acidic	O
C	O
-	O
terminal	O
region	O
of	O
I	B-GENE
kappa	I-GENE
B	I-GENE
alpha	I-GENE
is	O
not	O
required	O
for	O
protein	O
-	O
protein	O
binding	O
and	O
does	O
not	O
mask	O
the	O
nuclear	O
localization	O
signal	O
of	O
the	O
dimer	O
,	O
(	O
iii	O
)	O
the	O
same	O
C	O
-	O
terminal	O
region	O
is	O
required	O
for	O
inhibition	O
of	O
DNA	O
binding	O
,	O
and	O
(	O
iv	O
)	O
this	O
inhibition	O
may	O
be	O
accomplished	O
by	O
direct	O
interaction	O
between	O
the	O
PEST	B-GENE
-	I-GENE
like	I-GENE
region	I-GENE
and	O
the	O
DNA	O
-	O
binding	O
region	O
of	O
one	O
of	O
the	O
subunits	O
of	O
the	O
dimer	O
.	O

Activation	O
mediated	O
by	O
Cat8p	B-GENE
was	O
no	O
longer	O
detectable	O
in	O
a	O
cat1	B-GENE
mutant	I-GENE
.	O

EGF	B-GENE
acts	O
primarily	O
by	O
means	O
of	O
transactivation	O
domain	O
AF	B-GENE
-	I-GENE
1	I-GENE
,	O
whereas	O
cAMP	O
acts	O
via	O
transactivation	O
domain	O
AF	B-GENE
-	I-GENE
2	I-GENE
of	O
the	O
ER	O
.	O

Of	O
those	O
injuries	O
,	O
143	O
cases	O
were	O
snowboard	O
related	O
and	O
158	O
cases	O
were	O
ski	O
related	O
.	O

Diacylglycerol	B-GENE
kinase	I-GENE
(	O
DGK	B-GENE
)	O
attenuates	O
levels	O
of	O
second	O
messenger	O
diacylglycerol	O
in	O
cells	O
and	O
produces	O
another	O
(	O
putative	O
)	O
messenger	O
,	O
phosphatidic	O
acid	O
.	O

Unusual	O
course	O
of	O
plasmocytosis	O
.	O

4	O
)	O
PU	B-GENE
and	O
PD	B-GENE
lacked	O
the	O
canonical	O
TATA	O
or	O
CAAT	O
motifs	O
,	O
and	O
are	O
AT	O
-	O
rich	O
.	O

Their	O
use	O
established	O
that	O
the	O
BrAAP	O
activity	O
catalyzed	O
both	O
a	O
postproline	O
and	O
a	O
postglutamate	O
cleavage	O
and	O
therefore	O
has	O
a	O
broader	O
specificity	O
than	O
previously	O
recognized	O
.	O

We	O
have	O
found	O
that	O
PEA2	B-GENE
is	O
also	O
required	O
for	O
the	O
bipolar	O
budding	O
pattern	O
and	O
that	O
it	O
encodes	O
a	O
novel	O
protein	O
with	O
a	O
predicted	O
coiled	O
-	O
coil	O
domain	O
.	O

The	O
most	O
important	O
finding	O
,	O
however	O
,	O
was	O
that	O
IMT	O
values	O
were	O
related	O
with	O
24	O
h	O
SBP	O
or	O
PP	O
standard	O
deviation	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
a	O
measure	O
of	O
overall	O
SBP	O
or	O
PP	O
variability	O
.	O

We	O
recently	O
found	O
that	O
the	O
p72syk	B-GENE
protein	I-GENE
tyrosine	I-GENE
kinase	I-GENE
is	O
physically	O
associated	O
with	O
the	O
TCR	B-GENE
/	I-GENE
CD3	I-GENE
complex	I-GENE
and	O
is	O
rapidly	O
tyrosine	O
phosphorylated	O
and	O
activated	O
by	O
receptor	O
triggering	O
also	O
in	O
T	O
cells	O
lacking	O
p56lck	B-GENE
.	O

Similar	O
synergistic	O
activation	O
was	O
observed	O
in	O
the	O
IL	B-GENE
-	I-GENE
8	I-GENE
promoter	I-GENE
,	O
which	O
also	O
contains	O
both	O
NF	B-GENE
-	I-GENE
IL6	I-GENE
and	O
NF	B-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
binding	I-GENE
sites	I-GENE
.	O

To	O
identify	O
the	O
DNA	O
sequences	O
that	O
cis	O
-	O
regulate	O
the	O
expression	O
of	O
the	O
rat	B-GENE
liver	I-GENE
pyruvate	I-GENE
kinase	I-GENE
(	O
L	B-GENE
-	I-GENE
PK	I-GENE
)	O
genes	O
,	O
a	O
series	O
of	O
constructs	O
in	O
which	O
the	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
reporter	I-GENE
genes	I-GENE
is	O
driven	O
by	O
various	O
deleted	O
fragments	O
of	O
the	O
3200	O
base	O
pairs	O
(	O
bp	O
)	O
upstream	O
of	O
the	O
L	B-GENE
-	I-GENE
PK	I-GENE
gene	I-GENE
cap	I-GENE
site	I-GENE
have	O
been	O
assayed	O
for	O
transient	O
expression	O
after	O
introduction	O
into	O
hepatoma	O
HepG2	O
cells	O
,	O
rat	O
hepatocytes	O
in	O
primary	O
culture	O
,	O
fibroblast	O
LTK	O
-	O
cells	O
,	O
myogenic	O
C2C12	O
cells	O
,	O
and	O
CHO	O
cells	O
.	O

Stable	O
transfection	O
of	O
the	O
truncated	O
reduced	B-GENE
folate	I-GENE
carrier	I-GENE
cDNA	I-GENE
into	O
mouse	O
L1210	O
leukemia	O
cells	O
:	O
increased	O
folate	O
accumulation	O
,	O
decreased	O
their	O
leucovorin	O
and	O
folic	O
acid	O
growth	O
requirements	O
,	O
and	O
increased	O
their	O
sensitivity	O
to	O
methotrexate	O
.	O

Instead	O
,	O
TRPS1	B-GENE
potently	O
and	O
specifically	O
represses	O
transcriptional	O
activation	O
mediated	O
by	O
other	O
GATA	B-GENE
factors	I-GENE
.	O

Hyaluronan	O
treatment	O
stimulated	O
collagen	B-GENE
remodeling	O
in	O
the	O
peripheral	O
region	O
and	O
inhibited	O
swelling	O
of	O
the	O
meniscus	O
repaired	O
in	O
the	O
inner	O
region	O
.	O

Recombinant	B-GENE
human	I-GENE
TFIID	I-GENE
supported	O
weak	O
basal	O
transcription	O
in	O
heat	O
-	O
treated	O
nuclear	O
extracts	O
whereas	O
a	O
partially	O
purified	O
TFIID	B-GENE
fraction	O
from	O
HeLa	O
cells	O
reconstituted	O
a	O
maximal	O
level	O
of	O
transcription	O
.	O

We	O
can	O
classify	O
antibiotics	O
into	O
two	O
groups	O
based	O
on	O
initial	O
bactericidal	O
activity	O
against	O
P	O
.	O
aeruginosa	O
;	O
one	O
class	O
is	O
antibiotics	O
having	O
rapid	O
initial	O
killing	O
such	O
as	O
AMK	O
,	O
IPM	O
and	O
PAPM	O
,	O
the	O
other	O
is	O
CAZ	O
,	O
MEPM	O
showing	O
slow	O
initial	O
killing	O
.	O

X	O
-	O
ray	O
crystallographic	O
data	O
show	O
that	O
the	O
PLZF	B-GENE
BTB	B-GENE
/	I-GENE
POZ	I-GENE
domain	I-GENE
forms	O
an	O
obligate	O
homodimer	O
via	O
an	O
extensive	O
interface	O
.	O

We	O
have	O
previously	O
identified	O
mouse	B-GENE
and	I-GENE
human	I-GENE
cDNAs	I-GENE
encoding	I-GENE
UNC	I-GENE
-	I-GENE
51	I-GENE
-	I-GENE
like	I-GENE
kinase	I-GENE
(	O
ULK1	B-GENE
)	O
.	O

Sequencing	O
of	O
zebrafish	O
(	O
Danio	O
rerio	O
)	O
bacterial	O
artificial	O
chromosome	O
and	O
P1	O
artificial	O
chromosome	O
genomic	O
clone	O
fragments	O
and	O
of	O
cDNA	O
clones	O
has	O
led	O
to	O
the	O
identification	O
of	O
five	O
new	O
loci	O
coding	O
for	O
beta	B-GENE
subunits	I-GENE
of	I-GENE
proteasomes	I-GENE
(	O
PSMB	B-GENE
)	O
.	O

Penicillin	B-GENE
acylase	I-GENE
(	O
PA	B-GENE
)	O
from	O
Escherichia	O
coli	O
ATCC11105	O
is	O
a	O
periplasmic	O
heterodimer	O
consisting	O
of	O
a	O
24	O
kDa	O
small	O
subunit	O
and	O
a	O
65	O
kDa	O
large	O
subunit	O
.	O

Hepatocellular	O
injury	O
during	O
preservation	O
of	O
human	O
livers	O
with	O
UW	O
and	O
HTK	O
solution	O
.	O

There	O
was	O
a	O
significant	O
but	O
similar	O
elevation	O
of	O
mean	O
O2	O
uptake	O
during	O
40	O
min	O
postexercise	O
by	O
13	O
.	O
6	O
%	O
in	O
both	O
the	O
fasted	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
fed	O
state	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Intracellular	O
localization	O
studies	O
using	O
the	O
mDAP	B-GENE
-	I-GENE
3	I-GENE
/	I-GENE
EGFP	I-GENE
fusion	I-GENE
protein	I-GENE
,	O
cell	O
fractionation	O
and	O
protease	O
protection	O
experiments	O
localized	O
mDAP	B-GENE
-	I-GENE
3	I-GENE
to	O
the	O
mitochondrial	O
matrix	O
.	O

CONCLUSION	O
:	O
The	O
study	O
demonstrates	O
that	O
transvaginal	O
ultrasonography	O
has	O
an	O
efficiency	O
of	O
88	O
%	O
in	O
differentiating	O
endometriomas	O
from	O
other	O
ovarian	O
masses	O
with	O
a	O
specificity	O
of	O
90	O
%	O
.	O

Two	O
polyadenylation	O
sites	O
were	O
used	O
,	O
one	O
at	O
the	O
end	O
of	O
the	O
early	B-GENE
(	I-GENE
E	I-GENE
)	I-GENE
region	I-GENE
of	O
the	O
viral	O
DNA	O
,	O
the	O
other	O
at	O
the	O
end	O
of	O
the	O
late	B-GENE
(	I-GENE
L	I-GENE
)	I-GENE
region	I-GENE
.	O

We	O
concluded	O
that	O
Ga	O
-	O
fbg	O
scintigraphy	O
is	O
a	O
very	O
simple	O
method	O
and	O
sufficiently	O
useful	O
for	O
detecting	O
active	O
left	O
ventricular	O
thrombi	O
and	O
for	O
monitoring	O
the	O
effect	O
of	O
anticoagulant	O
therapy	O
.	O

The	O
carcass	O
of	O
a	O
great	O
horned	O
owl	O
(	O
Bubo	O
virginianus	O
)	O
,	O
which	O
had	O
been	O
found	O
moribund	O
in	O
southern	O
Ontario	O
,	O
was	O
presented	O
for	O
necropsy	O
.	O

NGF	B-GENE
elicits	O
a	O
more	O
delayed	O
and	O
sustained	O
ERK	B-GENE
phosphorylation	O
than	O
EGF	B-GENE
,	O
consistent	O
with	O
previous	O
reports	O
.	O

Compound	O
1	O
is	O
either	O
21	O
-	O
O	O
-	O
angeloyl	O
,	O
22	O
-	O
O	O
-	O
tigloyl	O
R1	O
-	O
barrigenol	O
,	O
or	O
21	O
-	O
O	O
-	O
tigloyl	O
,	O
22	O
-	O
O	O
-	O
angeloyl	O
R1	O
-	O
barrigenol	O
.	O

The	O
enhancer	O
region	O
of	O
Akv	O
murine	O
leukemia	O
virus	O
contains	O
the	O
sequence	B-GENE
motif	I-GENE
ACAGATGG	I-GENE
.	O

We	O
show	O
that	O
in	O
contrast	O
to	O
SRC1	B-GENE
,	O
direct	O
binding	O
of	O
CBP	B-GENE
to	O
the	O
estrogen	B-GENE
receptor	I-GENE
is	O
weak	O
,	O
suggesting	O
that	O
SRC1	B-GENE
functions	O
primarily	O
as	O
an	O
adaptor	O
to	O
recruit	O
CBP	B-GENE
and	O
p300	B-GENE
.	O

Immuno	O
-	O
cytochemistry	O
,	O
using	O
antisera	O
against	O
Campylobacter	O
jejuni	O
,	O
showed	O
that	O
the	O
positive	O
staining	O
in	O
altered	O
epithelial	O
cells	O
were	O
restricted	O
to	O
intracellular	O
organisms	O
having	O
a	O
structure	O
resembling	O
Campylobacter	O
spp	O
.	O

The	O
translation	O
products	O
of	O
both	O
clones	O
are	O
highly	O
homologous	O
to	O
APS1	B-GENE
(	O
66	O
and	O
86	O
%	O
identity	O
,	O
respectively	O
)	O
over	O
their	O
entire	O
lengths	O
,	O
including	O
amino	O
terminal	O
sequences	O
resembling	O
transit	O
peptides	O
for	O
plastid	O
localization	O
.	O

Organization	O
of	O
the	O
human	B-GENE
LU	I-GENE
gene	I-GENE
and	O
molecular	O
basis	O
of	O
the	O
Lu	B-GENE
(	I-GENE
a	I-GENE
)	I-GENE
/	I-GENE
Lu	I-GENE
(	I-GENE
b	I-GENE
)	I-GENE
blood	I-GENE
group	I-GENE
polymorphism	I-GENE
.	O

The	O
MCA	O
and	O
UA	O
PI	O
values	O
showed	O
the	O
greatest	O
deviation	O
for	O
any	O
single	O
-	O
vessel	O
parameter	O
.	O

A	O
decrease	O
of	O
erythrocyte	O
Mn	O
with	O
age	O
,	O
expressed	O
in	O
nmol	O
/	O
L	O
,	O
was	O
noted	O
(	O
p	O
<	O
0	O
.	O
02	O
)	O
.	O

Progressive	O
100	O
-	O
mmHg	O
stepwise	O
decreases	O
in	O
superfusate	O
oxygen	O
partial	O
pressure	O
(	O
PO2	O
)	O
from	O
control	O
(	O
95	O
%	O
O2	O
aeration	O
,	O
PO2	O
,	O
620	O
-	O
650	O
mmHg	O
)	O
were	O
produced	O
,	O
and	O
subsequent	O
changes	O
in	O
isometric	O
active	O
and	O
resting	O
tension	O
were	O
measured	O
.	O

Results	O
of	O
the	O
long	O
-	O
term	O
observation	O
and	O
treatment	O
of	O
patients	O
with	O
arterial	O
hypertension	O
.	O

Jean	O
Klig	O
reviews	O
recent	O
literature	O
about	O
lower	O
respiratory	O
tract	O
infection	O
in	O
children	O
.	O

In	O
particular	O
,	O
the	O
highly	O
expressed	O
ADH1	B-GENE
gene	I-GENE
is	O
represented	O
in	O
this	O
database	O
by	O
no	O
less	O
than	O
20	O
EST	O
sequences	O
.	O

Transient	O
expression	O
of	O
human	B-GENE
and	I-GENE
chicken	I-GENE
progesterone	I-GENE
receptors	I-GENE
does	O
not	O
support	O
alternative	O
translational	O
initiation	O
from	O
a	O
single	O
mRNA	O
as	O
the	O
mechanism	O
generating	O
two	O
receptor	O
isoforms	O
.	O

In	O
some	O
cases	O
,	O
factor	O
-	O
induced	O
Rac	B-GENE
activation	O
results	O
in	O
Rho	B-GENE
activation	O
,	O
and	O
factor	O
-	O
induced	O
Cdc42	B-GENE
activation	O
leads	O
to	O
Rac	B-GENE
activation	O
,	O
as	O
determined	O
by	O
specific	O
morphological	O
changes	O
.	O

A	O
sequence	O
comparison	O
reveals	O
two	O
CCAAT	B-GENE
/	I-GENE
enhancer	I-GENE
binding	I-GENE
protein	I-GENE
(	O
C	B-GENE
/	I-GENE
EBP	I-GENE
)	O
consensus	O
sequences	O
,	O
basic	O
DNA	O
binding	O
region	O
and	O
leucine	O
zippers	O
1	O
and	O
2	O
(	O
bZIP1	O
and	O
bZIP2	O
)	O
,	O
within	O
this	O
region	O
.	O

In	O
the	O
lattice	O
,	O
23	O
%	O
of	O
the	O
sites	O
are	O
occupied	O
,	O
95	O
%	O
of	O
the	O
atoms	O
are	O
in	O
the	O
lowest	O
energy	O
magnetic	O
sublevel	O
,	O
and	O
37	O
%	O
are	O
in	O
the	O
lowest	O
3D	O
vibrational	O
state	O
.	O

Arsenic	O
contents	O
in	O
native	O
copper	O
.	O

Complexes	O
containing	O
wild	O
-	O
type	O
and	O
either	O
his175	B-GENE
or	I-GENE
his273	I-GENE
mutant	I-GENE
p53	I-GENE
proteins	I-GENE
are	O
completely	O
unable	O
to	O
bind	O
to	O
the	O
RGC	B-GENE
DNA	I-GENE
sequence	I-GENE
.	O

Analysis	O
of	O
human	O
genomic	O
DNA	O
reveals	O
an	O
intronless	O
sequence	O
with	O
strong	O
homology	O
to	O
human	B-GENE
G	I-GENE
alpha	I-GENE
q	I-GENE
cDNA	I-GENE
.	O

The	O
risk	O
factors	O
studied	O
were	O
male	O
sex	O
,	O
hypertension	O
,	O
diabetes	O
mellitus	O
,	O
hypercholesterolemia	O
,	O
cigarette	O
smoking	O
,	O
sedentary	O
life	O
-	O
style	O
,	O
and	O
family	O
history	O
.	O

CONCLUSIONS	O
:	O
Pretreatment	O
with	O
OCs	O
prior	O
to	O
pituitary	O
suppression	O
in	O
the	O
early	O
follicular	O
phase	O
decreases	O
ovarian	O
cyst	O
formation	O
,	O
without	O
an	O
apparent	O
effect	O
on	O
subsequent	O
follicular	O
recruitment	O
or	O
pregnancy	O
rates	O
.	O

SV1	B-GENE
has	O
a	O
33	O
-	O
amino	O
acid	O
insert	O
in	O
the	O
S1	B-GENE
transmembrane	I-GENE
domain	I-GENE
that	O
does	O
not	O
alter	O
S1	B-GENE
overall	O
hydrophobicity	O
,	O
but	O
makes	O
the	O
S0	B-GENE
-	I-GENE
S1	I-GENE
linker	I-GENE
longer	O
.	O

Four	O
transcription	O
initiation	O
sites	O
have	O
been	O
identified	O
by	O
full	O
-	O
length	O
RNA	O
ligase	O
-	O
mediated	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
(	O
RLM	O
-	O
RACE	O
)	O
between	O
-	O
61	O
and	O
-	O
32	O
bp	O
from	O
the	O
translation	O
initiation	O
codon	O
.	O
Reverse	O
transcription	O
-	O
PCR	O
analysis	O
revealed	O
that	O
PFK	B-GENE
-	I-GENE
A	I-GENE
,	O
PFK	B-GENE
-	I-GENE
B	I-GENE
and	O
PFK	B-GENE
-	I-GENE
C	I-GENE
genes	I-GENE
were	O
expressed	O
,	O
in	O
all	O
mouse	O
tissues	O
tested	O
,	O
at	O
varying	O
levels	O
.	O

The	O
small	O
size	O
and	O
placement	O
of	O
the	O
mutagenesis	O
marker	O
(	O
the	O
supF	B-GENE
suppressor	I-GENE
tRNA	I-GENE
gene	I-GENE
from	I-GENE
Escherichia	I-GENE
coli	I-GENE
)	O
within	O
the	O
vector	O
substantially	O
reduced	O
the	O
frequency	O
of	O
spontaneous	O
mutations	O
normally	O
observed	O
after	O
transfection	O
of	O
mammalian	O
cells	O
with	O
plasmid	O
DNA	O
;	O
hence	O
,	O
UV	O
-	O
induced	O
mutations	O
were	O
easily	O
identified	O
above	O
the	O
spontaneous	O
background	O
.	O

Although	O
not	O
consistently	O
identified	O
in	O
all	O
samples	O
,	O
secondary	O
Academic	O
,	O
Personal	O
Responsibility	O
,	O
and	O
Community	O
/	O
Vocational	O
dimensions	O
were	O
also	O
identified	O
.	O

It	O
can	O
be	O
concluded	O
that	O
in	O
normotensive	O
subjects	O
,	O
uric	O
acid	O
and	O
xanthine	B-GENE
oxidase	I-GENE
have	O
significant	O
association	O
with	O
blood	O
pressure	O
and	O
thus	O
are	O
one	O
of	O
the	O
many	O
factors	O
which	O
are	O
involved	O
in	O
the	O
cause	O
or	O
effect	O
of	O
hypertension	O
.	O

Hybridization	O
analysis	O
showed	O
that	O
the	O
size	O
of	O
the	O
mRNA	O
is	O
about	O
1	O
.	O
4	O
kilobases	O
.	O

The	O
heterogeneous	O
nuclear	B-GENE
ribonucleoprotein	I-GENE
C	I-GENE
protein	I-GENE
tetramer	I-GENE
binds	O
U1	B-GENE
,	O
U2	B-GENE
,	O
and	O
U6	B-GENE
snRNAs	I-GENE
through	O
its	O
high	O
affinity	O
RNA	O
binding	O
domain	O
(	O
the	O
bZIP	B-GENE
-	I-GENE
like	I-GENE
motif	I-GENE
)	O
.	O

Canadian	O
survey	O
reveals	O
widespread	O
dissatisfaction	O
among	O
physicians	O
.	O

Topoisomerase	B-GENE
II	I-GENE
is	O
a	O
major	O
target	O
of	O
the	O
protein	B-GENE
kinase	I-GENE
casein	I-GENE
kinase	I-GENE
2	I-GENE
(	O
PK	B-GENE
CK2	I-GENE
)	O
in	O
vivo	O
.	O

Its	O
transcription	O
product	O
,	O
a	O
1	O
.	O
3	O
kb	O
mRNA	O
,	O
is	O
polyadenylated	O
at	O
a	O
site	O
containing	O
consensus	O
eukaryotic	O
polyadenylation	O
signals	O
and	O
mapping	O
87	O
bp	O
downstream	O
of	O
the	O
translation	O
termination	O
codon	O
for	O
CG30	B-GENE
.	O

The	O
AL	O
-	O
R8	O
SI	O
:	O
the	O
next	O
generation	O
staging	O
container	O
for	O
plutonium	O
pits	O
at	O
the	O
USDOE	O
Pantex	O
Plant	O
.	O

The	O
rad9	B-GENE
.	I-GENE
192	I-GENE
DNA	I-GENE
repair	I-GENE
mutant	I-GENE
from	I-GENE
the	I-GENE
fission	I-GENE
yeast	I-GENE
,	I-GENE
Schizosaccharomyces	I-GENE
pombe	I-GENE
,	O
is	O
sensitive	O
to	O
both	O
UV	O
and	O
ionising	O
radiation	O
.	O

Seven	O
patients	O
(	O
8	O
.	O
3	O
percent	O
)	O
had	O
latent	O
hypothyroidism	O
only	O
discovered	O
by	O
hormonal	O
determinations	O
.	O

In	O
contrast	O
to	O
other	O
known	O
retroviruses	O
,	O
the	O
FV	B-GENE
pol	I-GENE
genes	I-GENE
are	O
expressed	O
via	O
spliced	O
transcripts	O
.	O

Two	O
basic	O
patterns	O
of	O
locomotor	O
behavior	O
and	O
corresponding	O
torso	O
morphology	O
exist	O
among	O
extant	O
anthropoids	O
.	O

Collagen	B-GENE
was	O
extracted	O
from	O
the	O
skin	O
,	O
and	O
the	O
lack	O
of	O
type	B-GENE
III	I-GENE
collagen	I-GENE
was	O
determined	O
by	O
means	O
of	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
.	O

High	O
fibrinogen	B-GENE
levels	O
could	O
thus	O
be	O
a	O
risk	O
for	O
perioperative	O
thrombosis	O
.	O

Cooperative	O
roles	O
of	O
Bozozok	B-GENE
/	I-GENE
Dharma	I-GENE
and	O
Nodal	B-GENE
-	I-GENE
related	I-GENE
proteins	I-GENE
in	O
the	O
formation	O
of	O
the	O
dorsal	O
organizer	O
in	O
zebrafish	O
.	O

Newcastle	O
disease	O
virus	O
surveillance	O
in	O
Hong	O
Kong	O
on	O
local	O
and	O
imported	O
poultry	O
.	O

RESULTS	O
:	O
Auditory	O
thresholds	O
collected	O
during	O
audiometric	O
tests	O
increased	O
gradually	O
in	O
proportion	O
with	O
age	O
,	O
especially	O
in	O
the	O
hypertensive	O
group	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
this	O
case	O
the	O
degree	O
of	O
promoter	O
methylation	O
,	O
which	O
could	O
extend	O
beyond	O
the	O
T	O
-	O
DNA	O
borders	O
,	O
was	O
not	O
correlated	O
with	O
the	O
reduction	O
in	O
steady	O
-	O
state	O
poly	O
(	O
A	O
)	O
+	O
mRNA	O
levels	O
,	O
the	O
silenced	O
state	O
was	O
transmitted	O
through	O
meiosis	O
and	O
reactivation	O
lasted	O
several	O
generations	O
.	O

Specimens	O
were	O
assayed	O
for	O
alpha	B-GENE
-	I-GENE
fetoprotein	I-GENE
,	O
unconjugated	O
estriol	O
,	O
free	O
alpha	B-GENE
hCG	I-GENE
,	O
and	O
total	O
hCG	B-GENE
.	O

We	O
report	O
the	O
use	O
of	O
a	O
new	O
technetium	O
-	O
99m	O
-	O
albumin	O
colloid	O
white	O
blood	O
cell	O
(	O
TAC	O
-	O
WBC	O
)	O
scan	O
in	O
the	O
evaluation	O
of	O
appendicitis	O
.	O

Thus	O
,	O
SOX8	B-GENE
is	O
a	O
good	O
candidate	O
gene	O
contributing	O
to	O
the	O
mental	O
retardation	O
phenotype	O
seen	O
in	O
ATR	O
-	O
16	O
patients	O
.	O

The	O
concentrations	O
of	O
C4	B-GENE
and	O
C1	B-GENE
-	I-GENE
INH	I-GENE
increased	O
with	O
advancing	O
stage	O
of	O
disease	O
and	O
were	O
above	O
normal	O
mean	O
values	O
in	O
all	O
stages	O
.	O

We	O
measured	O
serum	B-GENE
hepatocyte	I-GENE
growth	I-GENE
factor	I-GENE
(	O
HGF	B-GENE
)	O
in	O
patients	O
with	O
acute	O
myocardial	O
infarction	O
,	O
angina	O
pectoris	O
,	O
and	O
other	O
heart	O
diseases	O
.	O

The	O
Man9	B-GENE
-	I-GENE
mannosidase	I-GENE
specificity	O
of	O
the	O
cDNA	O
construct	O
was	O
verified	O
by	O
the	O
observation	O
that	O
all	O
peptide	O
sequences	O
derived	O
from	O
a	O
previously	O
purified	O
,	O
catalytically	O
active	O
49	O
-	O
kDa	O
fragment	O
were	O
found	O
within	O
the	O
coding	O
region	O
.	O

Cranio	O
-	O
caudal	O
differences	O
in	O
granulation	O
tissue	O
formation	O
:	O
an	O
experimental	O
study	O
in	O
the	O
rat	O
.	O

Here	O
we	O
show	O
that	O
for	O
expression	O
of	O
snRNA	O
genes	O
in	O
maize	O
,	O
a	O
monocotyledonous	O
plant	O
,	O
the	O
USE	O
and	O
TATA	O
elements	O
are	O
essential	O
,	O
but	O
not	O
sufficient	O
,	O
for	O
transcription	O
.	O

The	O
PETCO2	O
measurement	O
during	O
precordial	O
compression	O
predicted	O
the	O
success	O
of	O
defibrillation	O
with	O
return	O
of	O
spontaneous	O
circulation	O
.	O

RESULTS	O
:	O
The	O
binding	O
of	O
99mTc	O
d	O
,	O
1	O
-	O
HMPAO	O
to	O
human	O
placenta	O
ranged	O
from	O
2	O
.	O
95	O
%	O
+	O
/	O
-	O
1	O
.	O
5	O
%	O
to	O
5	O
.	O
82	O
%	O
+	O
/	O
-	O
0	O
.	O
3	O
%	O
per	O
1	O
ml	O
standard	O
solution	O
.	O

Low	O
NA	O
and	O
A	O
may	O
participate	O
in	O
lowering	O
the	O
plasma	B-GENE
renin	I-GENE
activity	O
which	O
in	O
PA	O
in	O
suppressed	O
,	O
sometimes	O
disproportionately	O
to	O
the	O
actual	O
body	O
sodium	O
content	O
.	O

These	O
results	O
suggest	O
that	O
indoramin	O
may	O
have	O
Class	O
III	O
antiarrhythmic	O
activity	O
.	O

A	O
9	B-GENE
.	I-GENE
5	I-GENE
-	I-GENE
kb	I-GENE
KpnI	I-GENE
-	I-GENE
SalI	I-GENE
fragment	I-GENE
,	O
where	O
all	O
the	O
DNA	O
changes	O
associated	O
with	O
su	B-GENE
(	I-GENE
Hw	I-GENE
)	I-GENE
mutations	I-GENE
were	O
mapped	O
,	O
was	O
able	O
to	O
rescue	O
the	O
su	B-GENE
(	I-GENE
Hw	I-GENE
)	I-GENE
mutant	I-GENE
phenotype	O
after	O
P	O
-	O
element	O
-	O
mediated	O
germ	O
-	O
line	O
transformation	O
.	O

A	O
panel	O
of	O
pharmacologic	O
inhibitors	O
was	O
used	O
to	O
investigate	O
the	O
signal	O
transduction	O
pathways	O
involved	O
in	O
TRAIL	B-GENE
gene	I-GENE
induction	O
following	O
T	O
lymphocyte	O
activation	O
.	O

Scanning	O
electron	O
microscopic	O
investigations	O
on	O
the	O
formation	O
of	O
Reissner	O
'	O
s	O
fiber	O
in	O
Rattus	O
rattus	O
.	O

Changes	O
in	O
dopamine	B-GENE
receptor	I-GENE
sensitivity	O
in	O
humans	O
after	O
heavy	O
alcohol	O
intake	O
.	O

The	O
sample	O
is	O
deproteinized	O
and	O
after	O
centrifugation	O
valproic	O
acid	O
in	O
the	O
supernatant	O
is	O
measured	O
in	O
the	O
free	O
form	O
by	O
direct	O
injection	O
into	O
the	O
gas	O
chromatograph	O
.	O

Further	O
,	O
intracerebroventricular	O
injections	O
of	O
KA	O
resulted	O
in	O
the	O
substantial	O
loss	O
of	O
pyramidal	O
cells	O
in	O
the	O
whole	O
CA3	O
field	O
of	O
the	O
hippocampus	O
.	O

Gabapentin	O
for	O
opiod	O
-	O
related	O
myoclonus	O
in	O
cancer	O
patients	O
.	O

Heterogeneous	O
electron	O
transfer	O
of	O
cytochrome	B-GENE
c	I-GENE
facilitated	O
by	O
polypyrrole	O
and	O
methylene	O
blue	O
polypyrrole	O
film	O
modified	O
electrodes	O
.	O

Sequence	O
analysis	O
revealed	O
:	O
1	O
)	O
a	O
kinase	B-GENE
catalytic	I-GENE
domain	I-GENE
most	O
characteristic	O
of	O
serine	B-GENE
/	I-GENE
threonine	I-GENE
kinases	I-GENE
but	O
hybrid	O
between	O
members	O
of	O
the	O
family	O
of	O
microtubule	B-GENE
-	I-GENE
associated	I-GENE
protein	I-GENE
kinase	I-GENE
kinase	I-GENE
kinases	I-GENE
and	O
the	O
fibroblast	B-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
family	I-GENE
;	O
2	O
)	O
two	O
putative	O
alpha	O
-	O
helical	O
leucine	O
zipper	O
motifs	O
separated	O
by	O
a	O
25	O
-	O
amino	O
acid	O
charged	O
intermediate	O
segment	O
but	O
lacking	O
an	O
NH2	O
-	O
terminal	O
basic	O
domain	O
;	O
and	O
3	O
)	O
COOH	O
-	O
terminal	O
and	O
NH2	O
-	O
terminal	O
proline	O
-	O
rich	O
domains	O
suggestive	O
of	O
src	B-GENE
homology	I-GENE
3	I-GENE
(	O
SH3	B-GENE
)	O
domain	O
binding	O
regions	O
.	O

Epithelial	O
damage	O
was	O
not	O
observed	O
in	O
any	O
controls	O
but	O
was	O
in	O
all	O
tissues	O
exposed	O
to	O
SO2	O
.	O

Distribution	O
and	O
correlations	O
of	O
serum	O
uric	O
-	O
acid	O
in	O
two	O
French	O
adult	O
populations	O
:	O
13	O
,	O
885	O
men	O
and	O
6	O
,	O
861	O
women	O
.	O

Effects	O
of	O
cortisone	O
,	O
starvation	O
,	O
and	O
rickets	O
on	O
oxidative	O
enzyme	O
activities	O
of	O
epiphyseal	O
cartilage	O
from	O
rats	O
.	O

Transient	O
overexpression	O
of	O
mutant	B-GENE
EphB1	I-GENE
receptors	I-GENE
(	O
Y594F	B-GENE
)	O
blocked	O
Nck	B-GENE
recruitment	O
to	O
EphB1	B-GENE
,	O
attenuated	O
downstream	O
JNK	B-GENE
activation	O
,	O
and	O
blocked	O
cell	O
attachment	O
responses	O
.	O

Analysis	O
of	O
the	O
upstream	O
untranslated	O
region	O
of	O
CHL15	B-GENE
revealed	O
the	O
presence	O
of	O
the	O
hexamer	O
element	O
,	O
ACGCGT	B-GENE
(	O
an	O
MluI	B-GENE
restriction	I-GENE
site	I-GENE
)	O
controlling	O
both	O
the	O
periodic	O
expression	O
and	O
coordinate	O
regulation	O
of	O
the	O
DNA	O
synthesis	O
genes	O
in	O
budding	O
yeast	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
expression	O
of	O
Cktsf1b1	B-GENE
,	O
a	O
gene	O
associated	O
with	O
early	O
development	O
and	O
cell	O
transformation	O
,	O
is	O
sensitive	O
to	O
MKK	B-GENE
levels	O
and	O
may	O
be	O
regulated	O
via	O
multiple	O
transcription	O
factor	O
complexes	O
.	O

Drugs	O
suppressed	O
>	O
or	O
=	O
75	O
%	O
of	O
the	O
total	O
premature	O
ventricular	O
contractions	O
in	O
all	O
patients	O
who	O
had	O
both	O
use	O
-	O
dependent	O
QRS	O
prolongation	O
and	O
reverse	O
use	O
-	O
dependent	O
QT	O
prolongation	O
,	O
in	O
79	O
%	O
of	O
patients	O
with	O
use	O
-	O
dependent	O
QRS	O
prolongation	O
alone	O
,	O
in	O
70	O
%	O
with	O
reverse	O
use	O
-	O
dependent	O
QT	O
prolongation	O
alone	O
,	O
and	O
in	O
11	O
%	O
with	O
neither	O
use	O
-	O
dependent	O
QRS	O
prolongation	O
nor	O
reverse	O
use	O
-	O
dependent	O
QT	O
prolongation	O
.	O

CONCLUSION	O
:	O
NBP	O
pre	O
-	O
treatment	O
or	O
post	O
-	O
treatment	O
markedly	O
enhanced	O
the	O
rCBF	O
to	O
striatum	O
in	O
RMCAO	O
rats	O
.	O

Thioredoxin	B-GENE
(	O
TR	B-GENE
)	O
is	O
a	O
small	O
ubiquitous	O
dithiol	B-GENE
-	I-GENE
reductase	I-GENE
enzyme	I-GENE
first	O
identified	O
in	O
bacteria	O
and	O
plants	O
.	O

4	O
Five	O
patients	O
died	O
within	O
one	O
month	O
of	O
captopril	O
and	O
five	O
between	O
four	O
and	O
seven	O
months	O
,	O
three	O
of	O
whom	O
had	O
improved	O
to	O
class	O
IIM	O
and	O
one	O
to	O
IIS	O
before	O
death	O
.	O

We	O
have	O
partially	O
sequenced	O
the	O
RAP74	B-GENE
protein	I-GENE
from	O
purified	O
HeLa	O
cells	O
,	O
cloned	O
its	O
complementary	O
DNA	O
and	O
shown	O
that	O
its	O
translation	O
product	O
can	O
interact	O
with	O
RAP30	B-GENE
in	O
vitro	O
as	O
well	O
as	O
in	O
vivo	O
.	O

Regulation	O
of	O
the	O
human	B-GENE
p21	I-GENE
/	I-GENE
WAF1	I-GENE
/	I-GENE
Cip1	I-GENE
promoter	I-GENE
in	O
hepatic	O
cells	O
by	O
functional	O
interactions	O
between	O
Sp1	B-GENE
and	O
Smad	B-GENE
family	I-GENE
members	I-GENE
.	O

Nonetheless	O
,	O
that	O
ventricular	O
afferents	O
,	O
in	O
certain	O
special	O
settings	O
,	O
are	O
able	O
to	O
induce	O
e	O
.	O
g	O
.	O
generalised	O
vasodilation	O
and	O
hypotension	O
cannot	O
be	O
excluded	O
.	O

A	O
comparison	O
of	O
the	O
nucleotide	O
and	O
deduced	O
amino	O
acid	O
sequences	O
of	O
the	O
core	O
regions	O
of	O
the	O
RNA	B-GENE
-	I-GENE
dependent	I-GENE
RNA	I-GENE
polymerase	I-GENE
domains	I-GENE
found	O
in	O
these	O
three	O
dsRNAs	B-GENE
suggested	O
that	O
these	O
dsRNAs	B-GENE
probably	O
evolved	O
independently	O
within	O
each	O
host	O
plant	O
from	O
a	O
common	O
ancestor	O
.	O

CASE	O
REPORT	O
:	O
We	O
observed	O
a	O
congenital	O
skin	O
defect	O
located	O
exclusively	O
on	O
the	O
trunk	O
.	O

The	O
small	B-GENE
GTPase	I-GENE
Rho	B-GENE
is	O
implicated	O
in	O
physiological	O
functions	O
associated	O
with	O
actin	O
-	O
myosin	O
filaments	O
such	O
as	O
cytokinesis	O
,	O
cell	O
motility	O
,	O
and	O
smooth	O
muscle	O
contraction	O
.	O

Canine	O
reproduction	O
:	O
effects	O
of	O
a	O
single	O
injection	O
of	O
medroxyprogesterone	O
acetate	O
on	O
the	O
reproductive	O
organs	O
of	O
the	O
bitch	O
.	O

The	O
size	O
of	O
the	O
infarct	O
was	O
determined	O
using	O
the	O
creatine	B-GENE
kinase	I-GENE
integral	O
method	O
.	O

The	O
identified	O
isolates	O
of	O
CSF	O
(	O
20	O
of	O
29	O
)	O
were	O
:	O
ECHO	O
30	O
(	O
9	O
)	O
,	O
ECHO	O
11	O
(	O
7	O
)	O
,	O
ECHO	O
9	O
(	O
3	O
)	O
and	O
ECHO	O
7	O
(	O
1	O
)	O
.	O

The	O
cDNA	O
clone	O
was	O
used	O
as	O
a	O
homologous	O
probe	O
to	O
isolate	O
a	O
truncated	O
genomic	O
clone	O
encoding	O
H2A1	B-GENE
.	O

RESULTS	O
:	O
Plasma	B-GENE
AVP	I-GENE
responses	O
to	O
osmotic	O
stimulation	O
,	O
and	O
non	O
-	O
osmotic	O
inhibition	O
by	O
drinking	O
,	O
were	O
normal	O
in	O
patients	O
with	O
compulsive	O
water	O
drinking	O
.	O

Moreover	O
,	O
in	O
rats	O
allowed	O
to	O
choose	O
in	O
a	O
T	O
-	O
maze	O
between	O
immediate	O
-	O
but	O
-	O
small	O
vs	O
.	O
delayed	O
-	O
but	O
-	O
large	O
reward	O
,	O
BZP	O
significantly	O
decreased	O
the	O
frequency	O
with	O
which	O
the	O
delayed	O
reward	O
was	O
chosen	O
,	O
with	O
5	O
-	O
HT	O
uptake	O
blockers	O
producing	O
opposite	O
effects	O
.	O

Both	O
the	O
intact	B-GENE
A1	I-GENE
protein	I-GENE
and	O
its	O
proteolytic	O
fragment	O
,	O
the	O
UP1	B-GENE
protein	I-GENE
,	O
can	O
be	O
cleaved	O
by	O
Staphylococcus	B-GENE
aureus	I-GENE
V	I-GENE
-	I-GENE
8	I-GENE
protease	I-GENE
to	O
produce	O
two	O
polypeptides	O
of	O
92	O
amino	O
acids	O
.	O

The	O
human	B-GENE
p100	I-GENE
protein	I-GENE
was	O
recently	O
identified	O
as	O
a	O
coactivator	O
of	O
the	O
Epstein	B-GENE
-	I-GENE
Barr	I-GENE
virus	I-GENE
nuclear	I-GENE
antigen	I-GENE
2	I-GENE
.	O

OBJECTIVES	O
:	O
To	O
measure	O
coagulation	B-GENE
factor	I-GENE
VIII	I-GENE
:	O
coagulant	O
(	O
F	B-GENE
.	I-GENE
VIII	I-GENE
:	O
C	O
)	O
and	O
C1	B-GENE
-	I-GENE
esterase	I-GENE
inhibitor	I-GENE
(	O
C1	B-GENE
-	I-GENE
INH	I-GENE
)	O
,	O
hemostasis	O
-	O
associated	O
acute	O
-	O
phase	O
reactant	O
proteins	O
and	O
coagulation	B-GENE
factors	I-GENE
VII	I-GENE
(	I-GENE
F	I-GENE
.	I-GENE
VII	I-GENE
)	I-GENE
,	I-GENE
IX	I-GENE
(	I-GENE
F	I-GENE
.	I-GENE
IX	I-GENE
)	I-GENE
,	I-GENE
and	I-GENE
X	I-GENE
(	I-GENE
F	I-GENE
.	I-GENE
X	I-GENE
)	I-GENE
,	O
hemostasis	O
proteins	O
not	O
associated	O
with	O
an	O
acute	O
-	O
phase	O
response	O
,	O
in	O
a	O
select	O
population	O
of	O
horses	O
with	O
colic	O
and	O
hemostasis	O
abnormalities	O
,	O
and	O
presumed	O
to	O
have	O
acute	O
-	O
phase	O
changes	O
.	O

SAM	O
-	O
TR	O
-	O
68	O
-	O
54	O
.	O

Consistent	O
with	O
the	O
hypothesis	O
that	O
it	O
acts	O
as	O
transcriptional	O
regulator	O
,	O
wild	B-GENE
-	I-GENE
type	I-GENE
p53	I-GENE
protein	I-GENE
binds	O
DNA	O
and	O
activates	O
transcription	O
of	O
several	O
promoters	O
.	O

Critique	O
of	O
"	O
Interactive	O
Effects	O
of	O
Test	O
Anxiety	O
and	O
Credit	O
/	O
No	O
Credit	O
or	O
A	O
-	O
F	O
Grade	O
Condition	O
upon	O
Short	O
-	O
term	O
and	O
Long	O
-	O
term	O
Recall	O
of	O
Course	O
Information	O
.	O

The	O
distribution	O
of	O
red	O
rice	O
cultivation	O
in	O
Sri	O
Lanka	O
is	O
coincident	O
with	O
the	O
HIDD	O
villages	O
.	O

It	O
was	O
not	O
possible	O
to	O
study	O
the	O
basis	O
for	O
tissue	O
-	O
specific	O
expression	O
of	O
this	O
gene	O
,	O
because	O
the	O
beta	B-GENE
3	I-GENE
gene	I-GENE
promoter	I-GENE
had	O
not	O
been	O
isolated	O
previously	O
.	O

The	O
E1	B-GENE
replication	I-GENE
protein	I-GENE
of	O
bovine	O
papillomavirus	O
type	O
1	O
contains	O
an	O
extended	O
nuclear	O
localization	O
signal	O
that	O
includes	O
a	O
p34cdc2	B-GENE
phosphorylation	O
site	O
.	O

Stoichiometric	O
phosphorylation	O
of	O
human	B-GENE
p53	I-GENE
at	O
Ser315	O
stimulates	O
p53	O
-	O
dependent	O
transcription	O
.	O
p53	B-GENE
protein	I-GENE
activity	O
as	O
a	O
transcription	O
factor	O
can	O
be	O
activated	O
in	O
vivo	O
by	O
antibodies	O
that	O
target	O
its	O
C	O
-	O
terminal	O
negative	O
regulatory	O
domain	O
suggesting	O
that	O
cellular	O
enzymes	O
that	O
target	O
this	O
domain	O
may	O
play	O
a	O
role	O
in	O
stimulating	O
p53	O
-	O
dependent	O
gene	O
expression	O
.	O

Commutative	O
saccadic	O
generator	O
is	O
sufficient	O
to	O
control	O
a	O
3	O
-	O
D	O
ocular	O
plant	O
with	O
pulleys	O
.	O

Measurements	O
in	O
the	O
LWS	O
p	O
.	O
a	O
.	O
,	O
LWS	O
lat	O
.	O
and	O
at	O
Ward	O
'	O
s	O
triangle	O
were	O
made	O
in	O
a	O
total	O
of	O
100	O
patients	O
.	O

This	O
suggests	O
that	O
helicase	B-GENE
-	I-GENE
like	I-GENE
genes	I-GENE
may	O
be	O
involved	O
in	O
the	O
biosynthesis	O
of	O
nucleic	O
acids	O
and	O
proteins	O
,	O
and	O
that	O
the	O
genes	O
can	O
be	O
transcriptionally	O
activated	O
by	O
heat	O
shock	O
to	O
compensate	O
for	O
the	O
repressed	O
synthesis	O
of	O
mRNA	O
and	O
protein	O
.	O

Elledge	O
,	O
P	O
.	O

With	O
the	O
modified	O
fingertip	O
-	O
to	O
-	O
floor	O
(	O
MFTF	O
)	O
method	O
,	O
patients	O
stand	O
on	O
a	O
stool	O
and	O
forward	O
bend	O
so	O
that	O
measurements	O
can	O
be	O
taken	O
on	O
patients	O
who	O
are	O
able	O
to	O
touch	O
the	O
floor	O
or	O
reach	O
beyond	O
the	O
level	O
of	O
the	O
floor	O
.	O

Clicking	O
on	O
"	O
Examples	O
and	O
Explanations	O
of	O
APA	O
Form	O
"	O
provides	O
a	O
help	O
system	O
with	O
examples	O
of	O
the	O
various	O
sections	O
of	O
a	O
review	O
article	O
,	O
journal	O
article	O
that	O
has	O
one	O
experiment	O
,	O
or	O
journal	O
article	O
that	O
has	O
two	O
or	O
more	O
experiments	O
.	O

This	O
proposed	O
method	O
is	O
similar	O
in	O
principle	O
to	O
the	O
sets	O
technique	O
but	O
is	O
shown	O
to	O
have	O
much	O
better	O
expected	O
time	O
to	O
alarm	O
properties	O
.	O

After	O
phosphorylation	O
,	O
STAT	B-GENE
proteins	I-GENE
are	O
transported	O
into	O
the	O
nucleus	O
and	O
exhibit	O
transcriptional	O
activity	O
.	O

Morphine	O
produced	O
a	O
dose	O
-	O
dependent	O
bradycardia	O
followed	O
by	O
tachycardia	O
.	O

For	O
the	O
first	O
30	O
min	O
following	O
insulin	B-GENE
administration	O
,	O
the	O
rate	O
of	O
change	O
in	O
glucose	O
levels	O
was	O
significantly	O
less	O
among	O
the	O
patients	O
with	O
major	O
depressive	O
disorder	O
than	O
among	O
either	O
the	O
patients	O
with	O
dysthymic	O
disorder	O
or	O
the	O
normal	O
control	O
subjects	O
.	O

The	O
expression	O
of	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
was	O
detected	O
within	O
1	O
h	O
after	O
infection	O
of	O
cells	O
with	O
recombinant	O
virus	O
,	O
reflecting	O
the	O
early	O
nature	O
of	O
the	O
promoters	O
used	O
.	O

Bioplastique	O
granuloma	O
presents	O
with	O
irregularly	O
shaped	O
cystic	O
spaces	O
of	O
varying	O
size	O
containing	O
jagged	O
,	O
translucent	O
,	O
nonbirefringent	O
foreign	O
bodies	O
whereas	O
Artecoll	O
granuloma	O
shows	O
numerous	O
round	O
vacuoles	O
nearly	O
identical	O
in	O
size	O
and	O
shape	O
enclosing	O
round	O
and	O
sharply	O
circumscribed	O
,	O
translucent	O
,	O
nonbirefringent	O
foreign	O
bodies	O
.	O

Pharmacokinetics	O
of	O
Carbamazepine	O
in	O
man	O
:	O
a	O
review	O
.	O

Two	O
transcripts	O
of	O
1	O
.	O
6	O
kb	O
and	O
5	O
.	O
8	O
kb	O
are	O
5	O
'	O
coterminal	O
and	O
may	O
both	O
encode	O
the	O
novel	O
glycoprotein	B-GENE
gene	I-GENE
EUS4	I-GENE
.	O

A	O
randomised	O
,	O
controlled	O
trial	O
was	O
undertaken	O
in	O
40	O
patients	O
with	O
active	O
Crohn	O
'	O
s	O
disease	O
to	O
evaluate	O
clinical	O
and	O
nutritional	O
outcomes	O
after	O
an	O
amino	O
acid	O
based	O
diet	O
containing	O
3	O
%	O
fat	O
was	O
given	O
by	O
a	O
feeding	O
tube	O
compared	O
with	O
a	O
peptide	O
based	O
diet	O
containing	O
33	O
%	O
fat	O
.	O

Recombinant	B-GENE
human	I-GENE
erythropoietin	I-GENE
(	O
epoetin	B-GENE
)	O
is	O
approved	O
to	O
be	O
administered	O
by	O
the	O
intravenous	O
(	O
i	O
.	O
v	O
.	O
)	O
or	O
subcutaneous	O
(	O
SC	O
)	O
route	O
.	O

We	O
speculate	O
that	O
mast	O
cell	O
degranulation	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
necrobiosis	O
by	O
altering	O
fibroblast	O
enzyme	O
activity	O
and	O
/	O
or	O
producing	O
prolonged	O
inflammatory	O
reactions	O
.	O

Hypomorphic	O
dSLBP	B-GENE
alleles	I-GENE
support	O
zygotic	O
development	O
but	O
cause	O
female	O
sterility	O
.	O

Molecular	O
cloning	O
and	O
characterization	O
of	O
a	O
cDNA	O
,	O
CHEMR1	B-GENE
,	O
encoding	O
a	O
chemokine	B-GENE
receptor	I-GENE
with	O
a	O
homology	O
to	O
the	O
human	B-GENE
C	I-GENE
-	I-GENE
C	I-GENE
chemokine	I-GENE
receptor	I-GENE
,	O
CCR	B-GENE
-	I-GENE
4	I-GENE
.	O

To	O
achieve	O
complete	O
dissection	O
of	O
the	O
anterior	O
vitreous	O
,	O
we	O
remove	O
even	O
a	O
clear	O
lens	O
during	O
the	O
first	O
surgical	O
intervention	O
in	O
selected	O
cases	O
.	O

Suggestive	O
evidence	O
was	O
obtained	O
that	O
cstA	B-GENE
is	O
involved	O
in	O
peptide	O
utilization	O
.	O

QBMDs	O
for	O
a	O
5	O
%	O
change	O
in	O
response	O
(	O
QBMD05	O
)	O
were	O
6	O
-	O
fold	O
lower	O
,	O
on	O
average	O
,	O
than	O
the	O
corresponding	O
NOAEL	O
.	O

Recombinant	B-GENE
FVIIa	I-GENE
was	O
stable	O
in	O
the	O
infusion	O
pump	O
for	O
several	O
days	O
at	O
room	O
temperature	O
and	O
for	O
24	O
h	O
at	O
body	O
temperature	O
.	O

Using	O
the	O
polymerase	B-GENE
chain	O
reaction	O
,	O
Whipple	B-GENE
-	I-GENE
specific	I-GENE
DNA	I-GENE
fragments	I-GENE
of	O
284	O
base	O
pairs	O
from	O
the	O
genome	O
of	O
the	O
Whipple	O
bacterium	O
(	O
Tropheryma	O
whippelii	O
)	O
were	O
demonstrated	O
.	O

We	O
have	O
previously	O
reported	O
that	O
depletion	O
of	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
by	O
long	O
-	O
term	O
treatment	O
of	O
B16	O
mouse	O
melanoma	O
cells	O
with	O
phorbol	O
dibutyrate	O
(	O
PDBu	O
)	O
prevented	O
cell	O
density	O
-	O
dependent	O
melanogenesis	O
.	O

PM	O
12	O
or	O
18	O
mg	O
/	O
kg	O
daily	O
plus	O
a	O
standard	O
dose	O
of	O
SB	O
for	O
21	O
days	O
was	O
statistically	O
more	O
effective	O
than	O
SB	O
in	O
producing	O
a	O
final	O
cure	O
for	O
patients	O
with	O
VL	O
in	O
Bihar	O
,	O
India	O
.	O

Visidex	O
I	O
is	O
unsuitable	O
for	O
storage	O
and	O
re	O
-	O
reading	O
.	O

A	O
pathway	O
for	O
regulation	O
of	O
B	B-GENE
lymphocyte	I-GENE
antigen	I-GENE
receptor	O
-	O
induced	O
calcium	O
flux	O
.	O

Silicosis	O
mortality	O
.	O

Rats	O
with	O
one	O
olfactory	O
bulb	O
removed	O
and	O
the	O
contralateral	O
naris	O
closed	O
can	O
detect	O
odors	O
.	O

Specimen	O
mass	O
reduction	O
increased	O
with	O
irradiance	O
from	O
19	O
to	O
72	O
%	O
of	O
the	O
initial	O
mass	O
for	O
9	O
-	O
-	O
31	O
W	O
/	O
cm	O
(	O
2	O
)	O
,	O
respectively	O
.	O

The	O
transcription	O
factor	O
Jun	B-GENE
(	O
c	B-GENE
-	I-GENE
Jun	I-GENE
)	O
functions	O
as	O
a	O
recipient	O
of	O
extracellular	O
growth	O
signals	O
and	O
converts	O
them	O
into	O
patterns	O
of	O
gene	O
expression	O
.	O

The	O
encoded	O
polypeptide	O
is	O
similar	O
in	O
sequence	O
to	O
the	O
ABA	B-GENE
-	I-GENE
1	I-GENE
allergen	I-GENE
of	I-GENE
Ascaris	I-GENE
,	O
the	O
gp15	B-GENE
/	I-GENE
400	I-GENE
'	I-GENE
ladder	I-GENE
'	I-GENE
protein	I-GENE
of	I-GENE
Brugia	I-GENE
malayi	I-GENE
,	I-GENE
Brugia	I-GENE
pahangi	I-GENE
and	I-GENE
Wuchereria	I-GENE
bancrofti	I-GENE
,	O
and	O
a	O
15	B-GENE
-	I-GENE
kDa	I-GENE
antigen	I-GENE
of	I-GENE
Dirofilaria	I-GENE
immitis	I-GENE
.	O

We	O
now	O
describe	O
the	O
identification	O
of	O
DEK	B-GENE
as	O
this	O
43	B-GENE
-	I-GENE
kDa	I-GENE
pets	I-GENE
factor	I-GENE
.	O

TH	B-GENE
-	I-GENE
SH3	I-GENE
binding	O
in	O
vitro	O
is	O
abolished	O
by	O
specific	O
,	O
single	O
amino	O
acid	O
substitutions	O
within	O
the	O
Btk	B-GENE
TH	B-GENE
domain	I-GENE
or	O
the	O
Fyn	B-GENE
SH3	B-GENE
domain	I-GENE
.	O

Nuclear	O
extracts	O
prepared	O
from	O
both	O
neural	O
and	O
non	O
-	O
neural	O
cell	O
lines	O
,	O
mouse	O
brain	O
,	O
and	O
mouse	O
liver	O
contain	O
proteins	O
that	O
recognize	O
and	O
bind	O
to	O
the	O
PROX	B-GENE
and	O
PAL	B-GENE
sequences	I-GENE
indicating	O
that	O
proteins	O
which	O
bind	O
to	O
these	O
target	O
sequences	O
are	O
widespread	O
.	O

The	O
exon	O
-	O
intron	O
distribution	O
of	O
Cdebp	B-GENE
appears	O
strikingly	O
similar	O
to	O
that	O
of	O
the	O
App	B-GENE
gene	I-GENE
in	O
the	O
regions	O
encoding	O
the	O
conserved	O
domains	O
,	O
with	O
a	O
divergent	O
structure	O
in	O
the	O
other	O
parts	O
.	O

A	O
region	O
in	O
the	O
C	O
-	O
terminus	O
of	O
adenovirus	B-GENE
2	I-GENE
/	I-GENE
5	I-GENE
E1a	I-GENE
protein	I-GENE
is	O
required	O
for	O
association	O
with	O
a	O
cellular	O
phosphoprotein	O
and	O
important	O
for	O
the	O
negative	O
modulation	O
of	O
T24	B-GENE
-	I-GENE
ras	I-GENE
mediated	O
transformation	O
,	O
tumorigenesis	O
and	O
metastasis	O
.	O

We	O
also	O
review	O
the	O
role	O
of	O
grains	O
in	O
the	O
formation	O
of	O
complex	O
molecules	O
in	O
interstellar	O
molecular	O
clouds	O
.	O

Identification	O
of	O
an	O
enhancer	O
and	O
an	O
alternative	O
promoter	O
in	O
the	O
first	O
intron	O
of	O
the	O
alpha	B-GENE
-	I-GENE
fetoprotein	I-GENE
gene	I-GENE
.	O

Spontaneous	O
burst	O
firing	O
in	O
cat	O
primary	O
auditory	O
cortex	O
:	O
age	O
and	O
depth	O
dependence	O
and	O
its	O
effect	O
on	O
neural	O
interaction	O
measures	O
.	O

Second	O
,	O
plasmid	O
-	O
derived	O
transgenes	O
and	O
gene	O
targeting	O
of	O
the	O
endogenous	B-GENE
Hnf3g	I-GENE
gene	I-GENE
locus	I-GENE
were	O
used	O
to	O
demonstrate	O
that	O
the	O
3	O
'	O
-	O
flanking	O
region	O
of	O
the	O
gene	O
is	O
necessary	O
and	O
sufficient	O
to	O
direct	O
reporter	O
gene	O
expression	O
in	O
liver	O
,	O
pancreas	O
,	O
stomach	O
and	O
small	O
intestine	O
.	O

Polysome	O
analyses	O
in	O
a	O
temperature	O
-	O
sensitive	O
fal1	B-GENE
-	I-GENE
1	I-GENE
mutant	I-GENE
and	O
a	O
Fal1p	O
-	O
depleted	O
strain	O
reveal	O
a	O
decrease	O
in	O
the	O
number	O
of	O
40S	B-GENE
ribosomal	I-GENE
subunits	I-GENE
.	O

Consistent	O
with	O
a	O
possible	O
role	O
in	O
transcription	O
,	O
Paf1p	B-GENE
is	O
localized	O
to	O
the	O
nucleus	O
.	O

However	O
,	O
if	O
the	O
spatial	O
resolution	O
is	O
not	O
critical	O
and	O
interest	O
is	O
to	O
compare	O
a	O
pathologic	O
area	O
with	O
a	O
contralateral	O
VOI	O
,	O
then	O
the	O
acquisition	O
of	O
two	O
single	O
-	O
voxel	O
spectra	O
may	O
be	O
preferred	O
.	O

Angiographic	O
work	O
-	O
up	O
in	O
a	O
patient	O
with	O
late	O
vaginal	O
metastasis	O
from	O
a	O
renal	O
carcinoma	O
.	O

Adaptation	O
of	O
taurocholate	O
transport	O
maximum	O
to	O
increased	O
secretory	O
load	O
in	O
the	O
rat	O
.	O

The	O
molecular	O
mechanism	O
of	O
Tax	O
-	O
mediated	O
trans	O
-	O
activation	O
has	O
been	O
well	O
investigated	O
.	O

This	O
suggested	O
that	O
delta	O
6	O
and	O
delta	O
5	O
desaturation	O
activities	O
are	O
normal	O
in	O
these	O
conditions	O
with	O
this	O
C18	O
:	O
2w6	O
supply	O
.	O

The	O
mean	O
values	O
of	O
the	O
first	O
three	O
components	O
were	O
not	O
significantly	O
different	O
in	O
ARVD	O
patients	O
and	O
control	O
subjects	O
.	O

Additional	O
information	O
including	O
echocardiographic	O
sequences	O
,	O
perioperative	O
video	O
sequences	O
,	O
x	O
-	O
ray	O
analysis	O
,	O
angiograms	O
,	O
etc	O
.	O
is	O
represented	O
in	O
the	O
program	O
.	O

Classification	O
according	O
to	O
the	O
ILAR	O
criteria	O
was	O
possible	O
in	O
321	O
patients	O
;	O
290	O
patients	O
had	O
a	O
disease	O
duration	O
>	O
or	O
=	O
3	O
months	O
and	O
were	O
classified	O
according	O
to	O
the	O
EULAR	O
criteria	O
.	O

METHODS	O
:	O
109	O
suspected	O
cases	O
with	O
SS	O
underwent	O
the	O
biopsies	O
.	O

In	O
order	O
to	O
delineate	O
structural	O
motifs	O
regulating	O
substrate	O
affinity	O
and	O
recognition	O
for	O
the	O
human	B-GENE
dopamine	I-GENE
transporter	I-GENE
(	O
DAT	B-GENE
)	O
,	O
we	O
assessed	O
[	O
3H	O
]	O
dopamine	O
uptake	O
kinetics	O
and	O
[	O
3H	O
]	O
CFT	O
binding	O
characteristics	O
of	O
COS	O
-	O
7	O
cells	O
transiently	O
expressing	O
mutant	B-GENE
DATs	I-GENE
in	O
which	O
the	O
COOH	O
terminus	O
was	O
truncated	O
or	O
substituted	O
.	O

Thus	O
,	O
methylation	O
of	O
Pph21p	B-GENE
is	O
important	O
for	O
formation	O
of	O
PP2A	B-GENE
trimeric	I-GENE
and	I-GENE
dimeric	I-GENE
complexes	I-GENE
,	O
and	O
consequently	O
,	O
for	O
PP2A	B-GENE
function	O
.	O

157	O
+	O
/	O
-	O
16	O
mg	O
/	O
dl	O
;	O
NS	O
)	O
,	O
glucose	O
levels	O
,	O
and	O
basal	O
(	O
17	O
+	O
/	O
-	O
4	O
vs	O
.	O

Collectively	O
,	O
these	O
experiments	O
demonstrate	O
that	O
CFTR	B-GENE
'	I-GENE
s	I-GENE
NBF1	I-GENE
+	I-GENE
R	I-GENE
region	I-GENE
and	O
its	O
NBF2	B-GENE
domain	I-GENE
,	O
after	O
folding	O
separately	O
as	O
distinct	O
units	O
,	O
have	O
a	O
strong	O
propensity	O
to	O
interact	O
and	O
that	O
this	O
interaction	O
is	O
stable	O
in	O
the	O
absence	O
of	O
added	O
nucleotides	O
or	O
exogenously	O
induced	O
phosphorylation	O
.	O

Recurrent	O
acute	O
rhinosinusitis	O
was	O
common	O
in	O
both	O
groups	O
of	O
patients	O
,	O
but	O
the	O
development	O
of	O
chronic	O
rhinosinusitis	O
was	O
only	O
found	O
in	O
patients	O
with	O
CVID	O
,	O
indicating	O
the	O
more	O
severe	O
nature	O
of	O
this	O
condition	O
compared	O
with	O
selective	O
IgA	B-GENE
deficiency	O
.	O

In	O
patients	O
who	O
were	O
not	O
vented	O
,	O
there	O
was	O
overall	O
significant	O
depression	O
of	O
function	O
(	O
67	O
+	O
/	O
-	O
5	O
%	O
of	O
control	O
;	O
range	O
,	O
91	O
-	O
-	O
45	O
%	O
,	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Value	O
of	O
the	O
method	O
of	O
passive	O
hemagglutination	O
with	O
polysaccharide	O
C	O
in	O
detecting	O
C	B-GENE
-	I-GENE
reactive	I-GENE
protein	I-GENE
as	O
compared	O
to	O
precipitation	O
in	O
capillaries	O
and	O
slide	O
latex	O
test	O
with	O
anti	B-GENE
-	I-GENE
CRP	I-GENE
serum	O
.	O

2	O
new	O
Algerian	O
cases	O
.	O

Expression	O
of	O
the	O
src	B-GENE
homology	I-GENE
3	I-GENE
(	O
SH3	B-GENE
)	O
-	O
encoding	O
,	O
expressed	O
in	O
tumorigenic	O
astrocytes	O
(	O
SETA	O
)	O
gene	O
is	O
associated	O
with	O
astrocyte	O
transformation	O
in	O
culture	O
and	O
tumors	O
in	O
the	O
adult	O
brain	O
.	O

AIM	O
:	O
To	O
understand	O
the	O
role	O
of	O
nutritional	O
status	O
in	O
cirrhotic	O
patients	O
without	O
clinical	O
porto	O
-	O
systemic	O
encephalopathy	O
(	O
PSE	O
)	O
.	O
METHODS	O
:	O
Fifty	O
-	O
one	O
non	O
-	O
alcoholic	O
patients	O
with	O
cirrhosis	O
without	O
PSE	O
were	O
studied	O
prospectively	O
and	O
compared	O
with	O
20	O
healthy	O
volunteers	O
.	O

We	O
have	O
recently	O
detected	O
high	O
levels	O
of	O
CKB	B-GENE
mRNA	I-GENE
in	O
HeLa	O
cells	O
and	O
,	O
in	O
this	O
study	O
,	O
have	O
tested	O
whether	O
this	O
may	O
be	O
due	O
to	O
the	O
extremely	O
low	O
amounts	O
of	O
p53	B-GENE
protein	I-GENE
present	O
in	O
HeLa	O
cells	O
.	O

Video	O
images	O
of	O
the	O
nostrils	O
were	O
captured	O
and	O
then	O
analyzed	O
for	O
area	O
,	O
perimeter	O
,	O
centroid	O
,	O
principal	O
axis	O
,	O
moments	O
about	O
the	O
major	O
and	O
minor	O
axes	O
(	O
I11	O
,	O
I22	O
)	O
,	O
anisometry	O
,	O
bulkiness	O
,	O
lateral	O
offset	O
,	O
internostril	O
angle	O
,	O
and	O
rotational	O
angle	O
.	O

A	O
randomized	O
mix	O
of	O
180	O
sections	O
(	O
10	O
samples	O
x	O
3	O
tissues	O
x	O
3	O
stains	O
x	O
2	O
)	O
gave	O
90	O
matched	O
pairs	O
.	O

Four	O
out	O
of	O
10	O
patients	O
showed	O
clinical	O
improvement	O
according	O
to	O
Ritchie	O
-	O
Index	O
,	O
pain	O
score	O
,	O
ESR	O
and	O
CRP	O
.	O

The	O
results	O
of	O
these	O
analyses	O
indicate	O
that	O
the	O
proteinase	B-GENE
cleaves	O
at	O
amino	O
acid	O
residues	O
E960	O
-	O
A961	O
,	O
E1071	O
-	O
S1072	O
,	O
E1345	O
-	O
T1346	O
,	O
and	O
E1419	O
-	O
G1420	O
;	O
however	O
,	O
the	O
cleavage	O
efficiency	O
is	O
varied	O
.	O

Experiments	O
with	O
recombinant	O
proteins	O
showed	O
that	O
p50	B-GENE
/	I-GENE
p65	I-GENE
and	O
high	B-GENE
-	I-GENE
mobility	I-GENE
-	I-GENE
group	I-GENE
I	I-GENE
(	I-GENE
Y	I-GENE
)	I-GENE
protein	I-GENE
cooperatively	O
facilitated	O
the	O
binding	O
of	O
IRF	B-GENE
-	I-GENE
1	I-GENE
to	O
the	O
VCAM1	B-GENE
IRF	B-GENE
binding	I-GENE
site	I-GENE
and	O
that	O
IRF	B-GENE
-	I-GENE
1	I-GENE
physically	O
interacted	O
with	O
p50	B-GENE
and	O
with	O
high	B-GENE
-	I-GENE
mobility	I-GENE
-	I-GENE
group	I-GENE
I	I-GENE
(	I-GENE
Y	I-GENE
)	I-GENE
protein	I-GENE
.	O

Control	O
intact	O
rats	O
were	O
age	O
-	O
matched	O
to	O
the	O
different	O
treated	O
groups	O
.	O

Platelet	O
function	O
and	O
platelet	O
-	O
polymorphonuclear	O
-	O
neutrophil	O
interaction	O
in	O
patients	O
with	O
deficient	O
platelet	B-GENE
lipoxygenase	I-GENE
activity	O
.	O

This	O
machine	O
drift	O
,	O
which	O
was	O
not	O
associated	O
with	O
a	O
rise	O
in	O
water	O
phantom	O
temperature	O
and	O
did	O
not	O
consistently	O
correlate	O
with	O
estimated	O
x	O
-	O
ray	O
tube	O
heat	O
,	O
could	O
result	O
in	O
a	O
significant	O
overestimation	O
of	O
regional	O
cerebral	O
blood	O
flow	O
(	O
rCBF	O
)	O
for	O
a	O
xenon	O
/	O
CT	O
rCBF	O
protocol	O
involving	O
5	O
-	O
7	O
sequential	O
scans	O
obtained	O
at	O
1	O
-	O
min	O
interscan	O
intervals	O
.	O

In	O
addition	O
,	O
negatively	O
regulatory	O
region	O
may	O
exist	O
from	O
-	O
1782	O
to	O
-	O
1295	O
bp	O
.	O

In	O
this	O
report	O
,	O
we	O
present	O
two	O
lines	O
of	O
evidence	O
that	O
all	O
ribosomes	O
which	O
synthesize	O
GCN4	B-GENE
have	O
previously	O
translated	O
uORF1	B-GENE
,	O
resumed	O
scanning	O
,	O
and	O
reinitiated	O
at	O
the	O
GCN4	B-GENE
start	O
site	O
.	O

A	O
36	O
year	O
-	O
old	O
woman	O
was	O
given	O
Ergotamine	O
Tartrate	O
4	O
.	O
5	O
mg	O
p	O
.	O
d	O
.	O
during	O
seven	O
days	O
,	O
after	O
an	O
abortion	O
(	O
a	O
still	O
birth	O
)	O
.	O

An	O
economic	O
analysis	O
using	O
West	O
of	O
Scotland	O
Coronary	O
Prevention	O
Study	O
(	O
WOSCOPS	O
)	O
findings	O
indicates	O
that	O
statin	O
treatment	O
would	O
have	O
prevented	O
318	O
events	O
per	O
10	O
,	O
000	O
patients	O
in	O
a	O
population	O
similar	O
to	O
that	O
in	O
WOSCOPS	O
(	O
average	O
1	O
.	O
5	O
%	O
annual	O
risk	O
of	O
a	O
cardiovascular	O
event	O
)	O
at	O
a	O
discounted	O
cost	O
per	O
life	O
-	O
year	O
gained	O
of	O
pound20	O
,	O
375	O
(	O
$	O
31	O
,	O
818	O
)	O
.	O

The	O
titer	O
of	O
TSH	B-GENE
binding	I-GENE
inhibitor	I-GENE
immunoglobulin	I-GENE
(	O
TBII	B-GENE
)	O
,	O
which	O
had	O
been	O
8	O
.	O
6	O
%	O
at	O
initial	O
presentation	O
,	O
rose	O
to	O
14	O
.	O
9	O
%	O
in	O
2	O
weeks	O
.	O

Y	O
.	O

A	O
possible	O
decrease	O
in	O
theophylline	O
'	O
s	O
volume	O
of	O
distribution	O
at	O
4	O
days	O
,	O
but	O
not	O
immediately	O
,	O
after	O
administration	O
of	O
chloroquine	O
was	O
suggested	O
,	O
although	O
this	O
just	O
failed	O
to	O
achieve	O
statistical	O
significance	O
(	O
p	O
=	O
0	O
.	O
055	O
)	O
.	O

There	O
was	O
no	O
correlation	O
between	O
secretor	O
status	O
and	O
clinical	O
status	O
,	O
spirometry	O
measurements	O
,	O
salivary	B-GENE
and	I-GENE
serum	I-GENE
lysozyme	I-GENE
levels	O
or	O
rates	O
of	O
respiratory	O
tract	O
colonization	O
with	O
P	O
.	O
aeruginosa	O
and	O
S	O
.	O
aureus	O
.	O

The	O
results	O
presented	O
in	O
this	O
report	O
suggest	O
that	O
the	O
SV40	O
G	O
-	O
C	O
-	O
rich	O
sequences	O
can	O
function	O
as	O
independent	O
RNA	B-GENE
polymerase	I-GENE
II	I-GENE
transcriptional	O
-	O
control	O
elements	O
.	O

To	O
determine	O
if	O
signing	O
,	O
when	O
established	O
,	O
would	O
compete	O
with	O
SIB	O
when	O
both	O
were	O
reinforced	O
,	O
extinction	O
was	O
then	O
withdrawn	O
.	O

The	O
structure	O
of	O
the	O
calcineurin	B-GENE
A	I-GENE
gene	I-GENE
was	O
determined	O
by	O
comparison	O
of	O
the	O
genomic	O
and	O
cDNA	O
sequences	O
.	O

Fructokinase	B-GENE
activity	O
is	O
elevated	O
up	O
to	O
twofold	O
when	O
Z	O
.	O
mobilis	O
was	O
grown	O
on	O
fructose	O
instead	O
of	O
glucose	O
,	O
and	O
there	O
was	O
a	O
parallel	O
increase	O
in	O
frk	B-GENE
mRNA	I-GENE
levels	O
.	O

Mycoplasma	O
pneumoniae	O
was	O
isolated	O
from	O
the	O
pleural	O
fluid	O
of	O
this	O
patient	O
.	O

We	O
found	O
that	O
T3	B-GENE
(	O
10	O
(	O
-	O
8	O
)	O
M	O
)	O
selectively	O
stimulates	O
transcription	O
from	O
rGH	O
-	O
TRE	O
-	O
and	O
TREpal	O
-	O
,	O
but	O
not	O
ME	O
-	O
TRE	O
-	O
and	O
F2	O
-	O
TRE	O
-	O
,	O
containing	O
templates	O
in	O
which	O
these	O
TREs	O
are	O
linked	O
in	O
front	O
of	O
the	O
rGH	B-GENE
minimal	I-GENE
promoter	I-GENE
containing	O
only	O
the	O
TATA	B-GENE
box	I-GENE
binding	I-GENE
protein	I-GENE
,	O
but	O
not	O
any	O
other	O
proximal	O
binding	O
protein	O
,	O
sequence	O
.	O

On	O
the	O
basis	O
of	O
a	O
patient	O
'	O
s	O
report	O
of	O
one	O
inaccurate	O
Clinitemp	O
,	O
we	O
undertook	O
to	O
investigate	O
the	O
accuracy	O
of	O
this	O
thermometer	O
.	O

Oligonucleotide	O
-	O
directed	O
mutagenesis	O
was	O
used	O
to	O
create	O
an	O
NdeI	B-GENE
restriction	I-GENE
site	I-GENE
at	O
the	O
natural	O
ATG	O
of	O
the	O
yeast	O
R	O
.	O

However	O
,	O
three	O
Hm1	B-GENE
mutants	I-GENE
that	O
were	O
moderately	O
deficient	O
in	O
stimulating	O
PI	O
turnover	O
displayed	O
normal	O
sequestration	O
,	O
suggesting	O
distinct	O
mechanisms	O
.	O

Therefore	O
,	O
it	O
would	O
be	O
advantageous	O
to	O
identify	O
such	O
persons	O
and	O
treat	O
them	O
preferentially	O
.	O

Large	O
scale	O
electronic	O
structure	O
calculations	O
.	O

Southern	O
blot	O
hybridization	O
experiments	O
suggest	O
the	O
presence	O
of	O
one	O
copy	O
of	O
Atcys1	B-GENE
,	O
Athyp1	B-GENE
and	O
AKin10	B-GENE
per	O
haploid	O
genome	O
,	O
and	O
Northern	O
blot	O
analysis	O
demonstrates	O
that	O
the	O
three	O
genes	O
are	O
differentially	O
expressed	O
in	O
roots	O
,	O
shoots	O
and	O
leaves	O
.	O

The	O
results	O
obtained	O
are	O
similar	O
to	O
those	O
described	O
with	O
the	O
previous	O
Cremophor	O
formulation	O
although	O
greater	O
variability	O
in	O
induction	O
and	O
recovery	O
times	O
was	O
noted	O
with	O
the	O
emulsion	O
formulation	O
.	O

Indeed	O
the	O
predicted	O
folding	O
of	O
the	O
5	O
'	O
and	O
3	O
'	O
-	O
untranslated	O
regions	O
revealed	O
patterns	O
of	O
stem	O
and	O
loop	O
structures	O
conserved	O
for	O
all	O
tick	O
-	O
borne	O
flaviviruses	O
suggesting	O
a	O
purifying	O
selection	O
for	O
preservation	O
of	O
essential	O
RNA	O
secondary	O
structures	O
which	O
could	O
be	O
involved	O
in	O
translational	O
control	O
and	O
replication	O
.	O

Taurine	O
deficiency	O
significantly	O
depressed	O
the	O
amplitude	O
of	O
OP1	O
and	O
OP4	O
.	O

The	O
promoter	O
region	O
showed	O
no	O
consensus	O
TATA	O
box	O
but	O
it	O
contains	O
CCAAT	O
and	O
CreA	B-GENE
boxes	I-GENE
known	O
to	O
be	O
involved	O
in	O
both	O
stress	O
and	O
carbon	O
-	O
catabolite	O
regulation	O
of	O
fungal	O
promoters	O
.	O

We	O
remain	O
convinced	O
that	O
antilymphocyte	B-GENE
globulin	I-GENE
(	O
ALG	B-GENE
)	O
is	O
a	O
potent	O
immunosuppressive	O
agent	O
in	O
humans	O
.	O

According	O
to	O
out	O
field	O
research	O
,	O
the	O
tick	O
fauna	O
was	O
very	O
rich	O
throughout	O
that	O
area	O
,	O
and	O
it	O
was	O
permissible	O
enough	O
to	O
determine	O
ticks	O
as	O
the	O
vectors	O
,	O
based	O
on	O
arising	O
of	O
anti	B-GENE
-	I-GENE
SF	I-GENE
group	I-GENE
rickettsiae	I-GENE
(	O
SFGR	B-GENE
)	O
antibody	O
in	O
mice	O
inoculated	O
with	O
some	O
tick	O
emulsions	O
,	O
findings	O
of	O
rickettsiae	O
reactive	O
to	O
patient	O
sera	O
or	O
a	O
species	O
-	O
specific	O
monoclonal	O
antibody	O
to	O
JSFR	B-GENE
in	O
the	O
hemolymph	O
cells	O
of	O
some	O
ticks	O
,	O
and	O
electron	O
microscopical	O
observations	O
of	O
SFGR	B-GENE
in	O
various	O
internal	O
organs	O
including	O
the	O
salivary	O
gland	O
of	O
ticks	O
.	O

An	O
increase	O
in	O
hypothalamic	O
expression	O
of	O
at	O
least	O
two	O
of	O
the	O
erbB	B-GENE
receptors	I-GENE
is	O
initiated	O
before	O
the	O
pubertal	O
augmentation	O
of	O
gonadal	O
steroid	O
secretion	O
and	O
is	O
completed	O
on	O
the	O
day	O
of	O
the	O
first	O
preovulatory	O
surge	O
of	O
gonadotropins	B-GENE
.	O

These	O
data	O
indicate	O
that	O
phosphorylation	O
of	O
M	B-GENE
protein	I-GENE
at	O
the	O
major	O
in	O
vivo	O
sites	O
is	O
not	O
essential	O
for	O
virus	O
assembly	O
.	O

Aviators	O
from	O
the	O
Light	O
Attack	O
Wing	O
,	O
Pacific	O
were	O
surveyed	O
and	O
the	O
results	O
were	O
categorized	O
by	O
aircraft	O
type	O
.	O

Identification	O
of	O
mutations	O
in	O
the	O
coding	O
sequence	O
of	O
the	O
proto	B-GENE
-	I-GENE
oncogene	I-GENE
c	I-GENE
-	I-GENE
kit	I-GENE
in	O
a	O
human	O
mast	O
cell	O
leukemia	O
cell	O
line	O
causing	O
ligand	O
-	O
independent	O
activation	O
of	O
c	B-GENE
-	I-GENE
kit	I-GENE
product	I-GENE
.	O

Deletion	O
from	O
either	O
the	O
N	O
-	O
or	O
C	O
-	O
terminal	O
ends	O
of	O
repA	B-GENE
(	O
28	O
and	O
69	O
codons	O
,	O
respectively	O
,	O
out	O
of	O
the	O
286	O
-	O
codon	O
open	O
reading	O
frame	O
)	O
affected	O
the	O
initiator	O
but	O
not	O
the	O
inhibitory	O
activity	O
.	O

73	O
:	O
658	O
-	O
666	O
,	O
1999	O
)	O
.	O

A	O
patient	O
is	O
described	O
with	O
skin	O
lesions	O
resembling	O
Kaposi	O
'	O
s	O
sarcoma	O
(	O
KS	O
)	O
.	O

Such	O
mutations	O
are	O
thought	O
to	O
exert	O
their	O
dominant	O
phenotype	O
by	O
sequestration	O
of	O
the	O
guanine	B-GENE
nucleotide	I-GENE
exchange	I-GENE
factor	I-GENE
(	O
GNEF	B-GENE
)	O
.	O

Induction	O
of	O
AtP5CS1	B-GENE
mRNA	I-GENE
accumulation	O
in	O
salt	O
-	O
treated	O
seedlings	O
involves	O
an	O
immediate	O
early	O
transcriptional	O
response	O
regulated	O
by	O
ABA	B-GENE
signalling	O
that	O
is	O
not	O
inhibited	O
by	O
cycloheximide	O
,	O
but	O
abolished	O
by	O
the	O
deficiency	O
of	O
ABA	B-GENE
biosynthesis	O
in	O
the	O
aba1	B-GENE
Arabidopsis	I-GENE
mutant	I-GENE
.	O

NF	B-GENE
-	I-GENE
kappaB	I-GENE
pathway	O
activation	O
occurs	O
during	O
transformation	O
induced	O
by	O
a	O
number	O
of	O
classical	O
oncogenes	O
,	O
including	O
Bcr	B-GENE
/	I-GENE
Abl	I-GENE
,	O
Ras	B-GENE
and	O
Rac	B-GENE
,	O
and	O
is	O
necessary	O
for	O
full	O
transforming	O
potential	O
.	O

L	O
-	O
canavanine	O
,	O
a	O
selective	O
inhibitor	O
of	O
the	O
inducible	O
nitric	B-GENE
oxide	I-GENE
synthase	I-GENE
,	O
increases	O
the	O
mean	O
systemic	O
filling	O
pressure	O
,	O
thereby	O
improving	O
venous	O
return	O
,	O
under	O
these	O
conditions	O
.	O

One	O
of	O
these	O
SEBPs	B-GENE
,	O
SEBP2	B-GENE
,	O
was	O
shown	O
to	O
be	O
the	O
product	O
of	O
the	O
homeotic	B-GENE
gene	I-GENE
fork	B-GENE
head	I-GENE
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
using	O
purified	O
glucocorticoid	B-GENE
receptor	I-GENE
DNA	I-GENE
binding	I-GENE
domain	I-GENE
(	O
DBD	O
)	O
demonstrated	O
that	O
both	O
GRE	B-GENE
-	I-GENE
2	I-GENE
and	I-GENE
-	I-GENE
3	I-GENE
motifs	I-GENE
interact	O
with	O
DBD	O
and	O
oligonucleotide	O
competition	O
experiments	O
established	O
that	O
these	O
have	O
different	O
affinities	O
for	O
DBD	O
.	O

Human	B-GENE
T	I-GENE
-	I-GENE
cell	I-GENE
leukemia	I-GENE
virus	I-GENE
type	I-GENE
I	I-GENE
(	I-GENE
HTLV	I-GENE
-	I-GENE
I	I-GENE
)	I-GENE
Tax	I-GENE
is	O
a	O
potent	O
transcriptional	O
regulator	O
that	O
can	O
activate	O
or	O
repress	O
specific	O
cellular	O
genes	O
and	O
that	O
has	O
been	O
proposed	O
to	O
contribute	O
to	O
leukemogenesis	O
in	O
adult	O
T	O
-	O
cell	O
leukemia	O
.	O

The	O
major	O
inserted	O
DNA	O
has	O
no	O
significant	O
homology	O
to	O
published	O
human	O
nucleic	O
acid	O
sequences	O
.	O

CONCLUSION	O
:	O
Presence	O
of	O
APOE	B-GENE
epsilon4	I-GENE
/	I-GENE
*	I-GENE
seems	O
to	O
increase	O
the	O
risk	O
for	O
dementia	O
and	O
AD	O
independently	O
of	O
its	O
effect	O
on	O
dyslipidemia	O
and	O
atherogenesis	O
.	O

Experimental	O
pancreatitis	O
in	O
pigs	O
.	O

These	O
IgG	B-GENE
antibodies	I-GENE
in	O
the	O
babies	O
diminished	O
rapidly	O
after	O
delivery	O
,	O
and	O
were	O
detectable	O
only	O
in	O
3	O
cases	O
at	O
2	O
,	O
3	O
,	O
and	O
5	O
months	O
of	O
ages	O
out	O
of	O
38	O
babies	O
up	O
to	O
21	O
months	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
One	O
hundred	O
eighty	O
-	O
four	O
chemotherapy	O
-	O
naive	O
patients	O
receiving	O
high	O
-	O
dose	O
cisplatin	O
(	O
81	O
to	O
120	O
mg	O
/	O
m2	O
)	O
were	O
randomized	O
to	O
receive	O
one	O
of	O
four	O
granisetron	O
doses	O
(	O
5	O
,	O
10	O
,	O
20	O
,	O
or	O
40	O
micrograms	O
/	O
kg	O
)	O
administered	O
before	O
chemotherapy	O
.	O

The	O
O2	O
deficit	O
was	O
not	O
related	O
to	O
blood	O
lactate	O
during	O
submaximal	O
exercise	O
,	O
muscle	O
enzyme	O
activity	O
(	O
citrate	B-GENE
synthase	I-GENE
,	O
3	B-GENE
-	I-GENE
hydroxyacyl	I-GENE
-	I-GENE
CoA	I-GENE
-	I-GENE
dehydrogenase	I-GENE
,	O
lactate	B-GENE
dehydrogenase	I-GENE
)	O
,	O
number	O
of	O
muscle	O
capillaries	O
,	O
%	O
ST	O
fibres	O
or	O
muscle	O
buffer	O
capacity	O
.	O

Subtraction	O
hybridization	O
identified	O
melanoma	B-GENE
differentiation	I-GENE
associated	I-GENE
gene	I-GENE
-	I-GENE
7	I-GENE
(	O
mda	B-GENE
-	I-GENE
7	I-GENE
)	O
,	O
as	O
a	O
gene	O
induced	O
during	O
these	O
physiological	O
changes	O
in	O
human	O
melanoma	O
cells	O
.	O

The	O
euglobulin	O
clot	O
lysis	O
time	O
was	O
slightly	O
longer	O
in	O
the	O
smokers	O
than	O
in	O
the	O
non	O
-	O
smokers	O
in	O
all	O
three	O
experimental	O
situations	O
,	O
but	O
the	O
differences	O
were	O
not	O
significant	O
.	O

The	O
two	O
IL6	B-GENE
mRNA	I-GENE
species	O
are	O
generated	O
by	O
alternative	O
polyadenylation	O
at	O
sites	O
separated	O
by	O
a	O
distance	O
of	O
1	O
.	O
2	O
kilobases	O
.	O

We	O
previously	O
reported	O
that	O
Tax	B-GENE
induced	O
cell	O
cycle	O
progression	O
from	O
G0	O
/	O
G1	O
phase	O
to	O
S	O
and	O
G2	O
/	O
M	O
phases	O
in	O
human	O
T	O
-	O
cell	O
line	O
Kit	O
225	O
cells	O
.	O

The	O
variations	O
were	O
caused	O
by	O
opposite	O
shifts	O
in	O
TSH	B-GENE
frequency	O
distribution	O
in	O
mothers	O
and	O
neonates	O
.	O

In	O
the	O
last	O
20	O
years	O
,	O
the	O
therapeutic	O
uses	O
of	O
botulinum	B-GENE
toxin	I-GENE
,	O
a	O
potent	O
neurotoxin	O
,	O
have	O
been	O
investigated	O
.	O

Obstruction	O
of	O
the	O
ERF	B-GENE
repressor	I-GENE
function	O
by	O
the	O
transactivating	O
members	O
of	O
the	O
ets	B-GENE
family	I-GENE
of	O
genes	O
(	O
i	O
.	O
e	O
.	O
gag	O
-	O
myb	O
-	O
ets	O
)	O
may	O
be	O
essential	O
for	O
the	O
control	O
of	O
genes	O
involved	O
in	O
cell	O
proliferation	O
and	O
may	O
also	O
underlie	O
their	O
tumorigenic	O
effects	O
.	O

Intraventricular	O
injection	O
of	O
(	O
2S	O
,	O
1	O
'	O
R	O
,	O
2	O
'	O
R	O
,	O
3	O
'	O
R	O
)	O
-	O
2	O
-	O
(	O
2	O
,	O
3	O
-	O
dicarboxycyclopropyl	O
)	O
glycine	O
(	O
DCG	O
-	O
IV	O
)	O
,	O
a	O
potent	O
agonist	O
for	O
metabotropic	O
glutamate	B-GENE
receptors	I-GENE
,	O
to	O
rats	O
retarded	O
dose	O
-	O
dependently	O
the	O
recovery	O
from	O
halothane	O
anesthesia	O
at	O
a	O
dose	O
range	O
from	O
30	O
to	O
300	O
pmol	O
/	O
rat	O
.	O

The	O
single	O
most	O
important	O
element	O
,	O
by	O
linker	O
-	O
scanning	O
analysis	O
,	O
is	O
a	O
10	O
-	O
bp	O
region	O
that	O
contains	O
a	O
CCAAT	O
motif	O
.	O

An	O
FP	B-GENE
mutant	I-GENE
,	O
AcFP875	B-GENE
-	I-GENE
2	I-GENE
,	O
had	O
a	O
1	O
.	O
6	O
-	O
kbp	O
insertion	O
of	O
S	O
.	O
frugiperda	O
DNA	O
near	O
the	O
5	O
'	O
end	O
of	O
these	O
transcripts	O
which	O
by	O
S1	O
analysis	O
were	O
shown	O
to	O
initiate	O
within	O
the	O
host	O
cell	O
sequence	O
.	O

We	O
took	O
advantage	O
of	O
the	O
high	O
degree	O
of	O
aa	O
sequence	O
homology	O
between	O
DAHPSs	B-GENE
from	O
several	O
species	O
to	O
isolate	O
ARO3	B-GENE
homologues	I-GENE
from	O
the	O
pathogenic	O
yeast	O
Candida	O
albicans	O
.	O

The	O
serum	O
levels	O
of	O
beta	B-GENE
-	I-GENE
human	I-GENE
chorionic	I-GENE
gonadotropin	I-GENE
(	O
HCG	B-GENE
)	O
and	O
placental	B-GENE
alkaline	I-GENE
phosphatase	I-GENE
(	O
PLAP	B-GENE
)	O
were	O
not	O
elevated	O
.	O

Effects	O
of	O
aging	O
and	O
beta	O
-	O
adrenergic	O
-	O
blockade	O
on	O
standing	O
-	O
induced	O
QT	O
/	O
QS2	O
changes	O
.	O

Several	O
nuclear	O
factors	O
that	O
interact	O
with	O
sequences	O
in	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
mouse	B-GENE
tyrosinase	I-GENE
gene	I-GENE
were	O
identified	O
using	O
band	O
shift	O
and	O
methylation	O
interference	O
assays	O
.	O

Only	O
one	O
of	O
these	O
bands	O
was	O
supershifted	O
by	O
antibody	O
to	O
p50	B-GENE
,	O
whereas	O
antibodies	O
to	O
p65	B-GENE
or	O
other	O
NF	B-GENE
-	I-GENE
kappaB	I-GENE
proteins	I-GENE
had	O
no	O
effect	O
.	O

All	O
corneal	O
buttons	O
were	O
processed	O
for	O
histopathologic	O
and	O
electron	O
microscopic	O
studies	O
.	O

In	O
gel	O
mobility	O
shift	O
assays	O
,	O
we	O
found	O
no	O
evidence	O
for	O
VDR	B-GENE
-	I-GENE
TR	I-GENE
heterodimer	I-GENE
interaction	O
with	O
any	O
tested	O
element	O
.	O

A	O
combined	O
series	O
of	O
patients	O
experienced	O
a	O
TOL	O
after	O
two	O
or	O
more	O
previous	O
cesarean	O
deliveries	O
;	O
the	O
rate	O
of	O
vaginal	O
delivery	O
was	O
66	O
%	O
,	O
and	O
there	O
was	O
virtually	O
no	O
morbidity	O
.	O

The	O
two	O
drugs	O
increase	O
the	O
rate	O
of	O
early	O
diastolic	O
filling	O
.	O

Furthermore	O
,	O
p150	B-GENE
suppresses	O
actin	B-GENE
gelation	O
,	O
which	O
is	O
induced	O
by	O
smooth	B-GENE
muscle	I-GENE
alpha	I-GENE
-	I-GENE
actinin	I-GENE
.	O

3	O
-	O
-	O
It	O
is	O
necessary	O
to	O
think	O
about	O
cosmetic	O
consequences	O
of	O
the	O
chinese	O
flap	O
and	O
consider	O
other	O
possibilities	O
of	O
the	O
flap	O
choice	O
.	O

The	O
HPLC	O
method	O
involves	O
an	O
octadecylsilane	O
column	O
at	O
55	O
degrees	O
C	O
,	O
a	O
mixture	O
of	O
water	O
-	O
acetonitrile	O
-	O
orthophosphoric	O
acid	O
(	O
779	O
:	O
220	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
as	O
mobile	O
phase	O
and	O
detection	O
at	O
226	O
nm	O
.	O

The	O
results	O
indicate	O
that	O
hrpRS	B-GENE
and	O
hrpL	B-GENE
are	O
part	O
of	O
a	O
regulatory	O
cascade	O
in	O
which	O
HrpR	B-GENE
and	O
HrpS	B-GENE
activate	O
expression	O
of	O
hrpL	B-GENE
and	O
HrpL	B-GENE
,	O
a	O
putative	O
sigma	B-GENE
factor	I-GENE
,	O
induces	O
expression	O
of	O
HrpL	B-GENE
-	I-GENE
responsive	I-GENE
genes	I-GENE
.	O

In	O
Xenopus	O
embryos	O
,	O
the	O
engineered	B-GENE
PDGF	I-GENE
receptor	I-GENE
protein	I-GENE
induced	O
the	O
formation	O
of	O
mesoderm	O
from	O
animal	O
-	O
pole	O
explants	O
in	O
an	O
FK1012	O
-	O
dependent	O
manner	O
.	O

Mutations	O
within	O
human	O
UTR1	O
modulate	O
NRF	B-GENE
-	I-GENE
1	I-GENE
expression	O
by	O
interfering	O
with	O
mRNA	O
translational	O
efficiency	O
in	O
transfected	O
cells	O
and	O
in	O
an	O
in	O
vitro	O
translation	O
system	O
.	O

In	O
particular	O
,	O
Western	O
,	O
supershift	O
,	O
and	O
promoter	O
deletion	O
analyses	O
suggested	O
a	O
role	O
for	O
CCAAT	B-GENE
/	I-GENE
enhancer	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
-	I-GENE
beta	I-GENE
(	O
C	B-GENE
/	I-GENE
EBP	I-GENE
-	I-GENE
beta	I-GENE
)	O
binding	O
site	O
between	O
-	O
2010	O
and	O
-	O
1954	O
in	O
regulating	O
transcription	O
of	O
collagenase	B-GENE
-	I-GENE
1	I-GENE
in	O
monocytic	O
cells	O
.	O

Mus81p	B-GENE
also	O
shares	O
homology	O
with	O
motifs	O
found	O
in	O
the	O
XPF	B-GENE
endonuclease	I-GENE
superfamily	I-GENE
.	O

In	O
the	O
Rett	O
syndrome	O
we	O
,	O
therefore	O
,	O
suspect	O
there	O
are	O
disturbances	O
in	O
the	O
brain	O
stem	O
functions	O
especially	O
in	O
the	O
ascending	O
reticular	O
activating	O
system	O
which	O
is	O
related	O
to	O
elevation	O
of	O
the	O
conscious	O
level	O
.	O

Multistep	O
transformation	O
by	O
defined	O
fragments	O
of	O
herpes	B-GENE
simplex	I-GENE
virus	I-GENE
type	I-GENE
2	I-GENE
DNA	I-GENE
:	I-GENE
oncogenic	I-GENE
region	I-GENE
and	O
its	O
gene	O
product	O
.	O

The	O
gcd2	B-GENE
-	I-GENE
503	I-GENE
mutation	O
also	O
results	O
in	O
polysome	O
runoff	O
,	O
accumulation	O
of	O
inactive	O
80S	B-GENE
ribosomal	I-GENE
couples	I-GENE
,	O
and	O
accumulation	O
of	O
at	O
least	O
one	O
of	O
the	O
subunits	O
of	O
the	O
general	B-GENE
translation	I-GENE
initiation	I-GENE
factor	I-GENE
2	I-GENE
(	O
eIF	B-GENE
-	I-GENE
2	I-GENE
alpha	I-GENE
)	O
in	O
43S	B-GENE
-	I-GENE
48S	I-GENE
particles	I-GENE
following	O
a	O
shift	O
to	O
the	O
restrictive	O
temperature	O
.	O

Similarly	O
,	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
activator	B-GENE
protein	I-GENE
1	I-GENE
(	O
AP	B-GENE
-	I-GENE
1	I-GENE
)	O
is	O
modified	O
by	O
a	O
DNA	B-GENE
repair	I-GENE
enzyme	I-GENE
,	O
redox	B-GENE
factor	I-GENE
1	I-GENE
(	O
Ref	B-GENE
-	I-GENE
1	I-GENE
)	O
,	O
which	O
is	O
identical	O
to	O
a	O
DNA	B-GENE
repair	I-GENE
enzyme	I-GENE
,	O
AP	B-GENE
endonuclease	I-GENE
.	O

Stereotactic	O
radiofrequency	O
lesioning	O
of	O
the	O
hamartoma	O
resulted	O
in	O
seizure	O
remission	O
without	O
complications	O
20	O
months	O
after	O
surgery	O
.	O

Gastric	O
CO2	O
/	O
HCO3	O
was	O
determined	O
in	O
absence	O
of	O
simultaneous	O
inhibition	O
of	O
acid	O
secretion	O
by	O
intra	O
-	O
and	O
extragastric	O
pCO2	O
/	O
pH	O
measurements	O
in	O
23	O
persons	O
and	O
calculated	O
using	O
the	O
equation	O
of	O
Henderson	O
-	O
Hasselbalch	O
.	O
pCO2	O
was	O
measured	O
with	O
use	O
of	O
a	O
new	O
electrode	O
.	O

The	O
microdensitometric	O
scores	O
and	O
their	O
side	O
-	O
to	O
-	O
side	O
differences	O
in	O
patients	O
correlated	O
negatively	O
with	O
the	O
serum	O
25	O
-	O
OHD	O
concentration	O
and	O
positively	O
with	O
the	O
degree	O
of	O
paralysis	O
.	O

The	O
investigation	O
was	O
thereafter	O
continued	O
in	O
an	O
open	O
fashion	O
by	O
administering	O
a	O
single	O
10	O
mg	O
dose	O
of	O
the	O
MAO	B-GENE
-	I-GENE
B	I-GENE
inhibitor	O
deprenyl	O
to	O
the	O
same	O
subjects	O
.	O

Immunofluoresence	O
data	O
indicated	O
that	O
once	O
bound	O
to	O
the	O
mutant	O
receptor	O
,	O
fluorescent	O
-	O
labeled	O
RAP	B-GENE
co	O
-	O
localized	O
with	O
markers	O
of	O
the	O
endosomal	O
pathway	O
,	O
whereas	O
,	O
in	O
cells	O
expressing	O
the	O
wild	O
-	O
type	O
receptor	O
,	O
RAP	B-GENE
fluorescence	O
co	O
-	O
localized	O
with	O
lysosomal	O
markers	O
.	O

In	O
14	O
patients	O
whose	O
PaCO2	O
was	O
greater	O
than	O
or	O
equal	O
to	O
39	O
torr	O
(	O
range	O
39	O
to	O
58	O
torr	O
)	O
and	O
clinical	O
asthma	O
score	O
was	O
6	O
or	O
greater	O
,	O
PaCO2	O
decreased	O
a	O
mean	O
of	O
11	O
.	O
7	O
torr	O
during	O
a	O
mean	O
of	O
8	O
.	O
1	O
hours	O
.	O

Deletion	O
analysis	O
revealed	O
that	O
the	O
essential	O
domain	O
of	O
this	O
promoter	O
,	O
termed	O
the	O
ORF5	B-GENE
/	I-GENE
deltaX	I-GENE
transcript	I-GENE
promoter	I-GENE
,	O
mapped	O
to	O
nucleotides	O
1525	O
-	O
1625	O
.	O

The	O
need	O
for	O
including	O
forensic	O
medical	O
expertise	O
in	O
the	O
list	O
of	O
urgent	O
criminal	O
investigative	O
actions	O
.	O

Expression	O
of	O
thymidine	B-GENE
kinase	I-GENE
gene	I-GENE
in	O
normal	O
human	O
diploid	O
cells	O
is	O
both	O
cell	O
cycle	O
-	O
and	O
age	O
-	O
dependent	O
and	O
appears	O
to	O
be	O
transcriptionally	O
regulated	O
.	O

By	O
using	O
interleukin	O
-	O
3	O
-	O
dependent	O
cells	O
that	O
ectopically	O
express	O
the	O
three	O
ErbB	B-GENE
proteins	I-GENE
or	O
their	O
combinations	O
,	O
we	O
found	O
that	O
ErbB	B-GENE
-	I-GENE
3	I-GENE
is	O
devoid	O
of	O
any	O
biological	O
activity	O
but	O
both	O
ErbB	B-GENE
-	I-GENE
1	I-GENE
and	O
ErbB	B-GENE
-	I-GENE
2	I-GENE
can	O
reconstitute	O
its	O
extremely	O
potent	O
mitogenic	O
activity	O
.	O

This	O
suggests	O
that	O
while	O
underpredictions	O
of	O
pain	O
do	O
not	O
hurt	O
more	O
,	O
disruption	O
on	O
primary	O
tasks	O
and	O
physiological	O
impact	O
are	O
higher	O
.	O

Marine	O
oils	O
and	O
cardiovascular	O
reactivity	O
.	O

Psychiatry	O
and	O
the	O
skin	O
.	O

The	O
entire	O
human	B-GENE
teneurin	I-GENE
-	I-GENE
1	I-GENE
(	O
TEN1	B-GENE
)	O
gene	O
is	O
contained	O
in	O
eight	O
PAC	O
clones	O
representing	O
part	O
of	O
the	O
chromosomal	O
locus	O
Xq25	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
identified	O
a	O
strong	O
positive	O
cis	O
-	O
regulatory	O
element	O
at	O
-	O
70	O
bp	O
to	O
-	O
75	O
bp	O
in	O
the	O
LpS1	B-GENE
beta	I-GENE
promoter	I-GENE
with	O
the	O
sequence	O
(	O
G	O
)	O
6	O
and	O
a	O
similar	O
,	O
more	O
distal	O
cis	O
-	O
element	O
at	O
-	O
721	O
bp	O
to	O
-	O
726	O
bp	O
.	O

Several	O
artifacts	O
occurred	O
that	O
interfered	O
with	O
visualization	O
of	O
the	O
diaphragm	O
.	O

Developmental	O
follow	O
-	O
up	O
at	O
age	O
2	O
years	O
was	O
performed	O
.	O

On	O
the	O
third	O
occasion	O
water	O
(	O
W	O
)	O
was	O
ingested	O
throughout	O
the	O
run	O
.	O

The	O
JS78	O
mutation	O
changes	O
Gln243	O
in	O
gp0	O
.	O
7	O
to	O
an	O
amber	O
codon	O
,	O
which	O
explains	O
the	O
production	O
of	O
the	O
truncated	O
,	O
30	B-GENE
-	I-GENE
kDa	I-GENE
gp0	I-GENE
.	I-GENE
7	I-GENE
-	I-GENE
related	I-GENE
polypeptide	I-GENE
,	O
and	O
implicates	O
the	O
11	O
-	O
kDa	O
C	O
-	O
terminal	O
domain	O
in	O
host	O
transcription	O
shut	O
-	O
off	O
.	O

Both	O
pancreatic	O
and	O
intestinal	O
cell	O
lines	O
were	O
found	O
to	O
express	O
a	O
number	O
of	O
POU	B-GENE
(	O
OCT	O
binding	O
)	O
homeodomain	B-GENE
proteins	I-GENE
examined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Sequencing	O
of	O
the	O
16p	O
11	O
.	O
1	O
/	O
Xq28	O
duplication	O
breakpoints	O
has	O
revealed	O
the	O
presence	O
of	O
repetitive	O
immunoglobulin	B-GENE
-	I-GENE
like	I-GENE
CAGGG	I-GENE
pentamer	I-GENE
sequences	I-GENE
at	O
or	O
near	O
the	O
paralogy	O
boundaries	O
.	O

Thus	O
,	O
the	O
synergistic	O
effects	O
of	O
HNF	B-GENE
-	I-GENE
1beta	I-GENE
and	O
the	O
GR	B-GENE
on	O
dexamethasone	O
-	O
stimulated	O
promoter	O
activity	O
require	O
that	O
they	O
are	O
bound	O
to	O
the	O
HNF	B-GENE
-	I-GENE
1	I-GENE
site	I-GENE
and	O
the	O
GRE	B-GENE
,	O
respectively	O
,	O
and	O
may	O
involve	O
protein	O
-	O
protein	O
interactions	O
between	O
the	O
transcription	O
factors	O
,	O
or	O
between	O
them	O
and	O
the	O
basal	O
transcription	O
machinery	O
or	O
a	O
steroid	B-GENE
receptor	I-GENE
coactivator	I-GENE
.	O

In	O
the	O
control	O
preparation	O
before	O
weight	O
was	O
allowed	O
to	O
increase	O
,	O
isogravimetric	O
capillary	O
pressure	O
(	O
Pci	O
)	O
averaged	O
8	O
mmHg	O
lower	O
than	O
colloid	O
osmotic	O
pressure	O
of	O
the	O
plasma	O
(	O
IIp	O
)	O
.	O

Construction	O
of	O
human	O
cell	O
lines	O
which	O
contain	O
and	O
express	O
the	O
adenovirus	B-GENE
DNA	I-GENE
binding	I-GENE
protein	I-GENE
gene	I-GENE
by	O
cotransformation	O
with	O
the	O
HSV	B-GENE
-	I-GENE
1	I-GENE
tk	I-GENE
gene	I-GENE
.	O

The	O
occurrence	O
,	O
maintenance	O
and	O
possible	O
involvement	O
of	O
these	O
repeated	O
sequences	O
,	O
capable	O
of	O
forming	O
stable	O
secondary	O
structures	O
,	O
are	O
discussed	O
in	O
relation	O
to	O
their	O
location	O
in	O
the	O
region	O
of	O
control	O
signals	O
.	O

This	O
subfamily	O
of	O
genes	O
all	O
have	O
a	O
single	O
ATP	O
-	O
binding	O
domain	O
at	O
the	O
N	O
-	O
terminus	O
and	O
a	O
single	O
C	O
-	O
terminal	O
set	O
of	O
transmembrane	O
segments	O
.	O

Approximately	O
65	O
%	O
of	O
the	O
total	O
cAMP	B-GENE
-	I-GENE
dependent	I-GENE
phosphotransferase	I-GENE
activity	O
is	O
recovered	O
in	O
particulate	O
fractions	O
of	O
homogenates	O
prepared	O
from	O
asynchronous	O
populations	O
of	O
C	O
.	O
elegans	O
.	O

The	O
various	O
available	O
data	O
strongly	O
suggesting	O
an	O
environmental	O
toxic	O
origin	O
for	O
the	O
"	O
sperm	O
fall	O
"	O
will	O
be	O
presented	O
as	O
well	O
as	O
the	O
most	O
frequently	O
suspected	O
class	O
of	O
substances	O
,	O
the	O
xenoestrogens	O
.	O

The	O
predicted	O
Pay4p	B-GENE
sequence	I-GENE
contains	O
two	O
putative	O
ATP	O
-	O
binding	O
domains	O
and	O
shows	O
structural	O
relationships	O
to	O
other	O
potential	O
ATP	O
-	O
binding	O
proteins	O
involved	O
in	O
biological	O
processes	O
as	O
diverse	O
as	O
peroxisome	O
biogenesis	O
,	O
vesicle	O
-	O
mediated	O
protein	O
transport	O
,	O
cell	O
cycle	O
control	O
,	O
and	O
transcriptional	O
regulation	O
.	O

DNA	O
recognition	O
by	O
F	B-GENE
factor	I-GENE
TraI36	B-GENE
:	O
highly	O
sequence	O
-	O
specific	O
binding	O
of	O
single	O
-	O
stranded	O
DNA	O
.	O

We	O
have	O
followed	O
37	O
phenytoin	O
-	O
treated	O
patients	O
with	O
reduced	O
serum	B-GENE
IgA	I-GENE
concentrations	O
for	O
2	O
-	O
7	O
years	O
.	O

Erythema	O
exsudativum	O
multiforme	O
induced	O
by	O
granulocyte	B-GENE
colony	I-GENE
-	I-GENE
stimulating	I-GENE
factor	I-GENE
in	O
an	O
allogeneic	O
peripheral	O
blood	O
stem	O
cell	O
donor	O
.	O

The	O
expression	O
of	O
the	O
first	O
two	O
genes	O
located	O
in	O
this	O
unit	O
(	O
c	B-GENE
-	I-GENE
gvpD	I-GENE
and	O
c	B-GENE
-	I-GENE
gvpE	I-GENE
)	O
was	O
also	O
monitored	O
by	O
Western	O
blot	O
(	O
immunoblot	O
)	O
analyses	O
using	O
antisera	O
raised	O
against	O
these	O
proteins	O
synthesized	O
in	O
Escherichia	O
coli	O
.	O

This	O
region	O
also	O
contains	O
a	O
gene	O
specifying	O
a	O
Leu	B-GENE
-	I-GENE
tRNA	I-GENE
precursor	I-GENE
and	O
a	O
remnant	O
of	O
a	O
tau	B-GENE
element	I-GENE
.	O

In	O
summary	O
,	O
at	O
equianesthetic	O
concentrations	O
,	O
desflurane	O
and	O
isoflurane	O
produced	O
similar	O
hemodynamic	O
effects	O
;	O
however	O
,	O
in	O
the	O
absence	O
of	O
drugs	O
that	O
inhibit	O
autonomic	O
reflexes	O
,	O
desflurane	O
had	O
less	O
negative	O
inotropic	O
activity	O
and	O
produced	O
less	O
decrease	O
in	O
arterial	O
pressure	O
.	O

Sparfloxacin	O
and	O
clinafloxacin	O
were	O
evaluated	O
against	O
Enterococcus	O
faecium	O
SF2149	O
and	O
Enterococcus	O
faecalis	O
WH245	O
,	O
respectively	O
.	O

A	O
330	O
-	O
kb	O
YAC	O
,	O
A148A7	O
,	O
spanned	O
from	O
the	O
HLA	B-GENE
-	I-GENE
DQA1	I-GENE
locus	I-GENE
through	O
the	O
Y3	B-GENE
/	I-GENE
Ring	I-GENE
4	I-GENE
locus	I-GENE
and	O
extended	O
at	O
least	O
130	O
kb	O
centromeric	O
of	O
YAC	O
B1D12	O
.	O

Modification	O
of	O
dopamine	B-GENE
D2	I-GENE
receptor	I-GENE
activity	O
by	O
pergolide	O
in	O
Parkinson	O
'	O
s	O
disease	O
:	O
an	O
in	O
vivo	O
study	O
by	O
PET	O
.	O

The	O
highest	O
doses	O
were	O
found	O
for	O
drivers	O
who	O
transported	O
large	O
numbers	O
of	O
99Mo	O
generators	O
.	O

National	O
certification	O
:	O
a	O
vital	O
component	O
of	O
quality	O
assurance	O
.	O

Effects	O
of	O
dopamine	O
and	O
of	O
a	O
dopaminergic	O
blocker	O
,	O
haloperidol	O
,	O
on	O
the	O
responses	O
of	O
carotid	O
body	O
chemoreceptors	O
to	O
hypoxia	O
and	O
hypercapnia	O
were	O
investigated	O
in	O
16	O
anesthetized	O
cats	O
.	O

Mutational	O
analysis	O
of	O
a	O
DNA	O
sequence	O
involved	O
in	O
linking	O
gene	O
expression	O
to	O
the	O
cell	O
cycle	O
.	O

PCR	O
/	O
Southern	O
blot	O
analysis	O
of	O
human	O
kidney	O
cDNA	O
using	O
primers	O
flanking	O
the	O
hKID	B-GENE
coding	I-GENE
sequence	I-GENE
revealed	O
expression	O
of	O
a	O
full	O
-	O
length	O
mRNA	O
and	O
short	O
transcripts	O
with	O
partial	O
exon	O
1	O
and	O
partial	O
exon	O
4	O
deletions	O
.	O

E	O
.	O
,	O
Hession	O
,	O
C	O
.	O
,	O
Goff	O
,	O
D	O
.	O
,	O
Griffiths	O
,	O
B	O
.	O
,	O
Tizard	O
,	O
R	O
.	O
,	O
Newman	O
,	O
B	O
.	O
,	O
Chi	O
-	O
Rosso	O
,	O
G	O
.	O
,	O
and	O
Lobb	O
,	O
R	O
.	O
,	O
(	O
1990	O
)	O
Cell	O
63	O
,	O
1349	O
-	O
1356	O
)	O
.	O

The	O
NF	B-GENE
-	I-GENE
kappaB	I-GENE
responsive	O
reporter	O
construct	O
,	O
(	B-GENE
PRDII	I-GENE
)	I-GENE
(	I-GENE
4	I-GENE
)	I-GENE
-	I-GENE
CAT	I-GENE
,	O
was	O
used	O
to	O
explore	O
transcription	O
resulting	O
from	O
NF	B-GENE
-	I-GENE
kappaB	I-GENE
activated	O
by	O
Tat	B-GENE
.	O

Transcriptional	O
regulation	O
of	O
fbp1	B-GENE
promoter	I-GENE
constructs	I-GENE
containing	O
only	O
UAS1	B-GENE
or	O
UAS2	B-GENE
confirms	O
that	O
the	O
PKA	B-GENE
and	O
MAPK	B-GENE
regulation	O
is	O
targeted	O
to	O
both	O
sites	O
.	O

Furthermore	O
,	O
formation	O
of	O
foci	O
of	O
transformed	O
RECs	O
by	O
the	O
c	B-GENE
-	I-GENE
jun	I-GENE
/	I-GENE
ras	I-GENE
combination	I-GENE
was	O
augmented	O
3	O
-	O
fold	O
by	O
the	O
tumor	O
promoter	O
phorbol	O
12	O
-	O
tetradecanoate	O
13	O
-	O
acetate	O
.	O

Commonly	O
used	O
stressors	O
are	O
mental	O
arithmetics	O
,	O
speech	O
tasks	O
,	O
the	O
Stroop	O
test	O
,	O
videogame	O
playing	O
,	O
films	O
or	O
videotapes	O
and	O
interviews	O
.	O

The	O
highly	O
restrained	O
girls	O
had	O
a	O
significantly	O
higher	O
EAT	O
score	O
than	O
the	O
low	O
-	O
restrained	O
girls	O
,	O
and	O
shared	O
with	O
their	O
mothers	O
a	O
susceptibility	O
to	O
the	O
disinhibitory	O
effects	O
of	O
negative	O
mood	O
states	O
on	O
their	O
eating	O
behaviour	O
.	O

It	O
was	O
proposed	O
that	O
the	O
synthetase	O
-	O
related	O
sequences	O
of	O
GCN2	B-GENE
stimulate	O
the	O
activity	O
of	O
the	O
kinase	O
by	O
interacting	O
directly	O
with	O
uncharged	O
tRNA	O
that	O
accumulates	O
during	O
amino	O
acid	O
limitation	O
.	O

99mTc	O
phytate	O
,	O
198Au	O
colloid	O
,	O
and	O
99mTc	O
antimony	O
sulfide	O
have	O
been	O
used	O
;	O
the	O
last	O
appears	O
to	O
have	O
been	O
the	O
most	O
satisfactory	O
.	O

Invited	O
editorial	O
on	O
"	O
Acute	O
and	O
chronic	O
effects	O
of	O
exercise	O
on	O
leptin	B-GENE
levels	O
in	O
humans	O
"	O
.	O

Pharmacologic	O
properties	O
of	O
serotonergic	O
agents	O
and	O
antidepressant	O
drugs	O
.	O

LCBF	O
in	O
normal	O
and	O
hypoxic	O
puppies	O
was	O
correlated	O
with	O
local	O
cerebral	O
glucose	O
utilization	O
(	O
LCGU	O
)	O
obtained	O
under	O
the	O
same	O
experimental	O
conditions	O
(	O
Duffy	O
et	O
al	O
,	O
1982	O
)	O
.	O

Retinoids	O
participate	O
in	O
the	O
onset	O
of	O
differentiation	O
,	O
apoptosis	O
and	O
the	O
inhibition	O
of	O
growth	O
in	O
a	O
wide	O
variety	O
of	O
normal	O
and	O
cancerous	O
cells	O
.	O

The	O
results	O
revealed	O
a	O
hierarchy	O
of	O
ligand	O
affinities	O
that	O
mirrored	O
their	O
adhesive	O
activity	O
(	O
rsVCAM	B-GENE
-	I-GENE
1	I-GENE
>	O
fibronectin	B-GENE
variants	I-GENE
containing	O
CS1	B-GENE
>	O
>	O
other	O
fibronectin	B-GENE
variants	I-GENE
)	O
.	O

The	O
diagnosis	O
of	O
miliary	O
tuberculosis	O
should	O
be	O
systematically	O
considered	O
in	O
ARDS	O
of	O
unknown	O
origin	O
.	O

After	O
giving	O
a	O
survey	O
on	O
the	O
situation	O
of	O
antibiotic	O
resistance	O
in	O
the	O
region	O
of	O
Northern	O
Bavaria	O
during	O
1973	O
/	O
74	O
and	O
comparing	O
the	O
activity	O
of	O
a	O
sulfamethoxazole	O
(	O
SMZ	O
)	O
trimethoprim	O
(	O
TMP	O
)	O
combination	O
to	O
other	O
commonly	O
used	O
antibiotics	O
and	O
chemotherapeutic	O
agents	O
,	O
the	O
results	O
of	O
tests	O
with	O
the	O
new	O
combination	O
of	O
N1	O
-	O
(	O
4	O
,	O
5	O
-	O
dimethyl	O
-	O
2	O
-	O
oxazolyl	O
)	O
-	O
sulfanilamide	O
)	O
(	O
sulfamoxole	O
)	O
and	O
2	O
,	O
4	O
-	O
diamino	O
-	O
5	O
-	O
(	O
3	O
,	O
4	O
,	O
5	O
-	O
trimethoxy	O
-	O
benzyl	O
)	O
-	O
pyrimidine	O
(	O
trimethoprim	O
)	O
at	O
a	O
ratio	O
of	O
5	O
:	O
1	O
(	O
CN	O
3123	O
;	O
Nevin	O
,	O
Supristol	O
)	O
are	O
compared	O
to	O
those	O
of	O
tests	O
with	O
TMP	O
/	O
SMZ	O
.	O

The	O
psychological	O
tests	O
consisted	O
of	O
a	O
free	O
-	O
recall	O
task	O
,	O
a	O
test	O
for	O
visuomotor	O
coordination	O
and	O
a	O
recognition	O
task	O
.	O

Coronary	O
vasoconstriction	O
caused	O
by	O
endothelin	B-GENE
-	I-GENE
1	I-GENE
is	O
enhanced	O
by	O
ischemia	O
-	O
reperfusion	O
and	O
by	O
norepinephrine	O
present	O
in	O
concentrations	O
typically	O
observed	O
after	O
neonatal	O
cardiopulmonary	O
bypass	O
.	O

The	O
plasmid	O
shuffle	O
technique	O
was	O
used	O
to	O
replace	O
the	O
wild	O
-	O
type	O
gene	O
with	O
the	O
mutant	O
form	O
,	O
resulting	O
in	O
failure	O
of	O
the	O
yeast	O
cells	O
to	O
grow	O
.	O

Late	O
mRNA	O
selected	O
by	O
a	O
cDNA	O
homologous	O
to	O
the	O
HindIII	B-GENE
-	I-GENE
P	I-GENE
/	I-GENE
EcoRI	I-GENE
-	I-GENE
B	I-GENE
region	I-GENE
of	O
the	O
AcNPV	O
map	O
directed	O
the	O
synthesis	O
of	O
31K	O
and	O
30K	O
proteins	O
which	O
comigrated	O
with	O
the	O
31K	O
and	O
30K	O
proteins	O
translated	O
from	O
RNA	O
selected	O
by	O
the	O
HindIII	B-GENE
-	I-GENE
A	I-GENE
/	I-GENE
EcoRI	I-GENE
-	I-GENE
C	I-GENE
/	I-GENE
SstI	I-GENE
-	I-GENE
G	I-GENE
cDNA	I-GENE
.	O

To	O
determine	O
whether	O
the	O
NTP	O
-	O
binding	O
motif	O
is	O
important	O
for	O
Rad24	B-GENE
function	O
,	O
we	O
mutated	O
the	O
conserved	O
lysine	O
(	O
115	O
)	O
residue	O
in	O
this	O
motif	O
.	O

Copper	O
and	O
ceruloplasmin	B-GENE
content	O
in	O
pregnant	O
women	O
and	O
in	O
women	O
with	O
certain	O
gynecological	O
diseases	O
.	O

Constitutive	O
activation	O
of	O
Rac1	B-GENE
and	O
RhoA	B-GENE
causes	O
tumorigenic	O
transformation	O
of	O
NIH	O
3T3	O
cells	O
,	O
and	O
their	O
functions	O
may	O
be	O
required	O
for	O
full	O
Ras	B-GENE
transformation	O
.	O

Proposals	O
on	O
authorization	O
;	O
by	O
a	O
group	O
of	O
nurses	O
from	O
psychiatric	O
hospitals	O
.	O

RESULTS	O
:	O
The	O
cardiac	O
index	O
significantly	O
changed	O
with	O
varying	O
PaCO2	O
levels	O
(	O
hypocapnia	O
,	O
-	O
9	O
%	O
;	O
hypercapnia	O
,	O
13	O
%	O
)	O
.	O

The	O
DNA	O
sequence	O
of	O
the	O
sulfate	B-GENE
activation	I-GENE
locus	I-GENE
from	O
Escherichia	O
coli	O
K	O
-	O
12	O
has	O
been	O
determined	O
.	O

Transforming	B-GENE
growth	I-GENE
factor	I-GENE
-	I-GENE
beta	I-GENE
(	O
TGF	B-GENE
-	I-GENE
beta	I-GENE
)	O
induced	O
growth	O
arrest	O
of	O
cells	O
involves	O
regulation	O
of	O
the	O
activities	O
of	O
both	O
D	B-GENE
-	I-GENE
and	I-GENE
E	I-GENE
-	I-GENE
type	I-GENE
cyclin	I-GENE
kinase	I-GENE
complexes	I-GENE
thought	O
to	O
be	O
mediated	O
primarily	O
by	O
the	O
regulation	O
of	O
p15	B-GENE
(	I-GENE
Ink4b	I-GENE
)	I-GENE
and	O
p27	B-GENE
(	I-GENE
Kip1	I-GENE
)	I-GENE
cyclin	I-GENE
kinase	I-GENE
inhibitors	I-GENE
.	O

Epstein	B-GENE
-	I-GENE
Barr	I-GENE
virus	I-GENE
-	I-GENE
encoded	I-GENE
latent	I-GENE
membrane	I-GENE
protein	I-GENE
1	I-GENE
activates	O
the	O
JNK	B-GENE
pathway	O
through	O
its	O
extreme	O
C	O
terminus	O
via	O
a	O
mechanism	O
involving	O
TRADD	B-GENE
and	O
TRAF2	B-GENE
.	O

WA	O
constructs	O
afforded	O
relaxed	O
and	O
positive	O
topoisomers	O
,	O
and	O
cyclization	O
kinetics	O
indicated	O
slow	O
interconversion	O
of	O
precursors	O
to	O
the	O
two	O
topoisomers	O
.	O

These	O
changes	O
may	O
be	O
the	O
result	O
of	O
,	O
on	O
the	O
one	O
hand	O
,	O
an	O
increased	O
sensitivity	O
of	O
the	O
neuromuscular	O
transmission	O
and	O
/	O
or	O
decreased	O
muscle	O
contractility	O
and	O
,	O
on	O
the	O
other	O
hand	O
,	O
the	O
result	O
of	O
a	O
reduced	O
plasma	O
clearance	O
during	O
hypothermia	O
.	O

G	O
-	O
box	O
-	O
directed	O
expression	O
in	O
leaves	O
required	O
the	O
presence	O
of	O
an	O
enhancer	O
region	O
from	O
the	O
cauliflower	O
mosaic	O
virus	O
(	O
CaMV	O
)	O
35S	B-GENE
promoter	I-GENE
.	O

Binding	O
specificity	O
and	O
modulation	O
of	O
the	O
ApoA	B-GENE
-	I-GENE
I	I-GENE
promoter	I-GENE
activity	O
by	O
homo	O
-	O
and	O
heterodimers	O
of	O
nuclear	O
receptors	O
.	O

Different	O
thermoluminescent	O
detectors	O
(	O
TLD	O
)	O
have	O
been	O
used	O
to	O
measure	O
the	O
contribution	O
of	O
the	O
low	O
linear	O
energy	O
transfer	O
component	O
(	O
LET	O
<	O
10	O
keV	O
/	O
micrometer	O
)	O
and	O
plastic	O
nuclear	O
track	O
detectors	O
(	O
PNTD	O
)	O
for	O
the	O
high	O
linear	O
energy	O
tranfer	O
(	O
LET	O
)	O
component	O
.	O

Deletion	O
mapping	O
experiments	O
determined	O
that	O
the	O
sequences	O
required	O
for	O
full	O
activity	O
in	O
MSC	O
-	O
1	O
cells	O
were	O
included	O
within	O
619	O
bp	O
of	O
the	O
start	O
site	O
and	O
identified	O
several	O
regions	O
that	O
demonstrated	O
increased	O
luciferase	B-GENE
activity	O
:	O
the	O
-	O
583	O
bp	O
to	O
-	O
564	O
bp	O
,	O
-	O
503	O
bp	O
to	O
-	O
484	O
bp	O
,	O
and	O
-	O
114	O
bp	O
to	O
-	O
65	O
regions	O
.	O

Like	O
the	O
p190	B-GENE
-	I-GENE
B	I-GENE
exon	O
,	O
the	O
first	O
exon	O
of	O
p190	B-GENE
-	I-GENE
A	I-GENE
is	O
extremely	O
large	O
(	O
3	O
.	O
7	O
kb	O
in	O
length	O
)	O
,	O
encoding	O
both	O
the	O
GTPase	B-GENE
and	O
middle	O
domains	O
(	O
residues	O
1	O
-	O
1228	O
)	O
,	O
but	O
not	O
the	O
remaining	O
GAP	B-GENE
domain	I-GENE
,	O
suggesting	O
a	O
high	O
conservation	O
of	O
genomic	O
structure	O
between	O
two	O
p190	B-GENE
genes	I-GENE
.	O

We	O
have	O
cloned	O
a	O
novel	O
mouse	O
protein	O
,	O
TAF	B-GENE
(	I-GENE
II	I-GENE
)	I-GENE
140	I-GENE
,	O
containing	O
an	O
HFD	B-GENE
and	O
a	O
plant	B-GENE
homeodomain	I-GENE
(	O
PHD	B-GENE
)	O
finger	O
,	O
which	O
we	O
demonstrated	O
by	O
immunoprecipitation	O
to	O
be	O
a	O
mammalian	B-GENE
TFIID	I-GENE
component	I-GENE
.	O

The	O
eukaryotic	O
cell	O
cycle	O
is	O
governed	O
in	O
part	O
by	O
the	O
periodic	O
transcription	O
of	O
cyclin	B-GENE
genes	I-GENE
,	O
whose	O
protein	O
products	O
associate	O
with	O
and	O
positively	O
regulate	O
the	O
cyclin	B-GENE
-	I-GENE
dependent	I-GENE
kinases	I-GENE
.	O

Dopamine	B-GENE
beta	I-GENE
-	I-GENE
hydroxylase	I-GENE
(	O
DBH	B-GENE
)	O
catalyzes	O
the	O
conversion	O
of	O
dopamine	O
to	O
noradrenaline	O
and	O
is	O
selectively	O
expressed	O
in	O
noradrenergic	O
and	O
adrenergic	O
neurons	O
and	O
neuroendocrine	O
cells	O
.	O

Cooperative	O
dimerization	O
of	O
paired	O
class	O
homeo	O
domains	O
on	O
DNA	O
.	O

G	O
.	O
,	O
and	O
Hyde	O
,	O
C	O
.	O

The	O
cellular	O
part	O
of	O
the	O
third	O
chimeric	O
clone	O
shows	O
significant	O
homology	O
to	O
an	O
exon	O
of	O
the	O
human	B-GENE
tyrosine	I-GENE
phosphatase	I-GENE
1	I-GENE
gene	I-GENE
,	O
although	O
oriented	O
in	O
the	O
antisense	O
direction	O
compared	O
to	O
the	O
adjacent	O
LTR	O
.	O

Mobilization	O
with	O
cyclophosphamide	O
and	O
granulocyte	B-GENE
-	I-GENE
colony	I-GENE
stimulating	I-GENE
factor	I-GENE
was	O
effective	O
in	O
terms	O
of	O
CD34	B-GENE
+	I-GENE
cell	O
shift	O
to	O
peripheral	O
blood	O
and	O
the	O
good	O
quality	O
autograft	O
reliaebly	O
led	O
to	O
haematopoetic	O
recovery	O
after	O
megachemotherapy	O
.	O

Both	O
parents	O
are	O
clinically	O
normal	O
and	O
unrelated	O
.	O

The	O
results	O
show	O
that	O
the	O
structure	O
of	O
the	O
decorin	B-GENE
gene	I-GENE
promoter	I-GENE
is	O
different	O
from	O
that	O
of	O
any	O
other	O
proteoglycan	O
promoter	O
characterized	O
so	O
far	O
and	O
indicate	O
that	O
the	O
pur	O
/	O
pyr	O
segment	O
plays	O
a	O
role	O
in	O
the	O
regulation	O
of	O
gene	O
transcription	O
.	O

Ammonia	O
concentration	O
dropped	O
significantly	O
in	O
all	O
treatments	O
,	O
a	O
finding	O
which	O
suggests	O
a	O
protective	O
effect	O
on	O
protein	O
nitrogen	O
degradation	O
to	O
non	O
-	O
protein	O
nitrogen	O
(	O
NH3	O
)	O
.	O

Thus	O
,	O
IRF	B-GENE
-	I-GENE
7	I-GENE
exhibits	O
functional	O
similarity	O
to	O
IRF	B-GENE
-	I-GENE
3	I-GENE
;	O
however	O
,	O
the	O
preferential	O
expression	O
of	O
IRF	B-GENE
-	I-GENE
7	I-GENE
in	O
lymphoid	O
cells	O
(	O
the	O
cell	O
type	O
that	O
expresses	O
IFNA	B-GENE
)	O
suggests	O
that	O
IRF	B-GENE
-	I-GENE
7	I-GENE
may	O
play	O
a	O
critical	O
role	O
in	O
regulating	O
the	O
IFNA	B-GENE
gene	I-GENE
expression	O
.	O

Rather	O
,	O
complete	O
skipping	O
of	O
exon	O
V	O
and	O
subsequent	O
joining	O
of	O
exon	O
IV	O
to	O
exon	O
VI	O
caused	O
a	O
shift	O
in	O
the	O
open	O
reading	O
frame	O
,	O
which	O
remodeled	O
GPHe	B-GENE
(	I-GENE
P2	I-GENE
)	I-GENE
with	O
an	O
elongated	O
new	O
hydrophobic	O
sequence	O
for	O
membrane	O
anchoring	O
.	O

All	O
stimulations	O
were	O
down	O
-	O
regulated	O
with	O
GnRH	B-GENE
-	I-GENE
a	I-GENE
commenced	O
on	O
day	O
21	O
in	O
a	O
long	O
protocol	O
before	O
gonadotropin	B-GENE
stimulation	O
.	O

The	O
consensus	O
highlights	O
the	O
importance	O
of	O
residues	O
other	O
than	O
the	O
eight	O
motifs	O
that	O
are	O
often	O
associated	O
with	O
DEAD	B-GENE
-	I-GENE
box	I-GENE
RNA	I-GENE
helicases	I-GENE
,	O
as	O
well	O
as	O
de	O
-	O
emphasising	O
the	O
importance	O
of	O
the	O
"	O
A	O
"	O
residue	O
within	O
the	O
"	B-GENE
DEAD	I-GENE
"	I-GENE
motif	I-GENE
.	O

Fortunately	O
DDT	O
-	O
,	O
HCH	O
-	O
and	O
HCB	O
-	O
levels	O
decreased	O
in	O
breast	O
milk	O
during	O
the	O
last	O
years	O
.	O

Two	O
other	O
peptides	O
,	O
either	O
partially	O
or	O
totally	O
lacking	O
the	O
basic	O
region	O
,	O
but	O
containing	O
the	O
intact	O
leucine	O
zipper	O
domain	O
,	O
readily	O
form	O
dimers	O
but	O
do	O
not	O
bind	O
to	O
the	O
CRE	B-GENE
.	O

The	O
duration	O
of	O
diabetes	O
mellitus	O
in	O
these	O
patients	O
was	O
from	O
5	O
months	O
to	O
6	O
years	O
,	O
and	O
in	O
all	O
patients	O
this	O
was	O
the	O
first	O
myocardial	O
infarction	O
.	O

We	O
detected	O
mos	B-GENE
transcripts	I-GENE
by	O
Northern	O
(	O
RNA	O
)	O
analyses	O
in	O
RNA	O
prepared	O
from	O
chicken	O
and	O
quail	O
ovaries	O
and	O
testes	O
.	O

Nursing	O
home	O
discharges	O
in	O
clinical	O
practice	O
.	O

Seven	O
clones	O
encoding	O
interferon	B-GENE
response	I-GENE
element	I-GENE
binding	I-GENE
factors	I-GENE
have	O
been	O
isolated	O
from	O
a	O
mouse	O
fibroblast	O
lambda	O
gt11	O
cDNA	O
library	O
by	O
using	O
a	O
32P	O
end	O
-	O
labeled	O
tandem	O
trimer	O
of	O
the	O
mouse	B-GENE
(	I-GENE
2	I-GENE
'	I-GENE
-	I-GENE
5	I-GENE
'	I-GENE
)	I-GENE
oligoadenylate	I-GENE
synthetase	I-GENE
gene	I-GENE
interferon	B-GENE
response	I-GENE
element	I-GENE
as	O
a	O
probe	O
.	O

The	O
patient	O
initially	O
attained	O
complete	O
remission	O
(	O
CR1	O
)	O
with	O
conventional	O
chemotherapy	O
and	O
then	O
relapsed	O
14	O
months	O
later	O
.	O

Truncation	O
variants	O
of	O
peptides	O
isolated	O
from	O
MHC	B-GENE
class	I-GENE
II	I-GENE
molecules	I-GENE
suggest	O
sequence	O
motifs	O
.	O

Recombinant	B-GENE
I	I-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
alpha	I-GENE
inhibited	O
kappa	B-GENE
B	I-GENE
motif	I-GENE
binding	O
by	O
nuclear	B-GENE
factor	I-GENE
-	I-GENE
kappa	I-GENE
B1	I-GENE
,	O
RelA	B-GENE
,	O
and	O
c	B-GENE
-	I-GENE
Rel	I-GENE
as	O
indicated	O
by	O
studies	O
using	O
UV	O
radiation	O
-	O
induced	O
covalent	O
cross	O
-	O
linking	O
to	O
a	O
bromodeoxyuridine	O
-	O
substituted	O
kappa	B-GENE
B	I-GENE
oligonucleotide	I-GENE
.	O

Cells	O
lacking	O
p116	B-GENE
exhibit	O
a	O
striking	O
defect	O
in	O
the	O
formation	O
of	O
these	O
macropinocytic	O
structures	O
,	O
a	O
concomitant	O
reduction	O
in	O
the	O
rate	O
of	O
fluid	O
phase	O
pinocytosis	O
,	O
a	O
significant	O
decrease	O
in	O
the	O
efficiency	O
of	O
chemotactic	O
aggregation	O
,	O
and	O
a	O
decrease	O
in	O
cellular	O
F	B-GENE
-	I-GENE
actin	I-GENE
content	O
.	O

Promoter	O
region	O
of	O
the	O
transcriptional	O
unit	O
for	O
human	B-GENE
alpha	I-GENE
1	I-GENE
-	I-GENE
chimaerin	I-GENE
,	O
a	O
neuron	B-GENE
-	I-GENE
specific	I-GENE
GTPase	I-GENE
-	I-GENE
activating	I-GENE
protein	I-GENE
for	O
p21rac	B-GENE
.	O
alpha	B-GENE
1	I-GENE
-	I-GENE
chimaerin	I-GENE
is	O
a	O
neuron	B-GENE
-	I-GENE
specific	I-GENE
GTPase	I-GENE
-	I-GENE
activating	I-GENE
protein	I-GENE
for	O
p21rac	B-GENE
,	O
a	O
protein	O
involved	O
in	O
morphological	O
events	O
.	O

Surprisingly	O
,	O
the	O
COOH	O
-	O
terminal	O
domain	O
of	O
RanGAP1	B-GENE
was	O
also	O
found	O
to	O
harbor	O
a	O
nuclear	O
localization	O
signal	O
.	O

Thus	O
,	O
the	O
anti	O
-	O
interferon	O
functions	O
of	O
vIRF	B-GENE
-	I-GENE
2	I-GENE
may	O
contribute	O
to	O
the	O
establishment	O
of	O
a	O
chronic	O
or	O
latent	O
infection	O
.	O

For	O
EPV	O
3	O
,	O
10	O
,	O
or	O
40	O
,	O
the	O
bias	O
exceeded	O
25	O
%	O
for	O
7	O
,	O
3	O
,	O
and	O
1	O
in	O
the	O
8	O
-	O
predictor	O
model	O
respectively	O
,	O
when	O
a	O
conventional	O
selection	O
criterion	O
was	O
used	O
(	O
alpha	O
=	O
0	O
.	O
05	O
)	O
.	O

Position	O
22	O
is	O
an	O
isoleucine	O
in	O
the	O
complete	B-GENE
SsoL12	I-GENE
protein	I-GENE
sequence	I-GENE
,	O
coded	O
by	O
an	O
AUA	O
codon	O
.	O

Plasma	O
concentrations	O
of	O
ANF	B-GENE
(	O
pANF	B-GENE
)	O
,	O
aldosterone	O
(	O
PAC	O
)	O
and	O
renin	B-GENE
(	O
PRC	B-GENE
)	O
were	O
measured	O
daily	O
,	O
as	O
were	O
hemodynamic	O
parameters	O
.	O

Immunochemical	O
studies	O
with	O
filarial	O
antigens	O
.	O

RPM	B-GENE
/	I-GENE
RGL3	I-GENE
resembled	O
AF	B-GENE
-	I-GENE
6	I-GENE
and	O
Nore1	B-GENE
in	O
interacting	O
strongly	O
with	O
constitutively	O
active	O
M	B-GENE
-	I-GENE
Ras	I-GENE
and	O
p21	B-GENE
Ras	B-GENE
.	O

To	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
case	O
in	O
which	O
a	O
probable	O
association	O
between	O
cholelithiasis	O
and	O
Wildervanck	O
'	O
s	O
syndrome	O
has	O
been	O
recorded	O
.	O

The	O
results	O
are	O
discussed	O
in	O
relation	O
to	O
acoustical	O
models	O
of	O
sound	O
propagation	O
and	O
physiology	O
,	O
and	O
it	O
is	O
suggested	O
that	O
height	O
-	O
dependent	O
degradation	O
within	O
a	O
forest	O
is	O
an	O
important	O
selection	O
pressure	O
for	O
transmissibility	O
in	O
avian	O
communication	O
.	O

To	O
identify	O
the	O
important	O
cis	O
-	O
DNA	O
regulatory	O
element	O
(	O
s	O
)	O
involved	O
in	O
the	O
tissue	O
-	O
,	O
region	O
-	O
,	O
and	O
cell	O
-	O
specific	O
expression	O
of	O
the	O
mE	B-GENE
-	I-GENE
RABP	I-GENE
gene	I-GENE
,	O
the	O
5	O
-	O
kb	O
DNA	O
fragment	O
was	O
sequenced	O
.	O

The	O
two	O
larger	O
peptides	O
,	O
one	O
containing	O
amino	O
acids	O
1	O
-	O
228	O
and	O
the	O
other	O
containing	O
amino	O
acids	O
85	O
-	O
228	O
,	O
formed	O
dimers	O
in	O
solution	O
and	O
bound	O
DNA	O
specifically	O
as	O
a	O
dimer	O
.	O

Here	O
the	O
cloning	O
and	O
molecular	O
analysis	O
of	O
the	O
Zm	B-GENE
-	I-GENE
ERabp1	I-GENE
,	O
Zm	B-GENE
-	I-GENE
ERabp4	I-GENE
,	O
and	O
Zm	B-GENE
-	I-GENE
ERabp5	I-GENE
genes	I-GENE
is	O
presented	O
.	O

Mechanism	O
of	O
enhancement	O
of	O
DNA	O
expression	O
consequent	O
to	O
cointernalization	O
of	O
a	O
replication	O
-	O
deficient	O
adenovirus	O
and	O
unmodified	O
plasmid	O
DNA	O
.	O

Using	O
this	O
method	O
,	O
VLPs	O
were	O
obtained	O
in	O
quantities	O
sufficient	O
for	O
further	O
characterization	O
.	O

Lactate	O
accumulation	O
peak	O
was	O
unaffected	O
by	O
supplementation	O
(	O
HMB	O
,	O
8	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
1	O
mM	O
;	O
LEU	O
,	O
6	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
8	O
mM	O
;	O
CON	O
,	O
7	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
3	O
mM	O
)	O
.	O

W	O
.	O

Tissue	O
pressure	O
,	O
rCBF	O
,	O
and	O
water	O
content	O
were	O
measured	O
from	O
gray	O
matter	O
in	O
the	O
central	O
core	O
and	O
the	O
peripheral	O
margin	O
of	O
the	O
MCA	O
territory	O
over	O
6	O
h	O
after	O
MCAO	O
.	O

Exons	O
III	O
to	O
VIII	O
,	O
which	O
cover	O
the	O
coding	O
region	O
and	O
the	O
3	O
'	O
untranslated	O
region	O
,	O
are	O
almost	O
identical	O
in	O
all	O
types	O
of	O
PST	B-GENE
or	O
AST	B-GENE
cDNAs	I-GENE
.	O

Alena	O
is	O
a	O
nurse	O
in	O
Prague	O
-	O
-	O
she	O
dreams	O
of	O
higher	O
wages	O
and	O
a	O
trip	O
across	O
the	O
ocean	O
.	O

An	O
experiment	O
examined	O
the	O
effects	O
of	O
treatment	O
with	O
gonadotrophin	O
releasing	O
hormone	O
(	O
100	O
micrograms	O
GnRH	B-GENE
injected	O
24	O
h	O
after	O
progestagen	O
sponge	O
removal	O
)	O
,	O
season	O
of	O
treatment	O
(	O
autumn	O
v	O
.	O
spring	O
)	O
,	O
the	O
effect	O
of	O
supplementary	O
feeding	O
with	O
lupin	O
grain	O
(	O
in	O
autumn	O
only	O
,	O
from	O
12	O
days	O
before	O
until	O
8	O
days	O
after	O
sponge	O
removal	O
)	O
on	O
the	O
time	O
of	O
ovulation	O
in	O
182	O
mature	O
Merino	O
ewes	O
superovulated	O
with	O
a	O
combination	O
of	O
400	O
I	O
.	O
U	O
.	O
pregnant	B-GENE
mare	I-GENE
serum	I-GENE
gonadotrophin	I-GENE
(	O
PMSG	B-GENE
)	O
and	O
12	O
mg	O
follicle	B-GENE
stimulating	I-GENE
hormone	I-GENE
(	O
FSH	B-GENE
-	I-GENE
P	I-GENE
)	O
.	O

The	O
early	O
lethality	O
of	O
the	O
left	O
-	O
sided	O
resectio	O
was	O
0	O
%	O
and	O
the	O
postoperative	O
survival	O
-	O
-	O
5	O
-	O
10	O
months	O
.	O

EIAV	B-GENE
LTR	I-GENE
sequence	I-GENE
variability	O
is	O
confined	O
mostly	O
to	O
a	O
small	O
portion	O
of	O
the	O
enhancer	O
within	O
the	O
U3	B-GENE
segment	I-GENE
of	O
the	O
LTR	B-GENE
.	O

In	O
the	O
context	O
of	O
liver	O
allograft	O
shortage	O
,	O
our	O
results	O
suggest	O
that	O
an	O
ELT	O
should	O
not	O
be	O
performed	O
in	O
patients	O
with	O
cardiac	O
failure	O
,	O
more	O
than	O
two	O
OSF	O
,	O
or	O
an	O
APACHE	O
II	O
score	O
higher	O
than	O
30	O
.	O

If	O
no	O
alloantibodies	O
are	O
detected	O
,	O
further	O
analysis	O
to	O
define	O
a	O
role	O
of	O
drug	O
-	O
related	O
or	O
autoantibodies	O
is	O
required	O
.	O

The	O
protein	O
mixtures	O
of	O
sesame	O
flour	O
and	O
soybean	O
flour	O
were	O
well	O
accepted	O
.	O

The	O
site	O
of	O
autophosphorylation	O
is	O
Tyr397	O
which	O
corresponds	O
to	O
the	O
consensus	O
autophosphorylation	O
site	O
of	O
other	O
Src	B-GENE
family	I-GENE
tyrosine	B-GENE
kinases	I-GENE
.	O

Our	O
results	O
favor	O
the	O
possibility	O
that	O
the	O
Drosophila	B-GENE
EGF	I-GENE
receptor	I-GENE
DER	B-GENE
/	I-GENE
Egfr	I-GENE
expressed	O
by	O
the	O
EMA	O
cells	O
functions	O
as	O
a	O
receptor	O
for	O
Vein	B-GENE
.	O

Infrared	O
measurements	O
of	O
temperature	O
changes	O
and	O
estimates	O
of	O
the	O
heating	O
produced	O
at	O
the	O
mical	O
.	O

Northern	O
blot	O
and	O
reverse	O
transcription	O
-	O
PCR	O
analyses	O
of	O
human	O
mRNA	O
samples	O
demonstrate	O
that	O
RNR	B-GENE
is	O
expressed	O
exclusively	O
in	O
the	O
retina	O
,	O
with	O
transcripts	O
of	O
approximately	O
7	O
.	O
5	O
kb	O
,	O
approximately	O
3	O
.	O
0	O
kb	O
,	O
and	O
approximately	O
2	O
.	O
3	O
kb	O
by	O
Northern	O
blot	O
analysis	O
.	O

One	O
group	O
of	O
six	O
cDNA	O
clones	O
was	O
derived	O
from	O
a	O
2	O
.	O
9	O
-	O
kilobase	O
early	O
transcript	O
encoded	O
by	O
the	O
IR2	B-GENE
repeat	I-GENE
element	I-GENE
and	O
showed	O
restriction	O
site	O
polymorphism	O
for	O
the	O
enzyme	B-GENE
SmaI	I-GENE
.	O

Compared	O
to	O
controls	O
,	O
both	O
UB	O
and	O
OCS	O
rats	O
showed	O
a	O
small	O
but	O
significant	O
post	O
-	O
operative	O
reduction	O
in	O
the	O
nocturnality	O
of	O
drinking	O
.	O

Recombinant	B-GENE
human	I-GENE
serum	I-GENE
albumin	I-GENE
(	O
rHSA	B-GENE
)	O
produced	O
by	O
cultured	O
fermentation	O
has	O
been	O
prepared	O
in	O
the	O
form	O
of	O
microcapsules	O
nominally	O
3	O
-	O
5	O
microns	O
in	O
diameter	O
and	O
radiolabelled	O
with	O
technetium	O
-	O
99m	O
following	O
reduction	O
with	O
stannous	O
chloride	O
.	O

These	O
data	O
suggest	O
that	O
proper	O
direct	O
binding	O
of	O
Nhp2p	B-GENE
to	O
H	B-GENE
/	I-GENE
ACA	I-GENE
snoRNAs	I-GENE
is	O
required	O
for	O
the	O
assembly	O
of	O
H	B-GENE
/	I-GENE
ACA	I-GENE
snoRNPs	I-GENE
and	O
hence	O
for	O
the	O
stability	O
of	O
some	O
of	O
their	O
components	O
.	O

This	O
mode	O
of	O
ternary	O
complex	O
formation	O
is	O
in	O
contrast	O
to	O
the	O
one	O
seen	O
in	O
the	O
promoter	O
of	O
the	O
c	B-GENE
-	I-GENE
fos	I-GENE
protooncogene	I-GENE
,	O
where	O
formation	O
of	O
the	O
ternary	O
complex	O
is	O
dependent	O
on	O
the	O
prior	O
assembly	O
of	O
the	O
serum	B-GENE
response	I-GENE
factor	I-GENE
-	I-GENE
DNA	I-GENE
binary	I-GENE
complex	I-GENE
.	O

Bile	O
bilirubin	O
did	O
not	O
rise	O
within	O
12	O
h	O
after	O
haem	O
infusion	O
a	O
finding	O
which	O
warrants	O
further	O
investigation	O
.	O

Following	O
intravenous	O
administration	O
,	O
the	O
myocardial	O
concentration	O
of	O
tracer	O
thallium	O
-	O
201	O
,	O
potassium	O
-	O
43	O
,	O
and	O
rubidium	O
-	O
81	O
were	O
determined	O
in	O
mice	O
;	O
thallium	O
was	O
present	O
in	O
the	O
greatest	O
concentration	O
in	O
the	O
myocardium	O
(	O
2	O
.	O
08	O
%	O
compared	O
1	O
.	O
25	O
%	O
for	O
potassium	O
and	O
1	O
.	O
15	O
%	O
for	O
rubidium	O
at	O
10	O
minutes	O
)	O
.	O

It	O
acts	O
on	O
Cdks	B-GENE
in	O
the	O
G1	O
and	O
S	O
phases	O
of	O
the	O
cell	O
cycle	O
,	O
and	O
also	O
binds	O
to	O
proliferating	B-GENE
cell	I-GENE
nuclear	I-GENE
antigen	I-GENE
(	O
PCNA	B-GENE
)	O
,	O
blocking	O
DNA	O
replication	O
in	O
vitro	O
.	O

The	O
mutation	O
within	O
the	O
asgB480	B-GENE
allele	I-GENE
was	O
identified	O
as	O
an	O
A	O
-	O
to	O
-	O
G	O
transition	O
that	O
results	O
in	O
a	O
threonine	O
-	O
to	O
-	O
alanine	O
substitution	O
in	O
the	O
predicted	O
protein	O
product	O
.	O

Nucleotide	O
sequence	O
and	O
transcriptional	O
analysis	O
of	O
the	O
polyhedrin	B-GENE
gene	I-GENE
of	O
Spodoptera	O
exigua	O
nuclear	O
polyhedrosis	O
virus	O
.	O

In	O
12	O
cases	O
(	O
3	O
.	O
1	O
%	O
)	O
,	O
a	O
change	O
in	O
stage	O
resulted	O
.	O

Inherent	O
hematology	O
of	O
old	O
age	O
.	O

We	O
couldn	O
'	O
t	O
detect	O
any	O
effect	O
of	O
n	O
-	O
3	O
FA	O
supplementation	O
on	O
total	O
cholesterol	O
,	O
HDL	O
cholesterol	O
,	O
LDL	B-GENE
cholesterol	O
,	O
apo	B-GENE
A1	I-GENE
,	O
Lp	B-GENE
(	I-GENE
a	I-GENE
)	I-GENE
,	O
HbA1C	B-GENE
,	O
glucose	O
,	O
fibrinogen	B-GENE
,	O
factor	B-GENE
VIII	I-GENE
,	O
antithrombin	B-GENE
III	I-GENE
,	O
plasminogen	B-GENE
activator	I-GENE
inhibitor	I-GENE
,	O
tissue	B-GENE
plasminogen	I-GENE
activator	I-GENE
and	O
von	B-GENE
Willebrand	I-GENE
factor	I-GENE
concentration	O
,	O
on	O
bleeding	O
time	O
or	O
on	O
systolic	O
or	O
diastolic	O
blood	O
pressure	O
.	O

A	O
multi	O
-	O
centre	O
evaluation	O
of	O
the	O
card	O
indirect	O
agglutination	O
test	O
for	O
trypanosomiasis	O
(	O
TrypTect	O
CIATT	O
)	O
.	O

Indeed	O
,	O
A	O
-	O
MuLV	O
pseudotyped	O
with	O
some	O
viruses	O
,	O
such	O
as	O
the	O
Moloney	O
MuLV	O
,	O
has	O
been	O
shown	O
to	O
be	O
highly	O
lymphogenic	O
,	O
whereas	O
A	O
-	O
MuLV	O
pseudotyped	O
with	O
other	O
viruses	O
,	O
such	O
as	O
the	O
BALB	O
/	O
c	O
endogenous	O
N	O
-	O
tropic	O
MuLV	O
,	O
has	O
been	O
shown	O
to	O
be	O
devoid	O
of	O
lymphogenic	O
potential	O
(	O
N	O
.	O

Whole	O
-	O
mount	O
in	O
situ	O
hybridization	O
to	O
early	O
mouse	O
embryos	O
of	O
9	O
.	O
5	O
-	O
10	O
.	O
5	O
days	O
indicated	O
a	O
complex	O
pattern	O
of	O
Arp1	B-GENE
expression	O
spatially	O
overlapping	O
with	O
the	O
expression	O
of	O
All1	B-GENE
.	O

Conjugated	O
estrogens	O
shorten	O
bleeding	O
time	O
in	O
uraemia	O
:	O
a	O
possible	O
role	O
of	O
serotonin	O
?	O

The	O
subunit	B-GENE
-	I-GENE
a	I-GENE
gene	I-GENE
is	O
preceded	O
by	O
a	O
gene	O
coding	O
for	O
a	O
small	O
hydrophobic	O
protein	O
,	O
as	O
has	O
been	O
observed	O
previously	O
in	O
the	O
atp	B-GENE
operons	I-GENE
in	O
E	O
.	O
coli	O
,	O
bacterium	O
PS3	O
and	O
cyanobacteria	O
.	O

US	O
-	O
Doppler	O
has	O
recently	O
gained	O
attention	O
as	O
a	O
noninvasive	O
method	O
for	O
the	O
functional	O
evaluation	O
of	O
arteriovenous	O
fistulas	O
(	O
FAV	O
)	O
.	O

The	O
physical	O
and	O
chemical	O
stability	O
of	O
a	O
combination	O
of	O
drugs	O
commonly	O
administered	O
into	O
the	O
epidural	O
or	O
intrathecal	O
space	O
for	O
the	O
treatment	O
of	O
chronic	O
pain	O
was	O
investigated	O
.	O

Are	O
low	O
P300	O
amplitudes	O
a	O
marker	O
for	O
schizophrenia	O
.	O

The	O
human	O
pathogenic	O
bacterium	O
group	O
A	O
Streptococcus	O
produces	O
an	O
extracellular	B-GENE
cysteine	I-GENE
protease	I-GENE
[	B-GENE
streptococcal	I-GENE
pyrogenic	I-GENE
exotoxin	I-GENE
B	I-GENE
(	O
SpeB	B-GENE
)	O
]	O
that	O
is	O
a	O
critical	O
virulence	O
factor	O
for	O
invasive	O
disease	O
episodes	O
.	O

Restriction	O
analysis	O
and	O
Southern	O
hybridization	O
revealed	O
the	O
presence	O
of	O
Tn5422	B-GENE
in	O
all	O
the	O
plasmid	O
-	O
mediated	O
cadmium	O
-	O
resistant	O
L	O
.	O
monocytogenes	O
strains	O
tested	O
but	O
not	O
in	O
strains	O
encoding	O
cadmium	O
resistance	O
on	O
the	O
chromosome	O
.	O

Another	O
full	O
ORF	O
was	O
found	O
on	O
the	O
opposite	O
strand	O
downstream	O
from	O
the	O
nspC	B-GENE
gene	I-GENE
.	O

These	O
two	O
mAbs	O
used	O
the	O
same	O
V	B-GENE
(	I-GENE
H	I-GENE
)	I-GENE
and	O
J	B-GENE
(	I-GENE
H	I-GENE
)	I-GENE
gene	I-GENE
segments	I-GENE
,	O
but	O
different	O
D	B-GENE
,	O
Vkappa	B-GENE
,	O
and	O
Jkappa	B-GENE
genes	I-GENE
.	O

Similarity	O
is	O
most	O
striking	O
in	O
the	O
zinc	B-GENE
knuckle	I-GENE
region	I-GENE
,	O
a	O
region	O
characteristic	O
of	O
gag	B-GENE
genes	I-GENE
of	O
most	O
replication	O
-	O
competent	O
retroelements	O
.	O

The	O
up	O
-	O
regulation	O
of	O
E	B-GENE
-	I-GENE
selectin	I-GENE
,	O
one	O
of	O
the	O
adhesion	O
molecules	O
on	O
the	O
endothelium	O
,	O
is	O
an	O
important	O
event	O
in	O
the	O
mediation	O
of	O
the	O
inflammatory	O
response	O
.	O

IGF	B-GENE
I	I-GENE
and	O
insulin	B-GENE
receptors	I-GENE
are	O
homologous	O
proteins	O
that	O
function	O
in	O
distinct	O
physiological	O
pathways	O
.	O

Side	O
effect	O
including	O
subjective	O
and	O
objective	O
symptoms	O
were	O
strictly	O
evaluated	O
in	O
163	O
cases	O
(	O
KS	O
-	O
R1	O
group	O
in	O
83	O
cases	O
,	O
oral	O
group	O
in	O
80	O
cases	O
)	O
,	O
but	O
the	O
incidence	O
rate	O
which	O
was	O
22	O
.	O
9	O
%	O
for	O
the	O
KS	O
-	O
R1	O
group	O
and	O
23	O
.	O
8	O
%	O
for	O
the	O
oral	O
group	O
showed	O
no	O
significant	O
difference	O
.	O

Increased	O
plasma	O
IgE	B-GENE
was	O
also	O
confirmed	O
in	O
the	O
NC	O
mice	O
,	O
and	O
treatment	O
with	O
FK506	O
ointment	O
reduced	O
the	O
plasma	O
IgE	B-GENE
level	O
.	O

We	O
found	O
that	O
the	O
amplitude	O
of	O
the	O
cortical	O
evoked	O
potentials	O
(	O
amplitude	O
of	O
the	O
N2	O
/	O
P2	O
peak	O
)	O
increased	O
from	O
5	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
7	O
microV	O
at	O
5	O
mA	O
to	O
16	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
1	O
microV	O
at	O
20	O
mA	O
.	O

Disruption	O
of	O
RB	B-GENE
/	I-GENE
E2F	I-GENE
-	I-GENE
1	I-GENE
interaction	O
by	O
single	O
point	O
mutations	O
in	O
E2F	B-GENE
-	I-GENE
1	I-GENE
enhances	O
S	O
-	O
phase	O
entry	O
and	O
apoptosis	O
.	O

Ventilatory	O
management	O
casebook	O
.	O

Plots	O
of	O
RV	O
,	O
LV	O
+	O
S	O
and	O
2A	O
weight	O
vs	O
real	O
hematocrit	O
showed	O
sharp	O
upward	O
inflections	O
at	O
real	O
hematocrit	O
65	O
%	O
,	O
suggesting	O
a	O
possible	O
role	O
of	O
increased	O
viscosity	O
in	O
CO	O
cardiomegaly	O
at	O
the	O
higher	O
hematocrit	O
.	O

We	O
conclude	O
that	O
DNA	O
ploidy	O
is	O
a	O
major	O
objective	O
prognostic	O
factor	O
and	O
therapeutic	O
determinant	O
for	O
endometrial	O
carcinoma	O
.	O

When	O
phosphorylation	O
of	O
exogenous	O
peptide	O
substrates	O
was	O
measured	O
as	O
a	O
function	O
of	O
receptor	O
self	O
-	O
phosphorylation	O
,	O
tyrosine	B-GENE
kinase	I-GENE
activity	O
was	O
found	O
to	O
be	O
enhanced	O
two	O
to	O
threefold	O
at	O
1	O
-	O
2	O
mol	O
of	O
phosphate	O
per	O
mol	O
of	O
receptor	O
.	O

It	O
is	O
exclusively	O
observed	O
in	O
smooth	O
muscle	O
cells	O
by	O
Northern	O
blotting	O
and	O
immunohistochemical	O
analysis	O
and	O
therefore	O
designated	O
"	B-GENE
smoothelin	I-GENE
.	I-GENE
"	I-GENE
A	O
human	O
smooth	O
muscle	O
cDNA	O
library	O
was	O
screened	O
with	O
the	O
monoclonal	B-GENE
antibody	I-GENE
R4A	I-GENE
,	O
and	O
a	O
full	O
-	O
size	O
cDNA	O
of	O
the	O
protein	O
was	O
selected	O
.	O

The	O
native	O
enzyme	O
purified	O
from	O
protease	O
-	O
B	O
-	O
deficient	O
URA2	O
-	O
transformed	O
cells	O
,	O
was	O
phosphorylated	O
in	O
vitro	O
using	O
catalytic	O
subunits	O
of	O
pure	O
cAMP	B-GENE
-	I-GENE
dependent	I-GENE
protein	I-GENE
kinase	I-GENE
.	O

Sodium	O
polystyrene	O
sulfonate	O
treatment	O
for	O
lithium	O
toxicity	O
:	O
effects	O
on	O
serum	O
potassium	O
concentrations	O
.	O

BACKGROUND	O
:	O
We	O
conducted	O
a	O
phase	O
I	O
study	O
with	O
MDL	O
73	O
,	O
147EF	O
,	O
a	O
new	O
5	B-GENE
hydroxytryptamine	I-GENE
3	I-GENE
(	I-GENE
5	I-GENE
-	I-GENE
HT3	I-GENE
)	I-GENE
receptor	I-GENE
antagonist	O
,	O
in	O
25	O
patients	O
requiring	O
emetogenic	O
chemotherapy	O
.	O

We	O
examined	O
Akt	B-GENE
activation	O
in	O
Lyn	O
-	O
,	O
Syk	O
-	O
and	O
Btk	O
-	O
deficient	O
DT40	O
cells	O
and	O
B	O
cells	O
from	O
Lyn	B-GENE
(	I-GENE
-	I-GENE
/	I-GENE
-	I-GENE
)	I-GENE
mice	O
.	O

Large	O
strain	O
differences	O
were	O
found	O
for	O
all	O
variables	O
recorded	O
,	O
i	O
.	O
e	O
.	O
,	O
the	O
proportion	O
of	O
attacking	O
males	O
,	O
the	O
time	O
spent	O
in	O
the	O
brightly	O
lit	O
box	O
,	O
and	O
the	O
number	O
of	O
transitions	O
between	O
the	O
lit	O
and	O
the	O
dark	O
boxes	O
.	O

During	O
ISO	O
+	O
AT	O
infusion	O
,	O
abdominal	O
fat	O
blood	O
flow	O
was	O
still	O
significantly	O
increased	O
as	O
compared	O
with	O
control	O
values	O
in	O
lean	O
and	O
obese	O
subjects	O
.	O

Twenty	O
-	O
two	O
of	O
the	O
24	O
patients	O
had	O
a	O
rise	O
in	O
the	O
total	O
serum	O
amylase	B-GENE
following	O
ERCP	O
.	O

MCh	O
infusion	O
caused	O
a	O
concentration	O
-	O
dependent	O
increase	O
in	O
airway	O
resistance	O
at	O
constant	O
QBA	O
.	O

We	O
obtained	O
the	O
prevalence	O
of	O
IgG	B-GENE
antibodies	I-GENE
against	O
Trypanosoma	O
cruzi	O
among	O
1076	O
blood	O
donors	O
at	O
the	O
Instituto	O
Nacional	O
de	O
Cardiologia	O
"	O
Ignacio	O
Chavez	O
"	O
in	O
Mexico	O
City	O
.	O

In	O
particular	O
,	O
the	O
potential	O
for	O
prostate	O
cancer	O
chemoprevention	O
using	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
cyclo	B-GENE
-	I-GENE
oxygenase	I-GENE
inhibitors	O
;	O
NSAIDs	O
)	O
has	O
received	O
little	O
attention	O
.	O

Both	O
TRE	B-GENE
-	I-GENE
like	I-GENE
elements	I-GENE
were	O
capable	O
of	O
binding	O
AP1	B-GENE
.	O

Anamnestic	O
data	O
were	O
obtained	O
from	O
case	O
history	O
,	O
smoking	O
habits	O
were	O
not	O
known	O
in	O
collective	O
A	O
and	O
C	O
.	O

Using	O
a	O
conditional	O
-	O
lethal	O
mutant	O
allele	O
of	O
SUP45	B-GENE
(	O
sup45	B-GENE
-	I-GENE
2	I-GENE
)	O
and	O
a	O
combination	O
of	O
in	O
vivo	O
and	O
in	O
vitro	O
approaches	O
,	O
we	O
demonstrate	O
that	O
the	O
product	O
of	O
the	O
SUP45	B-GENE
gene	I-GENE
(	O
Sup45p	B-GENE
or	O
eRF1	B-GENE
)	O
is	O
a	O
factor	O
required	O
for	O
translation	O
termination	O
in	O
yeast	O
.	O

Large	O
differences	O
between	O
the	O
groups	O
were	O
not	O
observed	O
in	O
HA	O
-	O
synthesizing	O
enzyme	O
activity	O
,	O
but	O
degradative	O
enzyme	O
activity	O
was	O
much	O
higher	O
in	O
aspirin	O
-	O
induced	O
asthma	O
-	O
related	O
polyps	O
than	O
in	O
other	O
types	O
of	O
nasal	O
polyps	O
tested	O
.	O

The	O
progression	O
of	O
non	O
-	O
A	O
,	O
non	O
-	O
B	O
hepatitis	O
to	O
chronic	O
diseases	O
,	O
and	O
the	O
transformation	O
to	O
hepatocellular	O
carcinoma	O
.	O

This	O
study	O
investigated	O
the	O
degree	O
to	O
which	O
racial	O
identity	O
influences	O
Mexican	O
-	O
Americans	O
'	O
performance	O
on	O
the	O
L	O
,	O
K	O
,	O
and	O
MF	O
scales	O
of	O
the	O
MMPI	O
-	O
2	O
.	O

The	O
results	O
show	O
that	O
both	O
the	O
amino	O
and	O
carboxy	O
termini	O
of	O
the	O
NS1	B-GENE
protein	I-GENE
molecule	I-GENE
and	O
the	O
cysteines	O
at	O
residues	O
337	O
and	O
340	O
are	O
essential	O
for	O
tubule	O
formation	O
.	O

Several	O
cytokines	O
exhibit	O
a	O
high	O
degree	O
of	O
temporal	O
regulation	O
as	O
well	O
as	O
somnogenic	O
potency	O
(	O
e	O
.	O
g	O
.	O
,	O
interleukin	B-GENE
-	I-GENE
1	I-GENE
[	B-GENE
IL	I-GENE
-	I-GENE
1	I-GENE
]	I-GENE
,	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
-	I-GENE
alpha	I-GENE
[	B-GENE
TNF	I-GENE
-	I-GENE
alpha	I-GENE
]	I-GENE
)	O
.	O

Effects	O
of	O
single	O
and	O
combined	O
maltose	O
tetrapalmitate	O
immunotherapy	O
,	O
cyclophosphamide	O
chemotherapy	O
and	O
radiotherapy	O
on	O
ethyl	O
carbamate	O
accelerated	O
primary	O
lung	O
cancer	O
in	O
A	O
/	O
J	O
mice	O
.	O

The	O
authors	O
evaluate	O
the	O
clinical	O
efficacy	O
of	O
EMB	O
AZS	O
in	O
recurrent	O
ulcer	O
after	O
operation	O
on	O
the	O
stomach	O
caused	O
by	O
a	O
high	O
level	O
of	O
acid	O
production	O
and	O
ulcerative	O
gastroduodenal	O
bleeding	O
.	O

Vacuum	O
Rabi	O
splitting	O
as	O
a	O
feature	O
of	O
linear	O
-	O
dispersion	O
theory	O
:	O
Analysis	O
and	O
experimental	O
observations	O
.	O

Successive	O
abdominal	O
scintillation	O
with	O
131	O
-	O
I	O
-	O
tagged	O
BSP	O
-	O
-	O
description	O
of	O
the	O
thyroid	O
gland	O
,	O
kidney	O
and	O
spleen	O
(	O
comparison	O
with	O
131	O
-	O
I	O
-	O
RB	O
)	O
.	O

The	O
operation	O
recommended	O
is	O
excision	O
of	O
3	O
mm	O
of	O
central	O
slip	O
followed	O
by	O
end	O
-	O
to	O
-	O
end	O
repair	O
of	O
the	O
tendon	O
.	O

The	O
Scales	O
of	O
Cognitive	O
Impairment	O
Rated	O
From	O
Institutional	O
Records	O
(	O
SCIRFIR	O
)	O
,	O
a	O
battery	O
based	O
on	O
commonly	O
used	O
dementia	O
rating	O
instruments	O
,	O
was	O
tested	O
on	O
the	O
records	O
of	O
26	O
chronically	O
institutionalized	O
,	O
elderly	O
schizophrenia	O
patients	O
,	O
for	O
the	O
purpose	O
of	O
retrospectively	O
evaluating	O
the	O
long	O
-	O
term	O
course	O
of	O
cognitive	O
change	O
in	O
schizophrenia	O
and	O
relating	O
it	O
to	O
available	O
autopsy	O
materials	O
.	O

We	O
report	O
an	O
odd	O
case	O
of	O
marked	O
enlargement	O
of	O
suprapineal	O
recess	O
in	O
a	O
patient	O
with	O
triventricular	O
hydrocephalus	O
.	O

Molecular	O
cloning	O
and	O
characterization	O
of	O
OsPSK	B-GENE
,	O
a	O
gene	O
encoding	O
a	O
precursor	O
for	O
phytosulfokine	B-GENE
-	I-GENE
alpha	I-GENE
,	O
required	O
for	O
rice	O
cell	O
proliferation	O
.	O

Cross	O
-	O
talking	O
among	O
Drosophila	B-GENE
nuclear	I-GENE
receptors	I-GENE
at	O
the	O
promiscuous	B-GENE
response	I-GENE
element	I-GENE
of	O
the	O
ng	B-GENE
-	I-GENE
1	I-GENE
and	O
ng	B-GENE
-	I-GENE
2	I-GENE
intermolt	I-GENE
genes	I-GENE
.	O

The	O
results	O
of	O
supershift	O
analysis	O
using	O
specific	O
antibodies	O
against	O
transcription	O
factors	O
suggested	O
that	O
both	O
binding	O
complexes	O
contained	O
the	O
NF	B-GENE
-	I-GENE
kappaB	I-GENE
components	O
p50	B-GENE
and	O
p65	B-GENE
,	O
and	O
did	O
not	O
contain	O
other	O
NF	B-GENE
-	I-GENE
kappaB	I-GENE
proteins	I-GENE
(	O
p52	B-GENE
,	O
c	B-GENE
-	I-GENE
Rel	I-GENE
,	O
Rel	B-GENE
B	I-GENE
)	O
,	O
AP	B-GENE
-	I-GENE
1	I-GENE
proteins	I-GENE
(	O
c	B-GENE
-	I-GENE
Fos	I-GENE
,	O
C	B-GENE
-	I-GENE
Jun	I-GENE
)	O
,	O
CREB	B-GENE
or	O
C	B-GENE
/	I-GENE
EBPbeta	I-GENE
(	O
NF	B-GENE
-	I-GENE
IL6	I-GENE
)	O
.	O

The	O
COOH	O
-	O
terminal	O
46	O
codons	O
of	O
slyD	B-GENE
encode	O
a	O
remarkable	O
histidine	O
-	O
rich	O
peptide	O
sequence	O
which	O
is	O
at	O
least	O
partly	O
dispensable	O
for	O
slyD	B-GENE
function	O
in	O
E	O
-	O
mediated	O
lysis	O
.	O

These	O
results	O
confirmed	O
that	O
cleavage	O
of	O
the	O
leader	O
peptide	O
is	O
the	O
last	O
step	O
in	O
nisin	B-GENE
maturation	O
and	O
is	O
necessary	O
to	O
generate	O
a	O
biologically	O
active	O
peptide	O
.	O

It	O
is	O
concluded	O
that	O
axillo	O
-	O
axillary	O
by	O
-	O
pass	O
is	O
a	O
simple	O
solution	O
for	O
a	O
complex	O
haemodynamic	O
,	O
clinical	O
and	O
therapeutic	O
problem	O
.	O

Under	O
these	O
conditions	O
,	O
transfections	O
with	O
cDNAs	O
of	O
the	O
NF	B-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
p50	I-GENE
and	O
serum	B-GENE
response	I-GENE
factor	I-GENE
(	O
SRF	B-GENE
)	O
produced	O
a	O
factor	O
(	O
s	O
)	O
that	O
mediated	O
Tax	B-GENE
binding	O
to	O
the	O
NF	B-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
site	I-GENE
and	O
the	O
CArG	B-GENE
box	I-GENE
respectively	O
.	O

Here	O
we	O
report	O
that	O
Dbp5p	B-GENE
and	O
Rat7p	B-GENE
interact	O
through	O
their	O
Nterminal	O
domains	O
.	O

Comparisons	O
with	O
the	O
available	O
amino	O
acid	O
residue	O
(	O
aa	O
)	O
sequence	O
information	O
from	O
the	O
complete	O
CPMV	B-GENE
RNA	I-GENE
1	I-GENE
sequence	I-GENE
and	O
the	O
partial	O
sequence	O
of	O
red	B-GENE
clover	I-GENE
mottle	I-GENE
virus	I-GENE
RNA	I-GENE
1	I-GENE
suggest	O
that	O
CPSMV	B-GENE
RNA	I-GENE
1	I-GENE
specifies	O
the	O
expected	O
set	O
of	O
five	O
mature	O
proteins	O
:	O
32K	B-GENE
proteinase	I-GENE
cofactor	I-GENE
,	O
58K	B-GENE
presumed	I-GENE
helicase	I-GENE
,	O
VPg	B-GENE
5	I-GENE
'	I-GENE
-	I-GENE
linked	I-GENE
protein	I-GENE
of	O
the	O
genomic	O
RNAs	O
,	O
24K	B-GENE
proteinase	I-GENE
,	O
and	O
87K	B-GENE
presumed	I-GENE
polymerase	I-GENE
,	O
separated	O
by	O
four	O
cleavage	O
sites	O
.	O

Reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
assays	O
showed	O
that	O
PKRDeltaE7	B-GENE
is	O
expressed	O
in	O
a	O
broad	O
range	O
of	O
human	O
tissues	O
at	O
variable	O
levels	O
.	O

Two	O
mammalian	O
enzymes	O
,	O
the	O
haem	B-GENE
-	I-GENE
controlled	I-GENE
repressor	I-GENE
(	O
HCR	B-GENE
)	O
and	O
the	O
double	B-GENE
-	I-GENE
stranded	I-GENE
RNA	I-GENE
-	I-GENE
activated	I-GENE
inhibitor	I-GENE
(	O
dsI	B-GENE
)	O
,	O
phosphorylate	O
Ser	O
-	O
51	O
of	O
the	O
alpha	O
subunit	O
,	O
thereby	O
inhibiting	O
the	O
exchange	O
of	O
bound	O
nucleotides	O
on	O
,	O
and	O
thus	O
the	O
recycling	O
of	O
,	O
eIF	B-GENE
-	I-GENE
2	I-GENE
.	O

The	O
mean	O
serum	O
creatinine	O
levels	O
were	O
similar	O
at	O
one	O
year	O
(	O
SPK	O
1	O
.	O
8	O
,	O
KTA	O
1	O
.	O
9	O
mg	O
/	O
d	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Urinary	O
excretion	O
of	O
oestrone	O
,	O
oestradiol	O
-	O
17	O
beta	O
and	O
oestriol	O
in	O
pregnancies	O
complicated	O
by	O
steroid	B-GENE
sulphatase	I-GENE
deficiency	O
.	O

Although	O
a	O
great	O
deal	O
is	O
understood	O
about	O
how	O
bHLH	B-GENE
factors	I-GENE
activate	O
gene	O
transcription	O
via	O
E	O
-	O
box	O
DNA	O
consensus	O
sequences	O
,	O
studies	O
of	O
bHLH	B-GENE
factor	I-GENE
function	O
in	O
higher	O
eukaryotes	O
often	O
have	O
been	O
hindered	O
by	O
the	O
presence	O
of	O
multiple	O
family	O
members	O
.	O

However	O
these	O
search	O
engines	O
respond	O
with	O
such	O
cumbersome	O
results	O
that	O
domain	O
specific	O
experts	O
can	O
not	O
tolerate	O
.	O

Previous	O
genetic	O
studies	O
led	O
to	O
the	O
conclusion	O
that	O
nitrate	O
and	O
nitrite	O
induction	O
of	O
nasF	B-GENE
operon	I-GENE
expression	O
is	O
determined	O
by	O
a	O
transcriptional	O
antitermination	O
mechanism	O
.	O

According	O
to	O
symptoms	O
,	O
signs	O
,	O
imaging	O
features	O
,	O
operation	O
findings	O
,	O
the	O
original	O
places	O
and	O
the	O
expansive	O
directions	O
of	O
the	O
tumor	O
,	O
they	O
were	O
divided	O
into	O
four	O
clinical	O
types	O
:	O
sellar	O
,	O
clival	O
,	O
occipito	O
-	O
temporal	O
and	O
extent	O
.	O

ID	O
-	O
PaGIA	O
diphtheria	B-GENE
toxin	I-GENE
polymer	O
particle	O
diagnostic	O
agent	O
manufactured	O
by	O
DiaMed	O
AG	O
,	O
Switzerland	O
,	O
was	O
tried	O
at	O
bacteriological	O
laboratory	O
of	O
Institute	O
of	O
Childhood	O
Infections	O
in	O
St	O
.	O

The	O
localization	O
of	O
ZAP	B-GENE
-	I-GENE
70	I-GENE
to	O
the	O
cell	O
cortex	O
is	O
,	O
therefore	O
,	O
regulated	O
by	O
the	O
activity	O
of	O
SRC	B-GENE
-	I-GENE
family	I-GENE
kinases	I-GENE
,	O
independently	O
of	O
their	O
ability	O
to	O
phosphorylate	O
immunoreceptor	O
tyrosine	O
-	O
based	O
activation	O
motifs	O
of	O
the	O
TCR	B-GENE
.	O

Revascularization	O
after	O
anterior	O
maxillary	O
and	O
mandibular	O
osteotomy	O
.	O

Short	O
-	O
course	O
amphotericin	O
B	O
therapy	O
for	O
candidemia	O
in	O
pediatric	O
patients	O
.	O

RESULTS	O
:	O
Fournier	O
'	O
s	O
gangrene	O
occurs	O
worldwide	O
.	O

Kindling	O
of	O
the	O
primary	O
visual	O
cortex	O
(	O
VC	O
)	O
was	O
compared	O
with	O
that	O
of	O
the	O
amygdala	O
in	O
cats	O
.	O

To	O
study	O
the	O
regulation	O
of	O
its	O
expression	O
,	O
the	O
human	B-GENE
aldehyde	I-GENE
reductase	I-GENE
gene	I-GENE
and	O
promoter	O
were	O
cloned	O
and	O
characterized	O
.	O

Serodiagnosis	O
of	O
trypanosomiasis	O
in	O
dromedary	O
camels	O
using	O
a	O
card	O
agglutination	O
test	O
set	O
(	O
Testryp	O
CATT	O
)	O
.	O

The	O
impact	O
of	O
social	O
support	O
on	O
the	O
relationships	O
of	O
gay	O
male	O
couples	O
is	O
examined	O
.	O

RESULTS	O
:	O
The	O
bilinear	O
model	O
provided	O
a	O
significantly	O
better	O
fit	O
to	O
the	O
acuity	O
outcome	O
data	O
.	O

Atherosclerosis	O
.	O

Tobacco	O
mosaic	O
virus	O
-	O
infected	O
tobacco	O
(	O
Nicotiana	O
tabacum	O
var	O
.	O

The	O
long	O
-	O
term	O
prediction	O
is	O
based	O
on	O
an	O
algorithm	O
for	O
R	O
-	O
R	O
interval	O
estimation	O
.	O

Despite	O
these	O
limitations	O
the	O
CHIME	O
monitor	O
provides	O
an	O
opportunity	O
to	O
record	O
physiological	O
data	O
previously	O
unavailable	O
in	O
the	O
home	O
.	O

Diffuse	O
white	O
matter	O
injury	O
can	O
be	O
attributed	O
to	O
radiation	O
and	O
associated	O
with	O
neurological	O
deficits	O
,	O
but	O
leukoencephalopathy	O
is	O
rarely	O
observed	O
in	O
the	O
absence	O
of	O
chemotherapy	O
.	O

The	O
biology	O
of	O
Hyostrongylus	O
ruidus	O
.	O

This	O
observation	O
cannot	O
be	O
explained	O
by	O
the	O
scanning	O
model	O
for	O
ribosomal	O
initiation	O
and	O
suggests	O
that	O
ribosomes	O
may	O
be	O
binding	O
directly	O
at	O
an	O
internal	O
mRNA	O
site	O
at	O
or	O
near	O
the	O
initiator	O
AUG	O
codon	O
for	O
the	O
C	B-GENE
protein	I-GENE
.	O

Several	O
new	O
techniques	O
are	O
available	O
for	O
monitoring	O
control	O
of	O
diabetes	O
.	O

Static	O
and	O
dynamic	O
compliance	O
was	O
measured	O
after	O
induction	O
of	O
anesthesia	O
,	O
before	O
and	O
immediately	O
after	O
filtration	O
in	O
the	O
operating	O
theater	O
,	O
1	O
hour	O
after	O
return	O
to	O
the	O
pediatric	O
intensive	O
care	O
unit	O
,	O
and	O
24	O
hours	O
after	O
the	O
operation	O
.	O

Large	O
ones	O
were	O
similar	O
in	O
size	O
to	O
the	O
main	O
lobe	O
and	O
small	O
ones	O
were	O
approximately	O
1	O
/	O
4	O
of	O
the	O
length	O
of	O
the	O
main	O
lobe	O
.	O

Two	O
families	O
with	O
concordant	O
inheritance	O
of	O
DNAH9	B-GENE
alleles	I-GENE
in	O
affected	O
individuals	O
were	O
observed	O
.	O

Serum	B-GENE
IgM	I-GENE
and	O
IgE	B-GENE
concentrations	O
,	O
allergen	B-GENE
-	I-GENE
specific	I-GENE
IgE	I-GENE
scores	O
,	O
and	O
the	O
tumor	O
E2R	B-GENE
status	O
were	O
combined	O
to	O
construct	O
a	O
three	O
-	O
level	O
risk	O
classification	O
that	O
was	O
more	O
prognostic	O
than	O
any	O
of	O
the	O
individual	O
components	O
.	O

Hyperprolactinaemia	O
,	O
moderate	O
hypogonadism	O
,	O
infraclinical	O
neuropathies	O
,	O
arterial	O
stenoses	O
and	O
moderate	O
venous	O
leakages	O
seem	O
to	O
play	O
a	O
partial	O
role	O
of	O
organic	O
starter	O
or	O
cofactor	O
,	O
the	O
sexual	O
consequences	O
of	O
which	O
are	O
amplified	O
by	O
psychological	O
factors	O
,	O
partly	O
secondary	O
to	O
the	O
initial	O
sexual	O
failures	O
.	O

The	O
resurgence	O
of	O
drug	O
-	O
resistant	O
malaria	O
makes	O
urgent	O
the	O
evaluation	O
of	O
new	O
antimalarial	O
agents	O
.	O

The	O
spectrum	O
of	O
phenotypes	O
caused	O
by	O
these	O
mutations	O
was	O
strikingly	O
different	O
than	O
mutations	O
in	O
the	O
adaptor	O
for	O
the	O
VP16	B-GENE
activation	I-GENE
domain	I-GENE
.	O

CONCLUSIONS	O
:	O
Congenital	O
horizontal	O
tarsal	O
kink	O
is	O
rare	O
and	O
its	O
cause	O
is	O
unknown	O
.	O

The	O
transforming	O
gene	O
of	O
the	O
avian	B-GENE
sarcoma	I-GENE
virus	I-GENE
CT10	I-GENE
encodes	O
a	O
fusion	O
protein	O
(	O
p47gag	B-GENE
-	I-GENE
crk	I-GENE
or	O
v	B-GENE
-	I-GENE
Crk	I-GENE
)	O
containing	O
viral	B-GENE
Gag	I-GENE
sequences	I-GENE
fused	O
to	O
cellular	O
sequences	O
consisting	O
primarily	O
of	O
Src	B-GENE
homology	I-GENE
regions	I-GENE
2	I-GENE
and	I-GENE
3	I-GENE
(	O
SH2	B-GENE
and	O
SH3	B-GENE
sequences	I-GENE
)	O
.	O

It	O
is	O
likely	O
that	O
other	O
pathways	O
involve	O
alternate	O
signal	O
transduction	O
events	O
(	O
e	O
.	O
g	O
.	O
,	O
calcium	O
mobilization	O
)	O
and	O
promoter	O
response	O
elements	O
(	O
e	O
.	O
g	O
.	O
,	O
SRE	O
)	O
.	O

Their	O
studies	O
have	O
revealed	O
a	O
considerable	O
increase	O
of	O
CSF	B-GENE
AP	I-GENE
activity	O
in	O
purulent	O
meningitides	O
whereas	O
in	O
serous	O
meningitides	O
it	O
grows	O
negligibly	O
.	O

The	O
ORF3	O
probe	O
also	O
hybridized	O
to	O
a	O
540	O
bp	O
transcript	O
consistent	O
with	O
the	O
size	O
of	O
ORF3	O
alone	O
and	O
supportive	O
of	O
the	O
mutagenesis	O
data	O
of	O
non	O
-	O
linkage	O
.	O

In	O
these	O
cases	O
,	O
greatly	O
increased	O
human	B-GENE
chorionic	I-GENE
gonadotropin	I-GENE
(	O
hCG	B-GENE
)	O
levels	O
and	O
suppressed	O
TSH	B-GENE
levels	O
suggest	O
that	O
hCG	B-GENE
has	O
thyrotropic	O
activity	O
.	O

Disturbance	O
of	O
regeneration	O
in	O
the	O
above	O
pathological	O
condition	O
results	O
from	O
the	O
damage	O
to	O
tunica	O
propria	O
and	O
loss	O
of	O
its	O
function	O
for	O
the	O
support	O
of	O
structural	O
homeostasis	O
.	O

However	O
,	O
a	O
correlation	O
was	O
observed	O
between	O
SF	O
levels	O
of	O
IL	B-GENE
-	I-GENE
8	I-GENE
with	O
those	O
of	O
lactate	O
,	O
LDH	B-GENE
,	O
beta	B-GENE
2	I-GENE
-	I-GENE
microglobulin	I-GENE
and	O
glucose	O
.	O

The	O
recently	O
developed	O
gamma	B-GENE
-	I-GENE
interferon	I-GENE
(	O
IFN	B-GENE
-	I-GENE
gamma	I-GENE
)	O
assay	O
system	O
for	O
the	O
diagnosis	O
of	O
bovine	O
tuberculosis	O
in	O
cattle	O
has	O
been	O
accredited	O
by	O
the	O
Standing	O
Committee	O
on	O
Agriculture	O
for	O
use	O
in	O
Australia	O
.	O

Substrates	O
for	O
p210	B-GENE
(	I-GENE
bcr	I-GENE
-	I-GENE
abl	I-GENE
)	I-GENE
are	O
likely	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
CML	O
.	O

Comparison	O
of	O
cDNA	O
sequences	O
revealed	O
that	O
the	O
two	O
mRNA	O
species	O
arise	O
as	O
a	O
result	O
of	O
alternate	O
use	O
of	O
poly	O
(	O
A	O
)	O
-	O
addition	O
sites	O
.	O

Polyprotein	O
processing	O
in	O
Southampton	O
virus	O
:	O
identification	O
of	O
3C	B-GENE
-	I-GENE
like	I-GENE
protease	I-GENE
cleavage	O
sites	O
by	O
in	O
vitro	O
mutagenesis	O
.	O

Assay	O
of	O
serum	B-GENE
immunoreactive	I-GENE
trypsin	I-GENE
in	O
dried	O
blood	O
spots	O
and	O
the	O
early	O
detection	O
of	O
cystic	O
fibrosis	O
.	O

Reliability	O
of	O
cervical	O
range	O
of	O
motion	O
using	O
the	O
OSI	O
CA	O
6000	O
spine	O
motion	O
analyser	O
on	O
asymptomatic	O
and	O
symptomatic	O
subjects	O
.	O

Implications	O
of	O
this	O
observation	O
for	O
pediatrics	O
are	O
discussed	O
.	O

At	O
some	O
sites	O
,	O
%	O
T	O
is	O
greatly	O
increased	O
by	O
Cl	O
-	O
concentrations	O
up	O
to	O
1	O
M	O
,	O
while	O
at	O
other	O
sites	O
%	O
T	O
is	O
reduced	O
or	O
unaffected	O
by	O
these	O
conditions	O
.	O

Northern	O
blot	O
analysis	O
demonstrated	O
the	O
ubiquitous	O
expression	O
of	O
2	O
.	O
9	O
kb	O
and	O
3	O
.	O

Objective	O
responses	O
also	O
occurred	O
in	O
studies	O
that	O
explored	O
sequential	O
use	O
of	O
exemestane	O
after	O
failure	O
of	O
aminoglutethimide	O
(	O
26	O
%	O
with	O
exemestane	O
200	O
mg	O
/	O
day	O
)	O
or	O
other	O
nonsteroidal	O
aromatase	B-GENE
inhibitors	O
(	O
6	O
.	O
6	O
%	O
with	O
exemestane	O
25	O
mg	O
/	O
day	O
)	O
.	O

Thus	O
,	O
sgRNA2	B-GENE
has	O
the	O
3	B-GENE
'	I-GENE
TE	I-GENE
in	O
its	O
5	O
'	O
UTR	O
.	O

Such	O
a	O
concept	O
is	O
crucial	O
to	O
our	O
understanding	O
of	O
the	O
pathology	O
of	O
ageing	O
in	O
general	O
.	O

After	O
the	O
application	O
of	O
RS	O
86	O
,	O
REM	O
latency	O
was	O
shortened	O
in	O
all	O
groups	O
under	O
investigation	O
.	O

Two	O
additional	O
cis	O
-	O
acting	O
sequences	O
,	O
conserved	O
in	O
both	O
the	O
region	O
1	O
and	O
3	O
promoters	O
,	O
were	O
identified	O
,	O
suggesting	O
a	O
role	O
for	O
these	O
sequences	O
in	O
the	O
coordinate	O
regulation	O
of	O
transcription	O
from	O
these	O
promoters	O
.	O

BRCA1	B-GENE
,	O
a	O
familial	O
breast	O
and	O
ovarian	O
cancer	O
susceptibility	O
gene	O
encodes	O
nuclear	O
phosphoproteins	O
that	O
function	O
as	O
tumor	O
suppressors	O
in	O
human	O
breast	O
cancer	O
cells	O
.	O

A	O
high	O
efficacy	O
of	O
the	O
combined	O
use	O
of	O
nontoxic	O
doses	O
of	O
two	O
pharmaceuticals	O
:	O
cystamine	O
(	O
50	O
mg	O
/	O
kg	O
)	O
and	O
mexamine	O
(	O
25	O
mg	O
/	O
kg	O
)	O
under	O
the	O
conditions	O
of	O
short	O
-	O
term	O
exogenous	O
hypoxia	O
(	O
7	O
.	O
5	O
%	O
O2	O
)	O
was	O
found	O
in	O
(	O
CBA	O
X	O
C57Bl	O
)	O
F1	O
mice	O
.	O

In	O
contrast	O
,	O
both	O
Sp1	B-GENE
and	O
ETS	B-GENE
proteins	I-GENE
are	O
required	O
to	O
bring	O
about	O
full	O
promoter	O
activity	O
in	O
the	O
Surf	B-GENE
-	I-GENE
1	I-GENE
direction	O
.	O

The	O
epidemic	O
occurred	O
in	O
a	O
group	O
of	O
26	O
community	O
members	O
(	O
23	O
men	O
and	O
3	O
women	O
,	O
mean	O
age	O
,	O
28	O
.	O
9	O
-	O
-	O
3	O
years	O
)	O
living	O
and	O
working	O
together	O
,	O
who	O
underwent	O
acute	O
and	O
convalescent	O
serologic	O
tests	O
for	O
Mycoplasma	O
pneumoniae	O
,	O
Legionella	O
pneumophila	O
,	O
cytomegalovirus	O
,	O
adenovirus	O
,	O
Coxiella	O
burnetii	O
,	O
and	O
Chlamydia	O
pneumoniae	O
.	O

We	O
found	O
strand	O
selective	O
repair	O
in	O
DNA	O
fragments	O
within	O
two	O
active	O
genes	O
,	O
DHFR	B-GENE
and	O
an	O
unknown	O
gene	O
adjacent	O
to	O
DHFR	B-GENE
.	O

Six	O
(	O
four	O
FAP	O
;	O
two	O
primary	O
amyloidosis	O
)	O
also	O
had	O
diffusely	O
positive	O
myocardial	O
uptakes	O
,	O
but	O
the	O
intensity	O
was	O
less	O
than	O
that	O
of	O
the	O
sternum	O
.	O

The	O
minimum	O
inhibitory	O
concentrations	O
(	O
MICs	O
)	O
of	O
ketoconazole	O
,	O
miconazole	O
,	O
itraconazole	O
,	O
fluconazole	O
,	O
and	O
amphotericin	O
B	O
were	O
significantly	O
influenced	O
by	O
the	O
inoculum	O
size	O
,	O
regardless	O
of	O
the	O
techniques	O
used	O
.	O

The	O
major	O
phenotypes	O
resulting	O
from	O
Fab1p	B-GENE
kinase	I-GENE
inactivation	O
include	O
temperature	O
-	O
sensitive	O
growth	O
,	O
vacuolar	O
acidification	O
defects	O
,	O
and	O
dramatic	O
increases	O
in	O
vacuolar	O
size	O
.	O

These	O
results	O
demonstrate	O
Ras	O
-	O
and	O
Raf	O
-	O
independent	O
ERK	B-GENE
MAPK	I-GENE
activation	O
maintains	O
cell	O
viability	O
following	O
heat	O
shock	O
.	O

Initial	O
control	O
of	O
bleeding	O
is	O
similar	O
,	O
but	O
eradication	O
is	O
achieved	O
in	O
fewer	O
sessions	O
with	O
EVL	O
.	O

Naloxone	O
(	O
2	O
mg	O
/	O
kg	O
bolus	O
+	O
2	O
mg	O
X	O
kg	O
-	O
1	O
X	O
h	O
-	O
1	O
)	O
was	O
given	O
with	O
one	O
of	O
the	O
two	O
doses	O
of	O
the	O
lipopolysaccharide	O
.	O

Moreover	O
,	O
a	O
complex	O
containing	O
PTP	B-GENE
phi	I-GENE
,	O
paxillin	B-GENE
,	O
and	O
a	O
paxillin	B-GENE
-	I-GENE
associated	I-GENE
tyrosine	I-GENE
kinase	I-GENE
,	O
Pyk2	B-GENE
,	O
can	O
be	O
immunoprecipitated	O
from	O
macrophage	O
lysates	O
,	O
and	O
the	O
catalytic	O
domain	O
of	O
PTP	B-GENE
phi	I-GENE
selectively	O
binds	O
paxillin	B-GENE
and	O
Pyk2	B-GENE
in	O
vitro	O
.	O

Action	O
of	O
strontium	O
-	O
90	O
and	O
metaphos	O
on	O
Cyprinus	O
carpio	O
.	O

In	O
the	O
pRb	B-GENE
(	I-GENE
-	I-GENE
)	I-GENE
SAOS	O
-	O
2	O
cell	O
line	O
transiently	O
transfected	O
with	O
a	O
reporter	O
plasmid	O
containing	O
six	O
tal	B-GENE
-	I-GENE
1	I-GENE
binding	I-GENE
site	I-GENE
,	O
pRb	B-GENE
enhances	O
the	O
transcriptional	O
activity	O
of	O
tal	B-GENE
-	I-GENE
1	I-GENE
-	I-GENE
E12	I-GENE
-	I-GENE
Lmo2	I-GENE
and	O
tal	B-GENE
-	I-GENE
1	I-GENE
-	I-GENE
E12	I-GENE
-	I-GENE
Lmo2	I-GENE
-	I-GENE
Ldb1	I-GENE
complexes	I-GENE
but	O
not	O
that	O
of	O
a	O
tal	B-GENE
-	I-GENE
1	I-GENE
-	I-GENE
E12	I-GENE
heterodimer	I-GENE
.	O

The	O
flux	O
rates	O
of	O
p	O
-	O
toluidine	O
decreased	O
as	O
the	O
pH	O
value	O
in	O
the	O
donor	O
solution	O
increased	O
.	O

Using	O
immunochemical	O
co	O
-	O
precipitation	O
methods	O
,	O
we	O
also	O
found	O
that	O
the	O
two	O
proteins	O
are	O
bound	O
in	O
vivo	O
.	O

Transcription	O
start	O
site	O
mapping	O
identified	O
the	O
presence	O
of	O
an	O
aphidicolin	O
-	O
sensitive	O
late	O
transcript	O
arising	O
from	O
a	O
TAAG	B-GENE
motif	I-GENE
located	O
at	O
-	O
352	O
nucleotides	O
and	O
an	O
aphidicolin	O
-	O
insensitive	O
early	O
transcript	O
originating	O
from	O
a	O
TTGT	B-GENE
motif	I-GENE
located	O
35	O
nucleotides	O
downstream	O
to	O
a	O
TATA	O
box	O
at	O
-	O
312	O
nucleotides	O
,	O
with	O
respect	O
to	O
the	O
+	O
1	O
ATG	O
of	O
lef2	B-GENE
.	O

Anesthesiologists	O
often	O
use	O
more	O
than	O
one	O
drug	O
in	O
a	O
patient	O
to	O
achieve	O
a	O
target	O
response	O
,	O
such	O
as	O
a	O
desired	O
blood	O
pressure	O
.	O

Aneurysmectomy	O
and	O
the	O
performance	O
of	O
CABG	O
were	O
not	O
significantly	O
associated	O
with	O
postoperative	O
ECG	O
changes	O
,	O
but	O
more	O
bypass	O
grafts	O
per	O
patient	O
grafted	O
appeared	O
in	O
the	O
group	O
with	O
postoperative	O
ECG	O
changes	O
,	O
suggesting	O
that	O
coronary	O
artery	O
disease	O
may	O
be	O
more	O
severe	O
in	O
that	O
group	O
.	O

The	O
average	O
values	O
were	O
199	O
and	O
424	O
revertants	O
/	O
g	O
for	O
the	O
hamburgers	O
and	O
hot	O
dogs	O
,	O
respectively	O
.	O

Of	O
208	O
eligible	O
subjects	O
,	O
82	O
received	O
supervised	O
IPT	O
at	O
a	O
dose	O
of	O
900	O
mg	O
twice	O
weekly	O
for	O
6	O
mo	O
(	O
Regimen	O
A	O
)	O
,	O
73	O
received	O
unsupervised	O
IPT	O
900	O
mg	O
twice	O
weekly	O
for	O
6	O
mo	O
(	O
Regimen	O
B	O
)	O
,	O
and	O
53	O
received	O
unsupervised	O
IPT	O
300	O
mg	O
daily	O
for	O
6	O
mo	O
(	O
Regimen	O
C	O
)	O
.	O

We	O
demonstrate	O
that	O
a	O
VT	O
+	O
peptide	O
was	O
specifically	O
phosphorylated	O
by	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
(	O
PKC	B-GENE
)	O
in	O
vitro	O
,	O
but	O
not	O
by	O
protein	B-GENE
kinase	I-GENE
A	I-GENE
(	O
PKA	B-GENE
)	O
.	O

Plasma	O
and	O
erthrocyte	O
lipid	O
profile	O
and	O
lipoprotein	B-GENE
lipase	I-GENE
activity	O
in	O
postheparin	O
plasma	O
on	O
vasectomized	O
rabbits	O
were	O
studied	O
and	O
also	O
the	O
incidence	O
of	O
atherosclerosis	O
in	O
different	O
arterial	O
beds	O
.	O

Treatment	O
of	O
meat	O
muscle	O
800	O
V	O
for	O
45	O
s	O
reduced	O
weeping	O
but	O
increased	O
slightly	O
the	O
rate	O
of	O
autoxidation	O
of	O
lipids	O
.	O

The	O
single	O
-	O
stranded	O
DNA	O
Pur	B-GENE
alpha	I-GENE
recognition	I-GENE
element	I-GENE
disrupts	O
these	O
complexes	O
.	O

Our	O
data	O
provide	O
a	O
biochemical	O
explanation	O
for	O
the	O
similarity	O
in	O
phenotype	O
between	O
A	O
-	O
T	O
and	O
NBS	O
.	O

The	O
role	O
of	O
calcitonin	B-GENE
,	O
and	O
other	O
agonists	O
which	O
activate	O
the	O
cAMP	O
pathway	O
,	O
in	O
regulating	O
transcription	O
of	O
the	O
human	B-GENE
parathyroid	I-GENE
hormone	I-GENE
-	I-GENE
related	I-GENE
protein	I-GENE
(	O
PTHrP	B-GENE
)	O
gene	O
was	O
investigated	O
in	O
a	O
human	O
lung	O
cancer	O
cell	O
line	O
(	O
BEN	O
)	O
.	O

The	O
extended	O
rat	B-GENE
SP	I-GENE
-	I-GENE
A	I-GENE
isoforms	I-GENE
were	O
enriched	O
in	O
the	O
more	O
fully	O
glycosylated	O
and	O
multimeric	O
SP	B-GENE
-	I-GENE
A	I-GENE
species	O
separated	O
on	O
SDS	O
-	O
PAGE	O
gels	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
We	O
report	O
our	O
experience	O
with	O
seven	O
children	O
with	O
active	O
small	O
bowel	O
Crohn	O
'	O
s	O
disease	O
given	O
a	O
casein	O
-	O
based	O
,	O
polymeric	O
feed	O
rich	O
in	O
TGF	B-GENE
-	I-GENE
beta	I-GENE
2	I-GENE
(	O
Specific	O
Polymeric	O
Diet	O
;	O
Nestle	O
-	O
Clintec	O
;	O
Vevey	O
,	O
Switzerland	O
)	O
as	O
complete	O
nutrition	O
for	O
8	O
weeks	O
.	O

The	O
action	O
of	O
nef	O
was	O
specific	O
to	O
the	O
LTR	O
,	O
as	O
expression	O
of	O
nef	B-GENE
had	O
no	O
effect	O
on	O
the	O
activity	O
of	O
the	O
simian	O
virus	O
40	O
,	O
c	B-GENE
-	I-GENE
fms	I-GENE
,	O
urokinase	B-GENE
plasminogen	I-GENE
activator	I-GENE
,	O
or	O
type	B-GENE
5	I-GENE
acid	I-GENE
phosphatase	I-GENE
promoter	I-GENE
.	O
trans	O
-	O
activating	O
activity	O
was	O
also	O
manifested	O
by	O
a	O
frameshift	O
mutant	O
expressing	O
only	O
the	O
first	O
35	O
amino	O
acids	O
of	O
the	O
protein	O
.	O

Kf	O
,	O
c	O
and	O
CT	O
(	O
referenced	O
to	O
the	O
initial	O
lung	O
mass	O
)	O
decreased	O
linearly	O
with	O
reductions	O
in	O
lung	O
mass	O
%	O
delta	O
Kf	O
,	O
c	O
=	O
1	O
.	O
26	O
-	O
0	O
.	O
98	O
%	O
mass	O
removed	O
(	O
r	O
=	O
0	O
.	O
90	O
,	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
and	O
%	O
delta	O
CT	O
=	O
-	O
3	O
.	O
99	O
-	O
0	O
.	O
98	O
%	O
mass	O
removed	O
(	O
r	O
=	O
0	O
.	O
82	O
,	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
relationships	O
that	O
were	O
not	O
altered	O
by	O
blocker	O
pretreatment	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

During	O
1985	O
,	O
1990	O
,	O
and	O
1995	O
,	O
respectively	O
,	O
11	O
.	O
7	O
,	O
11	O
.	O
3	O
,	O
and	O
11	O
.	O
4	O
infants	O
per	O
100	O
,	O
000	O
live	O
births	O
had	O
a	O
diagnosis	O
of	O
HSV	O
(	O
P	O
=	O
.	O
98	O
)	O
.	O

The	O
Wilms	B-GENE
'	I-GENE
tumour	I-GENE
suppressor	I-GENE
protein	I-GENE
(	O
WT1	B-GENE
)	O
is	O
a	O
putative	O
transcriptional	O
regulatory	O
protein	O
with	O
four	O
zinc	O
fingers	O
,	O
the	O
last	O
three	O
of	O
which	O
have	O
extensive	O
sequence	O
homology	O
to	O
the	O
early	B-GENE
growth	I-GENE
response	I-GENE
-	I-GENE
1	I-GENE
(	O
EGR	B-GENE
-	I-GENE
1	I-GENE
)	O
protein	O
.	O

This	O
study	O
demonstrates	O
secretion	O
of	O
bicarbonate	O
by	O
the	O
human	O
stomach	O
in	O
vivo	O
at	O
a	O
rate	O
equivalent	O
to	O
10	O
-	O
-	O
20	O
%	O
of	O
basal	O
acid	O
secretion	O
.	O

Commonly	O
observed	O
systemic	O
toxic	O
effects	O
(	O
bone	O
marrow	O
,	O
gastrointestinal	O
tract	O
,	O
and	O
heart	O
)	O
were	O
not	O
seen	O
in	O
this	O
study	O
.	O

Correlating	O
with	O
the	O
previous	O
observation	O
that	O
CBF	B-GENE
binding	O
to	O
the	O
78C1	O
site	O
is	O
enhanced	O
by	O
EGTA	O
and	O
EDTA	O
,	O
these	O
divalent	O
cation	O
chelators	O
specifically	O
stimulate	O
78C1	O
-	O
directed	O
transcription	O
.	O

At	O
pH	O
6	O
.	O
9	O
,	O
the	O
same	O
lidocaine	O
concentrations	O
significantly	O
reduced	O
resting	O
potential	O
(	O
3	O
-	O
10	O
%	O
)	O
,	O
action	O
potential	O
amplitude	O
(	O
3	O
-	O
8	O
%	O
)	O
and	O
Vmax	O
(	O
14	O
-	O
22	O
%	O
)	O
.	O

The	O
methylation	O
of	O
nuclear	O
and	O
chloroplast	O
DNAs	O
has	O
been	O
examined	O
in	O
relation	O
to	O
the	O
known	O
differential	O
expression	O
of	O
C4	B-GENE
photosynthesis	I-GENE
genes	I-GENE
in	O
the	O
bundle	O
sheath	O
and	O
mesophyll	O
cells	O
of	O
etiolated	O
,	O
greening	O
,	O
and	O
fully	O
green	O
maize	O
leaves	O
.	O

Marinol	O
/	O
marijuana	O
usage	O
was	O
associated	O
with	O
depressed	O
CD4	B-GENE
+	I-GENE
counts	O
and	O
elevated	O
amylase	B-GENE
levels	O
within	O
the	O
DDI	O
subgroup	O
.	O

Two	O
Pax2	B-GENE
/	I-GENE
5	I-GENE
/	I-GENE
8	I-GENE
-	I-GENE
binding	I-GENE
sites	I-GENE
in	O
Engrailed2	B-GENE
are	O
required	O
for	O
proper	O
initiation	O
of	O
endogenous	O
mid	O
-	O
hindbrain	O
expression	O
.	O

The	O
SH3	B-GENE
domains	I-GENE
of	O
Grb2	B-GENE
bound	O
in	O
vitro	O
to	O
specific	O
proline	O
-	O
rich	O
motifs	O
in	O
the	O
HPK1	B-GENE
tail	O
and	O
functioned	O
synergistically	O
to	O
direct	O
the	O
stable	O
binding	O
of	O
Grb2	B-GENE
to	O
HPK1	B-GENE
in	O
transfected	O
Cos1	O
cells	O
.	O

An	O
approximately	O
37	O
-	O
kDa	O
cytoplasmic	O
protein	O
is	O
rapidly	O
tyrosine	O
-	O
phosphorylated	O
in	O
the	O
response	O
of	O
mouse	O
BAC1	O
.	O
2F5	O
macrophages	O
to	O
colony	B-GENE
stimulating	I-GENE
factor	I-GENE
-	I-GENE
1	I-GENE
(	O
CSF	B-GENE
-	I-GENE
1	I-GENE
)	O
.	O
pp37	B-GENE
was	O
purified	O
from	O
the	O
cytosolic	O
fraction	O
by	O
anti	B-GENE
-	I-GENE
Tyr	I-GENE
(	I-GENE
P	I-GENE
)	I-GENE
affinity	O
chromatography	O
,	O
size	O
exclusion	O
chromatography	O
,	O
and	O
C4	O
reverse	O
phase	O
high	O
pressure	O
liquid	O
chromatography	O
.	O

The	O
immunophilin	B-GENE
,	O
which	O
can	O
be	O
of	O
the	O
FK506	O
-	O
or	O
cyclosporin	O
A	O
-	O
binding	O
class	O
,	O
binds	O
to	O
hsp90	B-GENE
via	O
its	O
tetratricopeptide	O
repeat	O
(	O
TPR	O
)	O
domain	O
,	O
and	O
different	O
receptor	O
heterocomplexes	O
exist	O
depending	O
upon	O
which	O
immunophilin	B-GENE
occupies	O
the	O
TPR	B-GENE
-	I-GENE
binding	I-GENE
region	I-GENE
of	O
hsp90	B-GENE
.	O

Cocaine	O
-	O
treated	O
rats	O
acquired	O
a	O
preference	O
for	O
cocaine	O
-	O
associated	O
contextual	O
stimuli	O
(	O
CS	O
)	O
relative	O
to	O
saline	O
-	O
injected	O
control	O
rats	O
.	O

Primer	O
extension	O
and	O
S1	B-GENE
nuclease	I-GENE
mapping	O
experiments	O
were	O
used	O
to	O
locate	O
the	O
transcription	O
initiation	O
site	O
of	O
Nramp1	B-GENE
and	O
revealed	O
the	O
presence	O
of	O
one	O
major	O
and	O
several	O
minor	O
initiation	O
sites	O
.	O

Feeding	O
behavior	O
,	O
circannual	O
body	O
weight	O
and	O
hibernation	O
rhythms	O
in	O
European	O
hamsters	O
lesioned	O
in	O
the	O
noradrenergic	O
ascending	O
bundles	O
.	O

Double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

We	O
have	O
identified	O
two	O
overlapping	O
expressed	O
sequence	O
tag	O
clones	O
,	O
which	O
contain	O
the	O
missing	O
4	O
.	O
4	O
-	O
kb	O
3	O
'	O
-	O
UTR	O
of	O
the	O
human	B-GENE
D2	I-GENE
(	O
hD2	B-GENE
)	O
cDNA	O
.	O

Eight	O
induced	O
cDNA	O
sequences	O
were	O
identified	O
and	O
designated	O
message	B-GENE
up	I-GENE
-	I-GENE
regulated	I-GENE
during	I-GENE
death	I-GENE
(	O
mud	B-GENE
)	O
-	O
1	O
-	O
8	O
.	O

Several	O
highly	O
conserved	O
regions	O
were	O
identified	O
at	O
the	O
near	O
N	O
terminus	O
,	O
middle	O
and	O
C	O
terminus	O
.	O

S	O
.	O
,	O
K	O
.	O

Aryl	B-GENE
hydrocarbon	I-GENE
receptor	I-GENE
nuclear	I-GENE
translocator	I-GENE
(	O
ARNT	B-GENE
)	O
is	O
a	O
component	O
of	O
the	O
transcription	O
factors	O
,	O
aryl	B-GENE
hydrocarbon	I-GENE
receptor	I-GENE
(	O
AhR	B-GENE
)	O
and	O
hypoxia	B-GENE
-	I-GENE
inducible	I-GENE
factor	I-GENE
1	I-GENE
,	O
which	O
transactivate	O
their	O
target	O
genes	O
,	O
such	O
as	O
CYP1A1	B-GENE
and	O
erythropoietin	B-GENE
,	O
in	O
response	O
to	O
xenobiotic	O
aromatic	O
hydrocarbons	O
and	O
to	O
low	O
O2	O
concentration	O
,	O
respectively	O
.	O

Deletion	O
and	O
mutational	O
analyses	O
revealed	O
two	O
positive	O
cis	O
-	O
regulatory	O
elements	O
in	O
this	O
region	O
that	O
are	O
essential	O
for	O
CSX1	B-GENE
expression	O
in	O
cardiomyocytes	O
.	O

This	O
mechanism	O
is	O
in	O
contrast	O
to	O
other	O
cases	O
of	O
splicing	O
regulation	O
by	O
PTB	B-GENE
,	O
in	O
which	O
the	O
protein	O
represses	O
the	O
splice	O
site	O
to	O
which	O
it	O
binds	O
.	O

Time	O
shifts	O
increase	O
growth	B-GENE
hormone	I-GENE
release	O
.	O

The	O
pharmacological	O
effects	O
of	O
the	O
novel	O
compound	O
WEB	O
1881	O
FU	O
(	O
4	O
-	O
amino	O
-	O
methyl	O
-	O
1	O
-	O
benzyl	O
-	O
pyrrolidine	O
-	O
2	O
-	O
one	O
-	O
fumarate	O
)	O
were	O
investigated	O
.	O

Phenazone	O
potentiates	O
the	O
local	O
anaesthetic	O
effect	O
of	O
lidocaine	O
in	O
mice	O
.	O

Salzburg	O
,	O
9	O
-	O
12	O
September	O
1987	O
.	O

There	O
was	O
a	O
trend	O
in	O
all	O
studies	O
favouring	O
PVI	O
.	O

Estimation	O
of	O
L	O
-	O
alanine	O
in	O
serum	O
or	O
plasma	O
using	O
the	O
LKB	O
reaction	O
rate	O
analyser	O
.	O

We	O
have	O
carried	O
out	O
a	O
comprehensive	O
and	O
systematic	O
mutagenesis	O
of	O
the	O
Cse4p	B-GENE
N	I-GENE
terminus	I-GENE
to	O
analyze	O
its	O
function	O
.	O

On	O
the	O
diagnosis	O
of	O
bovine	O
leucosis	O
and	O
its	O
control	O
in	O
southern	O
Lower	O
Saxony	O
.	O

HL	B-GENE
-	I-GENE
A	I-GENE
antibodies	I-GENE
in	O
polytransfused	O
patients	O
.	O

Analysis	O
of	O
cell	O
cycle	O
regulation	O
in	O
the	O
budding	O
yeast	O
Saccharomyces	O
cerevisiae	O
has	O
shown	O
that	O
a	O
central	O
regulatory	O
protein	B-GENE
kinase	I-GENE
,	O
Cdc28	B-GENE
,	O
undergoes	O
changes	O
in	O
activity	O
through	O
the	O
cell	O
cycle	O
by	O
associating	O
with	O
distinct	O
groups	O
of	O
cyclins	B-GENE
that	O
accumulate	O
at	O
different	O
times	O
.	O

Ischaemia	O
was	O
induced	O
by	O
a	O
low	O
flow	O
rate	O
of	O
0	O
.	O
8	O
mL	O
min	O
-	O
1	O
for	O
30	O
min	O
,	O
and	O
was	O
followed	O
by	O
a	O
40	O
-	O
minute	O
reperfusion	O
.	O

They	O
also	O
indicate	O
that	O
direct	O
interactions	O
between	O
C	B-GENE
/	I-GENE
EBPs	I-GENE
and	O
specific	O
Ets	B-GENE
family	O
members	O
,	O
together	O
with	O
GATA	B-GENE
-	I-GENE
1	I-GENE
,	O
are	O
important	O
for	O
eosinophil	O
lineage	O
determination	O
.	O

To	O
understand	O
the	O
molecular	O
regulation	O
of	O
these	O
genes	O
in	O
thyroid	O
cells	O
,	O
the	O
effect	O
of	O
thyroid	B-GENE
transcription	I-GENE
factor	I-GENE
1	I-GENE
(	O
TTF	B-GENE
-	I-GENE
1	I-GENE
)	O
and	O
the	O
paired	B-GENE
domain	I-GENE
-	I-GENE
containing	I-GENE
protein	I-GENE
8	I-GENE
(	O
Pax	B-GENE
-	I-GENE
8	I-GENE
)	O
on	O
the	O
transcriptional	O
activity	O
of	O
the	O
deiodinase	B-GENE
promoters	I-GENE
were	O
studied	O
.	O

To	O
begin	O
to	O
understand	O
this	O
role	O
,	O
we	O
overexpressed	O
ATF	B-GENE
-	I-GENE
2	I-GENE
in	O
a	O
human	O
cancer	O
cell	O
line	O
.	O

CD	O
was	O
determined	O
using	O
the	O
Farnsworth	O
D	O
-	O
15	O
method	O
.	O

During	O
insulin	B-GENE
infusion	O
,	O
a	O
20	O
%	O
dextrose	O
solution	O
was	O
infused	O
by	O
a	O
Biostator	O
in	O
order	O
to	O
maintain	O
the	O
patient	O
'	O
s	O
glycemia	O
at	O
90	O
mg	O
/	O
dl	O
.	O

An	O
approximately	O
2	O
-	O
kilobase	O
B2	O
transcript	O
was	O
expressed	O
in	O
all	O
alfalfa	O
organs	O
tested	O
.	O

Doxorubicin	O
,	O
dacarbazine	O
,	O
vincristine	O
,	O
and	O
cyclophosphamide	O
in	O
the	O
treatment	O
of	O
advanced	O
gastrointestinal	O
leiomyosarcoma	O
.	O

A	O
cohort	O
of	O
Swedish	O
children	O
was	O
monitored	O
from	O
6	O
months	O
to	O
11	O
years	O
of	O
age	O
.	O

We	O
provide	O
community	O
metabolic	O
data	O
that	O
indicate	O
that	O
large	O
changes	O
in	O
CO2	O
concentration	O
can	O
occur	O
in	O
coral	O
reef	O
waters	O
via	O
biogeochemical	O
processes	O
not	O
directly	O
associated	O
with	O
photosynthesis	O
,	O
respiration	O
,	O
calcification	O
,	O
and	O
CaCO3	O
dissolution	O
.	O

Effect	O
of	O
aging	O
on	O
respiratory	O
skeletal	O
muscles	O
.	O

Mutational	O
analysis	O
of	O
yeast	B-GENE
CEG1	I-GENE
demonstrated	O
that	O
four	O
of	O
the	O
five	O
conserved	O
motifs	O
are	O
essential	O
for	O
capping	O
enzyme	O
function	O
in	O
vivo	O
.	O

Chronic	O
hypophosphatemia	O
is	O
the	O
most	O
common	O
type	O
of	O
"	O
resistant	O
"	O
rickets	O
.	O

Abbreviations	O
:	O
CAS	B-GENE
,	O
CRK	B-GENE
-	I-GENE
associated	I-GENE
substrate	I-GENE
;	O
CH	B-GENE
,	O
calponin	B-GENE
-	I-GENE
homology	I-GENE
domain	I-GENE
;	O
CSK	B-GENE
,	O
C	B-GENE
-	I-GENE
terminal	I-GENE
SRC	I-GENE
kinase	I-GENE
;	O
E6	B-GENE
,	O
Papillomavirus	B-GENE
E6	I-GENE
protein	I-GENE
;	O
FAK	B-GENE
,	O
focal	B-GENE
adhesion	I-GENE
kinase	I-GENE
;	O
GIT	B-GENE
,	O
GRK	B-GENE
interacter	I-GENE
;	O
GPCR	B-GENE
,	O
heterotrimeric	B-GENE
-	I-GENE
G	I-GENE
-	I-GENE
protein	I-GENE
-	I-GENE
coupled	I-GENE
receptor	I-GENE
;	O
GRK	B-GENE
,	O
G	B-GENE
-	I-GENE
protein	I-GENE
-	I-GENE
coupled	I-GENE
-	I-GENE
receptor	I-GENE
kinase	I-GENE
;	O
MAPK	B-GENE
,	O
mitogen	B-GENE
-	I-GENE
activated	I-GENE
protein	I-GENE
kinase	I-GENE
(	O
ERK	B-GENE
,	O
p38	B-GENE
,	O
JNK	B-GENE
)	O
;	O
PAK	B-GENE
,	O
p21	B-GENE
-	I-GENE
activated	I-GENE
kinase	I-GENE
;	O
PBS	B-GENE
,	O
paxillin	B-GENE
-	I-GENE
binding	I-GENE
subdomain	I-GENE
;	O
PIX	B-GENE
,	O
PAK	B-GENE
-	I-GENE
interacting	I-GENE
exchange	I-GENE
factor	I-GENE
;	O
PKL	B-GENE
,	O
paxillin	B-GENE
kinase	I-GENE
linker	I-GENE
;	O
POR1	B-GENE
,	O
partner	B-GENE
of	I-GENE
Rac	I-GENE
;	O
PS	O
,	O
phosphoserine	O
;	O
PT	O
,	O
phosphothreonine	O
;	O
PY	O
,	O
phosphotyrosine	O
;	O
RTK	B-GENE
,	O
growth	B-GENE
factor	I-GENE
receptor	I-GENE
tyrosine	I-GENE
kinase	I-GENE
;	O
SH	B-GENE
,	O
SRC	B-GENE
-	I-GENE
homology	I-GENE
domain	I-GENE
.	O

We	O
have	O
identified	O
SWI5	O
'	O
s	O
nuclear	O
localization	O
signal	O
(	O
NLS	O
)	O
and	O
show	O
that	O
it	O
can	O
confer	O
cell	O
cycle	O
-	O
dependent	O
nuclear	O
entry	O
to	O
a	O
heterologous	O
protein	O
.	O

We	O
found	O
that	O
PML	B-GENE
was	O
expressed	O
at	O
a	O
lower	O
level	O
in	O
S	O
,	O
G2	O
,	O
and	O
M	O
phases	O
and	O
at	O
a	O
significantly	O
higher	O
level	O
in	O
G1	O
phase	O
.	O

Electroglottography	O
is	O
a	O
useful	O
,	O
non	O
-	O
invasive	O
technique	O
that	O
can	O
assist	O
in	O
the	O
assessment	O
of	O
vocal	O
fold	O
dysfunction	O
.	O

The	O
three	O
-	O
dimensional	O
structure	O
of	O
RT	B-GENE
shows	O
that	O
it	O
is	O
a	O
strikingly	O
asymmetric	O
heterodimer	O
consisting	O
of	O
two	O
differently	O
folded	O
subunits	O
(	O
molecular	O
weights	O
66	O
kDa	O
and	O
51	O
kDa	O
)	O
with	O
identical	O
amino	O
-	O
terminal	O
amino	O
acid	O
sequences	O
(	O
residues	O
1	O
-	O
428	O
)	O
.	O

Metformin	O
plasma	O
concentrations	O
remained	O
unchanged	O
except	O
for	O
patients	O
transferred	O
from	O
1	O
.	O
5	O
to	O
2	O
.	O
0	O
g	O
daily	O
to	O
850	O
mg	O
twice	O
daily	O
;	O
in	O
these	O
patients	O
plasma	O
concentrations	O
increased	O
from	O
1	O
.	O
83	O
+	O
/	O
-	O
0	O
.	O
87	O
to	O
2	O
.	O
50	O
+	O
/	O
-	O
0	O
.	O
89	O
micrograms	O
/	O
l	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

From	O
the	O
National	O
Institutes	O
of	O
Health	O
.	O

The	O
TYAC	O
/	O
P1	O
resource	O
,	O
derivative	O
STSs	O
,	O
and	O
polymorphisms	O
constitute	O
an	O
enabling	O
resource	O
to	O
further	O
studies	O
of	O
telomere	O
structure	O
and	O
function	O
and	O
a	O
means	O
for	O
physical	O
and	O
genetic	O
map	O
integration	O
and	O
closure	O
.	O

One	O
complex	O
most	O
likely	O
contained	O
Sp1	B-GENE
,	O
and	O
another	O
complex	O
showed	O
S	O
-	O
phase	O
-	O
specific	O
binding	O
,	O
suggesting	O
a	O
direct	O
role	O
in	O
the	O
cell	O
-	O
cycle	O
-	O
dependent	O
R1	B-GENE
gene	I-GENE
expression	O
.	O

This	O
points	O
to	O
a	O
specific	O
interference	O
with	O
HSV	O
-	O
induced	O
DNA	O
amplification	O
.	O

The	O
cell	O
cycle	O
-	O
regulated	O
transcription	O
factor	O
E2F	B-GENE
is	O
also	O
known	O
to	O
bend	O
DNA	O
upon	O
binding	O
.	O

In	O
11	O
patients	O
with	O
Horton	O
'	O
s	O
headache	O
morphological	O
investigations	O
(	O
differential	O
white	O
blood	O
cell	O
count	O
)	O
,	O
cytoenzymatic	O
determinations	O
(	O
alkaline	B-GENE
and	I-GENE
acid	I-GENE
phosphatase	I-GENE
,	O
non	B-GENE
-	I-GENE
specific	I-GENE
esterase	I-GENE
)	O
and	O
cytoimmunological	O
tests	O
(	O
IgM	B-GENE
and	O
IgG	B-GENE
binding	O
)	O
were	O
carried	O
out	O
on	O
capillary	O
blood	O
neutrophils	O
obtained	O
from	O
the	O
area	O
of	O
pain	O
,	O
non	O
-	O
painful	O
area	O
of	O
the	O
skin	O
on	O
the	O
head	O
on	O
the	O
contralateral	O
side	O
,	O
and	O
from	O
the	O
finger	O
.	O

The	O
oxygen	O
uptake	O
(	O
VO2	O
)	O
,	O
carbon	O
dioxide	O
output	O
(	O
VCO2	O
)	O
,	O
respiratory	O
rate	O
(	O
fR	O
)	O
,	O
minute	O
ventilation	O
(	O
VE	O
)	O
,	O
alveolar	O
ventilation	O
(	O
VA	O
)	O
,	O
alveolar	O
oxygen	O
pressure	O
(	O
PAO2	O
)	O
,	O
and	O
VE	O
/	O
VO2	O
ratio	O
were	O
higher	O
in	O
the	O
cows	O
,	O
while	O
the	O
tidal	O
volume	O
(	O
VT	O
)	O
and	O
physiological	O
dead	O
space	O
(	O
VD	O
)	O
were	O
larger	O
in	O
the	O
horses	O
.	O

Two	O
cDNAs	O
encoding	O
casein	B-GENE
kinase	I-GENE
-	I-GENE
1	I-GENE
have	O
been	O
isolated	O
from	O
a	O
yeast	O
cDNA	O
library	O
and	O
termed	O
CKI1	B-GENE
and	O
CKI2	B-GENE
.	O

The	O
RAP74	B-GENE
subunit	I-GENE
of	O
TFIIF	B-GENE
alone	O
contained	O
the	O
stimulatory	O
activity	O
and	O
the	O
minimal	O
region	O
sufficient	O
for	O
stimulation	O
corresponds	O
to	O
COOH	O
-	O
terminal	O
residues	O
358	O
-	O
517	O
.	O

These	O
observations	O
of	O
elevated	O
serum	B-GENE
lipase	I-GENE
and	O
serum	O
CA	B-GENE
19	I-GENE
-	I-GENE
9	I-GENE
in	O
Sjogren	O
'	O
s	O
syndrome	O
without	O
evidence	O
of	O
malignancy	O
may	O
reflect	O
pancreatic	O
involvement	O
in	O
this	O
disorder	O
.	O

These	O
results	O
confirming	O
the	O
high	O
validity	O
of	O
NOM	O
inhibiting	O
test	O
in	O
the	O
diagnosis	O
of	O
tumoural	O
hyperprolactinemic	O
states	O
,	O
reveal	O
contradictory	O
responses	O
to	O
CD	O
/	O
LD	O
,	O
LD	O
and	O
DOM	O
,	O
with	O
sustain	O
the	O
existence	O
of	O
2	O
sub	O
-	O
group	O
of	O
Prolactinomas	O
:	O
with	O
or	O
without	O
a	O
maintained	O
DA	O
central	O
tonus	O
supporting	O
the	O
possibility	O
of	O
different	O
etiopathogenetical	O
factors	O
in	O
inducing	O
a	O
tumoural	O
hyperprolactinemic	O
states	O
.	O

Efficacy	O
of	O
first	O
-	O
generation	O
Cavermap	O
to	O
verify	O
location	O
and	O
function	O
of	O
cavernous	O
nerves	O
during	O
radical	O
prostatectomy	O
:	O
a	O
multi	O
-	O
institutional	O
evaluation	O
by	O
experienced	O
surgeons	O
.	O

In	O
order	O
to	O
characterize	O
the	O
functional	O
elements	O
of	O
the	O
promoter	O
that	O
in	O
some	O
way	O
must	O
respond	O
to	O
these	O
regulatory	O
signals	O
,	O
a	O
number	O
of	O
promoter	O
mutations	O
were	O
constructed	O
,	O
including	O
a	O
set	O
of	O
linker	O
-	O
scanning	O
mutations	O
across	O
the	O
entire	O
promoter	O
region	O
.	O

Skn	B-GENE
-	I-GENE
1a	I-GENE
lacking	O
the	O
C	O
-	O
terminal	O
region	O
completely	O
lost	O
transactivation	O
ability	O
,	O
irrespective	O
of	O
the	O
promoter	O
tested	O
,	O
and	O
was	O
able	O
to	O
block	O
transactivation	O
by	O
normal	O
Skn	B-GENE
-	I-GENE
1a	I-GENE
in	O
competition	O
assays	O
.	O

Structural	O
basis	O
for	O
activation	O
of	O
human	B-GENE
lymphocyte	I-GENE
kinase	I-GENE
Lck	B-GENE
upon	O
tyrosine	O
phosphorylation	O
.	O

Among	O
them	O
,	O
26	O
cases	O
were	O
benign	O
and	O
34	O
malignant	O
.	O

Such	O
transgenic	O
plants	O
should	O
enable	O
not	O
only	O
the	O
mutational	O
analysis	O
of	O
sequence	O
elements	O
within	O
the	O
replication	O
origin	O
region	O
,	O
but	O
also	O
the	O
construction	O
of	O
a	O
new	O
generation	O
of	O
vectors	O
for	O
gene	O
amplification	O
in	O
plants	O
,	O
based	O
on	O
a	O
minimal	O
virus	O
replicon	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
revealed	O
that	O
two	O
clusters	O
of	O
basic	O
amino	O
acids	O
within	O
a	O
conserved	O
basic	O
region	O
and	O
two	O
amphipathic	O
helices	O
within	O
the	O
adjacent	O
HLH	B-GENE
domain	I-GENE
are	O
essential	O
for	O
sequence	O
-	O
specific	O
DNA	O
binding	O
and	O
hetero	O
-	O
oligomerization	O
,	O
respectively	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
impact	O
of	O
the	O
introduction	O
of	O
clarithromycin	O
and	O
azithromycin	O
on	O
the	O
treatment	O
and	O
survival	O
of	O
patients	O
with	O
AIDS	O
and	O
disseminated	O
Mycobacterium	O
avium	O
complex	O
(	O
DMAC	O
)	O
.	O

At	O
this	O
stage	O
,	O
the	O
eventual	O
high	O
mortality	O
of	O
acute	O
ischemia	O
is	O
established	O
whatever	O
the	O
urgency	O
of	O
the	O
operation	O
or	O
the	O
skill	O
with	O
which	O
it	O
is	O
performed	O
.	O

The	O
relation	O
between	O
VE	O
/	O
VO2	O
and	O
Q	O
/	O
VO2	O
showed	O
a	O
significant	O
negative	O
correlation	O
(	O
r	O
=	O
-	O
0	O
.	O
93	O
,	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Indoor	O
concentrations	O
were	O
only	O
weakly	O
correlated	O
with	O
outdoor	O
concentrations	O
,	O
however	O
,	O
and	O
personal	O
exposures	O
were	O
even	O
more	O
poorly	O
correlated	O
with	O
outdoor	O
concentrations	O
.	O

However	O
,	O
when	O
a	O
second	O
,	O
upstream	B-GENE
IRE	I-GENE
-	I-GENE
like	I-GENE
sequence	I-GENE
was	O
evaluated	O
by	O
EMSA	O
,	O
a	O
DNA	O
binding	O
pattern	O
distinct	O
from	O
that	O
seen	O
following	O
exposure	O
to	O
IFN	B-GENE
-	I-GENE
gamma	I-GENE
alone	O
was	O
observed	O
after	O
prolonged	O
stimulation	O
with	O
both	O
IFN	B-GENE
-	I-GENE
alpha	I-GENE
and	O
IFN	B-GENE
-	I-GENE
gamma	I-GENE
.	O

Growth	B-GENE
factor	I-GENE
allows	O
effective	O
dose	O
-	O
intensive	O
regimen	O
in	O
advanced	O
breast	O
cancer	O
patients	O
.	O

Clone	O
4c	O
(	O
2681	O
bp	O
)	O
had	O
a	O
coding	O
region	O
identical	O
to	O
that	O
of	O
clone	O
22c	O
but	O
it	O
included	O
a	O
putative	O
intron	O
of	O
959	O
bp	O
.	O

These	O
results	O
indicate	O
that	O
an	O
internal	O
short	O
element	O
located	O
at	O
the	O
very	O
5	O
'	O
terminal	O
of	O
L1	B-GENE
sequence	I-GENE
and	O
the	O
nuclear	O
factor	O
binding	O
to	O
the	O
element	O
play	O
a	O
crucial	O
role	O
in	O
the	O
transcription	O
of	O
human	B-GENE
L1	O
.	O

E47	B-GENE
protein	I-GENE
levels	O
remain	O
high	O
until	O
the	O
double	O
positive	O
developmental	O
stage	O
,	O
at	O
which	O
point	O
they	O
drop	O
to	O
relatively	O
moderate	O
levels	O
,	O
and	O
are	O
further	O
downregulated	O
upon	O
transition	O
to	O
the	O
single	O
positive	O
stage	O
.	O

Laboratory	O
aspects	O
with	O
particular	O
reference	O
to	O
chemotherapy	O
and	O
control	O
.	O

The	O
transcriptional	O
unit	O
spans	O
a	O
chromosomal	O
region	O
of	O
about	O
55	O
kilobase	O
pairs	O
(	O
kbp	O
)	O
.	O

The	O
plant	O
protein	O
maintains	O
all	O
the	O
functional	O
domains	O
found	O
in	O
the	O
other	O
proteins	O
,	O
including	O
nuclear	O
localization	O
signal	O
,	O
DNA	O
-	O
binding	O
domain	O
and	O
helicase	B-GENE
motifs	I-GENE
,	O
suggesting	O
that	O
it	O
might	O
also	O
act	O
as	O
part	O
of	O
the	O
RNA	O
transcription	O
apparatus	O
,	O
as	O
well	O
as	O
nucleotide	O
excision	O
repair	O
in	O
plant	O
cells	O
.	O

SELECTION	O
CRITERIA	O
:	O
All	O
controlled	O
trials	O
where	O
adults	O
with	O
schizophrenia	O
or	O
similar	O
illnesses	O
were	O
randomised	O
to	O
quetiapine	O
,	O
placebo	O
or	O
other	O
neuroleptic	O
drugs	O
and	O
where	O
clinically	O
relevant	O
outcomes	O
were	O
reported	O
.	O

Transcriptional	O
control	O
signals	O
of	O
a	O
herpes	B-GENE
simplex	I-GENE
virus	I-GENE
type	I-GENE
1	I-GENE
late	I-GENE
(	I-GENE
gamma	I-GENE
2	I-GENE
)	I-GENE
gene	I-GENE
lie	O
within	O
bases	O
-	O
34	O
to	O
+	O
124	O
relative	O
to	O
the	O
5	O
'	O
terminus	O
of	O
the	O
mRNA	O
.	O

Although	O
it	O
has	O
been	O
shown	O
that	O
it	O
is	O
possible	O
to	O
use	O
orally	O
administered	O
testosterone	O
to	O
maintain	O
se	O
-	O
T	O
levels	O
in	O
the	O
normal	O
male	O
range	O
,	O
the	O
convenience	O
to	O
the	O
patient	O
must	O
be	O
balanced	O
against	O
the	O
cost	O
and	O
possible	O
side	O
effects	O
of	O
the	O
large	O
doses	O
required	O
.	O

The	O
congenital	O
forms	O
(	O
7	O
cases	O
)	O
all	O
occurred	O
in	O
female	O
infants	O
and	O
involved	O
the	O
mucosa	O
overlying	O
either	O
the	O
anterior	O
ridge	O
of	O
the	O
maxilla	O
or	O
the	O
mandible	O
.	O

The	O
recovery	O
value	O
of	O
systolic	O
pressure	O
was	O
higher	O
than	O
diastolic	O
pressure	O
and	O
pulse	O
pressure	O
increased	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
encodes	O
a	O
40	O
-	O
kDa	O
nuclear	O
protein	O
,	O
Tax	B-GENE
,	O
which	O
stimulates	O
transcription	O
from	O
three	O
21	O
-	O
base	O
pair	O
(	O
bp	O
)	O
repeats	O
in	O
its	O
U3	B-GENE
region	I-GENE
.	O

The	O
effect	O
of	O
ligustrazine	O
hydrochloride	O
(	O
LTH	O
)	O
on	O
depressing	O
pulmonary	O
artery	O
hypertension	O
has	O
been	O
proved	O
in	O
recent	O
studies	O
.	O

Band	O
-	O
shift	O
assays	O
were	O
performed	O
using	O
the	O
LPS	B-GENE
-	I-GENE
and	I-GENE
IL	I-GENE
-	I-GENE
1	I-GENE
-	I-GENE
responsive	I-GENE
element	I-GENE
(	O
LILRE	B-GENE
)	O
oligonucleotide	O
,	O
a	O
gamma	B-GENE
interferon	I-GENE
activation	I-GENE
site	I-GENE
-	I-GENE
like	I-GENE
site	I-GENE
that	O
is	O
present	O
in	O
the	O
human	B-GENE
IL	I-GENE
-	I-GENE
1beta	I-GENE
promoter	I-GENE
.	O

Here	O
we	O
suggest	O
that	O
uvrA	B-GENE
and	O
the	O
nucleotide	O
excision	O
repair	O
pathway	O
are	O
involved	O
in	O
the	O
repair	O
of	O
acid	O
-	O
induced	O
DNA	O
damage	O
and	O
are	O
associated	O
with	O
successful	O
adaptation	O
of	O
S	O
.	O
mutans	O
to	O
low	O
pH	O
.	O

A	O
protein	O
footprint	O
also	O
was	O
identified	O
for	O
a	O
GC	O
box	O
element	O
at	O
nucleotides	O
-	O
59	O
to	O
-	O
45	O
.	O

Thus	O
,	O
we	O
have	O
identified	O
a	O
GRE	B-GENE
sufficient	O
to	O
account	O
for	O
full	O
glucocorticoid	O
inducibility	O
and	O
an	O
HNF	B-GENE
-	I-GENE
1	I-GENE
site	I-GENE
close	O
to	O
the	O
promoter	O
that	O
are	O
major	O
determinants	O
of	O
transcriptional	O
control	O
of	O
the	O
Xenopus	B-GENE
fibrinogen	I-GENE
B	I-GENE
beta	I-GENE
subunit	I-GENE
gene	I-GENE
in	O
cells	O
from	O
normal	O
liver	O
tissue	O
.	O

Here	O
we	O
present	O
genetic	O
evidence	O
suggesting	O
that	O
PP2A	B-GENE
functions	O
downstream	O
of	O
Ras1	B-GENE
in	O
the	O
Sevenless	B-GENE
receptor	B-GENE
tyrosine	I-GENE
kinase	I-GENE
(	O
RTK	B-GENE
)	O
signal	O
transduction	O
pathway	O
that	O
specifies	O
R7	O
photoreceptor	O
cell	O
fate	O
in	O
the	O
developing	O
Drosophila	O
eye	O
.	O

CONCLUSION	O
:	O
In	O
our	O
animal	O
model	O
,	O
blood	O
-	O
brain	O
barrier	O
disruption	O
was	O
a	O
reproducible	O
,	O
integral	O
finding	O
of	O
single	O
-	O
fraction	O
,	O
high	O
-	O
dose	O
irradiation	O
injury	O
.	O

Three	O
radiologists	O
without	O
knowledge	O
of	O
patients	O
'	O
data	O
and	O
treatment	O
analyzed	O
30	O
angiograms	O
with	O
and	O
30	O
examinations	O
without	O
PGF	O
.	O

Mean	O
Hg	O
concentrations	O
in	O
the	O
livers	O
of	O
mice	O
at	O
some	O
sites	O
in	O
Isle	O
Royale	O
are	O
not	O
significantly	O
lower	O
(	O
P	O
=	O
0	O
.	O
62	O
)	O
than	O
Hg	O
concentrations	O
considered	O
by	O
some	O
government	O
agencies	O
to	O
be	O
unhealthy	O
for	O
human	O
consumption	O
.	O

axl	O
,	O
a	O
transforming	O
gene	O
isolated	O
from	O
primary	O
human	O
myeloid	O
leukemia	O
cells	O
,	O
encodes	O
a	O
novel	O
receptor	B-GENE
tyrosine	I-GENE
kinase	I-GENE
.	O

In	O
E	O
.	O
coli	O
,	O
CheW	B-GENE
mediates	O
the	O
physical	O
coupling	O
of	O
the	O
receptors	O
to	O
the	O
kinase	B-GENE
CheA	B-GENE
.	O

We	O
argue	O
that	O
this	O
is	O
the	O
general	O
property	O
of	O
QSAR	O
models	O
developed	O
using	O
LOO	O
cross	O
-	O
validation	O
.	O

Expression	O
in	O
established	O
LCLs	O
,	O
occurring	O
irrespective	O
of	O
virus	O
producer	O
status	O
,	O
was	O
not	O
a	O
consequence	O
of	O
continued	O
in	O
vitro	O
passage	O
;	O
thus	O
,	O
appropriately	O
spliced	O
BamHI	B-GENE
-	I-GENE
A	I-GENE
transcripts	I-GENE
could	O
be	O
amplified	O
from	O
normal	O
B	O
cells	O
within	O
1	O
day	O
of	O
their	O
experimental	O
infection	O
in	O
vitro	O
,	O
along	O
with	O
BamHI	B-GENE
-	I-GENE
C	I-GENE
/	I-GENE
W	I-GENE
promoter	O
-	O
initiated	O
but	O
not	O
BamHI	B-GENE
-	I-GENE
F	I-GENE
promoter	I-GENE
-	I-GENE
initiated	I-GENE
mRNAs	I-GENE
.	O

The	O
equivalent	O
of	O
the	O
third	O
ligand	O
,	O
H	B-GENE
-	I-GENE
87	I-GENE
,	O
is	O
T	O
-	O
47	O
in	O
the	O
PSTAIRE	B-GENE
sequence	I-GENE
motif	I-GENE
.	O

In	O
all	O
eight	O
cases	O
,	O
neither	O
FL	O
nor	O
DLL	O
cells	O
showed	O
alterations	O
of	O
bcl	B-GENE
-	I-GENE
2	I-GENE
gene	I-GENE
sequences	I-GENE
in	O
the	O
breakpoint	O
region	O
,	O
suggesting	O
high	O
conservation	O
of	O
the	O
bcl	B-GENE
-	I-GENE
2	I-GENE
gene	I-GENE
during	O
both	O
t	O
(	O
14	O
;	O
18	O
)	O
translocation	O
and	O
morphologic	O
transformation	O
of	O
the	O
FL	O
cells	O
.	O

The	O
transcriptional	O
activity	O
of	O
PPARgamma	B-GENE
is	O
positively	O
modulated	O
by	O
ligand	O
binding	O
and	O
negatively	O
regulated	O
by	O
phosphorylation	O
mediated	O
by	O
the	O
MEK	B-GENE
/	I-GENE
ERK	I-GENE
signaling	I-GENE
pathway	I-GENE
.	O

Furthermore	O
,	O
the	O
insertion	O
of	O
the	O
ColE1	B-GENE
cer	I-GENE
site	I-GENE
into	O
the	O
RK2	O
plasmid	O
deleted	O
for	O
the	O
par	O
region	O
failed	O
to	O
stabilize	O
the	O
plasmid	O
in	O
the	O
MC1061K	O
strain	O
,	O
indicating	O
that	O
the	O
multimer	O
resolution	O
activity	O
encoded	O
by	O
parCBA	B-GENE
is	O
not	O
by	O
itself	O
responsible	O
for	O
the	O
stabilization	O
activity	O
observed	O
for	O
this	O
operon	O
.	O

19F	O
NMR	O
studies	O
in	O
ABF4	O
-	O
type	O
layered	O
antiferromagnets	O
.	O

No	O
local	O
destruction	O
by	O
tumor	O
or	O
infection	O
could	O
be	O
demonstrated	O
apart	O
from	O
HIV	O
infection	O
.	O

We	O
have	O
identified	O
three	O
binding	O
sites	O
for	O
protein	O
complexes	O
:	O
a	O
palindrome	O
,	O
a	O
direct	O
repeat	O
,	O
and	O
a	O
C	O
+	O
T	O
sequence	O
that	O
corresponds	O
to	O
seven	O
GAGA	B-GENE
motifs	I-GENE
on	O
the	O
transcribed	O
strand	O
.	O

These	O
results	O
indicate	O
that	O
the	O
sulfhydryl	O
group	O
of	O
certain	O
angiotensin	B-GENE
converting	I-GENE
enzyme	I-GENE
inhibitors	O
can	O
potentiate	O
their	O
effect	O
on	O
the	O
endogenous	O
nitrovasodilator	O
EDRF	B-GENE
.	O

Selenium	O
,	O
as	O
a	O
constituent	O
of	O
glutathione	B-GENE
peroxidase	I-GENE
,	O
plays	O
a	O
role	O
in	O
the	O
antioxidant	O
defense	O
systems	O
of	O
the	O
body	O
,	O
but	O
other	O
metabolic	O
roles	O
for	O
selenium	O
may	O
yet	O
be	O
discovered	O
.	O

Since	O
the	O
UfAP	B-GENE
and	O
UTMP	B-GENE
share	O
many	O
biosynthetic	O
and	O
structural	O
features	O
that	O
include	O
site	O
of	O
biosynthesis	O
in	O
the	O
endometrium	O
,	O
P4	O
-	O
responsiveness	O
,	O
the	O
presence	O
of	O
the	O
mannose	O
6	O
-	O
phosphate	O
lysosomal	O
recognition	O
marker	O
,	O
and	O
considerable	O
sequence	O
similarity	O
,	O
the	O
UfAP	B-GENE
and	O
the	O
UTMP	B-GENE
may	O
have	O
homologous	O
function	O
which	O
for	O
both	O
still	O
remains	O
obscure	O
.	O

HVH2	B-GENE
mRNA	I-GENE
showed	O
an	O
expression	O
pattern	O
distinct	O
from	O
CL100	B-GENE
(	O
human	B-GENE
homologue	I-GENE
of	I-GENE
mouse	I-GENE
MKP1	I-GENE
)	O
and	O
PAC1	B-GENE
,	O
two	O
previously	O
identified	O
MAP	B-GENE
kinase	I-GENE
phosphatases	I-GENE
.	O

In	O
ciliates	O
,	O
both	O
mechanisms	O
are	O
readily	O
observed	O
.	O

We	O
have	O
studied	O
the	O
biokinetics	O
of	O
BLM	O
labeled	O
with	O
indium	O
-	O
111	O
(	O
In	O
-	O
111	O
)	O
.	O

Exon	O
A	O
is	O
located	O
approximately	O
7	O
kb	O
5	O
'	O
to	O
the	O
HSL	B-GENE
translation	I-GENE
start	I-GENE
site	I-GENE
.	O

In	O
contrast	O
,	O
transiently	O
transfected	O
cells	O
expressing	O
EBNA	B-GENE
-	I-GENE
3	I-GENE
revealed	O
a	O
sixfold	O
increase	O
in	O
EBNA	B-GENE
-	I-GENE
3	I-GENE
protein	I-GENE
expression	O
from	O
the	O
genomic	O
EBNA	B-GENE
-	I-GENE
3	I-GENE
gene	I-GENE
compared	O
to	O
EBNA	B-GENE
-	I-GENE
3	I-GENE
cDNA	I-GENE
.	O

SETTING	O
:	O
A	O
division	O
of	O
a	O
large	O
tea	O
plantation	O
in	O
Kandy	O
.	O

Imaging	O
features	O
of	O
splenic	O
epidermoid	O
cyst	O
with	O
pathologic	O
correlation	O
.	O

One	O
of	O
these	O
genes	O
,	O
REC114	B-GENE
,	O
is	O
described	O
here	O
,	O
and	O
the	O
data	O
confirm	O
that	O
REC114	B-GENE
is	O
a	O
meiosis	O
-	O
specific	O
recombination	O
gene	O
with	O
no	O
detectable	O
function	O
in	O
mitosis	O
.	O

2	O
)	O
The	O
time	O
-	O
sharing	O
principle	O
was	O
applied	O
to	O
gain	O
high	O
stability	O
.	O

The	O
corresponding	O
genotype	O
was	O
determined	O
with	O
a	O
restriction	O
enzyme	O
-	O
based	O
assay	O
.	O

In	O
patients	O
with	O
limited	O
disease	O
,	O
the	O
survival	O
in	O
the	O
alternating	O
arm	O
was	O
significantly	O
superior	O
to	O
the	O
survival	O
in	O
the	O
CAV	O
arm	O
(	O
P	O
=	O
.	O
014	O
)	O
or	O
the	O
survival	O
in	O
the	O
PE	O
arm	O
(	O
P	O
=	O
.	O
023	O
)	O
.	O

Analysis	O
of	O
disassociation	O
rates	O
indicates	O
that	O
the	O
Grf10	B-GENE
-	I-GENE
Swi5	I-GENE
-	I-GENE
DNA	I-GENE
complex	I-GENE
has	O
a	O
longer	O
half	O
-	O
life	O
than	O
protein	O
-	O
DNA	O
complexes	O
that	O
contain	O
only	O
Swi5	B-GENE
or	O
Grf10	B-GENE
.	O

Constructs	O
were	O
made	O
in	O
which	O
an	O
AATAAA	O
and	O
the	O
GT	O
-	O
rich	O
region	O
were	O
separated	O
by	O
various	O
distances	O
ranging	O
from	O
7	O
to	O
43	O
bp	O
.	O

The	O
prevalence	O
of	O
hepatitis	B-GENE
B	I-GENE
surface	I-GENE
antigen	I-GENE
(	O
HBsAg	B-GENE
)	O
and	O
anti	B-GENE
-	I-GENE
HBs	I-GENE
was	O
determined	O
by	O
a	O
sensitive	O
double	O
-	O
antibody	O
radio	O
-	O
immunoassay	O
technique	O
in	O
a	O
series	O
of	O
patients	O
with	O
chronic	O
liver	O
diseases	O
.	O

GCD10	B-GENE
binds	O
RNA	O
in	O
vitro	O
and	O
we	O
present	O
strong	O
biochemical	O
evidence	O
that	O
it	O
is	O
identical	O
to	O
the	O
RNA	O
-	O
binding	O
subunit	O
of	O
yeast	B-GENE
initiation	I-GENE
factor	I-GENE
-	I-GENE
3	I-GENE
(	O
eIF	B-GENE
-	I-GENE
3	I-GENE
)	O
.	O
eIF	B-GENE
-	I-GENE
3	I-GENE
is	O
a	O
multisubunit	O
complex	O
that	O
stimulates	O
translation	O
initiation	O
in	O
vitro	O
at	O
several	O
different	O
steps	O
.	O

Based	O
on	O
these	O
results	O
the	O
minimal	O
control	O
element	O
(	O
AX	B-GENE
470	I-GENE
)	O
specifying	O
the	O
anterior	O
boundary	O
of	O
Hox	B-GENE
expression	O
was	O
designated	O
as	O
Hoxa	B-GENE
-	I-GENE
7	I-GENE
enhancer	I-GENE
.	O

There	O
have	O
been	O
five	O
problems	O
(	O
extravasation	O
2	O
,	O
suspected	O
sepsis	O
1	O
,	O
and	O
hematoma	O
2	O
)	O
during	O
a	O
total	O
of	O
2	O
,	O
927	O
days	O
of	O
exposure	O
.	O

Plasma	O
lipid	O
and	O
lipoprotein	O
profiles	O
were	O
compared	O
in	O
elderly	O
female	O
runners	O
(	O
RU	O
:	O
n	O
=	O
15	O
,	O
aged	O
66	O
+	O
/	O
-	O
5	O
years	O
,	O
body	O
fat	O
20	O
+	O
/	O
-	O
4	O
%	O
,	O
training	O
distance	O
35	O
+	O
/	O
-	O
15	O
km	O
week	O
-	O
1	O
,	O
VO2max	O
36	O
+	O
/	O
-	O
4	O
ml	O
kg	O
-	O
1	O
min	O
-	O
1	O
,	O
mean	O
+	O
/	O
-	O
SD	O
)	O
and	O
age	O
-	O
matched	O
untrained	O
women	O
(	O
UT	O
:	O
n	O
=	O
28	O
,	O
66	O
+	O
/	O
-	O
4	O
years	O
,	O
body	O
fat	O
26	O
+	O
/	O
-	O
6	O
%	O
,	O
VO2max	O
26	O
+	O
/	O
-	O
3	O
ml	O
kg	O
-	O
1	O
min	O
-	O
1	O
)	O
.	O

Dementia	O
is	O
being	O
avoided	O
in	O
NHS	O
and	O
social	O
care	O
.	O

The	O
cDNA	O
has	O
an	O
open	O
reading	O
frame	O
of	O
900	O
amino	O
acids	O
capable	O
of	O
encoding	O
a	O
97	O
-	O
kDa	O
protein	O
.	O

Two	O
independent	O
transgenic	O
lines	O
were	O
produced	O
,	O
and	O
both	O
showed	O
expression	O
of	O
the	O
Gus	B-GENE
gene	I-GENE
specifically	O
in	O
the	O
endosperm	O
during	O
mid	O
-	O
development	O
(	O
first	O
detected	O
10	O
-	O
12	O
d	O
after	O
anthesis	O
)	O
.	O

The	O
second	O
complex	O
,	O
when	O
purified	O
,	O
contained	O
four	O
protein	O
components	O
including	O
the	O
36	O
-	O
kDa	O
protein	O
.	O

Histopathologic	O
observations	O
showed	O
that	O
both	O
somatostatin	B-GENE
and	O
triamcinolone	O
acetonide	O
reduced	O
the	O
inflammatory	O
signs	O
in	O
the	O
joint	O
structures	O
,	O
although	O
triamcinolone	O
acetonide	O
appeared	O
to	O
be	O
more	O
effective	O
.	O

Induction	O
in	O
AP	B-GENE
-	I-GENE
1	I-GENE
DNA	O
binding	O
correlates	O
with	O
a	O
concomitant	O
GH	B-GENE
trans	O
-	O
activation	O
of	O
c	B-GENE
-	I-GENE
jun	I-GENE
and	O
c	B-GENE
-	I-GENE
fos	I-GENE
genes	I-GENE
described	O
previously	O
.	O

HDL	O
-	O
cholesterol	O
(	O
+	O
6	O
%	O
,	O
P	O
less	O
than	O
.	O
01	O
)	O
and	O
apolipoprotein	B-GENE
A	I-GENE
-	I-GENE
I	I-GENE
(	O
+	O
6	O
%	O
,	O
P	O
less	O
than	O
.	O
01	O
)	O
concentrations	O
increased	O
significantly	O
only	O
in	O
the	O
young	O
.	O

We	O
have	O
generated	O
a	O
computer	O
model	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
the	O
434	O
repressor	O
based	O
on	O
the	O
crystal	O
structure	O
of	O
the	O
homologous	B-GENE
UmuD	I-GENE
'	I-GENE
protein	I-GENE
.	O

Activation	O
of	O
a	O
CRE	B-GENE
-	I-GENE
dependent	I-GENE
junB	I-GENE
promoter	I-GENE
/	I-GENE
chloramphenicol	I-GENE
acetyltransferase	I-GENE
(	O
CAT	B-GENE
)	O
reporter	O
gene	O
by	O
the	O
BCR	B-GENE
was	O
also	O
blocked	O
by	O
SB203580	O
.	O

Oxygen	O
delivery	O
and	O
consumption	O
and	O
P50	O
in	O
patients	O
with	O
acute	O
myocardial	O
infarction	O
.	O

The	O
tyrosine	B-GENE
hydroxylase	I-GENE
gene	I-GENE
(	O
TH	B-GENE
)	O
contains	O
a	O
single	O
copy	O
of	O
a	O
consensus	O
CRE	B-GENE
at	O
-	O
45	O
to	O
-	O
38	O
base	O
pair	O
(	O
bp	O
)	O
upstream	O
of	O
the	O
transcription	O
initiation	O
site	O
.	O

Adrenergic	O
system	O
activation	O
,	O
indicated	O
by	O
metanephrine	O
/	O
epinephrine	O
ratio	O
,	O
increased	O
with	O
time	O
in	O
losing	O
males	O
,	O
except	O
that	O
after	O
one	O
month	O
of	O
cohabitation	O
,	O
turnover	O
returned	O
to	O
levels	O
that	O
equaled	O
those	O
of	O
control	O
animals	O
.	O

In	O
C	O
.	O
albicans	O
,	O
HST6	B-GENE
is	O
expressed	O
constitutively	O
at	O
high	O
levels	O
in	O
the	O
different	O
cell	O
types	O
analysed	O
(	O
yeast	O
,	O
hyphae	O
,	O
white	O
and	O
opaque	O
)	O
,	O
demonstrating	O
that	O
HST6	B-GENE
transcription	O
is	O
not	O
repressed	O
in	O
this	O
diploid	O
yeast	O
,	O
unlike	O
in	O
diploid	O
S	O
.	O
cerevisiae	O
,	O
and	O
suggesting	O
a	O
basic	O
biological	O
function	O
for	O
the	O
Hst6p	B-GENE
transporter	O
in	O
C	O
.	O
albicans	O
.	O

Ketamine	O
in	O
the	O
treatment	O
of	O
bronchospasm	O
during	O
mechanical	O
ventilation	O
.	O

It	O
is	O
concluded	O
that	O
the	O
plasma	B-GENE
prolactin	I-GENE
response	O
to	O
12	O
.	O
5	O
micrograms	O
i	O
.	O
v	O
.	O

But	O
no	O
influence	O
was	O
observed	O
at	O
lower	O
concentrations	O
than	O
1	O
/	O
4	O
MIC	O
of	O
AMK	O
.	O

Three	O
patients	O
with	O
four	O
renoureteral	O
units	O
have	O
undergone	O
single	O
-	O
stage	O
reconstruction	O
involving	O
ureteroureterostomy	O
and	O
ipsilateral	O
ureteroneocystostomy	O
following	O
temporary	O
loop	O
cutaneous	O
ureterostomy	O
.	O

Oxygen	O
tension	O
of	O
the	O
small	O
lymph	O
vessels	O
(	O
PLO2	O
)	O
of	O
the	O
rabbit	O
hind	O
limb	O
was	O
measured	O
with	O
both	O
a	O
flow	O
-	O
through	O
micro	O
chamber	O
and	O
a	O
polarographic	O
catheter	O
-	O
tip	O
oxygen	O
electrode	O
to	O
obtain	O
experimental	O
data	O
on	O
the	O
source	O
of	O
oxygen	O
in	O
the	O
lymph	O
.	O

The	O
smaller	O
uptake	O
rate	O
and	O
faster	O
clearance	O
rate	O
resulted	O
in	O
the	O
lower	O
BCF	O
for	O
SWA	O
killifish	O
.	O

The	O
second	O
functional	O
pair	O
of	O
CreA	B-GENE
sites	I-GENE
is	O
located	O
between	O
the	O
two	O
transcription	O
initiation	O
sites	O
.	O

Six	O
out	O
of	O
ten	O
hearts	O
from	O
macerated	O
stillborn	O
infants	O
showed	O
varying	O
degrees	O
of	O
positive	O
staining	O
.	O

The	O
proliferation	O
-	O
specific	O
HNF	B-GENE
-	I-GENE
3	I-GENE
/	I-GENE
fork	I-GENE
head	I-GENE
homolog	I-GENE
-	I-GENE
11B	I-GENE
protein	I-GENE
(	O
HFH	B-GENE
-	I-GENE
11B	I-GENE
;	O
also	O
known	O
as	O
Trident	B-GENE
and	O
Win	B-GENE
)	O
is	O
a	O
family	O
member	O
of	O
the	O
winged	B-GENE
helix	I-GENE
/	I-GENE
fork	I-GENE
head	I-GENE
transcription	I-GENE
factors	I-GENE
and	O
in	O
regenerating	O
liver	O
its	O
expression	O
is	O
reactivated	O
prior	O
to	O
hepatocyte	O
entry	O
into	O
DNA	O
replication	O
(	O
S	O
phase	O
)	O
.	O

In	O
vitro	O
transcription	O
results	O
indicate	O
that	O
this	O
5	O
'	O
structure	O
functions	O
in	O
the	O
attenuation	O
mechanism	O
,	O
since	O
deletion	O
of	O
the	O
stem	O
-	O
loop	O
caused	O
an	O
increase	O
in	O
transcription	O
readthrough	O
.	O

Northern	O
blotting	O
showed	O
that	O
MDMX	B-GENE
,	O
like	O
MDM2	B-GENE
,	O
is	O
expressed	O
in	O
all	O
tissues	O
tested	O
,	O
and	O
that	O
several	O
mRNAs	O
for	O
MDMX	B-GENE
can	O
be	O
detected	O
.	O

The	O
mean	O
serum	O
creatinine	O
level	O
did	O
not	O
change	O
during	O
the	O
first	O
6	O
months	O
after	O
withdrawal	O
of	O
MMF	O
.	O

Control	O
subjects	O
'	O
evoked	O
potentials	O
(	O
EPs	O
)	O
were	O
characterized	O
by	O
an	O
initial	O
positivity	O
in	O
the	O
90	O
-	O
140	O
ms	O
range	O
(	O
P1	O
)	O
at	O
the	O
temporo	O
-	O
occipital	O
site	O
.	O

The	O
diagnostic	O
value	O
of	O
blood	O
serum	O
and	O
urinary	B-GENE
amylase	I-GENE
,	O
lipase	B-GENE
,	O
and	O
trypsin	B-GENE
in	O
exacerbations	O
of	O
chronic	O
relapsing	O
pancreatitis	O
is	O
discussed	O
.	O

Gel	O
filtration	O
,	O
sedimentation	O
velocity	O
,	O
and	O
immunoprecipitation	O
experiments	O
revealed	O
that	O
beta4	B-GENE
is	O
a	O
component	O
of	O
a	O
multisubunit	O
complex	O
(	O
AP	B-GENE
-	I-GENE
4	I-GENE
)	O
that	O
also	O
contains	O
the	O
sigma4	B-GENE
polypeptide	I-GENE
and	O
two	O
additional	O
adaptor	O
subunit	O
homologs	O
named	O
mu4	B-GENE
(	O
mu	B-GENE
-	I-GENE
ARP2	I-GENE
)	O
and	O
epsilon	B-GENE
.	O

Hexsyn	O
is	O
the	O
Goodyear	O
Tire	O
and	O
Rubber	O
Company	O
tradename	O
for	O
a	O
polyolefin	O
rubber	O
synthesized	O
from	O
1	O
-	O
hexene	O
with	O
3	O
-	O
5	O
%	O
methylhexadiene	O
as	O
the	O
source	O
of	O
residual	O
double	O
bonds	O
for	O
vulcanization	O
.	O

The	O
recessive	O
hos1	B-GENE
mutation	O
causes	O
enhanced	O
induction	O
of	O
the	O
CBF	B-GENE
transcription	I-GENE
factors	I-GENE
by	O
low	O
temperature	O
as	O
well	O
as	O
of	O
their	O
downstream	O
cold	O
-	O
responsive	O
genes	O
.	O

This	O
mutant	O
was	O
identified	O
by	O
screening	O
with	O
a	O
TGF	O
-	O
beta	O
-	O
inducible	O
vector	O
a	O
series	O
of	O
mink	O
lung	O
epithelial	O
cell	O
clones	O
that	O
have	O
normal	O
TGF	B-GENE
-	I-GENE
beta	I-GENE
binding	O
activity	O
but	O
have	O
lost	O
antiproliferative	O
and	O
transcriptional	O
responses	O
to	O
TGF	B-GENE
-	I-GENE
beta	I-GENE
.	O

Regulation	O
of	O
ASN1	B-GENE
and	O
ASN2	B-GENE
expression	O
was	O
studied	O
using	O
lacZ	B-GENE
fusions	I-GENE
and	O
both	O
genes	O
were	O
found	O
to	O
be	O
several	O
times	O
less	O
expressed	O
in	O
the	O
absence	O
of	O
the	O
transcription	O
activator	O
Gcn4p	B-GENE
.	O

GlcNAc	O
-	O
and	O
GlcNAc2	B-GENE
-	I-GENE
PP	I-GENE
-	I-GENE
Dolichol	I-GENE
biosynthesis	O
could	O
be	O
shown	O
with	O
isolated	O
S	O
.	O
cerevisiae	O
membranes	O
from	O
cells	O
harboring	O
the	O
recombinant	O
plasmid	O
and	O
grown	O
on	O
glucose	O
thus	O
suppressing	O
transcription	O
of	O
the	O
endogenous	O
gene	O
.	O

The	O
predicted	O
domain	O
structures	O
of	O
FkbB	B-GENE
and	O
FkbC	B-GENE
are	O
analogous	O
to	O
that	O
of	O
FkbA	B-GENE
and	O
comprise	O
30	O
fatty	B-GENE
-	I-GENE
acid	I-GENE
-	I-GENE
synthase	I-GENE
(	I-GENE
FAS	I-GENE
)	I-GENE
-	I-GENE
like	I-GENE
domains	I-GENE
arranged	O
in	O
6	O
modules	O
.	O

The	O
observation	O
that	O
beta	B-GENE
2m	I-GENE
with	O
covalently	O
attached	O
peptide	O
can	O
effectively	O
create	O
CTL	O
target	O
structures	O
in	O
vitro	O
offers	O
new	O
possibilities	O
for	O
the	O
in	O
vivo	O
induction	O
of	O
epitope	O
-	O
specific	O
CTL	O
responses	O
by	O
either	O
DNA	O
immunization	O
or	O
injection	O
of	O
the	O
purified	O
epitope	O
-	O
linked	O
beta	B-GENE
2m	O
.	O

The	O
mechanistic	O
implications	O
of	O
aromatic	O
non	O
-	O
responsiveness	O
of	O
autonomously	O
expressed	O
A	O
-	O
domain	O
,	O
despite	O
its	O
demonstrated	O
ability	O
to	O
bind	O
phenol	O
,	O
are	O
discussed	O
.	O

No	O
systematic	O
L	O
-	O
R	O
differences	O
were	O
observed	O
.	O

Computerized	O
detection	O
of	O
abnormal	O
asymmetry	O
in	O
digital	O
chest	O
radiographs	O
.	O

When	O
pollen	O
allergen	O
from	O
three	O
grass	O
species	O
were	O
used	O
,	O
The	O
RAST	O
-	O
test	O
results	O
did	O
not	O
differ	O
from	O
duplicate	O
values	O
either	O
.	O

In	O
1990	O
,	O
an	O
International	O
Commission	O
for	O
the	O
Certification	O
of	O
Eradication	O
of	O
Poliomyelitis	O
Eradication	O
(	O
ICCPE	O
)	O
was	O
established	O
by	O
the	O
Pan	O
American	O
Health	O
Organization	O
to	O
eventually	O
determine	O
if	O
transmission	O
was	O
interrupted	O
.	O

New	O
diagnostic	O
strategies	O
for	O
lupus	O
anticoagulants	O
and	O
antiphospholipid	B-GENE
antibodies	I-GENE
.	O

A	O
genetic	O
and	O
molecular	O
analysis	O
of	O
non	O
-	O
inducible	O
qutA	B-GENE
mutants	I-GENE
showed	O
that	O
all	O
23	O
mutations	O
analysed	O
map	O
within	O
the	O
N	O
-	O
terminal	O
half	O
of	O
the	O
encoded	O
QUTA	B-GENE
protein	I-GENE
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
SNTCS	O
is	O
highly	O
malignant	O
.	O

Motile	O
nocardoid	O
Actinomycetales	O
.	O

Our	O
data	O
complement	O
other	O
studies	O
of	O
circumpolar	O
populations	O
and	O
reinforce	O
the	O
reported	O
high	O
prevalences	O
of	O
SPA	O
and	O
HLA	B-GENE
-	I-GENE
B27	I-GENE
among	O
those	O
populations	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
transfected	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cell	O
line	O
expressing	O
a	O
murine	B-GENE
CD4	I-GENE
fragment	I-GENE
containing	O
the	O
first	O
two	O
N	O
-	O
terminal	O
domains	O
secretes	O
both	O
monomeric	O
molecules	O
and	O
disulfide	O
-	O
linked	O
multimers	O
.	O

